curated_by,assay_tissue,assay_id,assay_strain,src_assay_id,tid,doc_id,relationship_type,assay_category,description,assay_subcellular_fraction,bao_format,assay_type,assay_test_type,chembl_id,src_id,tissue_id,variant_id,assay_tax_id,assay_cell_type,confidence_score,cell_id,assay_organism
Autocuration,,1.0,,,12052.0,11087.0,H,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,BAO_0000019,B,,CHEMBL615117,1.0,,,,,8.0,,
Autocuration,,2.0,,,22226.0,684.0,U,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,BAO_0000219,F,,CHEMBL615118,1.0,,,,,0.0,,
Autocuration,,3.0,,,22226.0,15453.0,U,,,,BAO_0000019,B,,CHEMBL615119,1.0,,,,,0.0,,
Autocuration,,4.0,,,104729.0,17841.0,H,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,BAO_0000249,B,,CHEMBL615120,1.0,,,9913.0,,4.0,,Bos taurus
Intermediate,,5.0,,,80001.0,17430.0,N,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,BAO_0000219,F,,CHEMBL615121,1.0,,,9606.0,143B,1.0,163.0,Homo sapiens
Intermediate,,6.0,,,80001.0,17430.0,N,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,BAO_0000219,F,,CHEMBL615122,1.0,,,9606.0,143B,1.0,163.0,Homo sapiens
Intermediate,,7.0,,,80001.0,13799.0,N,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,BAO_0000219,F,,CHEMBL615123,1.0,,,10090.0,143B,1.0,163.0,Mus musculus
Expert,,8.0,,,80001.0,17774.0,N,,In vitro cell cytotoxicity was determined against 143B cell line,,BAO_0000219,F,,CHEMBL615124,1.0,,,9606.0,143B,1.0,163.0,Homo sapiens
Intermediate,,9.0,,,80001.0,3801.0,N,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,BAO_0000219,F,,CHEMBL615125,1.0,,,9606.0,143B,1.0,163.0,Homo sapiens
Intermediate,,10.0,,,80001.0,17430.0,N,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,BAO_0000219,F,,CHEMBL615126,1.0,,,9606.0,143B,1.0,163.0,Homo sapiens
Intermediate,,11.0,,,80001.0,17430.0,N,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,BAO_0000219,F,,CHEMBL615127,1.0,,,9606.0,143B,1.0,163.0,Homo sapiens
Expert,,12.0,,,80001.0,17774.0,N,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,BAO_0000219,F,,CHEMBL615128,1.0,,,9606.0,143B,1.0,163.0,Homo sapiens
Intermediate,,13.0,,,50185.0,11324.0,N,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,F,,CHEMBL857900,1.0,,,1280.0,,1.0,,Staphylococcus aureus
Intermediate,,14.0,,,50185.0,11324.0,N,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,F,,CHEMBL615129,1.0,,,1280.0,,1.0,,Staphylococcus aureus
Intermediate,,15.0,,,50185.0,11324.0,N,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,F,,CHEMBL615130,1.0,,,1280.0,,1.0,,Staphylococcus aureus
Intermediate,,16.0,,,50185.0,11324.0,N,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,F,,CHEMBL615131,1.0,,,1280.0,,1.0,,Staphylococcus aureus
Expert,,17.0,,,100122.0,11347.0,D,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,BAO_0000357,A,,CHEMBL884521,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,18.0,,,12054.0,16474.0,H,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,B,,CHEMBL615132,1.0,,,,,8.0,,
Autocuration,,19.0,,,12054.0,10091.0,H,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,BAO_0000019,B,,CHEMBL615133,1.0,,,,,8.0,,
Autocuration,,20.0,,,12054.0,16474.0,H,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,B,,CHEMBL615134,1.0,,,,,8.0,,
Autocuration,,21.0,,,12054.0,16474.0,H,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,B,,CHEMBL615135,1.0,,,,,8.0,,
Autocuration,,22.0,,,12054.0,16474.0,H,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,B,,CHEMBL615136,1.0,,,,,8.0,,
Autocuration,,23.0,,,12054.0,16474.0,H,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,BAO_0000357,B,,CHEMBL615137,1.0,,,,,8.0,,
Autocuration,,24.0,,,12054.0,16474.0,H,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,BAO_0000357,B,,CHEMBL615138,1.0,,,,,8.0,,
Autocuration,,25.0,,,22226.0,14352.0,U,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,BAO_0000219,B,,CHEMBL836324,1.0,,,,,0.0,,
Autocuration,,26.0,,,12054.0,5646.0,H,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,BAO_0000357,B,,CHEMBL615139,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Autocuration,,27.0,,,12054.0,5646.0,H,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,BAO_0000357,B,,CHEMBL615140,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Autocuration,,28.0,,,12426.0,10997.0,H,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,BAO_0000219,B,,CHEMBL615141,1.0,,,,,8.0,,
Autocuration,,29.0,,,12054.0,6309.0,H,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,BAO_0000357,B,,CHEMBL615142,1.0,,,3847.0,,8.0,,soya bean
Autocuration,,30.0,,,12054.0,167.0,H,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,BAO_0000357,B,,CHEMBL615143,1.0,,,3847.0,,8.0,,Glycine max
Autocuration,,31.0,,,12054.0,167.0,H,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,BAO_0000357,B,,CHEMBL615144,1.0,,,3847.0,,8.0,,Glycine max
Autocuration,,32.0,,,12054.0,11087.0,H,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,BAO_0000357,B,,CHEMBL872867,1.0,,,3847.0,,8.0,,Glycine max
Autocuration,,33.0,,,12054.0,11087.0,H,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,BAO_0000357,B,,CHEMBL615145,1.0,,,3847.0,,8.0,,Glycine max
Autocuration,,34.0,,,12054.0,13622.0,H,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,BAO_0000357,B,,CHEMBL615146,1.0,,,3847.0,,8.0,,Glycine max
Autocuration,,35.0,,,12054.0,13622.0,H,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,BAO_0000357,B,,CHEMBL615147,1.0,,,3847.0,,8.0,,Glycine max
Autocuration,,36.0,,,22226.0,11347.0,U,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,BAO_0000019,A,,CHEMBL615148,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,37.0,,,22226.0,5926.0,U,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,BAO_0000019,B,,CHEMBL615149,1.0,,,562.0,,0.0,,Escherichia coli
Autocuration,,38.0,,,22226.0,4567.0,U,,Dissociation constant with dimeric 16S rRNA RNA construct B,,BAO_0000019,B,,CHEMBL615150,1.0,,,,,0.0,,
Intermediate,,39.0,,,22222.0,3782.0,M,,Dissociation constant towards 16S rRNA construct A,,BAO_0000225,B,,CHEMBL615151,1.0,,,,,3.0,,
Intermediate,,40.0,,,22222.0,3782.0,M,,Dissociation constant towards 16S rRNA construct B,,BAO_0000225,B,,CHEMBL615152,1.0,,,,,3.0,,
Expert,,41.0,,,100263.0,4466.0,M,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,BAO_0000225,B,,CHEMBL615153,1.0,,,562.0,,3.0,,Escherichia coli
Expert,,42.0,,,100263.0,6592.0,M,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,BAO_0000225,B,,CHEMBL615154,1.0,,,562.0,,3.0,,Escherichia coli
Autocuration,,43.0,,,13053.0,898.0,H,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,BAO_0000019,B,,CHEMBL615155,1.0,,,,,8.0,,
Autocuration,,44.0,,,13053.0,898.0,H,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,BAO_0000019,B,,CHEMBL615156,1.0,,,,,8.0,,
Autocuration,,45.0,,,20001.0,13163.0,H,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,BAO_0000019,B,,CHEMBL615157,1.0,,,9606.0,,8.0,,Homo sapiens
Autocuration,,46.0,,,20001.0,13163.0,H,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,BAO_0000019,B,,CHEMBL615158,1.0,,,9606.0,,8.0,,Homo sapiens
Expert,,47.0,,,12971.0,10691.0,D,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,BAO_0000019,B,,CHEMBL615159,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,48.0,,,12971.0,10691.0,D,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,BAO_0000019,B,,CHEMBL615172,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,49.0,,,12971.0,10691.0,D,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,BAO_0000019,B,,CHEMBL615173,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,50.0,,,12971.0,10691.0,D,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,BAO_0000019,B,,CHEMBL615174,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,51.0,,,13053.0,898.0,H,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,BAO_0000019,B,,CHEMBL884518,1.0,,,,,8.0,,
Autocuration,,52.0,,,11512.0,912.0,H,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,BAO_0000357,B,,CHEMBL615175,1.0,,,,,8.0,,
Autocuration,,53.0,,,11512.0,912.0,H,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,BAO_0000357,B,,CHEMBL615176,1.0,,,,,8.0,,
Autocuration,,54.0,,,11512.0,912.0,H,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,BAO_0000357,B,,CHEMBL615177,1.0,,,,,8.0,,
Autocuration,,55.0,,,104740.0,15103.0,D,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,Membranes,BAO_0000249,B,,CHEMBL615178,1.0,,,10116.0,,5.0,,Rattus norvegicus
Intermediate,,56.0,,,80002.0,5116.0,N,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,BAO_0000219,F,,CHEMBL615179,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Autocuration,,57.0,,,104835.0,14578.0,D,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,BAO_0000219,F,,CHEMBL615180,1.0,,,10116.0,Oocytes,7.0,,Rattus norvegicus
Autocuration,,58.0,,,104821.0,14578.0,D,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,BAO_0000219,F,,CHEMBL615181,1.0,,,10116.0,Oocytes,7.0,,Rattus norvegicus
Autocuration,,59.0,,,104848.0,14578.0,D,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,BAO_0000219,F,,CHEMBL615182,1.0,,,10116.0,Oocytes,7.0,,Rattus norvegicus
Expert,,60.0,,,80002.0,4787.0,N,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,BAO_0000219,F,,CHEMBL615183,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Intermediate,,61.0,,,80002.0,4787.0,N,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,BAO_0000219,F,,CHEMBL615184,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Intermediate,,62.0,,,80002.0,3547.0,N,,Cytotoxic activity against human ovarian cancer (1A9) cell line,,BAO_0000219,F,,CHEMBL615185,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Intermediate,,63.0,,,80002.0,3547.0,N,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,BAO_0000219,F,,CHEMBL615186,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Intermediate,,64.0,,,80002.0,6726.0,N,,Effective dose of compound against replication of 1A9 cell line was evaluated,,BAO_0000219,F,,CHEMBL615187,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Expert,,65.0,,,80002.0,3455.0,N,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,BAO_0000219,F,,CHEMBL885343,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Intermediate,,66.0,,,80002.0,5726.0,N,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,BAO_0000219,F,,CHEMBL615188,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Intermediate,,67.0,,,80002.0,5726.0,N,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,BAO_0000219,F,,CHEMBL615189,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Intermediate,,68.0,,,80002.0,5726.0,N,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,BAO_0000219,F,,CHEMBL615190,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Intermediate,,69.0,,,80002.0,3395.0,N,,Inhibitory activity against Taxol resistant 1A9 cell lines,,BAO_0000219,F,,CHEMBL615191,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Expert,,70.0,,,80002.0,3415.0,N,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,BAO_0000219,F,,CHEMBL615192,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Expert,,71.0,,,80002.0,3415.0,N,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,BAO_0000219,F,,CHEMBL827083,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Expert,,72.0,,,80002.0,17099.0,N,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,BAO_0000219,F,,CHEMBL615193,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Intermediate,,73.0,,,80002.0,17099.0,N,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,BAO_0000219,F,,CHEMBL615194,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Intermediate,,74.0,,,80002.0,17099.0,N,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,BAO_0000219,F,,CHEMBL615195,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Intermediate,,75.0,,,80002.0,17099.0,N,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,BAO_0000219,F,,CHEMBL615196,1.0,,,9606.0,1A9,1.0,506.0,Homo sapiens
Intermediate,,76.0,,,81072.0,17721.0,N,,Inhibitory concentration against Jurkat cells,,BAO_0000219,F,,CHEMBL615197,1.0,,,9606.0,Jurkat,1.0,503.0,Homo sapiens
Intermediate,,77.0,,,22226.0,1229.0,U,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,BAO_0000019,F,,CHEMBL615198,1.0,,,,,0.0,,
Expert,,78.0,,,100121.0,11347.0,D,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,BAO_0000357,A,,CHEMBL615199,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,79.0,,,11231.0,17117.0,H,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,BAO_0000357,B,,CHEMBL615200,1.0,,,,,8.0,,
Expert,,80.0,,,11231.0,17117.0,H,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,BAO_0000357,B,,CHEMBL615201,1.0,,,,,8.0,,
Expert,,81.0,,,11231.0,17117.0,H,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,BAO_0000357,B,,CHEMBL615202,1.0,,,,,8.0,,
Autocuration,,82.0,,,11231.0,11375.0,H,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",Microsomes,BAO_0000251,B,,CHEMBL615203,1.0,,,5476.0,,8.0,,Candida albicans
Autocuration,,83.0,,,11231.0,11375.0,H,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",Microsomes,BAO_0000251,B,,CHEMBL615204,1.0,,,5476.0,,8.0,,Candida albicans
Autocuration,,84.0,,,11231.0,11375.0,H,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",Microsomes,BAO_0000251,B,,CHEMBL615205,1.0,,,4932.0,,8.0,,Saccharomyces cerevisiae
Autocuration,,85.0,,,11231.0,11375.0,H,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",Microsomes,BAO_0000251,B,,CHEMBL615206,1.0,,,4932.0,,8.0,,Saccharomyces cerevisiae
Autocuration,Liver,86.0,,,12083.0,11375.0,H,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Microsomes,BAO_0000251,B,,CHEMBL615207,1.0,2107.0,,9823.0,,8.0,,Sus scrofa
Autocuration,,87.0,,,11231.0,791.0,H,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,BAO_0000019,B,,CHEMBL827084,1.0,,,10116.0,,8.0,,Rattus norvegicus
Autocuration,,88.0,,,11231.0,791.0,H,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,BAO_0000019,B,,CHEMBL615208,1.0,,,10116.0,,8.0,,Rattus norvegicus
Autocuration,,89.0,,,11231.0,791.0,H,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,BAO_0000019,B,,CHEMBL615209,1.0,,,10116.0,,8.0,,Rattus norvegicus
Autocuration,Liver,90.0,,,12083.0,11375.0,D,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Microsomes,BAO_0000251,B,,CHEMBL615210,1.0,2107.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Liver,91.0,,,12083.0,11375.0,D,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Microsomes,BAO_0000251,B,,CHEMBL615211,1.0,2107.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Liver,92.0,,,12083.0,153.0,D,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Microsomes,BAO_0000251,B,,CHEMBL615212,1.0,2107.0,,10116.0,,9.0,,Rattus norvegicus
Expert,,93.0,,,11377.0,8269.0,H,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,BAO_0000357,B,,CHEMBL615213,1.0,,,,,8.0,,
Expert,,94.0,,,11377.0,8269.0,H,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,BAO_0000357,B,,CHEMBL615273,1.0,,,,,8.0,,
Expert,,95.0,,,81020.0,17653.0,N,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,BAO_0000219,F,,CHEMBL615274,1.0,,,9606.0,HepG2,1.0,726.0,Homo sapiens
Intermediate,,96.0,,,81020.0,14277.0,N,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,BAO_0000219,F,,CHEMBL615275,1.0,,,9606.0,HepG2,1.0,726.0,Homo sapiens
Intermediate,,97.0,,,81020.0,1717.0,N,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,BAO_0000219,F,,CHEMBL615276,1.0,,,9606.0,HepG2,1.0,726.0,Homo sapiens
Intermediate,,98.0,,,81020.0,14091.0,N,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,BAO_0000219,F,,CHEMBL615277,1.0,,,9606.0,HepG2,1.0,726.0,Homo sapiens
Intermediate,,99.0,,,81020.0,14091.0,N,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,BAO_0000219,F,,CHEMBL615326,1.0,,,9606.0,HepG2,1.0,726.0,Homo sapiens
Expert,,100.0,,,50606.0,17653.0,N,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,BAO_0000218,F,,CHEMBL883130,1.0,,,10407.0,,1.0,,Hepatitis B virus
Intermediate,,101.0,,,81020.0,13105.0,N,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,BAO_0000219,F,,CHEMBL884519,1.0,,,9606.0,HepG2,1.0,726.0,Homo sapiens
Intermediate,,102.0,,,81020.0,1717.0,N,,Concentration required to inhibit 50% of 2.2.15 cell line,,BAO_0000219,F,,CHEMBL615327,1.0,,,9606.0,HepG2,1.0,726.0,Homo sapiens
Intermediate,,103.0,,,81020.0,13105.0,N,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,BAO_0000219,A,,CHEMBL615328,1.0,,,9606.0,HepG2,1.0,726.0,Homo sapiens
Intermediate,,104.0,,,50587.0,13600.0,N,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,BAO_0000218,F,,CHEMBL615329,1.0,,,9606.0,2.2.15,1.0,,Homo sapiens
Intermediate,,105.0,,,50587.0,13467.0,N,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,BAO_0000218,F,,CHEMBL615330,1.0,,,9606.0,2.2.15,1.0,,Homo sapiens
Expert,,106.0,,,50606.0,17477.0,N,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,BAO_0000218,F,,CHEMBL615331,1.0,,,10407.0,2.2.15,1.0,,Hepatitis B virus
Intermediate,,107.0,,,50587.0,1593.0,N,,In vitro anti-HBV activity in 2.2.15 cells,,BAO_0000218,F,,CHEMBL615332,1.0,,,9606.0,2.2.15,1.0,,Homo sapiens
Intermediate,,108.0,,,50587.0,1593.0,N,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,BAO_0000218,F,,CHEMBL615333,1.0,,,9606.0,2.2.15,1.0,,Homo sapiens
Intermediate,,109.0,,,50587.0,15089.0,N,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,BAO_0000218,F,,CHEMBL615334,1.0,,,9606.0,2.2.15,1.0,,Homo sapiens
Intermediate,,110.0,,,50587.0,15089.0,N,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,BAO_0000218,F,,CHEMBL615335,1.0,,,9606.0,2.2.15,1.0,,Homo sapiens
Intermediate,,111.0,,,50587.0,1593.0,N,,Cytotoxicity in 2.2.15 cells,,BAO_0000218,F,,CHEMBL615336,1.0,,,9606.0,2.2.15,1.0,,Homo sapiens
Intermediate,,112.0,,,50587.0,1593.0,N,,Cytotoxicity in 2.2.15 cells; Not determined,,BAO_0000218,F,,CHEMBL615337,1.0,,,9606.0,2.2.15,1.0,,Homo sapiens
Intermediate,,113.0,,,50587.0,13600.0,N,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,BAO_0000218,F,,CHEMBL615338,1.0,,,9606.0,2.2.15,1.0,,Homo sapiens
Intermediate,,114.0,,,50587.0,13467.0,N,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,BAO_0000218,F,,CHEMBL615339,1.0,,,9606.0,2.2.15,1.0,,Homo sapiens
Intermediate,,115.0,,,50587.0,13467.0,N,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,BAO_0000218,F,,CHEMBL615340,1.0,,,9606.0,2.2.15,1.0,,Homo sapiens
Intermediate,,116.0,,,81020.0,14764.0,N,,Antiviral activity against HBV was determined in 2.215 cell line,,BAO_0000219,F,,CHEMBL615341,1.0,,,9606.0,HepG2,1.0,726.0,Homo sapiens
Autocuration,,117.0,,,22226.0,6531.0,U,,Inhibition of 20-HETE synthesis in human renal microsomes,Microsomes,BAO_0000251,B,,CHEMBL615342,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,118.0,,,22226.0,17322.0,U,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,BAO_0000019,B,,CHEMBL615343,1.0,,,,,0.0,,
Intermediate,,119.0,,,80612.0,17072.0,N,,Inhibitory concentration against 2008 (ovarian) cells,,BAO_0000219,F,,CHEMBL615344,1.0,,,9606.0,2008,1.0,388.0,Homo sapiens
Intermediate,,120.0,,,80612.0,16936.0,N,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,BAO_0000219,F,,CHEMBL615345,1.0,,,9606.0,2008,1.0,388.0,Homo sapiens
Intermediate,,121.0,,,80612.0,16936.0,N,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,BAO_0000219,F,,CHEMBL615346,1.0,,,9606.0,2008,1.0,388.0,Homo sapiens
Intermediate,,122.0,,,80612.0,17146.0,N,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,BAO_0000219,F,,CHEMBL615347,1.0,,,9606.0,2008,1.0,388.0,Homo sapiens
Intermediate,,123.0,,,80612.0,17146.0,N,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,BAO_0000219,F,,CHEMBL615348,1.0,,,9606.0,2008,1.0,388.0,Homo sapiens
Intermediate,,124.0,,,80613.0,10797.0,N,,In vitro inhibition of 2008/R ovarian cancer cell line,,BAO_0000219,F,,CHEMBL827085,1.0,,,9606.0,2008/R,1.0,561.0,Homo sapiens
Intermediate,,125.0,,,80613.0,10797.0,N,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,BAO_0000219,F,,CHEMBL615349,1.0,,,9606.0,2008/R,1.0,561.0,Homo sapiens
Intermediate,,126.0,,,80614.0,10797.0,N,,In vitro inhibition of 2008/S ovarian cancer cell line,,BAO_0000219,F,,CHEMBL615350,1.0,,,9606.0,2008/S,1.0,389.0,Homo sapiens
Intermediate,,127.0,,,80614.0,10797.0,N,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,BAO_0000219,F,,CHEMBL615351,1.0,,,9606.0,2008/S,1.0,389.0,Homo sapiens
Expert,,128.0,,,100256.0,4823.0,S,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,BAO_0000220,B,,CHEMBL615352,1.0,,,9606.0,,2.0,,Homo sapiens
Intermediate,,129.0,,,100256.0,12912.0,S,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,BAO_0000220,B,,CHEMBL615353,1.0,,,9606.0,,2.0,,Homo sapiens
Expert,,130.0,,,100256.0,2957.0,S,,Inhibition of chymotrypsin-like activity of 20S proteasome,,BAO_0000220,B,,CHEMBL615354,1.0,,,,,2.0,,
Expert,,131.0,,,100256.0,2957.0,S,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,BAO_0000220,B,,CHEMBL615355,1.0,,,,,2.0,,
Intermediate,,132.0,,,100256.0,3260.0,S,,Inhibitory activity against 20S proteosome,,BAO_0000220,B,,CHEMBL615356,1.0,,,,,2.0,,
Autocuration,,133.0,,,22226.0,3451.0,U,,Compound was tested for inhibitory activity against tryptase,,BAO_0000019,B,,CHEMBL615357,1.0,,,9606.0,,0.0,,Homo sapiens
Intermediate,,134.0,,,81020.0,13885.0,N,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,BAO_0000219,F,,CHEMBL615358,1.0,,,9606.0,HepG2,1.0,726.0,Homo sapiens
Intermediate,,135.0,,,81020.0,13885.0,N,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,BAO_0000219,F,,CHEMBL827086,1.0,,,9606.0,HepG2,1.0,726.0,Homo sapiens
Autocuration,,136.0,,,22226.0,3676.0,U,,Compound was tested for the inhibition of Alpha-glucosidase,,BAO_0000019,B,,CHEMBL615359,1.0,,,,,0.0,,
Autocuration,,137.0,,,235.0,6043.0,H,,Inhibitory concentration against human neutrophil elastase (HNE),,BAO_0000357,B,,CHEMBL615360,1.0,,,,,8.0,,
Autocuration,Heart,138.0,,,22226.0,11140.0,U,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,BAO_0000218,F,,CHEMBL615361,1.0,948.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,139.0,,,19640.0,10543.0,H,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000019,F,,CHEMBL615362,1.0,,,,,8.0,,
Expert,,140.0,,,19640.0,10543.0,H,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000019,F,,CHEMBL615363,1.0,,,,,8.0,,
Autocuration,,141.0,,,19640.0,10543.0,H,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000357,B,,CHEMBL615364,1.0,,,,,8.0,,
Expert,,142.0,,,19640.0,10543.0,H,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000019,F,,CHEMBL615365,1.0,,,,,8.0,,
Intermediate,,143.0,,,80360.0,11365.0,N,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,BAO_0000219,F,,CHEMBL615366,1.0,,,10090.0,P338,1.0,524.0,Mus musculus
Intermediate,,144.0,,,80360.0,11365.0,N,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,BAO_0000219,F,,CHEMBL615367,1.0,,,10090.0,P338,1.0,524.0,Mus musculus
Intermediate,,145.0,,,80384.0,11803.0,N,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,BAO_0000219,F,,CHEMBL615368,1.0,,,9606.0,PBL,1.0,554.0,Homo sapiens
Autocuration,,146.0,,,22226.0,11803.0,U,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,BAO_0000019,F,,CHEMBL615369,1.0,,,9940.0,,0.0,,Ovis aries
Autocuration,,147.0,,,22226.0,11803.0,U,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,BAO_0000019,F,,CHEMBL615370,1.0,,,9940.0,,0.0,,Ovis aries
Autocuration,,148.0,,,191.0,12278.0,H,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,BAO_0000357,B,,CHEMBL615673,1.0,,,,,8.0,,
Autocuration,,149.0,,,22226.0,8249.0,U,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,BAO_0000019,F,,CHEMBL615674,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,150.0,,,22226.0,8249.0,U,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,BAO_0000019,F,,CHEMBL615675,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,151.0,,,22226.0,8249.0,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,BAO_0000219,F,,CHEMBL615676,1.0,,,9606.0,CCRF-CEM,0.0,635.0,Homo sapiens
Autocuration,,152.0,,,22226.0,8249.0,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,BAO_0000219,F,,CHEMBL615677,1.0,,,9606.0,CCRF-CEM,0.0,635.0,Homo sapiens
Autocuration,,153.0,,,22226.0,8249.0,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,BAO_0000219,F,,CHEMBL615678,1.0,,,9606.0,CCRF-CEM,0.0,635.0,Homo sapiens
Autocuration,,154.0,,,22226.0,8249.0,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,BAO_0000219,F,,CHEMBL615679,1.0,,,9606.0,CCRF-CEM,0.0,635.0,Homo sapiens
Autocuration,,155.0,,,22226.0,8249.0,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,BAO_0000019,F,,CHEMBL615680,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,156.0,,,22226.0,8249.0,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,BAO_0000019,F,,CHEMBL615681,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,157.0,,,104290.0,16992.0,H,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,BAO_0000249,B,,CHEMBL857972,1.0,,,,,6.0,,
Intermediate,,158.0,,,50264.0,10543.0,N,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,BAO_0000218,F,,CHEMBL857899,1.0,,,1314.0,,1.0,,Streptococcus pyogenes
Intermediate,,159.0,,,50527.0,17833.0,N,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,BAO_0000218,F,,CHEMBL615371,1.0,,,10335.0,,1.0,,Human herpesvirus 3
Expert,,160.0,,,50527.0,17290.0,N,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,BAO_0000218,F,,CHEMBL615372,1.0,,,10335.0,HEL,1.0,468.0,vericilla zoster virus
Intermediate,,161.0,,,50527.0,17290.0,N,,Antiviral activity against 07/1 strain of VZV; ND: No data,,BAO_0000218,F,,CHEMBL615373,1.0,,,10335.0,,1.0,,vericilla zoster virus
Intermediate,,162.0,,,50527.0,17290.0,N,,Antiviral activity against 07/1 strain of VZV; ND=No data,,BAO_0000218,F,,CHEMBL615374,1.0,,,10335.0,,1.0,,vericilla zoster virus
Intermediate,,163.0,,,50145.0,10932.0,N,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,BAO_0000218,F,,CHEMBL615375,1.0,,,561.0,,1.0,,escherichia cloac
Autocuration,,164.0,,,22226.0,9707.0,U,,Ratio of Ki at A2 to Ki at A1 receptors,,BAO_0000019,B,,CHEMBL615376,1.0,,,,,0.0,,
Expert,,165.0,,,11143.0,2346.0,H,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,BAO_0000249,B,,CHEMBL615377,1.0,,,5476.0,,8.0,,Candida albicans
Expert,,166.0,,,18077.0,2205.0,H,,"Inhibition of 1,3-beta-glucan synthase",,BAO_0000357,B,,CHEMBL615378,1.0,,,284593.0,,8.0,,Candida glabrata CBS 138
Intermediate,,167.0,,,80609.0,11900.0,N,,Inhibition of growth of 1-87 human tumor cell line,,BAO_0000219,F,,CHEMBL615379,1.0,,,9606.0,1-87 tumor cell line,1.0,832.0,Homo sapiens
Expert,,168.0,,,12166.0,14864.0,D,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,BAO_0000219,B,,CHEMBL615380,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,169.0,,,100171.0,16474.0,D,,Inhibitory activity against soybean 1-lipoxygenase (SLO),,BAO_0000357,B,,CHEMBL615381,1.0,,,3847.0,,9.0,,Glycine max
Autocuration,,170.0,,,100171.0,16474.0,D,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,BAO_0000357,B,,CHEMBL615382,1.0,,,3847.0,,9.0,,Glycine max
Autocuration,,171.0,,,100171.0,16474.0,D,,% inhibition against soybean 1-lipoxygenase (SLO),,BAO_0000357,B,,CHEMBL615383,1.0,,,3847.0,,9.0,,Glycine max
Autocuration,,172.0,,,100171.0,16474.0,D,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,BAO_0000357,B,,CHEMBL615384,1.0,,,3847.0,,9.0,,Glycine max
Autocuration,,173.0,,,100171.0,3094.0,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,BAO_0000357,B,,CHEMBL615385,1.0,,,3847.0,,9.0,,Glycine max
Autocuration,,174.0,,,100171.0,3094.0,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,BAO_0000357,B,,CHEMBL615386,1.0,,,3847.0,,9.0,,Glycine max
Autocuration,,175.0,,,100171.0,3094.0,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,BAO_0000357,B,,CHEMBL615387,1.0,,,3847.0,,9.0,,Glycine max
Autocuration,,176.0,,,100171.0,3094.0,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,BAO_0000357,B,,CHEMBL615388,1.0,,,3847.0,,9.0,,Glycine max
Autocuration,,177.0,,,100171.0,3094.0,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,BAO_0000357,B,,CHEMBL615214,1.0,,,3847.0,,9.0,,Glycine max
Autocuration,,178.0,,,100171.0,3094.0,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,BAO_0000357,B,,CHEMBL827087,1.0,,,3847.0,,9.0,,Glycine max
Autocuration,,179.0,,,100171.0,3094.0,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,BAO_0000357,B,,CHEMBL615215,1.0,,,3847.0,,9.0,,Glycine max
Autocuration,,180.0,,,100171.0,3094.0,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,BAO_0000357,B,,CHEMBL615216,1.0,,,3847.0,,9.0,,Glycine max
Autocuration,,181.0,,,100171.0,3094.0,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,BAO_0000357,B,,CHEMBL615217,1.0,,,3847.0,,9.0,,Glycine max
Autocuration,,182.0,,,100171.0,3094.0,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,BAO_0000357,B,,CHEMBL615218,1.0,,,3847.0,,9.0,,Glycine max
Autocuration,,183.0,,,100171.0,3094.0,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,BAO_0000357,B,,CHEMBL615219,1.0,,,3847.0,,9.0,,Glycine max
Autocuration,,184.0,,,22226.0,10413.0,U,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,BAO_0000019,B,,CHEMBL615220,1.0,,,10090.0,,0.0,,Mus musculus
Intermediate,,185.0,,,80049.0,16929.0,N,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,BAO_0000219,F,,CHEMBL615221,1.0,,,10090.0,C3H 10T1/2,1.0,294.0,Mus musculus
Intermediate,,186.0,,,22226.0,1229.0,U,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,BAO_0000019,F,,CHEMBL615222,1.0,,,,,0.0,,
Autocuration,,187.0,,,11489.0,16587.0,H,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,BAO_0000357,B,,CHEMBL615223,1.0,,,,,8.0,,
Autocuration,,188.0,,,11862.0,16587.0,H,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,BAO_0000357,B,,CHEMBL615224,1.0,,,,,8.0,,
Autocuration,,189.0,,,11862.0,16587.0,H,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,BAO_0000357,B,,CHEMBL615225,1.0,,,,,8.0,,
Autocuration,,190.0,,,11489.0,16587.0,H,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,BAO_0000357,B,,CHEMBL615226,1.0,,,,,8.0,,
Autocuration,,191.0,,,11862.0,16587.0,H,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,BAO_0000357,B,,CHEMBL615227,1.0,,,,,8.0,,
Expert,,192.0,,,12347.0,8058.0,D,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,BAO_0000019,F,,CHEMBL615228,1.0,,,9913.0,,9.0,,Bos taurus
Expert,,193.0,,,100120.0,9065.0,D,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,BAO_0000357,B,,CHEMBL615229,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,Adrenal gland,194.0,,,100120.0,8865.0,D,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,BAO_0000357,B,,CHEMBL615230,1.0,2369.0,,10116.0,,9.0,,Rattus norvegicus
Expert,,195.0,,,100120.0,9066.0,D,,Inhibition of rat adrenal 11-beta-hydroxylase,,BAO_0000357,B,,CHEMBL615231,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,196.0,,,100120.0,8394.0,D,,Inhibition of rat adrenal 11-beta-hydroxylase,,BAO_0000357,B,,CHEMBL884520,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,197.0,,,100120.0,8394.0,D,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,BAO_0000357,B,,CHEMBL615232,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,198.0,,,10328.0,6431.0,H,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,BAO_0000019,B,,CHEMBL615233,1.0,,,,,8.0,,
Autocuration,,199.0,,,11490.0,6431.0,H,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,BAO_0000357,B,,CHEMBL827088,1.0,,,,,8.0,,
Autocuration,,200.0,,,11490.0,6431.0,H,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,BAO_0000357,B,,CHEMBL615234,1.0,,,,,8.0,,
Autocuration,,201.0,,,11134.0,9295.0,H,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,BAO_0000019,F,,CHEMBL615235,1.0,,,,,8.0,,
Autocuration,,202.0,,,12052.0,10193.0,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,BAO_0000019,B,,CHEMBL615236,1.0,,,,,8.0,,
Autocuration,,203.0,,,11134.0,13622.0,H,,Compound was tested in vitro for inhibition of 12-LO human platelet,,BAO_0000019,B,,CHEMBL615237,1.0,,,,,8.0,,
Autocuration,,204.0,,,11134.0,12079.0,H,,Inhibitory concentration against human platelet 12-lipoxygenase,,BAO_0000019,F,,CHEMBL615238,1.0,,,,,8.0,,
Autocuration,,205.0,,,11134.0,13622.0,H,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,BAO_0000019,B,,CHEMBL615239,1.0,,,,,8.0,,
Autocuration,,206.0,,,11134.0,12079.0,D,,Inhibitory concentration against human platelet 12-lipoxygenase,,BAO_0000019,F,,CHEMBL615240,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,207.0,,,11835.0,13500.0,H,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,BAO_0000019,B,,CHEMBL615241,1.0,,,,,8.0,,
Expert,,208.0,,,11601.0,13723.0,H,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,BAO_0000357,B,,CHEMBL615242,1.0,,,,,8.0,,
Autocuration,,209.0,,,11134.0,16474.0,H,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,BAO_0000019,B,,CHEMBL615243,1.0,,,,,8.0,,
Autocuration,,210.0,,,11134.0,1630.0,H,,Inhibitory activity against human platelet 12-lipoxygenase,,BAO_0000019,B,,CHEMBL615244,1.0,,,,,8.0,,
Autocuration,,211.0,,,11134.0,167.0,H,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,BAO_0000019,B,,CHEMBL615245,1.0,,,,,8.0,,
Autocuration,,212.0,,,11134.0,16474.0,H,,% inhibition against human platelet 12-lipoxygenase (12-HLO),,BAO_0000019,B,,CHEMBL615246,1.0,,,,,8.0,,
Autocuration,,213.0,,,11134.0,167.0,H,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,BAO_0000019,B,,CHEMBL615247,1.0,,,,,8.0,,
Autocuration,,214.0,,,11134.0,16474.0,H,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,BAO_0000019,B,,CHEMBL615248,1.0,,,,,8.0,,
Autocuration,,215.0,,,11601.0,10091.0,H,,Inhibitory activity towards porcine 12-lipoxygenase,,BAO_0000357,B,,CHEMBL615249,1.0,,,,,8.0,,
Autocuration,,216.0,,,11601.0,11966.0,H,,Tested for inhibition against porcine 12-LO,,BAO_0000357,B,,CHEMBL615250,1.0,,,,,8.0,,
Autocuration,,217.0,,,12052.0,951.0,H,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,BAO_0000019,B,,CHEMBL615251,1.0,,,,,8.0,,
Autocuration,,218.0,,,12052.0,10997.0,H,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,BAO_0000019,B,,CHEMBL615252,1.0,,,,,8.0,,
Expert,,219.0,,,12052.0,10193.0,H,,In vitro inhibition of rat platelet 12-lipoxygenase,,BAO_0000019,B,,CHEMBL828340,1.0,,,,,8.0,,
Autocuration,,220.0,,,12052.0,10193.0,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,BAO_0000019,B,,CHEMBL615253,1.0,,,,,8.0,,
Autocuration,,221.0,,,12052.0,10193.0,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,BAO_0000019,B,,CHEMBL615254,1.0,,,,,8.0,,
Autocuration,,222.0,,,12052.0,10193.0,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,BAO_0000019,B,,CHEMBL615255,1.0,,,,,8.0,,
Autocuration,,223.0,,,12052.0,10193.0,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,BAO_0000019,B,,CHEMBL615256,1.0,,,,,8.0,,
Autocuration,,224.0,,,12052.0,10193.0,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,BAO_0000019,B,,CHEMBL615257,1.0,,,,,8.0,,
Autocuration,,225.0,,,12052.0,11087.0,H,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,BAO_0000019,B,,CHEMBL615258,1.0,,,,,8.0,,
Intermediate,,226.0,,,80007.0,15569.0,N,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,BAO_0000219,F,,CHEMBL615259,1.0,,,9606.0,41M,1.0,621.0,Homo sapiens
Expert,,227.0,,,80007.0,12989.0,N,,In vitro antitumor activity against 41M cell line.,,BAO_0000219,F,,CHEMBL615260,1.0,,,9606.0,41M,1.0,621.0,Homo sapiens
Intermediate,,228.0,,,80007.0,16745.0,N,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,BAO_0000219,F,,CHEMBL615261,1.0,,,9606.0,41M,1.0,621.0,Homo sapiens
Intermediate,,229.0,,,80007.0,15569.0,N,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,BAO_0000219,F,,CHEMBL615262,1.0,,,9606.0,41M,1.0,621.0,Homo sapiens
Expert,,230.0,,,80007.0,12989.0,N,,In vitro antitumor activity against 41McisR cell line.,,BAO_0000219,F,,CHEMBL615263,1.0,,,9606.0,41M,1.0,621.0,Homo sapiens
Expert,,231.0,,,80007.0,12989.0,N,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,BAO_0000219,F,,CHEMBL838393,1.0,,,9606.0,41M,1.0,621.0,Homo sapiens
Intermediate,,232.0,,,80007.0,16745.0,N,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,BAO_0000219,F,,CHEMBL615264,1.0,,,9606.0,41M,1.0,621.0,Homo sapiens
Expert,,233.0,,,84.0,6210.0,D,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,BAO_0000357,B,,CHEMBL615265,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,234.0,,,68.0,6210.0,D,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,BAO_0000357,B,,CHEMBL615266,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,235.0,,,68.0,6226.0,H,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,BAO_0000357,B,,CHEMBL615267,1.0,,,,,8.0,,
Expert,,236.0,,,10201.0,17855.0,H,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,BAO_0000357,B,,CHEMBL615268,1.0,,,,,8.0,,
Expert,,237.0,,,10201.0,17855.0,H,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,BAO_0000357,B,,CHEMBL615269,1.0,,,,,8.0,,
Expert,,238.0,,,10201.0,17855.0,H,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,BAO_0000357,B,,CHEMBL615270,1.0,,,,,8.0,,
Autocuration,,239.0,,,12220.0,10413.0,H,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,BAO_0000357,B,,CHEMBL615271,1.0,,,,,8.0,,
Autocuration,,240.0,,,11303.0,10413.0,H,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,BAO_0000357,B,,CHEMBL615272,1.0,,,562.0,,8.0,,Escherichia coli
Autocuration,,241.0,,,11303.0,10413.0,H,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,BAO_0000357,B,,CHEMBL615103,1.0,,,562.0,,8.0,,Escherichia coli
Autocuration,,242.0,,,11303.0,10413.0,H,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,BAO_0000357,B,,CHEMBL615104,1.0,,,562.0,,8.0,,Escherichia coli
Autocuration,,243.0,,,12220.0,10413.0,H,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,BAO_0000357,B,,CHEMBL615105,1.0,,,,,8.0,,
Autocuration,,244.0,,,12220.0,10413.0,H,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,BAO_0000357,B,,CHEMBL872866,1.0,,,,,8.0,,
Autocuration,,245.0,,,11303.0,7587.0,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,BAO_0000357,B,,CHEMBL615106,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,246.0,,,11303.0,7587.0,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,BAO_0000019,B,,CHEMBL615107,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,247.0,,,11303.0,7587.0,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,BAO_0000357,B,,CHEMBL615108,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,248.0,,,11303.0,7587.0,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,BAO_0000357,B,,CHEMBL615109,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,249.0,,,11303.0,7587.0,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,BAO_0000357,B,,CHEMBL615110,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,250.0,,,11303.0,7587.0,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,BAO_0000019,B,,CHEMBL840105,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,251.0,,,11303.0,7587.0,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,BAO_0000019,B,,CHEMBL615111,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,252.0,,,11303.0,7587.0,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,BAO_0000019,B,,CHEMBL615112,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,253.0,,,11303.0,7587.0,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,BAO_0000019,B,,CHEMBL615113,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,254.0,,,11303.0,7587.0,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,BAO_0000019,B,,CHEMBL615114,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,255.0,,,11303.0,7587.0,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,BAO_0000357,B,,CHEMBL615115,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,256.0,,,11303.0,7587.0,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,BAO_0000019,B,,CHEMBL615116,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,257.0,,,11303.0,7323.0,H,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,BAO_0000357,B,,CHEMBL615698,1.0,,,,,8.0,,
Autocuration,,258.0,,,22226.0,7587.0,U,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,BAO_0000019,B,,CHEMBL615699,1.0,,,9823.0,,0.0,,Sus scrofa
Autocuration,,259.0,,,22226.0,7587.0,U,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,BAO_0000019,B,,CHEMBL615700,1.0,,,9823.0,,0.0,,Sus scrofa
Expert,,260.0,,,100249.0,13750.0,H,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,BAO_0000357,B,,CHEMBL615701,1.0,,,4932.0,,8.0,,Saccharomyces cerevisiae
Autocuration,,261.0,,,22226.0,7662.0,U,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,BAO_0000019,B,,CHEMBL615702,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,262.0,,,22226.0,7662.0,U,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,BAO_0000019,B,,CHEMBL615703,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,263.0,,,22226.0,7662.0,U,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,BAO_0000019,B,,CHEMBL615704,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,264.0,,,104698.0,12211.0,H,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,BAO_0000019,F,,CHEMBL615705,1.0,,,,,6.0,,
Autocuration,,265.0,,,104698.0,12211.0,H,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,BAO_0000019,F,,CHEMBL615706,1.0,,,,,6.0,,
Intermediate,Ileum,266.0,,,20033.0,12211.0,D,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,BAO_0000221,F,,CHEMBL615707,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Expert,,267.0,,,10623.0,12211.0,H,,Stimulatory activity of intragastric pressure was tested in the rat,,BAO_0000019,F,,CHEMBL615708,1.0,,,,,8.0,,
Autocuration,,268.0,,,121.0,15453.0,H,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,BAO_0000357,B,,CHEMBL615709,1.0,,,,,8.0,,
Autocuration,,269.0,,,22226.0,11884.0,U,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,BAO_0000218,F,,CHEMBL615710,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,270.0,,,12688.0,7185.0,H,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,BAO_0000019,F,,CHEMBL615711,1.0,,,,,8.0,,
Expert,,271.0,,,121.0,6876.0,D,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,BAO_0000357,B,,CHEMBL615712,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,272.0,,,121.0,6876.0,D,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,BAO_0000357,B,,CHEMBL836325,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,273.0,,,12198.0,11863.0,H,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,BAO_0000019,F,,CHEMBL615713,1.0,,,,,8.0,,
Autocuration,,274.0,,,12198.0,11863.0,H,,Inhibition constant of high-affinity 5-HT uptake,,BAO_0000357,B,,CHEMBL615714,1.0,,,,,8.0,,
Autocuration,,275.0,,,12198.0,11863.0,H,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,BAO_0000019,F,,CHEMBL615715,1.0,,,,,8.0,,
Autocuration,,276.0,,,12198.0,11863.0,H,,Maximum rate was determined for high affinity transport of 5-HT,,BAO_0000019,F,,CHEMBL615716,1.0,,,,,8.0,,
Autocuration,,277.0,,,104714.0,4639.0,H,,Compound was tested for agonistic activity against 5-HT uptake,,BAO_0000019,F,,CHEMBL615717,1.0,,,,,4.0,,
Expert,,278.0,,,10577.0,15796.0,H,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,BAO_0000019,B,,CHEMBL881818,1.0,,,,,8.0,,
Expert,,279.0,,,105.0,15796.0,H,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,BAO_0000357,B,,CHEMBL884540,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,280.0,,,104744.0,12801.0,D,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,BAO_0000224,B,,CHEMBL615718,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,281.0,,,104744.0,12801.0,H,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,BAO_0000224,B,,CHEMBL615719,1.0,,,,,4.0,,
Autocuration,,282.0,,,104744.0,12120.0,H,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,Membranes,BAO_0000249,B,,CHEMBL615720,1.0,,,,,4.0,,
Autocuration,,283.0,,,104744.0,12120.0,H,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,Membranes,BAO_0000249,B,,CHEMBL615721,1.0,,,,,4.0,,
Autocuration,,284.0,,,104744.0,11963.0,H,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,B,,CHEMBL615722,1.0,,,,,4.0,,
Autocuration,,285.0,,,51.0,11701.0,H,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,BAO_0000019,F,,CHEMBL615723,1.0,,,,,8.0,,
Autocuration,Hippocampus,286.0,,,51.0,9995.0,H,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,B,,CHEMBL615724,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,287.0,,,51.0,9995.0,H,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,B,,CHEMBL615725,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,288.0,,,51.0,9995.0,H,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,B,,CHEMBL615726,1.0,10000000.0,,,,8.0,,
Autocuration,,289.0,,,10576.0,16394.0,H,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,BAO_0000218,F,In vivo,CHEMBL615727,1.0,,,,,8.0,,
Intermediate,,290.0,,,105570.0,11574.0,D,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,BAO_0000019,F,,CHEMBL615728,1.0,,,10141.0,,9.0,,Cavia porcellus
Autocuration,,291.0,,,279.0,15779.0,H,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,B,,CHEMBL857971,1.0,,,,CHO,8.0,449.0,
Autocuration,,292.0,,,107.0,15363.0,H,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL615729,1.0,,,,,8.0,,
Expert,,293.0,,,12687.0,15363.0,D,,Efficacy against 5-hydroxytryptamine 2A receptor,,BAO_0000019,F,,CHEMBL615730,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,294.0,,,12687.0,15329.0,H,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,BAO_0000019,F,,CHEMBL615731,1.0,,,,,8.0,,
Expert,,295.0,,,12687.0,15329.0,H,,Relative potency towards 5-HT2A receptor of rat tail artery,,BAO_0000019,F,,CHEMBL615732,1.0,,,,,8.0,,
Expert,,296.0,,,12687.0,15329.0,H,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,BAO_0000019,F,,CHEMBL615733,1.0,,,,,8.0,,
Expert,,297.0,,,12687.0,15329.0,H,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,BAO_0000019,F,,CHEMBL615734,1.0,,,,,8.0,,
Autocuration,,298.0,,,12687.0,15329.0,H,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,BAO_0000019,F,,CHEMBL615735,1.0,,,,,8.0,,
Expert,,299.0,,,12687.0,15329.0,H,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,BAO_0000019,F,,CHEMBL615736,1.0,,,,,8.0,,
Intermediate,Ileum,300.0,,,20033.0,273.0,D,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,BAO_0000221,F,,CHEMBL615737,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,301.0,,,20033.0,273.0,D,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,BAO_0000221,F,,CHEMBL615738,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,302.0,,,20033.0,273.0,D,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,BAO_0000221,F,,CHEMBL615739,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Autocuration,,303.0,,,10623.0,12092.0,H,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,BAO_0000357,B,,CHEMBL615278,1.0,,,,,8.0,,
Expert,,304.0,,,10623.0,1317.0,D,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,BAO_0000019,F,,CHEMBL615279,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,305.0,,,168.0,12409.0,H,,Binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL615280,1.0,,,,,8.0,,
Autocuration,,306.0,,,22226.0,11126.0,U,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,BAO_0000019,B,,CHEMBL615281,1.0,,,9031.0,,0.0,,Gallus gallus
Autocuration,,307.0,,,22226.0,11126.0,U,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,BAO_0000019,F,,CHEMBL615282,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,308.0,,,22226.0,11126.0,U,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,BAO_0000019,F,,CHEMBL615283,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,309.0,,,80156.0,11126.0,N,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,BAO_0000219,B,,CHEMBL615284,1.0,,,9606.0,HL-60,1.0,649.0,Homo sapiens
Autocuration,,310.0,,,22226.0,11126.0,U,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,BAO_0000019,B,,CHEMBL615285,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,311.0,,,22226.0,11126.0,U,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,BAO_0000019,B,,CHEMBL615286,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,312.0,,,104703.0,17807.0,D,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,BAO_0000219,B,,CHEMBL615287,1.0,,,9606.0,Oocytes,7.0,,Homo sapiens
Intermediate,,313.0,,,100256.0,16575.0,S,,Chymotryptic inhibitory activity against 26S proteasome,,BAO_0000220,F,,CHEMBL615288,1.0,,,,,2.0,,
Intermediate,,314.0,,,100256.0,15407.0,S,,Inhibitory activity against 26S proteasome degradation of IkB,,BAO_0000220,B,,CHEMBL615289,1.0,,,,,2.0,,
Intermediate,,315.0,,,81034.0,10797.0,N,,In vitro inhibition of 2780/DOX ovarian cancer cell line,,BAO_0000219,F,,CHEMBL615290,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,316.0,,,81034.0,10797.0,N,,In vitro inhibition of 2780/S ovarian cancer cell line,,BAO_0000219,F,,CHEMBL884522,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Autocuration,,317.0,,,22226.0,3469.0,U,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,BAO_0000019,F,,CHEMBL615291,1.0,,,9606.0,,0.0,,Homo sapiens
Intermediate,,318.0,,,22222.0,16037.0,M,,Association constant for binding to AATT 28-mer AATT hairpin,,BAO_0000225,B,,CHEMBL615292,1.0,,,,,3.0,,
Intermediate,,319.0,,,22222.0,16037.0,M,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,BAO_0000225,B,,CHEMBL615293,1.0,,,,,3.0,,
Intermediate,,320.0,,,22222.0,16037.0,M,,Reaction Rate Parameter for 28-mer AATT hairpin,,BAO_0000225,B,,CHEMBL615294,1.0,,,,,3.0,,
Intermediate,,321.0,,,22222.0,16037.0,M,,Reaction Rate Parameter for 28-mer AATT hairpin,,BAO_0000225,B,,CHEMBL615295,1.0,,,,,3.0,,
Autocuration,,322.0,,,22226.0,16524.0,U,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,BAO_0000019,F,,CHEMBL825021,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,323.0,,,22226.0,16524.0,U,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,BAO_0000019,F,,CHEMBL615296,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,324.0,,,22226.0,16524.0,U,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,BAO_0000019,F,,CHEMBL615297,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,325.0,,,22226.0,16758.0,U,,Cytotoxicity against cell line 2SC/20 determined by MTT test,,BAO_0000019,F,,CHEMBL615298,1.0,,,10029.0,,0.0,,Cricetulus griseus
Autocuration,,326.0,,,22226.0,16758.0,U,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,BAO_0000019,F,,CHEMBL615299,1.0,,,10029.0,,0.0,,Cricetulus griseus
Autocuration,,327.0,,,22226.0,16758.0,U,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,BAO_0000019,F,,CHEMBL615300,1.0,,,10029.0,,0.0,,Cricetulus griseus
Autocuration,,328.0,,,241.0,14360.0,H,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,BAO_0000357,B,,CHEMBL615301,1.0,,,,,8.0,,
Expert,,329.0,,,241.0,14360.0,D,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,BAO_0000357,B,,CHEMBL615302,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,330.0,,,22226.0,9964.0,U,,Selectivity ratio of ID50 in liver and heart,,BAO_0000019,B,,CHEMBL615303,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,331.0,,,12132.0,9964.0,H,,"Selectivity, ratio of relative ID50 in liver and heart",,BAO_0000019,B,,CHEMBL615304,1.0,,,,,8.0,,
Autocuration,,332.0,,,12132.0,9964.0,H,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,BAO_0000019,B,,CHEMBL615305,1.0,,,,,8.0,,
Autocuration,,333.0,,,12132.0,9964.0,H,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,B,,CHEMBL615306,1.0,,,,,8.0,,
Autocuration,,334.0,,,12132.0,9964.0,H,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,B,,CHEMBL615307,1.0,,,,,8.0,,
Autocuration,,335.0,,,12132.0,9964.0,H,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,B,In vivo,CHEMBL615308,1.0,,,,,8.0,,
Autocuration,,336.0,,,12132.0,9964.0,H,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,F,In vivo,CHEMBL615309,1.0,,,,,8.0,,
Autocuration,,337.0,,,22226.0,9964.0,U,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,BAO_0000019,B,,CHEMBL615310,1.0,,,,,0.0,,
Autocuration,,338.0,,,12132.0,9964.0,H,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,BAO_0000019,B,,CHEMBL615311,1.0,,,,,8.0,,
Autocuration,,339.0,,,22226.0,9964.0,U,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,BAO_0000019,B,,CHEMBL615312,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,340.0,,,12132.0,9964.0,H,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,BAO_0000019,B,,CHEMBL615313,1.0,,,,,8.0,,
Autocuration,,341.0,,,12132.0,9964.0,H,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,BAO_0000019,F,,CHEMBL615314,1.0,,,,,8.0,,
Autocuration,,342.0,,,12132.0,9964.0,H,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,BAO_0000019,B,,CHEMBL615315,1.0,,,,,8.0,,
Autocuration,,343.0,,,22226.0,9964.0,U,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,BAO_0000218,B,,CHEMBL615316,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,344.0,,,12132.0,9964.0,H,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,BAO_0000218,B,In vivo,CHEMBL615317,1.0,,,,,8.0,,
Autocuration,,345.0,,,12132.0,9964.0,H,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,B,,CHEMBL615318,1.0,,,,,8.0,,
Autocuration,,346.0,,,22226.0,9964.0,U,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,BAO_0000218,B,,CHEMBL615319,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,347.0,,,12132.0,9964.0,H,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,BAO_0000019,B,,CHEMBL615320,1.0,,,,,8.0,,
Autocuration,,348.0,,,12132.0,9964.0,H,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,BAO_0000019,F,,CHEMBL615321,1.0,,,,,8.0,,
Autocuration,,349.0,,,22226.0,3796.0,U,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,BAO_0000019,B,,CHEMBL615322,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,350.0,,,19690.0,4251.0,H,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,BAO_0000357,B,,CHEMBL615323,1.0,,,562.0,,8.0,,Escherichia coli
Autocuration,,351.0,,,19690.0,4251.0,H,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,BAO_0000357,B,,CHEMBL615407,1.0,,,562.0,,8.0,,Escherichia coli
Autocuration,,352.0,,,19690.0,4251.0,H,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,BAO_0000357,B,,CHEMBL857267,1.0,,,562.0,,8.0,,Escherichia coli
Autocuration,,353.0,,,19690.0,4251.0,H,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,BAO_0000357,B,,CHEMBL615408,1.0,,,562.0,,8.0,,Escherichia coli
Autocuration,,354.0,,,19690.0,166.0,H,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,BAO_0000357,B,,CHEMBL615409,1.0,,,,,8.0,,
Autocuration,,355.0,,,19690.0,17861.0,H,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,BAO_0000357,B,,CHEMBL615410,1.0,,,,,8.0,,
Autocuration,,356.0,,,19690.0,166.0,H,,Inhibition constant against 3-dehydroquinate synthase,,BAO_0000357,B,,CHEMBL615411,1.0,,,,,8.0,,
Autocuration,,357.0,,,19690.0,166.0,H,,Association rate constant against 3-dehydroquinate synthase,,BAO_0000357,B,,CHEMBL615412,1.0,,,,,8.0,,
Autocuration,,358.0,,,19690.0,166.0,H,,Rate constant against 3-dehydroquinate synthase,,BAO_0000357,B,,CHEMBL615413,1.0,,,,,8.0,,
Autocuration,,359.0,,,22226.0,3548.0,U,,Inhibitory activity against fuc-TVII,,BAO_0000019,B,,CHEMBL615414,1.0,,,,,0.0,,
Autocuration,Liver,360.0,,,12236.0,9877.0,D,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,BAO_0000251,B,,CHEMBL615415,1.0,2107.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Liver,361.0,,,12236.0,9877.0,D,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,BAO_0000251,B,,CHEMBL615416,1.0,2107.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Liver,362.0,,,12236.0,9877.0,D,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,BAO_0000251,B,,CHEMBL615417,1.0,2107.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Liver,363.0,,,12236.0,9877.0,D,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,BAO_0000251,B,,CHEMBL615418,1.0,2107.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Liver,364.0,,,12236.0,9877.0,D,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,BAO_0000251,B,,CHEMBL615419,1.0,2107.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Liver,365.0,,,12236.0,9877.0,D,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Microsomes,BAO_0000251,B,,CHEMBL615420,1.0,2107.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Liver,366.0,,,12236.0,9877.0,D,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Microsomes,BAO_0000251,B,,CHEMBL615421,1.0,2107.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Liver,367.0,,,12236.0,9877.0,D,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Microsomes,BAO_0000251,B,,CHEMBL615422,1.0,2107.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Liver,368.0,,,12236.0,9877.0,D,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Microsomes,BAO_0000251,B,,CHEMBL615423,1.0,2107.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Liver,369.0,,,12236.0,9877.0,D,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Microsomes,BAO_0000251,B,,CHEMBL872868,1.0,2107.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Liver,370.0,,,12236.0,9877.0,D,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Microsomes,BAO_0000251,B,,CHEMBL615424,1.0,2107.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,371.0,,,104832.0,3003.0,H,,Inhibitory activity against 3-phosphoglycerate kinase.,,BAO_0000224,B,,CHEMBL825022,1.0,,,,,4.0,,
Autocuration,,372.0,,,104832.0,3003.0,H,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,BAO_0000224,B,,CHEMBL615425,1.0,,,,,4.0,,
Autocuration,,373.0,,,104832.0,3003.0,H,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,BAO_0000224,B,,CHEMBL615426,1.0,,,,,4.0,,
Expert,,374.0,,,10612.0,17185.0,D,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,BAO_0000357,B,,CHEMBL615427,1.0,,,9606.0,,9.0,,Homo sapiens
Intermediate,,375.0,,,80616.0,6072.0,N,,Cytotoxicity on 3677 melanoma cells,,BAO_0000219,F,,CHEMBL615428,1.0,,,9606.0,3677 melanoma cell line,1.0,844.0,Homo sapiens
Intermediate,,376.0,,,80616.0,6072.0,N,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,BAO_0000219,F,,CHEMBL615429,1.0,,,9606.0,3677 melanoma cell line,1.0,844.0,Homo sapiens
Intermediate,,377.0,,,80617.0,5018.0,N,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,BAO_0000219,F,,CHEMBL615430,1.0,,,10090.0,MC-38,1.0,700.0,Mus musculus
Intermediate,,378.0,,,22226.0,2852.0,U,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,BAO_0000019,F,,CHEMBL615431,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,379.0,,,22226.0,8663.0,U,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,BAO_0000218,F,,CHEMBL615432,1.0,,,,B16,0.0,798.0,
Autocuration,,380.0,,,22226.0,8663.0,U,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,BAO_0000218,F,,CHEMBL615433,1.0,,,,B16,0.0,798.0,
Expert,,381.0,,,12464.0,3245.0,D,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,BAO_0000019,F,,CHEMBL615434,1.0,,,12131.0,,9.0,,Human rhinovirus 14
Intermediate,,382.0,,,50085.0,3245.0,N,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,BAO_0000218,F,,CHEMBL615435,1.0,,,169066.0,,1.0,,Human rhinovirus sp.
Intermediate,,383.0,,,50679.0,3877.0,N,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,BAO_0000218,F,,CHEMBL615436,1.0,,,169066.0,,1.0,,human rhinovirus type 14
Intermediate,,384.0,,,50679.0,3877.0,N,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,BAO_0000218,F,,CHEMBL615437,1.0,,,169066.0,,1.0,,human rhinovirus type 14
Expert,,385.0,,,12464.0,5861.0,D,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,BAO_0000019,F,,CHEMBL615438,1.0,,,12131.0,,9.0,,Human rhinovirus 14
Expert,,386.0,,,12464.0,5861.0,D,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,BAO_0000019,F,,CHEMBL615439,1.0,,,12131.0,,9.0,,Human rhinovirus 14
Expert,,387.0,,,12464.0,5861.0,D,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,BAO_0000019,F,,CHEMBL615440,1.0,,,12131.0,,9.0,,Human rhinovirus 14
Expert,,388.0,,,12464.0,5861.0,D,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,BAO_0000019,F,,CHEMBL615441,1.0,,,12131.0,,9.0,,Human rhinovirus 14
Intermediate,,389.0,,,50665.0,13748.0,N,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,BAO_0000218,F,,CHEMBL615641,1.0,,,12059.0,,1.0,,Enterovirus
Intermediate,,390.0,,,50665.0,13748.0,N,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,BAO_0000218,F,,CHEMBL872065,1.0,,,12059.0,,1.0,,Enterovirus
Intermediate,,391.0,,,50665.0,13748.0,N,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,BAO_0000218,F,,CHEMBL825023,1.0,,,12059.0,,1.0,,Enterovirus
Intermediate,,392.0,,,50665.0,13748.0,N,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,BAO_0000218,F,,CHEMBL615642,1.0,,,12059.0,,1.0,,Enterovirus
Expert,,393.0,,,12464.0,13748.0,H,,Inhibition of human rhinovirus 3C protease,,BAO_0000357,B,,CHEMBL615643,1.0,,,147712.0,,8.0,,Human rhinovirus B
Autocuration,,394.0,,,22226.0,17699.0,U,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,BAO_0000019,B,,CHEMBL615644,1.0,,,9606.0,,0.0,,Homo sapiens
Intermediate,,395.0,,,80619.0,7145.0,N,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,BAO_0000218,F,,CHEMBL615645,1.0,,,10090.0,3EM 37,1.0,833.0,Mus musculus
Intermediate,,396.0,,,80619.0,7145.0,N,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,BAO_0000218,F,,CHEMBL615646,1.0,,,10090.0,3EM 37,1.0,833.0,Mus musculus
Intermediate,,397.0,,,80619.0,7145.0,N,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,BAO_0000218,F,,CHEMBL615647,1.0,,,10090.0,3EM 37,1.0,833.0,Mus musculus
Intermediate,,398.0,,,80619.0,7145.0,N,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,BAO_0000218,F,,CHEMBL615648,1.0,,,10090.0,3EM 37,1.0,833.0,Mus musculus
Intermediate,,399.0,,,80619.0,7145.0,N,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,BAO_0000218,F,,CHEMBL615649,1.0,,,10090.0,3EM 37,1.0,833.0,Mus musculus
Intermediate,,400.0,,,80619.0,7145.0,N,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,BAO_0000218,F,,CHEMBL615650,1.0,,,10090.0,3EM 37,1.0,833.0,Mus musculus
Intermediate,,401.0,,,80620.0,5325.0,N,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,BAO_0000218,F,,CHEMBL615651,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,402.0,,,80620.0,5325.0,N,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,BAO_0000218,F,,CHEMBL615652,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Expert,,403.0,,,80620.0,5325.0,N,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,BAO_0000218,F,,CHEMBL615653,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,404.0,,,80620.0,16169.0,N,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,BAO_0000219,F,,CHEMBL615654,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,405.0,,,80620.0,16169.0,N,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,BAO_0000219,F,,CHEMBL615655,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,406.0,,,80620.0,16169.0,N,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,BAO_0000219,F,,CHEMBL825024,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,407.0,,,80620.0,16169.0,N,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,BAO_0000219,F,,CHEMBL615656,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,408.0,,,80620.0,16169.0,N,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,BAO_0000219,F,,CHEMBL615657,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,409.0,,,80620.0,16169.0,N,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,BAO_0000219,F,,CHEMBL615658,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,410.0,,,80620.0,16169.0,N,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,BAO_0000219,F,,CHEMBL615659,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,411.0,,,80620.0,16169.0,N,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,BAO_0000219,F,,CHEMBL615660,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,412.0,,,80620.0,16169.0,N,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,BAO_0000219,F,,CHEMBL615661,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,413.0,,,80620.0,16169.0,N,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,BAO_0000219,F,,CHEMBL615662,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,414.0,,,80620.0,16169.0,N,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,BAO_0000219,F,,CHEMBL615663,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,415.0,,,80620.0,16169.0,N,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,BAO_0000219,F,,CHEMBL615664,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,416.0,,,80620.0,16169.0,N,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,BAO_0000219,F,,CHEMBL615665,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,417.0,,,80620.0,16169.0,N,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,BAO_0000219,F,,CHEMBL615666,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,418.0,,,80620.0,16169.0,N,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,BAO_0000219,F,,CHEMBL615667,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,419.0,,,80620.0,16169.0,N,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,BAO_0000219,F,,CHEMBL615668,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,420.0,,,80620.0,16169.0,N,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,BAO_0000219,F,,CHEMBL615669,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,421.0,,,80620.0,16169.0,N,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,BAO_0000219,F,,CHEMBL615670,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,422.0,,,80620.0,16169.0,N,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,BAO_0000219,F,,CHEMBL836739,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,423.0,,,80620.0,16169.0,N,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,BAO_0000219,F,,CHEMBL615671,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,424.0,,,80620.0,16169.0,N,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,BAO_0000219,F,,CHEMBL615672,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,425.0,,,80620.0,16169.0,N,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,BAO_0000219,F,,CHEMBL615791,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,426.0,,,80620.0,16169.0,N,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,BAO_0000219,F,,CHEMBL615792,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,427.0,,,80620.0,16169.0,N,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,BAO_0000219,F,,CHEMBL615793,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,428.0,,,80620.0,16169.0,N,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,BAO_0000219,F,,CHEMBL615794,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,429.0,,,80620.0,16169.0,N,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,BAO_0000219,F,,CHEMBL615795,1.0,,,10090.0,3LL cell line,1.0,847.0,Mus musculus
Intermediate,,430.0,,,80621.0,15547.0,N,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,BAO_0000219,F,,CHEMBL615590,1.0,,,9606.0,3LLD122,1.0,971.0,Homo sapiens
Autocuration,,431.0,,,22226.0,8663.0,U,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,BAO_0000218,F,,CHEMBL615591,1.0,,,,,0.0,,
Autocuration,,432.0,,,22226.0,8663.0,U,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,BAO_0000218,F,,CHEMBL615592,1.0,,,,,0.0,,
Autocuration,,433.0,,,22226.0,8663.0,U,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,BAO_0000218,F,,CHEMBL615593,1.0,,,,,0.0,,
Autocuration,,434.0,,,22226.0,8663.0,U,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,BAO_0000218,F,,CHEMBL615594,1.0,,,,,0.0,,
Intermediate,,435.0,,,80951.0,4504.0,N,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,BAO_0000219,F,,CHEMBL615595,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,436.0,,,80951.0,4504.0,N,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,BAO_0000219,F,,CHEMBL615596,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,437.0,,,11169.0,12695.0,H,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,BAO_0000219,F,,CHEMBL615597,1.0,,,,NIH3T3,8.0,723.0,
Intermediate,,438.0,,,80951.0,12695.0,N,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,BAO_0000219,F,,CHEMBL615598,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,439.0,,,80951.0,12695.0,N,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,BAO_0000219,F,,CHEMBL615599,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,440.0,,,80951.0,17642.0,N,,Effective dose against murine 3T3 fibroblasts cells,,BAO_0000219,F,,CHEMBL615600,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,441.0,,,80951.0,17642.0,N,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,BAO_0000219,F,,CHEMBL615601,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,442.0,,,80951.0,12340.0,N,,Cytotoxic effect on 3T3 cells,,BAO_0000219,F,,CHEMBL615602,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,443.0,,,80951.0,12340.0,N,,Cytotoxic effect on 3T3 cells,,BAO_0000219,F,,CHEMBL615603,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,444.0,,,80951.0,12716.0,N,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,BAO_0000219,F,,CHEMBL615604,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,445.0,,,80951.0,6277.0,N,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,BAO_0000219,F,,CHEMBL615605,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,446.0,,,80951.0,6277.0,N,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,BAO_0000219,F,,CHEMBL615606,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,447.0,,,80951.0,6277.0,N,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,BAO_0000219,F,,CHEMBL884526,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,448.0,,,80951.0,6277.0,N,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,BAO_0000219,F,,CHEMBL615607,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,449.0,,,80951.0,6277.0,N,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,BAO_0000219,F,,CHEMBL615608,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,450.0,,,80951.0,6277.0,N,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,BAO_0000219,F,,CHEMBL615609,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,451.0,,,80951.0,6277.0,N,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,BAO_0000219,F,,CHEMBL615682,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,452.0,,,80951.0,6277.0,N,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,BAO_0000219,F,,CHEMBL615683,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,453.0,,,80951.0,17780.0,N,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,BAO_0000218,F,,CHEMBL615684,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Autocuration,,454.0,,,104860.0,12751.0,D,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,BAO_0000219,F,,CHEMBL615685,1.0,,,10090.0,,7.0,,Mus musculus
Expert,,455.0,,,80951.0,12380.0,N,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,BAO_0000219,F,,CHEMBL615686,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,456.0,,,80951.0,14892.0,N,,Inhibitory activity against 3T3 cell line,,BAO_0000219,F,,CHEMBL615687,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,457.0,,,80951.0,12695.0,N,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,BAO_0000219,F,,CHEMBL884523,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,458.0,,,11169.0,12695.0,H,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,BAO_0000019,F,,CHEMBL615688,1.0,,,,,8.0,,
Intermediate,,459.0,,,80951.0,12695.0,N,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,BAO_0000219,F,,CHEMBL615689,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,460.0,,,80951.0,12695.0,N,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,BAO_0000219,F,,CHEMBL615690,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,461.0,,,11169.0,12695.0,H,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,BAO_0000019,F,,CHEMBL615691,1.0,,,,,8.0,,
Expert,,462.0,,,11169.0,12695.0,H,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,BAO_0000019,F,,CHEMBL615692,1.0,,,,,8.0,,
Intermediate,,463.0,,,80951.0,6277.0,N,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,BAO_0000219,F,,CHEMBL615693,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,464.0,,,80951.0,6277.0,N,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,BAO_0000219,F,,CHEMBL615324,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,465.0,,,9.0,4959.0,D,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,BAO_0000219,F,,CHEMBL615325,1.0,,,9606.0,NIH3T3,9.0,723.0,Homo sapiens
Expert,,466.0,,,9.0,4959.0,D,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,BAO_0000219,F,,CHEMBL615490,1.0,,,9606.0,NIH3T3,9.0,723.0,Homo sapiens
Expert,,467.0,,,188.0,4959.0,D,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,BAO_0000219,F,,CHEMBL615491,1.0,,,9606.0,NIH3T3,9.0,723.0,Homo sapiens
Expert,,468.0,,,188.0,4959.0,D,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,BAO_0000219,F,,CHEMBL615492,1.0,,,9606.0,NIH3T3,9.0,723.0,Homo sapiens
Intermediate,,469.0,,,80951.0,12082.0,N,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,BAO_0000219,F,,CHEMBL615493,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,470.0,,,80951.0,12082.0,N,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,BAO_0000219,F,,CHEMBL615494,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,471.0,,,80951.0,12082.0,N,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,BAO_0000219,F,,CHEMBL615495,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,472.0,,,80951.0,12082.0,N,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,BAO_0000219,F,,CHEMBL615496,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,473.0,,,80951.0,2643.0,N,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,BAO_0000219,F,,CHEMBL615497,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,474.0,,,80951.0,11926.0,N,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,BAO_0000219,F,,CHEMBL615498,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,475.0,,,80951.0,15204.0,N,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,BAO_0000219,A,,CHEMBL615499,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,476.0,,,80951.0,15992.0,N,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,BAO_0000219,F,,CHEMBL835522,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,477.0,,,80951.0,16279.0,N,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,BAO_0000219,F,,CHEMBL615500,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,478.0,,,80951.0,16279.0,N,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,F,,CHEMBL615501,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,479.0,,,80951.0,16279.0,N,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,F,,CHEMBL615502,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,480.0,,,80951.0,16279.0,N,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,F,,CHEMBL615503,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,481.0,,,80951.0,16279.0,N,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,F,,CHEMBL615504,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,482.0,,,80951.0,16279.0,N,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,F,,CHEMBL615505,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Expert,,483.0,,,80951.0,12831.0,N,,Inhibition of swiss 3T3 mouse fibroblast proliferation,,BAO_0000219,F,,CHEMBL615506,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,484.0,,,80951.0,13497.0,N,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,BAO_0000219,F,,CHEMBL615507,1.0,,,10090.0,NIH3T3,1.0,723.0,Mus musculus
Intermediate,,485.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,BAO_0000218,F,,CHEMBL615508,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,486.0,,,80006.0,13618.0,N,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,BAO_0000219,F,,CHEMBL615509,1.0,,,10090.0,3T3-L1,1.0,620.0,Mus musculus
Intermediate,,487.0,,,80006.0,11902.0,N,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,BAO_0000219,F,,CHEMBL615510,1.0,,,10090.0,3T3-L1,1.0,620.0,Mus musculus
Intermediate,,488.0,,,80006.0,11902.0,N,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,BAO_0000219,F,,CHEMBL615511,1.0,,,10090.0,3T3-L1,1.0,620.0,Mus musculus
Intermediate,,489.0,,,80006.0,11902.0,N,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,BAO_0000219,F,,CHEMBL615512,1.0,,,10090.0,3T3-L1,1.0,620.0,Mus musculus
Intermediate,,490.0,,,80006.0,14840.0,N,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,BAO_0000218,F,,CHEMBL615513,1.0,,,10090.0,3T3-L1,1.0,620.0,Mus musculus
Intermediate,,491.0,,,80006.0,14840.0,N,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,BAO_0000218,F,,CHEMBL615514,1.0,,,10090.0,3T3-L1,1.0,620.0,Mus musculus
Intermediate,,492.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,BAO_0000219,F,,CHEMBL615515,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,493.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,BAO_0000219,F,,CHEMBL615516,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,494.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,BAO_0000219,F,,CHEMBL615517,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,495.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,BAO_0000219,F,,CHEMBL615518,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,496.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,BAO_0000219,F,,CHEMBL615519,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,497.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,BAO_0000218,F,,CHEMBL615520,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,498.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,BAO_0000218,F,,CHEMBL615521,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,499.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,BAO_0000218,F,,CHEMBL615522,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,500.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,BAO_0000218,F,,CHEMBL615523,1.0,,,,3T3-L1,1.0,620.0,
Expert,,501.0,,,80006.0,13715.0,N,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,BAO_0000218,F,,CHEMBL615524,1.0,,,,3T3-L1,1.0,620.0,
Expert,,502.0,,,80006.0,13715.0,N,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,BAO_0000218,F,,CHEMBL615525,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,503.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,BAO_0000218,F,,CHEMBL615526,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,504.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,BAO_0000218,F,,CHEMBL615527,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,505.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,BAO_0000218,F,,CHEMBL615528,1.0,,,,3T3-L1,1.0,620.0,
Expert,,506.0,,,80006.0,13715.0,N,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,BAO_0000218,F,,CHEMBL615529,1.0,,,,3T3-L1,1.0,620.0,
Expert,,507.0,,,80006.0,13715.0,N,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,BAO_0000218,F,,CHEMBL615530,1.0,,,,3T3-L1,1.0,620.0,
Expert,,508.0,,,80006.0,13715.0,N,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,BAO_0000218,F,,CHEMBL615531,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,509.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,BAO_0000219,F,,CHEMBL615532,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,510.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,BAO_0000219,F,,CHEMBL615533,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,511.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,BAO_0000219,F,,CHEMBL615534,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,512.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,BAO_0000218,F,,CHEMBL615535,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,513.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,BAO_0000218,F,,CHEMBL615536,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,514.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,BAO_0000218,F,,CHEMBL615537,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,515.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,BAO_0000218,F,,CHEMBL615538,1.0,,,,3T3-L1,1.0,620.0,
Intermediate,,516.0,,,80006.0,13715.0,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,BAO_0000218,F,,CHEMBL836166,1.0,,,,3T3-L1,1.0,620.0,
Expert,,517.0,,,11214.0,6411.0,H,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,BAO_0000219,F,,CHEMBL615539,1.0,,,,3T3-L1,8.0,620.0,
Intermediate,,518.0,,,80006.0,6411.0,N,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,BAO_0000219,F,,CHEMBL615540,1.0,,,10090.0,3T3-L1,1.0,620.0,Mus musculus
Expert,,519.0,,,11214.0,6411.0,H,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,BAO_0000219,F,,CHEMBL615541,1.0,,,,3T3-L1,8.0,620.0,
Expert,,520.0,,,80006.0,3966.0,N,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,BAO_0000219,F,,CHEMBL615542,1.0,,,10090.0,3T3-L1,1.0,620.0,Mus musculus
Intermediate,,521.0,,,80006.0,3966.0,N,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,BAO_0000219,F,,CHEMBL615543,1.0,,,10090.0,3T3-L1,1.0,620.0,Mus musculus
Expert,,522.0,,,80006.0,15556.0,N,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,BAO_0000219,F,,CHEMBL615544,1.0,,,10090.0,3T3-L1,1.0,620.0,Mus musculus
Expert,,523.0,,,80006.0,5845.0,N,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,BAO_0000219,F,,CHEMBL615545,1.0,,,10090.0,3T3-L1,1.0,620.0,Mus musculus
Expert,,524.0,,,80006.0,14422.0,N,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,BAO_0000219,F,,CHEMBL615546,1.0,,,10090.0,3T3-L1,1.0,620.0,Mus musculus
Expert,,525.0,,,80006.0,5845.0,N,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,BAO_0000219,F,,CHEMBL615547,1.0,,,10090.0,3T3-L1,1.0,620.0,Mus musculus
Expert,,526.0,,,80006.0,14508.0,N,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,BAO_0000219,F,,CHEMBL615548,1.0,,,10090.0,3T3-L1,1.0,620.0,Mus musculus
Expert,,527.0,,,80006.0,14508.0,N,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,BAO_0000219,F,,CHEMBL615549,1.0,,,10090.0,3T3-L1,1.0,620.0,Mus musculus
Expert,,528.0,,,80006.0,14508.0,N,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,BAO_0000219,F,,CHEMBL615550,1.0,,,10090.0,3T3-L1,1.0,620.0,Mus musculus
Intermediate,,529.0,,,80622.0,6349.0,N,,Inhibitory activity against rat fibroblast (3Y1) cell line,,BAO_0000219,F,,CHEMBL615551,1.0,,,10116.0,3Y1 cell line,1.0,1118.0,Rattus norvegicus
Expert,,530.0,,,80622.0,15899.0,N,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,BAO_0000219,F,,CHEMBL615552,1.0,,,10116.0,3Y1 cell line,1.0,1118.0,Rattus norvegicus
Expert,,531.0,,,80622.0,15899.0,N,,Cytotoxicity in 3Y1 cells.,,BAO_0000219,F,,CHEMBL615553,1.0,,,10116.0,3Y1 cell line,1.0,1118.0,Rattus norvegicus
Expert,,532.0,,,80622.0,15899.0,N,,Cytostatic effect in 3Y1 cells.,,BAO_0000219,F,,CHEMBL615554,1.0,,,10116.0,3Y1 cell line,1.0,1118.0,Rattus norvegicus
Intermediate,,533.0,,,80622.0,15899.0,N,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,BAO_0000219,F,,CHEMBL615555,1.0,,,10116.0,3Y1 cell line,1.0,1118.0,Rattus norvegicus
Expert,,534.0,,,80622.0,17038.0,N,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,BAO_0000219,F,,CHEMBL615556,1.0,,,10116.0,3Y1 cell line,1.0,1118.0,Rattus norvegicus
Autocuration,,535.0,,,22226.0,12421.0,U,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,BAO_0000019,B,,CHEMBL615557,1.0,,,,,0.0,,
Autocuration,,536.0,,,22226.0,12947.0,U,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,BAO_0000019,B,,CHEMBL615558,1.0,,,,,0.0,,
Autocuration,,537.0,,,22226.0,12947.0,U,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,BAO_0000019,B,,CHEMBL872066,1.0,,,,,0.0,,
Expert,,538.0,,,11607.0,4896.0,D,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,BAO_0000019,B,,CHEMBL615559,1.0,,,9823.0,,9.0,,Sus scrofa
Autocuration,,539.0,,,11607.0,6148.0,H,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,BAO_0000019,B,,CHEMBL615560,1.0,,,,,8.0,,
Autocuration,,540.0,,,11607.0,16432.0,H,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,BAO_0000019,B,,CHEMBL615561,1.0,,,,,8.0,,
Expert,,541.0,,,11607.0,4978.0,H,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,BAO_0000019,B,,CHEMBL857062,1.0,,,,,8.0,,
Expert,,542.0,,,11607.0,4978.0,H,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,BAO_0000019,B,,CHEMBL615562,1.0,,,,,8.0,,
Autocuration,,543.0,,,11607.0,3723.0,H,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,BAO_0000019,B,,CHEMBL615563,1.0,,,,,8.0,,
Autocuration,,544.0,,,11607.0,3518.0,H,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,BAO_0000357,B,,CHEMBL615564,1.0,,,,,8.0,,
Autocuration,,545.0,,,11607.0,4164.0,H,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,BAO_0000019,B,,CHEMBL615565,1.0,,,,,8.0,,
Autocuration,,546.0,,,11607.0,3518.0,H,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,BAO_0000019,B,,CHEMBL615566,1.0,,,,,8.0,,
Expert,,547.0,,,11607.0,4164.0,D,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,BAO_0000019,B,,CHEMBL615567,1.0,,,9823.0,,9.0,,Sus scrofa
Autocuration,,548.0,,,11607.0,3518.0,H,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,BAO_0000019,B,,CHEMBL615568,1.0,,,,,8.0,,
Autocuration,,549.0,,,11607.0,3518.0,H,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,BAO_0000357,B,,CHEMBL615569,1.0,,,,,8.0,,
Autocuration,,550.0,,,11607.0,4978.0,H,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,BAO_0000019,B,,CHEMBL615570,1.0,,,,,8.0,,
Autocuration,,551.0,,,11607.0,4978.0,H,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,BAO_0000019,B,,CHEMBL615571,1.0,,,,,8.0,,
Autocuration,,552.0,,,104733.0,6455.0,H,,Binding affinity against melatonin (MT1) receptor (pC1),,BAO_0000224,B,,CHEMBL615572,1.0,,,,,4.0,,
Autocuration,,553.0,,,22226.0,2222.0,U,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,BAO_0000019,B,,CHEMBL615573,1.0,,,,,0.0,,
Autocuration,,554.0,,,22226.0,13020.0,U,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,BAO_0000019,B,,CHEMBL615574,1.0,,,,,0.0,,
Autocuration,,555.0,,,22226.0,13021.0,U,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,BAO_0000019,B,,CHEMBL615575,1.0,,,,,0.0,,
Autocuration,,556.0,,,10619.0,14532.0,H,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,BAO_0000357,B,,CHEMBL615576,1.0,,,,,8.0,,
Autocuration,,557.0,,,10619.0,14118.0,H,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL615577,1.0,,,,,8.0,,
Autocuration,Hippocampus,558.0,,,51.0,11884.0,H,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,BAO_0000221,B,,CHEMBL615578,1.0,10000000.0,,,,8.0,,
Expert,,559.0,,,51.0,13969.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL615579,1.0,,,,,8.0,,
Expert,,560.0,,,51.0,13392.0,H,,Binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615580,1.0,,,,,8.0,,
Expert,,561.0,,,51.0,14430.0,H,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,BAO_0000019,B,,CHEMBL615581,1.0,,,,,8.0,,
Autocuration,Hippocampus,562.0,,,51.0,12248.0,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,BAO_0000221,B,,CHEMBL615582,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,563.0,,,51.0,12249.0,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,BAO_0000221,B,,CHEMBL615583,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,564.0,,,51.0,9995.0,H,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,B,,CHEMBL615584,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,565.0,,,51.0,9995.0,H,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,B,,CHEMBL833691,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,566.0,,,51.0,9995.0,H,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,B,,CHEMBL615585,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,567.0,,,51.0,9995.0,H,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,B,,CHEMBL615586,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,568.0,,,51.0,9995.0,H,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,B,,CHEMBL884524,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,569.0,,,51.0,12249.0,H,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,BAO_0000221,B,,CHEMBL615587,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,570.0,,,51.0,11799.0,H,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,BAO_0000221,B,,CHEMBL615588,1.0,10000000.0,,,,8.0,,
Expert,,571.0,,,10576.0,14331.0,D,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,Membranes,BAO_0000249,B,,CHEMBL615589,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,Hippocampus,572.0,,,51.0,11884.0,H,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,BAO_0000221,B,,CHEMBL615442,1.0,10000000.0,,9913.0,,8.0,,Bos taurus
Autocuration,Hippocampus,573.0,,,51.0,14331.0,H,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,BAO_0000221,B,,CHEMBL615443,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,574.0,,,51.0,11701.0,H,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,BAO_0000221,B,,CHEMBL615444,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,575.0,,,51.0,11701.0,H,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,BAO_0000221,B,,CHEMBL615445,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,576.0,,,51.0,12248.0,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,BAO_0000221,B,,CHEMBL615446,1.0,10000000.0,,,,8.0,,
Autocuration,,577.0,,,51.0,12248.0,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,BAO_0000219,B,,CHEMBL615447,1.0,,,,CHO,8.0,449.0,
Expert,Hippocampus,578.0,,,51.0,12248.0,H,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,BAO_0000221,B,,CHEMBL615448,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,579.0,,,51.0,12249.0,H,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,BAO_0000221,B,,CHEMBL615449,1.0,10000000.0,,,,8.0,,
Autocuration,,580.0,,,51.0,12248.0,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,B,,CHEMBL615450,1.0,,,,CHO,8.0,449.0,
Expert,Hippocampus,581.0,,,51.0,11799.0,H,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,BAO_0000221,B,,CHEMBL615451,1.0,10000000.0,,,,8.0,,
Autocuration,,582.0,,,51.0,634.0,H,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,BAO_0000357,B,,CHEMBL615452,1.0,,,,,8.0,,
Autocuration,Hippocampus,583.0,,,51.0,9995.0,H,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,B,,CHEMBL615453,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,584.0,,,51.0,9995.0,H,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,B,,CHEMBL615454,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,585.0,,,51.0,9995.0,H,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,B,,CHEMBL615455,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,586.0,,,51.0,9995.0,H,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,B,,CHEMBL615456,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,587.0,,,51.0,9995.0,H,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,B,,CHEMBL615457,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,588.0,,,51.0,12210.0,H,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,BAO_0000218,B,,CHEMBL615458,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,589.0,,,51.0,13311.0,H,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,B,,CHEMBL615459,1.0,10000000.0,,,,8.0,,
Expert,,590.0,,,51.0,2331.0,D,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,BAO_0000219,B,,CHEMBL615460,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,591.0,,,51.0,1375.0,H,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,BAO_0000019,F,,CHEMBL615461,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,592.0,,,51.0,1375.0,H,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,BAO_0000019,F,,CHEMBL615462,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,Hippocampus,593.0,,,51.0,11574.0,H,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,BAO_0000221,F,,CHEMBL615463,1.0,10000000.0,,10141.0,,8.0,,Cavia porcellus
Autocuration,Ileum,594.0,,,51.0,12867.0,H,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,BAO_0000221,B,,CHEMBL615464,1.0,2116.0,,10141.0,,8.0,,Cavia porcellus
Autocuration,Ileum,595.0,,,51.0,12867.0,H,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,BAO_0000221,B,,CHEMBL615465,1.0,2116.0,,10141.0,,8.0,,Cavia porcellus
Autocuration,Ileum,596.0,,,51.0,12867.0,H,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,BAO_0000221,B,,CHEMBL615466,1.0,2116.0,,10141.0,,8.0,,Cavia porcellus
Autocuration,Ileum,597.0,,,51.0,12867.0,H,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,BAO_0000221,B,,CHEMBL615467,1.0,2116.0,,10141.0,,8.0,,Cavia porcellus
Autocuration,Ileum,598.0,,,51.0,12867.0,H,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,BAO_0000221,B,,CHEMBL615468,1.0,2116.0,,10141.0,,8.0,,Cavia porcellus
Autocuration,Ileum,599.0,,,51.0,12867.0,H,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,BAO_0000221,B,,CHEMBL615469,1.0,2116.0,,10141.0,,8.0,,Cavia porcellus
Autocuration,,600.0,,,51.0,11574.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615470,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,601.0,,,51.0,13114.0,H,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615471,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,602.0,,,51.0,13181.0,H,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615472,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,Hippocampus,603.0,,,106.0,10639.0,H,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,BAO_0000221,B,,CHEMBL883242,1.0,10000000.0,,10141.0,,8.0,,Cavia porcellus
Autocuration,Hippocampus,604.0,,,106.0,10639.0,H,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,BAO_0000221,F,,CHEMBL615473,1.0,10000000.0,,10141.0,,8.0,,Cavia porcellus
Autocuration,,605.0,,,11863.0,11883.0,H,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,BAO_0000218,B,,CHEMBL615474,1.0,,,10029.0,CHO,8.0,449.0,Cricetulus griseus
Autocuration,,606.0,,,51.0,17785.0,H,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615475,1.0,,,,,8.0,,
Autocuration,,607.0,,,51.0,1558.0,H,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,BAO_0000219,F,,CHEMBL615476,1.0,,,,HeLa,8.0,308.0,
Autocuration,,608.0,,,51.0,1558.0,H,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,BAO_0000219,F,,CHEMBL615477,1.0,,,,HeLa,8.0,308.0,
Autocuration,,609.0,,,51.0,15740.0,H,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,BAO_0000019,F,,CHEMBL615478,1.0,,,,,8.0,,
Autocuration,,610.0,,,51.0,17624.0,H,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,BAO_0000219,F,,CHEMBL615160,1.0,,,,CHO,8.0,449.0,
Expert,,611.0,,,51.0,17624.0,H,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,BAO_0000219,F,,CHEMBL615161,1.0,,,,CHO,8.0,449.0,
Autocuration,,612.0,,,51.0,17624.0,H,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,BAO_0000219,F,,CHEMBL615162,1.0,,,,CHO,8.0,449.0,
Autocuration,,613.0,,,51.0,17624.0,H,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,BAO_0000219,F,,CHEMBL615163,1.0,,,,CHO,8.0,449.0,
Expert,,614.0,,,51.0,17624.0,H,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,B,,CHEMBL615164,1.0,,,,CHO,8.0,449.0,
Expert,,615.0,,,51.0,17624.0,H,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,B,,CHEMBL615165,1.0,,,,CHO,8.0,449.0,
Autocuration,,616.0,,,51.0,17624.0,H,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,BAO_0000219,B,,CHEMBL615166,1.0,,,,CHO,8.0,449.0,
Autocuration,,617.0,,,51.0,14256.0,H,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,BAO_0000219,F,,CHEMBL615167,1.0,,,,,8.0,,
Expert,,618.0,,,51.0,3445.0,D,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,BAO_0000219,B,,CHEMBL615168,1.0,,,9606.0,HeLa,9.0,308.0,Homo sapiens
Expert,,619.0,,,51.0,3445.0,D,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,BAO_0000219,B,,CHEMBL615169,1.0,,,9606.0,HeLa,9.0,308.0,Homo sapiens
Expert,,620.0,,,51.0,17200.0,D,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000219,B,,CHEMBL615170,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Expert,,621.0,,,51.0,17200.0,D,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,BAO_0000219,B,,CHEMBL615171,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,622.0,,,51.0,15180.0,H,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,BAO_0000019,F,,CHEMBL615694,1.0,,,,,8.0,,
Autocuration,,623.0,,,51.0,15180.0,H,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,BAO_0000019,F,,CHEMBL615695,1.0,,,,,8.0,,
Autocuration,,624.0,,,51.0,16026.0,H,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,BAO_0000019,F,,CHEMBL615696,1.0,,,,,8.0,,
Autocuration,,625.0,,,51.0,2759.0,H,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,BAO_0000219,F,,CHEMBL615697,1.0,,,,CHO,8.0,449.0,
Expert,,626.0,,,51.0,2759.0,D,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,BAO_0000219,F,,CHEMBL859410,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,627.0,,,51.0,2759.0,H,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,BAO_0000219,F,,CHEMBL615841,1.0,,,,CHO,8.0,449.0,
Expert,,628.0,,,51.0,2759.0,D,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,BAO_0000219,F,,CHEMBL615842,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,629.0,,,51.0,2759.0,H,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,BAO_0000219,F,,CHEMBL835003,1.0,,,,CHO,8.0,449.0,
Autocuration,,630.0,,,51.0,2759.0,H,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,BAO_0000219,F,,CHEMBL615843,1.0,,,,CHO,8.0,449.0,
Expert,,631.0,,,51.0,2759.0,D,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,BAO_0000219,F,,CHEMBL615979,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,632.0,,,51.0,2759.0,H,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,BAO_0000219,F,,CHEMBL615980,1.0,,,,CHO,8.0,449.0,
Expert,,633.0,,,51.0,2759.0,D,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,BAO_0000219,F,,CHEMBL615981,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Expert,,634.0,,,51.0,3445.0,D,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,BAO_0000019,F,,CHEMBL615982,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,635.0,,,51.0,5272.0,D,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,F,,CHEMBL615983,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,636.0,,,51.0,5272.0,D,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,BAO_0000019,F,,CHEMBL615984,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,637.0,,,51.0,5272.0,D,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,F,,CHEMBL615985,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,638.0,,,51.0,17624.0,H,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,BAO_0000219,F,,CHEMBL615986,1.0,,,,CHO,8.0,449.0,
Autocuration,,639.0,,,51.0,17624.0,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,BAO_0000219,F,,CHEMBL615987,1.0,,,,CHO,8.0,449.0,
Autocuration,,640.0,,,51.0,17624.0,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,BAO_0000219,F,,CHEMBL615988,1.0,,,,CHO,8.0,449.0,
Expert,,641.0,,,51.0,17624.0,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,BAO_0000219,F,,CHEMBL615989,1.0,,,,CHO,8.0,449.0,
Autocuration,,642.0,,,51.0,17624.0,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,BAO_0000219,F,,CHEMBL615990,1.0,,,,CHO,8.0,449.0,
Autocuration,,643.0,,,51.0,17624.0,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,BAO_0000219,F,,CHEMBL615991,1.0,,,,CHO,8.0,449.0,
Autocuration,,644.0,,,51.0,17624.0,H,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,BAO_0000219,F,,CHEMBL615992,1.0,,,,CHO,8.0,449.0,
Autocuration,,645.0,,,51.0,17624.0,H,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,BAO_0000219,F,,CHEMBL615993,1.0,,,,CHO,8.0,449.0,
Expert,,646.0,,,51.0,17624.0,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,BAO_0000219,F,,CHEMBL615994,1.0,,,,CHO,8.0,449.0,
Autocuration,,647.0,,,51.0,17624.0,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,BAO_0000219,F,,CHEMBL615995,1.0,,,,CHO,8.0,449.0,
Autocuration,,648.0,,,51.0,17624.0,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,BAO_0000219,F,,CHEMBL615996,1.0,,,,CHO,8.0,449.0,
Autocuration,,649.0,,,51.0,17624.0,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,BAO_0000219,F,,CHEMBL615997,1.0,,,,CHO,8.0,449.0,
Autocuration,,650.0,,,51.0,6563.0,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,F,,CHEMBL615998,1.0,,,,,8.0,,
Autocuration,,651.0,,,51.0,6563.0,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,F,,CHEMBL615999,1.0,,,,,8.0,,
Autocuration,,652.0,,,51.0,6563.0,H,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,BAO_0000019,F,,CHEMBL616000,1.0,,,,,8.0,,
Autocuration,,653.0,,,51.0,17296.0,H,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,BAO_0000219,F,,CHEMBL616001,1.0,,,,HEK293,8.0,722.0,
Expert,,654.0,,,51.0,6876.0,D,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,BAO_0000019,F,,CHEMBL616002,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,655.0,,,51.0,6876.0,H,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,BAO_0000019,F,,CHEMBL616003,1.0,,,,,8.0,,
Expert,,656.0,,,51.0,5272.0,D,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,BAO_0000019,F,,CHEMBL616004,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,657.0,,,51.0,5272.0,D,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,BAO_0000019,F,,CHEMBL616005,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,658.0,,,51.0,5548.0,H,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,BAO_0000019,F,,CHEMBL616006,1.0,,,,,8.0,,
Expert,,659.0,,,51.0,5548.0,H,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,BAO_0000019,F,,CHEMBL616007,1.0,,,,,8.0,,
Autocuration,,660.0,,,51.0,5548.0,H,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,BAO_0000019,F,,CHEMBL616008,1.0,,,,,8.0,,
Autocuration,,661.0,,,51.0,5548.0,H,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,BAO_0000019,F,,CHEMBL616009,1.0,,,,,8.0,,
Expert,,662.0,,,51.0,5929.0,H,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,BAO_0000019,F,,CHEMBL616010,1.0,,,,,8.0,,
Expert,,663.0,,,51.0,5929.0,D,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,BAO_0000019,F,,CHEMBL616011,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,664.0,,,51.0,5929.0,D,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,BAO_0000019,F,,CHEMBL615740,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,665.0,,,51.0,16245.0,H,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,BAO_0000019,F,,CHEMBL615741,1.0,,,,,8.0,,
Expert,,666.0,,,51.0,5640.0,H,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,BAO_0000019,F,,CHEMBL615742,1.0,,,,,8.0,,
Autocuration,,667.0,,,51.0,5640.0,H,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,BAO_0000019,F,,CHEMBL615743,1.0,,,,,8.0,,
Autocuration,,668.0,,,51.0,14509.0,H,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,BAO_0000219,F,,CHEMBL615744,1.0,,,,CHO,8.0,449.0,
Expert,,669.0,,,51.0,14509.0,H,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,BAO_0000219,F,,CHEMBL615745,1.0,,,,CHO,8.0,449.0,
Autocuration,,670.0,,,51.0,15331.0,H,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,BAO_0000357,B,,CHEMBL615746,1.0,,,,,8.0,,
Autocuration,,671.0,,,51.0,15331.0,H,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,BAO_0000357,B,,CHEMBL615747,1.0,,,,,8.0,,
Autocuration,,672.0,,,51.0,6563.0,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,F,,CHEMBL615748,1.0,,,,,8.0,,
Autocuration,,673.0,,,51.0,6563.0,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,BAO_0000019,F,,CHEMBL615749,1.0,,,,,8.0,,
Autocuration,,674.0,,,51.0,6563.0,H,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,BAO_0000019,F,,CHEMBL615750,1.0,,,,,8.0,,
Expert,,675.0,,,51.0,6563.0,D,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,BAO_0000019,F,,CHEMBL616259,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,676.0,,,51.0,6563.0,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,F,,CHEMBL616260,1.0,,,,,8.0,,
Expert,,677.0,,,51.0,5272.0,D,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,BAO_0000019,F,,CHEMBL616261,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,678.0,,,51.0,5272.0,D,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,F,,CHEMBL616262,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,679.0,,,51.0,5272.0,D,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,BAO_0000019,F,,CHEMBL616263,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,680.0,,,51.0,5272.0,D,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,BAO_0000019,F,,CHEMBL616264,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,681.0,,,51.0,5272.0,D,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,BAO_0000019,F,,CHEMBL616265,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,682.0,,,51.0,5272.0,D,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,F,,CHEMBL616266,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,683.0,,,51.0,5272.0,D,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,BAO_0000019,F,,CHEMBL616267,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,684.0,,,51.0,5272.0,D,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,BAO_0000019,F,,CHEMBL616268,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,685.0,,,51.0,16146.0,D,,Inhibition of human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616269,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,686.0,,,51.0,17624.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,B,,CHEMBL884528,1.0,,,,CHO,8.0,449.0,
Expert,,687.0,,,105.0,13706.0,D,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,BAO_0000219,B,,CHEMBL616270,1.0,,,,HEK293,9.0,722.0,
Autocuration,,688.0,,,51.0,15250.0,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL616271,1.0,,,,CHO,8.0,449.0,
Autocuration,,689.0,,,51.0,17624.0,H,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,BAO_0000219,F,,CHEMBL616272,1.0,,,,CHO,8.0,449.0,
Expert,,690.0,,,51.0,6861.0,H,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,BAO_0000357,B,,CHEMBL616273,1.0,,,,,8.0,,
Expert,,691.0,,,51.0,17200.0,D,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616274,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,692.0,,,51.0,17624.0,H,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,B,,CHEMBL616275,1.0,,,,CHO,8.0,449.0,
Autocuration,,693.0,,,51.0,17624.0,H,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,B,,CHEMBL616276,1.0,,,,CHO,8.0,449.0,
Autocuration,,694.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,BAO_0000218,F,In vivo,CHEMBL616277,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,695.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,BAO_0000218,F,In vivo,CHEMBL616278,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,696.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,BAO_0000218,F,In vivo,CHEMBL616279,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,697.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,BAO_0000218,F,In vivo,CHEMBL616280,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,698.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,BAO_0000218,F,In vivo,CHEMBL616281,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,699.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,BAO_0000218,F,In vivo,CHEMBL616282,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,700.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,BAO_0000218,F,In vivo,CHEMBL616283,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,701.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,BAO_0000218,F,In vivo,CHEMBL616284,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,702.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,BAO_0000218,F,In vivo,CHEMBL616285,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,703.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,BAO_0000218,F,In vivo,CHEMBL616286,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,704.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,BAO_0000218,F,In vivo,CHEMBL616287,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,705.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,BAO_0000218,F,In vivo,CHEMBL616288,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,706.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,BAO_0000218,F,In vivo,CHEMBL616289,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,707.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,BAO_0000218,F,In vivo,CHEMBL615610,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,708.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,BAO_0000218,F,In vivo,CHEMBL615611,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,709.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,BAO_0000218,F,In vivo,CHEMBL615612,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,710.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,BAO_0000218,F,In vivo,CHEMBL615613,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,711.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,BAO_0000218,F,In vivo,CHEMBL615614,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,712.0,,,22226.0,12058.0,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,BAO_0000218,F,In vivo,CHEMBL615615,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,713.0,,,105093.0,11440.0,H,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,BAO_0000019,B,,CHEMBL615616,1.0,,,,,4.0,,
Autocuration,Hypothalamus,714.0,,,11923.0,6238.0,H,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,BAO_0000249,B,,CHEMBL615617,1.0,1898.0,,,,8.0,,
Autocuration,,715.0,,,10577.0,10046.0,H,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,BAO_0000019,B,,CHEMBL615618,1.0,,,,,8.0,,
Autocuration,,716.0,,,10577.0,10046.0,H,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,BAO_0000019,B,,CHEMBL615619,1.0,,,,,8.0,,
Expert,,717.0,,,10577.0,10046.0,H,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,BAO_0000019,B,,CHEMBL615620,1.0,,,,,8.0,,
Autocuration,,718.0,,,55.0,167.0,H,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,BAO_0000357,B,,CHEMBL615621,1.0,,,,,8.0,,
Autocuration,,719.0,,,55.0,167.0,H,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,BAO_0000357,B,,CHEMBL615622,1.0,,,,,8.0,,
Autocuration,,720.0,,,12166.0,11520.0,H,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,BAO_0000019,F,,CHEMBL615623,1.0,,,,,8.0,,
Autocuration,,721.0,,,12166.0,11520.0,H,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,BAO_0000019,F,,CHEMBL615624,1.0,,,,,8.0,,
Autocuration,,722.0,,,12166.0,11520.0,H,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,BAO_0000019,F,,CHEMBL615625,1.0,,,,,8.0,,
Autocuration,,723.0,,,12166.0,11520.0,H,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,BAO_0000019,F,,CHEMBL767045,1.0,,,,,8.0,,
Autocuration,,724.0,,,55.0,135.0,H,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,BAO_0000019,F,,CHEMBL615626,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,725.0,,,55.0,135.0,H,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,BAO_0000019,F,,CHEMBL615627,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,726.0,,,55.0,11311.0,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,BAO_0000019,B,,CHEMBL615628,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,727.0,,,55.0,10193.0,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,BAO_0000357,B,,CHEMBL615629,1.0,,,10141.0,,8.0,,Cavia porcellus
Expert,,728.0,,,55.0,12281.0,D,,Inhibitory concentration against 5-lipoxygenase from human whole blood,,BAO_0000357,B,,CHEMBL615630,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,729.0,,,55.0,11311.0,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,BAO_0000219,B,,CHEMBL615631,1.0,,,,,8.0,,
Autocuration,,730.0,,,17087.0,12576.0,H,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,BAO_0000218,F,,CHEMBL615632,1.0,,,,,8.0,,
Autocuration,,731.0,,,17087.0,12281.0,H,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,BAO_0000357,B,,CHEMBL615633,1.0,,,,,8.0,,
Autocuration,,732.0,,,17087.0,12576.0,H,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,BAO_0000218,F,,CHEMBL615634,1.0,,,,,8.0,,
Expert,,733.0,,,55.0,11089.0,H,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,BAO_0000019,B,,CHEMBL615635,1.0,,,9823.0,,8.0,,Sus scrofa
Expert,,734.0,,,12166.0,11006.0,H,,In vitro inhibition of rat 5-Lipoxygenase,,BAO_0000357,B,,CHEMBL615636,1.0,,,,,8.0,,
Expert,,735.0,,,12166.0,11481.0,D,,Inhibitory activity against 5-Lipoxygenase,,BAO_0000357,B,,CHEMBL615637,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,736.0,,,12166.0,10864.0,H,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,BAO_0000219,B,,CHEMBL615638,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,737.0,,,12166.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,BAO_0000219,B,,CHEMBL615639,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,738.0,,,12166.0,11311.0,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,BAO_0000219,B,,CHEMBL615640,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,739.0,,,12166.0,11311.0,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,BAO_0000019,B,,CHEMBL615796,1.0,,,,,8.0,,
Autocuration,,740.0,,,12166.0,11311.0,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,BAO_0000219,B,,CHEMBL615845,1.0,,,,,8.0,,
Autocuration,,741.0,,,12166.0,11006.0,H,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,BAO_0000357,B,,CHEMBL615846,1.0,,,,,8.0,,
Autocuration,,742.0,,,12166.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,BAO_0000219,B,,CHEMBL615847,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,743.0,,,12166.0,11311.0,H,,The compound was tested for inhibition of isolated 5-Lipoxygenase,,BAO_0000357,B,,CHEMBL615848,1.0,,,,,8.0,,
Autocuration,,744.0,,,22226.0,11481.0,U,,Ratio of IC50 against 5-LO and COX,,BAO_0000019,B,,CHEMBL615849,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,745.0,,,12166.0,11006.0,H,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,BAO_0000357,B,,CHEMBL615850,1.0,,,,,8.0,,
Autocuration,,746.0,,,12166.0,11006.0,H,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,BAO_0000357,B,,CHEMBL615851,1.0,,,,,8.0,,
Autocuration,,747.0,,,12166.0,11311.0,H,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,BAO_0000219,B,,CHEMBL615852,1.0,,,,,8.0,,
Autocuration,,748.0,,,12166.0,11006.0,H,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,BAO_0000019,F,,CHEMBL615853,1.0,,,,,8.0,,
Autocuration,Prostate gland,749.0,,,120.0,4288.0,H,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,BAO_0000357,B,,CHEMBL884527,1.0,2367.0,,,,8.0,,
Autocuration,,750.0,,,22226.0,7587.0,U,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,BAO_0000019,B,,CHEMBL872871,1.0,,,8932.0,,0.0,,Columba livia
Autocuration,,751.0,,,22226.0,7587.0,U,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,BAO_0000019,B,,CHEMBL615854,1.0,,,8932.0,,0.0,,Columba livia
Autocuration,,752.0,,,22226.0,7587.0,U,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,BAO_0000019,B,,CHEMBL767046,1.0,,,8932.0,,0.0,,Columba livia
Autocuration,,753.0,,,10732.0,11249.0,H,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,BAO_0000357,B,,CHEMBL615855,1.0,,,,,8.0,,
Expert,,754.0,,,12198.0,8003.0,D,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,BAO_0000019,F,,CHEMBL615856,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,755.0,,,12198.0,8003.0,D,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,BAO_0000019,F,,CHEMBL615857,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,756.0,,,12198.0,8003.0,D,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,BAO_0000019,F,,CHEMBL615858,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,Hippocampus,757.0,,,10576.0,12416.0,H,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,BAO_0000221,B,,CHEMBL615859,1.0,10000000.0,,,,8.0,,
Autocuration,,758.0,,,51.0,16293.0,H,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,BAO_0000357,B,,CHEMBL615860,1.0,,,,,8.0,,
Autocuration,,759.0,,,22226.0,13047.0,U,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,BAO_0000019,B,,CHEMBL615861,1.0,,,9986.0,,0.0,,Oryctolagus cuniculus
Autocuration,,760.0,,,22226.0,13047.0,U,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,BAO_0000019,B,,CHEMBL615862,1.0,,,9986.0,,0.0,,Oryctolagus cuniculus
Autocuration,,761.0,,,22226.0,13047.0,U,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,BAO_0000019,B,,CHEMBL615863,1.0,,,9986.0,,0.0,,Oryctolagus cuniculus
Autocuration,,762.0,,,22226.0,13047.0,U,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,BAO_0000019,B,,CHEMBL615864,1.0,,,9986.0,,0.0,,Oryctolagus cuniculus
Autocuration,Hippocampus,763.0,,,104744.0,10085.0,H,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,BAO_0000221,B,,CHEMBL615865,1.0,10000000.0,,,,4.0,,
Autocuration,Hippocampus,764.0,,,104744.0,10085.0,H,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,BAO_0000221,B,,CHEMBL615866,1.0,10000000.0,,,,4.0,,
Autocuration,Hippocampus,765.0,,,104744.0,10085.0,H,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,BAO_0000221,B,,CHEMBL615867,1.0,10000000.0,,,,4.0,,
Autocuration,,766.0,,,104744.0,9841.0,H,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,Membranes,BAO_0000249,B,,CHEMBL615868,1.0,,,,,4.0,,
Autocuration,,767.0,,,104744.0,8822.0,D,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,BAO_0000249,B,,CHEMBL615869,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,768.0,,,104744.0,9806.0,D,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,BAO_0000019,B,,CHEMBL615870,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,769.0,,,104744.0,9806.0,D,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,BAO_0000019,B,,CHEMBL615871,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,770.0,,,104744.0,8868.0,H,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,BAO_0000224,B,,CHEMBL615872,1.0,,,,,4.0,,
Autocuration,Hippocampus,771.0,,,104744.0,9036.0,H,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,BAO_0000221,B,,CHEMBL833492,1.0,10000000.0,,,,4.0,,
Autocuration,Hippocampus,772.0,,,104744.0,11374.0,H,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,BAO_0000221,B,,CHEMBL615873,1.0,10000000.0,,,,4.0,,
Autocuration,,773.0,,,104744.0,10881.0,H,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,BAO_0000224,B,,CHEMBL615479,1.0,,,,,4.0,,
Autocuration,,774.0,,,104744.0,8822.0,H,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,BAO_0000019,B,,CHEMBL615480,1.0,,,,,4.0,,
Autocuration,,775.0,,,104744.0,9806.0,D,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,BAO_0000249,B,,CHEMBL615481,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,776.0,,,104744.0,15463.0,H,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,B,,CHEMBL872869,1.0,,,,,4.0,,
Autocuration,,777.0,,,104744.0,15463.0,H,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,B,,CHEMBL615482,1.0,,,,,4.0,,
Autocuration,Brain,778.0,,,104744.0,14542.0,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,BAO_0000221,B,,CHEMBL615483,1.0,955.0,,,,4.0,,
Autocuration,Brain,779.0,,,104744.0,14542.0,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,BAO_0000221,B,,CHEMBL615484,1.0,955.0,,,,4.0,,
Autocuration,,780.0,,,104744.0,8569.0,H,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,BAO_0000019,B,,CHEMBL615485,1.0,,,,,4.0,,
Autocuration,,781.0,,,104744.0,10062.0,D,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,BAO_0000224,B,,CHEMBL615486,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,782.0,,,104744.0,4771.0,H,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,BAO_0000224,B,,CHEMBL615487,1.0,,,,,4.0,,
Autocuration,,783.0,,,104744.0,10062.0,H,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,BAO_0000224,B,,CHEMBL615488,1.0,,,,,4.0,,
Autocuration,,784.0,,,104744.0,10062.0,H,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,BAO_0000224,B,,CHEMBL615489,1.0,,,,,4.0,,
Autocuration,,785.0,,,104744.0,10062.0,H,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,BAO_0000224,B,,CHEMBL615389,1.0,,,,,4.0,,
Autocuration,,786.0,,,104744.0,15463.0,H,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,BAO_0000019,B,,CHEMBL615390,1.0,,,,,4.0,,
Autocuration,,787.0,,,104744.0,15463.0,H,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,BAO_0000019,B,,CHEMBL615391,1.0,,,,,4.0,,
Autocuration,,788.0,,,104744.0,9098.0,H,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,BAO_0000224,B,,CHEMBL615392,1.0,,,,,4.0,,
Autocuration,,789.0,,,22226.0,3070.0,U,,Affinity for 5-hydroxytryptamine 1 receptor,,BAO_0000019,B,,CHEMBL615393,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Brain,790.0,,,104744.0,14542.0,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,BAO_0000221,B,,CHEMBL615394,1.0,955.0,,,,4.0,,
Autocuration,Brain,791.0,,,104744.0,14542.0,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,BAO_0000221,B,,CHEMBL615395,1.0,955.0,,,,4.0,,
Autocuration,,792.0,,,104744.0,6398.0,H,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,BAO_0000224,B,,CHEMBL615396,1.0,,,,,4.0,,
Autocuration,Brain,793.0,,,104744.0,1344.0,H,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,BAO_0000221,B,,CHEMBL615397,1.0,955.0,,,,4.0,,
Autocuration,,794.0,,,104744.0,11963.0,H,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,B,,CHEMBL615398,1.0,,,,,4.0,,
Autocuration,,795.0,,,22226.0,8908.0,U,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,BAO_0000019,B,,CHEMBL615399,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,796.0,,,104744.0,9098.0,H,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,BAO_0000019,B,,CHEMBL615400,1.0,,,,,4.0,,
Autocuration,,797.0,,,104744.0,8841.0,D,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,BAO_0000019,B,,CHEMBL615401,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,798.0,,,22226.0,8814.0,U,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,BAO_0000019,B,,CHEMBL615402,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,799.0,,,104744.0,11752.0,H,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,BAO_0000019,B,,CHEMBL615403,1.0,,,,,4.0,,
Autocuration,Brain,800.0,,,104744.0,11642.0,H,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,BAO_0000221,B,,CHEMBL615404,1.0,955.0,,,,4.0,,
Autocuration,,801.0,,,104744.0,11642.0,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,BAO_0000019,B,,CHEMBL615781,1.0,,,,,4.0,,
Autocuration,Brain,802.0,,,104744.0,9231.0,H,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,BAO_0000220,B,,CHEMBL615782,1.0,955.0,,,,4.0,,
Autocuration,Brain,803.0,,,104744.0,11351.0,H,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,BAO_0000221,B,,CHEMBL615783,1.0,955.0,,,,4.0,,
Autocuration,,804.0,,,22226.0,4639.0,U,,Compound was tested for binding affinity against 5-HT1 receptor,,BAO_0000019,B,,CHEMBL873481,1.0,,,,,0.0,,
Autocuration,,805.0,,,22226.0,1205.0,U,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,BAO_0000019,B,,CHEMBL615784,1.0,,,,,0.0,,
Expert,,806.0,,,10576.0,10025.0,H,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,BAO_0000357,B,,CHEMBL615785,1.0,,,,,8.0,,
Autocuration,,807.0,,,10576.0,13241.0,H,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,BAO_0000249,F,,CHEMBL615786,1.0,,,,,8.0,,
Autocuration,,808.0,,,10576.0,16245.0,H,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,BAO_0000218,F,In vivo,CHEMBL615787,1.0,,,,,8.0,,
Autocuration,,809.0,,,10576.0,16245.0,H,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,BAO_0000218,F,In vivo,CHEMBL615788,1.0,,,,,8.0,,
Autocuration,,810.0,,,10576.0,12438.0,H,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,BAO_0000019,F,,CHEMBL767044,1.0,,,,,8.0,,
Autocuration,,811.0,,,10576.0,16245.0,H,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,BAO_0000218,F,In vivo,CHEMBL615789,1.0,,,,,8.0,,
Autocuration,,812.0,,,10576.0,16245.0,H,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,BAO_0000218,F,In vivo,CHEMBL615790,1.0,,,,,8.0,,
Autocuration,,813.0,,,10576.0,15740.0,H,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,BAO_0000019,F,,CHEMBL615813,1.0,,,,,8.0,,
Autocuration,,814.0,,,10576.0,15535.0,H,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,BAO_0000219,F,,CHEMBL615814,1.0,,,,,8.0,,
Expert,,815.0,,,51.0,15535.0,H,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,BAO_0000219,F,,CHEMBL615815,1.0,,,,,8.0,,
Autocuration,,816.0,,,10576.0,15535.0,H,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,BAO_0000219,F,,CHEMBL615816,1.0,,,,,8.0,,
Expert,,817.0,,,10576.0,9888.0,H,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,BAO_0000249,B,,CHEMBL615817,1.0,,,,,8.0,,
Autocuration,Hippocampus,818.0,,,10576.0,10085.0,H,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,BAO_0000221,B,,CHEMBL615818,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,819.0,,,10576.0,10085.0,H,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,BAO_0000221,B,,CHEMBL615819,1.0,10000000.0,,,,8.0,,
Expert,,820.0,,,10576.0,17331.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,Membranes,BAO_0000249,B,,CHEMBL615820,1.0,,,,,8.0,,
Expert,Hippocampus,821.0,,,10576.0,10845.0,D,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,BAO_0000221,B,,CHEMBL615821,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Expert,Hippocampus,822.0,,,10576.0,10845.0,D,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,BAO_0000221,B,,CHEMBL615822,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Expert,Hippocampus,823.0,,,10576.0,10845.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,BAO_0000221,B,,CHEMBL615823,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,824.0,,,10576.0,10845.0,D,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,BAO_0000221,B,,CHEMBL615824,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Expert,Hippocampus,825.0,,,10576.0,10845.0,D,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,BAO_0000221,B,,CHEMBL615825,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Expert,,826.0,,,10576.0,13730.0,H,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL615826,1.0,,,,,8.0,,
Expert,,827.0,,,10576.0,13508.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,BAO_0000249,B,,CHEMBL615827,1.0,,,,,8.0,,
Expert,Hippocampus,828.0,,,10576.0,13508.0,H,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,BAO_0000249,B,,CHEMBL615828,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,829.0,,,10576.0,12073.0,H,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,B,,CHEMBL615829,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,830.0,,,10576.0,4671.0,H,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,BAO_0000221,B,,CHEMBL615830,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,831.0,,,10576.0,13631.0,H,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,BAO_0000221,B,,CHEMBL615831,1.0,10000000.0,,,,8.0,,
Autocuration,,832.0,,,10576.0,12438.0,H,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615832,1.0,,,,,8.0,,
Autocuration,,833.0,,,10576.0,10483.0,H,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,BAO_0000019,B,,CHEMBL615833,1.0,,,,,8.0,,
Autocuration,Hippocampus,834.0,,,10576.0,10483.0,H,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,BAO_0000221,B,,CHEMBL615834,1.0,10000000.0,,,,8.0,,
Intermediate,,835.0,,,10576.0,12352.0,H,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,BAO_0000249,B,,CHEMBL615835,1.0,,,,,8.0,,
Autocuration,Hippocampus,836.0,,,10576.0,14732.0,H,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,BAO_0000249,B,,CHEMBL615836,1.0,10000000.0,,,,8.0,,
Expert,,837.0,,,10576.0,11049.0,D,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,BAO_0000019,B,,CHEMBL615837,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,838.0,,,10576.0,11049.0,D,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,BAO_0000019,B,,CHEMBL615838,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,839.0,,,10576.0,13657.0,H,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,BAO_0000249,B,,CHEMBL615839,1.0,,,,,8.0,,
Autocuration,,840.0,,,10576.0,11473.0,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,BAO_0000019,B,,CHEMBL884525,1.0,,,,,8.0,,
Autocuration,,841.0,,,10576.0,2014.0,H,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,BAO_0000249,B,,CHEMBL615840,1.0,,,,,8.0,,
Expert,Hippocampus,842.0,,,10576.0,3086.0,H,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,B,,CHEMBL615405,1.0,10000000.0,,,,8.0,,
Expert,,843.0,,,10576.0,15854.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,BAO_0000019,B,,CHEMBL615406,1.0,,,,,8.0,,
Expert,Hippocampus,844.0,,,10576.0,10922.0,H,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,BAO_0000221,B,,CHEMBL615900,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,845.0,,,10576.0,13346.0,H,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,BAO_0000221,B,,CHEMBL615901,1.0,10000000.0,,,,8.0,,
Expert,,846.0,,,10576.0,15311.0,H,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,BAO_0000357,B,,CHEMBL615902,1.0,,,,,8.0,,
Autocuration,Hippocampus,847.0,,,10576.0,10922.0,H,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,BAO_0000221,B,,CHEMBL615903,1.0,10000000.0,,,,8.0,,
Autocuration,,848.0,,,10576.0,10025.0,H,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,BAO_0000357,B,,CHEMBL615904,1.0,,,,,8.0,,
Expert,,849.0,,,10576.0,10025.0,H,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,BAO_0000357,B,,CHEMBL615905,1.0,,,,,8.0,,
Autocuration,,850.0,,,10576.0,9742.0,H,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,BAO_0000019,B,,CHEMBL615906,1.0,,,,,8.0,,
Autocuration,,851.0,,,10576.0,9742.0,H,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,BAO_0000019,F,,CHEMBL615907,1.0,,,,,8.0,,
Expert,,852.0,,,10576.0,12304.0,H,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,BAO_0000019,B,,CHEMBL615908,1.0,,,,,8.0,,
Autocuration,Hippocampus,853.0,,,10576.0,15789.0,H,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,BAO_0000221,B,,CHEMBL615909,1.0,10000000.0,,,,8.0,,
Autocuration,,854.0,,,10576.0,9912.0,H,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,BAO_0000019,B,,CHEMBL615910,1.0,,,,,8.0,,
Autocuration,,855.0,,,10576.0,9912.0,H,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,BAO_0000019,B,,CHEMBL615911,1.0,,,,,8.0,,
Autocuration,,856.0,,,10576.0,9912.0,H,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,BAO_0000019,B,,CHEMBL615912,1.0,,,,,8.0,,
Expert,,857.0,,,10576.0,16693.0,H,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,BAO_0000019,B,,CHEMBL615913,1.0,,,,,8.0,,
Expert,,858.0,,,10576.0,13276.0,H,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,BAO_0000357,B,,CHEMBL615914,1.0,,,,,8.0,,
Autocuration,Hippocampus,859.0,,,10576.0,12678.0,H,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,BAO_0000221,B,,CHEMBL615915,1.0,10000000.0,,,,8.0,,
Autocuration,,860.0,,,10576.0,11825.0,H,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,BAO_0000357,B,,CHEMBL615916,1.0,,,,,8.0,,
Expert,,861.0,,,10576.0,12443.0,H,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,BAO_0000357,B,,CHEMBL615917,1.0,,,,,8.0,,
Expert,,862.0,,,10576.0,13830.0,H,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615918,1.0,,,,,8.0,,
Expert,Hippocampus,863.0,,,10576.0,14286.0,H,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,BAO_0000249,B,,CHEMBL615919,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,864.0,,,10576.0,14356.0,D,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,BAO_0000221,B,,CHEMBL615920,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,865.0,,,10576.0,15306.0,H,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615921,1.0,,,,,8.0,,
Expert,,866.0,,,10576.0,15306.0,H,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,BAO_0000357,B,,CHEMBL615922,1.0,,,,,8.0,,
Expert,,867.0,,,10576.0,16616.0,D,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,BAO_0000249,F,,CHEMBL881290,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Hippocampus,868.0,,,10576.0,3651.0,H,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,BAO_0000221,B,,CHEMBL615923,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,869.0,,,10576.0,14331.0,H,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,F,,CHEMBL615924,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,870.0,,,10576.0,14331.0,H,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,F,,CHEMBL615925,1.0,10000000.0,,,,8.0,,
Expert,,871.0,,,10576.0,14178.0,D,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615926,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,872.0,,,10576.0,10639.0,D,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,BAO_0000019,B,,CHEMBL615927,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Hippocampus,873.0,,,10576.0,12306.0,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,BAO_0000221,B,,CHEMBL615928,1.0,10000000.0,,,,8.0,,
Expert,,874.0,,,10576.0,1348.0,D,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,BAO_0000357,B,,CHEMBL615929,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Hippocampus,875.0,,,10576.0,13605.0,H,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,BAO_0000221,B,,CHEMBL615930,1.0,10000000.0,,,,8.0,,
Autocuration,,876.0,,,51.0,17624.0,H,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,B,,CHEMBL615931,1.0,,,,CHO,8.0,449.0,
Autocuration,,877.0,,,51.0,17624.0,H,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,BAO_0000219,F,,CHEMBL615932,1.0,,,,CHO,8.0,449.0,
Autocuration,,878.0,,,51.0,17624.0,H,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,BAO_0000219,F,,CHEMBL615933,1.0,,,,CHO,8.0,449.0,
Autocuration,,879.0,,,51.0,15267.0,H,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615934,1.0,,,,,8.0,,
Autocuration,,880.0,,,51.0,16532.0,H,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,BAO_0000357,B,,CHEMBL615935,1.0,,,,,8.0,,
Autocuration,,881.0,,,51.0,6563.0,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,F,,CHEMBL615936,1.0,,,,,8.0,,
Autocuration,,882.0,,,51.0,4751.0,H,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,BAO_0000219,B,,CHEMBL615937,1.0,,,,CHO,8.0,449.0,
Autocuration,,883.0,,,51.0,15463.0,H,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615938,1.0,,,,,8.0,,
Autocuration,,884.0,,,51.0,3805.0,H,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,BAO_0000357,B,,CHEMBL615797,1.0,,,,,8.0,,
Autocuration,,885.0,,,51.0,5640.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL615798,1.0,,,,,8.0,,
Autocuration,,886.0,,,51.0,6563.0,H,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,BAO_0000357,B,,CHEMBL872870,1.0,,,,,8.0,,
Autocuration,,887.0,,,51.0,5548.0,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,BAO_0000357,B,,CHEMBL615799,1.0,,,,,8.0,,
Autocuration,,888.0,,,51.0,6347.0,H,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615800,1.0,,,,,8.0,,
Autocuration,,889.0,,,51.0,17296.0,H,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,BAO_0000219,F,,CHEMBL615801,1.0,,,,HEK293,8.0,722.0,
Autocuration,,890.0,,,51.0,13047.0,H,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,BAO_0000019,B,,CHEMBL615802,1.0,,,,,8.0,,
Autocuration,,891.0,,,51.0,15740.0,H,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,BAO_0000357,B,,CHEMBL615803,1.0,,,,,8.0,,
Expert,,892.0,,,51.0,5640.0,H,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,BAO_0000019,F,,CHEMBL835002,1.0,,,,,8.0,,
Autocuration,,893.0,,,51.0,5640.0,H,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,BAO_0000019,F,,CHEMBL615804,1.0,,,,,8.0,,
Expert,,894.0,,,51.0,17211.0,H,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,BAO_0000219,B,,CHEMBL615805,1.0,,,,HeLa,8.0,308.0,
Autocuration,,895.0,,,51.0,4751.0,H,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,BAO_0000219,B,,CHEMBL615806,1.0,,,,CHO,8.0,449.0,
Expert,,896.0,,,51.0,6491.0,D,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,BAO_0000357,B,,CHEMBL615807,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,897.0,,,51.0,4707.0,H,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,BAO_0000357,B,,CHEMBL615808,1.0,,,,,8.0,,
Expert,,898.0,,,51.0,13910.0,D,,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615809,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,899.0,,,51.0,16190.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,BAO_0000219,B,,CHEMBL615810,1.0,,,,HeLa,8.0,308.0,
Autocuration,,900.0,,,51.0,16633.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL615811,1.0,,,,,8.0,,
Autocuration,,901.0,,,51.0,11898.0,H,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,BAO_0000219,B,,CHEMBL615812,1.0,,,,CHO,8.0,449.0,
Autocuration,,902.0,,,51.0,11898.0,H,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,B,,CHEMBL615751,1.0,,,,CHO,8.0,449.0,
Autocuration,,903.0,,,51.0,14331.0,H,,Binding affinity against human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615752,1.0,,,,,8.0,,
Expert,,904.0,,,51.0,17624.0,H,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,BAO_0000219,B,,CHEMBL615753,1.0,,,,CHO,8.0,449.0,
Autocuration,,905.0,,,51.0,17624.0,H,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,BAO_0000219,B,,CHEMBL615754,1.0,,,,CHO,8.0,449.0,
Autocuration,,906.0,,,51.0,3307.0,H,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615755,1.0,,,,,8.0,,
Expert,,907.0,,,51.0,6563.0,D,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,BAO_0000219,B,,CHEMBL615756,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,908.0,,,51.0,14165.0,H,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,BAO_0000019,B,,CHEMBL615757,1.0,,,,,8.0,,
Autocuration,,909.0,,,51.0,5732.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,B,,CHEMBL615758,1.0,,,,,8.0,,
Expert,,910.0,,,51.0,13366.0,H,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,BAO_0000357,B,,CHEMBL615759,1.0,,,,,8.0,,
Autocuration,,911.0,,,51.0,17626.0,H,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615760,1.0,,,,,8.0,,
Expert,,912.0,,,51.0,6588.0,H,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,BAO_0000219,B,,CHEMBL615761,1.0,,,,HeLa,8.0,308.0,
Autocuration,,913.0,,,51.0,16209.0,H,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,BAO_0000357,B,,CHEMBL872104,1.0,,,,,8.0,,
Autocuration,,914.0,,,51.0,15463.0,H,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL615762,1.0,,,,,8.0,,
Autocuration,,915.0,,,51.0,15463.0,H,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL615763,1.0,,,,,8.0,,
Autocuration,,916.0,,,51.0,14770.0,H,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,BAO_0000357,B,,CHEMBL615764,1.0,,,,,8.0,,
Autocuration,,917.0,,,51.0,16245.0,H,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,BAO_0000219,B,,CHEMBL615765,1.0,,,,Cell line,8.0,1167.0,
Autocuration,,918.0,,,51.0,16245.0,H,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,BAO_0000019,B,,CHEMBL615766,1.0,,,,,8.0,,
Autocuration,,919.0,,,51.0,5548.0,H,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL615767,1.0,,,,,8.0,,
Expert,,920.0,,,51.0,5548.0,H,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL615768,1.0,,,,,8.0,,
Autocuration,,921.0,,,51.0,5548.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL615769,1.0,,,,,8.0,,
Expert,,922.0,,,51.0,6876.0,H,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,BAO_0000357,B,,CHEMBL615770,1.0,,,,,8.0,,
Autocuration,,923.0,,,51.0,2598.0,H,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL615771,1.0,,,,,8.0,,
Expert,,924.0,,,51.0,17785.0,H,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,BAO_0000357,B,,CHEMBL615772,1.0,,,,,8.0,,
Autocuration,,925.0,,,51.0,6013.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL615773,1.0,,,,,8.0,,
Expert,,926.0,,,51.0,5929.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL615774,1.0,,,,,8.0,,
Autocuration,,927.0,,,51.0,16633.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL615775,1.0,,,,,8.0,,
Autocuration,,928.0,,,51.0,1558.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,B,,CHEMBL615776,1.0,,,,,8.0,,
Expert,,929.0,,,51.0,16026.0,H,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL615777,1.0,,,,,8.0,,
Autocuration,,930.0,,,51.0,12469.0,H,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,BAO_0000219,B,,CHEMBL615778,1.0,,,,,8.0,,
Expert,,931.0,,,51.0,15874.0,D,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,BAO_0000357,B,,CHEMBL615779,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,932.0,,,51.0,15874.0,H,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,BAO_0000357,B,,CHEMBL615780,1.0,,,,,8.0,,
Autocuration,,933.0,,,51.0,3935.0,H,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616298,1.0,,,,,8.0,,
Autocuration,,934.0,,,51.0,15818.0,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616299,1.0,,,,,8.0,,
Autocuration,,935.0,,,51.0,13706.0,H,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,BAO_0000219,B,,CHEMBL616300,1.0,,,,CHO-K1,8.0,485.0,
Expert,,936.0,,,51.0,13729.0,H,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,BAO_0000219,F,,CHEMBL616301,1.0,,,,CHO-K1,8.0,485.0,
Autocuration,,937.0,,,51.0,15413.0,H,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,BAO_0000019,B,,CHEMBL616302,1.0,,,,,8.0,,
Autocuration,,938.0,,,51.0,15413.0,H,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,BAO_0000019,B,,CHEMBL616117,1.0,,,,,8.0,,
Autocuration,,939.0,,,51.0,15413.0,H,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,BAO_0000019,B,,CHEMBL616118,1.0,,,,,8.0,,
Autocuration,,940.0,,,51.0,15413.0,H,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,BAO_0000019,B,,CHEMBL616119,1.0,,,,,8.0,,
Expert,,941.0,,,51.0,3445.0,D,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,BAO_0000219,B,,CHEMBL616120,1.0,,,9606.0,HeLa,9.0,308.0,Homo sapiens
Autocuration,,942.0,,,51.0,15740.0,H,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616121,1.0,,,,,8.0,,
Autocuration,,943.0,,,51.0,15740.0,H,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,BAO_0000357,B,,CHEMBL616122,1.0,,,,,8.0,,
Autocuration,,944.0,,,51.0,17626.0,H,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616123,1.0,,,,,8.0,,
Expert,,945.0,,,51.0,4234.0,D,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616124,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,946.0,,,51.0,5640.0,H,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,BAO_0000357,B,,CHEMBL616125,1.0,,,,,8.0,,
Expert,,947.0,,,51.0,5272.0,H,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,BAO_0000357,B,,CHEMBL616126,1.0,,,10116.0,,8.0,,Rattus norvegicus
Autocuration,,948.0,,,51.0,4622.0,H,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,BAO_0000219,B,,CHEMBL616127,1.0,,,,CHO,8.0,449.0,
Expert,,949.0,,,51.0,17085.0,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,BAO_0000019,B,,CHEMBL616128,1.0,,,,,8.0,,
Autocuration,,950.0,,,51.0,3025.0,H,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,BAO_0000357,B,,CHEMBL616129,1.0,,,,,8.0,,
Expert,,951.0,,,51.0,15315.0,H,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616130,1.0,,,,,8.0,,
Autocuration,,952.0,,,51.0,15267.0,H,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,BAO_0000357,B,,CHEMBL616131,1.0,,,,,8.0,,
Autocuration,,953.0,,,51.0,17158.0,H,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,BAO_0000219,B,,CHEMBL616132,1.0,,,,HeLa,8.0,308.0,
Expert,,954.0,,,51.0,14214.0,D,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,BAO_0000219,B,,CHEMBL616133,1.0,,,9606.0,HeLa,9.0,308.0,Homo sapiens
Autocuration,,955.0,,,51.0,17133.0,H,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL616134,1.0,,,,,8.0,,
Autocuration,,956.0,,,51.0,16532.0,H,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,BAO_0000357,B,,CHEMBL616135,1.0,,,,,8.0,,
Expert,,957.0,,,51.0,2391.0,D,,Affinity for 5-hydroxytryptamine 1A receptor subtype,,BAO_0000357,B,,CHEMBL616136,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,958.0,,,51.0,14447.0,H,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,BAO_0000019,B,,CHEMBL616137,1.0,,,,,8.0,,
Autocuration,,959.0,,,51.0,14447.0,H,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,BAO_0000019,B,,CHEMBL872105,1.0,,,,,8.0,,
Autocuration,,960.0,,,51.0,15086.0,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,BAO_0000357,B,,CHEMBL616138,1.0,,,,,8.0,,
Expert,,961.0,,,51.0,13051.0,D,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616139,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,962.0,,,51.0,16026.0,H,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,BAO_0000019,F,,CHEMBL616140,1.0,,,,,8.0,,
Expert,,963.0,,,51.0,17085.0,H,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,BAO_0000019,B,,CHEMBL616141,1.0,,,,,8.0,,
Autocuration,,964.0,,,51.0,17133.0,H,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL616142,1.0,,,,,8.0,,
Autocuration,,965.0,,,51.0,17133.0,H,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,BAO_0000357,B,,CHEMBL616143,1.0,,,,,8.0,,
Autocuration,,966.0,,,51.0,17211.0,H,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,BAO_0000219,B,,CHEMBL616144,1.0,,,,HeLa,8.0,308.0,
Autocuration,,967.0,,,51.0,17211.0,H,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,BAO_0000219,B,,CHEMBL616145,1.0,,,,HeLa,8.0,308.0,
Autocuration,,968.0,,,51.0,17211.0,H,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,BAO_0000219,B,,CHEMBL616012,1.0,,,,HeLa,8.0,308.0,
Autocuration,,969.0,,,51.0,17211.0,H,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,BAO_0000219,B,,CHEMBL616013,1.0,,,,HeLa,8.0,308.0,
Autocuration,,970.0,,,51.0,16394.0,H,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,BAO_0000019,F,,CHEMBL616014,1.0,,,,,8.0,,
Autocuration,,971.0,,,51.0,16394.0,H,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,BAO_0000019,F,,CHEMBL616015,1.0,,,,,8.0,,
Autocuration,,972.0,,,51.0,16394.0,H,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,BAO_0000019,F,,CHEMBL616016,1.0,,,,,8.0,,
Autocuration,,973.0,,,51.0,16394.0,H,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,BAO_0000218,F,In vivo,CHEMBL616017,1.0,,,,,8.0,,
Autocuration,,974.0,,,51.0,16394.0,H,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,BAO_0000019,B,,CHEMBL616018,1.0,,,,,8.0,,
Autocuration,,975.0,,,51.0,15740.0,H,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,BAO_0000019,F,,CHEMBL616019,1.0,,,,,8.0,,
Autocuration,,976.0,,,51.0,15740.0,H,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,BAO_0000019,F,,CHEMBL616020,1.0,,,,,8.0,,
Autocuration,,977.0,,,51.0,15740.0,H,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL858018,1.0,,,,,8.0,,
Autocuration,,978.0,,,51.0,17296.0,H,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,BAO_0000219,F,,CHEMBL616021,1.0,,,,HEK293,8.0,722.0,
Expert,,979.0,,,51.0,5640.0,H,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,BAO_0000019,F,,CHEMBL616022,1.0,,,,,8.0,,
Autocuration,,980.0,,,51.0,5640.0,H,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,BAO_0000019,F,,CHEMBL616023,1.0,,,,,8.0,,
Autocuration,,981.0,,,51.0,5640.0,H,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,BAO_0000019,F,,CHEMBL616024,1.0,,,,,8.0,,
Autocuration,,982.0,,,51.0,5640.0,H,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,BAO_0000019,F,,CHEMBL616025,1.0,,,,,8.0,,
Autocuration,,983.0,,,51.0,2759.0,H,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,BAO_0000219,F,,CHEMBL616026,1.0,,,,CHO,8.0,449.0,
Autocuration,,984.0,,,51.0,16394.0,H,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,BAO_0000019,F,,CHEMBL616027,1.0,,,,,8.0,,
Expert,,985.0,,,51.0,16394.0,D,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,BAO_0000019,F,,CHEMBL616028,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,986.0,,,51.0,3445.0,D,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,BAO_0000019,F,,CHEMBL616029,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,987.0,,,51.0,4316.0,H,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,BAO_0000219,B,,CHEMBL616030,1.0,,,,CHO,8.0,449.0,
Expert,,988.0,,,51.0,4316.0,H,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,BAO_0000019,B,,CHEMBL616031,1.0,,,,,8.0,,
Expert,,989.0,,,51.0,15180.0,D,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,BAO_0000019,F,,CHEMBL616032,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,990.0,,,51.0,15180.0,D,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,BAO_0000019,F,,CHEMBL616033,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,991.0,,,51.0,15042.0,H,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,F,,CHEMBL616034,1.0,,,,,8.0,,
Autocuration,,992.0,,,51.0,15042.0,H,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,F,,CHEMBL616035,1.0,,,,,8.0,,
Autocuration,,993.0,,,51.0,15042.0,H,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000019,F,,CHEMBL616036,1.0,,,,,8.0,,
Autocuration,,994.0,,,51.0,15042.0,H,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,F,,CHEMBL616037,1.0,,,,,8.0,,
Autocuration,,995.0,,,51.0,15042.0,H,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,F,,CHEMBL616038,1.0,,,,,8.0,,
Autocuration,,996.0,,,51.0,15042.0,H,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,F,,CHEMBL616039,1.0,,,,,8.0,,
Autocuration,,997.0,,,51.0,15042.0,H,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000019,F,,CHEMBL616040,1.0,,,,,8.0,,
Expert,,998.0,,,51.0,15180.0,D,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,BAO_0000219,F,,CHEMBL616041,1.0,,,9606.0,HeLa,9.0,308.0,Homo sapiens
Expert,,999.0,,,51.0,15180.0,D,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,BAO_0000219,F,,CHEMBL616042,1.0,,,9606.0,HeLa,9.0,308.0,Homo sapiens
Expert,,1000.0,,,51.0,15180.0,D,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,BAO_0000219,F,,CHEMBL616043,1.0,,,9606.0,HeLa,9.0,308.0,Homo sapiens
Autocuration,,1001.0,,,51.0,16245.0,H,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,BAO_0000019,F,,CHEMBL616044,1.0,,,,,8.0,,
Autocuration,,1002.0,,,51.0,16026.0,H,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,BAO_0000019,F,,CHEMBL616045,1.0,,,,,8.0,,
Autocuration,,1003.0,,,51.0,17296.0,H,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,BAO_0000219,F,,CHEMBL616046,1.0,,,,HEK293,8.0,722.0,
Autocuration,,1004.0,,,51.0,2759.0,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,BAO_0000219,F,,CHEMBL616047,1.0,,,,CHO,8.0,449.0,
Autocuration,,1005.0,,,51.0,2759.0,H,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,BAO_0000219,F,,CHEMBL616048,1.0,,,,CHO,8.0,449.0,
Expert,,1006.0,,,51.0,2759.0,D,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,BAO_0000219,F,,CHEMBL616049,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,1007.0,,,51.0,2759.0,H,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,BAO_0000219,F,,CHEMBL616050,1.0,,,,CHO,8.0,449.0,
Expert,,1008.0,,,51.0,15419.0,H,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,BAO_0000219,F,,CHEMBL616051,1.0,,,,,8.0,,
Autocuration,,1009.0,,,51.0,15419.0,H,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,BAO_0000219,F,,CHEMBL616212,1.0,,,,,8.0,,
Autocuration,,1010.0,,,51.0,16026.0,H,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,BAO_0000019,F,,CHEMBL616213,1.0,,,,,8.0,,
Expert,,1011.0,,,51.0,1414.0,H,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,BAO_0000219,B,In vitro,CHEMBL616214,1.0,,,,,8.0,,
Expert,,1012.0,,,51.0,1414.0,H,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,BAO_0000219,B,In vitro,CHEMBL616215,1.0,,,,,8.0,,
Autocuration,,1013.0,,,51.0,12861.0,H,,Binding activity radioligand.,,BAO_0000357,B,,CHEMBL616216,1.0,,,,,8.0,,
Autocuration,,1014.0,,,51.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,B,,CHEMBL616217,1.0,,,,,8.0,,
Autocuration,,1015.0,,,51.0,5104.0,H,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616218,1.0,,,,,8.0,,
Autocuration,,1016.0,,,51.0,5105.0,H,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616219,1.0,,,,,8.0,,
Autocuration,,1017.0,,,51.0,16312.0,H,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616220,1.0,,,,,8.0,,
Expert,,1018.0,,,51.0,15180.0,D,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL833493,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,1019.0,,,51.0,5033.0,H,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616221,1.0,,,,,8.0,,
Expert,,1020.0,,,51.0,16909.0,D,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,BAO_0000219,B,,CHEMBL616222,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,1021.0,,,51.0,2590.0,H,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000019,F,,CHEMBL616223,1.0,,,,,8.0,,
Autocuration,,1022.0,,,51.0,2590.0,H,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,BAO_0000019,F,,CHEMBL616224,1.0,,,,,8.0,,
Expert,,1023.0,,,51.0,16394.0,H,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,BAO_0000019,B,,CHEMBL616225,1.0,,,,,8.0,,
Expert,,1024.0,,,51.0,4540.0,D,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,BAO_0000219,B,,CHEMBL616226,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Autocuration,,1025.0,,,51.0,17296.0,H,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,BAO_0000219,B,,CHEMBL616227,1.0,,,,HEK293,8.0,722.0,
Autocuration,,1026.0,,,51.0,17296.0,H,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,BAO_0000219,B,,CHEMBL616228,1.0,,,,HEK293,8.0,722.0,
Autocuration,,1027.0,,,51.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,BAO_0000219,B,,CHEMBL616229,1.0,,,,HEK293,8.0,722.0,
Autocuration,,1028.0,,,51.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,BAO_0000219,B,,CHEMBL616230,1.0,,,,HEK293,8.0,722.0,
Autocuration,,1029.0,,,51.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,BAO_0000219,B,,CHEMBL616231,1.0,,,,HEK293,8.0,722.0,
Autocuration,,1030.0,,,51.0,6166.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL616232,1.0,,,,,8.0,,
Autocuration,,1031.0,,,51.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,BAO_0000219,B,,CHEMBL616233,1.0,,,,HEK293,8.0,722.0,
Autocuration,,1032.0,,,51.0,4199.0,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,BAO_0000219,B,,CHEMBL857973,1.0,,,,HEK293,8.0,722.0,
Autocuration,,1033.0,,,51.0,15316.0,H,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,BAO_0000219,B,,CHEMBL616234,1.0,,,,,8.0,,
Autocuration,,1034.0,,,51.0,14875.0,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616235,1.0,,,,,8.0,,
Expert,,1035.0,,,51.0,14727.0,H,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,BAO_0000219,B,,CHEMBL616236,1.0,,,,HeLa,8.0,308.0,
Expert,,1036.0,,,51.0,14727.0,H,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,BAO_0000019,B,,CHEMBL616237,1.0,,,,,8.0,,
Autocuration,,1037.0,,,51.0,15146.0,H,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,BAO_0000219,B,,CHEMBL616238,1.0,,,,HEK293,8.0,722.0,
Autocuration,,1038.0,,,51.0,5213.0,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,BAO_0000219,B,,CHEMBL616239,1.0,,,,HEK293,8.0,722.0,
Autocuration,,1039.0,,,51.0,16429.0,H,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,BAO_0000219,B,,CHEMBL616240,1.0,,,,,8.0,,
Expert,,1040.0,,,51.0,15042.0,D,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,BAO_0000219,B,,CHEMBL616241,1.0,,,9606.0,HeLa,9.0,308.0,Homo sapiens
Autocuration,,1041.0,,,51.0,14818.0,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,BAO_0000219,B,,CHEMBL616242,1.0,,,,HEK293,8.0,722.0,
Autocuration,,1042.0,,,51.0,4829.0,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,BAO_0000219,B,,CHEMBL616243,1.0,,,,HEK293,8.0,722.0,
Expert,,1043.0,,,51.0,17200.0,D,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616244,1.0,,,,,9.0,,
Autocuration,,1044.0,,,51.0,13051.0,D,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616245,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,1045.0,,,106.0,5486.0,H,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,BAO_0000357,B,,CHEMBL616246,1.0,,,,,8.0,,
Autocuration,,1046.0,,,105.0,5254.0,H,,Binding affinity against 5-HT1D receptor,,BAO_0000357,B,,CHEMBL616247,1.0,,,,,8.0,,
Autocuration,,1047.0,,,105.0,5254.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616248,1.0,,,,,8.0,,
Autocuration,,1048.0,,,107.0,15331.0,H,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,BAO_0000357,B,,CHEMBL616249,1.0,,,,,8.0,,
Autocuration,,1049.0,,,10576.0,13506.0,H,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,BAO_0000357,B,,CHEMBL616250,1.0,,,9606.0,,8.0,,Homo sapiens
Autocuration,,1050.0,,,51.0,15267.0,H,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616251,1.0,,,,,8.0,,
Autocuration,,1051.0,,,11863.0,16616.0,H,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,BAO_0000218,F,In vivo,CHEMBL616252,1.0,,,,,8.0,,
Autocuration,,1052.0,,,11863.0,16616.0,H,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,BAO_0000218,F,In vivo,CHEMBL616253,1.0,,,,,8.0,,
Autocuration,,1053.0,,,11863.0,16616.0,H,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,BAO_0000218,F,In vivo,CHEMBL616254,1.0,,,,,8.0,,
Expert,,1054.0,,,11863.0,16616.0,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,BAO_0000218,F,,CHEMBL616255,1.0,,,10090.0,,9.0,,Mus musculus
Expert,,1055.0,,,11863.0,16616.0,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,BAO_0000218,F,,CHEMBL832872,1.0,,,10090.0,,9.0,,Mus musculus
Expert,,1056.0,,,11863.0,16616.0,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,BAO_0000218,F,,CHEMBL616256,1.0,,,10090.0,,9.0,,Mus musculus
Expert,,1057.0,,,11863.0,16616.0,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,BAO_0000218,F,,CHEMBL616257,1.0,,,10090.0,,9.0,,Mus musculus
Expert,,1058.0,,,11863.0,16616.0,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,BAO_0000218,F,,CHEMBL616258,1.0,,,10090.0,,9.0,,Mus musculus
Expert,,1059.0,,,11863.0,16616.0,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,BAO_0000218,F,,CHEMBL616384,1.0,,,10090.0,,9.0,,Mus musculus
Autocuration,Hippocampus,1060.0,,,11863.0,10297.0,H,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,BAO_0000221,B,,CHEMBL616385,1.0,10000000.0,,,,8.0,,
Expert,,1061.0,,,11863.0,13704.0,H,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,BAO_0000357,B,,CHEMBL616386,1.0,,,,,8.0,,
Expert,Hippocampus,1062.0,,,11863.0,10297.0,D,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,BAO_0000221,B,,CHEMBL616387,1.0,10000000.0,,10090.0,,9.0,,Mus musculus
Autocuration,Hippocampus,1063.0,,,11863.0,10297.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,BAO_0000221,B,,CHEMBL616388,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1064.0,,,11863.0,10297.0,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,BAO_0000221,B,,CHEMBL616389,1.0,10000000.0,,10090.0,,9.0,,Mus musculus
Autocuration,Hippocampus,1065.0,,,11863.0,10297.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,BAO_0000221,B,,CHEMBL616390,1.0,10000000.0,,,,8.0,,
Autocuration,,1066.0,,,11863.0,217.0,H,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,BAO_0000357,B,,CHEMBL616391,1.0,,,,,8.0,,
Expert,Hippocampus,1067.0,,,11863.0,10297.0,D,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,BAO_0000221,B,,CHEMBL616392,1.0,10000000.0,,10090.0,,9.0,,Mus musculus
Autocuration,,1068.0,,,51.0,4921.0,H,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616393,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1069.0,,,51.0,4921.0,H,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,BAO_0000357,B,,CHEMBL616394,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1070.0,,,51.0,4996.0,H,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,BAO_0000019,B,,CHEMBL616395,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1071.0,,,51.0,12918.0,H,,Compound was evaluated for the binding affinity at 5- HT1A receptor,,BAO_0000357,B,,CHEMBL616396,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1072.0,,,51.0,5333.0,H,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,BAO_0000019,B,,CHEMBL872907,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1073.0,,,51.0,4437.0,H,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,BAO_0000019,B,,CHEMBL616397,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1074.0,,,51.0,1742.0,H,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,BAO_0000019,B,,CHEMBL616398,1.0,,,9823.0,,8.0,,Sus scrofa
Expert,,1075.0,,,51.0,16688.0,H,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616399,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1076.0,,,51.0,12861.0,H,,Binding activity radioligand.,,BAO_0000357,B,,CHEMBL857065,1.0,,,9823.0,,8.0,,Sus scrofa
Expert,,1077.0,,,51.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,BAO_0000019,B,,CHEMBL616400,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1078.0,,,51.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,BAO_0000019,B,,CHEMBL616401,1.0,,,9823.0,,8.0,,Sus scrofa
Expert,,1079.0,,,10624.0,12490.0,H,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,BAO_0000019,B,,CHEMBL616402,1.0,,,,,8.0,,
Expert,,1080.0,,,51.0,11828.0,H,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,BAO_0000019,B,,CHEMBL616403,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,Hippocampus,1081.0,,,51.0,11866.0,H,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,BAO_0000221,B,,CHEMBL616404,1.0,10000000.0,,9823.0,,8.0,,Sus scrofa
Autocuration,,1082.0,,,51.0,12827.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,BAO_0000249,B,,CHEMBL616405,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1083.0,,,51.0,12918.0,H,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,BAO_0000019,B,,CHEMBL616406,1.0,,,9823.0,,8.0,,Sus scrofa
Expert,,1084.0,,,51.0,12919.0,H,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,BAO_0000019,F,,CHEMBL616407,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1085.0,,,51.0,13047.0,H,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,BAO_0000019,B,,CHEMBL616408,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Expert,,1086.0,,,10576.0,15796.0,D,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,BAO_0000249,B,,CHEMBL616409,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,Hippocampus,1087.0,,,10576.0,3651.0,D,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,BAO_0000221,B,,CHEMBL616410,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1088.0,,,10576.0,188.0,H,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,BAO_0000357,B,,CHEMBL616411,1.0,,,,,8.0,,
Expert,,1089.0,,,10576.0,16616.0,D,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Membranes,BAO_0000249,F,,CHEMBL616412,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,Hippocampus,1090.0,,,10576.0,16616.0,D,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Membranes,BAO_0000249,F,,CHEMBL616413,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Hippocampus,1091.0,,,10576.0,12306.0,H,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,BAO_0000221,B,,CHEMBL616414,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1092.0,,,10576.0,17167.0,D,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,BAO_0000221,B,,CHEMBL616415,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1093.0,,,10576.0,14776.0,H,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,BAO_0000019,B,,CHEMBL616416,1.0,,,,,8.0,,
Expert,,1094.0,,,10576.0,12158.0,H,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,BAO_0000357,B,,CHEMBL616417,1.0,,,,,8.0,,
Autocuration,,1095.0,,,10576.0,13481.0,H,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,BAO_0000357,B,,CHEMBL616418,1.0,,,,,8.0,,
Autocuration,,1096.0,,,10576.0,13427.0,H,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,BAO_0000219,B,In vitro,CHEMBL616419,1.0,,,,,8.0,,
Autocuration,,1097.0,,,10576.0,10210.0,H,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,BAO_0000357,B,,CHEMBL616420,1.0,,,,,8.0,,
Autocuration,,1098.0,,,10576.0,10205.0,H,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Membranes,BAO_0000249,B,,CHEMBL616421,1.0,,,,,8.0,,
Autocuration,,1099.0,,,10576.0,10205.0,H,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Membranes,BAO_0000249,B,,CHEMBL616422,1.0,,,,,8.0,,
Expert,,1100.0,,,10576.0,10205.0,H,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,Membranes,BAO_0000249,B,,CHEMBL616423,1.0,,,,,8.0,,
Expert,,1101.0,,,10576.0,12280.0,D,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,BAO_0000357,B,,CHEMBL616424,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,1102.0,,,10576.0,17386.0,H,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616425,1.0,,,,,8.0,,
Expert,,1103.0,,,10576.0,13654.0,H,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,BAO_0000357,B,,CHEMBL616426,1.0,,,,,8.0,,
Autocuration,Hippocampus,1104.0,,,10576.0,14423.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,BAO_0000221,B,,CHEMBL616427,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1105.0,,,10576.0,15412.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,BAO_0000221,B,,CHEMBL616428,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1106.0,,,10576.0,12073.0,H,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,B,,CHEMBL616290,1.0,10000000.0,,,,8.0,,
Expert,,1107.0,,,10576.0,4101.0,D,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616052,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1108.0,,,10576.0,10062.0,H,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616053,1.0,,,,,8.0,,
Autocuration,,1109.0,,,10576.0,6238.0,H,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,BAO_0000249,B,,CHEMBL616054,1.0,,,,,8.0,,
Autocuration,,1110.0,,,10576.0,16273.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616055,1.0,,,,,8.0,,
Autocuration,,1111.0,,,10576.0,11139.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,BAO_0000357,B,,CHEMBL616056,1.0,,,,,8.0,,
Expert,,1112.0,,,10576.0,16796.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,BAO_0000019,B,,CHEMBL616057,1.0,,,,,8.0,,
Expert,Brain,1113.0,,,10576.0,9548.0,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,BAO_0000221,B,,CHEMBL616058,1.0,955.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Brain,1114.0,,,10576.0,10381.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,BAO_0000221,B,,CHEMBL616059,1.0,955.0,,,,8.0,,
Autocuration,,1115.0,,,10576.0,13408.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,BAO_0000249,B,,CHEMBL616060,1.0,,,,,8.0,,
Expert,Hippocampus,1116.0,,,10576.0,13825.0,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,BAO_0000221,B,,CHEMBL616061,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Expert,Hippocampus,1117.0,,,10576.0,11147.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,BAO_0000221,B,,CHEMBL616062,1.0,10000000.0,,,,8.0,,
Autocuration,,1118.0,,,10576.0,10552.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,BAO_0000249,B,,CHEMBL616063,1.0,,,,,8.0,,
Autocuration,Striatum,1119.0,,,10576.0,10552.0,H,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,BAO_0000249,B,,CHEMBL616064,1.0,2435.0,,,,8.0,,
Expert,,1120.0,,,10576.0,17136.0,D,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,Membranes,BAO_0000249,B,,CHEMBL616065,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,1121.0,,,10576.0,5778.0,D,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,Membranes,BAO_0000249,B,,CHEMBL616066,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Hippocampus,1122.0,,,10576.0,13481.0,H,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000221,B,,CHEMBL616067,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1123.0,,,10576.0,13481.0,H,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,BAO_0000221,B,,CHEMBL616068,1.0,10000000.0,,,,8.0,,
Intermediate,Hippocampus,1124.0,,,10576.0,13630.0,H,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,BAO_0000221,B,,CHEMBL616069,1.0,10000000.0,,,,8.0,,
Expert,,1125.0,,,10576.0,16245.0,H,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,BAO_0000249,B,,CHEMBL616070,1.0,,,,,8.0,,
Autocuration,Hippocampus,1126.0,,,10576.0,14509.0,H,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,BAO_0000221,B,,CHEMBL616071,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1127.0,,,10576.0,14509.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,BAO_0000221,B,,CHEMBL616072,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1128.0,,,10576.0,14509.0,H,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,BAO_0000221,B,,CHEMBL616073,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1129.0,,,10576.0,14509.0,H,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,BAO_0000221,B,,CHEMBL616074,1.0,10000000.0,,,,8.0,,
Expert,,1130.0,,,10576.0,14256.0,H,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,BAO_0000019,B,,CHEMBL616075,1.0,,,,,8.0,,
Autocuration,,1131.0,,,10576.0,11139.0,H,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616076,1.0,,,,,8.0,,
Expert,,1132.0,,,10576.0,11047.0,D,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,BAO_0000019,B,,CHEMBL616077,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,1133.0,,,10576.0,11047.0,D,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,BAO_0000019,B,,CHEMBL616078,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,1134.0,,,10576.0,11047.0,D,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,BAO_0000019,B,,CHEMBL616079,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,1135.0,,,10576.0,2395.0,D,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,BAO_0000219,B,,CHEMBL616080,1.0,,,10116.0,CHO-K1,9.0,485.0,Rattus norvegicus
Autocuration,,1136.0,,,10576.0,9699.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616081,1.0,,,,,8.0,,
Expert,Hippocampus,1137.0,,,10576.0,12028.0,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,BAO_0000221,B,,CHEMBL616082,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Hippocampus,1138.0,,,10576.0,12028.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,BAO_0000221,B,,CHEMBL616083,1.0,10000000.0,,,,8.0,,
Autocuration,,1139.0,,,10576.0,5815.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,BAO_0000019,B,,CHEMBL616084,1.0,,,,,8.0,,
Expert,,1140.0,,,10576.0,16616.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,BAO_0000019,B,,CHEMBL616085,1.0,,,,,8.0,,
Autocuration,,1141.0,,,10576.0,5815.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,BAO_0000019,B,,CHEMBL616086,1.0,,,,,8.0,,
Autocuration,Hippocampus,1142.0,,,10576.0,2761.0,H,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,BAO_0000221,B,,CHEMBL616087,1.0,10000000.0,,,,8.0,,
Expert,,1143.0,,,10576.0,13133.0,H,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,BAO_0000357,B,,CHEMBL616088,1.0,,,,,8.0,,
Autocuration,,1144.0,,,10576.0,10444.0,H,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,BAO_0000019,B,,CHEMBL616089,1.0,,,,,8.0,,
Expert,,1145.0,,,10576.0,13278.0,D,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,BAO_0000357,B,,CHEMBL616090,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1146.0,,,10576.0,15874.0,H,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,BAO_0000357,B,,CHEMBL616091,1.0,,,,,8.0,,
Autocuration,Striatum,1147.0,,,10576.0,10552.0,H,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Membranes,BAO_0000249,B,,CHEMBL616092,1.0,2435.0,,,,8.0,,
Autocuration,,1148.0,,,10576.0,11130.0,H,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,BAO_0000357,B,,CHEMBL616093,1.0,,,,,8.0,,
Autocuration,,1149.0,,,10576.0,11130.0,H,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,BAO_0000218,B,In vivo,CHEMBL616094,1.0,,,,,8.0,,
Autocuration,Brain,1150.0,,,10576.0,14542.0,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,BAO_0000221,B,,CHEMBL616095,1.0,955.0,,,,8.0,,
Expert,,1151.0,,,10576.0,13670.0,D,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616096,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,1152.0,,,10576.0,9888.0,H,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,BAO_0000249,B,,CHEMBL616097,1.0,,,,,8.0,,
Expert,,1153.0,,,10576.0,3678.0,D,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,Membranes,BAO_0000249,B,,CHEMBL616098,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Hippocampus,1154.0,,,10576.0,11332.0,H,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,BAO_0000221,B,,CHEMBL616099,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1155.0,,,10576.0,11332.0,H,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,BAO_0000221,B,,CHEMBL616100,1.0,10000000.0,,,,8.0,,
Expert,,1156.0,,,10576.0,1185.0,H,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616101,1.0,,,,,8.0,,
Expert,,1157.0,,,10576.0,2014.0,H,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,BAO_0000249,B,,CHEMBL616102,1.0,,,,,8.0,,
Autocuration,,1158.0,,,10576.0,1185.0,H,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616103,1.0,,,,,8.0,,
Expert,,1159.0,,,10576.0,14429.0,H,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,BAO_0000019,B,,CHEMBL616104,1.0,,,,,8.0,,
Expert,,1160.0,,,10576.0,16288.0,H,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,BAO_0000019,B,,CHEMBL616105,1.0,,,,,8.0,,
Expert,,1161.0,,,10576.0,5432.0,D,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,BAO_0000019,B,,CHEMBL616106,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1162.0,,,10576.0,14429.0,H,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,BAO_0000019,B,,CHEMBL616107,1.0,,,,,8.0,,
Expert,,1163.0,,,10576.0,13672.0,H,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,BAO_0000357,B,,CHEMBL616108,1.0,,,,,8.0,,
Expert,Hippocampus,1164.0,,,10576.0,11296.0,H,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,BAO_0000221,B,,CHEMBL616109,1.0,10000000.0,,,,8.0,,
Autocuration,,1165.0,,,10576.0,11296.0,H,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,BAO_0000357,B,,CHEMBL616110,1.0,,,,,8.0,,
Expert,,1166.0,,,10576.0,14749.0,H,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,BAO_0000219,B,,CHEMBL616111,1.0,,,,CHO,8.0,449.0,
Expert,,1167.0,,,10576.0,15086.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,BAO_0000019,B,,CHEMBL616112,1.0,,,,,8.0,,
Autocuration,Hippocampus,1168.0,,,10576.0,13462.0,H,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,BAO_0000221,B,,CHEMBL616113,1.0,10000000.0,,,,8.0,,
Autocuration,,1169.0,,,10576.0,15363.0,H,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,BAO_0000019,B,,CHEMBL616114,1.0,,,,,8.0,,
Autocuration,,1170.0,,,10576.0,15363.0,H,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,BAO_0000019,B,,CHEMBL616115,1.0,,,,,8.0,,
Autocuration,,1171.0,,,10576.0,10796.0,H,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616116,1.0,,,,,8.0,,
Expert,Brain,1172.0,,,10576.0,12816.0,H,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,BAO_0000221,B,,CHEMBL615844,1.0,955.0,,,,8.0,,
Expert,Hippocampus,1173.0,,,10576.0,13542.0,H,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,BAO_0000221,B,,CHEMBL615939,1.0,10000000.0,,,,8.0,,
Expert,,1174.0,,,10576.0,13308.0,H,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,BAO_0000019,B,,CHEMBL615940,1.0,,,,,8.0,,
Expert,Hippocampus,1175.0,,,10576.0,13541.0,H,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,BAO_0000221,B,,CHEMBL615941,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1176.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,BAO_0000221,B,,CHEMBL615942,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1177.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,BAO_0000221,B,,CHEMBL615943,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1178.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,BAO_0000221,B,,CHEMBL615944,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1179.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,BAO_0000221,B,,CHEMBL615945,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1180.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,BAO_0000221,B,,CHEMBL615946,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1181.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,BAO_0000221,B,,CHEMBL615947,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1182.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,BAO_0000221,B,,CHEMBL615948,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1183.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,BAO_0000221,B,,CHEMBL615949,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1184.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,BAO_0000221,B,,CHEMBL615950,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1185.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,BAO_0000221,B,,CHEMBL615951,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1186.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,BAO_0000221,B,,CHEMBL615952,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1187.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,BAO_0000221,B,,CHEMBL615953,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1188.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,BAO_0000221,B,,CHEMBL615954,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1189.0,,,10576.0,10058.0,D,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,BAO_0000221,B,,CHEMBL615955,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Hippocampus,1190.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,BAO_0000221,B,,CHEMBL615956,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1191.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,BAO_0000221,B,,CHEMBL615957,1.0,10000000.0,,,,8.0,,
Expert,,1192.0,,,10576.0,12879.0,H,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,BAO_0000019,B,,CHEMBL615958,1.0,,,,,8.0,,
Expert,,1193.0,,,10576.0,11964.0,H,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,BAO_0000019,B,,CHEMBL615959,1.0,,,,,8.0,,
Autocuration,,1194.0,,,10576.0,11964.0,H,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,BAO_0000019,B,,CHEMBL615960,1.0,,,,,8.0,,
Autocuration,,1195.0,,,10576.0,11964.0,H,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,BAO_0000019,B,,CHEMBL615961,1.0,,,,,8.0,,
Expert,Brain,1196.0,,,10576.0,9548.0,H,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,BAO_0000221,B,,CHEMBL615962,1.0,955.0,,,,8.0,,
Expert,,1197.0,,,10576.0,9098.0,H,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,BAO_0000019,B,,CHEMBL615963,1.0,,,,,8.0,,
Autocuration,,1198.0,,,10576.0,9098.0,H,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,BAO_0000019,B,,CHEMBL615964,1.0,,,,,8.0,,
Autocuration,,1199.0,,,10576.0,9098.0,H,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,BAO_0000019,B,,CHEMBL615965,1.0,,,,,8.0,,
Expert,,1200.0,,,10576.0,13248.0,H,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,BAO_0000219,B,,CHEMBL615966,1.0,,,,CHO,8.0,449.0,
Expert,,1201.0,,,10576.0,3147.0,H,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,BAO_0000249,B,,CHEMBL615967,1.0,,,,,8.0,,
Expert,,1202.0,,,10576.0,13949.0,H,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,BAO_0000019,B,,CHEMBL615968,1.0,,,,,8.0,,
Autocuration,,1203.0,,,10576.0,11883.0,H,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,BAO_0000218,B,,CHEMBL615969,1.0,,,,CHO,8.0,449.0,
Autocuration,,1204.0,,,10576.0,11883.0,H,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,BAO_0000218,B,,CHEMBL615970,1.0,,,,,8.0,,
Expert,,1205.0,,,10576.0,11883.0,D,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,BAO_0000357,B,,CHEMBL615971,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,1206.0,,,10576.0,15535.0,H,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Membranes,BAO_0000249,B,,CHEMBL615972,1.0,,,,,8.0,,
Autocuration,,1207.0,,,10576.0,15535.0,H,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,BAO_0000249,B,,CHEMBL615973,1.0,,,,,8.0,,
Autocuration,,1208.0,,,10576.0,15535.0,H,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,BAO_0000249,B,,CHEMBL615974,1.0,,,,,8.0,,
Expert,,1209.0,,,51.0,16372.0,D,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,BAO_0000219,B,,CHEMBL615975,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Expert,,1210.0,,,10576.0,14608.0,H,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,BAO_0000249,B,,CHEMBL615976,1.0,,,,,8.0,,
Expert,Hippocampus,1211.0,,,10576.0,4795.0,D,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,BAO_0000221,B,,CHEMBL872106,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1212.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL615977,1.0,,,,,8.0,,
Autocuration,,1213.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,BAO_0000357,B,,CHEMBL615978,1.0,,,,,8.0,,
Autocuration,,1214.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,BAO_0000357,B,,CHEMBL616166,1.0,,,,,8.0,,
Autocuration,,1215.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,BAO_0000357,B,,CHEMBL616167,1.0,,,,,8.0,,
Autocuration,,1216.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,BAO_0000357,B,,CHEMBL616168,1.0,,,,,8.0,,
Autocuration,,1217.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,BAO_0000357,B,,CHEMBL616169,1.0,,,,,8.0,,
Autocuration,,1218.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,BAO_0000357,B,,CHEMBL616170,1.0,,,,,8.0,,
Autocuration,,1219.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,BAO_0000357,B,,CHEMBL616171,1.0,,,,,8.0,,
Autocuration,,1220.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,BAO_0000357,B,,CHEMBL616172,1.0,,,,,8.0,,
Autocuration,,1221.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,BAO_0000357,B,,CHEMBL616173,1.0,,,,,8.0,,
Autocuration,,1222.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,BAO_0000357,B,,CHEMBL616174,1.0,,,,,8.0,,
Autocuration,,1223.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,BAO_0000357,B,,CHEMBL616175,1.0,,,,,8.0,,
Autocuration,,1224.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,BAO_0000357,B,,CHEMBL616176,1.0,,,,,8.0,,
Autocuration,,1225.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,BAO_0000357,B,,CHEMBL616177,1.0,,,,,8.0,,
Autocuration,,1226.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,BAO_0000357,B,,CHEMBL616178,1.0,,,,,8.0,,
Autocuration,,1227.0,,,10576.0,9742.0,H,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,BAO_0000019,B,,CHEMBL616179,1.0,,,,,8.0,,
Autocuration,,1228.0,,,10576.0,12073.0,H,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616180,1.0,,,,,8.0,,
Autocuration,,1229.0,,,10576.0,4101.0,H,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,BAO_0000357,B,,CHEMBL616181,1.0,,,,,8.0,,
Autocuration,,1230.0,,,10576.0,15360.0,H,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,BAO_0000019,B,,CHEMBL616182,1.0,,,,,8.0,,
Autocuration,Hippocampus,1231.0,,,10576.0,11576.0,H,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,BAO_0000221,B,,CHEMBL616183,1.0,10000000.0,,,,8.0,,
Expert,,1232.0,,,10576.0,5834.0,H,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,BAO_0000019,B,,CHEMBL615874,1.0,,,,,8.0,,
Expert,,1233.0,,,10576.0,2395.0,D,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,BAO_0000219,B,,CHEMBL615875,1.0,,,10116.0,CHO-K1,9.0,485.0,Rattus norvegicus
Autocuration,,1234.0,,,10576.0,1375.0,H,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,BAO_0000019,B,,CHEMBL615876,1.0,,,,,8.0,,
Autocuration,,1235.0,,,10576.0,1375.0,H,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,BAO_0000019,B,,CHEMBL615877,1.0,,,,,8.0,,
Autocuration,,1236.0,,,10576.0,3967.0,H,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,BAO_0000357,B,,CHEMBL615878,1.0,,,,,8.0,,
Expert,,1237.0,,,10576.0,12884.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,BAO_0000357,B,,CHEMBL615879,1.0,,,,,8.0,,
Expert,,1238.0,,,10576.0,2343.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,BAO_0000357,B,,CHEMBL615880,1.0,,,,,8.0,,
Autocuration,,1239.0,,,10576.0,11511.0,H,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,BAO_0000019,B,,CHEMBL615881,1.0,,,,,8.0,,
Expert,,1240.0,,,10576.0,11511.0,D,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,BAO_0000019,B,,CHEMBL615882,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1241.0,,,10576.0,16394.0,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,BAO_0000218,F,In vivo,CHEMBL615883,1.0,,,,,8.0,,
Autocuration,,1242.0,,,10576.0,16394.0,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,BAO_0000218,F,In vivo,CHEMBL615884,1.0,,,,,8.0,,
Autocuration,,1243.0,,,10576.0,16394.0,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,BAO_0000218,F,In vivo,CHEMBL615885,1.0,,,,,8.0,,
Autocuration,,1244.0,,,10576.0,16394.0,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,BAO_0000218,F,In vivo,CHEMBL615886,1.0,,,,,8.0,,
Autocuration,,1245.0,,,10576.0,16394.0,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,BAO_0000218,F,In vivo,CHEMBL615887,1.0,,,,,8.0,,
Autocuration,,1246.0,,,10576.0,16394.0,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,BAO_0000218,F,In vivo,CHEMBL615888,1.0,,,,,8.0,,
Autocuration,,1247.0,,,10576.0,16394.0,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,BAO_0000218,F,In vivo,CHEMBL615889,1.0,,,,,8.0,,
Autocuration,,1248.0,,,10576.0,16394.0,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,BAO_0000218,F,In vivo,CHEMBL615890,1.0,,,,,8.0,,
Autocuration,,1249.0,,,10576.0,16394.0,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,BAO_0000218,F,In vivo,CHEMBL615891,1.0,,,,,8.0,,
Autocuration,,1250.0,,,10576.0,16394.0,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,BAO_0000218,F,In vivo,CHEMBL615892,1.0,,,,,8.0,,
Autocuration,,1251.0,,,10576.0,16394.0,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,BAO_0000218,F,In vivo,CHEMBL615893,1.0,,,,,8.0,,
Autocuration,,1252.0,,,10576.0,16394.0,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,BAO_0000218,F,In vivo,CHEMBL615894,1.0,,,,,8.0,,
Autocuration,,1253.0,,,10576.0,16394.0,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,BAO_0000218,F,In vivo,CHEMBL615895,1.0,,,,,8.0,,
Autocuration,,1254.0,,,10576.0,16394.0,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,BAO_0000218,F,In vivo,CHEMBL615896,1.0,,,,,8.0,,
Autocuration,,1255.0,,,10576.0,16394.0,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,BAO_0000218,F,In vivo,CHEMBL615897,1.0,,,,,8.0,,
Expert,,1256.0,,,10576.0,16616.0,D,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Membranes,BAO_0000249,F,,CHEMBL615898,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1257.0,,,10576.0,16796.0,H,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,BAO_0000019,B,,CHEMBL615899,1.0,,,,,8.0,,
Autocuration,,1258.0,,,10576.0,16796.0,H,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,BAO_0000019,B,,CHEMBL616291,1.0,,,,,8.0,,
Autocuration,,1259.0,,,10576.0,15629.0,H,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,BAO_0000357,B,,CHEMBL616292,1.0,,,,,8.0,,
Autocuration,,1260.0,,,10576.0,13241.0,H,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,BAO_0000249,F,,CHEMBL616293,1.0,,,,,8.0,,
Expert,Hippocampus,1261.0,,,10576.0,12073.0,H,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,B,,CHEMBL616294,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1262.0,,,10576.0,14286.0,H,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,BAO_0000249,B,,CHEMBL616295,1.0,10000000.0,,,,8.0,,
Autocuration,Brain,1263.0,,,10576.0,14542.0,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,BAO_0000221,B,,CHEMBL616296,1.0,955.0,,,,8.0,,
Autocuration,,1264.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,BAO_0000019,F,,CHEMBL616297,1.0,,,,,8.0,,
Autocuration,,1265.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,BAO_0000019,F,,CHEMBL616605,1.0,,,,,8.0,,
Autocuration,,1266.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,BAO_0000019,F,,CHEMBL616606,1.0,,,,,8.0,,
Autocuration,,1267.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,BAO_0000019,F,,CHEMBL616607,1.0,,,,,8.0,,
Expert,,1268.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,BAO_0000019,F,,CHEMBL616608,1.0,,,,,8.0,,
Autocuration,,1269.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,BAO_0000019,F,,CHEMBL616609,1.0,,,,,8.0,,
Expert,,1270.0,,,10576.0,13630.0,D,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,BAO_0000019,F,,CHEMBL616610,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1271.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,BAO_0000019,F,,CHEMBL616611,1.0,,,,,8.0,,
Expert,,1272.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,BAO_0000019,F,,CHEMBL616612,1.0,,,,,8.0,,
Autocuration,,1273.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,BAO_0000019,F,,CHEMBL616613,1.0,,,,,8.0,,
Expert,,1274.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,BAO_0000019,F,,CHEMBL616614,1.0,,,,,8.0,,
Autocuration,,1275.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,BAO_0000019,F,,CHEMBL616615,1.0,,,,,8.0,,
Expert,,1276.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,BAO_0000019,F,,CHEMBL616616,1.0,,,,,8.0,,
Autocuration,,1277.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,BAO_0000019,F,,CHEMBL616617,1.0,,,,,8.0,,
Autocuration,,1278.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,BAO_0000019,F,,CHEMBL616618,1.0,,,,,8.0,,
Autocuration,,1279.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,BAO_0000019,F,,CHEMBL616619,1.0,,,,,8.0,,
Expert,,1280.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,BAO_0000019,F,,CHEMBL616620,1.0,,,,,8.0,,
Expert,,1281.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,BAO_0000019,F,,CHEMBL616621,1.0,,,,,8.0,,
Autocuration,,1282.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,BAO_0000019,F,,CHEMBL616622,1.0,,,,,8.0,,
Expert,,1283.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,BAO_0000019,F,,CHEMBL616146,1.0,,,,,8.0,,
Autocuration,,1284.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,BAO_0000019,F,,CHEMBL832873,1.0,,,,,8.0,,
Autocuration,,1285.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,BAO_0000019,F,,CHEMBL616147,1.0,,,,,8.0,,
Autocuration,,1286.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,BAO_0000019,F,,CHEMBL872872,1.0,,,,,8.0,,
Autocuration,,1287.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,BAO_0000019,F,,CHEMBL616148,1.0,,,,,8.0,,
Autocuration,Hippocampus,1288.0,,,10576.0,9783.0,H,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,BAO_0000221,B,,CHEMBL616149,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1289.0,,,10576.0,9783.0,H,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,BAO_0000221,B,,CHEMBL616150,1.0,10000000.0,,,,8.0,,
Expert,,1290.0,,,10576.0,14331.0,D,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,Membranes,BAO_0000249,B,,CHEMBL616151,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,Hippocampus,1291.0,,,10576.0,15260.0,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,BAO_0000221,B,,CHEMBL872873,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1292.0,,,10576.0,15260.0,H,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,BAO_0000221,B,,CHEMBL616670,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1293.0,,,10576.0,15260.0,H,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,BAO_0000221,B,,CHEMBL616671,1.0,10000000.0,,,,8.0,,
Expert,,1294.0,,,10576.0,16616.0,D,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,BAO_0000249,F,,CHEMBL884861,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1295.0,,,10576.0,15629.0,H,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,BAO_0000357,B,,CHEMBL616672,1.0,,,,,8.0,,
Autocuration,,1296.0,,,10576.0,15086.0,H,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,BAO_0000019,B,,CHEMBL616673,1.0,,,,,8.0,,
Expert,,1297.0,,,10576.0,5717.0,H,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,BAO_0000019,F,,CHEMBL616674,1.0,,,,,8.0,,
Autocuration,,1298.0,,,10576.0,12652.0,H,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,BAO_0000357,B,,CHEMBL616675,1.0,,,,,8.0,,
Autocuration,Hippocampus,1299.0,,,10576.0,14608.0,H,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,BAO_0000221,B,,CHEMBL616676,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1300.0,,,10576.0,12306.0,H,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,BAO_0000221,B,,CHEMBL616677,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1301.0,,,10576.0,12306.0,H,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,BAO_0000221,B,,CHEMBL616678,1.0,10000000.0,,,,8.0,,
Expert,,1302.0,,,10576.0,15247.0,D,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616679,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,Hippocampus,1303.0,,,10576.0,17529.0,H,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,BAO_0000221,B,,CHEMBL616680,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1304.0,,,10576.0,14826.0,H,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,B,,CHEMBL616681,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1305.0,,,10576.0,14826.0,H,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,B,,CHEMBL616682,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1306.0,,,10576.0,13241.0,H,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,BAO_0000221,B,,CHEMBL616683,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1307.0,,,10576.0,14093.0,H,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,BAO_0000221,B,,CHEMBL616684,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1308.0,,,10576.0,14093.0,H,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,BAO_0000221,B,,CHEMBL616685,1.0,10000000.0,,,,8.0,,
Autocuration,Brain,1309.0,,,10576.0,14442.0,H,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,BAO_0000221,B,,CHEMBL616686,1.0,955.0,,,,8.0,,
Autocuration,,1310.0,,,10576.0,9919.0,H,,Affinity for 5-hydroxytryptamine 1A receptor site,,BAO_0000357,B,,CHEMBL616687,1.0,,,,,8.0,,
Autocuration,,1311.0,,,10576.0,9919.0,H,,Affinity for 5-hydroxytryptamine 1A receptor site,,BAO_0000357,B,,CHEMBL616688,1.0,,,,,8.0,,
Autocuration,Hippocampus,1312.0,,,10576.0,11440.0,H,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,BAO_0000221,B,,CHEMBL616689,1.0,10000000.0,,,,8.0,,
Autocuration,,1313.0,,,10576.0,11257.0,H,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,BAO_0000357,B,,CHEMBL616690,1.0,,,,,8.0,,
Expert,,1314.0,,,10576.0,10330.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL616691,1.0,,,,,8.0,,
Expert,Hippocampus,1315.0,,,10576.0,17331.0,D,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,BAO_0000221,B,,CHEMBL616692,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Expert,,1316.0,,,10576.0,16567.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,BAO_0000249,B,,CHEMBL616693,1.0,,,,,8.0,,
Expert,,1317.0,,,10576.0,12058.0,D,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,BAO_0000019,B,,CHEMBL616694,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Hippocampus,1318.0,,,10576.0,9699.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,BAO_0000221,B,,CHEMBL616695,1.0,10000000.0,,,,8.0,,
Autocuration,,1319.0,,,10576.0,9547.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,BAO_0000357,B,,CHEMBL616696,1.0,,,,,8.0,,
Autocuration,,1320.0,,,10576.0,10330.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,BAO_0000357,B,,CHEMBL616697,1.0,,,,,8.0,,
Autocuration,,1321.0,,,10576.0,14331.0,H,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616698,1.0,,,,,8.0,,
Expert,,1322.0,,,10576.0,14060.0,D,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,BAO_0000019,B,,CHEMBL616949,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Hippocampus,1323.0,,,10576.0,14744.0,H,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,BAO_0000221,B,,CHEMBL616950,1.0,10000000.0,,,,8.0,,
Autocuration,,1324.0,,,10576.0,13506.0,H,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,BAO_0000357,B,,CHEMBL832875,1.0,,,,,8.0,,
Expert,Brain,1325.0,,,10576.0,10862.0,H,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,BAO_0000221,B,,CHEMBL616951,1.0,955.0,,,,8.0,,
Expert,Brain,1326.0,,,10576.0,10862.0,H,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,BAO_0000221,B,,CHEMBL616952,1.0,955.0,,,,8.0,,
Expert,,1327.0,,,10576.0,10062.0,H,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,BAO_0000357,B,,CHEMBL616953,1.0,,,,,8.0,,
Autocuration,,1328.0,,,10576.0,12073.0,H,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,BAO_0000357,B,,CHEMBL616954,1.0,,,,,8.0,,
Autocuration,,1329.0,,,106.0,14875.0,H,,GTPgammaS radioligand binding assay,,BAO_0000357,B,,CHEMBL616955,1.0,,,,,8.0,,
Autocuration,,1330.0,,,106.0,2391.0,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,BAO_0000357,B,,CHEMBL616956,1.0,,,,,8.0,,
Autocuration,,1331.0,,,106.0,2391.0,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,BAO_0000019,F,,CHEMBL616957,1.0,,,,,8.0,,
Autocuration,,1332.0,,,106.0,2391.0,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,BAO_0000019,F,,CHEMBL616958,1.0,,,,,8.0,,
Autocuration,,1333.0,,,106.0,2391.0,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616959,1.0,,,,,8.0,,
Autocuration,,1334.0,,,106.0,2391.0,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,BAO_0000357,B,,CHEMBL616960,1.0,,,,,8.0,,
Autocuration,,1335.0,,,106.0,2391.0,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,BAO_0000019,F,,CHEMBL616961,1.0,,,,,8.0,,
Expert,,1336.0,,,106.0,17211.0,H,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,BAO_0000219,B,,CHEMBL616962,1.0,,,,HeLa,8.0,308.0,
Autocuration,,1337.0,,,106.0,17211.0,H,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,BAO_0000219,B,,CHEMBL616963,1.0,,,,HeLa,8.0,308.0,
Expert,,1338.0,,,106.0,6491.0,D,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,BAO_0000357,B,,CHEMBL616524,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,1339.0,,,106.0,16190.0,H,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,B,,CHEMBL616525,1.0,,,,CHO,8.0,449.0,
Autocuration,,1340.0,,,106.0,14165.0,H,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,BAO_0000019,B,,CHEMBL872908,1.0,,,,,8.0,,
Autocuration,,1341.0,,,106.0,14165.0,H,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,BAO_0000019,B,,CHEMBL616526,1.0,,,,,8.0,,
Expert,,1342.0,,,106.0,4234.0,D,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616527,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,1343.0,,,106.0,6328.0,H,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,BAO_0000219,B,,CHEMBL616528,1.0,,,,,8.0,,
Autocuration,,1344.0,,,106.0,14770.0,H,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,BAO_0000357,B,,CHEMBL616529,1.0,,,,,8.0,,
Autocuration,,1345.0,,,106.0,2598.0,H,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,BAO_0000357,B,,CHEMBL616530,1.0,,,,,8.0,,
Expert,,1346.0,,,106.0,6897.0,H,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616531,1.0,,,,,8.0,,
Autocuration,,1347.0,,,106.0,6897.0,H,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616532,1.0,,,,,8.0,,
Autocuration,,1348.0,,,106.0,6013.0,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616533,1.0,,,,,8.0,,
Expert,,1349.0,,,106.0,5843.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616534,1.0,,,,,8.0,,
Expert,,1350.0,,,106.0,14454.0,H,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,BAO_0000357,B,,CHEMBL616535,1.0,,,,,8.0,,
Autocuration,,1351.0,,,106.0,16209.0,H,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,BAO_0000357,B,,CHEMBL616536,1.0,,,,,8.0,,
Autocuration,,1352.0,,,106.0,3935.0,H,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616537,1.0,,,,,8.0,,
Expert,,1353.0,,,106.0,13729.0,H,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,BAO_0000219,F,,CHEMBL616538,1.0,,,,CHO-K1,8.0,485.0,
Expert,,1354.0,,,106.0,14251.0,H,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,BAO_0000019,F,,CHEMBL616539,1.0,,,,,8.0,,
Expert,,1355.0,,,106.0,17085.0,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,BAO_0000019,B,,CHEMBL616540,1.0,,,,,8.0,,
Autocuration,,1356.0,,,106.0,3025.0,H,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,BAO_0000357,B,,CHEMBL616429,1.0,,,,,8.0,,
Expert,,1357.0,,,106.0,15315.0,H,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616430,1.0,,,,,8.0,,
Expert,,1358.0,,,106.0,14214.0,D,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,BAO_0000219,B,,CHEMBL616431,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,1359.0,,,106.0,3804.0,D,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616432,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,1360.0,,,106.0,2391.0,D,,Affinity for 5-hydroxytryptamine 1B receptor subtype,,BAO_0000357,B,,CHEMBL616433,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,1361.0,,,106.0,4175.0,D,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616434,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,1362.0,,,106.0,17296.0,H,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,BAO_0000219,B,,CHEMBL616435,1.0,,,,CHO,8.0,449.0,
Expert,,1363.0,,,106.0,17085.0,H,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,BAO_0000019,B,,CHEMBL616436,1.0,,,,,8.0,,
Autocuration,,1364.0,,,106.0,17211.0,H,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,BAO_0000219,B,,CHEMBL616437,1.0,,,,HeLa,8.0,308.0,
Autocuration,,1365.0,,,106.0,17211.0,H,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,BAO_0000219,B,,CHEMBL616438,1.0,,,,HeLa,8.0,308.0,
Autocuration,,1366.0,,,106.0,17211.0,H,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,BAO_0000219,B,,CHEMBL616439,1.0,,,,HeLa,8.0,308.0,
Expert,,1367.0,,,106.0,15926.0,D,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,BAO_0000357,B,,CHEMBL616440,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,1368.0,,,106.0,16312.0,H,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,BAO_0000219,B,,CHEMBL616441,1.0,,,,CHO-K1,8.0,485.0,
Expert,,1369.0,,,106.0,5843.0,H,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,BAO_0000357,B,,CHEMBL616442,1.0,,,,,8.0,,
Autocuration,,1370.0,,,106.0,5843.0,H,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616443,1.0,,,,,8.0,,
Expert,,1371.0,,,106.0,16312.0,H,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,BAO_0000219,B,,CHEMBL616444,1.0,,,,CHO-K1,8.0,485.0,
Expert,,1372.0,,,106.0,15926.0,D,,Binding activity against human 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616445,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,1373.0,,,106.0,15926.0,D,,Binding activity against human 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616446,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,1374.0,,,106.0,4540.0,D,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,B,,CHEMBL616447,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,1375.0,,,106.0,6166.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,BAO_0000357,B,,CHEMBL616448,1.0,,,,,8.0,,
Autocuration,,1376.0,,,106.0,17296.0,H,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,BAO_0000219,B,,CHEMBL616449,1.0,,,,CHO,8.0,449.0,
Autocuration,,1377.0,,,106.0,17296.0,H,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,BAO_0000219,B,,CHEMBL616450,1.0,,,,CHO,8.0,449.0,
Autocuration,,1378.0,,,106.0,17296.0,H,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,BAO_0000219,B,,CHEMBL857974,1.0,,,,CHO,8.0,449.0,
Autocuration,,1379.0,,,106.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,B,,CHEMBL616451,1.0,,,,CHO,8.0,449.0,
Autocuration,,1380.0,,,106.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,B,,CHEMBL616452,1.0,,,,CHO,8.0,449.0,
Autocuration,,1381.0,,,106.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,BAO_0000219,B,,CHEMBL616453,1.0,,,,CHO,8.0,449.0,
Autocuration,,1382.0,,,106.0,4199.0,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,BAO_0000219,B,,CHEMBL616454,1.0,,,,CHO,8.0,449.0,
Expert,,1383.0,,,106.0,14875.0,D,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616455,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,1384.0,,,106.0,15146.0,H,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,BAO_0000219,B,,CHEMBL616456,1.0,,,,CHO,8.0,449.0,
Autocuration,,1385.0,,,106.0,5213.0,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,B,,CHEMBL616457,1.0,,,,,8.0,,
Autocuration,,1386.0,,,106.0,14818.0,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,BAO_0000219,B,,CHEMBL616458,1.0,,,,CHO,8.0,449.0,
Autocuration,,1387.0,,,106.0,4829.0,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,B,,CHEMBL616459,1.0,,,,CHO,8.0,449.0,
Expert,,1388.0,,,106.0,14454.0,H,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,BAO_0000019,F,,CHEMBL616460,1.0,,,,,8.0,,
Expert,,1389.0,,,106.0,14454.0,H,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,BAO_0000019,F,,CHEMBL616461,1.0,,,,,8.0,,
Autocuration,,1390.0,,,106.0,14875.0,H,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,BAO_0000219,F,,CHEMBL616462,1.0,,,,CHO,8.0,449.0,
Autocuration,,1391.0,,,106.0,14875.0,H,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,BAO_0000219,F,,CHEMBL616463,1.0,,,,CHO,8.0,449.0,
Autocuration,,1392.0,,,105.0,15250.0,H,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,BAO_0000019,F,,CHEMBL616464,1.0,,,,,8.0,,
Autocuration,,1393.0,,,105.0,15250.0,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,BAO_0000219,B,,CHEMBL616465,1.0,,,,CHO,8.0,449.0,
Autocuration,,1394.0,,,17105.0,15086.0,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL832874,1.0,,,,,8.0,,
Autocuration,,1395.0,,,106.0,3025.0,H,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,BAO_0000019,F,,CHEMBL616184,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Autocuration,,1396.0,,,106.0,14998.0,H,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,BAO_0000019,B,,CHEMBL616185,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Intermediate,,1397.0,,,106.0,14998.0,H,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,BAO_0000019,B,,CHEMBL616186,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Autocuration,,1398.0,,,106.0,14998.0,H,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,BAO_0000019,B,,CHEMBL616187,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Expert,,1399.0,,,10577.0,13969.0,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL616188,1.0,,,,,8.0,,
Intermediate,,1400.0,,,10577.0,13392.0,D,,Binding affinity for 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL873475,1.0,,,,,9.0,,
Expert,Striatum,1401.0,,,10577.0,3651.0,D,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,BAO_0000019,B,,CHEMBL616189,1.0,2435.0,,10116.0,,9.0,,Rattus norvegicus
Expert,,1402.0,,,10577.0,10025.0,H,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,BAO_0000357,B,,CHEMBL616190,1.0,,,,,8.0,,
Autocuration,,1403.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,BAO_0000357,B,,CHEMBL616191,1.0,,,,,8.0,,
Autocuration,,1404.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,BAO_0000357,B,,CHEMBL616192,1.0,,,,,8.0,,
Autocuration,,1405.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,BAO_0000357,B,,CHEMBL616193,1.0,,,,,8.0,,
Autocuration,,1406.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,BAO_0000357,B,,CHEMBL616194,1.0,,,,,8.0,,
Autocuration,,1407.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,BAO_0000357,B,,CHEMBL616195,1.0,,,,,8.0,,
Autocuration,,1408.0,,,10576.0,13863.0,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,BAO_0000357,B,,CHEMBL616196,1.0,,,,,8.0,,
Autocuration,Hippocampus,1409.0,,,10576.0,4622.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,BAO_0000249,B,,CHEMBL616197,1.0,10000000.0,,,,8.0,,
Intermediate,,1410.0,,,10576.0,14911.0,H,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,BAO_0000019,B,,CHEMBL616198,1.0,,,,,8.0,,
Autocuration,Hippocampus,1411.0,,,10576.0,12678.0,H,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,BAO_0000221,B,,CHEMBL616199,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1412.0,,,10576.0,12678.0,H,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,BAO_0000221,B,,CHEMBL616200,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1413.0,,,10576.0,14235.0,H,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000221,B,,CHEMBL616201,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1414.0,,,10576.0,14949.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,BAO_0000221,B,,CHEMBL616202,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1415.0,,,10576.0,14949.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,BAO_0000221,B,,CHEMBL616203,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1416.0,,,10576.0,14949.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,BAO_0000221,B,,CHEMBL616204,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1417.0,,,10576.0,14949.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,BAO_0000221,B,,CHEMBL616205,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1418.0,,,10576.0,14949.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,BAO_0000221,B,,CHEMBL616206,1.0,10000000.0,,,,8.0,,
Expert,,1419.0,,,10576.0,16118.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,BAO_0000249,B,,CHEMBL616207,1.0,,,,,8.0,,
Autocuration,,1420.0,,,10576.0,3268.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,BAO_0000249,B,,CHEMBL616208,1.0,,,,,8.0,,
Autocuration,,1421.0,,,10576.0,3268.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,BAO_0000249,B,,CHEMBL616209,1.0,,,,,8.0,,
Expert,,1422.0,,,10576.0,16117.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,BAO_0000357,B,,CHEMBL616210,1.0,,,,,8.0,,
Expert,Hippocampus,1423.0,,,10576.0,9783.0,H,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,BAO_0000221,B,,CHEMBL616211,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1424.0,,,10576.0,9783.0,H,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,BAO_0000221,B,,CHEMBL616504,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1425.0,,,10576.0,14356.0,D,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,BAO_0000221,B,,CHEMBL616505,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1426.0,,,10576.0,15740.0,H,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,BAO_0000019,F,,CHEMBL616506,1.0,,,,,8.0,,
Autocuration,Hippocampus,1427.0,,,10576.0,12306.0,H,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,BAO_0000221,B,,CHEMBL872107,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1428.0,,,10576.0,13348.0,D,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,BAO_0000221,B,,CHEMBL616507,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1429.0,,,10576.0,10394.0,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,BAO_0000249,B,,CHEMBL616303,1.0,,,,,8.0,,
Autocuration,Hippocampus,1430.0,,,10576.0,15260.0,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,BAO_0000221,B,,CHEMBL616304,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1431.0,,,10576.0,10046.0,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,BAO_0000221,B,,CHEMBL616305,1.0,10000000.0,,,,8.0,,
Intermediate,Hippocampus,1432.0,,,10576.0,15260.0,H,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,BAO_0000221,F,,CHEMBL616306,1.0,10000000.0,,,,8.0,,
Autocuration,,1433.0,,,10576.0,12851.0,H,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616307,1.0,,,,,8.0,,
Expert,Hippocampus,1434.0,,,10576.0,2148.0,D,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,BAO_0000221,B,,CHEMBL881829,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Expert,,1435.0,,,10576.0,13134.0,H,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,BAO_0000357,B,,CHEMBL616308,1.0,,,,,8.0,,
Autocuration,,1436.0,,,10576.0,12462.0,H,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,BAO_0000019,B,,CHEMBL616309,1.0,,,,,8.0,,
Expert,,1437.0,,,10576.0,12462.0,H,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,BAO_0000019,B,,CHEMBL616310,1.0,,,,,8.0,,
Autocuration,,1438.0,,,10576.0,12462.0,H,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,BAO_0000219,B,,CHEMBL616311,1.0,,,,CHO,8.0,449.0,
Expert,,1439.0,,,10576.0,11933.0,H,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL616312,1.0,,,,,8.0,,
Autocuration,,1440.0,,,10576.0,11933.0,H,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,BAO_0000357,B,,CHEMBL616313,1.0,,,,,8.0,,
Expert,Hippocampus,1441.0,,,10576.0,403.0,D,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,BAO_0000221,B,,CHEMBL616314,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Hippocampus,1442.0,,,10576.0,15538.0,H,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,B,,CHEMBL616315,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1443.0,,,10576.0,15538.0,H,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,BAO_0000221,B,,CHEMBL616567,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1444.0,,,10576.0,15538.0,H,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,BAO_0000221,B,,CHEMBL616568,1.0,10000000.0,,,,8.0,,
Intermediate,,1445.0,,,10576.0,12464.0,H,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,BAO_0000019,B,,CHEMBL616569,1.0,,,,,8.0,,
Expert,,1446.0,,,10576.0,1455.0,H,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,BAO_0000357,B,,CHEMBL616570,1.0,,,,,8.0,,
Autocuration,,1447.0,,,10576.0,12652.0,H,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,BAO_0000357,B,,CHEMBL616571,1.0,,,,,8.0,,
Autocuration,Hippocampus,1448.0,,,10576.0,12639.0,H,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,BAO_0000221,B,,CHEMBL616572,1.0,10000000.0,,,,8.0,,
Expert,,1449.0,,,10576.0,13949.0,H,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,BAO_0000249,B,,CHEMBL616573,1.0,,,,,8.0,,
Expert,,1450.0,,,10576.0,12463.0,D,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,BAO_0000357,B,,CHEMBL616574,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,Hippocampus,1451.0,,,10576.0,14829.0,H,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,BAO_0000221,B,,CHEMBL616575,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1452.0,,,10576.0,14829.0,H,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,BAO_0000221,B,,CHEMBL872108,1.0,10000000.0,,,,8.0,,
Autocuration,,1453.0,,,10576.0,12092.0,H,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,BAO_0000357,B,,CHEMBL616576,1.0,,,,,8.0,,
Autocuration,,1454.0,,,10576.0,403.0,H,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,BAO_0000249,B,,CHEMBL616577,1.0,,,,,8.0,,
Autocuration,,1455.0,,,10576.0,403.0,H,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,BAO_0000249,B,,CHEMBL616578,1.0,,,,,8.0,,
Expert,,1456.0,,,10576.0,3967.0,H,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,BAO_0000357,B,,CHEMBL616579,1.0,,,,,8.0,,
Expert,,1457.0,,,10576.0,12771.0,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,BAO_0000019,B,,CHEMBL616580,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1458.0,,,10576.0,15086.0,H,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,BAO_0000019,B,,CHEMBL616581,1.0,,,,,8.0,,
Autocuration,Hippocampus,1459.0,,,10576.0,14909.0,H,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,B,,CHEMBL616582,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1460.0,,,10576.0,14949.0,H,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,B,,CHEMBL616583,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1461.0,,,10576.0,2309.0,D,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,BAO_0000221,B,,CHEMBL616584,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Expert,,1462.0,,,10576.0,4170.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616585,1.0,,,,,8.0,,
Expert,Hippocampus,1463.0,,,10576.0,11642.0,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,BAO_0000221,B,,CHEMBL616586,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Hippocampus,1464.0,,,10576.0,11642.0,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,BAO_0000221,B,,CHEMBL616587,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1465.0,,,10576.0,12953.0,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,BAO_0000221,B,,CHEMBL616588,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1466.0,,,10576.0,12953.0,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,BAO_0000221,B,,CHEMBL616589,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1467.0,,,10576.0,12953.0,H,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,BAO_0000221,B,,CHEMBL616590,1.0,10000000.0,,,,8.0,,
Expert,,1468.0,,,10576.0,12903.0,H,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,BAO_0000219,B,,CHEMBL616591,1.0,,,,CHO,8.0,449.0,
Expert,,1469.0,,,10576.0,12536.0,H,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616592,1.0,,,,,8.0,,
Autocuration,,1470.0,,,10576.0,10058.0,H,,The inhibition activity of 5-HT1A at 1 uM,,BAO_0000357,B,,CHEMBL616593,1.0,,,,,8.0,,
Expert,,1471.0,,,10576.0,12902.0,H,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,BAO_0000219,B,,CHEMBL616594,1.0,,,,CHO-K1,8.0,485.0,
Expert,,1472.0,,,10576.0,14057.0,H,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,BAO_0000249,B,,CHEMBL616595,1.0,,,,,8.0,,
Autocuration,,1473.0,,,10576.0,11296.0,H,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,BAO_0000357,B,,CHEMBL616596,1.0,,,,,8.0,,
Autocuration,Hippocampus,1474.0,,,10576.0,11296.0,H,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,BAO_0000221,B,,CHEMBL616597,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1475.0,,,10576.0,11296.0,H,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,BAO_0000221,B,,CHEMBL616598,1.0,10000000.0,,,,8.0,,
Expert,,1476.0,,,10576.0,16616.0,D,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,Membranes,BAO_0000249,F,,CHEMBL616599,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,Hippocampus,1477.0,,,10576.0,16616.0,D,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Membranes,BAO_0000249,F,,CHEMBL616600,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1478.0,,,10576.0,16567.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,BAO_0000019,B,,CHEMBL616601,1.0,,,,,8.0,,
Autocuration,,1479.0,,,10576.0,16567.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,BAO_0000019,B,,CHEMBL616602,1.0,,,,,8.0,,
Autocuration,,1480.0,,,10576.0,16567.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,BAO_0000019,B,,CHEMBL616603,1.0,,,,,8.0,,
Autocuration,,1481.0,,,10576.0,16567.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,BAO_0000019,B,,CHEMBL616604,1.0,,,,,8.0,,
Autocuration,,1482.0,,,10576.0,17136.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,BAO_0000249,B,,CHEMBL616316,1.0,,,,,8.0,,
Autocuration,,1483.0,,,10576.0,17136.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,BAO_0000249,B,,CHEMBL616317,1.0,,,,,8.0,,
Expert,,1484.0,,,10576.0,16616.0,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,BAO_0000019,B,,CHEMBL616318,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Hippocampus,1485.0,,,10576.0,17331.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,BAO_0000221,B,,CHEMBL616319,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1486.0,,,10576.0,17331.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,BAO_0000221,B,,CHEMBL616320,1.0,10000000.0,,,,8.0,,
Expert,Hippocampus,1487.0,,,10576.0,17167.0,D,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,BAO_0000221,B,,CHEMBL616321,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1488.0,,,10576.0,15740.0,H,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,BAO_0000019,F,,CHEMBL616322,1.0,,,,,8.0,,
Autocuration,,1489.0,,,10576.0,15740.0,H,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,BAO_0000019,F,,CHEMBL616323,1.0,,,,,8.0,,
Autocuration,,1490.0,,,10576.0,4671.0,H,,Ratio of binding affinity to 5-HT 1A and D2 receptor,,BAO_0000357,B,,CHEMBL616324,1.0,,,,,8.0,,
Autocuration,Hippocampus,1491.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,BAO_0000221,B,,CHEMBL616325,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1492.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,BAO_0000221,B,,CHEMBL616326,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1493.0,,,10576.0,10058.0,H,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,BAO_0000221,B,,CHEMBL616327,1.0,10000000.0,,,,8.0,,
Autocuration,,1494.0,,,10576.0,12073.0,H,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616328,1.0,,,,,8.0,,
Autocuration,,1495.0,,,10576.0,2759.0,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,BAO_0000249,B,,CHEMBL858110,1.0,,,,,8.0,,
Autocuration,,1496.0,,,10576.0,2759.0,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,BAO_0000249,F,,CHEMBL616329,1.0,,,,,8.0,,
Autocuration,,1497.0,,,10576.0,2759.0,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,BAO_0000249,B,,CHEMBL616330,1.0,,,,,8.0,,
Autocuration,,1498.0,,,10576.0,2759.0,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,BAO_0000249,F,,CHEMBL616331,1.0,,,,,8.0,,
Autocuration,,1499.0,,,10576.0,2759.0,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,BAO_0000249,F,,CHEMBL616332,1.0,,,,,8.0,,
Autocuration,Brain,1500.0,,,10576.0,9737.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,BAO_0000249,B,,CHEMBL857063,1.0,955.0,,,,8.0,,
Autocuration,,1501.0,,,10576.0,9737.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,BAO_0000019,B,,CHEMBL616333,1.0,,,,,8.0,,
Expert,,1502.0,,,10576.0,5717.0,H,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,BAO_0000019,F,,CHEMBL616334,1.0,,,,,8.0,,
Autocuration,Hippocampus,1503.0,,,10576.0,12253.0,H,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,BAO_0000221,B,,CHEMBL616335,1.0,10000000.0,,,,8.0,,
Autocuration,,1504.0,,,10576.0,14025.0,H,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,BAO_0000019,B,,CHEMBL616336,1.0,,,,,8.0,,
Expert,,1505.0,,,10576.0,10425.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,BAO_0000249,B,,CHEMBL616337,1.0,,,,,8.0,,
Autocuration,,1506.0,,,10576.0,14998.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,BAO_0000019,B,,CHEMBL616338,1.0,,,,,8.0,,
Autocuration,Hippocampus,1507.0,,,10576.0,13694.0,H,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,BAO_0000221,B,,CHEMBL616339,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,1508.0,,,10576.0,13694.0,H,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,BAO_0000221,B,,CHEMBL616340,1.0,10000000.0,,,,8.0,,
Autocuration,,1509.0,,,10576.0,4342.0,H,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,B,,CHEMBL616341,1.0,,,,,8.0,,
Expert,,1510.0,,,10576.0,12936.0,D,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616342,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,1511.0,,,10576.0,13144.0,D,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,BAO_0000019,B,,CHEMBL616343,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,1512.0,,,10576.0,13343.0,H,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,BAO_0000019,B,,CHEMBL616344,1.0,,,,,8.0,,
Expert,,1513.0,,,10576.0,12132.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,BAO_0000357,B,,CHEMBL616345,1.0,,,,,8.0,,
Expert,,1514.0,,,10576.0,15419.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,BAO_0000019,B,,CHEMBL616346,1.0,,,,,8.0,,
Autocuration,Hippocampus,1515.0,,,10576.0,1479.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,BAO_0000221,B,,CHEMBL616347,1.0,10000000.0,,,,8.0,,
Expert,,1516.0,,,10576.0,14287.0,H,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,BAO_0000019,B,,CHEMBL616348,1.0,,,,,8.0,,
Expert,,1517.0,,,10576.0,13116.0,H,,Binding affinity at 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616349,1.0,,,,,8.0,,
Expert,,1518.0,,,10576.0,2759.0,D,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,Membranes,BAO_0000249,B,,CHEMBL616152,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1519.0,,,10576.0,2759.0,H,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,BAO_0000249,B,,CHEMBL616153,1.0,,,,,8.0,,
Expert,,1520.0,,,10576.0,14748.0,H,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,BAO_0000019,B,,CHEMBL616154,1.0,,,,,8.0,,
Autocuration,,1521.0,,,10576.0,12304.0,H,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,BAO_0000019,B,,CHEMBL616155,1.0,,,,,8.0,,
Expert,Hippocampus,1522.0,,,10576.0,12409.0,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,BAO_0000221,B,,CHEMBL616156,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Expert,Hippocampus,1523.0,,,10576.0,12409.0,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,BAO_0000221,B,,CHEMBL616157,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Hippocampus,1524.0,,,10576.0,13267.0,H,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,BAO_0000221,B,,CHEMBL616158,1.0,10000000.0,,,,8.0,,
Autocuration,,1525.0,,,10576.0,15194.0,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,BAO_0000357,B,,CHEMBL616159,1.0,,,,,8.0,,
Expert,,1526.0,,,10576.0,14256.0,H,,pKi value against rat 5-hydroxytryptamine 1A receptor.,,BAO_0000357,B,,CHEMBL616160,1.0,,,,,8.0,,
Autocuration,,1527.0,,,10576.0,16567.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,BAO_0000019,B,,CHEMBL616161,1.0,,,,,8.0,,
Autocuration,,1528.0,,,10576.0,15740.0,H,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,BAO_0000019,F,,CHEMBL616162,1.0,,,,,8.0,,
Expert,,1529.0,,,12687.0,13278.0,D,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,BAO_0000357,B,,CHEMBL616163,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,1530.0,,,10626.0,1970.0,H,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Membranes,BAO_0000249,B,,CHEMBL616164,1.0,,,,,8.0,,
Autocuration,Brain,1531.0,,,10576.0,10034.0,H,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,BAO_0000221,B,,CHEMBL616165,1.0,955.0,,,,8.0,,
Autocuration,,1532.0,,,51.0,13348.0,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,BAO_0000019,B,,CHEMBL616355,1.0,,,10116.0,,8.0,,Rattus norvegicus
Autocuration,,1533.0,,,10576.0,13630.0,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,BAO_0000019,F,,CHEMBL616356,1.0,,,,,8.0,,
Autocuration,Brain,1534.0,,,10576.0,10862.0,H,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,BAO_0000221,B,,CHEMBL616357,1.0,955.0,,,,8.0,,
Autocuration,,1535.0,,,10576.0,12058.0,H,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,BAO_0000019,B,,CHEMBL616358,1.0,,,,,8.0,,
Autocuration,,1536.0,,,51.0,4639.0,H,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616359,1.0,,,,,8.0,,
Expert,,1537.0,,,51.0,15453.0,H,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,BAO_0000357,B,,CHEMBL616360,1.0,,,,,8.0,,
Expert,,1538.0,,,51.0,4820.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616361,1.0,,,,,8.0,,
Autocuration,,1539.0,,,51.0,1089.0,H,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616362,1.0,,,,,8.0,,
Autocuration,,1540.0,,,51.0,386.0,H,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,Brain membranes,BAO_0000249,B,,CHEMBL616363,1.0,,,,,8.0,,
Autocuration,,1541.0,,,51.0,6011.0,H,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,BAO_0000357,B,,CHEMBL616364,1.0,,,,,8.0,,
Autocuration,,1542.0,,,51.0,5014.0,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616365,1.0,,,,,8.0,,
Expert,,1543.0,,,51.0,4402.0,H,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL616366,1.0,,,,,8.0,,
Expert,,1544.0,,,51.0,17066.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL872906,1.0,,,,,8.0,,
Autocuration,,1545.0,,,51.0,17515.0,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,BAO_0000357,B,,CHEMBL616367,1.0,,,,,8.0,,
Autocuration,,1546.0,,,51.0,2474.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616368,1.0,,,,,8.0,,
Autocuration,,1547.0,,,51.0,4775.0,H,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,B,,CHEMBL616369,1.0,,,,,8.0,,
Expert,,1548.0,,,51.0,14294.0,D,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,BAO_0000357,B,,CHEMBL616370,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,1549.0,,,51.0,14294.0,D,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,BAO_0000357,B,,CHEMBL616371,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,1550.0,,,51.0,12249.0,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,B,,CHEMBL616372,1.0,,,,CHO,8.0,449.0,
Expert,,1551.0,,,51.0,11376.0,H,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,BAO_0000219,B,,CHEMBL616373,1.0,,,,,8.0,,
Autocuration,,1552.0,,,51.0,2474.0,H,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000218,B,In vivo,CHEMBL616374,1.0,,,,,8.0,,
Autocuration,Hippocampus,1553.0,,,51.0,13311.0,H,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,B,,CHEMBL616375,1.0,10000000.0,,,,8.0,,
Autocuration,,1554.0,,,51.0,4373.0,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,B,,CHEMBL616376,1.0,,,,,8.0,,
Expert,,1555.0,,,51.0,1633.0,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,BAO_0000357,B,,CHEMBL857064,1.0,,,,,8.0,,
Autocuration,,1556.0,,,51.0,11866.0,H,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,B,,CHEMBL616377,1.0,,,,,8.0,,
Autocuration,,1557.0,,,51.0,4373.0,H,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,B,,CHEMBL616378,1.0,,,,,8.0,,
Autocuration,,1558.0,,,51.0,4687.0,H,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616379,1.0,,,,,8.0,,
Autocuration,,1559.0,,,11863.0,16946.0,H,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616380,1.0,,,,,8.0,,
Autocuration,,1560.0,,,11863.0,13291.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,BAO_0000357,B,,CHEMBL616381,1.0,,,,,8.0,,
Autocuration,,1561.0,,,11863.0,14159.0,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616382,1.0,,,,,8.0,,
Autocuration,,1562.0,,,11863.0,10812.0,H,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,BAO_0000357,B,,CHEMBL616383,1.0,,,,,8.0,,
Expert,,1563.0,,,11863.0,3032.0,D,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,BAO_0000219,B,,CHEMBL616350,1.0,,,10090.0,CHO,9.0,449.0,Mus musculus
Autocuration,,1564.0,,,11863.0,16655.0,H,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616351,1.0,,,,,8.0,,
Autocuration,,1565.0,,,11863.0,14532.0,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,BAO_0000357,B,,CHEMBL616352,1.0,,,,,8.0,,
Autocuration,,1566.0,,,11863.0,13944.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616353,1.0,,,,,8.0,,
Autocuration,,1567.0,,,11863.0,13033.0,H,,Binding affinity against serotonergic 5-HT1a receptor,,BAO_0000357,B,,CHEMBL616354,1.0,,,,,8.0,,
Autocuration,,1568.0,,,11863.0,10321.0,H,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL616508,1.0,,,,,8.0,,
Expert,,1569.0,,,11863.0,2968.0,D,,Binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616559,1.0,,,10090.0,,9.0,,Mus musculus
Autocuration,,1570.0,,,11863.0,13964.0,H,,Binding affinity at 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616560,1.0,,,,,8.0,,
Autocuration,,1571.0,,,11863.0,15527.0,H,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,BAO_0000357,B,,CHEMBL616561,1.0,,,,,8.0,,
Autocuration,,1572.0,,,11863.0,12248.0,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,B,,CHEMBL616562,1.0,,,,CHO,8.0,449.0,
Autocuration,,1573.0,,,11863.0,12249.0,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,B,,CHEMBL616563,1.0,,,,CHO,8.0,449.0,
Autocuration,,1574.0,,,11863.0,15120.0,H,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616564,1.0,,,,,8.0,,
Autocuration,,1575.0,,,11863.0,13313.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL616565,1.0,,,,,8.0,,
Autocuration,,1576.0,,,11863.0,2613.0,H,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,BAO_0000218,B,,CHEMBL616566,1.0,,,,,8.0,,
Autocuration,,1577.0,,,11863.0,16700.0,H,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,BAO_0000357,B,,CHEMBL616989,1.0,,,,,8.0,,
Autocuration,,1578.0,,,11863.0,2201.0,H,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL857975,1.0,,,,,8.0,,
Expert,,1579.0,,,11863.0,1274.0,D,,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616990,1.0,,,10090.0,,9.0,,Mus musculus
Autocuration,,1580.0,,,11863.0,1317.0,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,BAO_0000357,B,,CHEMBL616991,1.0,,,,,8.0,,
Autocuration,,1581.0,,,11863.0,12146.0,H,,Tested against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616992,1.0,,,,,8.0,,
Autocuration,,1582.0,,,11863.0,14059.0,H,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL616993,1.0,,,,,8.0,,
Expert,,1583.0,,,106.0,14025.0,H,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,BAO_0000019,B,,CHEMBL616994,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Autocuration,,1584.0,,,106.0,14025.0,H,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,BAO_0000019,B,,CHEMBL616995,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Intermediate,,1585.0,,,105571.0,14447.0,D,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,BAO_0000219,B,,CHEMBL616996,1.0,,,9593.0,HEK293,9.0,722.0,Gorilla gorilla
Autocuration,,1586.0,,,106.0,3025.0,H,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,BAO_0000218,F,In vivo,CHEMBL616997,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,1587.0,,,106.0,3025.0,H,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,BAO_0000218,F,In vivo,CHEMBL616998,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,1588.0,,,106.0,15329.0,H,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,BAO_0000019,F,,CHEMBL616999,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,1589.0,,,106.0,15329.0,H,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,BAO_0000019,F,,CHEMBL617000,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,1590.0,,,106.0,15847.0,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,BAO_0000019,F,,CHEMBL617001,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,1591.0,,,106.0,15847.0,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,BAO_0000019,F,,CHEMBL858111,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,1592.0,,,106.0,14165.0,H,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,BAO_0000019,F,,CHEMBL617002,1.0,,,,,8.0,,
Autocuration,,1593.0,,,106.0,14214.0,H,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,BAO_0000019,F,,CHEMBL617003,1.0,,,,,8.0,,
Autocuration,,1594.0,,,106.0,14214.0,H,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,BAO_0000019,F,,CHEMBL617004,1.0,,,,,8.0,,
Expert,,1595.0,,,106.0,14214.0,D,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,BAO_0000019,F,,CHEMBL617005,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,1596.0,,,106.0,13729.0,D,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,BAO_0000219,F,,CHEMBL616623,1.0,,,9606.0,CHO-K1,9.0,485.0,Homo sapiens
Autocuration,,1597.0,,,106.0,3025.0,H,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,BAO_0000219,F,,CHEMBL616624,1.0,,,,CHO,8.0,449.0,
Autocuration,,1598.0,,,106.0,2391.0,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL883243,1.0,,,,,8.0,,
Autocuration,,1599.0,,,106.0,2391.0,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,BAO_0000019,F,,CHEMBL616625,1.0,,,,,8.0,,
Expert,,1600.0,,,106.0,14956.0,H,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,BAO_0000219,F,,CHEMBL616626,1.0,,,,CHO,8.0,449.0,
Autocuration,,1601.0,,,106.0,2598.0,H,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,BAO_0000219,F,,CHEMBL616627,1.0,,,,CHO,8.0,449.0,
Autocuration,,1602.0,,,106.0,2598.0,H,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,BAO_0000219,F,,CHEMBL616628,1.0,,,,CHO,8.0,449.0,
Autocuration,,1603.0,,,106.0,2598.0,H,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,BAO_0000219,F,,CHEMBL616629,1.0,,,,CHO,8.0,449.0,
Autocuration,,1604.0,,,106.0,2598.0,H,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,BAO_0000219,F,,CHEMBL616630,1.0,,,,CHO,8.0,449.0,
Expert,,1605.0,,,106.0,14956.0,H,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,BAO_0000019,F,,CHEMBL616631,1.0,,,,,8.0,,
Autocuration,,1606.0,,,106.0,14956.0,H,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,BAO_0000019,F,,CHEMBL616632,1.0,,,,,8.0,,
Expert,,1607.0,,,106.0,14214.0,D,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616633,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,1608.0,,,106.0,3463.0,H,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,BAO_0000219,B,,CHEMBL616634,1.0,,,,CHO,8.0,449.0,
Autocuration,,1609.0,,,106.0,15331.0,H,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,BAO_0000357,B,,CHEMBL616635,1.0,,,,,8.0,,
Expert,,1610.0,,,106.0,16146.0,D,,Binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL885358,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,1611.0,,,106.0,14159.0,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,BAO_0000219,B,,CHEMBL616636,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Expert,,1612.0,,,106.0,14158.0,H,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,BAO_0000219,B,,CHEMBL616637,1.0,,,,CHO,8.0,449.0,
Autocuration,,1613.0,,,106.0,14159.0,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616638,1.0,,,,,8.0,,
Expert,,1614.0,,,106.0,15250.0,H,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL616639,1.0,,,,CHO,8.0,449.0,
Expert,,1615.0,,,106.0,15250.0,H,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,BAO_0000219,B,,CHEMBL616640,1.0,,,,CHO,8.0,449.0,
Expert,,1616.0,,,106.0,15331.0,H,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL616641,1.0,,,,CHO,8.0,449.0,
Expert,,1617.0,,,106.0,15332.0,H,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,BAO_0000219,B,,CHEMBL616642,1.0,,,,CHO,8.0,449.0,
Expert,,1618.0,,,106.0,14956.0,H,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,BAO_0000219,B,,CHEMBL616643,1.0,,,,CHO,8.0,449.0,
Autocuration,,1619.0,,,106.0,3805.0,H,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,BAO_0000357,B,,CHEMBL616644,1.0,,,,,8.0,,
Autocuration,,1620.0,,,106.0,14875.0,H,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,BAO_0000357,B,,CHEMBL616645,1.0,,,,,8.0,,
Autocuration,,1621.0,,,105.0,14454.0,H,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,BAO_0000019,F,,CHEMBL616646,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Expert,,1622.0,,,105.0,14454.0,H,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,BAO_0000019,F,,CHEMBL616647,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Autocuration,,1623.0,,,105.0,16288.0,H,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,BAO_0000357,B,,CHEMBL616509,1.0,,,,,8.0,,
Autocuration,,1624.0,,,105.0,16288.0,H,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,BAO_0000357,B,,CHEMBL616510,1.0,,,,,8.0,,
Autocuration,,1625.0,,,105.0,16312.0,H,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616511,1.0,,,,,8.0,,
Expert,,1626.0,,,105.0,1348.0,H,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,BAO_0000357,B,,CHEMBL616512,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1627.0,,,105.0,5834.0,H,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,BAO_0000357,B,,CHEMBL616513,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,Striatum,1628.0,,,105.0,13366.0,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,BAO_0000019,B,,CHEMBL616514,1.0,2435.0,,9913.0,,8.0,,Bos taurus
Expert,,1629.0,,,105.0,1414.0,H,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,BAO_0000357,B,,CHEMBL616515,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1630.0,,,105.0,14998.0,H,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,BAO_0000019,B,,CHEMBL616516,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1631.0,,,105.0,11473.0,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,BAO_0000357,B,,CHEMBL616517,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1632.0,,,105.0,11473.0,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,BAO_0000357,B,,CHEMBL616518,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1633.0,,,105.0,10639.0,H,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,BAO_0000357,B,,CHEMBL616519,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1634.0,,,105.0,10639.0,H,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,BAO_0000357,B,,CHEMBL616520,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1635.0,,,105.0,1375.0,H,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,BAO_0000357,B,,CHEMBL616521,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1636.0,,,105.0,1375.0,H,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,BAO_0000357,B,,CHEMBL616522,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1637.0,,,105.0,16532.0,H,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,BAO_0000357,B,,CHEMBL884531,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1638.0,,,105.0,11147.0,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL616523,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,Striatum,1639.0,,,105.0,13366.0,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,BAO_0000019,B,,CHEMBL616731,1.0,2435.0,,9913.0,,8.0,,Bos taurus
Autocuration,,1640.0,,,105.0,10444.0,H,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,BAO_0000019,B,,CHEMBL616732,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1641.0,,,105.0,16532.0,H,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,BAO_0000357,B,,CHEMBL616733,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1642.0,,,105.0,16532.0,H,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,BAO_0000357,B,,CHEMBL616734,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1643.0,,,105.0,12827.0,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,BAO_0000249,B,,CHEMBL616735,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1644.0,,,105.0,12827.0,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,BAO_0000249,B,,CHEMBL616736,1.0,,,9913.0,,8.0,,Bos taurus
Expert,,1645.0,,,105.0,12919.0,H,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,F,,CHEMBL616737,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1646.0,,,105.0,14025.0,H,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,BAO_0000019,B,,CHEMBL616738,1.0,,,9913.0,,8.0,,Bos taurus
Expert,,1647.0,,,105.0,12919.0,H,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,F,,CHEMBL616739,1.0,,,9913.0,,8.0,,Bos taurus
Expert,,1648.0,,,105.0,12919.0,H,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,F,,CHEMBL616740,1.0,,,9913.0,,8.0,,Bos taurus
Expert,,1649.0,,,105.0,12919.0,H,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,F,,CHEMBL616741,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1650.0,,,105.0,14447.0,H,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,BAO_0000219,B,,CHEMBL616742,1.0,,,9593.0,HEK293,8.0,722.0,Gorilla gorilla
Intermediate,,1651.0,,,105570.0,1375.0,D,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,BAO_0000019,B,,CHEMBL616743,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,1652.0,,,105570.0,1375.0,D,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,BAO_0000019,B,,CHEMBL616744,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,1653.0,,,105570.0,12409.0,D,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,BAO_0000019,F,,CHEMBL616745,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,1654.0,,,105570.0,12409.0,D,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000019,F,,CHEMBL616746,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,1655.0,,,105570.0,12409.0,D,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,BAO_0000019,F,,CHEMBL616747,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,1656.0,,,105570.0,12409.0,D,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,BAO_0000019,F,,CHEMBL616748,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,1657.0,,,105570.0,12409.0,D,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,BAO_0000019,F,,CHEMBL616648,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,1658.0,,,105570.0,11574.0,D,,Binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616649,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,1659.0,,,105570.0,1558.0,D,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,BAO_0000357,B,,CHEMBL616650,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,1660.0,,,105570.0,12409.0,D,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000218,F,,CHEMBL616651,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,1661.0,,,105570.0,12409.0,D,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000218,F,,CHEMBL616652,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,1662.0,,,105570.0,12409.0,D,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000218,F,,CHEMBL616653,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,1663.0,,,105570.0,12409.0,D,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,BAO_0000218,F,,CHEMBL616654,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,1664.0,,,105570.0,12253.0,D,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,BAO_0000019,B,,CHEMBL616655,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,1665.0,,,105570.0,12936.0,D,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616656,1.0,,,10141.0,,9.0,,Cavia porcellus
Autocuration,,1666.0,,,105.0,13181.0,H,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,BAO_0000019,B,,CHEMBL616657,1.0,,,10141.0,,8.0,,Cavia porcellus
Intermediate,Striatum,1667.0,,,105570.0,12409.0,D,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,BAO_0000357,B,,CHEMBL616658,1.0,2435.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,,1668.0,,,105570.0,10639.0,D,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,BAO_0000357,B,,CHEMBL616659,1.0,,,10141.0,,9.0,,Cavia porcellus
Autocuration,,1669.0,,,51.0,5254.0,H,,Binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616660,1.0,,,,,8.0,,
Autocuration,,1670.0,,,106.0,13051.0,H,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,B,,CHEMBL616661,1.0,,,,,8.0,,
Expert,,1671.0,,,105.0,3463.0,H,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,BAO_0000019,F,,CHEMBL616662,1.0,,,,,8.0,,
Autocuration,,1672.0,,,105.0,15315.0,H,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,F,,CHEMBL616663,1.0,,,,,8.0,,
Autocuration,,1673.0,,,105.0,6011.0,H,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,F,,CHEMBL616664,1.0,,,,,8.0,,
Expert,,1674.0,,,105.0,14159.0,D,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,BAO_0000219,F,,CHEMBL881820,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,1675.0,,,105.0,14159.0,H,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,BAO_0000219,F,,CHEMBL616665,1.0,,,,CHO,8.0,449.0,
Expert,,1676.0,,,105.0,15250.0,H,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,BAO_0000219,B,,CHEMBL616666,1.0,,,,CHO,8.0,449.0,
Autocuration,,1677.0,,,105.0,15250.0,H,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,BAO_0000219,B,,CHEMBL616667,1.0,,,,CHO,8.0,449.0,
Expert,,1678.0,,,105.0,15331.0,H,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,BAO_0000219,F,,CHEMBL616668,1.0,,,,CHO,8.0,449.0,
Expert,,1679.0,,,105.0,15332.0,D,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,BAO_0000219,F,,CHEMBL616669,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Expert,,1680.0,,,105.0,15332.0,H,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,BAO_0000219,F,,CHEMBL617040,1.0,,,,CHO,8.0,449.0,
Autocuration,,1681.0,,,105.0,3294.0,H,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,BAO_0000219,F,,CHEMBL617041,1.0,,,,CHO,8.0,449.0,
Expert,,1682.0,,,105.0,14158.0,H,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,BAO_0000219,F,,CHEMBL617042,1.0,,,,CHO,8.0,449.0,
Expert,,1683.0,,,105.0,14956.0,H,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,BAO_0000219,F,,CHEMBL617043,1.0,,,,CHO,8.0,449.0,
Autocuration,,1684.0,,,105.0,12469.0,H,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,BAO_0000019,F,,CHEMBL617044,1.0,,,,,8.0,,
Expert,,1685.0,,,105.0,3463.0,H,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,BAO_0000219,F,,CHEMBL617045,1.0,,,,CHO,8.0,449.0,
Expert,,1686.0,,,105.0,15250.0,D,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,BAO_0000219,F,,CHEMBL617046,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Expert,,1687.0,,,105.0,15250.0,D,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,BAO_0000219,F,,CHEMBL617047,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Expert,,1688.0,,,105.0,14956.0,H,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,BAO_0000019,F,,CHEMBL617048,1.0,,,,,8.0,,
Autocuration,,1689.0,,,105.0,14159.0,H,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,BAO_0000019,F,,CHEMBL616897,1.0,,,,,8.0,,
Expert,,1690.0,,,105.0,14159.0,D,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,BAO_0000019,F,,CHEMBL616898,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,1691.0,,,105.0,14499.0,D,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,BAO_0000219,F,,CHEMBL858201,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,1692.0,,,105.0,15315.0,H,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,BAO_0000019,F,,CHEMBL616899,1.0,,,,,8.0,,
Autocuration,,1693.0,,,105.0,3294.0,H,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,BAO_0000219,B,In vitro,CHEMBL616900,1.0,,,,,8.0,,
Expert,,1694.0,,,105.0,3463.0,H,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,BAO_0000219,B,,CHEMBL616901,1.0,,,,CHO,8.0,449.0,
Autocuration,,1695.0,,,105.0,15331.0,H,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,BAO_0000357,B,,CHEMBL616902,1.0,,,,,8.0,,
Expert,,1696.0,,,105.0,14159.0,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,BAO_0000219,B,,CHEMBL616903,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Expert,,1697.0,,,105.0,14158.0,H,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,BAO_0000219,B,,CHEMBL616904,1.0,,,,CHO,8.0,449.0,
Autocuration,,1698.0,,,105.0,14159.0,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616905,1.0,,,,,8.0,,
Expert,,1699.0,,,105.0,15250.0,H,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,BAO_0000219,B,,CHEMBL616906,1.0,,,,CHO,8.0,449.0,
Expert,,1700.0,,,105.0,15250.0,H,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL616907,1.0,,,,CHO,8.0,449.0,
Expert,,1701.0,,,105.0,15331.0,H,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL616908,1.0,,,,CHO,8.0,449.0,
Expert,,1702.0,,,105.0,15332.0,D,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,BAO_0000219,B,,CHEMBL616909,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Expert,,1703.0,,,105.0,14499.0,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,BAO_0000219,B,,CHEMBL616910,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Expert,,1704.0,,,105.0,15332.0,H,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL616911,1.0,,,,CHO,8.0,449.0,
Expert,,1705.0,,,105.0,14956.0,H,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,BAO_0000219,B,,CHEMBL616912,1.0,,,,CHO,8.0,449.0,
Autocuration,,1706.0,,,105.0,3805.0,H,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,BAO_0000357,B,,CHEMBL616913,1.0,,,,,8.0,,
Expert,,1707.0,,,105.0,6011.0,D,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,BAO_0000219,B,,CHEMBL616914,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,1708.0,,,105.0,16190.0,H,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,B,,CHEMBL616915,1.0,,,,CHO,8.0,449.0,
Autocuration,,1709.0,,,105.0,14165.0,H,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,BAO_0000019,B,,CHEMBL616916,1.0,,,,,8.0,,
Expert,,1710.0,,,105.0,4234.0,D,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616917,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,1711.0,,,105.0,15527.0,H,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,BAO_0000357,B,,CHEMBL616918,1.0,,,,,8.0,,
Expert,,1712.0,,,105.0,6328.0,H,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,BAO_0000219,B,,CHEMBL616919,1.0,,,,,8.0,,
Autocuration,,1713.0,,,105.0,16209.0,H,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL616920,1.0,,,,,8.0,,
Autocuration,,1714.0,,,105.0,14770.0,H,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,BAO_0000357,B,,CHEMBL872914,1.0,,,,,8.0,,
Autocuration,,1715.0,,,105.0,2598.0,H,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,BAO_0000357,B,,CHEMBL616921,1.0,,,,,8.0,,
Expert,,1716.0,,,105.0,6897.0,H,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616922,1.0,,,,,8.0,,
Autocuration,,1717.0,,,105.0,6013.0,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616923,1.0,,,,,8.0,,
Expert,,1718.0,,,105.0,5843.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616924,1.0,,,,,8.0,,
Expert,,1719.0,,,105.0,14454.0,H,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,BAO_0000357,B,,CHEMBL875909,1.0,,,,,8.0,,
Autocuration,,1720.0,,,105.0,14454.0,H,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,BAO_0000357,B,,CHEMBL616925,1.0,,,,,8.0,,
Autocuration,,1721.0,,,105.0,14454.0,H,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,BAO_0000357,B,,CHEMBL616926,1.0,,,,,8.0,,
Autocuration,,1722.0,,,105.0,15818.0,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616927,1.0,,,,,8.0,,
Expert,,1723.0,,,105.0,13729.0,H,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,BAO_0000219,F,,CHEMBL616928,1.0,,,,CHO-K1,8.0,485.0,
Expert,,1724.0,,,105.0,6011.0,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,BAO_0000219,B,In vitro,CHEMBL616929,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,1725.0,,,105.0,4234.0,D,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616930,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,1726.0,,,105.0,17085.0,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,B,,CHEMBL616931,1.0,,,,,8.0,,
Autocuration,,1727.0,,,105.0,3025.0,H,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,BAO_0000357,B,,CHEMBL616932,1.0,,,,,8.0,,
Expert,,1728.0,,,105.0,15315.0,H,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616933,1.0,,,,,8.0,,
Expert,,1729.0,,,105.0,14214.0,D,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,BAO_0000219,B,,CHEMBL616934,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,1730.0,,,105.0,3804.0,D,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616935,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,1731.0,,,105.0,16700.0,H,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,BAO_0000357,B,,CHEMBL616936,1.0,,,,,8.0,,
Expert,,1732.0,,,105.0,2391.0,D,,Affinity for 5-hydroxytryptamine 1D receptor subtype,,BAO_0000357,B,,CHEMBL616937,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,1733.0,,,105.0,4175.0,D,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616938,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,1734.0,,,105.0,17085.0,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,B,,CHEMBL616939,1.0,,,,,8.0,,
Expert,,1735.0,,,105.0,17085.0,H,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,BAO_0000019,B,,CHEMBL616940,1.0,,,,,8.0,,
Expert,,1736.0,,,105.0,15926.0,D,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,BAO_0000357,B,,CHEMBL616941,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,1737.0,,,105.0,16312.0,H,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,BAO_0000219,B,,CHEMBL616942,1.0,,,,CHO-K1,8.0,485.0,
Autocuration,,1738.0,,,105.0,16312.0,H,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,BAO_0000219,B,,CHEMBL616943,1.0,,,,CHO-K1,8.0,485.0,
Autocuration,,1739.0,,,104802.0,14956.0,H,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,BAO_0000219,B,,CHEMBL616944,1.0,,,,CHO,4.0,449.0,
Autocuration,,1740.0,,,105.0,3294.0,H,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,BAO_0000019,F,,CHEMBL616945,1.0,,,,,8.0,,
Autocuration,,1741.0,,,105.0,12861.0,H,,Binding activity radioligand.,,BAO_0000357,B,,CHEMBL616946,1.0,,,,,8.0,,
Autocuration,,1742.0,,,105.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,B,,CHEMBL616947,1.0,,,,,8.0,,
Expert,,1743.0,,,105.0,16312.0,H,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,BAO_0000219,B,,CHEMBL616948,1.0,,,,CHO-K1,8.0,485.0,
Autocuration,,1744.0,,,105.0,5104.0,H,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616851,1.0,,,,,8.0,,
Autocuration,,1745.0,,,105.0,5105.0,H,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616852,1.0,,,,,8.0,,
Autocuration,,1746.0,,,105.0,14499.0,H,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616853,1.0,,,,,8.0,,
Expert,,1747.0,,,105.0,15926.0,D,,Binding activity against human 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616854,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,1748.0,,,105.0,4540.0,D,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,B,,CHEMBL616855,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,1749.0,,,105.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,BAO_0000219,B,,CHEMBL616856,1.0,,,,CHO,8.0,449.0,
Autocuration,,1750.0,,,105.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,B,,CHEMBL616857,1.0,,,,CHO,8.0,449.0,
Autocuration,,1751.0,,,105.0,6166.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616858,1.0,,,,,8.0,,
Autocuration,,1752.0,,,105.0,15779.0,H,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,B,,CHEMBL616859,1.0,,,,CHO,8.0,449.0,
Autocuration,,1753.0,,,105.0,15779.0,H,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,BAO_0000219,B,,CHEMBL616860,1.0,,,,CHO,8.0,449.0,
Autocuration,,1754.0,,,105.0,17451.0,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,BAO_0000219,B,,CHEMBL616861,1.0,,,,HEK293,8.0,722.0,
Autocuration,,1755.0,,,105.0,17451.0,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,BAO_0000219,B,,CHEMBL616541,1.0,,,,HEK293,8.0,722.0,
Autocuration,,1756.0,,,105.0,17451.0,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,BAO_0000219,B,,CHEMBL616542,1.0,,,,HEK293,8.0,722.0,
Autocuration,,1757.0,,,105.0,4199.0,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,BAO_0000219,B,,CHEMBL616543,1.0,,,,CHO,8.0,449.0,
Expert,,1758.0,,,105.0,14875.0,D,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616544,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,1759.0,,,105.0,15146.0,H,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,BAO_0000219,B,,CHEMBL616545,1.0,,,,CHO,8.0,449.0,
Autocuration,,1760.0,,,105.0,5213.0,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,B,,CHEMBL616546,1.0,,,,,8.0,,
Autocuration,,1761.0,,,105.0,14818.0,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,BAO_0000219,B,,CHEMBL616547,1.0,,,,CHO,8.0,449.0,
Autocuration,,1762.0,,,105.0,4829.0,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,B,,CHEMBL616548,1.0,,,,CHO,8.0,449.0,
Expert,,1763.0,,,105.0,14454.0,H,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,BAO_0000019,F,,CHEMBL616549,1.0,,,,,8.0,,
Expert,,1764.0,,,105.0,14454.0,H,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,BAO_0000019,F,,CHEMBL616550,1.0,,,,,8.0,,
Autocuration,,1765.0,,,108.0,5254.0,H,,Binding affinity against 5-HT2C receptor,,BAO_0000357,B,,CHEMBL857066,1.0,,,,,8.0,,
Autocuration,,1766.0,,,108.0,5254.0,H,,Binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616551,1.0,,,,,8.0,,
Autocuration,,1767.0,,,10577.0,10639.0,H,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,BAO_0000357,B,,CHEMBL616552,1.0,,,,,8.0,,
Autocuration,,1768.0,,,10577.0,10639.0,H,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,BAO_0000019,F,,CHEMBL832876,1.0,,,,,8.0,,
Expert,,1769.0,,,10577.0,12352.0,H,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,BAO_0000019,B,,CHEMBL616553,1.0,,,,,8.0,,
Autocuration,,1770.0,,,10577.0,9098.0,H,,Binding affinity towards 5-HT1B was determined,,BAO_0000357,B,,CHEMBL616554,1.0,,,,,8.0,,
Expert,,1771.0,,,10577.0,14430.0,H,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,BAO_0000019,B,,CHEMBL616555,1.0,,,,,8.0,,
Expert,,1772.0,,,10577.0,13657.0,H,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,BAO_0000019,B,,CHEMBL616556,1.0,,,,,8.0,,
Autocuration,,1773.0,,,10577.0,13657.0,H,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,BAO_0000019,B,,CHEMBL616557,1.0,,,,,8.0,,
Expert,,1774.0,,,10577.0,15854.0,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,BAO_0000019,B,,CHEMBL616558,1.0,,,,,8.0,,
Expert,,1775.0,,,10577.0,10639.0,D,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,BAO_0000019,B,,CHEMBL616749,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1776.0,,,10577.0,10025.0,H,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,BAO_0000357,B,,CHEMBL616750,1.0,,,,,8.0,,
Autocuration,,1777.0,,,10577.0,10025.0,H,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,BAO_0000357,B,,CHEMBL616751,1.0,,,,,8.0,,
Autocuration,,1778.0,,,10577.0,14286.0,H,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,BAO_0000249,B,,CHEMBL616752,1.0,,,,,8.0,,
Autocuration,Striatum,1779.0,,,10577.0,3651.0,H,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,BAO_0000019,B,,CHEMBL616753,1.0,2435.0,,,,8.0,,
Expert,,1780.0,,,10577.0,14178.0,D,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616754,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1781.0,,,10577.0,10639.0,H,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,BAO_0000019,B,,CHEMBL616755,1.0,,,,,8.0,,
Autocuration,Striatum,1782.0,,,10577.0,13605.0,H,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,BAO_0000019,B,,CHEMBL616756,1.0,2435.0,,,,8.0,,
Autocuration,Striatum,1783.0,,,10577.0,5834.0,H,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,BAO_0000019,B,,CHEMBL616757,1.0,2435.0,,,,8.0,,
Autocuration,Striatum,1784.0,,,10577.0,10922.0,H,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,BAO_0000357,B,,CHEMBL616758,1.0,2435.0,,,,8.0,,
Autocuration,,1785.0,,,10577.0,14286.0,H,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,BAO_0000249,B,,CHEMBL616759,1.0,,,,,8.0,,
Autocuration,,1786.0,,,10577.0,11825.0,H,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,BAO_0000357,B,,CHEMBL616760,1.0,,,,,8.0,,
Autocuration,Striatum,1787.0,,,10577.0,14826.0,H,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,BAO_0000019,B,,CHEMBL616761,1.0,2435.0,,,,8.0,,
Autocuration,Striatum,1788.0,,,10577.0,9699.0,H,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,BAO_0000019,B,,CHEMBL616762,1.0,2435.0,,,,8.0,,
Autocuration,,1789.0,,,10577.0,14423.0,H,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,BAO_0000019,B,,CHEMBL616763,1.0,,,,,8.0,,
Expert,,1790.0,,,10577.0,10062.0,H,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,BAO_0000357,B,,CHEMBL872909,1.0,,,,,8.0,,
Autocuration,,1791.0,,,10577.0,10062.0,H,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616764,1.0,,,,,8.0,,
Expert,,1792.0,,,10577.0,12280.0,D,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616765,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Striatum,1793.0,,,10577.0,15412.0,H,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,BAO_0000357,B,,CHEMBL616766,1.0,2435.0,,,,8.0,,
Autocuration,Striatum,1794.0,,,10577.0,15412.0,H,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,BAO_0000357,B,,CHEMBL616767,1.0,2435.0,,,,8.0,,
Autocuration,,1795.0,,,10577.0,10062.0,H,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616768,1.0,,,,,8.0,,
Autocuration,,1796.0,,,10577.0,11147.0,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL616769,1.0,,,,,8.0,,
Autocuration,,1797.0,,,10577.0,9547.0,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,BAO_0000019,B,,CHEMBL616770,1.0,,,,,8.0,,
Autocuration,,1798.0,,,10577.0,10444.0,H,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,BAO_0000019,B,,CHEMBL616771,1.0,,,,,8.0,,
Autocuration,Striatum,1799.0,,,10577.0,12469.0,H,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,BAO_0000019,B,,CHEMBL616772,1.0,2435.0,,,,8.0,,
Expert,,1800.0,,,10577.0,9098.0,H,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,BAO_0000019,B,,CHEMBL616773,1.0,,,,,8.0,,
Autocuration,,1801.0,,,10577.0,9098.0,H,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,BAO_0000019,B,,CHEMBL616774,1.0,,,,,8.0,,
Autocuration,,1802.0,,,10577.0,9699.0,H,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616775,1.0,,,,,8.0,,
Autocuration,,1803.0,,,10577.0,10394.0,H,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,BAO_0000249,B,,CHEMBL616776,1.0,,,,,8.0,,
Autocuration,,1804.0,,,10577.0,12092.0,H,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,BAO_0000357,B,,CHEMBL616777,1.0,,,,,8.0,,
Autocuration,,1805.0,,,10577.0,16700.0,H,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,BAO_0000357,B,,CHEMBL616778,1.0,,,,,8.0,,
Expert,,1806.0,,,10577.0,403.0,D,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,BAO_0000249,B,,CHEMBL616779,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,1807.0,,,10577.0,12771.0,D,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616780,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1808.0,,,10577.0,11642.0,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,BAO_0000019,B,,CHEMBL616781,1.0,,,,,8.0,,
Autocuration,,1809.0,,,10577.0,12953.0,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL616782,1.0,,,,,8.0,,
Autocuration,,1810.0,,,10577.0,12953.0,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,BAO_0000357,B,,CHEMBL616783,1.0,,,,,8.0,,
Expert,Striatum,1811.0,,,10577.0,12953.0,H,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,BAO_0000019,B,,CHEMBL616784,1.0,2435.0,,,,8.0,,
Autocuration,,1812.0,,,10577.0,12953.0,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,BAO_0000357,B,,CHEMBL616785,1.0,,,,,8.0,,
Autocuration,Brain,1813.0,,,10577.0,9737.0,H,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,BAO_0000249,B,,CHEMBL857067,1.0,955.0,,,,8.0,,
Autocuration,,1814.0,,,10577.0,9737.0,H,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,BAO_0000019,B,,CHEMBL616786,1.0,,,,,8.0,,
Autocuration,Brain,1815.0,,,10577.0,9737.0,H,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,BAO_0000249,B,,CHEMBL616787,1.0,955.0,,,,8.0,,
Autocuration,,1816.0,,,10577.0,12827.0,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,BAO_0000357,B,,CHEMBL616788,1.0,,,,,8.0,,
Autocuration,,1817.0,,,10577.0,5033.0,H,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616789,1.0,,,,,8.0,,
Expert,,1818.0,,,10577.0,9786.0,D,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,BAO_0000019,B,,CHEMBL616790,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,1819.0,,,10577.0,13116.0,H,,Binding affinity at 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616791,1.0,,,,,8.0,,
Autocuration,,1820.0,,,10577.0,16429.0,H,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,BAO_0000019,B,,CHEMBL616792,1.0,,,,,8.0,,
Expert,,1821.0,,,10577.0,12409.0,D,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,BAO_0000249,B,,CHEMBL616793,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1822.0,,,10577.0,15194.0,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL616794,1.0,,,,,8.0,,
Autocuration,,1823.0,,,10577.0,15194.0,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,BAO_0000357,B,,CHEMBL616795,1.0,,,,,8.0,,
Autocuration,,1824.0,,,104686.0,5486.0,H,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,BAO_0000019,B,,CHEMBL616796,1.0,,,,,4.0,,
Autocuration,,1825.0,,,106.0,4639.0,H,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616797,1.0,,,,,8.0,,
Autocuration,,1826.0,,,106.0,386.0,H,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,Brain membranes,BAO_0000249,B,,CHEMBL616798,1.0,,,,,8.0,,
Autocuration,,1827.0,,,106.0,2474.0,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,BAO_0000357,B,,CHEMBL616799,1.0,,,,,8.0,,
Autocuration,,1828.0,,,106.0,6011.0,H,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,BAO_0000357,B,,CHEMBL616800,1.0,,,,,8.0,,
Autocuration,,1829.0,,,106.0,5014.0,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616801,1.0,,,,,8.0,,
Autocuration,,1830.0,,,106.0,17515.0,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,BAO_0000357,B,,CHEMBL616802,1.0,,,,,8.0,,
Autocuration,,1831.0,,,106.0,4373.0,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,BAO_0000357,B,,CHEMBL616803,1.0,,,,,8.0,,
Expert,,1832.0,,,106.0,1633.0,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,BAO_0000357,B,,CHEMBL857068,1.0,,,,,8.0,,
Autocuration,,1833.0,,,106.0,1633.0,H,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,BAO_0000357,B,,CHEMBL616804,1.0,,,,,8.0,,
Autocuration,,1834.0,,,106.0,4373.0,H,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,BAO_0000357,B,,CHEMBL616805,1.0,,,,,8.0,,
Autocuration,,1835.0,,,106.0,4687.0,H,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616806,1.0,,,,,8.0,,
Autocuration,,1836.0,,,106.0,11574.0,H,,Binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,B,,CHEMBL616807,1.0,,,,,8.0,,
Autocuration,,1837.0,,,106.0,10321.0,H,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL616808,1.0,,,,,8.0,,
Autocuration,,1838.0,,,106.0,15527.0,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,BAO_0000357,B,,CHEMBL616809,1.0,,,,,8.0,,
Autocuration,,1839.0,,,106.0,17200.0,H,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,BAO_0000357,B,,CHEMBL616810,1.0,,,,,8.0,,
Autocuration,,1840.0,,,104802.0,14423.0,H,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,BAO_0000224,B,,CHEMBL616811,1.0,,,,,4.0,,
Autocuration,,1841.0,,,108.0,5834.0,H,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,BAO_0000357,B,,CHEMBL616812,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,1842.0,,,108.0,11473.0,H,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,BAO_0000357,B,,CHEMBL616813,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1843.0,,,108.0,11473.0,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,BAO_0000357,B,,CHEMBL616814,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1844.0,,,108.0,10639.0,H,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,BAO_0000357,B,,CHEMBL616815,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1845.0,,,108.0,10639.0,H,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,BAO_0000357,B,,CHEMBL616816,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1846.0,,,108.0,14331.0,H,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,BAO_0000357,B,,CHEMBL616817,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1847.0,,,108.0,10796.0,H,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,BAO_0000357,B,,CHEMBL616818,1.0,,,9823.0,,8.0,,Sus scrofa
Expert,,1848.0,,,108.0,9098.0,H,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,BAO_0000357,B,,CHEMBL616819,1.0,,,9823.0,,8.0,,Sus scrofa
Expert,,1849.0,,,108.0,14331.0,H,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,BAO_0000357,B,,CHEMBL616820,1.0,,,9823.0,,8.0,,Sus scrofa
Expert,,1850.0,,,108.0,11828.0,H,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,BAO_0000019,B,,CHEMBL616821,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1851.0,,,108.0,11866.0,H,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,BAO_0000357,B,,CHEMBL616822,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,1852.0,,,108.0,13047.0,H,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,BAO_0000019,B,,CHEMBL616823,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Autocuration,,1853.0,,,12689.0,188.0,D,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,BAO_0000357,B,,CHEMBL616824,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1854.0,,,12689.0,11825.0,D,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,BAO_0000357,B,,CHEMBL616825,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1855.0,,,12689.0,11825.0,D,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,BAO_0000357,B,,CHEMBL616826,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,1856.0,,,12689.0,11624.0,D,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,BAO_0000019,B,,CHEMBL616827,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1857.0,,,12689.0,11139.0,D,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,BAO_0000357,B,,CHEMBL616828,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1858.0,,,12689.0,11147.0,D,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,BAO_0000357,B,,CHEMBL616829,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1859.0,,,12689.0,10444.0,D,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,BAO_0000019,B,,CHEMBL616830,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,1860.0,,,12689.0,11624.0,D,,Binding affinity against 5-hydroxytryptamine 1C receptor,,BAO_0000357,B,,CHEMBL616831,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1861.0,,,12689.0,11662.0,D,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,B,,CHEMBL616832,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1862.0,,,12689.0,11662.0,D,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,B,,CHEMBL616833,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,1863.0,,,12689.0,11662.0,D,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,B,,CHEMBL616834,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1864.0,,,12689.0,11662.0,D,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,B,,CHEMBL829595,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1865.0,,,12689.0,9098.0,D,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,BAO_0000357,B,,CHEMBL616835,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1866.0,,,12689.0,10394.0,D,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,BAO_0000249,B,,CHEMBL872910,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,1867.0,,,12689.0,11933.0,H,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,BAO_0000357,B,,CHEMBL616836,1.0,,,,,8.0,,
Autocuration,,1868.0,,,12689.0,12092.0,D,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,BAO_0000357,B,,CHEMBL616837,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1869.0,,,12689.0,12253.0,D,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,BAO_0000019,B,,CHEMBL616466,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,1870.0,,,12689.0,12253.0,D,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,BAO_0000219,B,,CHEMBL616467,1.0,,,10116.0,HEK293,9.0,722.0,Rattus norvegicus
Autocuration,,1871.0,,,108.0,1558.0,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,BAO_0000357,B,,CHEMBL616468,1.0,,,,,8.0,,
Autocuration,,1872.0,,,108.0,2474.0,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,BAO_0000357,B,,CHEMBL616469,1.0,,,,,8.0,,
Autocuration,,1873.0,,,108.0,2474.0,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,BAO_0000357,B,,CHEMBL616470,1.0,,,,,8.0,,
Autocuration,,1874.0,,,12689.0,11574.0,H,,Binding affinity against 5-hydroxytryptamine 1C receptor,,BAO_0000357,B,,CHEMBL616471,1.0,,,,,8.0,,
Autocuration,,1875.0,,,12689.0,1558.0,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,BAO_0000357,B,,CHEMBL616472,1.0,,,,,8.0,,
Autocuration,,1876.0,,,12689.0,13944.0,H,,Binding affinity against 5-hydroxytryptamine 1C receptor,,BAO_0000357,B,,CHEMBL616473,1.0,,,,,8.0,,
Autocuration,,1877.0,,,12689.0,13033.0,H,,Binding affinity against serotonergic 5-HT1c receptor,,BAO_0000357,B,,CHEMBL616474,1.0,,,,,8.0,,
Autocuration,,1878.0,,,12689.0,10321.0,H,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,BAO_0000357,B,,CHEMBL616475,1.0,,,,,8.0,,
Autocuration,,1879.0,,,12689.0,11866.0,H,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,BAO_0000357,B,,CHEMBL616476,1.0,,,,,8.0,,
Autocuration,,1880.0,,,105.0,14454.0,H,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,BAO_0000019,B,,CHEMBL616477,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Autocuration,,1881.0,,,104686.0,11574.0,H,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,BAO_0000224,B,,CHEMBL616478,1.0,,,,,4.0,,
Autocuration,,1882.0,,,104686.0,11574.0,H,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,BAO_0000224,B,,CHEMBL616479,1.0,,,,,4.0,,
Autocuration,,1883.0,,,104686.0,13631.0,H,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,BAO_0000019,B,,CHEMBL616480,1.0,,,,,4.0,,
Autocuration,,1884.0,,,104686.0,9630.0,D,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,BAO_0000019,B,,CHEMBL616481,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,1885.0,,,104686.0,8822.0,D,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,BAO_0000249,B,,CHEMBL616482,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,Brain,1886.0,,,104686.0,9064.0,D,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,BAO_0000221,B,,CHEMBL884713,1.0,955.0,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,1887.0,,,104686.0,8868.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,BAO_0000224,B,,CHEMBL616483,1.0,,,,,4.0,,
Autocuration,,1888.0,,,104686.0,9064.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,BAO_0000224,B,,CHEMBL616484,1.0,,,,,4.0,,
Autocuration,,1889.0,,,104686.0,9806.0,H,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,BAO_0000019,B,,CHEMBL616485,1.0,,,,,4.0,,
Autocuration,,1890.0,,,104686.0,9098.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,B,,CHEMBL616486,1.0,,,,,4.0,,
Autocuration,,1891.0,,,104686.0,8868.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,BAO_0000224,B,,CHEMBL616487,1.0,,,,,4.0,,
Autocuration,,1892.0,,,104686.0,12765.0,H,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,BAO_0000224,B,,CHEMBL616488,1.0,,,,,4.0,,
Autocuration,,1893.0,,,104686.0,11049.0,H,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,B,,CHEMBL616489,1.0,,,,,4.0,,
Autocuration,,1894.0,,,104686.0,11049.0,H,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,B,,CHEMBL616490,1.0,,,,,4.0,,
Autocuration,,1895.0,,,104686.0,11049.0,H,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,BAO_0000019,B,,CHEMBL616491,1.0,,,,,4.0,,
Autocuration,,1896.0,,,104686.0,11049.0,H,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,BAO_0000019,B,,CHEMBL616492,1.0,,,,,4.0,,
Autocuration,,1897.0,,,104686.0,11049.0,H,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,B,,CHEMBL616493,1.0,,,,,4.0,,
Autocuration,,1898.0,,,104686.0,11473.0,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,BAO_0000019,B,,CHEMBL616494,1.0,,,,,4.0,,
Autocuration,,1899.0,,,104686.0,11473.0,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,BAO_0000019,B,,CHEMBL616495,1.0,,,,,4.0,,
Autocuration,,1900.0,,,104686.0,3086.0,H,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,BAO_0000019,B,,CHEMBL616496,1.0,,,,,4.0,,
Autocuration,,1901.0,,,104686.0,11049.0,H,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,B,,CHEMBL616497,1.0,,,,,4.0,,
Autocuration,,1902.0,,,104686.0,11049.0,H,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,B,,CHEMBL616498,1.0,,,,,4.0,,
Autocuration,,1903.0,,,104686.0,10639.0,H,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,BAO_0000019,B,,CHEMBL616499,1.0,,,,,4.0,,
Autocuration,,1904.0,,,104686.0,10922.0,H,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,BAO_0000019,B,,CHEMBL616500,1.0,,,,,4.0,,
Autocuration,Brain,1905.0,,,104686.0,9064.0,D,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,BAO_0000221,B,,CHEMBL616501,1.0,955.0,,10116.0,,5.0,,Rattus norvegicus
Autocuration,Brain,1906.0,,,104686.0,10748.0,H,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,BAO_0000221,B,,CHEMBL616502,1.0,955.0,,,,4.0,,
Autocuration,,1907.0,,,104686.0,11614.0,H,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Membranes,BAO_0000249,B,,CHEMBL884529,1.0,,,,,4.0,,
Autocuration,,1908.0,,,104686.0,11615.0,H,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Membranes,BAO_0000249,B,,CHEMBL616503,1.0,,,,,4.0,,
Autocuration,,1909.0,,,104686.0,11615.0,H,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL616964,1.0,,,,,4.0,,
Autocuration,,1910.0,,,104686.0,11614.0,H,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Membranes,BAO_0000249,B,,CHEMBL616965,1.0,,,,,4.0,,
Autocuration,,1911.0,,,104686.0,11702.0,H,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,BAO_0000224,B,,CHEMBL616966,1.0,,,,,4.0,,
Autocuration,,1912.0,,,104686.0,11702.0,H,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,BAO_0000224,B,,CHEMBL616967,1.0,,,,,4.0,,
Autocuration,,1913.0,,,104686.0,11702.0,D,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL616968,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,1914.0,,,104686.0,11702.0,H,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,BAO_0000224,B,,CHEMBL616969,1.0,,,,,4.0,,
Autocuration,,1915.0,,,104686.0,13346.0,H,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,BAO_0000019,B,,CHEMBL884530,1.0,,,,,4.0,,
Autocuration,,1916.0,,,104686.0,10025.0,H,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL616970,1.0,,,,,4.0,,
Autocuration,,1917.0,,,104686.0,10025.0,H,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,BAO_0000224,B,,CHEMBL616971,1.0,,,,,4.0,,
Autocuration,,1918.0,,,104686.0,10025.0,H,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,BAO_0000224,B,,CHEMBL616972,1.0,,,,,4.0,,
Autocuration,,1919.0,,,104686.0,9036.0,H,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,BAO_0000224,B,,CHEMBL616973,1.0,,,,,4.0,,
Autocuration,,1920.0,,,104686.0,9036.0,H,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,BAO_0000224,B,,CHEMBL616974,1.0,,,,,4.0,,
Autocuration,,1921.0,,,104686.0,9161.0,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,BAO_0000019,B,,CHEMBL616975,1.0,,,,,4.0,,
Autocuration,,1922.0,,,104686.0,12304.0,H,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,BAO_0000019,B,,CHEMBL616976,1.0,,,,,4.0,,
Autocuration,,1923.0,,,104686.0,13276.0,H,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,BAO_0000224,B,,CHEMBL616977,1.0,,,,,4.0,,
Autocuration,,1924.0,,,104686.0,11825.0,H,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,BAO_0000224,B,,CHEMBL616978,1.0,,,,,4.0,,
Autocuration,,1925.0,,,104686.0,12443.0,H,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,BAO_0000224,B,,CHEMBL616979,1.0,,,,,4.0,,
Autocuration,,1926.0,,,104686.0,13830.0,H,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL616980,1.0,,,,,4.0,,
Autocuration,,1927.0,,,104686.0,9592.0,H,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,Membranes,BAO_0000249,B,,CHEMBL616981,1.0,,,,,4.0,,
Autocuration,,1928.0,,,104686.0,9592.0,H,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,Membranes,BAO_0000249,B,,CHEMBL616982,1.0,,,,,4.0,,
Autocuration,,1929.0,,,104686.0,10881.0,H,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,BAO_0000224,B,,CHEMBL616983,1.0,,,,,4.0,,
Autocuration,,1930.0,,,104686.0,13605.0,H,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,BAO_0000019,B,,CHEMBL616984,1.0,,,,,4.0,,
Autocuration,,1931.0,,,104686.0,11624.0,D,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL616985,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,1932.0,,,104686.0,4101.0,H,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,BAO_0000224,B,,CHEMBL616986,1.0,,,,,4.0,,
Autocuration,,1933.0,,,104686.0,4101.0,H,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,BAO_0000224,B,,CHEMBL616987,1.0,,,,,4.0,,
Autocuration,,1934.0,,,104686.0,15360.0,H,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,BAO_0000019,B,,CHEMBL616988,1.0,,,,,4.0,,
Autocuration,,1935.0,,,104686.0,11576.0,H,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,BAO_0000019,B,,CHEMBL617243,1.0,,,,,4.0,,
Autocuration,,1936.0,,,104686.0,5834.0,H,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,BAO_0000019,B,,CHEMBL617244,1.0,,,,,4.0,,
Autocuration,,1937.0,,,104686.0,2395.0,D,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,BAO_0000219,B,,CHEMBL617245,1.0,,,10116.0,CHO-K1,5.0,485.0,Rattus norvegicus
Autocuration,,1938.0,,,104686.0,11965.0,H,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Membranes,BAO_0000249,B,,CHEMBL617246,1.0,,,,,4.0,,
Autocuration,,1939.0,,,104686.0,3967.0,H,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,BAO_0000224,B,,CHEMBL617546,1.0,,,,,4.0,,
Autocuration,,1940.0,,,104686.0,11130.0,H,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),Brain membranes,BAO_0000249,B,,CHEMBL617547,1.0,,,,,4.0,,
Autocuration,,1941.0,,,104686.0,13427.0,H,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,BAO_0000219,B,In vitro,CHEMBL617548,1.0,,,,,4.0,,
Autocuration,,1942.0,,,104686.0,9443.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617549,1.0,,,,,4.0,,
Autocuration,,1943.0,,,104686.0,9443.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,BAO_0000224,B,,CHEMBL617550,1.0,,,,,4.0,,
Autocuration,,1944.0,,,104686.0,11825.0,H,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,BAO_0000224,B,,CHEMBL617551,1.0,,,,,4.0,,
Autocuration,,1945.0,,,104686.0,12120.0,H,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,Membranes,BAO_0000249,B,,CHEMBL617552,1.0,,,,,4.0,,
Autocuration,,1946.0,,,104686.0,12120.0,H,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,Membranes,BAO_0000249,B,,CHEMBL617553,1.0,,,,,4.0,,
Autocuration,Thoracic aorta,1947.0,,,104686.0,11963.0,H,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,BAO_0000019,F,,CHEMBL617554,1.0,1515.0,,,,4.0,,
Autocuration,,1948.0,,,104686.0,9069.0,H,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,BAO_0000019,B,,CHEMBL617555,1.0,,,,,4.0,,
Autocuration,,1949.0,,,104686.0,8868.0,H,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,BAO_0000224,B,,CHEMBL617556,1.0,,,,,4.0,,
Autocuration,,1950.0,,,10624.0,17200.0,H,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,BAO_0000357,B,,CHEMBL617557,1.0,,,,,8.0,,
Autocuration,,1951.0,,,10624.0,17200.0,H,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,BAO_0000357,B,,CHEMBL617558,1.0,,,,,8.0,,
Expert,,1952.0,,,17106.0,13969.0,H,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL617559,1.0,,,,,8.0,,
Expert,,1953.0,,,17106.0,13392.0,D,,Binding affinity for 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL617560,1.0,,,,,9.0,,
Autocuration,,1954.0,,,17106.0,1742.0,H,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,BAO_0000249,B,,CHEMBL617561,1.0,,,,,8.0,,
Autocuration,,1955.0,,,17106.0,1742.0,H,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,BAO_0000249,B,,CHEMBL617562,1.0,,,,,8.0,,
Autocuration,Striatum,1956.0,,,17106.0,14331.0,H,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,BAO_0000357,B,,CHEMBL617563,1.0,2435.0,,,,8.0,,
Autocuration,,1957.0,,,17106.0,12861.0,H,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,BAO_0000019,F,,CHEMBL617564,1.0,,,,,8.0,,
Expert,,1958.0,,,17106.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,BAO_0000019,B,,CHEMBL617565,1.0,,,,,8.0,,
Autocuration,,1959.0,,,17106.0,12861.0,H,,Binding activity radioligand.,,BAO_0000357,B,,CHEMBL856076,1.0,,,,,8.0,,
Autocuration,,1960.0,,,17106.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,BAO_0000019,B,,CHEMBL617566,1.0,,,,,8.0,,
Expert,,1961.0,,,17106.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,B,,CHEMBL875911,1.0,,,,,8.0,,
Autocuration,,1962.0,,,17106.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,BAO_0000019,B,,CHEMBL617567,1.0,,,,,8.0,,
Autocuration,,1963.0,,,17106.0,675.0,H,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,BAO_0000249,B,,CHEMBL617568,1.0,,,,,8.0,,
Expert,,1964.0,,,17106.0,12490.0,H,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,BAO_0000019,B,,CHEMBL617569,1.0,,,,,8.0,,
Expert,,1965.0,,,17106.0,11828.0,H,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,BAO_0000249,B,,CHEMBL617570,1.0,,,,,8.0,,
Autocuration,,1966.0,,,17106.0,11866.0,H,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,BAO_0000357,B,,CHEMBL617571,1.0,,,,,8.0,,
Autocuration,,1967.0,,,105.0,773.0,H,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,BAO_0000357,B,,CHEMBL617572,1.0,,,9823.0,,8.0,,Sus scrofa
Expert,,1968.0,,,105.0,13047.0,H,,The compound was tested for intrinsic activity against 5-HT1D receptor,,BAO_0000357,B,,CHEMBL617573,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Autocuration,,1969.0,,,105.0,13047.0,H,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,BAO_0000019,B,,CHEMBL617574,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Expert,,1970.0,,,105.0,13047.0,H,,The compound was tested for binding affinity against 5-HT1D receptor,,BAO_0000357,B,,CHEMBL617575,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Autocuration,,1971.0,,,10578.0,188.0,H,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,BAO_0000357,B,,CHEMBL617576,1.0,,,,,8.0,,
Autocuration,,1972.0,,,10578.0,10639.0,H,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,BAO_0000019,F,,CHEMBL617577,1.0,,,,,8.0,,
Autocuration,,1973.0,,,10578.0,12438.0,H,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,BAO_0000019,F,,CHEMBL617578,1.0,,,,,8.0,,
Autocuration,,1974.0,,,10578.0,12438.0,H,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL617579,1.0,,,,,8.0,,
Expert,,1975.0,,,10578.0,15854.0,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,BAO_0000019,B,,CHEMBL617580,1.0,,,,,8.0,,
Autocuration,,1976.0,,,10578.0,10394.0,H,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,BAO_0000249,B,,CHEMBL617581,1.0,,,,,8.0,,
Autocuration,,1977.0,,,10578.0,12092.0,H,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,BAO_0000357,B,,CHEMBL617582,1.0,,,,,8.0,,
Expert,,1978.0,,,10578.0,3389.0,H,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,BAO_0000019,B,,CHEMBL617583,1.0,,,,,8.0,,
Autocuration,,1979.0,,,105.0,6011.0,H,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,BAO_0000357,B,,CHEMBL617584,1.0,,,,,8.0,,
Autocuration,,1980.0,,,105.0,4639.0,H,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL617585,1.0,,,,,8.0,,
Autocuration,,1981.0,,,105.0,2474.0,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL875912,1.0,,,,,8.0,,
Autocuration,,1982.0,,,105.0,5014.0,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL617586,1.0,,,,,8.0,,
Autocuration,,1983.0,,,105.0,17515.0,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,BAO_0000357,B,,CHEMBL617587,1.0,,,,,8.0,,
Autocuration,,1984.0,,,105.0,11866.0,H,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,BAO_0000357,B,,CHEMBL617588,1.0,,,,,8.0,,
Autocuration,,1985.0,,,105.0,4687.0,H,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL857980,1.0,,,,,8.0,,
Autocuration,,1986.0,,,105.0,12146.0,H,,Tested against 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL617589,1.0,,,,,8.0,,
Autocuration,,1987.0,,,105.0,10321.0,H,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL617590,1.0,,,,,8.0,,
Autocuration,,1988.0,,,105.0,13267.0,H,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,BAO_0000219,B,,CHEMBL617591,1.0,,,,HEK293,8.0,722.0,
Expert,,1989.0,,,105.0,1274.0,D,,Binding affinity against 5-Hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL617592,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,1990.0,,,105.0,15250.0,H,,,,BAO_0000357,B,,CHEMBL617593,1.0,,,,,8.0,,
Autocuration,,1991.0,,,106.0,13706.0,H,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,BAO_0000219,B,,CHEMBL617594,1.0,,,,CHO-K1,8.0,485.0,
Autocuration,,1992.0,,,105.0,13706.0,H,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,BAO_0000219,B,,CHEMBL617595,1.0,,,,CHO-K1,8.0,485.0,
Autocuration,,1993.0,,,105.0,13706.0,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,BAO_0000219,B,,CHEMBL617596,1.0,,,,HEK293,8.0,722.0,
Autocuration,,1994.0,,,105.0,13706.0,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,BAO_0000219,B,,CHEMBL617597,1.0,,,,HEK293,8.0,722.0,
Autocuration,,1995.0,,,105.0,13047.0,H,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,BAO_0000019,B,,CHEMBL617598,1.0,,,,,8.0,,
Autocuration,,1996.0,,,105.0,13366.0,H,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,BAO_0000357,B,,CHEMBL872916,1.0,,,,,8.0,,
Expert,,1997.0,,,105.0,13366.0,H,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,BAO_0000357,B,,CHEMBL617599,1.0,,,,,8.0,,
Autocuration,,1998.0,,,105.0,1558.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,BAO_0000357,B,,CHEMBL617091,1.0,,,,,8.0,,
Expert,,1999.0,,,105.0,12902.0,H,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,BAO_0000219,B,,CHEMBL617092,1.0,,,,CHO-K1,8.0,485.0,
Autocuration,,2000.0,,,105.0,13706.0,H,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,BAO_0000219,B,,CHEMBL617093,1.0,,,,CHO-K1,8.0,485.0,
Autocuration,,2001.0,,,105.0,13706.0,H,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,F,,CHEMBL617094,1.0,,,,,8.0,,
Autocuration,,2002.0,,,105.0,13706.0,H,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,F,,CHEMBL617095,1.0,,,,,8.0,,
Autocuration,,2003.0,,,105.0,14251.0,H,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,BAO_0000019,F,,CHEMBL617096,1.0,,,,,8.0,,
Autocuration,,2004.0,,,105.0,14251.0,H,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,BAO_0000019,F,,CHEMBL617097,1.0,,,,,8.0,,
Autocuration,,2005.0,,,105.0,14251.0,H,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,BAO_0000019,F,,CHEMBL617098,1.0,,,,,8.0,,
Autocuration,,2006.0,,,105.0,13313.0,H,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL617301,1.0,,,,,8.0,,
Autocuration,,2007.0,,,105.0,13313.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL617302,1.0,,,,,8.0,,
Autocuration,,2008.0,,,105.0,13366.0,H,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,B,,CHEMBL617303,1.0,,,,,8.0,,
Expert,,2009.0,,,105.0,13051.0,H,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,B,,CHEMBL617304,1.0,,,,,8.0,,
Expert,,2010.0,,,105.0,12903.0,H,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,BAO_0000219,B,,CHEMBL617305,1.0,,,,CHO,8.0,449.0,
Autocuration,,2011.0,,,105.0,12469.0,D,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,BAO_0000219,B,,CHEMBL617306,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2012.0,,,17106.0,5619.0,H,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,BAO_0000357,B,,CHEMBL617307,1.0,,,,,8.0,,
Autocuration,,2013.0,,,105.0,13047.0,H,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,BAO_0000019,B,,CHEMBL617308,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Autocuration,,2014.0,,,105.0,16633.0,H,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,B,,CHEMBL617309,1.0,,,,,8.0,,
Autocuration,,2015.0,,,105.0,16633.0,H,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,B,,CHEMBL617310,1.0,,,,,8.0,,
Autocuration,,2016.0,,,105.0,16633.0,H,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,B,,CHEMBL617311,1.0,,,,,8.0,,
Autocuration,,2017.0,,,105.0,16633.0,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL617312,1.0,,,,,8.0,,
Autocuration,,2018.0,,,105.0,3269.0,H,,Affinity against 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,B,,CHEMBL617313,1.0,,,,,8.0,,
Expert,,2019.0,,,105.0,12409.0,H,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,B,,CHEMBL617314,1.0,,,,,8.0,,
Autocuration,,2020.0,,,106.0,13706.0,H,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,F,,CHEMBL617315,1.0,,,,,8.0,,
Autocuration,,2021.0,,,106.0,13706.0,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,BAO_0000219,B,,CHEMBL617316,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2022.0,,,106.0,13706.0,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,BAO_0000219,B,,CHEMBL617317,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2023.0,,,106.0,12903.0,H,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,BAO_0000219,B,,CHEMBL617318,1.0,,,,CHO,8.0,449.0,
Autocuration,,2024.0,,,106.0,13047.0,H,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,BAO_0000019,B,,CHEMBL617319,1.0,,,,,8.0,,
Expert,,2025.0,,,106.0,13366.0,D,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,B,,CHEMBL617320,1.0,,,,,9.0,,
Expert,,2026.0,,,106.0,13366.0,D,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,B,,CHEMBL617321,1.0,,,,,9.0,,
Expert,,2027.0,,,106.0,13366.0,D,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,B,,CHEMBL617322,1.0,,,,,9.0,,
Autocuration,,2028.0,,,106.0,13366.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL616862,1.0,,,,,8.0,,
Autocuration,,2029.0,,,106.0,13366.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,B,,CHEMBL616863,1.0,,,,,8.0,,
Autocuration,,2030.0,,,106.0,12469.0,H,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,BAO_0000219,B,,CHEMBL616864,1.0,,,,CHO,8.0,449.0,
Autocuration,,2031.0,,,106.0,13706.0,H,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,BAO_0000219,B,,CHEMBL616865,1.0,,,,CHO-K1,8.0,485.0,
Autocuration,,2032.0,,,106.0,13706.0,H,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,BAO_0000219,B,,CHEMBL616866,1.0,,,,CHO-K1,8.0,485.0,
Autocuration,,2033.0,,,106.0,13706.0,H,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,F,,CHEMBL616867,1.0,,,,,8.0,,
Expert,,2034.0,,,106.0,12902.0,H,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,BAO_0000219,B,,CHEMBL616868,1.0,,,,CHO-K1,8.0,485.0,
Expert,,2035.0,,,105.0,13051.0,H,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,B,,CHEMBL616869,1.0,,,,,8.0,,
Expert,,2036.0,,,106.0,12903.0,H,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,BAO_0000219,B,,CHEMBL616870,1.0,,,,CHO,8.0,449.0,
Autocuration,,2037.0,,,105.0,1558.0,H,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,BAO_0000219,F,,CHEMBL616871,1.0,,,,CHO-K1,8.0,485.0,
Autocuration,,2038.0,,,105.0,1558.0,H,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,BAO_0000219,F,,CHEMBL616872,1.0,,,,CHO-K1,8.0,485.0,
Autocuration,,2039.0,,,105.0,1558.0,H,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,BAO_0000219,F,,CHEMBL616873,1.0,,,,CHO-K1,8.0,485.0,
Autocuration,,2040.0,,,105.0,1558.0,H,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,BAO_0000219,F,,CHEMBL616838,1.0,,,,CHO-K1,8.0,485.0,
Autocuration,,2041.0,,,105.0,1558.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,BAO_0000357,B,,CHEMBL616839,1.0,,,,,8.0,,
Autocuration,,2042.0,,,106.0,13047.0,H,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,BAO_0000019,B,,CHEMBL616840,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Autocuration,,2043.0,,,105.0,13313.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,BAO_0000357,B,,CHEMBL616841,1.0,,,,,8.0,,
Autocuration,,2044.0,,,105.0,13313.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL616842,1.0,,,,,8.0,,
Expert,,2045.0,,,105.0,12409.0,H,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,B,,CHEMBL857976,1.0,,,,,8.0,,
Autocuration,,2046.0,,,10618.0,15250.0,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL616843,1.0,,,,CHO,8.0,449.0,
Expert,,2047.0,,,10618.0,1348.0,D,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,BAO_0000357,B,,CHEMBL616844,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2048.0,,,10618.0,1348.0,H,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,BAO_0000357,B,,CHEMBL616845,1.0,,,,,8.0,,
Expert,,2049.0,,,10618.0,4234.0,D,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,BAO_0000357,B,,CHEMBL616846,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2050.0,,,10618.0,16209.0,H,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL616847,1.0,,,,,8.0,,
Autocuration,,2051.0,,,10618.0,10444.0,H,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,BAO_0000019,B,,CHEMBL616848,1.0,,,,,8.0,,
Autocuration,,2052.0,,,10618.0,3935.0,H,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,BAO_0000357,B,,CHEMBL616849,1.0,,,,,8.0,,
Autocuration,,2053.0,,,10618.0,15818.0,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,BAO_0000357,B,,CHEMBL872911,1.0,,,,,8.0,,
Autocuration,,2054.0,,,10618.0,17085.0,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,BAO_0000019,B,,CHEMBL616850,1.0,,,,,8.0,,
Expert,,2055.0,,,10618.0,12936.0,D,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,BAO_0000219,B,,CHEMBL616699,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,2056.0,,,10618.0,6166.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,BAO_0000357,B,,CHEMBL616700,1.0,,,,,8.0,,
Autocuration,,2057.0,,,10618.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,B,,CHEMBL616701,1.0,,,,CHO,8.0,449.0,
Autocuration,,2058.0,,,10618.0,15779.0,H,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,B,,CHEMBL616702,1.0,,,,CHO,8.0,449.0,
Autocuration,,2059.0,,,10618.0,15779.0,H,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,BAO_0000219,B,,CHEMBL616703,1.0,,,,CHO,8.0,449.0,
Autocuration,,2060.0,,,10618.0,13181.0,H,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,BAO_0000357,B,,CHEMBL616704,1.0,,,,,8.0,,
Autocuration,,2061.0,,,10618.0,4199.0,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,BAO_0000219,B,,CHEMBL616705,1.0,,,,CHO,8.0,449.0,
Autocuration,,2062.0,,,10618.0,14875.0,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,BAO_0000357,B,,CHEMBL616706,1.0,,,,,8.0,,
Autocuration,,2063.0,,,10618.0,15146.0,H,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,BAO_0000219,B,,CHEMBL616707,1.0,,,,CHO,8.0,449.0,
Autocuration,,2064.0,,,10618.0,5213.0,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,B,,CHEMBL616708,1.0,,,,,8.0,,
Autocuration,,2065.0,,,10618.0,12146.0,H,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL616709,1.0,,,,,8.0,,
Autocuration,,2066.0,,,10618.0,13267.0,H,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,BAO_0000219,B,,CHEMBL616710,1.0,,,,CHO,8.0,449.0,
Autocuration,,2067.0,,,10618.0,14818.0,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,BAO_0000219,B,,CHEMBL616711,1.0,,,,CHO,8.0,449.0,
Autocuration,,2068.0,,,10618.0,4829.0,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,B,,CHEMBL616712,1.0,,,,CHO,8.0,449.0,
Autocuration,,2069.0,,,10618.0,4373.0,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,BAO_0000357,B,,CHEMBL616713,1.0,,,,,8.0,,
Autocuration,,2070.0,,,10618.0,4373.0,H,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,BAO_0000357,B,,CHEMBL616714,1.0,,,,,8.0,,
Autocuration,,2071.0,,,10618.0,14159.0,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,BAO_0000357,B,,CHEMBL616715,1.0,,,,,8.0,,
Autocuration,,2072.0,,,10618.0,16633.0,H,,Binding affinity towards 5-hydroxytryptamine 1E receptor,,BAO_0000357,B,,CHEMBL616716,1.0,,,,,8.0,,
Autocuration,,2073.0,,,279.0,17085.0,H,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,BAO_0000019,F,,CHEMBL616717,1.0,,,,,8.0,,
Expert,,2074.0,,,279.0,17085.0,H,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,BAO_0000019,F,,CHEMBL616718,1.0,,,,,8.0,,
Autocuration,,2075.0,,,279.0,16209.0,H,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,BAO_0000019,F,,CHEMBL875905,1.0,,,,,8.0,,
Autocuration,,2076.0,,,279.0,16209.0,H,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,BAO_0000019,F,,CHEMBL616719,1.0,,,,,8.0,,
Expert,,2077.0,,,279.0,17085.0,H,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,BAO_0000019,F,,CHEMBL616720,1.0,,,,,8.0,,
Autocuration,,2078.0,,,279.0,14159.0,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,BAO_0000357,B,,CHEMBL616721,1.0,,,,,8.0,,
Autocuration,,2079.0,,,279.0,15250.0,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL616722,1.0,,,,CHO,8.0,449.0,
Autocuration,,2080.0,,,279.0,3805.0,H,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,BAO_0000357,B,,CHEMBL616723,1.0,,,,,8.0,,
Autocuration,,2081.0,,,279.0,16190.0,H,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,BAO_0000219,B,,CHEMBL616724,1.0,,,,CHO,8.0,449.0,
Autocuration,,2082.0,,,279.0,16190.0,H,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,BAO_0000357,B,,CHEMBL616725,1.0,,,,,8.0,,
Autocuration,,2083.0,,,279.0,16209.0,H,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,BAO_0000357,B,,CHEMBL616726,1.0,,,,,8.0,,
Autocuration,,2084.0,,,279.0,16209.0,H,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,B,,CHEMBL616727,1.0,,,,,8.0,,
Autocuration,,2085.0,,,279.0,16209.0,H,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,BAO_0000357,B,,CHEMBL616728,1.0,,,,,8.0,,
Autocuration,,2086.0,,,279.0,6866.0,H,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,BAO_0000357,B,,CHEMBL616729,1.0,,,,,8.0,,
Expert,,2087.0,,,279.0,17085.0,H,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,BAO_0000019,B,,CHEMBL616730,1.0,,,,,8.0,,
Autocuration,,2088.0,,,279.0,16312.0,H,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,BAO_0000357,B,,CHEMBL617125,1.0,,,,,8.0,,
Autocuration,,2089.0,,,279.0,6166.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,B,,CHEMBL857977,1.0,,,,,8.0,,
Autocuration,,2090.0,,,279.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,B,,CHEMBL617126,1.0,,,,CHO,8.0,449.0,
Autocuration,,2091.0,,,279.0,4199.0,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,BAO_0000219,B,,CHEMBL617127,1.0,,,,CHO,8.0,449.0,
Autocuration,,2092.0,,,279.0,14875.0,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,BAO_0000357,B,,CHEMBL617128,1.0,,,,,8.0,,
Autocuration,,2093.0,,,279.0,15146.0,H,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,BAO_0000219,B,,CHEMBL617129,1.0,,,,CHO,8.0,449.0,
Autocuration,,2094.0,,,279.0,5213.0,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,B,,CHEMBL617130,1.0,,,,,8.0,,
Autocuration,,2095.0,,,279.0,14818.0,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,BAO_0000219,B,,CHEMBL617131,1.0,,,,CHO,8.0,449.0,
Autocuration,,2096.0,,,279.0,4829.0,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,B,,CHEMBL617132,1.0,,,,CHO,8.0,449.0,
Autocuration,,2097.0,,,279.0,4829.0,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,B,,CHEMBL617133,1.0,,,,CHO,8.0,449.0,
Autocuration,,2098.0,,,279.0,4373.0,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,B,,CHEMBL617134,1.0,,,,,8.0,,
Autocuration,,2099.0,,,279.0,4373.0,H,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,B,,CHEMBL617135,1.0,,,,,8.0,,
Autocuration,,2100.0,,,279.0,5014.0,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,BAO_0000357,B,,CHEMBL617136,1.0,,,,,8.0,,
Autocuration,,2101.0,,,104686.0,11662.0,H,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,BAO_0000019,B,,CHEMBL617137,1.0,,,,,4.0,,
Autocuration,,2102.0,,,104686.0,11662.0,H,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,BAO_0000019,B,,CHEMBL617138,1.0,,,,,4.0,,
Autocuration,,2103.0,,,104686.0,11662.0,H,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,BAO_0000019,B,,CHEMBL617139,1.0,,,,,4.0,,
Autocuration,,2104.0,,,12687.0,14093.0,H,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,BAO_0000019,B,,CHEMBL617140,1.0,,,,,8.0,,
Autocuration,,2105.0,,,104686.0,11200.0,H,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,BAO_0000218,F,In vivo,CHEMBL617141,1.0,,,,,4.0,,
Autocuration,,2106.0,,,104686.0,11200.0,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,F,,CHEMBL858112,1.0,,,,,4.0,,
Intermediate,,2107.0,,,17005.0,12352.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,BAO_0000019,B,,CHEMBL617142,1.0,,,,,8.0,,
Autocuration,,2108.0,,,22226.0,13657.0,U,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,BAO_0000019,B,,CHEMBL617143,1.0,,,9913.0,,0.0,,Bos taurus
Autocuration,,2109.0,,,22226.0,14331.0,U,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,BAO_0000019,B,,CHEMBL617144,1.0,,,9913.0,,0.0,,Bos taurus
Autocuration,,2110.0,,,22226.0,14331.0,U,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,BAO_0000019,B,,CHEMBL617145,1.0,,,9913.0,,0.0,,Bos taurus
Autocuration,,2111.0,,,22226.0,14331.0,U,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,BAO_0000019,B,,CHEMBL617146,1.0,,,,,0.0,,
Autocuration,,2112.0,,,104784.0,12685.0,H,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,BAO_0000019,B,,CHEMBL617147,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,2113.0,,,104784.0,14389.0,H,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,BAO_0000019,B,,CHEMBL617148,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,2114.0,,,104784.0,14386.0,H,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,BAO_0000019,B,,CHEMBL617149,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,2115.0,,,104784.0,5732.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,B,,CHEMBL617150,1.0,,,,,4.0,,
Autocuration,,2116.0,,,104784.0,16293.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,B,,CHEMBL617151,1.0,,,,,4.0,,
Autocuration,,2117.0,,,104784.0,2078.0,H,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617201,1.0,,,,,4.0,,
Autocuration,,2118.0,,,10209.0,5486.0,H,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,BAO_0000357,B,,CHEMBL617202,1.0,,,,,8.0,,
Autocuration,,2119.0,,,104826.0,11820.0,H,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,BAO_0000218,B,In vivo,CHEMBL617203,1.0,,,,,4.0,,
Autocuration,,2120.0,,,104826.0,10297.0,H,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,BAO_0000019,B,,CHEMBL617204,1.0,,,,,4.0,,
Autocuration,,2121.0,,,104826.0,13704.0,H,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,BAO_0000224,B,,CHEMBL617205,1.0,,,,,4.0,,
Autocuration,,2122.0,,,104826.0,10297.0,D,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,BAO_0000019,B,,CHEMBL617206,1.0,,,10090.0,,5.0,,Mus musculus
Autocuration,,2123.0,,,104826.0,11820.0,H,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,BAO_0000218,B,In vivo,CHEMBL617207,1.0,,,,,4.0,,
Autocuration,,2124.0,,,104826.0,10297.0,D,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,BAO_0000019,B,,CHEMBL617208,1.0,,,10090.0,,5.0,,Mus musculus
Autocuration,,2125.0,,,104826.0,11555.0,H,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617209,1.0,,,,,4.0,,
Autocuration,,2126.0,,,104826.0,11555.0,H,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,BAO_0000224,B,,CHEMBL617210,1.0,,,,,4.0,,
Autocuration,,2127.0,,,104826.0,11555.0,H,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,BAO_0000224,B,,CHEMBL617211,1.0,,,,,4.0,,
Autocuration,,2128.0,,,104826.0,10297.0,D,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,BAO_0000019,B,,CHEMBL617212,1.0,,,10090.0,,5.0,,Mus musculus
Autocuration,,2129.0,,,104784.0,16688.0,H,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,BAO_0000224,B,,CHEMBL617213,1.0,,,9823.0,,4.0,,Sus scrofa
Autocuration,,2130.0,,,104784.0,16688.0,H,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,BAO_0000224,B,,CHEMBL617214,1.0,,,9823.0,,4.0,,Sus scrofa
Autocuration,,2131.0,,,22226.0,5333.0,U,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,BAO_0000221,B,,CHEMBL617215,1.0,,,,,0.0,,
Autocuration,,2132.0,,,22226.0,4437.0,U,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,BAO_0000221,B,,CHEMBL617216,1.0,,,,,0.0,,
Autocuration,,2133.0,,,17005.0,5033.0,H,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,BAO_0000357,B,,CHEMBL617217,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,2134.0,,,104686.0,15267.0,H,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,B,,CHEMBL617218,1.0,,,,,4.0,,
Autocuration,,2135.0,,,104686.0,15267.0,H,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,B,,CHEMBL872913,1.0,,,,,4.0,,
Autocuration,,2136.0,,,104826.0,11820.0,H,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,BAO_0000019,B,,CHEMBL617219,1.0,,,,,4.0,,
Autocuration,,2137.0,,,104686.0,9069.0,H,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL873482,1.0,,,,,4.0,,
Autocuration,,2138.0,,,104686.0,9162.0,D,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,BAO_0000019,B,,CHEMBL617220,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2139.0,,,104686.0,9162.0,H,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,BAO_0000019,B,,CHEMBL617221,1.0,,,,,4.0,,
Autocuration,,2140.0,,,104686.0,9162.0,H,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,BAO_0000019,B,,CHEMBL617222,1.0,,,,,4.0,,
Autocuration,,2141.0,,,104686.0,10428.0,H,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,BAO_0000019,F,,CHEMBL875906,1.0,,,,,4.0,,
Autocuration,,2142.0,,,104686.0,9628.0,H,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,BAO_0000019,B,,CHEMBL617223,1.0,,,,,4.0,,
Autocuration,,2143.0,,,104686.0,12704.0,H,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617224,1.0,,,,,4.0,,
Autocuration,,2144.0,,,104686.0,15453.0,D,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,BAO_0000224,B,,CHEMBL617225,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2145.0,,,104686.0,188.0,H,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,BAO_0000224,B,,CHEMBL617226,1.0,,,,,4.0,,
Autocuration,,2146.0,,,104686.0,10349.0,H,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,BAO_0000224,B,,CHEMBL617227,1.0,,,,,4.0,,
Autocuration,,2147.0,,,104686.0,10349.0,H,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,BAO_0000224,B,,CHEMBL617228,1.0,,,,,4.0,,
Autocuration,,2148.0,,,104686.0,8868.0,H,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,BAO_0000224,B,,CHEMBL617229,1.0,,,,,4.0,,
Autocuration,,2149.0,,,104686.0,10025.0,H,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,BAO_0000224,B,,CHEMBL617230,1.0,,,,,4.0,,
Autocuration,,2150.0,,,104686.0,10025.0,H,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,BAO_0000224,B,,CHEMBL617231,1.0,,,,,4.0,,
Autocuration,,2151.0,,,104686.0,11702.0,H,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,BAO_0000224,B,,CHEMBL617232,1.0,,,,,4.0,,
Autocuration,,2152.0,,,104686.0,11702.0,H,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617233,1.0,,,,,4.0,,
Autocuration,,2153.0,,,104686.0,11702.0,H,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,BAO_0000224,B,,CHEMBL617234,1.0,,,,,4.0,,
Autocuration,,2154.0,,,104686.0,11702.0,H,,Compound was tested for the inhibition of quipazine induced head twitches in rats,,BAO_0000019,F,,CHEMBL617235,1.0,,,,,4.0,,
Autocuration,,2155.0,,,104686.0,11702.0,H,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,BAO_0000019,F,,CHEMBL617236,1.0,,,,,4.0,,
Autocuration,Hippocampus,2156.0,,,104686.0,10085.0,H,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,BAO_0000221,B,,CHEMBL617237,1.0,10000000.0,,,,4.0,,
Autocuration,Hippocampus,2157.0,,,104686.0,10085.0,H,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,BAO_0000221,B,,CHEMBL617238,1.0,10000000.0,,,,4.0,,
Autocuration,Brain,2158.0,,,104686.0,9630.0,D,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,BAO_0000221,B,,CHEMBL617239,1.0,955.0,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2159.0,,,104686.0,11070.0,H,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,BAO_0000019,B,,CHEMBL617240,1.0,,,,,4.0,,
Autocuration,,2160.0,,,104686.0,9841.0,H,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Membranes,BAO_0000249,B,,CHEMBL617241,1.0,,,,,4.0,,
Autocuration,,2161.0,,,104686.0,9841.0,H,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Membranes,BAO_0000249,B,,CHEMBL875907,1.0,,,,,4.0,,
Autocuration,,2162.0,,,104686.0,13291.0,H,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,BAO_0000019,B,,CHEMBL617242,1.0,,,,,4.0,,
Autocuration,,2163.0,,,104686.0,10590.0,H,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,BAO_0000019,F,,CHEMBL617152,1.0,,,,,4.0,,
Autocuration,Brain,2164.0,,,104686.0,9064.0,D,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,BAO_0000221,B,,CHEMBL617153,1.0,955.0,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2165.0,,,104686.0,12268.0,D,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,Membranes,BAO_0000249,B,,CHEMBL617154,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,Brain,2166.0,,,104686.0,13508.0,H,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,BAO_0000221,B,,CHEMBL617155,1.0,955.0,,,,4.0,,
Autocuration,,2167.0,,,104686.0,11279.0,H,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,BAO_0000019,F,,CHEMBL617156,1.0,,,,,4.0,,
Autocuration,,2168.0,,,104686.0,11200.0,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,BAO_0000019,F,,CHEMBL617157,1.0,,,,,4.0,,
Autocuration,,2169.0,,,104686.0,11200.0,H,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,F,,CHEMBL617158,1.0,,,,,4.0,,
Autocuration,,2170.0,,,104686.0,11200.0,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,BAO_0000019,F,,CHEMBL617159,1.0,,,,,4.0,,
Autocuration,,2171.0,,,104686.0,11200.0,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,BAO_0000019,F,,CHEMBL617160,1.0,,,,,4.0,,
Autocuration,,2172.0,,,104686.0,11200.0,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,F,,CHEMBL858113,1.0,,,,,4.0,,
Autocuration,Brain,2173.0,,,104686.0,9231.0,H,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,BAO_0000220,B,,CHEMBL617247,1.0,955.0,,,,4.0,,
Autocuration,,2174.0,,,104686.0,9737.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,BAO_0000019,B,,CHEMBL617248,1.0,,,,,4.0,,
Autocuration,Brain,2175.0,,,104686.0,9737.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,BAO_0000249,B,,CHEMBL617249,1.0,955.0,,,,4.0,,
Autocuration,,2176.0,,,104686.0,9737.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,BAO_0000019,B,,CHEMBL617250,1.0,,,,,4.0,,
Autocuration,,2177.0,,,104686.0,9737.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,BAO_0000019,B,,CHEMBL617251,1.0,,,,,4.0,,
Autocuration,,2178.0,,,104686.0,11828.0,D,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,BAO_0000019,B,,CHEMBL617252,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2179.0,,,104686.0,12253.0,H,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,BAO_0000019,B,,CHEMBL617006,1.0,,,,,4.0,,
Autocuration,,2180.0,,,104686.0,12253.0,H,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,BAO_0000019,B,,CHEMBL617007,1.0,,,,,4.0,,
Autocuration,,2181.0,,,104686.0,11279.0,H,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,BAO_0000019,F,,CHEMBL617008,1.0,,,,,4.0,,
Autocuration,,2182.0,,,104686.0,11866.0,H,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,BAO_0000019,B,,CHEMBL617009,1.0,,,,,4.0,,
Autocuration,,2183.0,,,104686.0,14424.0,D,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,BAO_0000224,B,,CHEMBL617010,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2184.0,,,104686.0,15180.0,D,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,B,,CHEMBL857978,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2185.0,,,104686.0,15180.0,D,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,B,,CHEMBL617011,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2186.0,,,104686.0,9786.0,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,BAO_0000019,B,,CHEMBL617012,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2187.0,,,104686.0,12132.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,BAO_0000224,B,,CHEMBL617013,1.0,,,,,4.0,,
Autocuration,,2188.0,,,104686.0,5486.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,BAO_0000249,B,,CHEMBL617014,1.0,,,,,4.0,,
Autocuration,,2189.0,,,104686.0,15316.0,H,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,BAO_0000019,B,,CHEMBL617015,1.0,,,,,4.0,,
Autocuration,,2190.0,,,104686.0,16429.0,H,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,BAO_0000019,B,,CHEMBL617016,1.0,,,,,4.0,,
Autocuration,,2191.0,,,104686.0,14617.0,H,,pKi value for 5-hydroxytryptamine 2 receptor binding site,,BAO_0000224,B,,CHEMBL617017,1.0,,,,,4.0,,
Autocuration,Brain,2192.0,,,104686.0,11351.0,H,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,BAO_0000221,B,,CHEMBL617018,1.0,955.0,,,,4.0,,
Autocuration,,2193.0,,,104686.0,11279.0,H,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,BAO_0000019,F,,CHEMBL617019,1.0,,,,,4.0,,
Autocuration,,2194.0,,,105075.0,9523.0,H,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,B,,CHEMBL617020,1.0,,,,,4.0,,
Autocuration,,2195.0,,,105075.0,9523.0,H,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,B,,CHEMBL617021,1.0,,,,,4.0,,
Autocuration,,2196.0,,,105075.0,9523.0,H,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,B,,CHEMBL617022,1.0,,,,,4.0,,
Autocuration,,2197.0,,,105075.0,9523.0,H,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,B,,CHEMBL617023,1.0,,,,,4.0,,
Autocuration,,2198.0,,,105075.0,9523.0,H,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,B,,CHEMBL617024,1.0,,,,,4.0,,
Autocuration,,2199.0,,,105075.0,9523.0,H,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,B,,CHEMBL617025,1.0,,,,,4.0,,
Autocuration,,2200.0,,,105075.0,9523.0,H,,Hill coefficient of compound was determined,,BAO_0000224,B,,CHEMBL617026,1.0,,,,,4.0,,
Autocuration,,2201.0,,,22226.0,4771.0,U,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,BAO_0000019,B,,CHEMBL617027,1.0,,,,,0.0,,
Autocuration,,2202.0,,,104686.0,5033.0,D,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,BAO_0000019,B,,CHEMBL617028,1.0,,,10116.0,,5.0,,Rattus norvegicus
Expert,,2203.0,,,12687.0,10845.0,H,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,BAO_0000019,B,,CHEMBL617029,1.0,,,,,8.0,,
Expert,,2204.0,,,12687.0,10845.0,H,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,BAO_0000019,B,,CHEMBL875908,1.0,,,,,8.0,,
Autocuration,,2205.0,,,12687.0,16288.0,H,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,BAO_0000357,B,,CHEMBL617030,1.0,,,,,8.0,,
Autocuration,,2206.0,,,12687.0,16288.0,H,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,BAO_0000019,B,,CHEMBL617031,1.0,,,,,8.0,,
Autocuration,,2207.0,,,12687.0,16190.0,H,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,BAO_0000019,B,,CHEMBL617032,1.0,,,,,8.0,,
Autocuration,,2208.0,,,104686.0,12463.0,D,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,BAO_0000224,B,,CHEMBL617033,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2209.0,,,104686.0,9699.0,H,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,BAO_0000224,B,,CHEMBL617034,1.0,,,,,4.0,,
Autocuration,,2210.0,,,104686.0,9699.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,BAO_0000224,B,,CHEMBL617035,1.0,,,,,4.0,,
Autocuration,,2211.0,,,104686.0,11662.0,H,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,BAO_0000019,B,,CHEMBL617036,1.0,,,,,4.0,,
Autocuration,,2212.0,,,104784.0,1205.0,H,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617037,1.0,,,,,4.0,,
Autocuration,,2213.0,,,22226.0,11376.0,U,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,BAO_0000219,B,,CHEMBL617038,1.0,,,,,0.0,,
Autocuration,,2214.0,,,104784.0,11376.0,H,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,BAO_0000219,B,,CHEMBL617039,1.0,,,,,4.0,,
Autocuration,,2215.0,,,104784.0,4639.0,H,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617161,1.0,,,,,4.0,,
Autocuration,,2216.0,,,104784.0,2222.0,H,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617162,1.0,,,,,4.0,,
Autocuration,,2217.0,,,104784.0,1558.0,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617163,1.0,,,,,4.0,,
Autocuration,,2218.0,,,104784.0,1089.0,H,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617164,1.0,,,,,4.0,,
Autocuration,,2219.0,,,104784.0,386.0,H,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,Brain membranes,BAO_0000249,B,,CHEMBL617165,1.0,,,,,4.0,,
Autocuration,,2220.0,,,104784.0,2474.0,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,BAO_0000224,B,,CHEMBL617166,1.0,,,,,4.0,,
Autocuration,,2221.0,,,104784.0,17066.0,H,,Binding affinity towards 5-HT2 receptor,,BAO_0000224,B,,CHEMBL617167,1.0,,,,,4.0,,
Autocuration,,2222.0,,,104784.0,959.0,H,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL872912,1.0,,,,,4.0,,
Autocuration,,2223.0,,,104784.0,6398.0,H,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,BAO_0000224,B,,CHEMBL617168,1.0,,,,,4.0,,
Autocuration,,2224.0,,,104686.0,11889.0,H,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,BAO_0000224,B,,CHEMBL617169,1.0,,,,,4.0,,
Autocuration,,2225.0,,,104784.0,4221.0,H,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617170,1.0,,,,,4.0,,
Autocuration,,2226.0,,,104784.0,11026.0,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,BAO_0000224,B,,CHEMBL617171,1.0,,,,,4.0,,
Autocuration,,2227.0,,,104784.0,11866.0,H,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,B,,CHEMBL617172,1.0,,,,,4.0,,
Autocuration,,2228.0,,,104784.0,4221.0,H,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617173,1.0,,,,,4.0,,
Autocuration,,2229.0,,,22226.0,13950.0,U,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000019,B,,CHEMBL617174,1.0,,,,,0.0,,
Autocuration,,2230.0,,,104784.0,1263.0,H,,5-hydroxytryptamine 2 receptor binding affinity,,BAO_0000224,B,,CHEMBL617175,1.0,,,,,4.0,,
Autocuration,,2231.0,,,17005.0,13291.0,H,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,BAO_0000357,B,,CHEMBL617176,1.0,,,,,8.0,,
Autocuration,,2232.0,,,17005.0,10812.0,H,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,BAO_0000357,B,,CHEMBL617177,1.0,,,,,8.0,,
Autocuration,,2233.0,,,104784.0,13020.0,H,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,BAO_0000224,B,,CHEMBL617178,1.0,,,,,4.0,,
Autocuration,,2234.0,,,104784.0,13021.0,H,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,BAO_0000224,B,,CHEMBL617179,1.0,,,,,4.0,,
Autocuration,,2235.0,,,104784.0,13020.0,H,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,BAO_0000224,B,,CHEMBL617180,1.0,,,,,4.0,,
Autocuration,,2236.0,,,17005.0,14532.0,H,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,BAO_0000357,B,,CHEMBL617181,1.0,,,,,8.0,,
Autocuration,,2237.0,,,17005.0,13944.0,H,,Binding affinity against 5-hydroxytryptamine 2 receptor,,BAO_0000357,B,,CHEMBL617182,1.0,,,,,8.0,,
Autocuration,,2238.0,,,17005.0,14331.0,H,,Binding affinity against 5-hydroxytryptamine 2 receptor,,BAO_0000357,B,,CHEMBL617183,1.0,,,,,8.0,,
Autocuration,,2239.0,,,17005.0,14118.0,H,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,BAO_0000357,B,,CHEMBL617184,1.0,,,,,8.0,,
Autocuration,,2240.0,,,17005.0,13033.0,H,,Binding affinity against serotonergic 5-HT2 receptor,,BAO_0000357,B,,CHEMBL617185,1.0,,,,,8.0,,
Autocuration,,2241.0,,,17005.0,10321.0,H,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,BAO_0000357,B,,CHEMBL617186,1.0,,,,,8.0,,
Autocuration,,2242.0,,,17005.0,12918.0,H,,Compound was evaluated for the binding affinity at 5- HT2 receptor,,BAO_0000357,B,,CHEMBL617187,1.0,,,,,8.0,,
Autocuration,,2243.0,,,17005.0,15120.0,H,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,BAO_0000357,B,,CHEMBL617188,1.0,,,,,8.0,,
Autocuration,,2244.0,,,17005.0,2613.0,H,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,BAO_0000218,B,,CHEMBL617189,1.0,,,,,8.0,,
Autocuration,,2245.0,,,104784.0,13378.0,D,,Inhibitory activity against cloned human 5-HT2 receptor,,BAO_0000224,B,,CHEMBL617190,1.0,,,9606.0,,5.0,,Homo sapiens
Autocuration,,2246.0,,,104784.0,2331.0,D,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,BAO_0000219,B,,CHEMBL617191,1.0,,,9606.0,CHO,5.0,449.0,Homo sapiens
Autocuration,,2247.0,,,104784.0,2331.0,D,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,BAO_0000219,B,,CHEMBL617192,1.0,,,9606.0,CHO,5.0,449.0,Homo sapiens
Autocuration,,2248.0,,,104784.0,2331.0,D,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,BAO_0000219,B,,CHEMBL617193,1.0,,,9606.0,CHO,5.0,449.0,Homo sapiens
Autocuration,,2249.0,,,104784.0,2331.0,D,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,BAO_0000219,B,,CHEMBL617194,1.0,,,9606.0,CHO,5.0,449.0,Homo sapiens
Autocuration,,2250.0,,,104784.0,4170.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617195,1.0,,,,,4.0,,
Autocuration,,2251.0,,,104784.0,15453.0,H,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,BAO_0000224,B,,CHEMBL881830,1.0,,,,,4.0,,
Autocuration,,2252.0,,,17005.0,1479.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000357,B,,CHEMBL617196,1.0,,,,,8.0,,
Autocuration,,2253.0,,,104686.0,11139.0,H,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,BAO_0000224,B,,CHEMBL617197,1.0,,,,,4.0,,
Expert,,2254.0,,,17005.0,13969.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,BAO_0000357,B,,CHEMBL617198,1.0,,,,,8.0,,
Expert,,2255.0,,,17005.0,13392.0,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL873476,1.0,,,,,8.0,,
Expert,,2256.0,,,17005.0,14430.0,H,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,BAO_0000019,B,,CHEMBL617199,1.0,,,,,8.0,,
Autocuration,,2257.0,,,107.0,13181.0,H,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617200,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,2258.0,,,51.0,17200.0,H,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,B,,CHEMBL617484,1.0,,,,,8.0,,
Autocuration,,2259.0,,,107.0,17200.0,H,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,B,,CHEMBL617485,1.0,,,,,8.0,,
Autocuration,,2260.0,,,51.0,17200.0,H,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,B,,CHEMBL617486,1.0,,,,,8.0,,
Autocuration,,2261.0,,,107.0,13463.0,H,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,BAO_0000357,B,,CHEMBL858022,1.0,,,,,8.0,,
Autocuration,,2262.0,,,107.0,6347.0,H,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,BAO_0000219,B,,CHEMBL617049,1.0,,,,CHO,8.0,449.0,
Expert,,2263.0,,,107.0,6857.0,D,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,BAO_0000219,F,,CHEMBL617050,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,2264.0,,,107.0,4176.0,H,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,BAO_0000219,F,,CHEMBL617051,1.0,,,,,8.0,,
Autocuration,,2265.0,,,107.0,4176.0,H,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,BAO_0000219,F,,CHEMBL617052,1.0,,,,,8.0,,
Autocuration,,2266.0,,,107.0,4176.0,H,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,BAO_0000219,F,,CHEMBL617053,1.0,,,,,8.0,,
Autocuration,,2267.0,,,107.0,6347.0,H,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,BAO_0000219,B,,CHEMBL617054,1.0,,,,CHO,8.0,449.0,
Autocuration,,2268.0,,,107.0,6347.0,H,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,BAO_0000219,B,,CHEMBL617055,1.0,,,,CHO,8.0,449.0,
Autocuration,,2269.0,,,107.0,15331.0,H,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,BAO_0000357,B,,CHEMBL882924,1.0,,,,,8.0,,
Expert,,2270.0,,,107.0,16146.0,D,,Inhibition of human 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617056,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2271.0,,,107.0,15250.0,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL617057,1.0,,,,CHO,8.0,449.0,
Expert,,2272.0,,,107.0,13631.0,H,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,BAO_0000219,B,,CHEMBL617058,1.0,,,,,8.0,,
Autocuration,,2273.0,,,107.0,3805.0,H,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,BAO_0000357,B,,CHEMBL617059,1.0,,,,,8.0,,
Autocuration,,2274.0,,,107.0,4011.0,H,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,BAO_0000219,B,,CHEMBL617060,1.0,,,,CHO,8.0,449.0,
Expert,,2275.0,,,107.0,4012.0,H,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,BAO_0000219,B,,CHEMBL617061,1.0,,,,CHO,8.0,449.0,
Expert,,2276.0,,,107.0,6366.0,H,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,BAO_0000219,B,,CHEMBL617062,1.0,,,,L929,8.0,307.0,
Expert,,2277.0,,,107.0,15949.0,H,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL617063,1.0,,,,CHO,8.0,449.0,
Autocuration,,2278.0,,,107.0,14093.0,H,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,BAO_0000019,F,,CHEMBL617064,1.0,,,,,8.0,,
Autocuration,,2279.0,,,107.0,13481.0,H,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000019,F,,CHEMBL617065,1.0,,,,,8.0,,
Autocuration,,2280.0,,,107.0,6347.0,H,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,BAO_0000219,B,,CHEMBL617066,1.0,,,,CHO,8.0,449.0,
Autocuration,,2281.0,,,107.0,6347.0,H,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,BAO_0000219,B,,CHEMBL617067,1.0,,,,CHO,8.0,449.0,
Autocuration,,2282.0,,,107.0,14093.0,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,BAO_0000019,F,,CHEMBL617068,1.0,,,,,8.0,,
Autocuration,,2283.0,,,107.0,14093.0,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,BAO_0000019,F,,CHEMBL617069,1.0,,,,,8.0,,
Autocuration,,2284.0,,,107.0,13481.0,H,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000019,F,,CHEMBL617070,1.0,,,,,8.0,,
Autocuration,,2285.0,,,107.0,14442.0,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,BAO_0000357,B,,CHEMBL617071,1.0,,,,,8.0,,
Autocuration,,2286.0,,,107.0,14442.0,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,B,,CHEMBL872915,1.0,,,,,8.0,,
Autocuration,,2287.0,,,107.0,14755.0,H,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,BAO_0000357,B,,CHEMBL617072,1.0,,,,,8.0,,
Autocuration,,2288.0,,,107.0,16441.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,BAO_0000357,B,,CHEMBL617073,1.0,,,,,8.0,,
Autocuration,,2289.0,,,107.0,14744.0,H,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,BAO_0000357,B,,CHEMBL617074,1.0,,,,,8.0,,
Expert,,2290.0,,,107.0,16659.0,H,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL617075,1.0,,,,CHO,8.0,449.0,
Autocuration,,2291.0,,,107.0,3307.0,H,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617076,1.0,,,,,8.0,,
Expert,,2292.0,,,107.0,6857.0,D,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,BAO_0000019,B,,CHEMBL617077,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,2293.0,,,107.0,5635.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,BAO_0000357,B,,CHEMBL617078,1.0,,,,,8.0,,
Expert,,2294.0,,,107.0,4234.0,D,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617079,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2295.0,,,107.0,15527.0,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,BAO_0000357,B,,CHEMBL617080,1.0,,,,,8.0,,
Expert,,2296.0,,,107.0,6588.0,H,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,BAO_0000219,B,,CHEMBL617081,1.0,,,,CHO,8.0,449.0,
Expert,,2297.0,,,107.0,13631.0,H,,Binding affinity towards human 5-HT2A receptor in BEK cells,,BAO_0000219,B,,CHEMBL617082,1.0,,,,,8.0,,
Autocuration,,2298.0,,,107.0,17723.0,H,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617083,1.0,,,,,8.0,,
Autocuration,,2299.0,,,107.0,14770.0,H,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,BAO_0000357,B,,CHEMBL617084,1.0,,,,,8.0,,
Expert,,2300.0,,,107.0,16293.0,D,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617085,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2301.0,,,107.0,16209.0,H,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000357,B,,CHEMBL617086,1.0,,,,,8.0,,
Autocuration,,2302.0,,,107.0,12469.0,H,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,BAO_0000219,B,,CHEMBL617087,1.0,,,,,8.0,,
Autocuration,,2303.0,,,107.0,15363.0,H,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617088,1.0,,,,,8.0,,
Autocuration,,2304.0,,,107.0,15363.0,H,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617089,1.0,,,,,8.0,,
Expert,,2305.0,,,107.0,16441.0,H,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,BAO_0000019,B,,CHEMBL617090,1.0,,,,,8.0,,
Autocuration,,2306.0,,,107.0,8.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,BAO_0000357,B,,CHEMBL617513,1.0,,,,,8.0,,
Autocuration,,2307.0,,,107.0,4176.0,H,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,BAO_0000219,B,,CHEMBL617514,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2308.0,,,107.0,17085.0,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,BAO_0000019,B,,CHEMBL617515,1.0,,,,,8.0,,
Autocuration,,2309.0,,,107.0,17200.0,H,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,B,,CHEMBL617516,1.0,,,,,8.0,,
Expert,,2310.0,,,107.0,17200.0,D,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,B,,CHEMBL617517,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,2311.0,,,107.0,4013.0,D,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,BAO_0000219,B,,CHEMBL617518,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,2312.0,,,107.0,5088.0,H,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617519,1.0,,,,,8.0,,
Expert,,2313.0,,,107.0,5088.0,D,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617520,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2314.0,,,107.0,5088.0,H,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,BAO_0000357,B,,CHEMBL617521,1.0,,,,,8.0,,
Expert,,2315.0,,,107.0,5088.0,D,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617522,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2316.0,,,107.0,5088.0,H,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL617523,1.0,,,,,8.0,,
Autocuration,,2317.0,,,107.0,5088.0,H,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,B,,CHEMBL617524,1.0,,,,,8.0,,
Autocuration,,2318.0,,,104686.0,9786.0,H,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,BAO_0000019,B,,CHEMBL617525,1.0,,,,,4.0,,
Autocuration,,2319.0,,,104686.0,9205.0,D,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,BAO_0000019,B,,CHEMBL617526,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2320.0,,,104686.0,11257.0,H,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,BAO_0000224,B,,CHEMBL617527,1.0,,,,,4.0,,
Autocuration,,2321.0,,,104686.0,9362.0,H,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,BAO_0000019,B,,CHEMBL617528,1.0,,,,,4.0,,
Autocuration,,2322.0,,,104686.0,9362.0,H,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,BAO_0000019,B,,CHEMBL617529,1.0,,,,,4.0,,
Autocuration,,2323.0,,,104686.0,10590.0,H,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,BAO_0000224,B,,CHEMBL617530,1.0,,,,,4.0,,
Autocuration,,2324.0,,,104686.0,10468.0,H,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,BAO_0000019,B,,CHEMBL617531,1.0,,,,,4.0,,
Autocuration,,2325.0,,,104686.0,13050.0,H,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,BAO_0000019,B,,CHEMBL617532,1.0,,,,,4.0,,
Autocuration,,2326.0,,,104686.0,11624.0,H,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,BAO_0000019,B,,CHEMBL617533,1.0,,,,,4.0,,
Autocuration,,2327.0,,,104686.0,10468.0,H,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,BAO_0000019,B,,CHEMBL617534,1.0,,,,,4.0,,
Autocuration,,2328.0,,,104686.0,10330.0,H,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,BAO_0000224,B,,CHEMBL617535,1.0,,,,,4.0,,
Autocuration,,2329.0,,,104686.0,10062.0,H,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,BAO_0000224,B,,CHEMBL617536,1.0,,,,,4.0,,
Autocuration,,2330.0,,,104686.0,11642.0,H,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617537,1.0,,,,,4.0,,
Autocuration,,2331.0,,,104686.0,10062.0,H,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617538,1.0,,,,,4.0,,
Autocuration,,2332.0,,,104686.0,13427.0,H,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,BAO_0000219,B,In vitro,CHEMBL617539,1.0,,,,,4.0,,
Autocuration,,2333.0,,,104686.0,12280.0,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617540,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2334.0,,,104686.0,4101.0,D,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,BAO_0000224,B,,CHEMBL617541,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2335.0,,,104686.0,10062.0,H,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617542,1.0,,,,,4.0,,
Autocuration,,2336.0,,,104686.0,11147.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,BAO_0000224,B,,CHEMBL617543,1.0,,,,,4.0,,
Autocuration,,2337.0,,,104686.0,2395.0,D,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,BAO_0000219,B,,CHEMBL617544,1.0,,,10116.0,CHO-K1,5.0,485.0,Rattus norvegicus
Autocuration,,2338.0,,,104686.0,2395.0,D,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,BAO_0000219,B,,CHEMBL617545,1.0,,,10116.0,CHO-K1,5.0,485.0,Rattus norvegicus
Autocuration,,2339.0,,,104686.0,9098.0,D,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,BAO_0000019,B,,CHEMBL617413,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2340.0,,,104686.0,9098.0,H,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,BAO_0000019,B,,CHEMBL617414,1.0,,,,,4.0,,
Autocuration,,2341.0,,,104686.0,9098.0,D,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,BAO_0000019,B,,CHEMBL617415,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2342.0,,,104686.0,9443.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617416,1.0,,,,,4.0,,
Autocuration,,2343.0,,,104686.0,9443.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,BAO_0000224,B,,CHEMBL617417,1.0,,,,,4.0,,
Autocuration,,2344.0,,,104686.0,9699.0,H,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,BAO_0000019,B,,CHEMBL617418,1.0,,,,,4.0,,
Autocuration,,2345.0,,,104686.0,9699.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,BAO_0000019,B,,CHEMBL617419,1.0,,,,,4.0,,
Autocuration,,2346.0,,,104686.0,9098.0,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,B,,CHEMBL617420,1.0,,,,,4.0,,
Autocuration,,2347.0,,,104686.0,3070.0,D,,Affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617421,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2348.0,,,104686.0,9547.0,H,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,BAO_0000224,B,,CHEMBL617422,1.0,,,,,4.0,,
Autocuration,,2349.0,,,104686.0,10444.0,H,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,BAO_0000019,B,,CHEMBL617423,1.0,,,,,4.0,,
Autocuration,,2350.0,,,104686.0,14617.0,H,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,BAO_0000019,B,,CHEMBL617424,1.0,,,,,4.0,,
Autocuration,,2351.0,,,104686.0,14617.0,H,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,BAO_0000019,B,,CHEMBL617425,1.0,,,,,4.0,,
Autocuration,,2352.0,,,104686.0,11130.0,H,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,BAO_0000224,B,,CHEMBL617426,1.0,,,,,4.0,,
Autocuration,,2353.0,,,104686.0,11130.0,H,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,BAO_0000218,B,In vivo,CHEMBL617427,1.0,,,,,4.0,,
Autocuration,Brain,2354.0,,,104686.0,14542.0,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,BAO_0000221,B,,CHEMBL617428,1.0,955.0,,,,4.0,,
Autocuration,,2355.0,,,104686.0,2797.0,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,BAO_0000224,B,,CHEMBL617429,1.0,,,,,4.0,,
Autocuration,,2356.0,,,104686.0,11332.0,H,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,BAO_0000019,B,,CHEMBL617430,1.0,,,,,4.0,,
Autocuration,,2357.0,,,104686.0,11332.0,H,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,BAO_0000019,B,,CHEMBL617431,1.0,,,,,4.0,,
Autocuration,Frontal cortex,2358.0,,,104686.0,10752.0,H,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,BAO_0000019,B,,CHEMBL617432,1.0,1870.0,,,,4.0,,
Autocuration,,2359.0,,,104686.0,1185.0,H,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617433,1.0,,,,,4.0,,
Autocuration,,2360.0,,,104686.0,1185.0,H,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617434,1.0,,,,,4.0,,
Autocuration,,2361.0,,,104686.0,11624.0,D,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,BAO_0000224,B,,CHEMBL617435,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2362.0,,,104686.0,1344.0,H,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,BAO_0000019,B,,CHEMBL617436,1.0,,,,,4.0,,
Autocuration,Striatum,2363.0,,,104686.0,15453.0,D,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,BAO_0000019,B,,CHEMBL617437,1.0,2435.0,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2364.0,,,104686.0,11662.0,H,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,BAO_0000019,B,,CHEMBL617438,1.0,,,,,4.0,,
Autocuration,,2365.0,,,104686.0,11662.0,H,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,BAO_0000019,B,,CHEMBL617439,1.0,,,,,4.0,,
Autocuration,,2366.0,,,104686.0,10796.0,H,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617440,1.0,,,,,4.0,,
Autocuration,,2367.0,,,104686.0,9069.0,H,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617441,1.0,,,,,4.0,,
Autocuration,,2368.0,,,104686.0,8814.0,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,BAO_0000019,B,,CHEMBL872918,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2369.0,,,104686.0,8908.0,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,BAO_0000019,B,,CHEMBL617442,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2370.0,,,104686.0,9098.0,H,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,BAO_0000019,B,,CHEMBL617443,1.0,,,,,4.0,,
Autocuration,,2371.0,,,104686.0,9098.0,H,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,BAO_0000019,B,,CHEMBL617444,1.0,,,,,4.0,,
Autocuration,,2372.0,,,104686.0,9098.0,H,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,BAO_0000019,B,,CHEMBL617445,1.0,,,,,4.0,,
Autocuration,,2373.0,,,104686.0,9098.0,H,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,BAO_0000019,B,,CHEMBL617446,1.0,,,,,4.0,,
Autocuration,,2374.0,,,104686.0,9098.0,H,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,BAO_0000249,B,,CHEMBL617447,1.0,,,,,4.0,,
Autocuration,,2375.0,,,104686.0,9098.0,H,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,BAO_0000019,B,,CHEMBL617448,1.0,,,,,4.0,,
Autocuration,,2376.0,,,104686.0,9098.0,H,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,BAO_0000019,B,,CHEMBL617449,1.0,,,,,4.0,,
Autocuration,,2377.0,,,104686.0,9161.0,H,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,BAO_0000019,B,,CHEMBL617450,1.0,,,,,4.0,,
Autocuration,,2378.0,,,104686.0,9161.0,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,BAO_0000019,B,,CHEMBL617451,1.0,,,,,4.0,,
Autocuration,,2379.0,,,104686.0,9161.0,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,BAO_0000019,B,,CHEMBL617452,1.0,,,,,4.0,,
Autocuration,,2380.0,,,104686.0,9161.0,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,BAO_0000019,B,,CHEMBL617453,1.0,,,,,4.0,,
Autocuration,,2381.0,,,104686.0,9161.0,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,BAO_0000019,B,,CHEMBL617660,1.0,,,,,4.0,,
Autocuration,,2382.0,,,104686.0,9161.0,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,BAO_0000019,B,,CHEMBL617661,1.0,,,,,4.0,,
Autocuration,,2383.0,,,104686.0,9161.0,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,BAO_0000019,B,,CHEMBL617662,1.0,,,,,4.0,,
Autocuration,,2384.0,,,104686.0,9161.0,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,BAO_0000019,B,,CHEMBL872919,1.0,,,,,4.0,,
Autocuration,,2385.0,,,104686.0,9161.0,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,BAO_0000019,B,,CHEMBL617663,1.0,,,,,4.0,,
Autocuration,,2386.0,,,104686.0,9161.0,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,BAO_0000019,B,,CHEMBL617664,1.0,,,,,4.0,,
Autocuration,,2387.0,,,104686.0,9161.0,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,BAO_0000019,B,,CHEMBL617665,1.0,,,,,4.0,,
Autocuration,,2388.0,,,104686.0,9161.0,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,BAO_0000019,B,,CHEMBL617666,1.0,,,,,4.0,,
Autocuration,,2389.0,,,104686.0,12094.0,H,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,BAO_0000019,B,,CHEMBL617667,1.0,,,,,4.0,,
Autocuration,,2390.0,,,104686.0,12018.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,BAO_0000249,B,,CHEMBL617668,1.0,,,,,4.0,,
Autocuration,,2391.0,,,104686.0,10394.0,H,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,BAO_0000249,B,,CHEMBL617669,1.0,,,,,4.0,,
Autocuration,,2392.0,,,104686.0,15260.0,H,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617670,1.0,,,,,4.0,,
Autocuration,,2393.0,,,104686.0,11624.0,D,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617671,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2394.0,,,104686.0,13654.0,H,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617672,1.0,,,,,4.0,,
Autocuration,,2395.0,,,104686.0,9541.0,H,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,BAO_0000019,B,,CHEMBL617673,1.0,,,,,4.0,,
Autocuration,,2396.0,,,104686.0,11933.0,H,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,BAO_0000224,B,,CHEMBL617674,1.0,,,,,4.0,,
Autocuration,,2397.0,,,104686.0,15538.0,H,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,BAO_0000019,B,,CHEMBL617675,1.0,,,,,4.0,,
Autocuration,,2398.0,,,104686.0,15538.0,H,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,BAO_0000019,B,,CHEMBL617676,1.0,,,,,4.0,,
Autocuration,,2399.0,,,104686.0,15538.0,H,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,BAO_0000019,B,,CHEMBL617677,1.0,,,,,4.0,,
Autocuration,,2400.0,,,104686.0,8841.0,D,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,BAO_0000019,B,,CHEMBL617678,1.0,,,,,5.0,,
Autocuration,,2401.0,,,104686.0,1455.0,H,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,BAO_0000224,B,,CHEMBL617679,1.0,,,,,4.0,,
Autocuration,,2402.0,,,104686.0,1455.0,H,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,BAO_0000224,B,,CHEMBL617680,1.0,,,,,4.0,,
Autocuration,,2403.0,,,104686.0,11752.0,H,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,BAO_0000019,B,,CHEMBL617681,1.0,,,,,4.0,,
Autocuration,Brain,2404.0,,,104686.0,11642.0,H,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,BAO_0000221,B,,CHEMBL617682,1.0,955.0,,,,4.0,,
Autocuration,,2405.0,,,104686.0,12092.0,H,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,BAO_0000224,B,,CHEMBL617683,1.0,,,,,4.0,,
Autocuration,,2406.0,,,104686.0,3967.0,H,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,BAO_0000224,B,,CHEMBL617684,1.0,,,,,4.0,,
Autocuration,,2407.0,,,104686.0,12771.0,D,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617685,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2408.0,,,104686.0,11642.0,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,BAO_0000019,B,,CHEMBL617686,1.0,,,,,4.0,,
Autocuration,,2409.0,,,104686.0,11628.0,H,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,BAO_0000224,B,,CHEMBL617687,1.0,,,,,4.0,,
Autocuration,,2410.0,,,104686.0,13654.0,H,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,B,,CHEMBL617688,1.0,,,,,4.0,,
Autocuration,,2411.0,,,104686.0,11200.0,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,F,,CHEMBL617689,1.0,,,,,4.0,,
Autocuration,,2412.0,,,104686.0,11200.0,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,F,,CHEMBL617690,1.0,,,,,4.0,,
Autocuration,,2413.0,,,104686.0,11200.0,H,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,BAO_0000218,F,In vivo,CHEMBL617691,1.0,,,,,4.0,,
Autocuration,,2414.0,,,104686.0,11200.0,H,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,BAO_0000218,F,In vivo,CHEMBL617692,1.0,,,,,4.0,,
Autocuration,,2415.0,,,104686.0,11200.0,H,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,BAO_0000218,F,In vivo,CHEMBL617693,1.0,,,,,4.0,,
Autocuration,,2416.0,,,104686.0,11200.0,H,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,BAO_0000218,F,In vivo,CHEMBL617694,1.0,,,,,4.0,,
Expert,Brain,2417.0,,,12687.0,15436.0,H,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,BAO_0000221,B,,CHEMBL857985,1.0,955.0,,,,8.0,,
Expert,,2418.0,,,12687.0,15436.0,D,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,BAO_0000019,B,,CHEMBL617695,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2419.0,,,12687.0,14025.0,H,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,BAO_0000019,B,,CHEMBL617696,1.0,,,,,8.0,,
Autocuration,,2420.0,,,12687.0,4342.0,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,B,,CHEMBL617697,1.0,,,,,8.0,,
Expert,,2421.0,,,12687.0,13735.0,D,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,BAO_0000019,B,,CHEMBL617257,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2422.0,,,12687.0,5816.0,D,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,BAO_0000357,B,,CHEMBL617258,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2423.0,,,12687.0,14287.0,H,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,BAO_0000019,B,,CHEMBL617259,1.0,,,,,8.0,,
Autocuration,,2424.0,,,12687.0,15738.0,H,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,BAO_0000357,B,,CHEMBL617260,1.0,,,,,8.0,,
Expert,,2425.0,,,12687.0,15738.0,D,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617261,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2426.0,,,12687.0,15026.0,H,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,BAO_0000019,B,,CHEMBL617262,1.0,,,,,8.0,,
Expert,,2427.0,,,12687.0,16647.0,H,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,BAO_0000019,B,,CHEMBL617263,1.0,,,,,8.0,,
Autocuration,,2428.0,,,12687.0,16647.0,H,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,BAO_0000019,B,,CHEMBL617264,1.0,,,,,8.0,,
Expert,,2429.0,,,12687.0,13345.0,D,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,BAO_0000019,B,,CHEMBL617265,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2430.0,,,12687.0,1543.0,H,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,Membranes,BAO_0000249,B,,CHEMBL617266,1.0,,,,,8.0,,
Autocuration,,2431.0,,,12687.0,12444.0,H,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,BAO_0000019,B,,CHEMBL617267,1.0,,,,,8.0,,
Expert,,2432.0,,,12687.0,16404.0,H,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,BAO_0000019,B,,CHEMBL617268,1.0,,,,,8.0,,
Autocuration,,2433.0,,,12687.0,16404.0,H,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,BAO_0000219,B,,CHEMBL617269,1.0,,,,CHO,8.0,449.0,
Expert,,2434.0,,,12687.0,15577.0,H,,Kinetic inhibition constant evaluated by measuring serotonergic activity,,BAO_0000357,B,,CHEMBL617323,1.0,,,,,8.0,,
Autocuration,,2435.0,,,12687.0,15577.0,H,,Serotonergic activity of the compound.,,BAO_0000357,B,,CHEMBL617324,1.0,,,,,8.0,,
Autocuration,,2436.0,,,12687.0,2495.0,H,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,BAO_0000249,B,,CHEMBL617325,1.0,,,,,8.0,,
Expert,,2437.0,,,12687.0,15042.0,D,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,BAO_0000019,B,,CHEMBL617326,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2438.0,,,12687.0,15026.0,H,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,BAO_0000249,B,,CHEMBL617327,1.0,,,,,8.0,,
Expert,,2439.0,,,12687.0,12919.0,D,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,F,,CHEMBL617328,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2440.0,,,12687.0,12919.0,D,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,F,,CHEMBL617329,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2441.0,,,12687.0,12919.0,D,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,F,,CHEMBL617330,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2442.0,,,12687.0,15194.0,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,B,,CHEMBL617331,1.0,,,,,8.0,,
Autocuration,,2443.0,,,12687.0,15194.0,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,BAO_0000357,B,,CHEMBL617332,1.0,,,,,8.0,,
Expert,,2444.0,,,107.0,4820.0,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617333,1.0,,,,,8.0,,
Autocuration,,2445.0,,,107.0,6736.0,H,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,BAO_0000357,B,,CHEMBL617334,1.0,,,,,8.0,,
Autocuration,,2446.0,,,107.0,5163.0,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,BAO_0000357,B,,CHEMBL617335,1.0,,,,,8.0,,
Autocuration,,2447.0,,,107.0,5163.0,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,BAO_0000357,B,,CHEMBL617336,1.0,,,,,8.0,,
Autocuration,,2448.0,,,107.0,6011.0,H,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,BAO_0000357,B,,CHEMBL617337,1.0,,,,,8.0,,
Expert,,2449.0,,,107.0,14294.0,D,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,BAO_0000357,B,,CHEMBL617338,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2450.0,,,107.0,5014.0,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617339,1.0,,,,,8.0,,
Expert,,2451.0,,,107.0,17066.0,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617340,1.0,,,,,8.0,,
Autocuration,,2452.0,,,107.0,17515.0,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,BAO_0000357,B,,CHEMBL617341,1.0,,,,,8.0,,
Expert,,2453.0,,,107.0,6736.0,H,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617342,1.0,,,,,8.0,,
Expert,,2454.0,,,107.0,5163.0,H,,Affinity for 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617343,1.0,,,,,8.0,,
Expert,,2455.0,,,107.0,16911.0,H,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,BAO_0000219,B,,CHEMBL617344,1.0,,,,NIH3T3,8.0,723.0,
Expert,,2456.0,,,107.0,6841.0,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,BAO_0000357,B,,CHEMBL617345,1.0,,,,,8.0,,
Expert,,2457.0,,,107.0,6119.0,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,BAO_0000357,B,,CHEMBL617346,1.0,,,,,8.0,,
Autocuration,,2458.0,,,107.0,3962.0,H,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617347,1.0,,,,,8.0,,
Autocuration,,2459.0,,,107.0,4373.0,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,B,,CHEMBL617348,1.0,,,,,8.0,,
Autocuration,,2460.0,,,107.0,4373.0,H,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,B,,CHEMBL617349,1.0,,,,,8.0,,
Autocuration,,2461.0,,,107.0,3962.0,H,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,BAO_0000019,F,,CHEMBL617350,1.0,,,,,8.0,,
Expert,,2462.0,,,107.0,1633.0,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,BAO_0000357,B,,CHEMBL872339,1.0,,,,,8.0,,
Autocuration,,2463.0,,,107.0,4373.0,H,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,B,,CHEMBL617351,1.0,,,,,8.0,,
Expert,,2464.0,,,107.0,6576.0,H,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617352,1.0,,,,,8.0,,
Autocuration,,2465.0,,,107.0,4687.0,H,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617353,1.0,,,,,8.0,,
Autocuration,,2466.0,,,107.0,16946.0,H,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617354,1.0,,,,,8.0,,
Autocuration,,2467.0,,,107.0,14159.0,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617355,1.0,,,,,8.0,,
Expert,,2468.0,,,107.0,3032.0,H,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,BAO_0000219,B,,CHEMBL617356,1.0,,,10090.0,CHO,8.0,449.0,Mus musculus
Autocuration,,2469.0,,,107.0,16655.0,H,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617357,1.0,,,,,8.0,,
Autocuration,,2470.0,,,107.0,13964.0,H,,Binding affinity at 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617358,1.0,,,,,8.0,,
Expert,,2471.0,,,107.0,16989.0,H,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617359,1.0,,,,,8.0,,
Autocuration,,2472.0,,,107.0,16117.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,B,,CHEMBL617360,1.0,,,,,8.0,,
Autocuration,,2473.0,,,107.0,16700.0,H,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,BAO_0000357,B,,CHEMBL875913,1.0,,,,,8.0,,
Autocuration,,2474.0,,,107.0,3269.0,H,,Affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617361,1.0,,,,,8.0,,
Expert,,2475.0,,,107.0,1274.0,D,,Binding affinity against 5-Hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617362,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2476.0,,,107.0,1317.0,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,BAO_0000357,B,,CHEMBL617363,1.0,,,,,8.0,,
Autocuration,,2477.0,,,107.0,12146.0,H,,Tested against 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617364,1.0,,,,,8.0,,
Autocuration,,2478.0,,,105075.0,12652.0,H,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,BAO_0000224,B,,CHEMBL617365,1.0,,,,,4.0,,
Autocuration,,2479.0,,,105075.0,12652.0,H,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,BAO_0000224,B,,CHEMBL617366,1.0,,,,,4.0,,
Autocuration,,2480.0,,,105075.0,12652.0,H,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,BAO_0000224,B,,CHEMBL617367,1.0,,,,,4.0,,
Autocuration,,2481.0,,,105075.0,12652.0,H,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,BAO_0000224,B,,CHEMBL617368,1.0,,,,,4.0,,
Autocuration,,2482.0,,,107.0,16647.0,H,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,BAO_0000357,B,,CHEMBL617369,1.0,,,,,8.0,,
Expert,,2483.0,,,227.0,15851.0,D,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,BAO_0000219,B,,CHEMBL617370,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,2484.0,,,227.0,6857.0,D,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,BAO_0000219,F,,CHEMBL617371,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,2485.0,,,227.0,3805.0,H,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,BAO_0000357,B,,CHEMBL617372,1.0,,,,,8.0,,
Expert,,2486.0,,,227.0,6491.0,D,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,BAO_0000357,B,,CHEMBL617373,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2487.0,,,227.0,14093.0,H,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,BAO_0000019,F,,CHEMBL617374,1.0,,,,,8.0,,
Autocuration,,2488.0,,,227.0,13481.0,H,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,BAO_0000019,F,,CHEMBL617375,1.0,,,,,8.0,,
Autocuration,,2489.0,,,227.0,14093.0,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,BAO_0000019,F,,CHEMBL617376,1.0,,,,,8.0,,
Autocuration,,2490.0,,,227.0,14093.0,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,BAO_0000019,F,,CHEMBL617377,1.0,,,,,8.0,,
Autocuration,,2491.0,,,227.0,14093.0,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,BAO_0000019,F,,CHEMBL617378,1.0,,,,,8.0,,
Autocuration,,2492.0,,,227.0,13481.0,H,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,BAO_0000019,F,,CHEMBL617379,1.0,,,,,8.0,,
Autocuration,,2493.0,,,227.0,14442.0,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,BAO_0000357,B,,CHEMBL617380,1.0,,,,,8.0,,
Autocuration,,2494.0,,,227.0,14442.0,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,BAO_0000357,B,,CHEMBL617381,1.0,,,,,8.0,,
Autocuration,,2495.0,,,227.0,14442.0,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,BAO_0000357,B,,CHEMBL617382,1.0,,,,,8.0,,
Autocuration,,2496.0,,,107.0,12369.0,H,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617383,1.0,,,,,8.0,,
Expert,,2497.0,,,107.0,12369.0,H,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,BAO_0000357,B,,CHEMBL617384,1.0,,,,,8.0,,
Expert,,2498.0,,,107.0,12369.0,H,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,BAO_0000357,B,,CHEMBL617385,1.0,,,,,8.0,,
Autocuration,,2499.0,,,107.0,14447.0,H,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,BAO_0000019,B,,CHEMBL617386,1.0,,,,,8.0,,
Autocuration,,2500.0,,,107.0,14447.0,H,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,BAO_0000019,B,,CHEMBL617387,1.0,,,,,8.0,,
Autocuration,,2501.0,,,107.0,17451.0,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,BAO_0000219,B,,CHEMBL617388,1.0,,,,NIH3T3,8.0,723.0,
Autocuration,,2502.0,,,107.0,6857.0,H,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,F,,CHEMBL617389,1.0,,,,CHO,8.0,449.0,
Expert,,2503.0,,,107.0,6857.0,D,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,F,,CHEMBL617390,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,2504.0,,,104817.0,5635.0,H,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,BAO_0000224,B,,CHEMBL617391,1.0,,,,,4.0,,
Autocuration,,2505.0,,,107.0,12861.0,H,,Binding activity radioligand.,,BAO_0000357,B,,CHEMBL617392,1.0,,,,,8.0,,
Autocuration,,2506.0,,,107.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,BAO_0000019,B,,CHEMBL617393,1.0,,,,,8.0,,
Autocuration,,2507.0,,,107.0,5105.0,H,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,BAO_0000219,B,,CHEMBL617394,1.0,,,,L929,8.0,307.0,
Expert,,2508.0,,,107.0,5104.0,H,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,BAO_0000219,B,,CHEMBL617395,1.0,,,,L929,8.0,307.0,
Expert,,2509.0,,,107.0,5105.0,H,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,BAO_0000219,B,,CHEMBL617396,1.0,,,,L929,8.0,307.0,
Autocuration,,2510.0,,,107.0,5105.0,H,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,BAO_0000219,B,,CHEMBL617397,1.0,,,,L929,8.0,307.0,
Autocuration,,2511.0,,,107.0,5254.0,H,,Binding affinity against 5-HT2A receptor,,BAO_0000357,B,,CHEMBL617398,1.0,,,,,8.0,,
Autocuration,,2512.0,,,107.0,5254.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617399,1.0,,,,,8.0,,
Autocuration,,2513.0,,,107.0,13267.0,H,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,BAO_0000219,B,,CHEMBL617400,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2514.0,,,107.0,13267.0,H,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,BAO_0000219,B,,CHEMBL617401,1.0,,,,HEK293,8.0,722.0,
Expert,,2515.0,,,107.0,14157.0,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,BAO_0000219,B,,CHEMBL617402,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,2516.0,,,107.0,12936.0,D,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,BAO_0000219,B,,CHEMBL617403,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,2517.0,,,107.0,14068.0,H,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,BAO_0000357,B,,CHEMBL617404,1.0,,,,,8.0,,
Expert,,2518.0,,,107.0,12936.0,D,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,BAO_0000219,B,,CHEMBL857981,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,2519.0,,,107.0,12936.0,D,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,BAO_0000219,B,,CHEMBL617405,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,2520.0,,,107.0,4540.0,D,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,BAO_0000219,B,,CHEMBL617253,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,2521.0,,,107.0,6166.0,H,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,BAO_0000357,B,,CHEMBL617254,1.0,,,,,8.0,,
Autocuration,,2522.0,,,107.0,17296.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,BAO_0000219,B,,CHEMBL617255,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2523.0,,,107.0,17296.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,BAO_0000219,B,,CHEMBL617256,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2524.0,,,107.0,17296.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,BAO_0000219,B,,CHEMBL616874,1.0,,,,HEK293,8.0,722.0,
Expert,,2525.0,,,107.0,15779.0,D,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,BAO_0000219,B,,CHEMBL616875,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,2526.0,,,107.0,14391.0,H,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,BAO_0000219,B,,CHEMBL616876,1.0,,,,HEK293,8.0,722.0,
Expert,,2527.0,,,107.0,15851.0,H,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,BAO_0000219,B,,CHEMBL616877,1.0,,,,HEK293,8.0,722.0,
Expert,,2528.0,,,107.0,15851.0,D,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,BAO_0000219,B,,CHEMBL616878,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,2529.0,,,107.0,3832.0,H,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,BAO_0000219,B,,CHEMBL616879,1.0,,,,HEK293,8.0,722.0,
Expert,,2530.0,,,107.0,3833.0,H,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,BAO_0000219,B,,CHEMBL616880,1.0,,,,HEK293,8.0,722.0,
Expert,,2531.0,,,107.0,12936.0,D,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,BAO_0000219,B,,CHEMBL616881,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Autocuration,,2532.0,,,107.0,17451.0,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,BAO_0000219,B,,CHEMBL616882,1.0,,,,NIH3T3,8.0,723.0,
Autocuration,,2533.0,,,107.0,17451.0,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,BAO_0000219,B,,CHEMBL616883,1.0,,,,NIH3T3,8.0,723.0,
Autocuration,,2534.0,,,107.0,17451.0,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,BAO_0000219,B,,CHEMBL616884,1.0,,,,NIH3T3,8.0,723.0,
Autocuration,,2535.0,,,107.0,4199.0,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,BAO_0000219,B,,CHEMBL616885,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2536.0,,,107.0,1883.0,H,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,BAO_0000219,B,,CHEMBL616886,1.0,,,,CHO-K1,8.0,485.0,
Expert,,2537.0,,,107.0,1883.0,H,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,BAO_0000219,B,,CHEMBL616887,1.0,,,,CHO-K1,8.0,485.0,
Expert,,2538.0,,,107.0,14875.0,D,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL616888,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2539.0,,,107.0,15146.0,H,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,BAO_0000219,B,,CHEMBL616889,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2540.0,,,107.0,5213.0,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,BAO_0000219,B,,CHEMBL616890,1.0,,,,HEK293,8.0,722.0,
Expert,,2541.0,,,107.0,16404.0,D,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,BAO_0000219,B,,CHEMBL616891,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,2542.0,,,107.0,14818.0,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,BAO_0000219,B,,CHEMBL616892,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2543.0,,,107.0,4829.0,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,BAO_0000219,B,,CHEMBL616893,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2544.0,,,10620.0,12652.0,H,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,BAO_0000219,F,,CHEMBL616894,1.0,,,,NIH3T3,8.0,723.0,
Expert,,2545.0,,,107.0,4682.0,H,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,BAO_0000219,B,,CHEMBL616895,1.0,,,,NIH3T3,8.0,723.0,
Autocuration,,2546.0,,,10620.0,12652.0,H,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,BAO_0000019,F,,CHEMBL616896,1.0,,,,,8.0,,
Autocuration,,2547.0,,,10621.0,4921.0,H,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617099,1.0,,,,,8.0,,
Autocuration,,2548.0,,,10621.0,4921.0,H,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,BAO_0000357,B,,CHEMBL617100,1.0,,,,,8.0,,
Autocuration,,2549.0,,,107.0,16312.0,H,,Binding affinity against rabbit aorta 5-HT2A receptor,,BAO_0000357,B,,CHEMBL884532,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Expert,,2550.0,,,107.0,14998.0,H,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,BAO_0000357,B,,CHEMBL617101,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Expert,,2551.0,,,107.0,14025.0,H,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,BAO_0000357,B,,CHEMBL617102,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Autocuration,,2552.0,,,107.0,13047.0,H,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,BAO_0000019,B,,CHEMBL617103,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Expert,,2553.0,,,107.0,13047.0,H,,The compound was tested for binding affinity against 5-HT2A receptor,,BAO_0000357,B,,CHEMBL617104,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Autocuration,,2554.0,,,10576.0,1883.0,H,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,BAO_0000219,B,,CHEMBL857979,1.0,,,,CHO-K1,8.0,485.0,
Autocuration,,2555.0,,,12687.0,13463.0,H,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,BAO_0000019,B,,CHEMBL857502,1.0,,,,,8.0,,
Autocuration,,2556.0,,,12687.0,13463.0,H,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,BAO_0000019,B,,CHEMBL617105,1.0,,,,,8.0,,
Autocuration,Stomach,2557.0,,,12687.0,13463.0,H,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,BAO_0000019,B,,CHEMBL858021,1.0,945.0,,,,8.0,,
Expert,Stomach,2558.0,,,12687.0,13463.0,D,,Binding affinity for 5-HT 2A in rat stomach fundus,,BAO_0000019,B,,CHEMBL875910,1.0,945.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2559.0,,,12687.0,13463.0,H,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,BAO_0000019,B,,CHEMBL617106,1.0,,,,,8.0,,
Expert,,2560.0,,,12687.0,16326.0,H,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,BAO_0000219,B,,CHEMBL617107,1.0,,,,NIH3T3,8.0,723.0,
Autocuration,,2561.0,,,12687.0,14093.0,H,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,BAO_0000019,F,,CHEMBL617108,1.0,,,,,8.0,,
Autocuration,,2562.0,,,12687.0,14093.0,H,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,BAO_0000019,F,,CHEMBL617109,1.0,,,,,8.0,,
Autocuration,,2563.0,,,12687.0,15740.0,H,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617110,1.0,,,,,8.0,,
Autocuration,,2564.0,,,12687.0,16633.0,H,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,BAO_0000357,B,,CHEMBL617111,1.0,,,,,8.0,,
Expert,,2565.0,,,12687.0,17200.0,D,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,BAO_0000019,F,,CHEMBL617112,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2566.0,,,12687.0,17133.0,H,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617113,1.0,,,,,8.0,,
Autocuration,,2567.0,,,12687.0,17133.0,H,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617114,1.0,,,,,8.0,,
Autocuration,,2568.0,,,12687.0,17133.0,H,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617115,1.0,,,,,8.0,,
Autocuration,,2569.0,,,12687.0,17200.0,H,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,BAO_0000219,F,,CHEMBL617116,1.0,,,,,8.0,,
Autocuration,,2570.0,,,12687.0,15363.0,H,,Efficacy at 5-hydroxytryptamine 2A receptor,,BAO_0000019,F,,CHEMBL617117,1.0,,,,,8.0,,
Autocuration,,2571.0,,,12687.0,17200.0,H,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,BAO_0000357,B,,CHEMBL617118,1.0,,,,,8.0,,
Expert,,2572.0,,,12687.0,17200.0,D,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,BAO_0000357,B,,CHEMBL617119,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2573.0,,,12687.0,17200.0,D,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,BAO_0000357,B,,CHEMBL617120,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2574.0,,,12687.0,17200.0,D,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,BAO_0000219,F,,CHEMBL617121,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2575.0,,,12687.0,17200.0,H,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,BAO_0000219,F,,CHEMBL617122,1.0,,,,,8.0,,
Autocuration,,2576.0,,,12687.0,17211.0,H,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,BAO_0000019,B,,CHEMBL617123,1.0,,,,,8.0,,
Expert,,2577.0,,,12687.0,17331.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,BAO_0000019,B,,CHEMBL617124,1.0,,,,,8.0,,
Expert,,2578.0,,,12687.0,13565.0,H,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,BAO_0000249,B,,CHEMBL617600,1.0,,,,,8.0,,
Expert,,2579.0,,,12687.0,13730.0,H,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,BAO_0000357,B,,CHEMBL617601,1.0,,,,,8.0,,
Expert,,2580.0,,,12687.0,12416.0,H,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,BAO_0000019,B,,CHEMBL882923,1.0,,,,,8.0,,
Autocuration,,2581.0,,,12687.0,15295.0,H,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617602,1.0,,,,,8.0,,
Autocuration,,2582.0,,,12687.0,1742.0,H,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,BAO_0000019,B,,CHEMBL617603,1.0,,,,,8.0,,
Autocuration,,2583.0,,,12687.0,15295.0,H,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617604,1.0,,,,,8.0,,
Expert,,2584.0,,,12687.0,14970.0,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,BAO_0000019,B,,CHEMBL617605,1.0,,,,,8.0,,
Expert,,2585.0,,,12687.0,16693.0,H,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,BAO_0000019,B,,CHEMBL617606,1.0,,,,,8.0,,
Expert,,2586.0,,,12687.0,14776.0,D,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,BAO_0000019,B,,CHEMBL617607,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2587.0,,,12687.0,14286.0,H,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,B,,CHEMBL617455,1.0,,,,,8.0,,
Expert,,2588.0,,,12687.0,17200.0,D,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,BAO_0000019,B,,CHEMBL617456,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2589.0,,,12687.0,15306.0,H,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,BAO_0000357,B,,CHEMBL617457,1.0,,,,,8.0,,
Expert,,2590.0,,,12687.0,14178.0,D,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617458,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2591.0,,,12687.0,14229.0,D,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,BAO_0000019,B,,CHEMBL617459,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2592.0,,,12687.0,12884.0,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,BAO_0000357,B,,CHEMBL617460,1.0,,,,,8.0,,
Expert,,2593.0,,,12687.0,13149.0,H,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,BAO_0000357,B,,CHEMBL617461,1.0,,,,,8.0,,
Expert,,2594.0,,,12687.0,15295.0,D,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,BAO_0000019,B,,CHEMBL617462,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2595.0,,,12687.0,15740.0,H,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,BAO_0000357,B,,CHEMBL617463,1.0,,,,,8.0,,
Autocuration,,2596.0,,,12687.0,15185.0,H,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,BAO_0000019,B,,CHEMBL617464,1.0,,,,,8.0,,
Autocuration,,2597.0,,,12687.0,15185.0,H,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,BAO_0000019,B,,CHEMBL617465,1.0,,,,,8.0,,
Expert,,2598.0,,,12687.0,17529.0,H,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,BAO_0000019,B,,CHEMBL617466,1.0,,,,,8.0,,
Autocuration,,2599.0,,,12687.0,14826.0,H,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,BAO_0000019,B,,CHEMBL617467,1.0,,,,,8.0,,
Expert,,2600.0,,,12687.0,17211.0,H,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,BAO_0000019,B,,CHEMBL617468,1.0,,,,,8.0,,
Autocuration,,2601.0,,,12687.0,14826.0,H,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,BAO_0000019,B,,CHEMBL617469,1.0,,,,,8.0,,
Autocuration,,2602.0,,,12687.0,14093.0,H,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,BAO_0000019,B,,CHEMBL617470,1.0,,,,,8.0,,
Autocuration,,2603.0,,,12687.0,14093.0,H,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,BAO_0000019,B,,CHEMBL617471,1.0,,,,,8.0,,
Expert,,2604.0,,,12687.0,13246.0,H,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,BAO_0000219,B,,CHEMBL617472,1.0,,,,NIH3T3,8.0,723.0,
Expert,,2605.0,,,12687.0,13246.0,H,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,BAO_0000357,B,,CHEMBL617473,1.0,,,,,8.0,,
Expert,,2606.0,,,12687.0,15436.0,D,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,BAO_0000019,B,,CHEMBL617474,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2607.0,,,12687.0,15436.0,D,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,BAO_0000019,B,,CHEMBL617475,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Brain,2608.0,,,12687.0,14442.0,H,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,BAO_0000221,B,,CHEMBL617476,1.0,955.0,,,,8.0,,
Expert,,2609.0,,,12687.0,12457.0,H,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617477,1.0,,,,,8.0,,
Expert,,2610.0,,,12687.0,12457.0,H,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000219,B,,CHEMBL617478,1.0,,,,NIH3T3,8.0,723.0,
Autocuration,,2611.0,,,12687.0,14755.0,H,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,BAO_0000221,F,,CHEMBL617479,1.0,,,,,8.0,,
Autocuration,,2612.0,,,12687.0,4707.0,H,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,BAO_0000357,B,,CHEMBL617480,1.0,,,,,8.0,,
Expert,,2613.0,,,12687.0,13297.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617481,1.0,,,,,8.0,,
Expert,,2614.0,,,12687.0,17331.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,BAO_0000019,B,,CHEMBL617482,1.0,,,,,8.0,,
Autocuration,,2615.0,,,12687.0,4664.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,BAO_0000019,B,,CHEMBL617483,1.0,,,,,8.0,,
Autocuration,,2616.0,,,12687.0,16633.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000357,B,,CHEMBL621528,1.0,,,,,8.0,,
Expert,,2617.0,,,12687.0,4664.0,D,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,BAO_0000219,B,,CHEMBL621529,1.0,,,10116.0,NIH3T3,9.0,723.0,Rattus norvegicus
Expert,,2618.0,,,12687.0,16133.0,H,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,B,,CHEMBL621530,1.0,,,,,8.0,,
Expert,,2619.0,,,12687.0,16133.0,H,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,B,,CHEMBL621531,1.0,,,,,8.0,,
Expert,,2620.0,,,12687.0,14060.0,D,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,BAO_0000019,B,,CHEMBL621532,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2621.0,,,12687.0,16326.0,H,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,B,,CHEMBL621533,1.0,,,,,8.0,,
Expert,,2622.0,,,12687.0,16659.0,H,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL621534,1.0,,,,CHO,8.0,449.0,
Autocuration,,2623.0,,,12687.0,14776.0,H,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,BAO_0000019,B,,CHEMBL621535,1.0,,,,,8.0,,
Autocuration,,2624.0,,,12687.0,13481.0,H,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,BAO_0000357,B,,CHEMBL621536,1.0,,,,,8.0,,
Autocuration,,2625.0,,,12687.0,17386.0,H,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL621537,1.0,,,,,8.0,,
Expert,,2626.0,,,12687.0,6611.0,D,,Binding affinity for 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL621538,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2627.0,,,12687.0,14423.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,BAO_0000019,B,,CHEMBL621539,1.0,,,,,8.0,,
Autocuration,,2628.0,,,12687.0,15412.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,BAO_0000019,B,,CHEMBL621540,1.0,,,,,8.0,,
Autocuration,,2629.0,,,12687.0,15412.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,BAO_0000019,B,,CHEMBL621541,1.0,,,,,8.0,,
Autocuration,,2630.0,,,12687.0,6238.0,H,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,BAO_0000019,B,,CHEMBL621542,1.0,,,,,8.0,,
Expert,,2631.0,,,12687.0,6648.0,H,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,BAO_0000357,B,,CHEMBL621543,1.0,,,,,8.0,,
Expert,,2632.0,,,12687.0,5667.0,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,BAO_0000357,B,,CHEMBL621544,1.0,,,,,8.0,,
Expert,,2633.0,,,12687.0,6611.0,D,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,BAO_0000357,B,,CHEMBL621545,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2634.0,,,12687.0,13481.0,H,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,B,,CHEMBL621546,1.0,,,,,8.0,,
Autocuration,,2635.0,,,12687.0,13481.0,H,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,BAO_0000357,B,,CHEMBL621547,1.0,,,,,8.0,,
Expert,,2636.0,,,12687.0,15558.0,H,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,BAO_0000219,B,,CHEMBL618692,1.0,,,,NIH3T3,8.0,723.0,
Autocuration,,2637.0,,,12687.0,6013.0,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL618693,1.0,,,,,8.0,,
Autocuration,,2638.0,,,12687.0,16633.0,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000357,B,,CHEMBL872922,1.0,,,,,8.0,,
Autocuration,,2639.0,,,12687.0,6013.0,H,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,BAO_0000357,B,,CHEMBL618694,1.0,,,,,8.0,,
Expert,,2640.0,,,12687.0,6013.0,D,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,BAO_0000357,B,,CHEMBL618695,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2641.0,,,12687.0,6013.0,H,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,BAO_0000357,B,,CHEMBL618696,1.0,,,,,8.0,,
Expert,,2642.0,,,12687.0,6013.0,H,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,BAO_0000357,B,,CHEMBL618697,1.0,,,,,8.0,,
Autocuration,,2643.0,,,12687.0,6013.0,H,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,BAO_0000357,B,,CHEMBL618892,1.0,,,,,8.0,,
Autocuration,,2644.0,,,12687.0,6013.0,H,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,BAO_0000357,B,,CHEMBL618893,1.0,,,,,8.0,,
Autocuration,,2645.0,,,12687.0,16293.0,H,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL618894,1.0,,,,,8.0,,
Expert,,2646.0,,,12687.0,17175.0,H,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,BAO_0000219,B,,CHEMBL618895,1.0,,,,NIH3T3,8.0,723.0,
Expert,,2647.0,,,12687.0,13278.0,D,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,BAO_0000357,B,,CHEMBL618896,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Caudate-putamen,2648.0,,,12687.0,3682.0,H,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,BAO_0000019,B,,CHEMBL618897,1.0,5383.0,,,,8.0,,
Autocuration,,2649.0,,,12687.0,2014.0,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,BAO_0000357,B,,CHEMBL618898,1.0,,,,,8.0,,
Autocuration,,2650.0,,,12687.0,2014.0,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,BAO_0000357,B,,CHEMBL618899,1.0,,,,,8.0,,
Autocuration,,2651.0,,,12687.0,4932.0,H,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,BAO_0000357,B,,CHEMBL618900,1.0,,,,,8.0,,
Autocuration,,2652.0,,,12687.0,4932.0,H,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,BAO_0000019,B,,CHEMBL618901,1.0,,,,,8.0,,
Autocuration,,2653.0,,,12687.0,3935.0,H,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL618902,1.0,,,,,8.0,,
Expert,Hippocampus,2654.0,,,12687.0,5432.0,D,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,BAO_0000221,B,,CHEMBL618903,1.0,10000000.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2655.0,,,12687.0,15818.0,H,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL618904,1.0,,,,,8.0,,
Autocuration,,2656.0,,,12687.0,13672.0,H,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,BAO_0000357,B,,CHEMBL618905,1.0,,,,,8.0,,
Autocuration,,2657.0,,,12687.0,13672.0,H,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,BAO_0000357,B,,CHEMBL618906,1.0,,,,,8.0,,
Expert,,2658.0,,,12687.0,14749.0,H,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,BAO_0000219,B,,CHEMBL618907,1.0,,,,NIH3T3,8.0,723.0,
Autocuration,,2659.0,,,12687.0,13462.0,H,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,BAO_0000019,B,,CHEMBL618908,1.0,,,,,8.0,,
Autocuration,,2660.0,,,12687.0,15740.0,H,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617909,1.0,,,,,8.0,,
Expert,,2661.0,,,12687.0,16647.0,H,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,BAO_0000019,B,,CHEMBL617910,1.0,,,,,8.0,,
Autocuration,Brain,2662.0,,,12687.0,13345.0,H,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,BAO_0000221,B,,CHEMBL617911,1.0,955.0,,,,8.0,,
Autocuration,,2663.0,,,12687.0,16740.0,H,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,B,,CHEMBL872923,1.0,,,,,8.0,,
Autocuration,,2664.0,,,12687.0,16740.0,H,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,B,,CHEMBL617912,1.0,,,,,8.0,,
Expert,,2665.0,,,12687.0,15535.0,D,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,BAO_0000019,B,,CHEMBL617913,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2666.0,,,12687.0,16740.0,H,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,B,,CHEMBL617914,1.0,,,,,8.0,,
Autocuration,,2667.0,,,12687.0,16740.0,H,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,B,,CHEMBL617915,1.0,,,,,8.0,,
Autocuration,,2668.0,,,12687.0,16740.0,H,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,B,,CHEMBL617916,1.0,,,,,8.0,,
Expert,,2669.0,,,12687.0,4795.0,D,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,BAO_0000019,B,,CHEMBL617917,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2670.0,,,12687.0,8.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,BAO_0000019,B,,CHEMBL617918,1.0,,,,,8.0,,
Autocuration,,2671.0,,,12687.0,8.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,BAO_0000019,B,,CHEMBL617919,1.0,,,,,8.0,,
Expert,,2672.0,,,12687.0,17200.0,D,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,BAO_0000019,B,,CHEMBL617920,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2673.0,,,12687.0,2148.0,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,BAO_0000019,B,,CHEMBL617921,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2674.0,,,105102.0,13345.0,D,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,BAO_0000224,B,,CHEMBL617922,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,2675.0,,,12687.0,5088.0,H,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,B,,CHEMBL617923,1.0,,,,,8.0,,
Autocuration,,2676.0,,,12687.0,5088.0,H,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,B,,CHEMBL617924,1.0,,,,,8.0,,
Autocuration,,2677.0,,,12687.0,17133.0,H,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,BAO_0000357,B,,CHEMBL617925,1.0,,,,,8.0,,
Expert,,2678.0,,,12687.0,17133.0,D,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,BAO_0000357,B,,CHEMBL617926,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2679.0,,,12687.0,16532.0,H,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,BAO_0000357,B,,CHEMBL617927,1.0,,,,,8.0,,
Autocuration,,2680.0,,,12687.0,15086.0,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,B,,CHEMBL617928,1.0,,,,,8.0,,
Expert,,2681.0,,,12687.0,2309.0,D,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,B,,CHEMBL617929,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2682.0,,,12687.0,12953.0,H,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,BAO_0000019,B,,CHEMBL617930,1.0,,,,,8.0,,
Autocuration,,2683.0,,,12687.0,12953.0,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,BAO_0000019,B,,CHEMBL617931,1.0,,,,,8.0,,
Autocuration,,2684.0,,,12687.0,12953.0,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,BAO_0000019,B,,CHEMBL617932,1.0,,,,,8.0,,
Autocuration,,2685.0,,,12687.0,16659.0,H,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,BAO_0000219,B,,CHEMBL617933,1.0,,,,CHO,8.0,449.0,
Autocuration,,2686.0,,,12687.0,16740.0,H,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,BAO_0000019,B,,CHEMBL617934,1.0,,,,,8.0,,
Autocuration,,2687.0,,,12687.0,16740.0,H,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,BAO_0000019,B,,CHEMBL617935,1.0,,,,,8.0,,
Autocuration,,2688.0,,,12687.0,17133.0,H,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,BAO_0000357,B,,CHEMBL617936,1.0,,,,,8.0,,
Autocuration,,2689.0,,,12687.0,17211.0,H,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,BAO_0000019,B,,CHEMBL617937,1.0,,,,,8.0,,
Autocuration,,2690.0,,,12687.0,17331.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,BAO_0000019,B,,CHEMBL617938,1.0,,,,,8.0,,
Autocuration,,2691.0,,,12687.0,16633.0,H,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,BAO_0000218,B,,CHEMBL617939,1.0,,,,,8.0,,
Autocuration,,2692.0,,,12687.0,16633.0,H,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,BAO_0000218,B,,CHEMBL617940,1.0,,,,,8.0,,
Autocuration,,2693.0,,,12687.0,16633.0,H,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,BAO_0000218,B,,CHEMBL617941,1.0,,,,,8.0,,
Expert,,2694.0,,,12687.0,15026.0,H,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,BAO_0000357,B,,CHEMBL617942,1.0,,,,,8.0,,
Expert,,2695.0,,,12687.0,15026.0,H,,Ratio of pKi of 5-HT2A to that of D2 receptor,,BAO_0000357,B,,CHEMBL617943,1.0,,,,,8.0,,
Expert,,2696.0,,,105093.0,16404.0,H,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,BAO_0000224,B,,CHEMBL617944,1.0,,,,,4.0,,
Expert,,2697.0,,,105093.0,16404.0,H,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,BAO_0000224,B,,CHEMBL617945,1.0,,,,,4.0,,
Expert,,2698.0,,,105075.0,16404.0,H,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,BAO_0000224,B,,CHEMBL617946,1.0,,,,,4.0,,
Autocuration,,2699.0,,,12687.0,16404.0,H,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,BAO_0000357,B,,CHEMBL617947,1.0,,,,,8.0,,
Expert,,2700.0,,,12687.0,16326.0,H,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,BAO_0000357,B,,CHEMBL617948,1.0,,,,,8.0,,
Autocuration,,2701.0,,,12687.0,15847.0,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,BAO_0000019,F,,CHEMBL858116,1.0,,,,,8.0,,
Autocuration,,2702.0,,,12687.0,15847.0,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,BAO_0000019,F,,CHEMBL617949,1.0,,,,,8.0,,
Autocuration,,2703.0,,,12687.0,15329.0,H,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,BAO_0000019,F,,CHEMBL617950,1.0,,,,,8.0,,
Expert,Thoracic aorta,2704.0,,,12687.0,16404.0,H,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,BAO_0000019,F,,CHEMBL617951,1.0,1515.0,,,,8.0,,
Expert,Thoracic aorta,2705.0,,,12687.0,16404.0,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,BAO_0000019,F,,CHEMBL617952,1.0,1515.0,,,,8.0,,
Autocuration,Thoracic aorta,2706.0,,,12687.0,16404.0,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,BAO_0000019,F,,CHEMBL617953,1.0,1515.0,,,,8.0,,
Autocuration,,2707.0,,,12687.0,12861.0,H,,Binding activity radioligand.,,BAO_0000357,B,,CHEMBL617954,1.0,,,,,8.0,,
Expert,,2708.0,,,12687.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,BAO_0000019,B,,CHEMBL617955,1.0,,,,,8.0,,
Autocuration,,2709.0,,,12687.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,BAO_0000019,B,,CHEMBL857071,1.0,,,,,8.0,,
Expert,,2710.0,,,12687.0,12490.0,H,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,BAO_0000019,B,,CHEMBL617270,1.0,,,,,8.0,,
Autocuration,,2711.0,,,12687.0,12827.0,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,BAO_0000219,B,,CHEMBL617271,1.0,,,,N1E-115,8.0,339.0,
Autocuration,,2712.0,,,12687.0,12827.0,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,BAO_0000219,B,,CHEMBL617272,1.0,,,,N1E-115,8.0,339.0,
Autocuration,,2713.0,,,12687.0,12918.0,H,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,BAO_0000019,B,,CHEMBL617273,1.0,,,,,8.0,,
Expert,,2714.0,,,12687.0,12919.0,D,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,BAO_0000019,F,,CHEMBL617274,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2715.0,,,108.0,17723.0,H,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617275,1.0,,,,,8.0,,
Autocuration,,2716.0,,,108.0,6013.0,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617276,1.0,,,,,8.0,,
Autocuration,,2717.0,,,108.0,16293.0,H,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617277,1.0,,,,,8.0,,
Expert,,2718.0,,,108.0,3857.0,H,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,BAO_0000019,B,,CHEMBL617278,1.0,,,,,8.0,,
Expert,,2719.0,,,108.0,3857.0,H,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,BAO_0000019,B,,CHEMBL617279,1.0,,,,,8.0,,
Expert,,2720.0,,,108.0,3857.0,H,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,BAO_0000019,B,,CHEMBL617280,1.0,,,,,8.0,,
Autocuration,,2721.0,,,108.0,15363.0,H,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617281,1.0,,,,,8.0,,
Autocuration,,2722.0,,,108.0,15363.0,H,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617282,1.0,,,,,8.0,,
Expert,,2723.0,,,108.0,16441.0,H,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,BAO_0000019,B,,CHEMBL617283,1.0,,,,,8.0,,
Expert,,2724.0,,,108.0,16441.0,H,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,BAO_0000019,B,,CHEMBL617284,1.0,,,,,8.0,,
Autocuration,,2725.0,,,108.0,4176.0,H,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,BAO_0000219,B,,CHEMBL617285,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2726.0,,,108.0,17085.0,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,BAO_0000019,B,,CHEMBL617286,1.0,,,,,8.0,,
Expert,,2727.0,,,108.0,17200.0,D,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,BAO_0000357,B,,CHEMBL617287,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,2728.0,,,108.0,5088.0,H,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,BAO_0000357,B,,CHEMBL617288,1.0,,,,,8.0,,
Autocuration,,2729.0,,,108.0,5088.0,H,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,BAO_0000357,B,,CHEMBL617289,1.0,,,,,8.0,,
Autocuration,,2730.0,,,108.0,5088.0,H,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,B,,CHEMBL872917,1.0,,,,,8.0,,
Autocuration,,2731.0,,,108.0,5088.0,H,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL617290,1.0,,,,,8.0,,
Autocuration,,2732.0,,,108.0,16659.0,H,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL617291,1.0,,,,CHO,8.0,449.0,
Autocuration,,2733.0,,,108.0,16659.0,H,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,BAO_0000219,B,,CHEMBL617292,1.0,,,,CHO,8.0,449.0,
Autocuration,,2734.0,,,108.0,17451.0,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,BAO_0000219,B,,CHEMBL617293,1.0,,,,NIH3T3,8.0,723.0,
Expert,,2735.0,,,108.0,6857.0,D,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,F,,CHEMBL617294,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Expert,,2736.0,,,108.0,3857.0,H,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,BAO_0000019,B,,CHEMBL617295,1.0,,,,,8.0,,
Autocuration,,2737.0,,,108.0,12861.0,H,,Binding activity radioligand.,,BAO_0000357,B,,CHEMBL617296,1.0,,,,,8.0,,
Autocuration,,2738.0,,,108.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,BAO_0000019,B,,CHEMBL617297,1.0,,,,,8.0,,
Expert,,2739.0,,,108.0,5104.0,H,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,BAO_0000219,B,,CHEMBL617298,1.0,,,,CHO,8.0,449.0,
Expert,,2740.0,,,108.0,5105.0,H,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,BAO_0000219,B,,CHEMBL617299,1.0,,,,CHO,8.0,449.0,
Autocuration,,2741.0,,,108.0,5105.0,H,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,BAO_0000219,B,,CHEMBL617300,1.0,,,,CHO,8.0,449.0,
Autocuration,,2742.0,,,108.0,5254.0,H,,Binding affinity against 5-HT2C receptor,,BAO_0000357,B,,CHEMBL617454,1.0,,,,,8.0,,
Autocuration,,2743.0,,,108.0,13267.0,H,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,BAO_0000219,B,,CHEMBL617505,1.0,,,,HEK293,8.0,722.0,
Expert,,2744.0,,,108.0,14157.0,D,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,BAO_0000219,B,,CHEMBL617506,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,2745.0,,,108.0,12936.0,D,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,BAO_0000219,B,,CHEMBL617507,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,2746.0,,,108.0,14068.0,H,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,BAO_0000357,B,,CHEMBL617508,1.0,,,,,8.0,,
Expert,,2747.0,,,108.0,12936.0,D,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,BAO_0000219,B,,CHEMBL857982,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,2748.0,,,108.0,4540.0,D,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,BAO_0000219,B,,CHEMBL617509,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,2749.0,,,108.0,4540.0,D,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,BAO_0000219,B,,CHEMBL617510,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Autocuration,,2750.0,,,108.0,6166.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,B,,CHEMBL617511,1.0,,,,,8.0,,
Autocuration,,2751.0,,,108.0,17296.0,H,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,BAO_0000219,B,,CHEMBL617512,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2752.0,,,108.0,17296.0,H,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,BAO_0000219,B,,CHEMBL617749,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2753.0,,,108.0,15779.0,H,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,BAO_0000219,B,,CHEMBL617750,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2754.0,,,108.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,BAO_0000219,B,,CHEMBL617751,1.0,,,,HEK293,8.0,722.0,
Expert,,2755.0,,,108.0,14391.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,BAO_0000219,B,,CHEMBL617752,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2756.0,,,108.0,15779.0,H,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,BAO_0000219,B,,CHEMBL617753,1.0,,,,HEK293,8.0,722.0,
Expert,,2757.0,,,108.0,15851.0,H,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,BAO_0000219,B,,CHEMBL617754,1.0,,,,HEK293,8.0,722.0,
Expert,,2758.0,,,108.0,15851.0,D,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,BAO_0000219,B,,CHEMBL617755,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Autocuration,,2759.0,,,108.0,15779.0,H,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,BAO_0000219,B,,CHEMBL617756,1.0,,,,HEK293,8.0,722.0,
Expert,,2760.0,,,108.0,3832.0,H,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,BAO_0000219,B,,CHEMBL617757,1.0,,,,HEK293,8.0,722.0,
Expert,,2761.0,,,108.0,3833.0,H,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,BAO_0000219,B,,CHEMBL617758,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2762.0,,,108.0,17451.0,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,BAO_0000219,B,,CHEMBL617759,1.0,,,,NIH3T3,8.0,723.0,
Autocuration,,2763.0,,,108.0,4199.0,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,BAO_0000219,B,,CHEMBL617760,1.0,,,,HEK293,8.0,722.0,
Expert,,2764.0,,,108.0,1883.0,H,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,BAO_0000219,B,,CHEMBL617761,1.0,,,,CHO-K1,8.0,485.0,
Expert,,2765.0,,,108.0,4321.0,D,,Binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617762,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2766.0,,,108.0,14875.0,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617763,1.0,,,,,8.0,,
Autocuration,,2767.0,,,108.0,15146.0,H,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,BAO_0000219,B,,CHEMBL857983,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2768.0,,,108.0,5213.0,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,BAO_0000219,B,,CHEMBL617764,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2769.0,,,108.0,16404.0,H,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,BAO_0000219,B,,CHEMBL617765,1.0,,,,HeLa,8.0,308.0,
Autocuration,,2770.0,,,108.0,13267.0,H,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,BAO_0000019,F,,CHEMBL617766,1.0,,,,,8.0,,
Autocuration,Hippocampus,2771.0,,,108.0,13267.0,H,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,BAO_0000221,F,,CHEMBL617767,1.0,10000000.0,,,,8.0,,
Autocuration,,2772.0,,,108.0,14818.0,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,BAO_0000219,B,,CHEMBL617768,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2773.0,,,108.0,4829.0,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,BAO_0000219,B,,CHEMBL617769,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2774.0,,,11864.0,13463.0,H,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,BAO_0000357,B,,CHEMBL858023,1.0,,,,,8.0,,
Autocuration,Stomach,2775.0,,,11864.0,13463.0,H,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,BAO_0000019,B,,CHEMBL617770,1.0,945.0,,,,8.0,,
Autocuration,Stomach,2776.0,,,11864.0,13463.0,H,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,BAO_0000019,B,,CHEMBL617771,1.0,945.0,,,,8.0,,
Autocuration,,2777.0,,,11864.0,12652.0,H,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,BAO_0000219,F,,CHEMBL617772,1.0,,,,A9,8.0,625.0,
Autocuration,,2778.0,,,11864.0,4682.0,H,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,BAO_0000219,B,,CHEMBL617773,1.0,,,,NIH3T3,8.0,723.0,
Autocuration,,2779.0,,,11864.0,4682.0,H,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,BAO_0000219,B,,CHEMBL617850,1.0,,,,NIH3T3,8.0,723.0,
Autocuration,,2780.0,,,11864.0,4682.0,H,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,BAO_0000219,B,,CHEMBL617851,1.0,,,,NIH3T3,8.0,723.0,
Autocuration,,2781.0,,,11864.0,12652.0,H,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,BAO_0000019,F,,CHEMBL617852,1.0,,,,,8.0,,
Autocuration,Stomach,2782.0,,,12689.0,13463.0,H,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,BAO_0000019,B,,CHEMBL858024,1.0,945.0,,10090.0,,8.0,,Mus musculus
Expert,Stomach,2783.0,,,12689.0,13463.0,D,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,BAO_0000019,B,,CHEMBL617853,1.0,945.0,,10116.0,,9.0,,Rattus norvegicus
Expert,,2784.0,,,108.0,13969.0,H,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,BAO_0000357,B,,CHEMBL617854,1.0,,,,,8.0,,
Expert,,2785.0,,,108.0,13392.0,H,,Binding affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL873477,1.0,,,9823.0,,8.0,,Sus scrofa
Expert,,2786.0,,,108.0,13392.0,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617855,1.0,,,,,8.0,,
Expert,,2787.0,,,108.0,14430.0,H,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,BAO_0000019,B,,CHEMBL617856,1.0,,,,,8.0,,
Autocuration,,2788.0,,,108.0,1742.0,H,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,BAO_0000019,B,,CHEMBL617857,1.0,,,,,8.0,,
Autocuration,,2789.0,,,108.0,14286.0,H,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,BAO_0000249,B,,CHEMBL617858,1.0,,,,,8.0,,
Autocuration,,2790.0,,,108.0,5619.0,H,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617859,1.0,,,,,8.0,,
Autocuration,,2791.0,,,108.0,15086.0,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617860,1.0,,,,,8.0,,
Autocuration,,2792.0,,,108.0,12861.0,H,,Binding activity radioligand.,,BAO_0000357,B,,CHEMBL617861,1.0,,,,,8.0,,
Expert,,2793.0,,,108.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,BAO_0000019,B,,CHEMBL617862,1.0,,,,,8.0,,
Autocuration,,2794.0,,,108.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,BAO_0000019,B,,CHEMBL617863,1.0,,,,,8.0,,
Autocuration,,2795.0,,,108.0,12827.0,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,BAO_0000249,B,,CHEMBL617864,1.0,,,,,8.0,,
Autocuration,,2796.0,,,108.0,12827.0,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,BAO_0000249,B,,CHEMBL617649,1.0,,,,,8.0,,
Expert,,2797.0,,,108.0,12919.0,H,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,BAO_0000019,F,,CHEMBL617650,1.0,,,9823.0,,8.0,,Sus scrofa
Expert,,2798.0,,,108.0,12919.0,H,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,BAO_0000019,F,,CHEMBL617651,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,2799.0,,,108.0,16429.0,H,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,BAO_0000357,B,,CHEMBL617652,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,2800.0,,,108.0,773.0,H,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,BAO_0000019,B,,CHEMBL857072,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,2801.0,,,108.0,5033.0,H,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617653,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,2802.0,,,12687.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,BAO_0000019,B,,CHEMBL617654,1.0,,,,,8.0,,
Autocuration,,2803.0,,,12689.0,14093.0,H,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,BAO_0000019,F,,CHEMBL617655,1.0,,,,,8.0,,
Expert,,2804.0,,,12689.0,14970.0,H,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,BAO_0000357,B,,CHEMBL617656,1.0,,,,,8.0,,
Autocuration,,2805.0,,,12689.0,14970.0,H,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,BAO_0000357,B,,CHEMBL617657,1.0,,,,,8.0,,
Autocuration,,2806.0,,,12689.0,14970.0,H,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,BAO_0000357,B,,CHEMBL617658,1.0,,,,,8.0,,
Expert,,2807.0,,,12689.0,14178.0,D,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617659,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2808.0,,,12689.0,14178.0,D,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617838,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,2809.0,,,12689.0,14229.0,D,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,Brain membranes,BAO_0000249,B,,CHEMBL617839,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2810.0,,,12689.0,16532.0,H,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,BAO_0000357,B,,CHEMBL617840,1.0,,,,,8.0,,
Autocuration,,2811.0,,,12689.0,14826.0,H,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,BAO_0000019,B,,CHEMBL617841,1.0,,,,,8.0,,
Autocuration,,2812.0,,,12689.0,17211.0,H,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,BAO_0000019,B,,CHEMBL875915,1.0,,,,,8.0,,
Expert,,2813.0,,,12689.0,17211.0,H,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,BAO_0000219,B,In vitro,CHEMBL617842,1.0,,,,,8.0,,
Expert,,2814.0,,,12689.0,13246.0,H,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,BAO_0000219,B,,CHEMBL617843,1.0,,,,NIH3T3,8.0,723.0,
Expert,,2815.0,,,12689.0,13246.0,H,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,BAO_0000357,B,,CHEMBL617844,1.0,,,,,8.0,,
Expert,,2816.0,,,12689.0,12457.0,H,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617845,1.0,,,,,8.0,,
Expert,,2817.0,,,12689.0,12457.0,H,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,BAO_0000219,B,,CHEMBL617846,1.0,,,,NIH3T3,8.0,723.0,
Autocuration,,2818.0,,,12689.0,4707.0,H,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,BAO_0000357,B,,CHEMBL617847,1.0,,,,,8.0,,
Expert,,2819.0,,,12689.0,13297.0,H,,Binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617848,1.0,,,,,8.0,,
Autocuration,,2820.0,,,12689.0,16633.0,H,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,BAO_0000357,B,,CHEMBL617849,1.0,,,,,8.0,,
Expert,,2821.0,,,12689.0,16133.0,H,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,B,,CHEMBL621507,1.0,,,,,8.0,,
Expert,,2822.0,,,12689.0,16326.0,H,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,BAO_0000357,B,,CHEMBL621508,1.0,,,,,8.0,,
Autocuration,,2823.0,,,12689.0,14423.0,H,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,BAO_0000019,B,,CHEMBL621509,1.0,,,,,8.0,,
Autocuration,,2824.0,,,12689.0,15412.0,H,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,BAO_0000019,B,,CHEMBL621510,1.0,,,,,8.0,,
Autocuration,,2825.0,,,12689.0,15412.0,H,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,BAO_0000019,B,,CHEMBL621511,1.0,,,,,8.0,,
Expert,,2826.0,,,12689.0,15558.0,H,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,BAO_0000219,B,,CHEMBL621512,1.0,,,,A9,8.0,625.0,
Autocuration,,2827.0,,,12689.0,16633.0,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,BAO_0000357,B,,CHEMBL621513,1.0,,,,,8.0,,
Expert,,2828.0,,,12689.0,6013.0,H,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,BAO_0000357,B,,CHEMBL621514,1.0,,,,,8.0,,
Expert,,2829.0,,,12689.0,17175.0,H,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,BAO_0000219,B,In vitro,CHEMBL621515,1.0,,,,,8.0,,
Autocuration,,2830.0,,,12689.0,12469.0,H,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,BAO_0000219,B,,CHEMBL621516,1.0,,,,,8.0,,
Autocuration,Caudate-putamen,2831.0,,,12689.0,3682.0,H,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,BAO_0000019,B,,CHEMBL621517,1.0,5383.0,,,,8.0,,
Autocuration,,2832.0,,,12689.0,4932.0,H,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,BAO_0000357,B,,CHEMBL621518,1.0,,,,,8.0,,
Autocuration,,2833.0,,,12689.0,4932.0,H,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,BAO_0000019,B,,CHEMBL621519,1.0,,,,,8.0,,
Autocuration,,2834.0,,,12689.0,3935.0,H,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL621520,1.0,,,,,8.0,,
Autocuration,,2835.0,,,12689.0,15818.0,H,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL621521,1.0,,,,,8.0,,
Autocuration,,2836.0,,,12689.0,15818.0,H,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL621522,1.0,,,,,8.0,,
Expert,,2837.0,,,12689.0,14749.0,H,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,BAO_0000219,B,,CHEMBL621523,1.0,,,,,8.0,,
Autocuration,,2838.0,,,12689.0,15740.0,H,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL621524,1.0,,,,,8.0,,
Expert,,2839.0,,,12689.0,17133.0,D,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,BAO_0000357,B,,CHEMBL621525,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2840.0,,,12689.0,16532.0,H,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,BAO_0000357,B,,CHEMBL872921,1.0,,,,,8.0,,
Autocuration,,2841.0,,,12689.0,12369.0,H,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL621526,1.0,,,,,8.0,,
Expert,,2842.0,,,12689.0,12369.0,H,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,BAO_0000219,B,,CHEMBL621527,1.0,,,,,8.0,,
Expert,,2843.0,,,12689.0,2309.0,D,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,BAO_0000019,B,,CHEMBL617865,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2844.0,,,12689.0,12953.0,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617866,1.0,,,,,8.0,,
Autocuration,,2845.0,,,12689.0,12953.0,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,BAO_0000019,B,,CHEMBL617867,1.0,,,,,8.0,,
Autocuration,,2846.0,,,12689.0,12953.0,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,BAO_0000357,B,,CHEMBL617487,1.0,,,,,8.0,,
Expert,,2847.0,,,12689.0,12953.0,H,,Binding affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617488,1.0,,,,,8.0,,
Autocuration,,2848.0,,,12689.0,17133.0,H,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,BAO_0000357,B,,CHEMBL617489,1.0,,,,,8.0,,
Autocuration,,2849.0,,,12689.0,17211.0,H,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,BAO_0000019,B,,CHEMBL617490,1.0,,,,,8.0,,
Autocuration,,2850.0,,,12689.0,17211.0,H,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,BAO_0000019,B,,CHEMBL617491,1.0,,,,,8.0,,
Autocuration,,2851.0,,,12689.0,14025.0,H,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,BAO_0000019,B,,CHEMBL617492,1.0,,,,,8.0,,
Autocuration,,2852.0,,,12689.0,14998.0,H,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,BAO_0000019,B,,CHEMBL617493,1.0,,,,,8.0,,
Autocuration,,2853.0,,,12689.0,4342.0,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,B,,CHEMBL617494,1.0,,,,,8.0,,
Expert,,2854.0,,,12689.0,13735.0,D,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,BAO_0000019,B,,CHEMBL617495,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2855.0,,,12689.0,13181.0,H,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL617496,1.0,,,,,8.0,,
Autocuration,,2856.0,,,12689.0,1883.0,H,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,BAO_0000219,B,,CHEMBL617497,1.0,,,,CHO-K1,8.0,485.0,
Autocuration,,2857.0,,,12689.0,15194.0,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,B,,CHEMBL617498,1.0,,,,,8.0,,
Autocuration,,2858.0,,,12689.0,15194.0,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,BAO_0000357,B,,CHEMBL617499,1.0,,,,,8.0,,
Autocuration,,2859.0,,,12689.0,14579.0,H,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,BAO_0000019,F,,CHEMBL617500,1.0,,,,,8.0,,
Autocuration,,2860.0,,,108.0,4639.0,H,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617501,1.0,,,,,8.0,,
Expert,,2861.0,,,108.0,4820.0,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617502,1.0,,,,,8.0,,
Autocuration,,2862.0,,,227.0,14442.0,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,BAO_0000357,B,,CHEMBL617503,1.0,,,,,8.0,,
Autocuration,,2863.0,,,227.0,14755.0,H,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,BAO_0000357,B,,CHEMBL617504,1.0,,,,,8.0,,
Autocuration,,2864.0,,,227.0,14744.0,H,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,BAO_0000357,B,,CHEMBL617406,1.0,,,,,8.0,,
Expert,,2865.0,,,227.0,6857.0,D,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,BAO_0000019,B,,CHEMBL617407,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2866.0,,,227.0,16209.0,H,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL617408,1.0,,,,,8.0,,
Autocuration,,2867.0,,,227.0,15363.0,H,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,BAO_0000357,B,,CHEMBL617409,1.0,,,,,8.0,,
Autocuration,,2868.0,,,227.0,15363.0,H,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,BAO_0000357,B,,CHEMBL617410,1.0,,,,,8.0,,
Autocuration,,2869.0,,,227.0,15363.0,H,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,BAO_0000357,B,,CHEMBL617411,1.0,,,,,8.0,,
Autocuration,,2870.0,,,227.0,17085.0,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,BAO_0000019,B,,CHEMBL617412,1.0,,,,,8.0,,
Expert,,2871.0,,,227.0,17200.0,D,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,BAO_0000357,B,,CHEMBL617774,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,2872.0,,,227.0,15851.0,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,BAO_0000219,B,,CHEMBL617775,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,2873.0,,,227.0,15851.0,D,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,BAO_0000219,B,,CHEMBL617776,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,2874.0,,,227.0,6857.0,D,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,F,,CHEMBL617777,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Expert,,2875.0,,,227.0,6857.0,D,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,F,,CHEMBL617778,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,2876.0,,,227.0,15779.0,H,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,BAO_0000219,B,,CHEMBL617779,1.0,,,,HEK293,8.0,722.0,
Expert,,2877.0,,,227.0,15851.0,H,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,BAO_0000219,B,,CHEMBL617780,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2878.0,,,227.0,15779.0,H,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,BAO_0000219,B,,CHEMBL617781,1.0,,,,HEK293,8.0,722.0,
Expert,,2879.0,,,227.0,14157.0,D,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,BAO_0000219,B,,CHEMBL617782,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,2880.0,,,227.0,4540.0,D,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,BAO_0000219,B,,CHEMBL617783,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Autocuration,,2881.0,,,227.0,6166.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,BAO_0000357,B,,CHEMBL617784,1.0,,,,,8.0,,
Autocuration,,2882.0,,,227.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,BAO_0000219,B,,CHEMBL617785,1.0,,,,HEK293,8.0,722.0,
Expert,,2883.0,,,227.0,14391.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,BAO_0000219,B,,CHEMBL857984,1.0,,,,HEK293,8.0,722.0,
Expert,,2884.0,,,227.0,3832.0,H,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,BAO_0000219,B,,CHEMBL617786,1.0,,,,HEK293,8.0,722.0,
Expert,,2885.0,,,227.0,3833.0,H,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,BAO_0000219,B,,CHEMBL617787,1.0,,,,HEK293,8.0,722.0,
Expert,,2886.0,,,227.0,15851.0,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,BAO_0000219,B,,CHEMBL617788,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,2887.0,,,227.0,15851.0,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,BAO_0000219,B,,CHEMBL617789,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Autocuration,,2888.0,,,227.0,4199.0,H,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,BAO_0000219,B,,CHEMBL617790,1.0,,,,HEK293,8.0,722.0,
Expert,,2889.0,,,227.0,1883.0,H,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,BAO_0000219,B,,CHEMBL617791,1.0,,,,CHO-K1,8.0,485.0,
Expert,,2890.0,,,227.0,4321.0,H,,Binding affinity against 5-hydroxytryptamine 2B receptor,,BAO_0000357,B,,CHEMBL617608,1.0,,,,,8.0,,
Autocuration,,2891.0,,,227.0,15146.0,H,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,BAO_0000219,B,,CHEMBL617609,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2892.0,,,227.0,5213.0,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,BAO_0000219,B,,CHEMBL617610,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2893.0,,,227.0,14818.0,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,BAO_0000219,B,,CHEMBL617611,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2894.0,,,227.0,4829.0,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,BAO_0000219,B,,CHEMBL617612,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2895.0,,,227.0,4829.0,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,BAO_0000219,B,,CHEMBL617613,1.0,,,,HEK293,8.0,722.0,
Autocuration,,2896.0,,,227.0,14025.0,H,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,BAO_0000019,B,,CHEMBL617614,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Expert,Stomach,2897.0,,,12688.0,13463.0,H,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,BAO_0000019,B,,CHEMBL617615,1.0,945.0,,,,8.0,,
Expert,Stomach,2898.0,,,12688.0,7259.0,H,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,BAO_0000357,B,,CHEMBL858114,1.0,945.0,,,,8.0,,
Autocuration,Stomach,2899.0,,,12688.0,7259.0,H,,Affinity against serotonergic receptor in the isolated rat stomach fundus,,BAO_0000357,B,,CHEMBL617616,1.0,945.0,,,,8.0,,
Expert,Stomach,2900.0,,,12688.0,7185.0,D,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,BAO_0000019,F,,CHEMBL617617,1.0,945.0,,10116.0,,9.0,,Rattus norvegicus
Expert,,2901.0,,,12688.0,7185.0,D,,Antagonistic against 5-hydroxytryptamine 2B receptor,,BAO_0000019,F,,CHEMBL875914,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Stomach,2902.0,,,12688.0,13267.0,H,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,BAO_0000019,F,,CHEMBL617618,1.0,945.0,,,,8.0,,
Expert,Stomach,2903.0,,,12688.0,13735.0,D,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,BAO_0000357,B,,CHEMBL617619,1.0,945.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2904.0,,,12688.0,15738.0,H,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,BAO_0000019,F,,CHEMBL617620,1.0,,,,,8.0,,
Autocuration,,2905.0,,,12688.0,15738.0,H,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,BAO_0000019,F,,CHEMBL617621,1.0,,,,,8.0,,
Autocuration,,2906.0,,,12688.0,15738.0,H,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,BAO_0000019,F,,CHEMBL617622,1.0,,,,,8.0,,
Expert,Stomach,2907.0,,,12688.0,12936.0,D,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,BAO_0000357,B,,CHEMBL617623,1.0,945.0,,10116.0,,9.0,,Rattus norvegicus
Expert,Stomach,2908.0,,,12688.0,12936.0,D,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,BAO_0000357,B,,CHEMBL617624,1.0,945.0,,10116.0,,9.0,,Rattus norvegicus
Expert,Stomach,2909.0,,,12688.0,12936.0,D,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,BAO_0000357,B,,CHEMBL617625,1.0,945.0,,10116.0,,9.0,,Rattus norvegicus
Expert,Stomach,2910.0,,,12688.0,12936.0,D,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,BAO_0000357,B,,CHEMBL617626,1.0,945.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Stomach,2911.0,,,12688.0,16404.0,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,BAO_0000019,F,,CHEMBL617627,1.0,945.0,,,,8.0,,
Expert,Stomach,2912.0,,,12688.0,16404.0,H,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,BAO_0000019,F,,CHEMBL617628,1.0,945.0,,,,8.0,,
Autocuration,Stomach,2913.0,,,12688.0,16404.0,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,BAO_0000019,F,,CHEMBL617629,1.0,945.0,,,,8.0,,
Autocuration,Stomach,2914.0,,,12688.0,16404.0,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,BAO_0000019,F,,CHEMBL858115,1.0,945.0,,,,8.0,,
Expert,Stomach,2915.0,,,12688.0,16404.0,D,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,BAO_0000019,F,,CHEMBL617630,1.0,945.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Thoracic aorta,2916.0,,,12688.0,16404.0,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,BAO_0000019,F,,CHEMBL617631,1.0,1515.0,,,,8.0,,
Autocuration,,2917.0,,,12688.0,7483.0,H,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,BAO_0000357,B,,CHEMBL617632,1.0,,,,,8.0,,
Expert,,2918.0,,,12688.0,7483.0,H,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,BAO_0000357,B,,CHEMBL617633,1.0,,,,,8.0,,
Autocuration,,2919.0,,,12688.0,7483.0,H,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,BAO_0000357,B,,CHEMBL617634,1.0,,,,,8.0,,
Autocuration,,2920.0,,,12688.0,7483.0,H,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,BAO_0000357,B,,CHEMBL617635,1.0,,,,,8.0,,
Autocuration,Stomach,2922.0,,,12688.0,16404.0,D,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,BAO_0000019,F,,CHEMBL617637,1.0,945.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,2923.0,,,227.0,6347.0,H,,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,B,,CHEMBL617638,1.0,,,,,8.0,,
Autocuration,,2924.0,,,227.0,4373.0,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,BAO_0000357,B,,CHEMBL617639,1.0,,,,,8.0,,
Autocuration,,2925.0,,,227.0,4373.0,H,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,BAO_0000357,B,,CHEMBL617640,1.0,,,,,8.0,,
Autocuration,,2926.0,,,227.0,4687.0,H,,Evaluated for the binding affinity to 5-HT 2B receptor,,BAO_0000357,B,,CHEMBL617641,1.0,,,,,8.0,,
Autocuration,,2927.0,,,227.0,16946.0,H,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,BAO_0000357,B,,CHEMBL617642,1.0,,,,,8.0,,
Autocuration,,2928.0,,,227.0,16633.0,H,,Binding affinities against 5-hydroxytryptamine 2B receptor,,BAO_0000357,B,,CHEMBL617643,1.0,,,,,8.0,,
Autocuration,,2929.0,,,227.0,16633.0,H,,Binding affinities towards 5-hydroxytryptamine 2B receptor,,BAO_0000357,B,,CHEMBL617644,1.0,,,,,8.0,,
Autocuration,,2930.0,,,227.0,16633.0,H,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,BAO_0000357,B,,CHEMBL617645,1.0,,,,,8.0,,
Expert,,2931.0,,,108.0,15026.0,H,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,BAO_0000357,B,,CHEMBL617646,1.0,,,,,8.0,,
Autocuration,,2932.0,,,108.0,15738.0,H,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,BAO_0000357,B,,CHEMBL617647,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,2933.0,,,108.0,15738.0,H,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,BAO_0000357,B,,CHEMBL617648,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,2934.0,,,108.0,15738.0,H,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,BAO_0000357,B,,CHEMBL617875,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,2935.0,,,108.0,15738.0,H,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,BAO_0000357,B,,CHEMBL617876,1.0,,,9913.0,,8.0,,Bos taurus
Expert,,2936.0,,,108.0,16404.0,H,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,BAO_0000357,B,,CHEMBL617877,1.0,,,9913.0,,8.0,,Bos taurus
Expert,,2937.0,,,108.0,15026.0,H,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,BAO_0000357,B,,CHEMBL617878,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,2938.0,,,108.0,15738.0,H,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,BAO_0000357,B,,CHEMBL617879,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,2939.0,,,108.0,16312.0,H,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,BAO_0000019,B,,CHEMBL617880,1.0,,,10141.0,,8.0,,Cavia porcellus
Intermediate,Striatum,2940.0,,,20033.0,5486.0,D,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,BAO_0000357,B,,CHEMBL617881,1.0,2435.0,,10141.0,,9.0,,Cavia porcellus
Autocuration,,2941.0,,,51.0,5254.0,H,,Binding affinity against 5-HT1A receptor,,BAO_0000357,B,,CHEMBL857073,1.0,,,,,8.0,,
Expert,,2942.0,,,108.0,3857.0,H,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,BAO_0000219,F,,CHEMBL617882,1.0,,,,CHO,8.0,449.0,
Expert,,2943.0,,,108.0,6857.0,D,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,BAO_0000219,F,,CHEMBL617883,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,2944.0,,,108.0,4176.0,H,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,BAO_0000219,F,,CHEMBL617884,1.0,,,,,8.0,,
Autocuration,,2945.0,,,108.0,6347.0,H,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,BAO_0000219,B,,CHEMBL617885,1.0,,,,CHO,8.0,449.0,
Autocuration,,2946.0,,,108.0,6347.0,H,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,BAO_0000219,B,,CHEMBL617886,1.0,,,,CHO,8.0,449.0,
Expert,,2947.0,,,108.0,16146.0,D,,Inhibition of human 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617887,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2948.0,,,108.0,3805.0,H,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,BAO_0000357,B,,CHEMBL617888,1.0,,,,,8.0,,
Autocuration,,2949.0,,,108.0,3857.0,H,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,BAO_0000019,B,,CHEMBL617889,1.0,,,,,8.0,,
Autocuration,,2950.0,,,108.0,5635.0,H,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL617890,1.0,,,,,8.0,,
Autocuration,,2951.0,,,108.0,5635.0,H,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,BAO_0000357,B,,CHEMBL617891,1.0,,,,,8.0,,
Autocuration,,2952.0,,,108.0,5635.0,H,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,BAO_0000357,B,,CHEMBL617892,1.0,,,,,8.0,,
Expert,,2953.0,,,108.0,4012.0,H,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,BAO_0000219,B,,CHEMBL617893,1.0,,,,CHO,8.0,449.0,
Expert,,2954.0,,,108.0,6366.0,H,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,BAO_0000219,B,,CHEMBL617894,1.0,,,,CHO,8.0,449.0,
Expert,,2955.0,,,108.0,15949.0,H,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL617895,1.0,,,,CHO,8.0,449.0,
Autocuration,,2956.0,,,108.0,17211.0,H,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,BAO_0000219,B,,CHEMBL617896,1.0,,,,CHO,8.0,449.0,
Expert,,2957.0,,,108.0,6491.0,D,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,BAO_0000357,B,,CHEMBL617897,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2958.0,,,108.0,14093.0,H,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,BAO_0000019,F,,CHEMBL617898,1.0,,,,,8.0,,
Autocuration,,2959.0,,,108.0,13481.0,H,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,BAO_0000019,F,,CHEMBL617899,1.0,,,,,8.0,,
Expert,,2960.0,,,108.0,6347.0,H,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,BAO_0000219,B,,CHEMBL617900,1.0,,,10116.0,CHO,8.0,449.0,Rattus norvegicus
Autocuration,,2961.0,,,108.0,14093.0,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,BAO_0000019,F,,CHEMBL617901,1.0,,,,,8.0,,
Autocuration,,2962.0,,,108.0,14093.0,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,BAO_0000019,F,,CHEMBL617902,1.0,,,,,8.0,,
Autocuration,,2963.0,,,108.0,13481.0,H,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000019,F,,CHEMBL617903,1.0,,,,,8.0,,
Autocuration,,2964.0,,,108.0,14442.0,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,BAO_0000357,B,,CHEMBL617904,1.0,,,,,8.0,,
Autocuration,,2965.0,,,108.0,14442.0,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,BAO_0000357,B,,CHEMBL617905,1.0,,,,,8.0,,
Autocuration,,2966.0,,,108.0,14442.0,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,BAO_0000357,B,,CHEMBL617906,1.0,,,,,8.0,,
Autocuration,,2967.0,,,108.0,14755.0,H,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,BAO_0000357,B,,CHEMBL617907,1.0,,,,,8.0,,
Autocuration,,2968.0,,,108.0,14744.0,H,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,BAO_0000357,B,,CHEMBL617908,1.0,,,,,8.0,,
Expert,,2969.0,,,108.0,16659.0,H,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL620617,1.0,,,,CHO,8.0,449.0,
Expert,,2970.0,,,108.0,6857.0,D,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,BAO_0000019,B,,CHEMBL620618,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,2971.0,,,108.0,5635.0,H,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,BAO_0000357,B,,CHEMBL620619,1.0,,,,,8.0,,
Expert,,2972.0,,,108.0,4234.0,D,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL620620,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,2973.0,,,108.0,16209.0,H,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,BAO_0000357,B,,CHEMBL620621,1.0,,,,,8.0,,
Autocuration,,2974.0,,,104698.0,5778.0,D,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,Membranes,BAO_0000249,B,,CHEMBL872920,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,2975.0,,,104698.0,5094.0,H,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,BAO_0000223,B,,CHEMBL620622,1.0,,,,,6.0,,
Autocuration,,2976.0,,,104698.0,809.0,D,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,BAO_0000019,B,,CHEMBL620623,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,2977.0,,,104698.0,1578.0,H,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,BAO_0000019,B,,CHEMBL620624,1.0,,,,,6.0,,
Autocuration,,2978.0,,,104698.0,809.0,H,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,BAO_0000019,B,,CHEMBL620625,1.0,,,,,6.0,,
Autocuration,,2979.0,,,104698.0,12469.0,H,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,BAO_0000219,B,,CHEMBL620626,1.0,,,,,6.0,,
Autocuration,,2980.0,,,104698.0,14290.0,H,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,BAO_0000019,B,,CHEMBL621307,1.0,,,,,6.0,,
Autocuration,,2981.0,,,104698.0,14290.0,H,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,BAO_0000019,B,,CHEMBL621308,1.0,,,,,6.0,,
Autocuration,,2982.0,,,104698.0,10609.0,H,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,BAO_0000223,B,,CHEMBL621309,1.0,,,,,6.0,,
Autocuration,,2983.0,,,104698.0,10609.0,H,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,BAO_0000223,B,,CHEMBL621310,1.0,,,,,6.0,,
Autocuration,,2984.0,,,104698.0,10609.0,H,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,BAO_0000223,B,,CHEMBL621311,1.0,,,,,6.0,,
Autocuration,,2985.0,,,104698.0,15253.0,H,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,BAO_0000249,B,,CHEMBL621502,1.0,,,,,6.0,,
Autocuration,,2986.0,,,104698.0,15253.0,H,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,BAO_0000249,B,,CHEMBL621503,1.0,,,,,6.0,,
Autocuration,,2987.0,,,104698.0,11683.0,H,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,Membranes,BAO_0000249,B,,CHEMBL621504,1.0,,,,,6.0,,
Autocuration,,2988.0,,,104698.0,12092.0,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL621505,1.0,,,,,6.0,,
Autocuration,,2989.0,,,104698.0,1946.0,H,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,BAO_0000019,B,,CHEMBL621506,1.0,,,,,6.0,,
Autocuration,,2990.0,,,104698.0,11623.0,H,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,BAO_0000223,B,,CHEMBL619781,1.0,,,,,6.0,,
Autocuration,,2991.0,,,104698.0,11623.0,H,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,BAO_0000223,B,,CHEMBL619782,1.0,,,,,6.0,,
Autocuration,,2992.0,,,104698.0,14788.0,H,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,BAO_0000019,B,,CHEMBL619783,1.0,,,,,6.0,,
Autocuration,,2993.0,,,104698.0,5432.0,D,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,BAO_0000019,B,,CHEMBL619784,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,2994.0,,,104698.0,14826.0,H,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,BAO_0000249,B,,CHEMBL619785,1.0,,,,,6.0,,
Autocuration,,2995.0,,,104698.0,2222.0,H,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL619786,1.0,,,,,6.0,,
Autocuration,,2996.0,,,104698.0,11963.0,H,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,BAO_0000019,B,,CHEMBL619787,1.0,,,,,6.0,,
Autocuration,,2997.0,,,104698.0,14145.0,H,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,BAO_0000019,B,,CHEMBL872925,1.0,,,,,6.0,,
Autocuration,,2998.0,,,104698.0,17819.0,H,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,BAO_0000019,B,,CHEMBL619788,1.0,,,,,6.0,,
Autocuration,,2999.0,,,104698.0,10394.0,H,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,BAO_0000249,B,,CHEMBL619789,1.0,,,,,6.0,,
Autocuration,,3000.0,,,104698.0,10394.0,H,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,BAO_0000249,B,,CHEMBL619790,1.0,,,,,6.0,,
Autocuration,,3001.0,,,104698.0,15034.0,H,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,BAO_0000019,B,,CHEMBL619791,1.0,,,,,6.0,,
Autocuration,,3002.0,,,104698.0,691.0,H,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,BAO_0000019,B,,CHEMBL619792,1.0,,,,,6.0,,
Autocuration,,3003.0,,,104698.0,12092.0,H,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,Membranes,BAO_0000249,B,,CHEMBL619793,1.0,,,,,6.0,,
Autocuration,,3004.0,,,104698.0,11752.0,D,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL619794,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,Brain,3005.0,,,104698.0,11752.0,H,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,BAO_0000221,B,,CHEMBL619795,1.0,955.0,,,,6.0,,
Autocuration,,3006.0,,,104698.0,301.0,H,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,BAO_0000019,B,,CHEMBL619796,1.0,,,,,6.0,,
Autocuration,,3007.0,,,104698.0,16532.0,H,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,BAO_0000223,B,,CHEMBL620448,1.0,,,,,6.0,,
Autocuration,,3008.0,,,104698.0,16532.0,H,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,BAO_0000223,B,,CHEMBL620449,1.0,,,,,6.0,,
Autocuration,,3009.0,,,104698.0,12092.0,H,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,BAO_0000223,B,,CHEMBL620450,1.0,,,,,6.0,,
Autocuration,,3010.0,,,104698.0,11684.0,H,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,BAO_0000223,B,,CHEMBL620451,1.0,,,,,6.0,,
Autocuration,,3011.0,,,104698.0,11684.0,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,BAO_0000223,B,,CHEMBL620631,1.0,,,,,6.0,,
Autocuration,,3012.0,,,104698.0,12953.0,H,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,BAO_0000019,B,,CHEMBL620632,1.0,,,,,6.0,,
Autocuration,,3013.0,,,104698.0,12953.0,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,BAO_0000019,B,,CHEMBL620633,1.0,,,,,6.0,,
Autocuration,,3014.0,,,104698.0,12953.0,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,BAO_0000223,B,,CHEMBL620634,1.0,,,,,6.0,,
Autocuration,,3015.0,,,104698.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,BAO_0000019,B,,CHEMBL620635,1.0,,,,,6.0,,
Autocuration,,3016.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620636,1.0,,,,,6.0,,
Autocuration,,3017.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620637,1.0,,,,,6.0,,
Autocuration,,3018.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620638,1.0,,,,,6.0,,
Autocuration,,3019.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620639,1.0,,,,,6.0,,
Autocuration,,3020.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620640,1.0,,,,,6.0,,
Autocuration,,3021.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620641,1.0,,,,,6.0,,
Autocuration,,3022.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620642,1.0,,,,,6.0,,
Autocuration,,3023.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620643,1.0,,,,,6.0,,
Autocuration,,3024.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620644,1.0,,,,,6.0,,
Autocuration,,3025.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620645,1.0,,,,,6.0,,
Autocuration,,3026.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620646,1.0,,,,,6.0,,
Autocuration,,3027.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620647,1.0,,,,,6.0,,
Autocuration,,3028.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620648,1.0,,,,,6.0,,
Autocuration,,3029.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620649,1.0,,,,,6.0,,
Autocuration,,3030.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620650,1.0,,,,,6.0,,
Autocuration,,3031.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620651,1.0,,,,,6.0,,
Autocuration,,3032.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL872875,1.0,,,,,6.0,,
Autocuration,,3033.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL620652,1.0,,,,,6.0,,
Autocuration,,3034.0,,,104698.0,10609.0,H,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,BAO_0000019,F,,CHEMBL620653,1.0,,,,,6.0,,
Autocuration,,3035.0,,,104698.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,BAO_0000019,B,,CHEMBL857076,1.0,,,,,6.0,,
Autocuration,,3036.0,,,104698.0,12861.0,D,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,BAO_0000019,B,,CHEMBL620654,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3037.0,,,104698.0,12861.0,H,,Binding activity radioligand.,,BAO_0000223,B,,CHEMBL620655,1.0,,,,,6.0,,
Autocuration,,3038.0,,,104698.0,10728.0,H,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,Brain membranes,BAO_0000249,B,,CHEMBL620656,1.0,,,,,6.0,,
Autocuration,,3039.0,,,104698.0,10728.0,H,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,Brain membranes,BAO_0000249,B,,CHEMBL620657,1.0,,,,,6.0,,
Autocuration,,3040.0,,,108.0,5163.0,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,BAO_0000357,B,,CHEMBL620658,1.0,,,,,8.0,,
Autocuration,,3041.0,,,108.0,5163.0,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,BAO_0000357,B,,CHEMBL620659,1.0,,,,,8.0,,
Autocuration,,3042.0,,,108.0,6011.0,H,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,BAO_0000357,B,,CHEMBL620660,1.0,,,,,8.0,,
Autocuration,,3043.0,,,108.0,5014.0,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL620661,1.0,,,,,8.0,,
Autocuration,,3044.0,,,108.0,5635.0,H,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL620662,1.0,,,,,8.0,,
Expert,,3045.0,,,108.0,5163.0,H,,Affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL620663,1.0,,,,,8.0,,
Autocuration,,3046.0,,,108.0,6841.0,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,B,,CHEMBL620664,1.0,,,,,8.0,,
Expert,,3047.0,,,108.0,6119.0,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,BAO_0000357,B,,CHEMBL620665,1.0,,,,,8.0,,
Autocuration,,3048.0,,,108.0,4373.0,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,B,,CHEMBL620666,1.0,,,,,8.0,,
Autocuration,,3049.0,,,108.0,1633.0,H,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,BAO_0000357,B,,CHEMBL620667,1.0,,,,,8.0,,
Expert,,3050.0,,,108.0,1633.0,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,BAO_0000357,B,,CHEMBL620668,1.0,,,,,8.0,,
Autocuration,,3051.0,,,108.0,4373.0,H,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,B,,CHEMBL620669,1.0,,,,,8.0,,
Expert,,3052.0,,,108.0,6576.0,H,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL620670,1.0,,,,,8.0,,
Autocuration,,3053.0,,,108.0,4687.0,H,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL620671,1.0,,,,,8.0,,
Autocuration,,3054.0,,,108.0,12146.0,H,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,BAO_0000357,B,,CHEMBL620672,1.0,,,,,8.0,,
Autocuration,,3055.0,,,108.0,12146.0,H,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,BAO_0000357,B,,CHEMBL620673,1.0,,,,,8.0,,
Autocuration,,3056.0,,,108.0,16946.0,H,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL620674,1.0,,,,,8.0,,
Autocuration,,3057.0,,,108.0,14159.0,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL620675,1.0,,,,,8.0,,
Autocuration,,3058.0,,,108.0,16700.0,H,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,BAO_0000357,B,,CHEMBL620676,1.0,,,,,8.0,,
Autocuration,,3059.0,,,108.0,3269.0,H,,Affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL621382,1.0,,,,,8.0,,
Expert,,3060.0,,,108.0,1274.0,D,,Binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL621383,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,3061.0,,,108.0,1317.0,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,BAO_0000357,B,,CHEMBL621384,1.0,,,,,8.0,,
Autocuration,,3062.0,,,144.0,5834.0,H,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,BAO_0000357,B,,CHEMBL621385,1.0,,,9913.0,,8.0,,Bos taurus
Autocuration,,3063.0,,,144.0,11147.0,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,BAO_0000357,B,,CHEMBL617989,1.0,,,9913.0,,8.0,,Bos taurus
Expert,,3064.0,,,104714.0,14145.0,H,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,BAO_0000019,F,,CHEMBL617990,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3065.0,,,104714.0,10561.0,H,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,BAO_0000221,B,,CHEMBL875085,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3066.0,,,104714.0,15847.0,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,BAO_0000019,F,,CHEMBL617991,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3067.0,,,104714.0,15847.0,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,BAO_0000019,F,,CHEMBL617992,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3068.0,,,104714.0,10561.0,H,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,BAO_0000221,B,,CHEMBL617993,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3069.0,,,104714.0,11454.0,H,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,BAO_0000221,B,,CHEMBL617994,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3070.0,,,104714.0,4639.0,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,BAO_0000019,F,,CHEMBL617995,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3071.0,,,104714.0,4639.0,H,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,BAO_0000019,F,,CHEMBL617996,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3072.0,,,104714.0,4639.0,H,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,BAO_0000019,F,,CHEMBL617997,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3073.0,,,104714.0,4639.0,H,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,BAO_0000019,F,,CHEMBL617998,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3074.0,,,104714.0,4639.0,H,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,BAO_0000019,F,,CHEMBL617999,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3075.0,,,104714.0,4639.0,H,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,BAO_0000019,F,,CHEMBL618000,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3076.0,,,104714.0,15253.0,H,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,BAO_0000221,F,,CHEMBL617815,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3077.0,,,104714.0,15253.0,H,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,BAO_0000221,F,,CHEMBL617816,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3078.0,,,104714.0,11963.0,H,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,BAO_0000221,F,,CHEMBL617817,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3079.0,,,104714.0,1946.0,H,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,BAO_0000221,B,,CHEMBL617818,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3080.0,,,104714.0,1946.0,H,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,BAO_0000221,B,,CHEMBL617819,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3081.0,,,104714.0,12045.0,H,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,BAO_0000223,B,,CHEMBL617820,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3082.0,,,104714.0,1559.0,H,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,BAO_0000221,B,,CHEMBL617821,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3083.0,,,104714.0,273.0,H,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,BAO_0000221,F,,CHEMBL617822,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3084.0,,,104714.0,273.0,H,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,BAO_0000221,F,,CHEMBL617823,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3085.0,,,104714.0,188.0,H,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,BAO_0000221,F,,CHEMBL617824,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3086.0,,,104714.0,12919.0,H,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,BAO_0000221,F,,CHEMBL617825,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3087.0,,,104714.0,12918.0,H,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,BAO_0000221,F,,CHEMBL617826,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3088.0,,,104714.0,1559.0,H,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,BAO_0000221,B,,CHEMBL617827,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3089.0,,,104714.0,273.0,H,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,BAO_0000221,F,,CHEMBL617828,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3090.0,,,104714.0,1559.0,H,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,BAO_0000221,B,,CHEMBL617829,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3091.0,,,104714.0,1559.0,H,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,BAO_0000221,B,,CHEMBL617830,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3092.0,,,104714.0,1559.0,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,BAO_0000221,B,,CHEMBL617831,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3093.0,,,104714.0,14424.0,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,BAO_0000221,B,,CHEMBL617832,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3094.0,,,22226.0,13181.0,U,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,BAO_0000019,B,,CHEMBL617833,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,,3095.0,,,51.0,5486.0,H,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,BAO_0000357,B,,CHEMBL617834,1.0,,,,,8.0,,
Expert,,3096.0,,,104714.0,6491.0,D,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,BAO_0000223,B,,CHEMBL617835,1.0,,,9606.0,,5.0,,Homo sapiens
Autocuration,,3097.0,,,104714.0,6013.0,H,,Binding affinity towards 5-HT3 receptor,,BAO_0000223,B,,CHEMBL617836,1.0,,,,,4.0,,
Autocuration,,3098.0,,,104714.0,12861.0,H,,Binding activity radioligand.,,BAO_0000223,B,,CHEMBL617837,1.0,,,,,4.0,,
Autocuration,,3099.0,,,104714.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,BAO_0000019,B,,CHEMBL620392,1.0,,,,,4.0,,
Autocuration,,3100.0,,,104714.0,5104.0,H,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL620393,1.0,,,,,4.0,,
Autocuration,,3101.0,,,104714.0,5105.0,H,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL620394,1.0,,,,,4.0,,
Autocuration,,3102.0,,,104714.0,5104.0,H,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,BAO_0000223,B,,CHEMBL620395,1.0,,,,,4.0,,
Autocuration,,3103.0,,,22226.0,3935.0,U,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,BAO_0000019,B,,CHEMBL620396,1.0,,,,,0.0,,
Expert,,3104.0,,,105030.0,13657.0,H,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,BAO_0000219,B,,CHEMBL620582,1.0,,,,NG108-15,4.0,433.0,
Autocuration,,3105.0,,,105030.0,10369.0,H,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,BAO_0000218,B,In vivo,CHEMBL620583,1.0,,,,,4.0,,
Autocuration,,3106.0,,,105030.0,10369.0,H,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,BAO_0000019,B,,CHEMBL620584,1.0,,,,,4.0,,
Autocuration,,3107.0,,,105030.0,12918.0,H,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,BAO_0000224,B,,CHEMBL620585,1.0,,,,,4.0,,
Autocuration,,3108.0,,,105030.0,12918.0,H,,Compound was evaluated for the binding affinity at 5- HT3 receptor,,BAO_0000224,B,,CHEMBL620586,1.0,,,,,4.0,,
Autocuration,,3109.0,,,105030.0,10369.0,H,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,BAO_0000019,B,,CHEMBL620587,1.0,,,,,4.0,,
Autocuration,,3110.0,,,105030.0,773.0,H,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,BAO_0000019,B,,CHEMBL620588,1.0,,,,,4.0,,
Autocuration,,3111.0,,,105030.0,12918.0,H,,5-hydroxytryptamine 3 receptor agonism in mouse,,BAO_0000218,F,,CHEMBL620589,1.0,,,,,4.0,,
Autocuration,,3112.0,,,105030.0,10561.0,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,BAO_0000219,B,,CHEMBL620590,1.0,,,,,4.0,,
Autocuration,,3113.0,,,105030.0,12827.0,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,BAO_0000019,B,,CHEMBL617956,1.0,,,,,4.0,,
Autocuration,,3114.0,,,105030.0,12827.0,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,BAO_0000019,B,,CHEMBL617957,1.0,,,,,4.0,,
Autocuration,,3115.0,,,105030.0,12918.0,H,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,BAO_0000224,B,,CHEMBL617958,1.0,,,,,4.0,,
Autocuration,,3116.0,,,105030.0,273.0,H,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,BAO_0000219,B,,CHEMBL617959,1.0,,,,,4.0,,
Autocuration,,3117.0,,,105030.0,273.0,H,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,BAO_0000219,B,,CHEMBL617960,1.0,,,,,4.0,,
Autocuration,,3118.0,,,105030.0,10561.0,H,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,BAO_0000224,B,,CHEMBL617961,1.0,,,,,4.0,,
Autocuration,,3119.0,,,105030.0,5033.0,H,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,BAO_0000219,B,In vitro,CHEMBL617962,1.0,,,,,4.0,,
Autocuration,,3120.0,,,105030.0,16429.0,H,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,BAO_0000219,B,,CHEMBL617963,1.0,,,,N1E-115,4.0,339.0,
Autocuration,,3121.0,,,11765.0,10322.0,H,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,BAO_0000019,B,,CHEMBL617964,1.0,,,,,8.0,,
Autocuration,,3122.0,,,11765.0,14331.0,H,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,BAO_0000219,B,,CHEMBL617965,1.0,,,,,8.0,,
Autocuration,,3123.0,,,10630.0,13462.0,D,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,BAO_0000357,B,,CHEMBL617966,1.0,,,10090.0,,9.0,,Mus musculus
Autocuration,,3124.0,,,17106.0,12861.0,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,B,,CHEMBL857074,1.0,,,,,8.0,,
Autocuration,,3125.0,,,144.0,15086.0,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,BAO_0000357,B,,CHEMBL617967,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,3126.0,,,144.0,12861.0,H,,Binding activity radioligand.,,BAO_0000357,B,,CHEMBL617968,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,3127.0,,,104714.0,10561.0,H,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,BAO_0000223,B,,CHEMBL617969,1.0,,,9986.0,,4.0,,Oryctolagus cuniculus
Autocuration,,3128.0,,,104714.0,10561.0,H,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,BAO_0000223,B,,CHEMBL617970,1.0,,,9986.0,,4.0,,Oryctolagus cuniculus
Autocuration,,3129.0,,,104714.0,10561.0,H,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,BAO_0000223,B,,CHEMBL617971,1.0,,,9986.0,,4.0,,Oryctolagus cuniculus
Autocuration,,3130.0,,,104714.0,10561.0,H,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,BAO_0000019,B,,CHEMBL617972,1.0,,,9986.0,,4.0,,Oryctolagus cuniculus
Autocuration,,3131.0,,,104714.0,273.0,H,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,BAO_0000019,F,,CHEMBL617973,1.0,,,9986.0,,4.0,,Oryctolagus cuniculus
Autocuration,,3132.0,,,104714.0,273.0,H,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,BAO_0000019,F,,CHEMBL617974,1.0,,,9986.0,,4.0,,Oryctolagus cuniculus
Autocuration,Ileum,3133.0,,,104714.0,273.0,H,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,BAO_0000221,F,,CHEMBL617975,1.0,2116.0,,9986.0,,4.0,,Oryctolagus cuniculus
Autocuration,,3134.0,,,104714.0,273.0,H,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,BAO_0000019,F,,CHEMBL617976,1.0,,,9986.0,,4.0,,Oryctolagus cuniculus
Autocuration,,3135.0,,,104714.0,273.0,H,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,BAO_0000019,F,,CHEMBL617977,1.0,,,9986.0,,4.0,,Oryctolagus cuniculus
Autocuration,,3136.0,,,104714.0,273.0,H,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,BAO_0000019,F,,CHEMBL617978,1.0,,,9986.0,,4.0,,Oryctolagus cuniculus
Autocuration,,3137.0,,,104714.0,273.0,H,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,BAO_0000019,F,,CHEMBL617979,1.0,,,9986.0,,4.0,,Oryctolagus cuniculus
Autocuration,,3138.0,,,104714.0,13047.0,H,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,B,,CHEMBL617980,1.0,,,9986.0,CHO,4.0,449.0,Oryctolagus cuniculus
Autocuration,,3139.0,,,104698.0,1650.0,D,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,BAO_0000019,B,,CHEMBL617981,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3140.0,,,12020.0,16288.0,H,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,BAO_0000019,B,,CHEMBL617982,1.0,,,,,8.0,,
Autocuration,,3141.0,,,12020.0,16288.0,H,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,BAO_0000357,B,,CHEMBL617983,1.0,,,,,8.0,,
Autocuration,,3142.0,,,104698.0,10254.0,D,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,BAO_0000019,B,,CHEMBL617984,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3143.0,,,104698.0,14532.0,H,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,BAO_0000019,B,,CHEMBL617985,1.0,,,,,6.0,,
Autocuration,Heart,3144.0,,,104698.0,13392.0,H,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,BAO_0000218,F,In vivo,CHEMBL617986,1.0,948.0,,,,6.0,,
Autocuration,Heart,3145.0,,,104698.0,13392.0,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,BAO_0000019,F,,CHEMBL617987,1.0,948.0,,,,6.0,,
Autocuration,Heart,3146.0,,,104698.0,13392.0,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,BAO_0000019,F,,CHEMBL617988,1.0,948.0,,,,6.0,,
Autocuration,Heart,3147.0,,,104698.0,13392.0,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,BAO_0000019,F,,CHEMBL617792,1.0,948.0,,,,6.0,,
Autocuration,Heart,3148.0,,,104698.0,13392.0,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,BAO_0000019,F,,CHEMBL617793,1.0,948.0,,,,6.0,,
Autocuration,,3149.0,,,104698.0,13392.0,H,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,F,,CHEMBL617794,1.0,,,,,6.0,,
Autocuration,,3150.0,,,104698.0,13392.0,H,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,F,,CHEMBL617795,1.0,,,,,6.0,,
Autocuration,,3151.0,,,104698.0,13392.0,H,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,F,,CHEMBL617796,1.0,,,,,6.0,,
Autocuration,,3152.0,,,104698.0,13392.0,H,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,F,,CHEMBL617797,1.0,,,,,6.0,,
Autocuration,,3153.0,,,104698.0,1089.0,D,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,BAO_0000218,F,In vivo,CHEMBL617798,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3154.0,,,104698.0,1089.0,H,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,BAO_0000218,F,In vivo,CHEMBL617799,1.0,,,,,6.0,,
Autocuration,,3155.0,,,104698.0,11454.0,D,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617800,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3156.0,,,104698.0,11454.0,D,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,BAO_0000019,F,,CHEMBL617801,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3157.0,,,104698.0,12205.0,D,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,BAO_0000218,F,In vivo,CHEMBL617802,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3158.0,,,104698.0,1089.0,D,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,BAO_0000019,F,,CHEMBL617803,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3159.0,,,104698.0,5094.0,H,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,BAO_0000019,B,,CHEMBL617804,1.0,,,,,6.0,,
Autocuration,,3160.0,,,104698.0,2622.0,D,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,BAO_0000019,B,,CHEMBL617805,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3161.0,,,104698.0,245.0,H,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL617806,1.0,,,,,6.0,,
Autocuration,,3162.0,,,104698.0,14788.0,H,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,BAO_0000019,B,,CHEMBL617807,1.0,,,,,6.0,,
Autocuration,,3163.0,,,104698.0,14788.0,H,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,BAO_0000019,B,,CHEMBL617808,1.0,,,,,6.0,,
Autocuration,,3164.0,,,104698.0,3020.0,H,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,BAO_0000249,B,,CHEMBL617809,1.0,,,,,6.0,,
Autocuration,,3165.0,,,104698.0,1742.0,H,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,BAO_0000019,B,,CHEMBL617810,1.0,,,,,6.0,,
Autocuration,Brain,3166.0,,,104698.0,17394.0,H,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,BAO_0000249,B,,CHEMBL617811,1.0,955.0,,,,6.0,,
Autocuration,Brain,3167.0,,,104698.0,17394.0,H,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,BAO_0000221,B,,CHEMBL617812,1.0,955.0,,,,6.0,,
Autocuration,,3168.0,,,104698.0,17394.0,H,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,BAO_0000249,B,,CHEMBL617813,1.0,,,,,6.0,,
Autocuration,,3169.0,,,104698.0,14286.0,H,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,BAO_0000249,B,,CHEMBL617814,1.0,,,,,6.0,,
Autocuration,,3170.0,,,104698.0,14178.0,H,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,BAO_0000019,B,,CHEMBL617698,1.0,,,,,6.0,,
Autocuration,,3171.0,,,104698.0,14178.0,D,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,BAO_0000019,B,,CHEMBL617699,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3172.0,,,104698.0,14178.0,D,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,BAO_0000019,B,,CHEMBL617700,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3173.0,,,104698.0,14178.0,D,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL617701,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3174.0,,,104698.0,15034.0,H,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,BAO_0000019,B,,CHEMBL617702,1.0,,,,,6.0,,
Autocuration,,3175.0,,,104698.0,1089.0,H,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",Membranes,BAO_0000249,B,,CHEMBL617703,1.0,,,,,6.0,,
Autocuration,,3176.0,,,104698.0,1089.0,D,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,BAO_0000019,B,,CHEMBL617704,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3177.0,,,104698.0,16532.0,H,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,BAO_0000223,B,,CHEMBL617705,1.0,,,,,6.0,,
Autocuration,,3178.0,,,104698.0,12801.0,D,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL617706,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3179.0,,,104698.0,15194.0,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,BAO_0000219,B,,CHEMBL617707,1.0,,,,NG108-15,6.0,433.0,
Autocuration,,3180.0,,,104698.0,15194.0,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,BAO_0000219,B,,CHEMBL617708,1.0,,,,NG108-15,6.0,433.0,
Autocuration,,3181.0,,,104698.0,15194.0,H,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,BAO_0000019,B,,CHEMBL617709,1.0,,,,,6.0,,
Autocuration,,3182.0,,,104698.0,15194.0,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,BAO_0000019,B,,CHEMBL617710,1.0,,,,,6.0,,
Autocuration,,3183.0,,,104698.0,15194.0,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,BAO_0000019,B,,CHEMBL882925,1.0,,,,,6.0,,
Autocuration,,3184.0,,,104698.0,15194.0,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,BAO_0000019,B,,CHEMBL617711,1.0,,,,,6.0,,
Autocuration,,3185.0,,,104698.0,10610.0,H,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,BAO_0000019,F,,CHEMBL617712,1.0,,,,,6.0,,
Autocuration,,3186.0,,,104698.0,10355.0,D,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,BAO_0000019,F,,CHEMBL617713,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3187.0,,,104698.0,691.0,H,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,BAO_0000019,F,,CHEMBL617714,1.0,,,,,6.0,,
Autocuration,,3188.0,,,104698.0,10611.0,H,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,BAO_0000218,F,,CHEMBL617715,1.0,,,,,6.0,,
Autocuration,,3189.0,,,104698.0,12801.0,H,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,BAO_0000218,F,In vivo,CHEMBL617716,1.0,,,,,6.0,,
Autocuration,,3190.0,,,104698.0,10609.0,H,,Inhibition of 5-HT evoked reflex bradycardia in rat.,,BAO_0000218,F,,CHEMBL617717,1.0,,,,,6.0,,
Autocuration,,3191.0,,,104698.0,11454.0,H,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617718,1.0,,,,,6.0,,
Autocuration,,3192.0,,,104698.0,11454.0,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617719,1.0,,,,,6.0,,
Autocuration,,3193.0,,,104698.0,11454.0,H,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,BAO_0000218,F,In vivo,CHEMBL617720,1.0,,,,,6.0,,
Autocuration,,3194.0,,,104698.0,11454.0,D,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617721,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3195.0,,,104698.0,11454.0,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617722,1.0,,,,,6.0,,
Autocuration,,3196.0,,,104698.0,11454.0,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,BAO_0000218,F,In vivo,CHEMBL617723,1.0,,,,,6.0,,
Autocuration,,3197.0,,,104698.0,11454.0,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617724,1.0,,,,,6.0,,
Autocuration,,3198.0,,,104698.0,11454.0,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617725,1.0,,,,,6.0,,
Autocuration,,3199.0,,,104698.0,11454.0,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617726,1.0,,,,,6.0,,
Autocuration,,3200.0,,,104698.0,11454.0,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617727,1.0,,,,,6.0,,
Autocuration,,3201.0,,,104698.0,11454.0,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617728,1.0,,,,,6.0,,
Autocuration,,3202.0,,,104698.0,11454.0,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617729,1.0,,,,,6.0,,
Autocuration,,3203.0,,,104698.0,11454.0,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617730,1.0,,,,,6.0,,
Autocuration,,3204.0,,,104698.0,11454.0,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617731,1.0,,,,,6.0,,
Autocuration,,3205.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617732,1.0,,,,,6.0,,
Autocuration,,3206.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617733,1.0,,,,,6.0,,
Autocuration,,3207.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617734,1.0,,,,,6.0,,
Autocuration,,3208.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,BAO_0000218,F,In vivo,CHEMBL872874,1.0,,,,,6.0,,
Autocuration,,3209.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,BAO_0000218,F,In vivo,CHEMBL617735,1.0,,,,,6.0,,
Autocuration,,3210.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,BAO_0000218,F,In vivo,CHEMBL617736,1.0,,,,,6.0,,
Autocuration,,3211.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,BAO_0000218,F,In vivo,CHEMBL617737,1.0,,,,,6.0,,
Autocuration,,3212.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,BAO_0000218,F,In vivo,CHEMBL617738,1.0,,,,,6.0,,
Autocuration,,3213.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617739,1.0,,,,,6.0,,
Autocuration,,3214.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617740,1.0,,,,,6.0,,
Autocuration,,3215.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617741,1.0,,,,,6.0,,
Autocuration,,3216.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617742,1.0,,,,,6.0,,
Autocuration,,3217.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617743,1.0,,,,,6.0,,
Autocuration,,3218.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617744,1.0,,,,,6.0,,
Autocuration,,3219.0,,,104698.0,11454.0,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,F,In vivo,CHEMBL617745,1.0,,,,,6.0,,
Autocuration,,3220.0,,,104698.0,670.0,H,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,BAO_0000218,F,,CHEMBL617746,1.0,,,,,6.0,,
Autocuration,,3221.0,,,104698.0,670.0,H,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,BAO_0000218,F,,CHEMBL617747,1.0,,,,,6.0,,
Autocuration,,3222.0,,,104698.0,10321.0,H,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,BAO_0000218,F,In vivo,CHEMBL617748,1.0,,,,,6.0,,
Autocuration,,3223.0,,,104698.0,10321.0,H,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,BAO_0000218,F,In vivo,CHEMBL618909,1.0,,,,,6.0,,
Autocuration,,3224.0,,,104698.0,10321.0,H,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,BAO_0000218,F,In vivo,CHEMBL618910,1.0,,,,,6.0,,
Autocuration,,3225.0,,,104698.0,10321.0,H,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,BAO_0000218,F,In vivo,CHEMBL618911,1.0,,,,,6.0,,
Autocuration,,3226.0,,,104698.0,10321.0,H,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,BAO_0000218,F,In vivo,CHEMBL618912,1.0,,,,,6.0,,
Autocuration,,3227.0,,,104698.0,10322.0,H,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,BAO_0000218,F,In vivo,CHEMBL618913,1.0,,,,,6.0,,
Autocuration,,3228.0,,,104698.0,15412.0,H,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,BAO_0000019,F,,CHEMBL618914,1.0,,,,,6.0,,
Autocuration,,3229.0,,,104698.0,15412.0,H,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,BAO_0000019,F,,CHEMBL618915,1.0,,,,,6.0,,
Autocuration,,3230.0,,,104698.0,15412.0,D,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL618916,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3231.0,,,104698.0,15412.0,H,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,BAO_0000019,F,,CHEMBL618917,1.0,,,,,6.0,,
Intermediate,Hippocampus,3232.0,,,104698.0,15412.0,D,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,BAO_0000221,B,,CHEMBL618918,1.0,10000000.0,,,,7.0,,
Autocuration,,3233.0,,,104698.0,15412.0,D,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,BAO_0000019,B,,CHEMBL618919,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3234.0,,,104698.0,17394.0,D,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,BAO_0000019,B,,CHEMBL618920,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3235.0,,,104698.0,12457.0,H,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL618921,1.0,,,,,6.0,,
Autocuration,,3236.0,,,104698.0,12457.0,H,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,BAO_0000019,B,,CHEMBL618922,1.0,,,,,6.0,,
Autocuration,,3237.0,,,104698.0,12205.0,H,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,BAO_0000019,B,,CHEMBL618923,1.0,,,,,6.0,,
Autocuration,,3238.0,,,104698.0,14532.0,H,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,BAO_0000019,B,,CHEMBL618924,1.0,,,,,6.0,,
Autocuration,,3239.0,,,104698.0,1122.0,H,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,BAO_0000019,B,,CHEMBL618925,1.0,,,,,6.0,,
Autocuration,,3240.0,,,104698.0,5094.0,H,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,BAO_0000019,B,,CHEMBL618926,1.0,,,,,6.0,,
Intermediate,Ileum,3241.0,,,20033.0,809.0,D,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,BAO_0000221,F,,CHEMBL618927,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3242.0,,,20033.0,809.0,D,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,BAO_0000221,F,,CHEMBL618928,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3243.0,,,20033.0,14290.0,D,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,BAO_0000221,F,,CHEMBL618929,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3244.0,,,20033.0,14290.0,D,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,BAO_0000221,F,,CHEMBL618930,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3245.0,,,20033.0,14290.0,D,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,BAO_0000221,F,,CHEMBL618931,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3246.0,,,20033.0,14290.0,D,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,BAO_0000221,F,,CHEMBL619594,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3247.0,,,20033.0,14290.0,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,BAO_0000221,F,,CHEMBL619595,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3248.0,,,20033.0,13961.0,D,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,BAO_0000221,F,,CHEMBL619596,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3249.0,,,20033.0,13961.0,D,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,BAO_0000221,F,,CHEMBL619755,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3250.0,,,20033.0,809.0,D,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,BAO_0000221,F,,CHEMBL619756,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3251.0,,,20033.0,809.0,D,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,BAO_0000221,F,,CHEMBL619757,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3252.0,,,20033.0,809.0,D,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,BAO_0000221,F,,CHEMBL619758,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3253.0,,,20033.0,14290.0,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,BAO_0000221,F,,CHEMBL619759,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3254.0,,,20033.0,14290.0,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,BAO_0000221,F,,CHEMBL619760,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3255.0,,,20033.0,14290.0,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,BAO_0000221,F,,CHEMBL619761,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3256.0,,,20033.0,14290.0,D,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,BAO_0000221,F,,CHEMBL619762,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3257.0,,,20033.0,14290.0,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,BAO_0000221,F,,CHEMBL619763,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3258.0,,,20033.0,14290.0,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,BAO_0000221,F,,CHEMBL617868,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3259.0,,,20033.0,15034.0,D,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,BAO_0000357,B,,CHEMBL617869,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,Striatum,3260.0,,,20033.0,5094.0,D,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,BAO_0000249,B,,CHEMBL882926,1.0,2435.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Striatum,3261.0,,,20033.0,5094.0,D,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,BAO_0000249,B,,CHEMBL617870,1.0,2435.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Striatum,3262.0,,,20033.0,5399.0,D,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,BAO_0000357,B,,CHEMBL617871,1.0,2435.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Striatum,3263.0,,,20033.0,17394.0,D,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,BAO_0000357,B,,CHEMBL617872,1.0,2435.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Striatum,3264.0,,,20033.0,17394.0,D,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,BAO_0000357,B,,CHEMBL617873,1.0,2435.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Striatum,3265.0,,,20033.0,17394.0,D,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,BAO_0000357,B,,CHEMBL617874,1.0,2435.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3266.0,,,20033.0,13961.0,D,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,BAO_0000221,F,,CHEMBL619067,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3267.0,,,20033.0,13961.0,D,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,BAO_0000221,F,,CHEMBL619068,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3268.0,,,20033.0,13961.0,D,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,BAO_0000221,F,,CHEMBL619069,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3269.0,,,20033.0,16946.0,D,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,BAO_0000357,B,,CHEMBL619070,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3270.0,,,20033.0,16946.0,D,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,BAO_0000357,B,,CHEMBL619071,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3271.0,,,20033.0,15034.0,D,,Agonistic activity against 5-hydroxytryptamine 4 receptor,,BAO_0000019,F,,CHEMBL619072,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3272.0,,,20033.0,15034.0,D,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,BAO_0000019,F,,CHEMBL619073,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3273.0,,,20033.0,12918.0,D,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,BAO_0000019,F,,CHEMBL619074,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3274.0,,,20033.0,16946.0,D,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL619075,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,Striatum,3275.0,,,20033.0,17394.0,D,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL619076,1.0,2435.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Striatum,3276.0,,,20033.0,15034.0,D,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,BAO_0000357,B,,CHEMBL619077,1.0,2435.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Striatum,3277.0,,,20033.0,5094.0,D,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,BAO_0000249,B,,CHEMBL619078,1.0,2435.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Striatum,3278.0,,,20033.0,5094.0,D,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,BAO_0000249,B,,CHEMBL619079,1.0,2435.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3279.0,,,20033.0,17358.0,D,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,BAO_0000221,B,,CHEMBL619080,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Expert,,3280.0,,,20033.0,12953.0,D,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,BAO_0000357,B,,CHEMBL619081,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3281.0,,,20033.0,12953.0,D,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,BAO_0000357,B,,CHEMBL619082,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3282.0,,,20033.0,12953.0,D,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,BAO_0000357,B,,CHEMBL619083,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3283.0,,,20033.0,12953.0,D,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,BAO_0000357,B,,CHEMBL619084,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3284.0,,,20033.0,273.0,D,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,BAO_0000221,F,,CHEMBL859397,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3285.0,,,20033.0,12918.0,D,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,BAO_0000221,F,,CHEMBL619085,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3286.0,,,20033.0,12919.0,D,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,BAO_0000221,F,,CHEMBL619086,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3287.0,,,20033.0,273.0,D,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,BAO_0000221,F,,CHEMBL619087,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3288.0,,,20033.0,273.0,D,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,BAO_0000221,F,,CHEMBL619088,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3289.0,,,20033.0,13181.0,D,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,BAO_0000357,B,,CHEMBL619089,1.0,,,10141.0,,9.0,,Cavia porcellus
Autocuration,,3290.0,,,168.0,13181.0,H,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,BAO_0000357,B,,CHEMBL619090,1.0,,,10141.0,,8.0,,Cavia porcellus
Intermediate,,3291.0,,,20033.0,15034.0,D,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,BAO_0000019,F,,CHEMBL619091,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3292.0,,,20033.0,5033.0,D,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL619092,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3293.0,,,20033.0,1980.0,D,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,BAO_0000019,B,,CHEMBL619093,1.0,,,10141.0,,9.0,,Cavia porcellus
Autocuration,,3294.0,,,168.0,13181.0,H,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,BAO_0000219,B,,CHEMBL619094,1.0,,,10141.0,HEK293,8.0,722.0,Cavia porcellus
Intermediate,,3295.0,,,20033.0,14287.0,D,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,BAO_0000019,B,,CHEMBL619095,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3296.0,,,20033.0,1317.0,D,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,BAO_0000357,B,,CHEMBL857988,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3297.0,,,20033.0,15316.0,D,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,BAO_0000357,B,,CHEMBL619096,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,Striatum,3298.0,,,20033.0,16429.0,D,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,BAO_0000357,B,,CHEMBL619097,1.0,2435.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Hippocampus,3299.0,,,20033.0,14818.0,D,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,BAO_0000221,B,,CHEMBL619098,1.0,10000000.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3300.0,,,20033.0,15194.0,D,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,BAO_0000357,B,,CHEMBL619751,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3301.0,,,20033.0,15194.0,D,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,BAO_0000357,B,,CHEMBL619752,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3302.0,,,20033.0,13961.0,D,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,BAO_0000221,F,,CHEMBL875096,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Autocuration,,3303.0,,,108.0,5486.0,H,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,BAO_0000357,B,,CHEMBL619004,1.0,,,,,8.0,,
Autocuration,,3304.0,,,168.0,16209.0,H,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL619005,1.0,,,,,8.0,,
Autocuration,,3305.0,,,168.0,17085.0,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,BAO_0000019,B,,CHEMBL619006,1.0,,,,,8.0,,
Autocuration,,3306.0,,,168.0,4199.0,H,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,BAO_0000219,B,,CHEMBL619007,1.0,,,,HeLa,8.0,308.0,
Autocuration,,3307.0,,,168.0,15146.0,H,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL619008,1.0,,,,,8.0,,
Autocuration,,3308.0,,,168.0,5213.0,H,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL619009,1.0,,,,,8.0,,
Autocuration,,3309.0,,,168.0,4829.0,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,BAO_0000219,B,,CHEMBL619010,1.0,,,,HeLa,8.0,308.0,
Autocuration,,3310.0,,,10622.0,17358.0,H,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,BAO_0000357,B,,CHEMBL619011,1.0,,,,,8.0,,
Autocuration,,3311.0,,,10622.0,17358.0,H,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,BAO_0000357,B,,CHEMBL619012,1.0,,,,,8.0,,
Autocuration,,3312.0,,,10622.0,16946.0,H,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,BAO_0000219,B,,CHEMBL619013,1.0,,,,,8.0,,
Autocuration,,3313.0,,,10622.0,17358.0,H,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,BAO_0000357,B,,CHEMBL619014,1.0,,,,,8.0,,
Autocuration,Cardiac atrium,3314.0,,,11249.0,268.0,H,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,BAO_0000019,F,,CHEMBL857503,1.0,2081.0,,,,8.0,,
Autocuration,Cardiac atrium,3315.0,,,11249.0,268.0,H,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,BAO_0000019,F,,CHEMBL619015,1.0,2081.0,,,,8.0,,
Autocuration,,3316.0,,,11249.0,15086.0,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL619016,1.0,,,,,8.0,,
Autocuration,Hippocampus,3317.0,,,11249.0,14875.0,H,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,BAO_0000221,B,,CHEMBL619017,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,3318.0,,,168.0,13267.0,H,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,BAO_0000221,B,,CHEMBL619018,1.0,10000000.0,,9823.0,,8.0,,Sus scrofa
Autocuration,,3319.0,,,168.0,13047.0,H,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,BAO_0000019,B,,CHEMBL619019,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Expert,,3320.0,,,10623.0,1650.0,D,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL619020,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,3321.0,,,10623.0,567.0,H,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,BAO_0000019,F,,CHEMBL619021,1.0,,,,,8.0,,
Autocuration,,3322.0,,,10623.0,17358.0,H,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,BAO_0000357,B,,CHEMBL619022,1.0,,,,,8.0,,
Autocuration,,3323.0,,,10623.0,188.0,H,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,BAO_0000357,B,,CHEMBL619023,1.0,,,,,8.0,,
Autocuration,,3324.0,,,10623.0,670.0,H,,lntrinsic activity relative to 5-HT receptor,,BAO_0000019,F,,CHEMBL619024,1.0,,,,,8.0,,
Autocuration,,3325.0,,,10623.0,204.0,H,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,BAO_0000019,F,,CHEMBL619025,1.0,,,,,8.0,,
Expert,,3326.0,,,10623.0,1946.0,H,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,BAO_0000019,F,,CHEMBL619026,1.0,,,,,8.0,,
Autocuration,,3327.0,,,10623.0,6398.0,H,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,BAO_0000019,F,,CHEMBL619027,1.0,,,,,8.0,,
Autocuration,,3328.0,,,10623.0,6398.0,H,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,BAO_0000019,F,,CHEMBL619028,1.0,,,,,8.0,,
Autocuration,,3329.0,,,10623.0,17358.0,H,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,BAO_0000019,F,,CHEMBL619029,1.0,,,,,8.0,,
Autocuration,,3330.0,,,10623.0,6398.0,H,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,BAO_0000019,F,,CHEMBL619030,1.0,,,,,8.0,,
Expert,,3331.0,,,10623.0,11752.0,H,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,BAO_0000357,B,,CHEMBL619031,1.0,,,,,8.0,,
Autocuration,,3332.0,,,10623.0,809.0,H,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,BAO_0000019,F,,CHEMBL619032,1.0,,,,,8.0,,
Expert,,3333.0,,,10623.0,14178.0,D,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL619033,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,3334.0,,,10623.0,567.0,H,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,BAO_0000357,B,,CHEMBL619034,1.0,,,,,8.0,,
Autocuration,,3335.0,,,10623.0,1946.0,H,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,BAO_0000357,B,,CHEMBL619035,1.0,,,,,8.0,,
Autocuration,,3336.0,,,10623.0,1946.0,H,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,BAO_0000357,B,,CHEMBL619036,1.0,,,,,8.0,,
Expert,,3337.0,,,10623.0,13961.0,D,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,BAO_0000019,B,,CHEMBL619037,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Striatum,3338.0,,,10623.0,6238.0,H,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,BAO_0000249,B,,CHEMBL619038,1.0,2435.0,,,,8.0,,
Autocuration,,3339.0,,,10623.0,14290.0,H,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,BAO_0000249,B,,CHEMBL619039,1.0,,,,,8.0,,
Expert,,3340.0,,,10623.0,14290.0,H,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,BAO_0000249,B,,CHEMBL619040,1.0,,,,,8.0,,
Expert,Striatum,3341.0,,,10623.0,809.0,D,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,BAO_0000019,B,,CHEMBL619041,1.0,2435.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,Striatum,3342.0,,,10623.0,1578.0,H,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,BAO_0000019,B,,CHEMBL619042,1.0,2435.0,,,,8.0,,
Expert,Striatum,3343.0,,,10623.0,16709.0,H,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,BAO_0000249,B,,CHEMBL619043,1.0,2435.0,,,,8.0,,
Expert,Striatum,3344.0,,,10623.0,1946.0,H,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,BAO_0000019,B,,CHEMBL619044,1.0,2435.0,,,,8.0,,
Expert,Striatum,3345.0,,,10623.0,15253.0,H,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,BAO_0000249,B,,CHEMBL619045,1.0,2435.0,,,,8.0,,
Expert,Striatum,3346.0,,,10623.0,4535.0,H,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,BAO_0000249,B,,CHEMBL619046,1.0,2435.0,,,,8.0,,
Expert,,3347.0,,,10623.0,13961.0,H,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,BAO_0000249,B,,CHEMBL619047,1.0,,,,,8.0,,
Autocuration,Brain,3348.0,,,10623.0,17358.0,H,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,BAO_0000221,F,,CHEMBL619048,1.0,955.0,,,,8.0,,
Autocuration,,3349.0,,,10623.0,15847.0,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,BAO_0000019,F,,CHEMBL859398,1.0,,,,,8.0,,
Autocuration,,3350.0,,,10623.0,15847.0,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,BAO_0000019,F,,CHEMBL619049,1.0,,,,,8.0,,
Autocuration,,3351.0,,,10623.0,670.0,H,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,BAO_0000019,F,,CHEMBL857886,1.0,,,,,8.0,,
Autocuration,,3352.0,,,10623.0,670.0,H,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,BAO_0000019,F,,CHEMBL619050,1.0,,,,,8.0,,
Autocuration,,3353.0,,,10623.0,1317.0,H,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,BAO_0000019,F,,CHEMBL620591,1.0,,,,,8.0,,
Expert,,3354.0,,,10623.0,12936.0,D,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL620592,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,Striatum,3355.0,,,10623.0,4535.0,H,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,BAO_0000249,B,,CHEMBL620593,1.0,2435.0,,,,8.0,,
Expert,,3356.0,,,10623.0,14424.0,D,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,BAO_0000019,F,,CHEMBL620594,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,3357.0,,,10623.0,14424.0,H,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,BAO_0000019,F,,CHEMBL875079,1.0,,,,,8.0,,
Expert,,3358.0,,,10623.0,14424.0,H,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,BAO_0000019,F,,CHEMBL620595,1.0,,,,,8.0,,
Expert,,3359.0,,,10623.0,14424.0,D,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,BAO_0000019,F,,CHEMBL620596,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,3360.0,,,10623.0,14424.0,H,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,BAO_0000019,F,,CHEMBL620597,1.0,,,,,8.0,,
Expert,,3361.0,,,10623.0,14424.0,H,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,BAO_0000019,F,,CHEMBL620598,1.0,,,,,8.0,,
Expert,,3362.0,,,10623.0,14424.0,H,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,BAO_0000218,F,,CHEMBL620599,1.0,,,,,8.0,,
Autocuration,,3363.0,,,10623.0,14424.0,H,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,BAO_0000019,F,,CHEMBL620600,1.0,,,,,8.0,,
Autocuration,,3364.0,,,168.0,1980.0,H,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,BAO_0000019,F,,CHEMBL620601,1.0,,,10116.0,,8.0,,Rattus norvegicus
Autocuration,,3365.0,,,168.0,4639.0,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,BAO_0000019,F,,CHEMBL620602,1.0,,,,,8.0,,
Autocuration,,3366.0,,,168.0,17358.0,H,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL620603,1.0,,,,,8.0,,
Autocuration,,3367.0,,,168.0,17358.0,H,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,BAO_0000357,B,,CHEMBL620604,1.0,,,,,8.0,,
Autocuration,,3368.0,,,168.0,17358.0,H,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,BAO_0000357,B,,CHEMBL620605,1.0,,,,,8.0,,
Autocuration,,3369.0,,,168.0,1558.0,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL620606,1.0,,,,,8.0,,
Autocuration,,3370.0,,,168.0,17358.0,H,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,BAO_0000019,F,,CHEMBL620607,1.0,,,,,8.0,,
Autocuration,,3371.0,,,168.0,16117.0,H,,In vitro binding affinity towards 5-HT4 receptor was determined,,BAO_0000357,B,,CHEMBL620608,1.0,,,,,8.0,,
Autocuration,,3372.0,,,168.0,17358.0,H,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,BAO_0000019,F,,CHEMBL620609,1.0,,,,,8.0,,
Autocuration,,3373.0,,,168.0,17358.0,H,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,BAO_0000019,F,,CHEMBL620610,1.0,,,,,8.0,,
Autocuration,,3374.0,,,168.0,17358.0,H,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL620611,1.0,,,,,8.0,,
Autocuration,,3375.0,,,168.0,17358.0,H,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,BAO_0000357,B,,CHEMBL620612,1.0,,,,,8.0,,
Autocuration,,3376.0,,,168.0,17358.0,H,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,BAO_0000357,B,,CHEMBL620613,1.0,,,,,8.0,,
Autocuration,,3377.0,,,168.0,17358.0,H,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,BAO_0000357,B,,CHEMBL620614,1.0,,,,,8.0,,
Expert,,3378.0,,,168.0,1274.0,H,,Binding affinity against 5-Hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL620615,1.0,,,,,8.0,,
Autocuration,,3379.0,,,104698.0,10728.0,H,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,Brain membranes,BAO_0000249,B,,CHEMBL857075,1.0,,,,,6.0,,
Autocuration,,3380.0,,,104698.0,11695.0,H,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,Brain membranes,BAO_0000249,B,,CHEMBL620616,1.0,,,,,6.0,,
Autocuration,,3381.0,,,104698.0,11695.0,H,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,Brain membranes,BAO_0000249,B,,CHEMBL619411,1.0,,,,,6.0,,
Autocuration,,3382.0,,,104698.0,12490.0,H,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,BAO_0000019,B,,CHEMBL619412,1.0,,,,,6.0,,
Autocuration,,3383.0,,,104698.0,11828.0,D,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,BAO_0000019,B,,CHEMBL619413,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,Hippocampus,3384.0,,,104698.0,12253.0,H,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,BAO_0000221,B,,CHEMBL619414,1.0,10000000.0,,,,6.0,,
Autocuration,,3385.0,,,104698.0,10561.0,H,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,BAO_0000019,B,,CHEMBL619415,1.0,,,,,6.0,,
Autocuration,,3386.0,,,104698.0,10561.0,H,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,BAO_0000019,B,,CHEMBL619416,1.0,,,,,6.0,,
Autocuration,,3387.0,,,104698.0,14432.0,H,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,BAO_0000019,F,,CHEMBL619417,1.0,,,,,6.0,,
Autocuration,,3388.0,,,104698.0,12936.0,D,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL619418,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3389.0,,,104698.0,1274.0,D,,Binding affinity against 5-Hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL619419,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3390.0,,,104698.0,1980.0,H,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,BAO_0000019,B,,CHEMBL619420,1.0,,,,,6.0,,
Autocuration,,3391.0,,,104698.0,670.0,H,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,BAO_0000249,B,,CHEMBL619421,1.0,,,,,6.0,,
Autocuration,,3392.0,,,104698.0,968.0,D,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,BAO_0000019,B,,CHEMBL619422,1.0,,,10116.0,,7.0,,Rattus norvegicus
Autocuration,,3393.0,,,104698.0,14287.0,H,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,BAO_0000019,B,,CHEMBL619423,1.0,,,,,6.0,,
Autocuration,,3394.0,,,104698.0,567.0,H,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,BAO_0000019,B,,CHEMBL875080,1.0,,,,,6.0,,
Autocuration,,3395.0,,,104698.0,13267.0,H,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,BAO_0000019,B,,CHEMBL619424,1.0,,,,,6.0,,
Autocuration,,3396.0,,,104698.0,14826.0,H,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,BAO_0000249,B,,CHEMBL619425,1.0,,,,,6.0,,
Autocuration,,3397.0,,,104698.0,15194.0,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,BAO_0000223,B,,CHEMBL619426,1.0,,,,,6.0,,
Autocuration,,3398.0,,,104698.0,15194.0,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,BAO_0000223,B,,CHEMBL619427,1.0,,,,,6.0,,
Autocuration,,3399.0,,,104698.0,10394.0,D,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL619645,1.0,,,10116.0,,7.0,,Rattus norvegicus
Expert,,3400.0,,,10576.0,13657.0,D,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,BAO_0000249,B,,CHEMBL619646,1.0,,,,,9.0,,
Autocuration,Brain,3401.0,,,12020.0,1879.0,H,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,BAO_0000221,F,,CHEMBL619647,1.0,955.0,,,,8.0,,
Autocuration,,3402.0,,,12020.0,1879.0,H,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,BAO_0000019,F,,CHEMBL619648,1.0,,,,,8.0,,
Autocuration,,3403.0,,,12020.0,1879.0,H,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,BAO_0000019,F,,CHEMBL619165,1.0,,,,,8.0,,
Autocuration,,3404.0,,,12020.0,204.0,H,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,BAO_0000218,F,In vivo,CHEMBL620719,1.0,,,,,8.0,,
Autocuration,,3405.0,,,12020.0,1879.0,H,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,BAO_0000019,B,,CHEMBL872924,1.0,,,,,8.0,,
Autocuration,,3406.0,,,12020.0,1879.0,H,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,B,,CHEMBL620720,1.0,,,,,8.0,,
Autocuration,,3407.0,,,12020.0,1879.0,H,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,BAO_0000019,B,,CHEMBL620721,1.0,,,,,8.0,,
Autocuration,,3408.0,,,12020.0,1879.0,H,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,BAO_0000019,B,,CHEMBL620722,1.0,,,,,8.0,,
Autocuration,,3409.0,,,104698.0,10641.0,H,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,BAO_0000019,B,,CHEMBL620723,1.0,,,,,6.0,,
Autocuration,,3410.0,,,12020.0,773.0,H,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,BAO_0000019,B,,CHEMBL620724,1.0,,,,,8.0,,
Autocuration,,3411.0,,,104698.0,11952.0,H,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,BAO_0000249,B,,CHEMBL620725,1.0,,,,,6.0,,
Autocuration,,3412.0,,,12020.0,14145.0,D,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,BAO_0000019,F,,CHEMBL620726,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,3413.0,,,144.0,17066.0,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,B,,CHEMBL620727,1.0,,,,,8.0,,
Autocuration,,3414.0,,,104714.0,6398.0,H,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,BAO_0000223,B,,CHEMBL620728,1.0,,,,,4.0,,
Autocuration,,3415.0,,,22226.0,10321.0,U,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,BAO_0000019,B,,CHEMBL620729,1.0,,,,,0.0,,
Autocuration,,3416.0,,,104714.0,511.0,H,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,BAO_0000019,F,,CHEMBL858288,1.0,,,,,4.0,,
Autocuration,,3417.0,,,104714.0,4639.0,H,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL620730,1.0,,,,,4.0,,
Autocuration,,3418.0,,,104714.0,4639.0,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL620731,1.0,,,,,4.0,,
Autocuration,,3419.0,,,104714.0,4639.0,H,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,BAO_0000019,F,,CHEMBL620732,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3420.0,,,104714.0,4639.0,H,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,BAO_0000019,F,,CHEMBL618042,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3421.0,,,104714.0,4639.0,H,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,BAO_0000019,F,,CHEMBL618043,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3422.0,,,104714.0,1558.0,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL618044,1.0,,,,,4.0,,
Autocuration,,3423.0,,,104714.0,268.0,H,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,BAO_0000019,F,,CHEMBL618045,1.0,,,,,4.0,,
Autocuration,,3424.0,,,104714.0,2474.0,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,BAO_0000223,B,,CHEMBL618046,1.0,,,,,4.0,,
Autocuration,,3425.0,,,104714.0,5067.0,H,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,BAO_0000019,F,,CHEMBL618047,1.0,,,,,4.0,,
Autocuration,,3426.0,,,104714.0,5067.0,H,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,BAO_0000019,F,,CHEMBL875084,1.0,,,,,4.0,,
Autocuration,,3427.0,,,104714.0,5067.0,H,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,BAO_0000019,F,,CHEMBL618048,1.0,,,,,4.0,,
Autocuration,,3428.0,,,104714.0,5067.0,H,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,BAO_0000223,B,,CHEMBL618049,1.0,,,,,4.0,,
Autocuration,,3429.0,,,104714.0,5067.0,H,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,BAO_0000019,F,,CHEMBL619764,1.0,,,,,4.0,,
Autocuration,,3430.0,,,104714.0,5067.0,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,BAO_0000019,F,,CHEMBL619765,1.0,,,,,4.0,,
Autocuration,,3431.0,,,104714.0,5067.0,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,BAO_0000019,F,,CHEMBL619766,1.0,,,,,4.0,,
Autocuration,,3432.0,,,104714.0,5067.0,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,BAO_0000223,B,,CHEMBL619767,1.0,,,,,4.0,,
Autocuration,,3433.0,,,104714.0,5067.0,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,BAO_0000223,B,,CHEMBL619768,1.0,,,,,4.0,,
Autocuration,,3434.0,,,104714.0,5067.0,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,BAO_0000019,F,,CHEMBL619769,1.0,,,,,4.0,,
Autocuration,,3435.0,,,104714.0,5067.0,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,BAO_0000223,B,,CHEMBL619770,1.0,,,,,4.0,,
Autocuration,,3436.0,,,104714.0,5067.0,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL619771,1.0,,,,,4.0,,
Autocuration,,3437.0,,,104714.0,14331.0,H,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,BAO_0000219,B,,CHEMBL619772,1.0,,,,,4.0,,
Autocuration,,3438.0,,,104714.0,5067.0,H,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,BAO_0000223,B,,CHEMBL619773,1.0,,,,,4.0,,
Autocuration,,3439.0,,,104714.0,6179.0,H,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,BAO_0000219,B,,CHEMBL619774,1.0,,,,NG108-15,4.0,433.0,
Autocuration,,3440.0,,,104714.0,4265.0,H,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,BAO_0000019,B,,CHEMBL875083,1.0,,,,,4.0,,
Autocuration,,3441.0,,,104714.0,4265.0,H,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,BAO_0000219,B,,CHEMBL620718,1.0,,,,NG108-15,4.0,433.0,
Autocuration,,3442.0,,,104714.0,17358.0,H,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,BAO_0000223,B,,CHEMBL618127,1.0,,,,,4.0,,
Autocuration,,3443.0,,,104714.0,17358.0,H,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,BAO_0000223,B,,CHEMBL618128,1.0,,,,,4.0,,
Autocuration,,3444.0,,,104714.0,13628.0,H,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,BAO_0000219,B,In vitro,CHEMBL618129,1.0,,,,,4.0,,
Autocuration,,3445.0,,,104714.0,4612.0,H,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,BAO_0000223,B,,CHEMBL618130,1.0,,,,,4.0,,
Autocuration,,3446.0,,,104714.0,17358.0,H,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,BAO_0000019,F,,CHEMBL618131,1.0,,,,,4.0,,
Autocuration,,3447.0,,,104714.0,4639.0,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,BAO_0000019,F,,CHEMBL618132,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3448.0,,,104714.0,4639.0,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,BAO_0000019,F,,CHEMBL618133,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3449.0,,,104714.0,4639.0,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,BAO_0000019,F,,CHEMBL618134,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3450.0,,,104714.0,4639.0,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,BAO_0000019,F,,CHEMBL618135,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3451.0,,,104714.0,511.0,H,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,BAO_0000223,B,,CHEMBL618136,1.0,,,,,4.0,,
Autocuration,,3452.0,,,104714.0,1479.0,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL618137,1.0,,,,,4.0,,
Autocuration,,3453.0,,,104714.0,1317.0,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,BAO_0000223,B,,CHEMBL618138,1.0,,,,,4.0,,
Autocuration,,3454.0,,,104714.0,12146.0,H,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,BAO_0000223,B,,CHEMBL618139,1.0,,,,,4.0,,
Autocuration,,3455.0,,,104714.0,12146.0,H,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,BAO_0000223,B,,CHEMBL618140,1.0,,,,,4.0,,
Autocuration,,3456.0,,,104714.0,13969.0,H,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,BAO_0000223,B,,CHEMBL618141,1.0,,,,,4.0,,
Expert,,3457.0,,,108.0,13392.0,H,,Binding affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,B,,CHEMBL873478,1.0,,,,,8.0,,
Autocuration,,3458.0,,,104698.0,13392.0,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL618142,1.0,,,,,6.0,,
Autocuration,,3459.0,,,144.0,14159.0,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,BAO_0000357,B,,CHEMBL618143,1.0,,,,,8.0,,
Autocuration,,3460.0,,,144.0,1558.0,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,B,,CHEMBL618144,1.0,,,,,8.0,,
Autocuration,,3461.0,,,144.0,16655.0,H,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,BAO_0000357,B,,CHEMBL618145,1.0,,,,,8.0,,
Autocuration,,3462.0,,,104714.0,13020.0,H,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,BAO_0000223,B,,CHEMBL618146,1.0,,,,,4.0,,
Autocuration,,3463.0,,,104714.0,13021.0,H,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,BAO_0000223,B,,CHEMBL618147,1.0,,,,,4.0,,
Autocuration,,3464.0,,,104714.0,13020.0,H,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,BAO_0000223,B,,CHEMBL618148,1.0,,,,,4.0,,
Autocuration,,3465.0,,,144.0,10321.0,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,BAO_0000019,B,,CHEMBL618149,1.0,,,,,8.0,,
Autocuration,,3466.0,,,144.0,15818.0,H,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,B,,CHEMBL872927,1.0,,,,,8.0,,
Autocuration,,3467.0,,,144.0,15818.0,H,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,B,,CHEMBL618150,1.0,,,,,8.0,,
Autocuration,,3468.0,,,144.0,17358.0,H,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,BAO_0000357,B,,CHEMBL618151,1.0,,,,,8.0,,
Autocuration,,3469.0,,,144.0,2222.0,H,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,BAO_0000357,B,,CHEMBL875094,1.0,,,,,8.0,,
Autocuration,,3470.0,,,144.0,10322.0,H,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,BAO_0000019,B,,CHEMBL618152,1.0,,,,,8.0,,
Autocuration,,3471.0,,,144.0,16117.0,H,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,BAO_0000357,B,,CHEMBL618153,1.0,,,,,8.0,,
Autocuration,,3472.0,,,144.0,17200.0,H,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,BAO_0000357,B,,CHEMBL618888,1.0,,,,,8.0,,
Autocuration,,3473.0,,,144.0,17358.0,H,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,BAO_0000019,F,,CHEMBL618889,1.0,,,,,8.0,,
Autocuration,,3474.0,,,144.0,16700.0,H,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,BAO_0000357,B,,CHEMBL618890,1.0,,,,,8.0,,
Autocuration,,3475.0,,,144.0,1980.0,H,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,BAO_0000019,B,,CHEMBL618891,1.0,,,,,8.0,,
Autocuration,,3476.0,,,144.0,1980.0,H,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,BAO_0000019,B,,CHEMBL619054,1.0,,,,,8.0,,
Autocuration,,3477.0,,,104714.0,12409.0,H,,Binding affinity against the 5-hydroxytryptamine 3 receptor,,BAO_0000223,B,,CHEMBL619055,1.0,,,,,4.0,,
Autocuration,,3478.0,,,144.0,4365.0,H,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,BAO_0000357,B,,CHEMBL619056,1.0,,,,,8.0,,
Autocuration,,3479.0,,,144.0,4365.0,H,,Percent efficacy against 5-hydroxytryptamine 3A receptor,,BAO_0000019,F,,CHEMBL619057,1.0,,,,,8.0,,
Autocuration,,3480.0,,,144.0,4365.0,H,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,BAO_0000357,B,,CHEMBL619058,1.0,,,,,8.0,,
Expert,,3481.0,,,12020.0,6769.0,D,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,BAO_0000219,F,,CHEMBL619059,1.0,,,10116.0,Oocytes,9.0,,Rattus norvegicus
Expert,,3482.0,,,12020.0,6769.0,D,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,BAO_0000219,F,,CHEMBL619060,1.0,,,10116.0,Oocytes,9.0,,Rattus norvegicus
Expert,,3483.0,,,12020.0,6769.0,D,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,BAO_0000219,F,,CHEMBL875095,1.0,,,10116.0,Oocytes,9.0,,Rattus norvegicus
Intermediate,Ileum,3484.0,,,20033.0,809.0,D,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,BAO_0000221,F,,CHEMBL619061,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3485.0,,,20033.0,809.0,D,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,BAO_0000221,F,,CHEMBL619062,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3486.0,,,20033.0,14290.0,D,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,BAO_0000019,F,,CHEMBL619063,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3487.0,,,20033.0,17358.0,D,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,BAO_0000221,B,,CHEMBL619064,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Intermediate,,3488.0,,,20033.0,17358.0,D,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,BAO_0000357,B,,CHEMBL619065,1.0,,,10141.0,,9.0,,Cavia porcellus
Intermediate,Ileum,3489.0,,,20033.0,17358.0,D,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,BAO_0000221,B,,CHEMBL619066,1.0,2116.0,,10141.0,,9.0,,Cavia porcellus
Autocuration,Ileum,3490.0,,,10209.0,17386.0,H,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,BAO_0000221,B,,CHEMBL619775,1.0,2116.0,,,,8.0,,
Autocuration,,3491.0,,,10209.0,3269.0,H,,Affinity against 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL619776,1.0,,,,,8.0,,
Autocuration,,3492.0,,,104841.0,7721.0,H,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,BAO_0000224,B,,CHEMBL619777,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3493.0,,,104841.0,7721.0,H,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,BAO_0000224,B,,CHEMBL619778,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,Ileum,3494.0,,,104841.0,9117.0,H,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,BAO_0000221,B,,CHEMBL619779,1.0,2116.0,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3495.0,,,104841.0,7721.0,H,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,BAO_0000224,B,,CHEMBL619780,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3496.0,,,104841.0,7721.0,H,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,BAO_0000224,B,,CHEMBL619166,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3497.0,,,104841.0,15796.0,H,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,BAO_0000019,F,,CHEMBL619167,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3498.0,,,104841.0,15796.0,H,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,BAO_0000019,F,,CHEMBL619168,1.0,,,10141.0,,4.0,,Cavia porcellus
Expert,Cardiac atrium,3499.0,,,168.0,15650.0,D,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,BAO_0000219,B,,CHEMBL619169,1.0,2081.0,,9606.0,,9.0,,Homo sapiens
Expert,Cardiac atrium,3500.0,,,168.0,15650.0,D,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,BAO_0000219,B,,CHEMBL619170,1.0,2081.0,,9606.0,,9.0,,Homo sapiens
Autocuration,,3501.0,,,104841.0,6866.0,D,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,BAO_0000019,F,,CHEMBL619171,1.0,,,9606.0,,5.0,,Homo sapiens
Expert,Cardiac atrium,3502.0,,,168.0,15650.0,D,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,BAO_0000219,F,,CHEMBL619172,1.0,2081.0,,9606.0,,9.0,,Homo sapiens
Autocuration,,3503.0,,,22226.0,10063.0,U,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,BAO_0000019,B,,CHEMBL619173,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,3504.0,,,22226.0,12665.0,U,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,BAO_0000019,B,,CHEMBL619174,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,3505.0,,,104705.0,7504.0,H,,5-hydroxytryptamine receptor binding affinity was determined in rats,,BAO_0000019,B,,CHEMBL619175,1.0,,,,,4.0,,
Autocuration,,3506.0,,,104705.0,7504.0,H,,Binding affinity at rat 5-hydroxytryptamine receptor.,,BAO_0000224,B,,CHEMBL619176,1.0,,,,,4.0,,
Autocuration,,3507.0,,,104705.0,7038.0,H,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,BAO_0000019,B,,CHEMBL619177,1.0,,,,,4.0,,
Autocuration,,3508.0,,,104705.0,7626.0,H,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,BAO_0000224,B,,CHEMBL619178,1.0,,,,,4.0,,
Autocuration,,3509.0,,,104705.0,7626.0,H,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,BAO_0000224,B,,CHEMBL619179,1.0,,,,,4.0,,
Autocuration,Stomach,3510.0,,,104705.0,7185.0,H,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,BAO_0000019,F,,CHEMBL619180,1.0,945.0,,,,4.0,,
Autocuration,Stomach,3511.0,,,104705.0,7185.0,H,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,BAO_0000019,F,,CHEMBL619181,1.0,945.0,,,,4.0,,
Autocuration,,3512.0,,,104705.0,7185.0,H,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,BAO_0000019,F,,CHEMBL619182,1.0,,,,,4.0,,
Autocuration,,3513.0,,,104705.0,6960.0,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,BAO_0000224,B,,CHEMBL619183,1.0,,,,,4.0,,
Autocuration,,3514.0,,,104705.0,6960.0,H,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,BAO_0000224,B,,CHEMBL619184,1.0,,,,,4.0,,
Autocuration,Hippocampus,3515.0,,,10576.0,12416.0,H,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,BAO_0000221,B,,CHEMBL619185,1.0,10000000.0,,,,8.0,,
Expert,,3516.0,,,12198.0,15753.0,H,,Binding affinity for rat 5-hydroxytryptamine transporter.,,BAO_0000357,B,,CHEMBL619186,1.0,,,,,8.0,,
Autocuration,,3517.0,,,104705.0,8062.0,H,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,BAO_0000019,B,,CHEMBL619187,1.0,,,,,4.0,,
Autocuration,,3518.0,,,104705.0,9036.0,D,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,BAO_0000019,B,,CHEMBL619188,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,3519.0,,,104705.0,15067.0,D,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,BAO_0000224,B,,CHEMBL619189,1.0,,,10116.0,,5.0,,Rattus norvegicus
Expert,Brain,3520.0,,,12198.0,15753.0,D,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,BAO_0000019,F,,CHEMBL619190,1.0,955.0,,10116.0,,9.0,,Rattus norvegicus
Expert,Cerebellum,3521.0,,,12198.0,15753.0,D,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,BAO_0000221,F,,CHEMBL619191,1.0,2037.0,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,3522.0,,,104705.0,15295.0,D,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,BAO_0000019,B,,CHEMBL619192,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,3523.0,,,104705.0,6347.0,D,,Percent binding affinity against 5-hydroxytryptamine receptor,,BAO_0000224,B,,CHEMBL619193,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,3524.0,,,22226.0,6763.0,U,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,BAO_0000019,B,,CHEMBL619194,1.0,,,,,0.0,,
Autocuration,,3525.0,,,104705.0,12092.0,D,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,BAO_0000224,B,,CHEMBL619195,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,,3526.0,,,104705.0,1579.0,D,,Affinity against 5-hydroxytryptamine receptor was determined,,BAO_0000224,B,,CHEMBL619196,1.0,,,10116.0,,5.0,,Rattus norvegicus
Autocuration,Stomach,3527.0,,,104705.0,1579.0,D,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,BAO_0000019,B,,CHEMBL619197,1.0,945.0,,10116.0,,5.0,,Rattus norvegicus
Expert,,3528.0,,,121.0,5963.0,D,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,BAO_0000219,B,In vitro,CHEMBL619198,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3529.0,,,121.0,5963.0,D,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,BAO_0000219,B,In vitro,CHEMBL875081,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,3530.0,,,18065.0,5030.0,H,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,BAO_0000357,B,,CHEMBL884712,1.0,,,,,8.0,,
Expert,,3531.0,,,121.0,15796.0,H,,Inhibition of 5-hydroxytryptamine reuptake,,BAO_0000357,B,,CHEMBL884710,1.0,,,,,8.0,,
Autocuration,,3532.0,,,18065.0,15413.0,H,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,BAO_0000019,F,,CHEMBL619199,1.0,,,,,8.0,,
Autocuration,,3533.0,,,18065.0,15413.0,H,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,BAO_0000019,F,,CHEMBL619200,1.0,,,,,8.0,,
Autocuration,,3534.0,,,18065.0,15413.0,H,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,BAO_0000019,F,,CHEMBL619201,1.0,,,,,8.0,,
Autocuration,,3535.0,,,18065.0,12409.0,H,,Tested for 5-hydroxytryptamine receptor uptake,,BAO_0000019,F,,CHEMBL619202,1.0,,,,,8.0,,
Expert,,3536.0,,,51.0,16909.0,D,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,BAO_0000219,B,,CHEMBL619203,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Expert,,3537.0,,,51.0,16909.0,D,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,BAO_0000019,F,,CHEMBL619204,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,3538.0,,,10576.0,15629.0,H,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,BAO_0000249,B,,CHEMBL619205,1.0,,,9606.0,,8.0,,Homo sapiens
Autocuration,,3539.0,,,10576.0,15629.0,H,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,BAO_0000357,B,,CHEMBL619206,1.0,,,,,8.0,,
Expert,,3540.0,,,10576.0,15629.0,H,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,BAO_0000249,B,,CHEMBL619207,1.0,,,,,8.0,,
Autocuration,Striatum,3541.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,BAO_0000019,F,,CHEMBL619208,1.0,2435.0,,,,8.0,,
Autocuration,Striatum,3542.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,BAO_0000019,F,,CHEMBL619209,1.0,2435.0,,,,8.0,,
Autocuration,Striatum,3543.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,BAO_0000019,F,,CHEMBL619210,1.0,2435.0,,,,8.0,,
Autocuration,Striatum,3544.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,BAO_0000019,F,,CHEMBL619211,1.0,2435.0,,,,8.0,,
Autocuration,Striatum,3545.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,BAO_0000019,F,,CHEMBL619212,1.0,2435.0,,,,8.0,,
Autocuration,Striatum,3546.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,BAO_0000019,F,,CHEMBL620681,1.0,2435.0,,,,8.0,,
Autocuration,Striatum,3547.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,BAO_0000019,F,,CHEMBL620682,1.0,2435.0,,,,8.0,,
Autocuration,Striatum,3548.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,BAO_0000019,F,,CHEMBL620683,1.0,2435.0,,,,8.0,,
Autocuration,Striatum,3549.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,BAO_0000019,F,,CHEMBL620684,1.0,2435.0,,,,8.0,,
Autocuration,Striatum,3550.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,BAO_0000019,F,,CHEMBL620685,1.0,2435.0,,,,8.0,,
Autocuration,Striatum,3551.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,BAO_0000019,F,,CHEMBL620686,1.0,2435.0,,,,8.0,,
Autocuration,Limbic system,3552.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,BAO_0000019,F,,CHEMBL620687,1.0,349.0,,,,8.0,,
Autocuration,Limbic system,3553.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,BAO_0000019,F,,CHEMBL620688,1.0,349.0,,,,8.0,,
Autocuration,Limbic system,3554.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,BAO_0000019,F,,CHEMBL620689,1.0,349.0,,,,8.0,,
Autocuration,Limbic system,3555.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,BAO_0000019,F,,CHEMBL620690,1.0,349.0,,,,8.0,,
Autocuration,Limbic system,3556.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,BAO_0000019,F,,CHEMBL620691,1.0,349.0,,,,8.0,,
Autocuration,Limbic system,3557.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,BAO_0000019,F,,CHEMBL620692,1.0,349.0,,,,8.0,,
Autocuration,Limbic system,3558.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,BAO_0000019,F,,CHEMBL620693,1.0,349.0,,,,8.0,,
Expert,,3559.0,,,168.0,1274.0,H,,Binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL620694,1.0,,,,,8.0,,
Autocuration,,3560.0,,,168.0,17358.0,H,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,BAO_0000019,F,,CHEMBL857986,1.0,,,,,8.0,,
Autocuration,,3561.0,,,168.0,14532.0,H,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,BAO_0000357,B,,CHEMBL620695,1.0,,,,,8.0,,
Expert,,3562.0,,,168.0,16989.0,H,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL620696,1.0,,,,,8.0,,
Autocuration,,3563.0,,,168.0,17200.0,H,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,BAO_0000357,B,,CHEMBL620697,1.0,,,,,8.0,,
Autocuration,,3564.0,,,168.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 4 receptor,,BAO_0000357,B,,CHEMBL620698,1.0,,,,,8.0,,
Autocuration,,3565.0,,,168.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,BAO_0000357,B,,CHEMBL620699,1.0,,,,,8.0,,
Autocuration,,3566.0,,,168.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,BAO_0000357,B,,CHEMBL620700,1.0,,,,,8.0,,
Autocuration,,3567.0,,,168.0,15650.0,H,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,BAO_0000219,B,,CHEMBL620701,1.0,,,,COS-7,8.0,643.0,
Autocuration,,3568.0,,,168.0,15650.0,H,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,BAO_0000219,B,,CHEMBL875082,1.0,,,,COS-7,8.0,643.0,
Autocuration,,3569.0,,,168.0,15650.0,H,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,BAO_0000219,B,,CHEMBL620702,1.0,,,,COS-7,8.0,643.0,
Autocuration,,3570.0,,,168.0,15650.0,H,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,BAO_0000219,B,,CHEMBL620703,1.0,,,,COS-7,8.0,643.0,
Autocuration,,3571.0,,,168.0,17046.0,H,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,BAO_0000219,B,,CHEMBL620704,1.0,,,,C6,8.0,673.0,
Expert,,3572.0,,,168.0,17046.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,BAO_0000219,B,,CHEMBL620705,1.0,,,,C6,8.0,673.0,
Expert,,3573.0,,,168.0,15650.0,H,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,BAO_0000219,B,,CHEMBL620706,1.0,,,,C6,8.0,673.0,
Expert,,3574.0,,,168.0,17046.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,BAO_0000219,B,,CHEMBL620707,1.0,,,,C6,8.0,673.0,
Expert,,3575.0,,,10624.0,17066.0,H,,Binding affinity towards 5-hydroxytryptamine 5 receptor,,BAO_0000357,B,,CHEMBL620708,1.0,,,,,8.0,,
Autocuration,,3576.0,,,105.0,17200.0,H,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,BAO_0000357,B,,CHEMBL620709,1.0,,,,,8.0,,
Expert,,3577.0,,,10624.0,16146.0,D,,Binding affinity against 5-hydroxytryptamine 5A receptor,,BAO_0000357,B,,CHEMBL620710,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,3578.0,,,10624.0,15250.0,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL620711,1.0,,,,CHO,8.0,449.0,
Expert,,3579.0,,,10624.0,6491.0,D,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,BAO_0000357,B,,CHEMBL620712,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3580.0,,,10624.0,17066.0,D,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,BAO_0000357,B,,CHEMBL620713,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3581.0,,,10624.0,17066.0,D,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,BAO_0000357,B,,CHEMBL620714,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3582.0,,,10624.0,4234.0,D,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,BAO_0000357,B,,CHEMBL620715,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,3583.0,,,10624.0,6013.0,H,,Binding affinity towards 5-HT5A receptor,,BAO_0000357,B,,CHEMBL620716,1.0,,,,,8.0,,
Expert,,3584.0,,,10624.0,17175.0,H,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,BAO_0000357,B,,CHEMBL620717,1.0,,,,,8.0,,
Autocuration,,3585.0,,,10624.0,15818.0,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,BAO_0000357,B,,CHEMBL618072,1.0,,,,,8.0,,
Autocuration,,3586.0,,,10624.0,6166.0,H,,Binding affinity towards cloned human 5-HT5A receptor was determined,,BAO_0000357,B,,CHEMBL857987,1.0,,,,,8.0,,
Autocuration,,3587.0,,,10624.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,BAO_0000219,B,,CHEMBL618073,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3588.0,,,10624.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,BAO_0000219,B,,CHEMBL618074,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3589.0,,,10624.0,5213.0,H,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,BAO_0000219,B,,CHEMBL618075,1.0,,,,HEK293,8.0,722.0,
Expert,,3590.0,,,10625.0,17066.0,D,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,BAO_0000357,B,,CHEMBL618076,1.0,,,10090.0,,9.0,,Mus musculus
Expert,,3591.0,,,10625.0,17066.0,D,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,BAO_0000357,B,,CHEMBL618077,1.0,,,10090.0,,9.0,,Mus musculus
Expert,,3592.0,,,10625.0,17066.0,D,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,BAO_0000357,B,,CHEMBL618078,1.0,,,10090.0,,9.0,,Mus musculus
Expert,,3593.0,,,10625.0,17066.0,D,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,BAO_0000357,B,,CHEMBL881821,1.0,,,10090.0,,9.0,,Mus musculus
Expert,,3594.0,,,10625.0,17066.0,D,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,BAO_0000357,B,,CHEMBL618079,1.0,,,10090.0,,9.0,,Mus musculus
Expert,,3595.0,,,10625.0,17175.0,H,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,BAO_0000357,B,,CHEMBL618080,1.0,,,,,8.0,,
Autocuration,,3596.0,,,10576.0,16190.0,H,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,BAO_0000219,B,,CHEMBL618081,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3597.0,,,10626.0,16190.0,H,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,BAO_0000219,B,,CHEMBL618082,1.0,,,,HEK293,8.0,722.0,
Expert,,3598.0,,,10624.0,4820.0,H,,Binding affinity towards 5-HT5a receptor,,BAO_0000357,B,,CHEMBL618083,1.0,,,,,8.0,,
Expert,,3599.0,,,10624.0,17066.0,D,,Binding affinity towards 5-hydroxytryptamine 5A receptor,,BAO_0000357,B,,CHEMBL618084,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3600.0,,,10624.0,17066.0,H,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,BAO_0000357,B,,CHEMBL618085,1.0,,,,,8.0,,
Expert,,3601.0,,,10624.0,17175.0,H,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,BAO_0000357,B,,CHEMBL618086,1.0,,,,,8.0,,
Autocuration,,3602.0,,,10624.0,16633.0,H,,Binding affinities against 5-hydroxytryptamine 5A receptor,,BAO_0000357,B,,CHEMBL875092,1.0,,,,,8.0,,
Autocuration,,3603.0,,,10624.0,16633.0,H,,Binding affinities towards 5-hydroxytryptamine 5A receptor,,BAO_0000357,B,,CHEMBL618087,1.0,,,,,8.0,,
Autocuration,,3604.0,,,10624.0,16700.0,H,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,BAO_0000357,B,,CHEMBL872926,1.0,,,,,8.0,,
Autocuration,,3605.0,,,104714.0,4639.0,H,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,BAO_0000019,F,,CHEMBL618088,1.0,,,10141.0,,4.0,,Cavia porcellus
Autocuration,,3606.0,,,104714.0,5486.0,H,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,BAO_0000223,B,,CHEMBL618089,1.0,,,,,4.0,,
Expert,,3607.0,,,10627.0,16146.0,D,,Inhibition of human 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL618090,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3608.0,,,10627.0,17273.0,D,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,BAO_0000357,B,,CHEMBL618091,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,3609.0,,,10627.0,17687.0,H,,Inhibition against human 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL618092,1.0,,,,,8.0,,
Expert,,3610.0,,,10627.0,6491.0,D,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,BAO_0000357,B,,CHEMBL618093,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3611.0,,,10627.0,16190.0,H,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,BAO_0000219,B,,CHEMBL618094,1.0,,,,HeLa,8.0,308.0,
Expert,,3612.0,,,10627.0,17066.0,D,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL618095,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3613.0,,,10627.0,17066.0,D,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL875093,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3614.0,,,10627.0,17066.0,D,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,BAO_0000357,B,,CHEMBL618096,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3615.0,,,10627.0,17066.0,D,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,BAO_0000357,B,,CHEMBL618118,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3616.0,,,10627.0,3555.0,D,,Binding affinity against 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL618119,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3617.0,,,10627.0,5808.0,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL618120,1.0,,,,,8.0,,
Autocuration,,3618.0,,,10627.0,6013.0,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL618121,1.0,,,,,8.0,,
Expert,,3619.0,,,10627.0,15818.0,H,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,BAO_0000219,B,,CHEMBL618122,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3620.0,,,10627.0,16209.0,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,BAO_0000357,B,,CHEMBL618123,1.0,,,,,8.0,,
Expert,,3621.0,,,10627.0,3935.0,H,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,BAO_0000219,B,,CHEMBL618124,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3622.0,,,10627.0,15818.0,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL618125,1.0,,,,,8.0,,
Expert,,3623.0,,,10627.0,3805.0,D,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,BAO_0000219,B,,CHEMBL618126,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,3624.0,,,10627.0,16441.0,H,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,BAO_0000019,B,,CHEMBL618236,1.0,,,,,8.0,,
Expert,,3625.0,,,10627.0,16441.0,H,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,BAO_0000019,B,,CHEMBL618237,1.0,,,,,8.0,,
Expert,,3626.0,,,10627.0,6786.0,H,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,BAO_0000219,B,,CHEMBL618238,1.0,,,,COS-7,8.0,643.0,
Expert,,3627.0,,,10627.0,4234.0,D,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL618239,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,3628.0,,,10627.0,17085.0,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,BAO_0000019,B,,CHEMBL618240,1.0,,,,,8.0,,
Autocuration,,3629.0,,,10627.0,17200.0,H,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,BAO_0000357,B,,CHEMBL618241,1.0,,,,,8.0,,
Autocuration,,3630.0,,,10627.0,17451.0,H,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,BAO_0000219,B,,CHEMBL859399,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3631.0,,,10627.0,3935.0,H,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,BAO_0000019,F,,CHEMBL618242,1.0,,,,,8.0,,
Autocuration,,3632.0,,,10627.0,5033.0,H,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL857991,1.0,,,,,8.0,,
Expert,,3633.0,,,10627.0,4540.0,H,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL619951,1.0,,,,,8.0,,
Expert,,3634.0,,,10627.0,4540.0,D,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,BAO_0000219,B,,CHEMBL619952,1.0,,,9606.0,HeLa,9.0,308.0,Homo sapiens
Expert,,3635.0,,,10627.0,4540.0,D,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,BAO_0000219,B,,CHEMBL619953,1.0,,,9606.0,HeLa,9.0,308.0,Homo sapiens
Autocuration,,3636.0,,,10627.0,17296.0,H,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,BAO_0000219,B,,CHEMBL619954,1.0,,,,HeLa,8.0,308.0,
Autocuration,,3637.0,,,10627.0,17296.0,H,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,BAO_0000219,B,,CHEMBL619955,1.0,,,,HeLa,8.0,308.0,
Autocuration,,3638.0,,,10627.0,17296.0,H,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,BAO_0000219,B,,CHEMBL619956,1.0,,,,HeLa,8.0,308.0,
Autocuration,,3639.0,,,10627.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,B,,CHEMBL619957,1.0,,,,CHO,8.0,449.0,
Autocuration,,3640.0,,,10627.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,BAO_0000219,B,,CHEMBL619958,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3641.0,,,10627.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,BAO_0000219,B,,CHEMBL620627,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3642.0,,,10627.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,BAO_0000219,B,,CHEMBL620628,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3643.0,,,10627.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,BAO_0000219,B,,CHEMBL620629,1.0,,,,HeLa,8.0,308.0,
Autocuration,,3644.0,,,10627.0,6166.0,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL620630,1.0,,,,,8.0,,
Autocuration,,3645.0,,,10627.0,17451.0,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,BAO_0000219,B,,CHEMBL620782,1.0,,,,HeLa,8.0,308.0,
Autocuration,,3646.0,,,10627.0,15316.0,H,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL620783,1.0,,,,,8.0,,
Expert,,3647.0,,,10627.0,4199.0,H,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL620784,1.0,,,,,8.0,,
Expert,,3648.0,,,10627.0,15146.0,H,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,BAO_0000219,B,,CHEMBL620785,1.0,,,,HeLa,8.0,308.0,
Autocuration,,3649.0,,,10627.0,5213.0,H,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,BAO_0000357,B,,CHEMBL857992,1.0,,,,,8.0,,
Autocuration,,3650.0,,,10627.0,16429.0,H,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,BAO_0000219,B,,CHEMBL620786,1.0,,,,,8.0,,
Autocuration,,3651.0,,,10627.0,14818.0,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,BAO_0000219,B,,CHEMBL620787,1.0,,,,HeLa,8.0,308.0,
Autocuration,,3652.0,,,10627.0,4829.0,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,BAO_0000219,B,,CHEMBL620788,1.0,,,,HeLa,8.0,308.0,
Autocuration,,3653.0,,,10627.0,4829.0,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,BAO_0000219,B,,CHEMBL620789,1.0,,,,HeLa,8.0,308.0,
Autocuration,,3654.0,,,10627.0,4829.0,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,BAO_0000219,B,,CHEMBL620790,1.0,,,,HeLa,8.0,308.0,
Autocuration,,3655.0,,,10628.0,15250.0,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL620791,1.0,,,,CHO,8.0,449.0,
Autocuration,,3656.0,,,10628.0,14423.0,H,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,BAO_0000019,B,,CHEMBL620792,1.0,,,,,8.0,,
Autocuration,,3657.0,,,10628.0,15086.0,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL620793,1.0,,,,,8.0,,
Autocuration,,3658.0,,,10628.0,4342.0,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,BAO_0000357,B,,CHEMBL620794,1.0,,,,,8.0,,
Autocuration,,3659.0,,,10627.0,16190.0,D,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,BAO_0000219,B,,CHEMBL620795,1.0,,,9606.0,HeLa,9.0,308.0,Homo sapiens
Expert,,3660.0,,,10627.0,4820.0,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL620796,1.0,,,,,8.0,,
Autocuration,,3661.0,,,10627.0,4639.0,H,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,BAO_0000357,B,,CHEMBL620797,1.0,,,,,8.0,,
Expert,,3662.0,,,10627.0,17066.0,D,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,BAO_0000019,F,,CHEMBL620798,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,3663.0,,,10627.0,6011.0,H,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,BAO_0000357,B,,CHEMBL620799,1.0,,,,,8.0,,
Expert,,3664.0,,,10627.0,17066.0,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL620800,1.0,,,,,8.0,,
Autocuration,,3665.0,,,10627.0,17515.0,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,BAO_0000357,B,,CHEMBL620801,1.0,,,,,8.0,,
Autocuration,,3666.0,,,10627.0,5014.0,H,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL875100,1.0,,,,,8.0,,
Autocuration,,3667.0,,,10627.0,4373.0,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,BAO_0000357,B,,CHEMBL620802,1.0,,,,,8.0,,
Expert,,3668.0,,,10627.0,17066.0,H,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,BAO_0000019,F,,CHEMBL620803,1.0,,,,,8.0,,
Expert,,3669.0,,,10627.0,17066.0,H,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,BAO_0000019,F,,CHEMBL620804,1.0,,,,,8.0,,
Autocuration,,3670.0,,,10627.0,4373.0,H,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,BAO_0000357,B,,CHEMBL620805,1.0,,,,,8.0,,
Autocuration,,3671.0,,,10627.0,4687.0,H,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL620806,1.0,,,,,8.0,,
Autocuration,,3672.0,,,10627.0,16946.0,H,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,BAO_0000357,B,,CHEMBL620807,1.0,,,,,8.0,,
Autocuration,,3673.0,,,10627.0,16946.0,H,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,BAO_0000357,B,,CHEMBL620808,1.0,,,,,8.0,,
Autocuration,,3674.0,,,10627.0,16633.0,H,,Binding affinities against 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL620809,1.0,,,,,8.0,,
Autocuration,,3675.0,,,10627.0,16633.0,H,,Binding affinities towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL620810,1.0,,,,,8.0,,
Expert,,3676.0,,,10627.0,17066.0,D,,Binding affinity towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL620811,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,3677.0,,,10627.0,16700.0,H,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,BAO_0000357,B,,CHEMBL620812,1.0,,,,,8.0,,
Autocuration,,3678.0,,,10627.0,3269.0,H,,Affinity against 5-hydroxytryptamine 6 receptor,,BAO_0000357,B,,CHEMBL620813,1.0,,,,,8.0,,
Autocuration,,3679.0,,,10627.0,5486.0,H,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,BAO_0000357,B,,CHEMBL620814,1.0,,,,,8.0,,
Expert,,3680.0,,,10209.0,16146.0,D,,Inhibition of human 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL620815,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,3681.0,,,10209.0,5014.0,H,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,BAO_0000219,B,,CHEMBL620816,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3682.0,,,10209.0,15463.0,H,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL620817,1.0,,,,,8.0,,
Autocuration,,3683.0,,,10209.0,3805.0,H,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,BAO_0000357,B,,CHEMBL620818,1.0,,,,,8.0,,
Expert,,3684.0,,,10209.0,5014.0,H,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,BAO_0000219,B,,CHEMBL620819,1.0,,,,HEK293,8.0,722.0,
Expert,,3685.0,,,10209.0,6491.0,D,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,BAO_0000357,B,,CHEMBL620820,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,3686.0,,,10209.0,16190.0,H,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,BAO_0000219,B,,CHEMBL620821,1.0,,,,CHO,8.0,449.0,
Expert,,3687.0,,,10209.0,17066.0,D,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL620822,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3688.0,,,10209.0,17066.0,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL620823,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3689.0,,,10209.0,3555.0,D,,Binding affinity against 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL620824,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3690.0,,,10209.0,6588.0,H,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,BAO_0000219,B,,CHEMBL620825,1.0,,,,CHO,8.0,449.0,
Autocuration,,3691.0,,,10209.0,15463.0,H,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,BAO_0000357,B,,CHEMBL872930,1.0,,,,,8.0,,
Autocuration,,3692.0,,,10209.0,6013.0,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL620826,1.0,,,,,8.0,,
Autocuration,,3693.0,,,10209.0,16209.0,H,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL620827,1.0,,,,,8.0,,
Autocuration,,3694.0,,,10209.0,3935.0,H,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL620828,1.0,,,,,8.0,,
Autocuration,,3695.0,,,10209.0,15818.0,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL620829,1.0,,,,,8.0,,
Expert,,3696.0,,,10209.0,5014.0,H,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,BAO_0000219,B,,CHEMBL620830,1.0,,,,HEK293,8.0,722.0,
Expert,,3697.0,,,10209.0,16441.0,H,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,BAO_0000019,B,,CHEMBL620831,1.0,,,,,8.0,,
Expert,,3698.0,,,10209.0,16441.0,H,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,BAO_0000019,B,,CHEMBL620832,1.0,,,,,8.0,,
Expert,,3699.0,,,10209.0,4234.0,D,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL621548,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,3700.0,,,10209.0,17085.0,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,BAO_0000019,B,,CHEMBL621549,1.0,,,,,8.0,,
Autocuration,,3701.0,,,10209.0,17200.0,H,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,BAO_0000357,B,,CHEMBL621550,1.0,,,,,8.0,,
Autocuration,,3702.0,,,10209.0,17451.0,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,BAO_0000219,B,,CHEMBL621551,1.0,,,,CHO,8.0,449.0,
Autocuration,,3703.0,,,10209.0,17085.0,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,BAO_0000019,B,,CHEMBL621552,1.0,,,,,8.0,,
Autocuration,,3704.0,,,10209.0,5104.0,H,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL857077,1.0,,,,,8.0,,
Autocuration,,3705.0,,,10209.0,5104.0,H,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,BAO_0000357,B,,CHEMBL618158,1.0,,,,,8.0,,
Expert,,3706.0,,,10209.0,5033.0,D,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,BAO_0000219,B,,CHEMBL618159,1.0,,,9606.0,COS-7,9.0,643.0,Homo sapiens
Autocuration,,3707.0,,,10209.0,5486.0,H,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,BAO_0000219,B,,CHEMBL875101,1.0,,,,COS-7,8.0,643.0,
Expert,,3708.0,,,10209.0,4540.0,D,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,BAO_0000219,B,,CHEMBL618160,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,3709.0,,,10209.0,6166.0,H,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,BAO_0000357,B,,CHEMBL618161,1.0,,,,,8.0,,
Expert,,3710.0,,,10209.0,17342.0,H,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,BAO_0000219,B,,CHEMBL618162,1.0,,,,HEK293,8.0,722.0,
Expert,,3711.0,,,10209.0,17342.0,H,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,BAO_0000357,B,,CHEMBL618163,1.0,,,,,8.0,,
Autocuration,,3712.0,,,10209.0,17296.0,H,,Binding affinity against 5-hydroxytryptamine 7 human receptors,,BAO_0000357,B,,CHEMBL618164,1.0,,,,,8.0,,
Expert,,3713.0,,,10209.0,16429.0,H,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,BAO_0000219,B,,CHEMBL618165,1.0,,,,,8.0,,
Autocuration,,3714.0,,,10209.0,15779.0,H,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,BAO_0000219,B,,CHEMBL618166,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3715.0,,,10209.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,BAO_0000219,B,,CHEMBL857989,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3716.0,,,10209.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,BAO_0000219,B,,CHEMBL619888,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3717.0,,,10209.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,BAO_0000219,B,,CHEMBL619889,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3718.0,,,10209.0,15779.0,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,BAO_0000219,B,,CHEMBL619890,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3719.0,,,10209.0,17451.0,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,BAO_0000219,B,,CHEMBL619891,1.0,,,,CHO,8.0,449.0,
Autocuration,,3720.0,,,10209.0,4199.0,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,BAO_0000219,B,,CHEMBL619892,1.0,,,,HEK293,8.0,722.0,
Expert,,3721.0,,,10209.0,4199.0,D,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,BAO_0000219,B,,CHEMBL619893,1.0,,,,HEK293,9.0,722.0,
Autocuration,,3722.0,,,10209.0,4199.0,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,BAO_0000219,B,,CHEMBL619894,1.0,,,,HEK293,8.0,722.0,
Intermediate,,3723.0,,,10209.0,3680.0,D,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,BAO_0000219,B,,CHEMBL619895,1.0,,,,HEK293,9.0,722.0,
Intermediate,,3724.0,,,10209.0,3680.0,D,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,BAO_0000357,B,,CHEMBL619896,1.0,,,,,9.0,,
Autocuration,,3725.0,,,10209.0,15316.0,H,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,BAO_0000219,B,,CHEMBL619897,1.0,,,,COS-7,8.0,643.0,
Autocuration,,3726.0,,,10209.0,15146.0,H,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,BAO_0000219,B,,CHEMBL619898,1.0,,,,HEK293,8.0,722.0,
Expert,,3727.0,,,10209.0,5213.0,H,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,BAO_0000219,B,,CHEMBL619899,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3728.0,,,10209.0,5213.0,H,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,BAO_0000219,B,,CHEMBL619900,1.0,,,,HEK293,8.0,722.0,
Expert,,3729.0,,,10209.0,14818.0,D,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,BAO_0000219,B,,CHEMBL619901,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Autocuration,,3730.0,,,10209.0,14818.0,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,BAO_0000219,B,,CHEMBL620580,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3731.0,,,10209.0,14818.0,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,BAO_0000219,B,,CHEMBL620581,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3732.0,,,10209.0,4829.0,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,BAO_0000219,B,,CHEMBL620733,1.0,,,,HEK293,8.0,722.0,
Autocuration,,3733.0,,,10209.0,17200.0,D,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,BAO_0000357,B,,CHEMBL620734,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3734.0,,,10022.0,17066.0,D,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL620735,1.0,,,10090.0,,9.0,,Mus musculus
Autocuration,,3735.0,,,10209.0,14025.0,H,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,BAO_0000019,B,,CHEMBL620736,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Autocuration,,3736.0,,,11923.0,15250.0,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,BAO_0000219,B,,CHEMBL620737,1.0,,,,CHO,8.0,449.0,
Autocuration,,3737.0,,,11923.0,16372.0,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,BAO_0000219,B,,CHEMBL620738,1.0,,,,CHO,8.0,449.0,
Autocuration,,3738.0,,,11923.0,16372.0,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,BAO_0000219,B,,CHEMBL620739,1.0,,,,CHO,8.0,449.0,
Autocuration,,3739.0,,,11923.0,16372.0,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,BAO_0000219,B,,CHEMBL620740,1.0,,,,CHO,8.0,449.0,
Autocuration,,3740.0,,,11923.0,16372.0,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,BAO_0000219,B,,CHEMBL620741,1.0,,,,CHO,8.0,449.0,
Autocuration,,3741.0,,,11923.0,16372.0,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,BAO_0000219,B,,CHEMBL620742,1.0,,,,CHO,8.0,449.0,
Autocuration,,3742.0,,,11923.0,16372.0,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,BAO_0000219,B,,CHEMBL620743,1.0,,,,CHO,8.0,449.0,
Autocuration,,3743.0,,,11923.0,16372.0,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,BAO_0000219,B,,CHEMBL620744,1.0,,,,CHO,8.0,449.0,
Autocuration,,3744.0,,,11923.0,16372.0,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,BAO_0000219,B,,CHEMBL620745,1.0,,,,CHO,8.0,449.0,
Autocuration,,3745.0,,,11923.0,16372.0,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,BAO_0000219,B,,CHEMBL620746,1.0,,,,CHO,8.0,449.0,
Autocuration,,3746.0,,,11923.0,16372.0,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,BAO_0000219,B,,CHEMBL620747,1.0,,,,CHO,8.0,449.0,
Autocuration,,3747.0,,,11923.0,16372.0,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,BAO_0000219,B,,CHEMBL620748,1.0,,,,CHO,8.0,449.0,
Autocuration,,3748.0,,,11923.0,16372.0,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,BAO_0000219,B,,CHEMBL620749,1.0,,,,CHO,8.0,449.0,
Expert,,3749.0,,,11923.0,17066.0,H,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL620750,1.0,,,,,8.0,,
Expert,,3750.0,,,11923.0,17066.0,D,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL620751,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,3751.0,,,11923.0,17386.0,H,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL620752,1.0,,,,,8.0,,
Autocuration,,3752.0,,,11923.0,14423.0,H,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,BAO_0000019,B,,CHEMBL872929,1.0,,,,,8.0,,
Expert,,3753.0,,,11923.0,15874.0,D,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,BAO_0000357,B,,CHEMBL620753,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,3754.0,,,11923.0,15874.0,D,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL620754,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,3755.0,,,11923.0,16372.0,D,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,BAO_0000219,B,,CHEMBL620755,1.0,,,10116.0,CHO,9.0,449.0,Rattus norvegicus
Autocuration,,3756.0,,,11923.0,4622.0,H,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL620756,1.0,,,,,8.0,,
Autocuration,,3757.0,,,11923.0,15086.0,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL620757,1.0,,,,,8.0,,
Autocuration,,3758.0,,,11923.0,16372.0,H,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,BAO_0000219,B,,CHEMBL620758,1.0,,,,CHO,8.0,449.0,
Autocuration,,3759.0,,,11923.0,16372.0,H,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,BAO_0000219,B,,CHEMBL620759,1.0,,,,CHO,8.0,449.0,
Autocuration,,3760.0,,,11923.0,16372.0,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,BAO_0000219,B,,CHEMBL620760,1.0,,,,CHO,8.0,449.0,
Autocuration,,3761.0,,,11923.0,16372.0,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,BAO_0000219,B,,CHEMBL620761,1.0,,,,CHO,8.0,449.0,
Autocuration,Ileum,3762.0,,,11923.0,17386.0,H,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,BAO_0000221,F,,CHEMBL620762,1.0,2116.0,,,,8.0,,
Autocuration,Ileum,3763.0,,,11923.0,17386.0,H,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,BAO_0000221,F,,CHEMBL620763,1.0,2116.0,,,,8.0,,
Autocuration,Ileum,3764.0,,,11923.0,17386.0,H,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,BAO_0000221,F,,CHEMBL620764,1.0,2116.0,,,,8.0,,
Expert,,3765.0,,,11923.0,5831.0,D,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,Membranes,BAO_0000249,B,,CHEMBL857990,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,3766.0,,,11923.0,4342.0,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,B,,CHEMBL620765,1.0,,,,,8.0,,
Expert,,3767.0,,,11923.0,17319.0,H,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,BAO_0000357,B,,CHEMBL620766,1.0,,,,,8.0,,
Expert,Hypothalamus,3768.0,,,11923.0,17342.0,H,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,BAO_0000019,B,,CHEMBL620767,1.0,1898.0,,,,8.0,,
Autocuration,,3769.0,,,11923.0,17342.0,H,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,BAO_0000357,B,,CHEMBL620768,1.0,,,,,8.0,,
Expert,Hypothalamus,3770.0,,,11923.0,3680.0,H,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,BAO_0000249,B,,CHEMBL619051,1.0,1898.0,,,,8.0,,
Expert,,3771.0,,,11923.0,3680.0,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL619052,1.0,,,,,8.0,,
Expert,,3772.0,,,11923.0,17319.0,D,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,BAO_0000219,F,,CHEMBL619053,1.0,,,10116.0,HEK293,9.0,722.0,Rattus norvegicus
Expert,,3773.0,,,11923.0,17319.0,D,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,BAO_0000219,F,,CHEMBL619703,1.0,,,10116.0,HEK293,9.0,722.0,Rattus norvegicus
Autocuration,,3774.0,,,11923.0,17319.0,D,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,BAO_0000219,F,,CHEMBL619704,1.0,,,10116.0,HEK293,9.0,722.0,Rattus norvegicus
Expert,,3775.0,,,10209.0,4820.0,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL619851,1.0,,,,,8.0,,
Autocuration,,3776.0,,,10209.0,4639.0,H,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,BAO_0000357,B,,CHEMBL619852,1.0,,,,,8.0,,
Autocuration,,3777.0,,,10209.0,6011.0,H,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,BAO_0000357,B,,CHEMBL619853,1.0,,,,,8.0,,
Expert,,3778.0,,,10209.0,17066.0,D,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL619854,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3779.0,,,10209.0,17066.0,H,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL619855,1.0,,,,,8.0,,
Autocuration,,3780.0,,,10209.0,17515.0,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,BAO_0000357,B,,CHEMBL619856,1.0,,,,,8.0,,
Autocuration,,3781.0,,,10209.0,4373.0,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,B,,CHEMBL619857,1.0,,,,,8.0,,
Expert,,3782.0,,,10209.0,17066.0,H,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,BAO_0000019,F,,CHEMBL619858,1.0,,,,,8.0,,
Autocuration,,3783.0,,,10209.0,4373.0,H,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,B,,CHEMBL619859,1.0,,,,,8.0,,
Autocuration,,3784.0,,,10209.0,4373.0,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,B,,CHEMBL619860,1.0,,,,,8.0,,
Autocuration,,3785.0,,,10209.0,4687.0,H,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL619861,1.0,,,,,8.0,,
Expert,,3786.0,,,10209.0,17342.0,H,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL619862,1.0,,,,,8.0,,
Autocuration,,3787.0,,,10209.0,16946.0,H,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,BAO_0000357,B,,CHEMBL619863,1.0,,,,,8.0,,
Autocuration,,3788.0,,,10209.0,16946.0,H,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,BAO_0000357,B,,CHEMBL619864,1.0,,,,,8.0,,
Autocuration,,3789.0,,,10209.0,16633.0,H,,Binding affinities against 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL872928,1.0,,,,,8.0,,
Autocuration,,3790.0,,,10209.0,16633.0,H,,Binding affinities towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL619865,1.0,,,,,8.0,,
Expert,,3791.0,,,10209.0,17066.0,H,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,BAO_0000357,B,,CHEMBL619866,1.0,,,,,8.0,,
Autocuration,,3792.0,,,10209.0,16700.0,H,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,BAO_0000357,B,,CHEMBL619867,1.0,,,,,8.0,,
Autocuration,Ileum,3793.0,,,10209.0,17386.0,H,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,BAO_0000221,B,,CHEMBL619868,1.0,2116.0,,,,8.0,,
Autocuration,,3794.0,,,55.0,14080.0,H,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,BAO_0000019,F,,CHEMBL619869,1.0,,,,,8.0,,
Expert,,3795.0,,,55.0,14080.0,D,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,BAO_0000019,F,,CHEMBL619870,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,3796.0,,,55.0,409.0,H,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,BAO_0000357,B,,CHEMBL619871,1.0,,,,,8.0,,
Autocuration,,3797.0,,,55.0,409.0,H,,In vitro inhibition of human recombinant lipoxygenase enzyme,,BAO_0000357,B,,CHEMBL619872,1.0,,,,,8.0,,
Autocuration,,3798.0,,,55.0,409.0,H,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,BAO_0000357,B,,CHEMBL619873,1.0,,,,,8.0,,
Expert,Blood,3799.0,,,55.0,11090.0,H,,Inhibition of 5-lipoxygenase in human whole blood.,,BAO_0000357,B,,CHEMBL619874,1.0,178.0,,,,8.0,,
Expert,Blood,3800.0,,,55.0,11090.0,H,,Inhibition of 5-lipoxygenase in human whole blood.,,BAO_0000357,B,,CHEMBL619875,1.0,178.0,,,,8.0,,
Autocuration,,3801.0,,,55.0,948.0,H,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,BAO_0000357,B,,CHEMBL619876,1.0,,,,,8.0,,
Autocuration,,3802.0,,,55.0,948.0,H,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,BAO_0000357,B,,CHEMBL619877,1.0,,,,,8.0,,
Expert,,3803.0,,,55.0,13622.0,H,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,BAO_0000219,F,,CHEMBL619878,1.0,,,,,8.0,,
Autocuration,Blood,3804.0,,,55.0,13622.0,H,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,BAO_0000019,F,,CHEMBL619879,1.0,178.0,,,,8.0,,
Autocuration,,3805.0,,,55.0,9637.0,H,,In vitro inhibition of 5-lipoxygenase from human polymorphs,,BAO_0000357,B,,CHEMBL619880,1.0,,,,,8.0,,
Autocuration,,3806.0,,,55.0,11320.0,H,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,BAO_0000357,B,,CHEMBL619881,1.0,,,,,8.0,,
Expert,,3807.0,,,55.0,11320.0,H,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,BAO_0000357,B,,CHEMBL619882,1.0,,,,,8.0,,
Autocuration,,3808.0,,,55.0,6838.0,H,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,BAO_0000357,B,,CHEMBL619883,1.0,,,,,8.0,,
Expert,Blood,3809.0,,,55.0,17667.0,D,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,BAO_0000357,B,,CHEMBL619884,1.0,178.0,,9606.0,,9.0,,Homo sapiens
Autocuration,,3810.0,,,55.0,12703.0,H,,In vitro potency against human 5-Lipoxygenase,,BAO_0000357,B,,CHEMBL619885,1.0,,,,,8.0,,
Expert,,3811.0,,,55.0,14312.0,D,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,BAO_0000019,F,,CHEMBL619886,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,Blood,3812.0,,,55.0,14312.0,H,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,BAO_0000019,F,,CHEMBL619887,1.0,178.0,,,,8.0,,
Autocuration,,3813.0,,,55.0,5364.0,H,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,BAO_0000019,F,,CHEMBL875097,1.0,,,,,8.0,,
Autocuration,,3814.0,,,55.0,951.0,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,BAO_0000219,B,,CHEMBL618001,1.0,,,,,8.0,,
Autocuration,,3815.0,,,55.0,951.0,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,BAO_0000219,B,,CHEMBL618002,1.0,,,,,8.0,,
Autocuration,,3816.0,,,55.0,951.0,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,BAO_0000219,B,,CHEMBL618003,1.0,,,,,8.0,,
Autocuration,,3817.0,,,55.0,951.0,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,BAO_0000219,B,,CHEMBL618004,1.0,,,,,8.0,,
Autocuration,,3818.0,,,55.0,12365.0,H,,Inhibition of human 5-lipoxygenase in human cells,,BAO_0000219,B,,CHEMBL618005,1.0,,,,,8.0,,
Expert,,3819.0,,,55.0,10603.0,H,,Inhibition of human neutrophil 5-lipoxygenase,,BAO_0000357,B,,CHEMBL618006,1.0,,,,,8.0,,
Autocuration,,3820.0,,,55.0,10501.0,H,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,BAO_0000019,B,,CHEMBL875086,1.0,,,,,8.0,,
Expert,Blood,3821.0,,,55.0,12281.0,H,,Inhibition of 5-lipoxygenase from human whole blood,,BAO_0000357,B,,CHEMBL618007,1.0,178.0,,,,8.0,,
Autocuration,,3822.0,,,55.0,2567.0,H,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,BAO_0000357,B,,CHEMBL618008,1.0,,,,,8.0,,
Autocuration,,3823.0,,,55.0,2567.0,H,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,BAO_0000219,B,,CHEMBL618009,1.0,,,,,8.0,,
Expert,,3824.0,,,55.0,10193.0,H,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,BAO_0000357,B,,CHEMBL618010,1.0,,,,,8.0,,
Autocuration,,3825.0,,,55.0,10193.0,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,BAO_0000357,B,,CHEMBL618011,1.0,,,,,8.0,,
Expert,,3826.0,,,55.0,13623.0,H,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,BAO_0000357,B,,CHEMBL618012,1.0,,,,,8.0,,
Autocuration,,3827.0,,,55.0,12780.0,H,,Tested against 5-lipoxygenase,,BAO_0000357,B,,CHEMBL882927,1.0,,,,,8.0,,
Autocuration,,3828.0,,,55.0,12780.0,H,,Tested for activity against 5-Lipoxygenase (5-LO),,BAO_0000357,B,,CHEMBL618013,1.0,,,,,8.0,,
Autocuration,,3829.0,,,55.0,12780.0,H,,Tested for activity against 5-lipoxygenase,,BAO_0000357,B,,CHEMBL618014,1.0,,,,,8.0,,
Autocuration,,3830.0,,,55.0,11966.0,H,,Tested for inhibition of 5-HPETE production by human 5-LO,,BAO_0000357,B,,CHEMBL618015,1.0,,,,,8.0,,
Autocuration,,3831.0,,,55.0,5364.0,H,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,BAO_0000019,F,,CHEMBL618016,1.0,,,,,8.0,,
Expert,,3832.0,,,55.0,13165.0,H,,Inhibition of Human 5-lipoxygenase,,BAO_0000357,B,,CHEMBL618017,1.0,,,,,8.0,,
Autocuration,,3833.0,,,55.0,5364.0,H,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,BAO_0000019,B,,CHEMBL618018,1.0,,,,,8.0,,
Autocuration,,3834.0,,,55.0,11311.0,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,BAO_0000219,B,,CHEMBL875087,1.0,,,,,8.0,,
Autocuration,,3835.0,,,55.0,11311.0,H,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,BAO_0000219,B,,CHEMBL618019,1.0,,,,,8.0,,
Autocuration,,3836.0,,,55.0,14863.0,H,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,BAO_0000019,B,,CHEMBL618020,1.0,,,,,8.0,,
Autocuration,,3837.0,,,55.0,14863.0,H,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,BAO_0000019,B,,CHEMBL618021,1.0,,,,,8.0,,
Autocuration,Blood,3838.0,,,55.0,11087.0,H,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,BAO_0000357,B,,CHEMBL618022,1.0,178.0,,,,8.0,,
Autocuration,,3839.0,,,55.0,455.0,H,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,BAO_0000357,B,,CHEMBL618023,1.0,,,,,8.0,,
Autocuration,,3840.0,,,55.0,13183.0,H,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,BAO_0000357,B,,CHEMBL618024,1.0,,,,,8.0,,
Expert,,3841.0,,,55.0,10319.0,H,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,BAO_0000019,B,,CHEMBL873950,1.0,,,,,8.0,,
Autocuration,,3842.0,,,55.0,10193.0,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,BAO_0000357,B,,CHEMBL618025,1.0,,,,,8.0,,
Autocuration,,3843.0,,,55.0,951.0,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,BAO_0000219,B,,CHEMBL618026,1.0,,,,,8.0,,
Autocuration,,3844.0,,,55.0,951.0,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,BAO_0000219,B,,CHEMBL618027,1.0,,,,,8.0,,
Autocuration,,3845.0,,,55.0,951.0,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,BAO_0000219,B,,CHEMBL618028,1.0,,,,,8.0,,
Autocuration,,3846.0,,,55.0,951.0,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,BAO_0000219,B,,CHEMBL618029,1.0,,,,,8.0,,
Expert,,3847.0,,,55.0,9859.0,H,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,BAO_0000357,B,,CHEMBL618030,1.0,,,,,8.0,,
Expert,,3848.0,,,55.0,9859.0,H,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,BAO_0000357,B,,CHEMBL618031,1.0,,,,,8.0,,
Autocuration,,3849.0,,,55.0,9859.0,H,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,BAO_0000357,B,,CHEMBL618032,1.0,,,,,8.0,,
Autocuration,,3850.0,,,55.0,2567.0,H,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,BAO_0000357,B,,CHEMBL618033,1.0,,,,,8.0,,
Autocuration,,3851.0,,,55.0,10193.0,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,BAO_0000357,B,,CHEMBL618034,1.0,,,,,8.0,,
Autocuration,,3852.0,,,55.0,10193.0,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,BAO_0000357,B,,CHEMBL875088,1.0,,,,,8.0,,
Autocuration,,3853.0,,,55.0,949.0,H,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,BAO_0000019,B,,CHEMBL618035,1.0,,,,,8.0,,
Autocuration,,3854.0,,,55.0,949.0,H,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,BAO_0000019,B,,CHEMBL618036,1.0,,,,,8.0,,
Expert,,3855.0,,,55.0,10603.0,H,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,BAO_0000357,B,,CHEMBL618037,1.0,,,,,8.0,,
Expert,,3856.0,,,55.0,10603.0,H,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,BAO_0000357,B,,CHEMBL618038,1.0,,,,,8.0,,
Autocuration,,3857.0,,,55.0,10603.0,H,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,BAO_0000019,F,,CHEMBL618761,1.0,,,,,8.0,,
Expert,,3858.0,,,55.0,10603.0,H,,Inhibition of lipoxygenase at the concentration of 0.1 uM,,BAO_0000357,B,,CHEMBL618762,1.0,,,,,8.0,,
Expert,,3859.0,,,55.0,10603.0,H,,Inhibition of lipoxygenase at the concentration of 1 uM,,BAO_0000357,B,,CHEMBL618763,1.0,,,,,8.0,,
Autocuration,,3860.0,,,55.0,10193.0,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,BAO_0000357,B,,CHEMBL618764,1.0,,,,,8.0,,
Expert,,3861.0,,,55.0,14580.0,D,,Inhibition of 5-Lipoxygenase (5-LOX),,BAO_0000357,B,,CHEMBL618765,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,3862.0,,,17087.0,11090.0,H,,Inhibition of 5-lipoxygenase in mouse macrophages.,,BAO_0000357,B,,CHEMBL618766,1.0,,,,,8.0,,
Expert,,3863.0,,,17087.0,11090.0,H,,Inhibition of 5-lipoxygenase in mouse macrophages.,,BAO_0000357,B,,CHEMBL618767,1.0,,,,,8.0,,
Autocuration,,3864.0,,,17087.0,6339.0,H,,Inhibitory activity against lipoxygenase-2 in mice,,BAO_0000357,B,,CHEMBL619380,1.0,,,,,8.0,,
Expert,,3865.0,,,17087.0,6339.0,H,,Inhibitory activity against murine lipoxygenase-2.,,BAO_0000357,B,,CHEMBL619381,1.0,,,,,8.0,,
Expert,,3866.0,,,17087.0,12281.0,D,,Inhibition of 5-lipoxygenase from mouse macrophage,,BAO_0000357,B,,CHEMBL619382,1.0,,,10090.0,,9.0,,Mus musculus
Autocuration,,3867.0,,,17087.0,11311.0,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,BAO_0000357,B,,CHEMBL619383,1.0,,,,,8.0,,
Autocuration,,3868.0,,,55.0,11089.0,H,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,BAO_0000019,B,,CHEMBL619384,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,3869.0,,,55.0,10091.0,H,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,BAO_0000019,B,,CHEMBL619385,1.0,,,9823.0,,8.0,,Sus scrofa
Autocuration,,3870.0,,,55.0,14352.0,H,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,BAO_0000019,B,,CHEMBL882928,1.0,,,9986.0,,8.0,,Oryctolagus cuniculus
Expert,,3871.0,,,12166.0,13329.0,D,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,BAO_0000019,B,,CHEMBL619386,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,3872.0,,,12166.0,13329.0,H,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,BAO_0000019,B,,CHEMBL619387,1.0,,,,,8.0,,
Autocuration,,3873.0,,,12166.0,13329.0,H,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,BAO_0000019,B,,CHEMBL619388,1.0,,,,,8.0,,
Autocuration,,3874.0,,,12166.0,13329.0,H,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,BAO_0000019,B,,CHEMBL619389,1.0,,,,,8.0,,
Expert,,3875.0,,,12166.0,13329.0,H,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,BAO_0000019,B,,CHEMBL619390,1.0,,,,,8.0,,
Expert,,3876.0,,,12166.0,13329.0,H,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,BAO_0000019,B,,CHEMBL619391,1.0,,,,,8.0,,
Autocuration,,3877.0,,,12166.0,13329.0,H,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,BAO_0000019,B,,CHEMBL619392,1.0,,,,,8.0,,
Autocuration,,3878.0,,,12166.0,11311.0,H,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,BAO_0000019,B,,CHEMBL619393,1.0,,,,,8.0,,
Autocuration,,3879.0,,,12166.0,11311.0,H,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,BAO_0000019,B,,CHEMBL619394,1.0,,,,,8.0,,
Autocuration,,3880.0,,,12166.0,105.0,H,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,BAO_0000219,B,,CHEMBL619395,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3881.0,,,12166.0,105.0,H,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,BAO_0000219,B,,CHEMBL619396,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3882.0,,,12166.0,9138.0,H,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,BAO_0000357,B,,CHEMBL619397,1.0,,,,,8.0,,
Autocuration,,3883.0,,,12166.0,9138.0,H,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,BAO_0000357,B,,CHEMBL619398,1.0,,,,,8.0,,
Autocuration,,3884.0,,,12166.0,9138.0,H,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,BAO_0000357,B,,CHEMBL619399,1.0,,,,,8.0,,
Autocuration,,3885.0,,,12166.0,14427.0,H,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,BAO_0000357,B,,CHEMBL619400,1.0,,,,,8.0,,
Autocuration,,3886.0,,,12166.0,13329.0,H,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,BAO_0000019,B,,CHEMBL619401,1.0,,,,,8.0,,
Autocuration,,3887.0,,,12166.0,13329.0,H,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,BAO_0000019,B,,CHEMBL619402,1.0,,,,,8.0,,
Expert,,3888.0,,,12166.0,14427.0,D,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,BAO_0000219,B,,CHEMBL619403,1.0,,,10116.0,RBL-2H3,9.0,663.0,Rattus norvegicus
Autocuration,,3889.0,,,12166.0,14427.0,H,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,BAO_0000357,B,,CHEMBL619404,1.0,,,,,8.0,,
Autocuration,,3890.0,,,12166.0,14427.0,H,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,BAO_0000357,B,,CHEMBL619405,1.0,,,,,8.0,,
Expert,,3891.0,,,12166.0,10293.0,H,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,BAO_0000219,B,,CHEMBL619406,1.0,,,,RBL-1,8.0,702.0,
Expert,,3892.0,,,12166.0,338.0,D,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,BAO_0000219,B,,CHEMBL619407,1.0,,,10116.0,RBL-1,9.0,702.0,Rattus norvegicus
Autocuration,,3893.0,,,12166.0,303.0,H,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,BAO_0000357,B,,CHEMBL619408,1.0,,,,,8.0,,
Autocuration,,3894.0,,,12166.0,303.0,H,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,BAO_0000219,B,,CHEMBL619409,1.0,,,,RBL-1,8.0,702.0,
Expert,,3895.0,,,12166.0,9247.0,H,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,BAO_0000219,B,,CHEMBL619410,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3896.0,,,12166.0,9247.0,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,BAO_0000219,B,,CHEMBL619753,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3897.0,,,12166.0,137.0,H,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,BAO_0000219,B,,CHEMBL619754,1.0,,,,RBL-1,8.0,702.0,
Expert,,3898.0,,,12166.0,11481.0,H,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,BAO_0000357,B,,CHEMBL619903,1.0,,,,,8.0,,
Expert,,3899.0,,,12166.0,11481.0,H,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,BAO_0000357,B,,CHEMBL619904,1.0,,,,,8.0,,
Expert,,3900.0,,,12166.0,9029.0,H,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,BAO_0000357,B,,CHEMBL619905,1.0,,,,,8.0,,
Autocuration,,3901.0,,,12166.0,1701.0,H,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,BAO_0000019,B,,CHEMBL619906,1.0,,,,,8.0,,
Autocuration,,3902.0,,,12166.0,1701.0,H,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,BAO_0000019,B,,CHEMBL619907,1.0,,,,,8.0,,
Autocuration,,3903.0,,,12166.0,1701.0,H,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,BAO_0000019,B,,CHEMBL619908,1.0,,,,,8.0,,
Autocuration,,3904.0,,,12166.0,1701.0,H,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,BAO_0000019,B,,CHEMBL619909,1.0,,,,,8.0,,
Expert,,3905.0,,,12166.0,13358.0,H,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,BAO_0000219,F,,CHEMBL619910,1.0,,,,RBL-1,8.0,702.0,
Expert,,3906.0,,,12166.0,1175.0,H,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,BAO_0000219,B,,CHEMBL882929,1.0,,,,RBL-1,8.0,702.0,
Expert,,3907.0,,,12166.0,8797.0,H,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,BAO_0000219,B,,CHEMBL619911,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3908.0,,,12166.0,8797.0,H,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,BAO_0000019,B,,CHEMBL619912,1.0,,,,,8.0,,
Expert,,3909.0,,,12166.0,577.0,D,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,BAO_0000357,B,,CHEMBL619913,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,3910.0,,,12166.0,9295.0,H,,In vitro inhibitory activity against RBL-1 5-LO,,BAO_0000219,B,,CHEMBL619914,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3911.0,,,12166.0,9295.0,H,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,BAO_0000219,B,,CHEMBL619915,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3912.0,,,12166.0,9295.0,H,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,BAO_0000219,B,,CHEMBL619916,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3913.0,,,12166.0,9295.0,H,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,BAO_0000218,B,,CHEMBL619917,1.0,,,,,8.0,,
Autocuration,,3914.0,,,12166.0,9295.0,H,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,BAO_0000357,B,,CHEMBL619918,1.0,,,,,8.0,,
Autocuration,,3915.0,,,12166.0,216.0,H,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,BAO_0000218,B,,CHEMBL619919,1.0,,,,,8.0,,
Autocuration,,3916.0,,,12166.0,11090.0,H,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,BAO_0000219,B,,CHEMBL883710,1.0,,,,RBL-1,8.0,702.0,
Autocuration,Blood,3917.0,,,12166.0,11090.0,H,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,BAO_0000019,B,,CHEMBL619920,1.0,178.0,,,,8.0,,
Expert,,3918.0,,,12166.0,10091.0,H,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,BAO_0000357,B,,CHEMBL619921,1.0,,,,,8.0,,
Autocuration,,3919.0,,,12166.0,10274.0,H,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,BAO_0000019,F,,CHEMBL619922,1.0,,,,,8.0,,
Autocuration,,3920.0,,,12166.0,13622.0,H,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,BAO_0000219,F,,CHEMBL619923,1.0,,,,,8.0,,
Expert,,3921.0,,,12166.0,12118.0,H,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,BAO_0000219,B,,CHEMBL619924,1.0,,,,RBL-1,8.0,702.0,
Expert,,3922.0,,,12166.0,12576.0,H,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,BAO_0000357,B,,CHEMBL619925,1.0,,,,,8.0,,
Expert,,3923.0,,,12166.0,9546.0,H,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,BAO_0000219,B,,CHEMBL619926,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3924.0,,,12166.0,9521.0,H,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,BAO_0000219,B,,CHEMBL619927,1.0,,,,RBL-1,8.0,702.0,
Expert,,3925.0,,,12166.0,10626.0,H,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,BAO_0000219,B,,CHEMBL619928,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3926.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase,,BAO_0000219,B,,CHEMBL619929,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3927.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,BAO_0000219,B,,CHEMBL875089,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3928.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,BAO_0000219,B,,CHEMBL619930,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3929.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,BAO_0000219,B,,CHEMBL619931,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3930.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,BAO_0000219,B,,CHEMBL619932,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3931.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,BAO_0000219,B,,CHEMBL619933,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3932.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,BAO_0000219,B,,CHEMBL619934,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3933.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,BAO_0000219,B,,CHEMBL619935,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3934.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,BAO_0000219,B,,CHEMBL619936,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3935.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,BAO_0000219,B,,CHEMBL619937,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3936.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,BAO_0000219,B,,CHEMBL619938,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3937.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,BAO_0000219,B,,CHEMBL619939,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3938.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,BAO_0000219,B,,CHEMBL619940,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3939.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,BAO_0000219,B,,CHEMBL875090,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3940.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,BAO_0000219,B,,CHEMBL619941,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3941.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,BAO_0000219,B,,CHEMBL619942,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3942.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,BAO_0000219,B,,CHEMBL883711,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3943.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,BAO_0000219,B,,CHEMBL619943,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3944.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,BAO_0000219,B,,CHEMBL619944,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3945.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,BAO_0000219,B,,CHEMBL619945,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3946.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,BAO_0000219,B,,CHEMBL619946,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3947.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,BAO_0000219,B,,CHEMBL619947,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3948.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,BAO_0000219,B,,CHEMBL619948,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3949.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,BAO_0000219,B,,CHEMBL619949,1.0,,,,RBL-1,8.0,702.0,
Expert,,3950.0,,,12166.0,9401.0,H,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,BAO_0000019,B,,CHEMBL619950,1.0,,,,,8.0,,
Autocuration,,3951.0,,,12166.0,10325.0,H,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,BAO_0000019,B,,CHEMBL618050,1.0,,,,,8.0,,
Expert,,3952.0,,,12166.0,1556.0,H,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,BAO_0000219,F,,CHEMBL875091,1.0,,,,RBL-2H3,8.0,663.0,
Expert,,3953.0,,,12166.0,1556.0,H,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,BAO_0000219,F,,CHEMBL618051,1.0,,,,RBL-2H3,8.0,663.0,
Expert,,3954.0,,,12166.0,961.0,D,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,BAO_0000219,B,,CHEMBL618052,1.0,,,10116.0,RBL-1,9.0,702.0,Rattus norvegicus
Autocuration,,3955.0,,,12166.0,6838.0,H,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,BAO_0000019,B,,CHEMBL618053,1.0,,,,,8.0,,
Expert,,3956.0,,,12166.0,10325.0,H,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,BAO_0000019,B,,CHEMBL618054,1.0,,,,,8.0,,
Expert,,3957.0,,,12166.0,9209.0,D,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,BAO_0000219,B,,CHEMBL618055,1.0,,,10116.0,RBL-1,9.0,702.0,Rattus norvegicus
Expert,,3958.0,,,12166.0,11520.0,H,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,BAO_0000219,B,,CHEMBL618056,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3959.0,,,12166.0,137.0,H,,In vitro inhibitory activity against 5-lipoxygenase was determined,,BAO_0000357,B,,CHEMBL618057,1.0,,,,,8.0,,
Autocuration,,3960.0,,,12166.0,4717.0,H,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,BAO_0000219,B,,CHEMBL618058,1.0,,,,RBL-1,8.0,702.0,
Expert,,3961.0,,,12166.0,10636.0,H,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,BAO_0000219,B,,CHEMBL618059,1.0,,,,RBL-1,8.0,702.0,
Expert,,3962.0,,,12166.0,14312.0,D,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,BAO_0000019,F,,CHEMBL618060,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,3963.0,,,12166.0,1203.0,H,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,BAO_0000219,B,,CHEMBL618061,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3964.0,,,12166.0,1203.0,H,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,BAO_0000019,B,,CHEMBL618062,1.0,,,,,8.0,,
Expert,,3965.0,,,12166.0,13622.0,H,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,BAO_0000219,B,,CHEMBL618063,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3966.0,,,12166.0,9793.0,H,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,BAO_0000357,B,,CHEMBL618064,1.0,,,,,8.0,,
Expert,,3967.0,,,12166.0,1143.0,D,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,BAO_0000219,B,,CHEMBL618065,1.0,,,10116.0,RBL-1,9.0,702.0,Rattus norvegicus
Expert,,3968.0,,,12166.0,11854.0,D,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,BAO_0000219,B,,CHEMBL618066,1.0,,,10116.0,RBL-1,9.0,702.0,Rattus norvegicus
Autocuration,,3969.0,,,12166.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,BAO_0000219,B,,CHEMBL618067,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,3970.0,,,12166.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,BAO_0000219,B,,CHEMBL618068,1.0,,,,RBL-1,8.0,702.0,
Expert,,3971.0,,,12166.0,10501.0,D,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,BAO_0000219,B,,CHEMBL618069,1.0,,,10116.0,RBL-1,9.0,702.0,Rattus norvegicus
Expert,,3972.0,,,12166.0,12526.0,H,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,BAO_0000219,B,,CHEMBL618070,1.0,,,,RBL-1,8.0,702.0,
Autocuration,Limbic system,3973.0,,,10825.0,10034.0,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,BAO_0000019,F,,CHEMBL618071,1.0,349.0,,,,8.0,,
Autocuration,Limbic system,3974.0,,,10825.0,10034.0,H,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,BAO_0000019,F,,CHEMBL619247,1.0,349.0,,,,8.0,,
Autocuration,,3975.0,,,10825.0,10034.0,H,,Approximate dose levels for a half maximal reduction of 5-HTP levels,,BAO_0000019,F,,CHEMBL619248,1.0,,,,,8.0,,
Autocuration,Hippocampus,3976.0,,,10576.0,10046.0,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,BAO_0000221,B,,CHEMBL619249,1.0,10000000.0,,,,8.0,,
Autocuration,Hippocampus,3977.0,,,10576.0,10046.0,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,BAO_0000221,B,,CHEMBL619250,1.0,10000000.0,,,,8.0,,
Autocuration,,3978.0,,,10577.0,10046.0,H,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,BAO_0000019,B,,CHEMBL619251,1.0,,,,,8.0,,
Autocuration,Blood,3979.0,,,55.0,12079.0,H,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,BAO_0000019,F,,CHEMBL619252,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,3980.0,,,55.0,12079.0,H,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,BAO_0000019,F,,CHEMBL619253,1.0,178.0,,,,8.0,,
Autocuration,,3981.0,,,12166.0,11311.0,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,BAO_0000219,B,,CHEMBL619254,1.0,,,,,8.0,,
Expert,,3982.0,,,17140.0,12338.0,H,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,BAO_0000219,B,,CHEMBL619255,1.0,,,,,8.0,,
Expert,,3983.0,,,17140.0,12143.0,H,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,BAO_0000219,B,,CHEMBL619256,1.0,,,,,8.0,,
Autocuration,,3984.0,,,17140.0,12143.0,H,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,BAO_0000219,B,,CHEMBL875418,1.0,,,,,8.0,,
Expert,,3985.0,,,17140.0,12143.0,H,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,BAO_0000219,B,,CHEMBL619257,1.0,,,,,8.0,,
Autocuration,,3986.0,,,17140.0,12143.0,H,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,BAO_0000219,B,,CHEMBL619258,1.0,,,,,8.0,,
Expert,,3987.0,,,17140.0,12365.0,H,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,BAO_0000357,B,,CHEMBL619259,1.0,,,,,8.0,,
Expert,,3988.0,,,17140.0,13500.0,H,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,BAO_0000357,B,,CHEMBL619260,1.0,,,,,8.0,,
Autocuration,Blood,3989.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL619261,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,3990.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL619263,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,3991.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL619264,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,3992.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL619265,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,3993.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL619266,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,3994.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL619902,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,3995.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620058,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,3996.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620059,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,3997.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620060,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,3998.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620061,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,3999.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620062,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4000.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620063,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4001.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620064,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4002.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620065,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4003.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620066,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4004.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620067,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4005.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620068,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4006.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620069,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4007.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620070,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4008.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620071,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4009.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620072,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4010.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620036,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4011.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,F,In vivo,CHEMBL857702,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4012.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620037,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4013.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620038,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4014.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620039,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4015.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620040,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4016.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620041,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4017.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620042,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4018.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620043,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4019.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620044,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4020.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620045,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4021.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620046,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4022.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620047,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4023.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620048,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4024.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL857703,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4025.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620049,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4026.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620050,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4027.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL620051,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4028.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL619213,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4029.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL619214,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4030.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL619804,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4031.0,,,55.0,12832.0,H,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL619805,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4032.0,,,55.0,12832.0,H,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL619806,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4033.0,,,55.0,12832.0,H,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL619807,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,Blood,4034.0,,,55.0,12832.0,H,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,F,In vivo,CHEMBL619808,1.0,178.0,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,,4035.0,,,55.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,BAO_0000218,B,,CHEMBL619809,1.0,,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,,4036.0,,,55.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,BAO_0000218,B,,CHEMBL619810,1.0,,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,,4037.0,,,55.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,BAO_0000218,B,,CHEMBL619811,1.0,,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,,4038.0,,,55.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,BAO_0000218,B,,CHEMBL620769,1.0,,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,,4039.0,,,55.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,BAO_0000218,B,,CHEMBL620770,1.0,,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,,4040.0,,,55.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,BAO_0000218,B,,CHEMBL620771,1.0,,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,,4041.0,,,55.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,BAO_0000218,B,,CHEMBL620772,1.0,,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,,4042.0,,,55.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,BAO_0000218,B,,CHEMBL620773,1.0,,,9615.0,,8.0,,Canis lupus familiaris
Autocuration,,4043.0,,,55.0,9203.0,H,,Ability to inhibit 5-lipoxygenase in guinea pig,,BAO_0000357,B,,CHEMBL620774,1.0,,,10141.0,,8.0,,Cavia porcellus
Expert,,4044.0,,,55.0,82.0,H,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,BAO_0000357,B,,CHEMBL620775,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4045.0,,,55.0,11090.0,H,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,BAO_0000357,B,,CHEMBL620776,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,Blood,4046.0,,,55.0,12832.0,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,B,,CHEMBL620777,1.0,178.0,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4047.0,,,55.0,1065.0,H,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,BAO_0000357,B,,CHEMBL620778,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4048.0,,,55.0,1065.0,H,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,BAO_0000357,B,,CHEMBL620779,1.0,,,10141.0,,8.0,,Cavia porcellus
Expert,,4049.0,,,55.0,12832.0,H,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,BAO_0000019,B,,CHEMBL621500,1.0,,,10141.0,,8.0,,Cavia porcellus
Expert,,4050.0,,,55.0,12832.0,H,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,BAO_0000019,B,,CHEMBL621501,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4051.0,,,55.0,12832.0,H,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,BAO_0000019,B,,CHEMBL618098,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4052.0,,,55.0,10504.0,H,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,BAO_0000019,B,,CHEMBL618099,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4053.0,,,55.0,7788.0,H,,Inhibitory activity against 5-lipoxygenase,,BAO_0000357,B,,CHEMBL618100,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4054.0,,,55.0,10001.0,H,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,BAO_0000357,B,,CHEMBL618101,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4055.0,,,55.0,10193.0,H,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,BAO_0000357,B,,CHEMBL618102,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4056.0,,,55.0,13243.0,H,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,BAO_0000357,B,,CHEMBL618103,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4057.0,,,55.0,13243.0,H,,Inhibitory activity uM,,BAO_0000357,B,,CHEMBL618104,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4058.0,,,55.0,969.0,H,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,BAO_0000219,B,,CHEMBL883712,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4059.0,,,55.0,10001.0,H,,Inhibitory activity against 5-lipoxygenase at 10 uM,,BAO_0000357,B,,CHEMBL618105,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4060.0,,,55.0,7788.0,H,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,BAO_0000357,B,,CHEMBL618106,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4061.0,,,55.0,10001.0,H,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,BAO_0000357,B,,CHEMBL618107,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4062.0,,,55.0,10193.0,H,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,BAO_0000357,B,,CHEMBL618108,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4063.0,,,55.0,13243.0,H,,Inhibitory activity uM,,BAO_0000357,B,,CHEMBL618109,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4064.0,,,55.0,13243.0,H,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,BAO_0000357,B,,CHEMBL618110,1.0,,,10141.0,,8.0,,Cavia porcellus
Expert,,4065.0,,,55.0,13243.0,H,,Inhibitory activity uM,,BAO_0000357,B,,CHEMBL618111,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4066.0,,,55.0,13243.0,H,,Inhibitory activity uM,,BAO_0000019,F,,CHEMBL618112,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4067.0,,,55.0,10504.0,H,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,BAO_0000019,B,,CHEMBL618113,1.0,,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4068.0,,,55.0,7788.0,H,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,BAO_0000357,B,,CHEMBL618114,1.0,,,10141.0,,8.0,,Cavia porcellus
Expert,Ileum,4069.0,,,55.0,10546.0,H,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,BAO_0000221,F,,CHEMBL620871,1.0,2116.0,,10141.0,,8.0,,Cavia porcellus
Autocuration,,4070.0,,,55.0,13183.0,H,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,BAO_0000357,B,,CHEMBL620872,1.0,,,,,8.0,,
Autocuration,,4071.0,,,55.0,13183.0,H,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,BAO_0000357,B,,CHEMBL620873,1.0,,,,,8.0,,
Autocuration,,4072.0,,,55.0,2578.0,H,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,BAO_0000357,B,,CHEMBL620874,1.0,,,,,8.0,,
Expert,,4073.0,,,55.0,12780.0,H,,In vitro inhibition of human 5-Lipoxygenase.,,BAO_0000357,B,,CHEMBL620875,1.0,,,,,8.0,,
Autocuration,Liver,4074.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Microsomes,BAO_0000251,B,,CHEMBL620876,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4075.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Microsomes,BAO_0000251,B,,CHEMBL620877,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4076.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Microsomes,BAO_0000251,B,,CHEMBL857854,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4077.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Microsomes,BAO_0000251,B,,CHEMBL620878,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4078.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Microsomes,BAO_0000251,B,,CHEMBL620879,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4079.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Microsomes,BAO_0000251,B,,CHEMBL620880,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4080.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Microsomes,BAO_0000251,B,,CHEMBL620881,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4081.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Microsomes,BAO_0000251,B,,CHEMBL620882,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4082.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Microsomes,BAO_0000251,B,,CHEMBL620883,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4083.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Microsomes,BAO_0000251,B,,CHEMBL620884,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4084.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Microsomes,BAO_0000251,B,,CHEMBL620885,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4085.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Microsomes,BAO_0000251,B,,CHEMBL620886,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4086.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Microsomes,BAO_0000251,B,,CHEMBL620887,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4087.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Microsomes,BAO_0000251,B,,CHEMBL618039,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4088.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Microsomes,BAO_0000251,B,,CHEMBL618040,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4089.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Microsomes,BAO_0000251,B,,CHEMBL618041,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4090.0,,,22226.0,7411.0,U,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Microsomes,BAO_0000251,B,,CHEMBL618216,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4091.0,,,22226.0,7411.0,U,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Microsomes,BAO_0000251,B,,CHEMBL618217,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4092.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Microsomes,BAO_0000251,B,,CHEMBL618218,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4093.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Microsomes,BAO_0000251,B,,CHEMBL618219,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4094.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Microsomes,BAO_0000251,B,,CHEMBL618220,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4095.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Microsomes,BAO_0000251,B,,CHEMBL618221,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4096.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Microsomes,BAO_0000251,B,,CHEMBL618222,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4097.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Microsomes,BAO_0000251,B,,CHEMBL618223,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4098.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Microsomes,BAO_0000251,B,,CHEMBL618224,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4099.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Microsomes,BAO_0000251,B,,CHEMBL618225,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4100.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Microsomes,BAO_0000251,B,,CHEMBL618226,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4101.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Microsomes,BAO_0000251,B,,CHEMBL618227,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4102.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Microsomes,BAO_0000251,B,,CHEMBL618228,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4103.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Microsomes,BAO_0000251,B,,CHEMBL618229,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4104.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Microsomes,BAO_0000251,B,,CHEMBL618230,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4105.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Microsomes,BAO_0000251,B,,CHEMBL618231,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4106.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Microsomes,BAO_0000251,B,,CHEMBL618232,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4107.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Microsomes,BAO_0000251,B,,CHEMBL618233,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4108.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Microsomes,BAO_0000251,B,,CHEMBL618234,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4109.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Microsomes,BAO_0000251,B,,CHEMBL618235,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4110.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Microsomes,BAO_0000251,B,,CHEMBL618115,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4111.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Microsomes,BAO_0000251,B,,CHEMBL618116,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4112.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Microsomes,BAO_0000251,B,,CHEMBL618117,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4113.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Microsomes,BAO_0000251,B,,CHEMBL619968,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4114.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Microsomes,BAO_0000251,B,,CHEMBL619969,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4115.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Microsomes,BAO_0000251,B,,CHEMBL619970,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4116.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Microsomes,BAO_0000251,B,,CHEMBL619971,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4117.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Microsomes,BAO_0000251,B,,CHEMBL619972,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4118.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Microsomes,BAO_0000251,B,,CHEMBL619973,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4119.0,,,22226.0,7411.0,U,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Microsomes,BAO_0000251,B,,CHEMBL619974,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4120.0,,,22226.0,7411.0,U,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Microsomes,BAO_0000251,B,,CHEMBL619975,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,4121.0,,,22226.0,7411.0,U,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,Microsomes,BAO_0000251,B,,CHEMBL619976,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4122.0,,,22226.0,7411.0,U,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Microsomes,BAO_0000251,B,,CHEMBL619977,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4123.0,,,22226.0,7411.0,U,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Microsomes,BAO_0000251,B,,CHEMBL619978,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4124.0,,,22226.0,7411.0,U,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Microsomes,BAO_0000251,B,,CHEMBL619979,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4125.0,,,22226.0,7411.0,U,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Microsomes,BAO_0000251,B,,CHEMBL619980,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4126.0,,,22226.0,7411.0,U,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Microsomes,BAO_0000251,B,,CHEMBL619981,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Intermediate,,4127.0,,,80433.0,10797.0,N,,In vitro inhibition of 7226/S myeloma cancer cell line,,BAO_0000219,F,,CHEMBL619982,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,4128.0,,,80698.0,6881.0,N,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,BAO_0000219,F,,CHEMBL619983,1.0,,,9606.0,BEL-7404 tumor cell line,1.0,993.0,Homo sapiens
Intermediate,,4129.0,,,80640.0,3838.0,N,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,BAO_0000219,F,,CHEMBL620031,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4130.0,,,80640.0,3838.0,N,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,BAO_0000219,F,,CHEMBL620032,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Expert,,4131.0,,,81264.0,12981.0,N,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,BAO_0000219,F,,CHEMBL620033,1.0,,,10029.0,V79,1.0,505.0,Cricetulus griseus
Expert,,4132.0,,,81264.0,12981.0,N,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,BAO_0000219,F,,CHEMBL620034,1.0,,,10029.0,V79,1.0,505.0,Cricetulus griseus
Intermediate,,4133.0,,,80635.0,7653.0,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,BAO_0000219,F,,CHEMBL620035,1.0,,,10116.0,7800C1 cell line,1.0,1119.0,Rattus norvegicus
Intermediate,,4134.0,,,80635.0,7653.0,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,BAO_0000219,F,,CHEMBL618318,1.0,,,10116.0,7800C1 cell line,1.0,1119.0,Rattus norvegicus
Intermediate,,4135.0,,,80635.0,7653.0,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,BAO_0000219,F,,CHEMBL618319,1.0,,,10116.0,7800C1 cell line,1.0,1119.0,Rattus norvegicus
Intermediate,,4136.0,,,80635.0,7653.0,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,BAO_0000219,F,,CHEMBL618320,1.0,,,10116.0,7800C1 cell line,1.0,1119.0,Rattus norvegicus
Intermediate,,4137.0,,,80635.0,7653.0,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,BAO_0000219,F,,CHEMBL618321,1.0,,,10116.0,7800C1 cell line,1.0,1119.0,Rattus norvegicus
Intermediate,,4138.0,,,80635.0,7653.0,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,BAO_0000219,F,,CHEMBL883118,1.0,,,10116.0,7800C1 cell line,1.0,1119.0,Rattus norvegicus
Intermediate,,4139.0,,,80640.0,17229.0,N,,In vitro antitumor activity against renal 786-0 tumor cell lines,,BAO_0000219,F,,CHEMBL883795,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4140.0,,,80640.0,12858.0,N,,Cytotoxic activity against 786-0 Renal cancer cell line,,BAO_0000219,F,,CHEMBL618322,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4141.0,,,80640.0,16325.0,N,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,BAO_0000219,F,,CHEMBL618323,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4142.0,,,80640.0,16325.0,N,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,BAO_0000219,F,,CHEMBL618324,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4143.0,,,80640.0,5858.0,N,,In vitro antitumor activity against human renal 786-0 cell line,,BAO_0000219,F,,CHEMBL618325,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4144.0,,,80640.0,16325.0,N,,Inhibition of Renal cancer in 786-0 cancer cell lines,,BAO_0000219,F,,CHEMBL875416,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4145.0,,,80640.0,14696.0,N,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,BAO_0000219,F,,CHEMBL618326,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4146.0,,,80640.0,3786.0,N,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,BAO_0000219,F,,CHEMBL618327,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4147.0,,,80640.0,14696.0,N,,inhibition of the growth of renal cancer(786-0) cell line,,BAO_0000219,F,,CHEMBL619215,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4148.0,,,80640.0,14769.0,N,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,BAO_0000219,F,,CHEMBL619216,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4149.0,,,80640.0,15354.0,N,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,BAO_0000219,F,,CHEMBL619217,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4150.0,,,80640.0,14255.0,N,,The IC50 value was measured on 786-0 cell line in ovarian tumor,,BAO_0000219,F,,CHEMBL619218,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4151.0,,,80640.0,14255.0,N,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,BAO_0000219,F,,CHEMBL619219,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4152.0,,,80640.0,14255.0,N,,The IC50 value was measured on 786-0 cell line in renal tumor type.,,BAO_0000219,F,,CHEMBL619220,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4153.0,,,80640.0,14696.0,N,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,BAO_0000219,F,,CHEMBL619221,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4154.0,,,80640.0,12016.0,N,,Tested for cytotoxic activity against renal cancer 786-0 cell line,,BAO_0000219,F,,CHEMBL619222,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,4155.0,,,80640.0,2597.0,N,,Compound was tested for growth inhibitory activity against 786-0 cell line,,BAO_0000219,F,,CHEMBL857454,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Autocuration,,4156.0,,,12166.0,12526.0,H,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,BAO_0000219,B,,CHEMBL619223,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4157.0,,,12166.0,12526.0,H,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,BAO_0000219,B,,CHEMBL619224,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4158.0,,,12166.0,14799.0,H,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,BAO_0000019,B,,CHEMBL619225,1.0,,,,,8.0,,
Expert,,4159.0,,,12166.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,BAO_0000219,B,,CHEMBL619226,1.0,,,,RBL-1,8.0,702.0,
Expert,,4160.0,,,12166.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,BAO_0000219,B,,CHEMBL619227,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4161.0,,,12166.0,12767.0,H,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,BAO_0000357,B,,CHEMBL619228,1.0,,,,,8.0,,
Autocuration,,4162.0,,,12166.0,10997.0,H,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,BAO_0000219,B,,CHEMBL619229,1.0,,,,,8.0,,
Autocuration,,4163.0,,,12166.0,11388.0,H,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,BAO_0000219,B,,CHEMBL619230,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4164.0,,,12166.0,167.0,H,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,BAO_0000357,B,,CHEMBL619231,1.0,,,,,8.0,,
Autocuration,,4165.0,,,12166.0,167.0,H,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,BAO_0000357,B,,CHEMBL619232,1.0,,,,,8.0,,
Expert,,4166.0,,,12166.0,13744.0,H,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,BAO_0000357,B,,CHEMBL619233,1.0,,,,,8.0,,
Autocuration,,4167.0,,,12166.0,1630.0,H,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,BAO_0000357,B,,CHEMBL619234,1.0,,,,,8.0,,
Autocuration,,4168.0,,,12166.0,1630.0,H,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,BAO_0000357,B,,CHEMBL619235,1.0,,,,,8.0,,
Expert,,4169.0,,,12166.0,969.0,D,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,BAO_0000019,B,,CHEMBL619236,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,4170.0,,,12166.0,13621.0,H,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,BAO_0000219,B,,CHEMBL619237,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4171.0,,,12166.0,10089.0,H,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,BAO_0000357,B,,CHEMBL619238,1.0,,,,,8.0,,
Expert,,4172.0,,,12166.0,10193.0,H,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,BAO_0000357,B,,CHEMBL619239,1.0,,,,,8.0,,
Autocuration,,4173.0,,,12166.0,11966.0,H,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,BAO_0000357,B,,CHEMBL619240,1.0,,,,,8.0,,
Autocuration,,4174.0,,,12166.0,12251.0,H,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,BAO_0000019,B,,CHEMBL875417,1.0,,,,,8.0,,
Autocuration,,4175.0,,,12166.0,211.0,H,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,BAO_0000219,B,,CHEMBL619241,1.0,,,,RBL-1,8.0,702.0,
Expert,,4176.0,,,12166.0,12251.0,H,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,BAO_0000019,F,,CHEMBL619242,1.0,,,,,8.0,,
Autocuration,,4177.0,,,12166.0,12495.0,H,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,BAO_0000219,B,,CHEMBL883796,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4178.0,,,12166.0,414.0,H,,Tested for its inhibitory activity against 5-lipoxygenase,,BAO_0000357,B,,CHEMBL619243,1.0,,,,,8.0,,
Autocuration,,4179.0,,,12166.0,414.0,H,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,BAO_0000357,B,,CHEMBL619244,1.0,,,,,8.0,,
Expert,,4180.0,,,12166.0,10325.0,H,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,BAO_0000019,B,,CHEMBL619245,1.0,,,,,8.0,,
Expert,,4181.0,,,12166.0,11966.0,H,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,BAO_0000019,B,,CHEMBL619246,1.0,,,,,8.0,,
Expert,,4182.0,,,12166.0,165.0,H,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,BAO_0000219,B,,CHEMBL619984,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4183.0,,,12166.0,165.0,H,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,BAO_0000219,B,,CHEMBL619985,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4184.0,,,12166.0,165.0,H,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,BAO_0000219,B,,CHEMBL619986,1.0,,,,RBL-1,8.0,702.0,
Expert,,4185.0,,,12166.0,165.0,H,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,BAO_0000219,B,,CHEMBL619987,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4186.0,,,12166.0,11311.0,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,BAO_0000218,B,,CHEMBL619988,1.0,,,,,8.0,,
Autocuration,,4187.0,,,12166.0,11311.0,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,BAO_0000219,B,,CHEMBL619989,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4188.0,,,12166.0,11311.0,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,BAO_0000219,B,,CHEMBL619990,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4189.0,,,12166.0,11311.0,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,BAO_0000219,B,,CHEMBL619991,1.0,,,,,8.0,,
Autocuration,,4190.0,,,12166.0,11311.0,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,BAO_0000219,B,,CHEMBL619992,1.0,,,,,8.0,,
Autocuration,,4191.0,,,12166.0,11311.0,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,BAO_0000218,B,In vivo,CHEMBL619993,1.0,,,,,8.0,,
Autocuration,,4192.0,,,12166.0,11311.0,H,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,BAO_0000219,F,,CHEMBL619994,1.0,,,,RBL-2H3,8.0,663.0,
Autocuration,,4193.0,,,12166.0,11311.0,H,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,BAO_0000219,F,,CHEMBL619995,1.0,,,,RBL-2H3,8.0,663.0,
Autocuration,,4194.0,,,12166.0,11311.0,H,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,BAO_0000019,B,,CHEMBL619996,1.0,,,,,8.0,,
Autocuration,,4195.0,,,12166.0,11732.0,H,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,BAO_0000019,B,,CHEMBL619997,1.0,,,,,8.0,,
Expert,,4196.0,,,12166.0,11732.0,H,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,BAO_0000019,B,,CHEMBL619998,1.0,,,,,8.0,,
Expert,,4197.0,,,12166.0,11087.0,H,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,BAO_0000019,B,,CHEMBL619999,1.0,,,,,8.0,,
Autocuration,,4198.0,,,12166.0,11087.0,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,BAO_0000019,B,,CHEMBL620000,1.0,,,,,8.0,,
Autocuration,,4199.0,,,12166.0,11087.0,H,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,BAO_0000219,B,,CHEMBL620001,1.0,,,,RBL-1,8.0,702.0,
Expert,,4200.0,,,12166.0,11087.0,D,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,BAO_0000357,B,,CHEMBL620002,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,4201.0,,,12166.0,496.0,H,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,BAO_0000219,B,,CHEMBL620003,1.0,,,,RBL-1,8.0,702.0,
Expert,,4202.0,,,12166.0,13986.0,H,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,BAO_0000219,F,,CHEMBL620004,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4203.0,,,12166.0,11520.0,H,,Compound was evaluated for the inhibition of 5-lipoxygenase,,BAO_0000357,B,,CHEMBL874063,1.0,,,,,8.0,,
Autocuration,,4204.0,,,12166.0,10293.0,H,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,BAO_0000219,B,,CHEMBL620005,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4205.0,,,12166.0,303.0,H,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,BAO_0000219,B,,CHEMBL620006,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4206.0,,,12166.0,303.0,H,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,BAO_0000219,B,,CHEMBL620007,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4207.0,,,12166.0,9247.0,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,BAO_0000219,B,,CHEMBL620008,1.0,,,,RBL-1,8.0,702.0,
Expert,,4208.0,,,12166.0,9247.0,D,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,BAO_0000219,B,,CHEMBL620009,1.0,,,10116.0,RBL-1,9.0,702.0,Rattus norvegicus
Autocuration,,4209.0,,,12166.0,9247.0,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,BAO_0000219,B,,CHEMBL620010,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4210.0,,,12166.0,9247.0,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,BAO_0000219,B,,CHEMBL620011,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4211.0,,,12166.0,9247.0,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,BAO_0000219,B,,CHEMBL620677,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4212.0,,,12166.0,9247.0,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,BAO_0000219,B,,CHEMBL620678,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4213.0,,,12166.0,9247.0,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,BAO_0000219,B,,CHEMBL620679,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4214.0,,,12166.0,9247.0,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,BAO_0000219,B,,CHEMBL620680,1.0,,,,RBL-1,8.0,702.0,
Expert,,4215.0,,,12166.0,11481.0,D,,Inhibitory activity against 5-lipoxygenase at 10 uM,,BAO_0000357,B,,CHEMBL620838,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,4216.0,,,12166.0,105.0,H,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,BAO_0000357,B,,CHEMBL620839,1.0,,,,,8.0,,
Expert,,4217.0,,,12166.0,9029.0,H,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,BAO_0000357,B,,CHEMBL620840,1.0,,,,,8.0,,
Expert,,4218.0,,,12166.0,1175.0,H,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,BAO_0000219,B,,CHEMBL620841,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4219.0,,,12166.0,12118.0,H,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,BAO_0000219,B,,CHEMBL620842,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4220.0,,,12166.0,12118.0,H,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,BAO_0000219,B,,CHEMBL620843,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4221.0,,,12166.0,12118.0,H,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,BAO_0000219,B,,CHEMBL620844,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4222.0,,,12166.0,9225.0,H,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,BAO_0000219,B,,CHEMBL620845,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4223.0,,,12166.0,9401.0,H,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,BAO_0000019,B,,CHEMBL620846,1.0,,,,,8.0,,
Autocuration,,4224.0,,,12166.0,137.0,H,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,BAO_0000357,B,,CHEMBL873951,1.0,,,,,8.0,,
Autocuration,,4225.0,,,12166.0,137.0,H,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,BAO_0000357,B,,CHEMBL620847,1.0,,,,,8.0,,
Autocuration,,4226.0,,,12166.0,4717.0,H,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,BAO_0000219,B,,CHEMBL620848,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4227.0,,,12166.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,BAO_0000219,B,,CHEMBL620849,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4228.0,,,12166.0,10501.0,H,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,BAO_0000219,B,,CHEMBL620850,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4229.0,,,12166.0,10501.0,H,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,BAO_0000219,B,,CHEMBL620851,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4230.0,,,12166.0,10501.0,H,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,BAO_0000219,B,,CHEMBL620852,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4231.0,,,12166.0,12526.0,H,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,BAO_0000219,B,,CHEMBL875098,1.0,,,,RBL-1,8.0,702.0,
Expert,,4232.0,,,12166.0,14799.0,D,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,BAO_0000219,B,,CHEMBL620853,1.0,,,10116.0,RBL-1,9.0,702.0,Rattus norvegicus
Autocuration,,4233.0,,,12166.0,14799.0,H,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,BAO_0000019,B,,CHEMBL620854,1.0,,,,,8.0,,
Autocuration,,4234.0,,,12166.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,BAO_0000219,B,,CHEMBL620855,1.0,,,,RBL-1,8.0,702.0,
Expert,,4235.0,,,12166.0,3595.0,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,BAO_0000219,B,,CHEMBL839884,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4236.0,,,12166.0,12526.0,H,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,BAO_0000219,B,,CHEMBL620856,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4237.0,,,12166.0,12526.0,H,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,BAO_0000219,B,,CHEMBL620857,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4238.0,,,12166.0,10193.0,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,BAO_0000019,B,,CHEMBL620858,1.0,,,,,8.0,,
Autocuration,,4239.0,,,12166.0,10193.0,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,BAO_0000019,B,,CHEMBL620859,1.0,,,,,8.0,,
Autocuration,,4240.0,,,12166.0,10193.0,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,BAO_0000019,B,,CHEMBL620860,1.0,,,,,8.0,,
Autocuration,,4241.0,,,12166.0,10193.0,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,BAO_0000019,B,,CHEMBL620861,1.0,,,,,8.0,,
Expert,,4242.0,,,12166.0,9138.0,H,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,BAO_0000357,B,,CHEMBL620862,1.0,,,,,8.0,,
Autocuration,,4243.0,,,12166.0,9138.0,H,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,BAO_0000357,B,,CHEMBL620863,1.0,,,,,8.0,,
Autocuration,,4244.0,,,12166.0,11966.0,H,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,BAO_0000019,B,,CHEMBL620864,1.0,,,,,8.0,,
Autocuration,,4245.0,,,12166.0,165.0,H,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,BAO_0000219,B,,CHEMBL620865,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4246.0,,,12166.0,165.0,H,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,BAO_0000219,B,,CHEMBL620866,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4247.0,,,12166.0,11311.0,H,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,BAO_0000219,B,,CHEMBL620867,1.0,,,,RBL-2H3,8.0,663.0,
Autocuration,,4248.0,,,12166.0,11311.0,H,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,BAO_0000219,B,,CHEMBL620868,1.0,,,,RBL-2H3,8.0,663.0,
Autocuration,,4249.0,,,12166.0,11311.0,H,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,BAO_0000219,F,,CHEMBL620869,1.0,,,,RBL-2H3,8.0,663.0,
Autocuration,,4250.0,,,12166.0,11311.0,H,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,BAO_0000019,F,,CHEMBL873952,1.0,,,,,8.0,,
Autocuration,,4251.0,,,12166.0,11311.0,H,,The compound was tested for inhibition of isolated 5-lipoxygenase,,BAO_0000357,B,,CHEMBL875099,1.0,,,,,8.0,,
Autocuration,,4252.0,,,12166.0,11311.0,H,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,BAO_0000219,F,,CHEMBL620870,1.0,,,,RBL-2H3,8.0,663.0,
Autocuration,,4253.0,,,12166.0,11087.0,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,BAO_0000019,B,,CHEMBL618261,1.0,,,,,8.0,,
Autocuration,,4254.0,,,12166.0,11087.0,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,BAO_0000019,B,,CHEMBL618262,1.0,,,,,8.0,,
Autocuration,,4255.0,,,12166.0,11087.0,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,BAO_0000019,B,,CHEMBL619428,1.0,,,,,8.0,,
Autocuration,,4256.0,,,12166.0,11087.0,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,BAO_0000019,B,,CHEMBL619429,1.0,,,,,8.0,,
Autocuration,,4257.0,,,12166.0,11087.0,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,BAO_0000019,B,,CHEMBL619430,1.0,,,,,8.0,,
Autocuration,,4258.0,,,12166.0,496.0,H,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,BAO_0000219,B,,CHEMBL620017,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4259.0,,,12166.0,496.0,H,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,BAO_0000219,B,,CHEMBL620018,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4260.0,,,12166.0,13986.0,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,BAO_0000219,F,,CHEMBL620019,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4261.0,,,12166.0,13986.0,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,BAO_0000219,F,,CHEMBL620020,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4262.0,,,12166.0,13986.0,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,BAO_0000219,F,,CHEMBL620021,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4263.0,,,12166.0,13986.0,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,BAO_0000219,F,,CHEMBL620022,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4264.0,,,12166.0,13986.0,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,BAO_0000219,F,,CHEMBL620023,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4265.0,,,12166.0,13986.0,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,BAO_0000219,F,,CHEMBL620024,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4266.0,,,12166.0,13986.0,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,BAO_0000219,F,,CHEMBL620025,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4267.0,,,12166.0,13986.0,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,BAO_0000219,F,,CHEMBL620026,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4268.0,,,12166.0,13986.0,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,BAO_0000219,F,,CHEMBL620027,1.0,,,,RBL-1,8.0,702.0,
Expert,,4269.0,,,12166.0,13986.0,D,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,BAO_0000019,F,,CHEMBL620028,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,4270.0,,,12166.0,10193.0,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,BAO_0000357,B,,CHEMBL620029,1.0,,,,,8.0,,
Autocuration,,4271.0,,,12166.0,9295.0,H,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,BAO_0000357,B,,CHEMBL620030,1.0,,,,,8.0,,
Autocuration,,4272.0,,,12166.0,4717.0,H,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,BAO_0000219,B,,CHEMBL875415,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4273.0,,,12166.0,4717.0,H,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,BAO_0000219,B,,CHEMBL618256,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4274.0,,,12166.0,11854.0,H,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,BAO_0000219,B,,CHEMBL618257,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4275.0,,,12166.0,11854.0,H,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,BAO_0000219,B,,CHEMBL618258,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4276.0,,,12166.0,11854.0,H,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,BAO_0000219,B,,CHEMBL618259,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4277.0,,,12166.0,10193.0,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,BAO_0000019,B,,CHEMBL618260,1.0,,,,,8.0,,
Autocuration,,4278.0,,,12166.0,9295.0,H,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,BAO_0000219,B,,CHEMBL618215,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4279.0,,,12166.0,9295.0,H,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,BAO_0000219,B,,CHEMBL618390,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4280.0,,,12166.0,9295.0,H,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,BAO_0000219,B,,CHEMBL618391,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4281.0,,,12166.0,9295.0,H,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,BAO_0000219,B,,CHEMBL618392,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4282.0,,,12166.0,165.0,H,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,BAO_0000219,B,,CHEMBL618393,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4283.0,,,12166.0,11311.0,H,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,BAO_0000219,B,,CHEMBL618394,1.0,,,,,8.0,,
Expert,,4284.0,,,12166.0,10489.0,H,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,BAO_0000219,B,,CHEMBL618395,1.0,,,9606.0,RBL-1,8.0,702.0,Homo sapiens
Expert,,4285.0,,,12166.0,10489.0,D,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,BAO_0000219,B,,CHEMBL618396,1.0,,,10116.0,RBL-1,9.0,702.0,Rattus norvegicus
Expert,,4286.0,,,12166.0,10489.0,D,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,BAO_0000219,B,,CHEMBL858253,1.0,,,10116.0,RBL-1,9.0,702.0,Rattus norvegicus
Autocuration,,4287.0,,,12166.0,14799.0,D,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,BAO_0000019,B,,CHEMBL618397,1.0,,,10116.0,,9.0,,Rattus norvegicus
Autocuration,,4288.0,,,12054.0,9295.0,H,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,BAO_0000357,B,,CHEMBL618398,1.0,,,3847.0,,8.0,,Glycine max
Autocuration,,4289.0,,,22226.0,16811.0,U,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,BAO_0000019,B,,CHEMBL618399,1.0,,,,,0.0,,
Expert,,4290.0,,,55.0,168.0,H,,In vitro inhibition of 5-Lipoxygenase; Inactive.,,BAO_0000357,B,,CHEMBL618400,1.0,,,,,8.0,,
Autocuration,,4291.0,,,55.0,6309.0,H,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,BAO_0000357,B,,CHEMBL618401,1.0,,,,,8.0,,
Autocuration,,4292.0,,,55.0,6309.0,H,,Inhibitory concentration against 5-lipoxygenase; No inhibition,,BAO_0000357,B,,CHEMBL618402,1.0,,,,,8.0,,
Autocuration,,4293.0,,,55.0,3092.0,H,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,BAO_0000219,B,,CHEMBL876400,1.0,,,,RBL-1,8.0,702.0,
Expert,,4294.0,,,55.0,168.0,H,,Inhibitory activity against 5-lipoxygenase.,,BAO_0000357,B,,CHEMBL618403,1.0,,,,,8.0,,
Autocuration,,4295.0,,,55.0,168.0,H,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,BAO_0000357,B,,CHEMBL618404,1.0,,,,,8.0,,
Autocuration,,4296.0,,,55.0,168.0,H,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,BAO_0000357,B,,CHEMBL618405,1.0,,,,,8.0,,
Autocuration,,4297.0,,,55.0,168.0,H,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,BAO_0000357,B,,CHEMBL618406,1.0,,,,,8.0,,
Expert,,4298.0,,,55.0,12338.0,H,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,BAO_0000019,F,,CHEMBL618407,1.0,,,,,8.0,,
Autocuration,,4299.0,,,55.0,4501.0,H,,Tested for the inhibitory activity against 5-lipoxygenase,,BAO_0000357,B,,CHEMBL618408,1.0,,,,,8.0,,
Autocuration,,4300.0,,,55.0,1132.0,H,,Compound was tested for its inhibitory activity against 5-lipoxygenase,,BAO_0000357,B,,CHEMBL618409,1.0,,,,,8.0,,
Autocuration,,4301.0,,,55.0,2117.0,H,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,BAO_0000357,B,,CHEMBL618410,1.0,,,,,8.0,,
Autocuration,,4302.0,,,55.0,168.0,H,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,BAO_0000357,B,,CHEMBL618411,1.0,,,,,8.0,,
Autocuration,,4303.0,,,55.0,168.0,H,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,BAO_0000357,B,,CHEMBL618412,1.0,,,,,8.0,,
Autocuration,,4304.0,,,12166.0,13575.0,H,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,BAO_0000219,B,,CHEMBL618413,1.0,,,,RBL-1,8.0,702.0,
Autocuration,,4305.0,,,12166.0,11089.0,H,,,,BAO_0000357,B,,CHEMBL618414,1.0,,,,,8.0,,
Autocuration,,4306.0,,,10102.0,216.0,H,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,BAO_0000357,B,,CHEMBL618415,1.0,,,,,8.0,,
Autocuration,,4307.0,,,10102.0,13165.0,H,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,BAO_0000019,B,,CHEMBL618416,1.0,,,,,8.0,,
Autocuration,,4308.0,,,10102.0,3278.0,H,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,BAO_0000357,B,,CHEMBL876401,1.0,,,,,8.0,,
Expert,,4309.0,,,10102.0,3278.0,H,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,BAO_0000357,B,,CHEMBL618417,1.0,,,,,8.0,,
Autocuration,,4310.0,,,10102.0,11966.0,H,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,BAO_0000357,B,,CHEMBL618418,1.0,,,,,8.0,,
Autocuration,,4311.0,,,10102.0,175.0,H,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,BAO_0000357,B,,CHEMBL618419,1.0,,,,,8.0,,
Autocuration,,4312.0,,,10102.0,175.0,H,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,BAO_0000357,B,,CHEMBL618420,1.0,,,,,8.0,,
Autocuration,,4313.0,,,10102.0,13449.0,H,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,BAO_0000357,B,,CHEMBL618421,1.0,,,,,8.0,,
Autocuration,,4314.0,,,11238.0,12014.0,H,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,BAO_0000019,B,,CHEMBL618422,1.0,,,,,8.0,,
Autocuration,,4315.0,,,11238.0,12014.0,H,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,BAO_0000019,B,,CHEMBL618423,1.0,,,,,8.0,,
Autocuration,,4316.0,,,11238.0,12014.0,H,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,BAO_0000019,B,,CHEMBL618424,1.0,,,,,8.0,,
Intermediate,,4317.0,,,100284.0,99.0,S,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,BAO_0000220,B,,CHEMBL618425,1.0,,,,,2.0,,
Autocuration,,4318.0,,,22226.0,4349.0,U,,The dark toxicity against 543 human galactophore carcinoma cells,,BAO_0000019,F,,CHEMBL618426,1.0,,,9606.0,,0.0,,Homo sapiens
Expert,,4319.0,,,80623.0,4071.0,N,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,BAO_0000219,F,,CHEMBL618427,1.0,,,9606.0,Panel (56 tumour cell lines),1.0,390.0,Homo sapiens
Expert,,4320.0,,,80008.0,17589.0,N,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,BAO_0000219,F,,CHEMBL618428,1.0,,,9606.0,5637,1.0,345.0,Homo sapiens
Intermediate,,4321.0,,,80008.0,15002.0,N,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,BAO_0000219,F,,CHEMBL618429,1.0,,,9606.0,5637,1.0,345.0,Homo sapiens
Intermediate,,4322.0,,,80008.0,13958.0,N,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,BAO_0000219,F,,CHEMBL618430,1.0,,,9606.0,5637,1.0,345.0,Homo sapiens
Expert,,4323.0,,,80008.0,17589.0,N,,Growth inhibition against human 5637 cell lines,,BAO_0000219,F,,CHEMBL618431,1.0,,,9606.0,5637,1.0,345.0,Homo sapiens
Expert,,4324.0,,,80008.0,16748.0,N,,Antitumor activity against human bladder carcinoma 5637 cells.,,BAO_0000219,F,,CHEMBL883799,1.0,,,9606.0,5637,1.0,345.0,Homo sapiens
Intermediate,,4325.0,,,80008.0,16747.0,N,,Antitumor activity against human bladder carcinoma 5637 cells,,BAO_0000219,F,,CHEMBL618432,1.0,,,9606.0,5637,1.0,345.0,Homo sapiens
Intermediate,,4326.0,,,80008.0,16747.0,N,,Antitumor activity against human bladder carcinoma 5637 cells,,BAO_0000219,F,,CHEMBL618433,1.0,,,9606.0,5637,1.0,345.0,Homo sapiens
Expert,,4327.0,,,10443.0,15285.0,D,,In vitro inhibition of bovine trypsin(Trp).,,BAO_0000357,B,,CHEMBL618434,1.0,,,9913.0,,9.0,,Bos taurus
Expert,,4328.0,,,240.0,3726.0,H,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,BAO_0000219,B,,CHEMBL618435,1.0,,,9527.0,CV-1,8.0,407.0,Cercopithecidae
Autocuration,,4329.0,,,10577.0,5033.0,H,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,BAO_0000357,B,,CHEMBL876402,1.0,,,,,8.0,,
Autocuration,,4330.0,,,104698.0,11756.0,H,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,BAO_0000019,F,,CHEMBL618436,1.0,,,,,6.0,,
Autocuration,,4331.0,,,22226.0,11953.0,U,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,BAO_0000218,F,In vivo,CHEMBL618437,1.0,,,,,0.0,,
Intermediate,,4332.0,,,20033.0,5033.0,D,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,BAO_0000357,B,,CHEMBL618438,1.0,,,10141.0,,9.0,,Cavia porcellus
Expert,,4333.0,,,17045.0,11347.0,H,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Microsomes,BAO_0000251,A,,CHEMBL883800,1.0,,,10116.0,,8.0,,Rattus norvegicus
Expert,,4334.0,,,17045.0,11347.0,H,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Microsomes,BAO_0000251,A,,CHEMBL618439,1.0,,,10116.0,,8.0,,Rattus norvegicus
Intermediate,,4335.0,,,22226.0,1229.0,U,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,BAO_0000019,F,,CHEMBL618440,1.0,,,,,0.0,,
Intermediate,,4336.0,,,22226.0,1229.0,U,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,BAO_0000019,F,,CHEMBL618441,1.0,,,,,0.0,,
Expert,,4337.0,,,11938.0,17588.0,H,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,BAO_0000019,B,,CHEMBL618442,1.0,,,5691.0,,8.0,,Trypanosoma brucei
Autocuration,,4338.0,,,11938.0,17588.0,H,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,BAO_0000019,B,,CHEMBL618443,1.0,,,5691.0,,8.0,,Trypanosoma brucei
Expert,,4339.0,,,11938.0,17588.0,H,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,BAO_0000019,B,,CHEMBL619158,1.0,,,9940.0,,8.0,,Ovis aries
Autocuration,,4340.0,,,11938.0,17588.0,H,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,BAO_0000019,B,,CHEMBL620974,1.0,,,9940.0,,8.0,,Ovis aries
Autocuration,,4341.0,,,11938.0,16485.0,H,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,BAO_0000357,B,,CHEMBL620975,1.0,,,,,8.0,,
Intermediate,,4342.0,,,22226.0,4337.0,U,,Average inhibitory concentration against 60 human cell lines was reported,,BAO_0000019,F,,CHEMBL620976,1.0,,,9606.0,,0.0,,Homo sapiens
Expert,,4343.0,,,22226.0,4112.0,U,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,BAO_0000019,F,,CHEMBL620977,1.0,,,9606.0,,0.0,,Homo sapiens
Intermediate,,4344.0,,,80315.0,16160.0,N,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,BAO_0000219,F,,CHEMBL620978,1.0,,,9606.0,Panel NCI-60 (60 carcinoma cell lines),1.0,542.0,Homo sapiens
Intermediate,,4345.0,,,80315.0,16160.0,N,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,BAO_0000219,F,,CHEMBL620979,1.0,,,9606.0,Panel NCI-60 (60 carcinoma cell lines),1.0,542.0,Homo sapiens
Expert,,4346.0,,,80315.0,17376.0,N,,In vitro mean growth inhibitory activity against 60-cell panel,,BAO_0000219,F,,CHEMBL620980,1.0,,,,Panel NCI-60 (60 carcinoma cell lines),1.0,542.0,
Expert,,4347.0,,,80315.0,17376.0,N,,In vitro mean growth lethal concentration against 60-cell panel,,BAO_0000219,F,,CHEMBL620981,1.0,,,,Panel NCI-60 (60 carcinoma cell lines),1.0,542.0,
Expert,,4348.0,,,80315.0,17376.0,N,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,BAO_0000219,F,,CHEMBL620982,1.0,,,,Panel NCI-60 (60 carcinoma cell lines),1.0,542.0,
Expert,,4349.0,,,80315.0,17376.0,N,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,BAO_0000219,F,,CHEMBL620983,1.0,,,,Panel NCI-60 (60 carcinoma cell lines),1.0,542.0,
Autocuration,,4350.0,,,104775.0,3241.0,H,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,BAO_0000019,F,,CHEMBL620984,1.0,,,,,4.0,,
Autocuration,,4351.0,,,104775.0,3241.0,H,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,BAO_0000019,F,,CHEMBL620985,1.0,,,,,4.0,,
Expert,,4352.0,,,275.0,3725.0,H,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,BAO_0000357,B,,CHEMBL620986,1.0,,,,,8.0,,
Expert,,4353.0,,,50425.0,10805.0,N,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,BAO_0000218,F,,CHEMBL620987,1.0,,,5833.0,,1.0,,Plasmodium falciparum
Expert,,4354.0,,,50425.0,10805.0,N,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,BAO_0000218,F,,CHEMBL620988,1.0,,,5833.0,,1.0,,Plasmodium falciparum
Expert,,4355.0,,,50425.0,10805.0,N,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,BAO_0000218,F,,CHEMBL620989,1.0,,,5833.0,,1.0,,Plasmodium falciparum
Expert,,4356.0,,,50425.0,10805.0,N,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,BAO_0000218,F,,CHEMBL620990,1.0,,,5833.0,,1.0,,Plasmodium falciparum
Intermediate,,4357.0,,,50425.0,10805.0,N,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,BAO_0000218,F,,CHEMBL620991,1.0,,,5833.0,,1.0,,Plasmodium falciparum
Intermediate,,4358.0,,,80628.0,10144.0,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,BAO_0000218,F,,CHEMBL620992,1.0,,,10090.0,6C3HED,1.0,850.0,Mus musculus
Intermediate,,4359.0,,,80628.0,10144.0,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,BAO_0000218,F,,CHEMBL620993,1.0,,,10090.0,6C3HED,1.0,850.0,Mus musculus
Intermediate,,4360.0,,,80628.0,10144.0,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,BAO_0000218,F,,CHEMBL620994,1.0,,,10090.0,6C3HED,1.0,850.0,Mus musculus
Intermediate,,4361.0,,,80628.0,10144.0,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,BAO_0000218,F,,CHEMBL620995,1.0,,,10090.0,6C3HED,1.0,850.0,Mus musculus
Intermediate,,4362.0,,,80628.0,10144.0,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,BAO_0000218,F,,CHEMBL620996,1.0,,,10090.0,6C3HED,1.0,850.0,Mus musculus
Intermediate,,4363.0,,,80628.0,10144.0,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,BAO_0000218,F,,CHEMBL875581,1.0,,,10090.0,6C3HED,1.0,850.0,Mus musculus
Autocuration,,4364.0,,,22224.0,10685.0,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,BAO_0000218,F,In vivo,CHEMBL620997,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4365.0,,,22224.0,10685.0,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,BAO_0000218,F,In vivo,CHEMBL620998,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4366.0,,,22224.0,10685.0,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,BAO_0000218,F,In vivo,CHEMBL620999,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4367.0,,,22224.0,10685.0,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,BAO_0000218,F,In vivo,CHEMBL621000,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4368.0,,,22224.0,10685.0,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,BAO_0000218,F,In vivo,CHEMBL621001,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4369.0,,,22224.0,10685.0,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,BAO_0000218,F,In vivo,CHEMBL621002,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4370.0,,,22224.0,10685.0,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,BAO_0000218,F,In vivo,CHEMBL621003,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4371.0,,,22224.0,10685.0,U,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,BAO_0000218,F,In vivo,CHEMBL621004,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4372.0,,,22224.0,10685.0,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,BAO_0000218,F,In vivo,CHEMBL621005,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4373.0,,,22224.0,10685.0,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,BAO_0000218,F,In vivo,CHEMBL621006,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4374.0,,,22224.0,10685.0,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,BAO_0000218,F,In vivo,CHEMBL621007,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4375.0,,,22224.0,10144.0,U,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,BAO_0000218,F,,CHEMBL621008,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4376.0,,,22224.0,10144.0,U,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,BAO_0000218,F,,CHEMBL621009,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4377.0,,,22224.0,10144.0,U,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,BAO_0000218,F,,CHEMBL857705,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4378.0,,,22224.0,10144.0,U,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,BAO_0000218,F,,CHEMBL619828,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4379.0,,,22224.0,10685.0,U,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,BAO_0000218,F,,CHEMBL619829,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4380.0,,,22224.0,10685.0,U,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,BAO_0000218,F,,CHEMBL619830,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4381.0,,,22224.0,10685.0,U,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,BAO_0000218,F,,CHEMBL619831,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4382.0,,,22224.0,10685.0,U,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,BAO_0000218,F,,CHEMBL619832,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4383.0,,,22224.0,10685.0,U,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,BAO_0000218,A,,CHEMBL619833,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4384.0,,,22224.0,10685.0,U,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,BAO_0000218,A,,CHEMBL619834,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4385.0,,,22224.0,10685.0,U,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,BAO_0000218,A,,CHEMBL619835,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,4386.0,,,22224.0,10685.0,U,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,BAO_0000218,A,,CHEMBL619836,1.0,,,10090.0,,0.0,,Mus musculus
Intermediate,,4387.0,,,80628.0,8831.0,N,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,BAO_0000218,F,,CHEMBL619837,1.0,,,10090.0,6C3HED,1.0,850.0,Mus musculus
Autocuration,,4388.0,,,22224.0,11704.0,U,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,BAO_0000218,F,In vivo,CHEMBL619838,1.0,,,,,0.0,,
Intermediate,,4389.0,,,50594.0,11704.0,N,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,BAO_0000218,A,,CHEMBL619839,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4390.0,,,80628.0,10685.0,N,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,BAO_0000218,F,In vivo,CHEMBL619840,1.0,,,10090.0,6C3HED,1.0,850.0,Mus musculus
Intermediate,,4391.0,,,80628.0,10685.0,N,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,BAO_0000218,F,In vivo,CHEMBL619841,1.0,,,10090.0,6C3HED,1.0,850.0,Mus musculus
Expert,,4392.0,,,80628.0,11368.0,N,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,BAO_0000218,F,,CHEMBL857704,1.0,,,10090.0,6C3HED,1.0,850.0,Mus musculus
Intermediate,,4393.0,,,80628.0,11368.0,N,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,BAO_0000218,F,,CHEMBL619842,1.0,,,10090.0,6C3HED,1.0,850.0,Mus musculus
Expert,,4394.0,,,80628.0,11368.0,N,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,BAO_0000218,F,,CHEMBL619843,1.0,,,10090.0,6C3HED,1.0,850.0,Mus musculus
Autocuration,,4395.0,,,22226.0,17763.0,U,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,BAO_0000019,B,,CHEMBL619844,1.0,,,1280.0,,0.0,,Staphylococcus aureus
Autocuration,Liver,4396.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Microsomes,BAO_0000251,B,,CHEMBL857855,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4397.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Microsomes,BAO_0000251,B,,CHEMBL619845,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4398.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Microsomes,BAO_0000251,B,,CHEMBL619846,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4399.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Microsomes,BAO_0000251,B,,CHEMBL619847,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4400.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Microsomes,BAO_0000251,B,,CHEMBL619848,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4401.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Microsomes,BAO_0000251,B,,CHEMBL620893,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4402.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Microsomes,BAO_0000251,B,,CHEMBL620894,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4403.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Microsomes,BAO_0000251,B,,CHEMBL620895,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4404.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Microsomes,BAO_0000251,B,,CHEMBL620896,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4405.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Microsomes,BAO_0000251,B,,CHEMBL620897,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4406.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Microsomes,BAO_0000251,B,,CHEMBL620898,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Liver,4407.0,,,22226.0,7411.0,U,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Microsomes,BAO_0000251,B,,CHEMBL620899,1.0,2107.0,,10116.0,,0.0,,Rattus norvegicus
Autocuration,Plasma,4408.0,,,22224.0,347.0,U,,The apparent total plasma clearance in monkey,,BAO_0000218,A,In vivo,CHEMBL620900,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4409.0,,,22224.0,3341.0,U,,Compound was evaluated for Hepatic clearance in monkey,,BAO_0000218,A,In vivo,CHEMBL620901,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4410.0,,,22224.0,17853.0,U,,Lower clearance in monkey (i.v.) at 0.5 mpk,,BAO_0000218,A,In vivo,CHEMBL620902,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4411.0,,,22224.0,4514.0,U,,Plasma clearance in rhesus monkey,,BAO_0000218,A,In vivo,CHEMBL620903,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4412.0,,,22224.0,6062.0,U,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL620904,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4413.0,,,22224.0,6821.0,U,,Plasma clearance of compound was determined in monkey,,BAO_0000218,A,In vivo,CHEMBL620905,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4414.0,,,22224.0,6057.0,U,,Plasma clearance was calculated in rhesus monkey,,BAO_0000218,A,In vivo,CHEMBL620906,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4415.0,,,22224.0,5145.0,U,,Plasma clearance in rhesus monkey,,BAO_0000218,A,In vivo,CHEMBL875420,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4416.0,,,22224.0,6641.0,U,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,A,In vivo,CHEMBL620907,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4417.0,,,22224.0,5472.0,U,,Plasma clearance was evaluated in rhesus,,BAO_0000218,A,In vivo,CHEMBL620908,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4418.0,,,22224.0,4257.0,U,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,BAO_0000218,A,In vivo,CHEMBL620909,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4419.0,,,22224.0,5546.0,U,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,BAO_0000218,A,In vivo,CHEMBL620910,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4420.0,,,22224.0,5334.0,U,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,A,In vivo,CHEMBL620911,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4421.0,,,22224.0,5334.0,U,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,A,In vivo,CHEMBL620912,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4422.0,,,22224.0,17509.0,U,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,BAO_0000218,A,In vivo,CHEMBL620913,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4423.0,,,22224.0,6535.0,U,,Cmax in monkey after administration of 1 mg/kg iv,,BAO_0000218,A,In vivo,CHEMBL620914,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4424.0,,,22224.0,5668.0,U,,Cmax was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000218,A,In vivo,CHEMBL620915,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4425.0,,,22224.0,5922.0,U,,Cmax in cynomolgus monkey by iv administration,,BAO_0000218,A,In vivo,CHEMBL620916,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4426.0,,,22224.0,5922.0,U,,Cmax in cynomolgus monkey by po administration,,BAO_0000218,A,In vivo,CHEMBL620917,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4427.0,,,22224.0,6078.0,U,,Cmax value evaluated in monkey,,BAO_0000218,A,In vivo,CHEMBL620918,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4428.0,,,22224.0,2661.0,U,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000218,A,In vivo,CHEMBL620919,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,4429.0,,,22224.0,3249.0,U,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL620920,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,4430.0,,,22224.0,3249.0,U,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL620921,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,4431.0,,,22224.0,5553.0,U,,Maximal plasma concentration in squirrel monkeys,,BAO_0000218,A,In vivo,CHEMBL620922,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4432.0,,,22224.0,1916.0,U,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,A,In vivo,CHEMBL620923,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,4433.0,,,22224.0,6227.0,U,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL620924,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4434.0,,,22224.0,4809.0,U,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,A,In vivo,CHEMBL620925,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4435.0,,,22224.0,5355.0,U,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,A,In vivo,CHEMBL620926,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4436.0,,,22224.0,5355.0,U,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,A,In vivo,CHEMBL620927,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4437.0,,,22224.0,5355.0,U,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,BAO_0000218,A,In vivo,CHEMBL620928,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4438.0,,,22224.0,5355.0,U,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,BAO_0000218,A,In vivo,CHEMBL620929,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,4439.0,,,22224.0,6221.0,U,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,A,In vivo,CHEMBL620930,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4440.0,,,22224.0,167.0,U,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,BAO_0000218,A,,CHEMBL620931,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4441.0,,,22224.0,167.0,U,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,BAO_0000218,A,,CHEMBL620932,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4442.0,,,22224.0,4257.0,U,,Absolute bioavailability was evaluated in monkey,,BAO_0000218,A,In vivo,CHEMBL620933,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4443.0,,,22224.0,6221.0,U,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,A,In vivo,CHEMBL620934,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4444.0,,,22224.0,17667.0,U,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,BAO_0000218,A,In vivo,CHEMBL620935,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4445.0,,,22224.0,17267.0,U,,Bioavailability of compound was determined in rhesus monkey,,BAO_0000218,A,In vivo,CHEMBL620936,1.0,,,9544.0,,0.0,,Macaca mulatta
Autocuration,,4446.0,,,22224.0,4256.0,U,,Bioavailability determined after oral administration in marmoset,,BAO_0000218,A,In vivo,CHEMBL620937,1.0,,,38020.0,,0.0,,marmosets
Autocuration,,4447.0,,,22224.0,4256.0,U,,Oral bioavailability in cynomolgus monkey,,BAO_0000218,A,In vivo,CHEMBL620938,1.0,,,9541.0,,0.0,,Macaca fascicularis
Autocuration,,4448.0,,,22224.0,17853.0,U,,Bioavailability in monkey (p.o.) at 2.0 mpk,,BAO_0000218,A,In vivo,CHEMBL620939,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4449.0,,,22224.0,16365.0,U,,Bioavailability was evaluated after oral administration in monkey,,BAO_0000218,A,In vivo,CHEMBL620940,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4450.0,,,22224.0,1916.0,U,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,A,In vivo,CHEMBL620941,1.0,,,9541.0,,0.0,,Macaca fascicularis
Autocuration,,4451.0,,,22224.0,5334.0,U,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,A,In vivo,CHEMBL620942,1.0,,,9544.0,,0.0,,Macaca mulatta
Autocuration,,4452.0,,,22224.0,5334.0,U,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,A,In vivo,CHEMBL620943,1.0,,,9544.0,,0.0,,Macaca mulatta
Autocuration,,4453.0,,,22224.0,17592.0,U,,Bioavailability of the compound was determined in monkey,,BAO_0000218,A,In vivo,CHEMBL620944,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4454.0,,,22224.0,1399.0,U,,Bioavailability in squirrel monkey (dose 5 mg/kg),,BAO_0000218,A,In vivo,CHEMBL620945,1.0,,,9521.0,,0.0,,Saimiri sciureus
Autocuration,,4455.0,,,22224.0,4809.0,U,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,A,In vivo,CHEMBL620946,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4456.0,,,22224.0,3341.0,U,,Oral bioavailability in monkey,,BAO_0000218,A,In vivo,CHEMBL620947,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4457.0,,,22224.0,64.0,U,,Compound was tested for bioavailability in squirrel monkey,,BAO_0000218,A,In vivo,CHEMBL620948,1.0,,,9521.0,,0.0,,Saimiri sciureus
Autocuration,,4458.0,,,22224.0,5005.0,U,,Oral bioavailability in Rhesus monkey,,BAO_0000218,A,In vivo,CHEMBL620949,1.0,,,9544.0,,0.0,,Macaca mulatta
Autocuration,,4459.0,,,22224.0,5005.0,U,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,BAO_0000218,A,In vivo,CHEMBL620950,1.0,,,9544.0,,0.0,,Macaca mulatta
Autocuration,,4460.0,,,22224.0,5237.0,U,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,BAO_0000218,A,In vivo,CHEMBL620951,1.0,,,9541.0,,0.0,,Macaca fascicularis
Autocuration,,4461.0,,,22224.0,5237.0,U,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,BAO_0000218,A,In vivo,CHEMBL620952,1.0,,,9541.0,,0.0,,Macaca fascicularis
Autocuration,,4462.0,,,22224.0,5302.0,U,,Oral bioavailability in monkey (dose 5 mg/kg),,BAO_0000218,A,In vivo,CHEMBL875421,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4463.0,,,22224.0,17667.0,U,,Oral bioavailability of compound at 5 mg/kg in monkey,,BAO_0000218,A,In vivo,CHEMBL620953,1.0,,,9443.0,,0.0,,monkey
Intermediate,,4464.0,,,50588.0,6161.0,N,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,BAO_0000218,A,In vivo,CHEMBL873491,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,4465.0,,,50588.0,6161.0,N,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,BAO_0000218,A,In vivo,CHEMBL620954,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,4466.0,,,50588.0,3854.0,N,,Plasma half life determined,,BAO_0000218,A,,CHEMBL620955,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,4467.0,,,50588.0,993.0,N,,Plasma half life in dog,,BAO_0000218,A,,CHEMBL618097,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,4468.0,,,50588.0,4514.0,N,,Plasma half-life in Beagle dogs,,BAO_0000218,A,,CHEMBL618268,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,4469.0,,,50588.0,5334.0,N,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,BAO_0000218,A,In vivo,CHEMBL618269,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,4470.0,,,50588.0,5334.0,N,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,BAO_0000218,A,In vivo,CHEMBL618270,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,4471.0,,,50588.0,1466.0,N,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,BAO_0000218,A,In vivo,CHEMBL618271,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,4472.0,,,50588.0,1466.0,N,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,BAO_0000218,A,In vivo,CHEMBL873493,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,4473.0,,,50588.0,5313.0,N,,Tested for the half life period in dog,,BAO_0000218,A,,CHEMBL621031,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,4474.0,,,50588.0,5313.0,N,,Tested for the half life period in dog at dosage of 10 mpk,,BAO_0000218,A,In vivo,CHEMBL621032,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,4475.0,,,50588.0,3880.0,N,,The compound was tested for half life in dog,,BAO_0000218,A,,CHEMBL621033,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,4476.0,,,50588.0,3639.0,N,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,BAO_0000218,A,,CHEMBL621034,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,4477.0,,,50588.0,3880.0,N,,The half life was determined,,BAO_0000218,A,,CHEMBL621035,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,4478.0,,,50588.0,3918.0,N,,The plasma half-life in dogs,,BAO_0000218,A,,CHEMBL621036,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,4479.0,,,50588.0,16452.0,N,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,BAO_0000218,A,,CHEMBL621037,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,4480.0,,,50588.0,17796.0,N,,Half life in dog,,BAO_0000218,A,,CHEMBL619812,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,4481.0,,,50588.0,5983.0,N,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,BAO_0000218,A,In vivo,CHEMBL619813,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,4482.0,,,50588.0,1466.0,N,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,BAO_0000218,A,In vivo,CHEMBL873335,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,4483.0,,,50588.0,16456.0,N,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL619814,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Expert,,4484.0,,,50506.0,6113.0,N,,Cmax in ferrets after 30 mg/kg oral dose,,BAO_0000218,A,In vivo,CHEMBL619815,1.0,,,9669.0,,1.0,,Mustela putorius furo
Expert,,4485.0,,,50506.0,6113.0,N,,Emesis in ferrets at 30 mg/kg oral dose,,BAO_0000218,F,In vivo,CHEMBL619816,1.0,,,9669.0,,1.0,,Mustela putorius furo
Autocuration,,4486.0,,,22224.0,17796.0,U,,Bioavailability in cynomolgus monkey,,BAO_0000218,A,In vivo,CHEMBL619817,1.0,,,9541.0,,0.0,,Macaca fascicularis
Intermediate,,4487.0,,,100710.0,17796.0,N,,Volume of distribution in cynomolgus,,BAO_0000218,A,In vivo,CHEMBL619818,1.0,,,9541.0,,1.0,,Macaca fascicularis
Autocuration,Plasma,4488.0,,,22224.0,5308.0,U,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,BAO_0000218,A,,CHEMBL619819,1.0,1969.0,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4489.0,,,22224.0,4877.0,U,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,BAO_0000218,A,,CHEMBL619820,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4490.0,,,22224.0,4876.0,U,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,BAO_0000218,A,,CHEMBL875419,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,Plasma,4491.0,,,22224.0,4878.0,U,,AUC in guinea pig after 3mg/kg oral dose,,BAO_0000218,A,In vivo,CHEMBL619821,1.0,1969.0,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4492.0,,,22224.0,5308.0,U,,Bioavailability in guinea pig was tested,,BAO_0000218,A,In vivo,CHEMBL619822,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4493.0,,,22224.0,4877.0,U,,Tested for oral bioavailability in guinea pig at 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL619823,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4494.0,,,22224.0,4876.0,U,,Tested for the oral bioavailability of the compound,,BAO_0000218,A,In vivo,CHEMBL619824,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4495.0,,,22224.0,4876.0,U,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,BAO_0000218,A,In vivo,CHEMBL619825,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4496.0,,,22224.0,5308.0,U,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,BAO_0000218,A,In vivo,CHEMBL619826,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,Lung,4497.0,,,22224.0,4877.0,U,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL619827,1.0,2048.0,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4498.0,,,22224.0,4878.0,U,,Cmax in guinea pig after 3mg/kg oral dose,,BAO_0000218,A,In vivo,CHEMBL618167,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,Blood,4499.0,,,22224.0,5689.0,U,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,A,,CHEMBL618168,1.0,178.0,,10141.0,,0.0,,Cavia porcellus
Autocuration,Brain,4500.0,,,22224.0,5689.0,U,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,A,,CHEMBL618169,1.0,955.0,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4501.0,,,22224.0,5689.0,U,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,A,,CHEMBL618170,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,Intestine,4502.0,,,22224.0,5689.0,U,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,A,,CHEMBL618171,1.0,160.0,,10141.0,,0.0,,Cavia porcellus
Autocuration,Kidney,4503.0,,,22224.0,5689.0,U,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,A,,CHEMBL618172,1.0,2113.0,,10141.0,,0.0,,Cavia porcellus
Autocuration,Liver,4504.0,,,22224.0,5689.0,U,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,A,,CHEMBL618173,1.0,2107.0,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4505.0,,,22224.0,5689.0,U,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,A,,CHEMBL618174,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,Spleen,4506.0,,,22224.0,5689.0,U,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,A,,CHEMBL875408,1.0,2106.0,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4507.0,,,22224.0,14465.0,U,,Elimination T1/2 in Guinea pig (PO dose),,BAO_0000218,A,In vivo,CHEMBL839827,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4508.0,,,22224.0,5689.0,U,,Partition coefficient was measured as -log (counts per min ),,BAO_0000019,A,,CHEMBL618175,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4509.0,,,22224.0,611.0,U,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,BAO_0000218,A,In vivo,CHEMBL618176,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4510.0,,,22224.0,611.0,U,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,BAO_0000218,A,In vivo,CHEMBL618177,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4511.0,,,22224.0,14465.0,U,,Elimination T1/2 in Guinea pig (PO dose),,BAO_0000218,A,In vivo,CHEMBL618178,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4512.0,,,22224.0,4876.0,U,,"Tested for the half life period of the compound, intravenously",,BAO_0000218,A,In vivo,CHEMBL618179,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4513.0,,,22224.0,5689.0,U,,Half-life was measured,,BAO_0000019,A,,CHEMBL873489,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4514.0,,,22224.0,7515.0,U,,The time required for onset of inotropy after addition of a single dose of delta F75,,BAO_0000019,A,,CHEMBL618180,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4515.0,,,22224.0,17667.0,U,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,BAO_0000218,A,In vivo,CHEMBL618181,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4516.0,,,22224.0,17667.0,U,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,BAO_0000218,A,In vivo,CHEMBL618182,1.0,,,10141.0,,0.0,,Cavia porcellus
Autocuration,,4517.0,,,22224.0,4727.0,U,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,BAO_0000218,A,In vivo,CHEMBL618183,1.0,,,10029.0,,0.0,,Cricetulus griseus
Intermediate,,4518.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,A,In vivo,CHEMBL618184,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4519.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,A,In vivo,CHEMBL618185,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4520.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,A,In vivo,CHEMBL618186,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4521.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,A,In vivo,CHEMBL618187,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4522.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,BAO_0000218,A,In vivo,CHEMBL618188,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4523.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,A,In vivo,CHEMBL875409,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4524.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,A,In vivo,CHEMBL618189,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,4525.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,BAO_0000218,A,In vivo,CHEMBL618190,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,4526.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,BAO_0000218,A,In vivo,CHEMBL618191,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,4527.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,BAO_0000218,A,In vivo,CHEMBL618192,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Bone,4528.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,BAO_0000218,A,In vivo,CHEMBL618193,1.0,10000001.0,,10090.0,,1.0,,Mus musculus
Intermediate,Bone,4529.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,BAO_0000218,A,In vivo,CHEMBL618194,1.0,10000001.0,,10090.0,,1.0,,Mus musculus
Intermediate,Bone,4530.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,BAO_0000218,A,In vivo,CHEMBL618195,1.0,10000001.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,4531.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,BAO_0000218,A,In vivo,CHEMBL618196,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,4532.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,BAO_0000218,A,In vivo,CHEMBL618197,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,4533.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,BAO_0000218,A,In vivo,CHEMBL618198,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,4534.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,BAO_0000218,A,In vivo,CHEMBL618199,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,4535.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,BAO_0000218,A,In vivo,CHEMBL618200,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,4536.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,BAO_0000218,A,In vivo,CHEMBL618201,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Intestine,4537.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,BAO_0000218,A,In vivo,CHEMBL618202,1.0,160.0,,10090.0,,1.0,,Mus musculus
Intermediate,Intestine,4538.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,BAO_0000218,A,In vivo,CHEMBL618203,1.0,160.0,,10090.0,,1.0,,Mus musculus
Intermediate,Intestine,4539.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,BAO_0000218,A,In vivo,CHEMBL618204,1.0,160.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,4540.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,BAO_0000218,A,In vivo,CHEMBL618205,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,4541.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,BAO_0000218,A,In vivo,CHEMBL618206,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,4542.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,BAO_0000218,A,In vivo,CHEMBL618207,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,4543.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,BAO_0000218,A,In vivo,CHEMBL618208,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,4544.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,BAO_0000218,A,In vivo,CHEMBL618932,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,4545.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,BAO_0000218,A,In vivo,CHEMBL618933,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,4546.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,BAO_0000218,A,In vivo,CHEMBL618934,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,4547.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,BAO_0000218,A,In vivo,CHEMBL618935,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,4548.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,BAO_0000218,A,In vivo,CHEMBL618936,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Muscle tissue,4549.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,BAO_0000218,A,In vivo,CHEMBL618937,1.0,2385.0,,10090.0,,1.0,,Mus musculus
Intermediate,Muscle tissue,4550.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,BAO_0000218,A,In vivo,CHEMBL618938,1.0,2385.0,,10090.0,,1.0,,Mus musculus
Intermediate,Muscle tissue,4551.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,BAO_0000218,A,In vivo,CHEMBL619104,1.0,2385.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,4552.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,BAO_0000218,A,In vivo,CHEMBL619105,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,4553.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,BAO_0000218,A,In vivo,CHEMBL619106,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,4554.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,BAO_0000218,A,In vivo,CHEMBL619107,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,Stomach,4555.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,BAO_0000218,A,In vivo,CHEMBL875410,1.0,945.0,,10090.0,,1.0,,Mus musculus
Intermediate,Stomach,4556.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,BAO_0000218,A,In vivo,CHEMBL619108,1.0,945.0,,10090.0,,1.0,,Mus musculus
Intermediate,Stomach,4557.0,,,50594.0,3655.0,N,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,BAO_0000218,A,In vivo,CHEMBL619109,1.0,945.0,,10090.0,,1.0,,Mus musculus
Intermediate,,4558.0,,,50594.0,16597.0,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,BAO_0000218,A,In vivo,CHEMBL619110,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4559.0,,,50594.0,16597.0,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,BAO_0000218,F,In vivo,CHEMBL619111,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4560.0,,,50594.0,16597.0,N,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,A,In vivo,CHEMBL619112,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4561.0,,,50594.0,16597.0,N,,MRT value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,A,In vivo,CHEMBL619113,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4562.0,,,50594.0,17764.0,N,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,BAO_0000218,A,In vivo,CHEMBL619114,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4563.0,,,50594.0,17764.0,N,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,BAO_0000218,F,In vivo,CHEMBL619115,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4564.0,,,81034.0,3830.0,N,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,BAO_0000219,F,,CHEMBL619116,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4565.0,,,81034.0,3829.0,N,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,BAO_0000219,F,,CHEMBL619117,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4566.0,,,81034.0,2040.0,N,,Compound was evaluated for cytotoxicity against A2780 cell lines.,,BAO_0000219,F,,CHEMBL619118,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4567.0,,,81034.0,15684.0,N,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,BAO_0000219,F,,CHEMBL619119,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4568.0,,,81034.0,15684.0,N,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,BAO_0000219,F,,CHEMBL619120,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4569.0,,,81034.0,15684.0,N,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,BAO_0000219,F,,CHEMBL619121,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4570.0,,,81034.0,15684.0,N,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,BAO_0000219,F,,CHEMBL619122,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4571.0,,,81034.0,15684.0,N,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,BAO_0000219,F,,CHEMBL619123,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4572.0,,,81034.0,15684.0,N,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,BAO_0000219,F,,CHEMBL619124,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4573.0,,,81034.0,2859.0,N,,Compound was evaluated for cytotoxicity against A2780 cell line,,BAO_0000219,F,,CHEMBL619125,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4574.0,,,81034.0,5618.0,N,,In vitro inhibitory activity against human tumor cell line A2780,,BAO_0000219,F,,CHEMBL875411,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4575.0,,,81034.0,15684.0,N,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,BAO_0000219,F,,CHEMBL619126,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4576.0,,,81034.0,15684.0,N,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,BAO_0000219,F,,CHEMBL619127,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4577.0,,,81034.0,15684.0,N,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,BAO_0000219,F,,CHEMBL619128,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4578.0,,,81034.0,15684.0,N,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,BAO_0000219,F,,CHEMBL619129,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4579.0,,,81034.0,2113.0,N,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,BAO_0000219,F,,CHEMBL619130,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4580.0,,,81034.0,2113.0,N,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,BAO_0000219,F,,CHEMBL619131,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4581.0,,,81034.0,16745.0,N,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,BAO_0000219,F,,CHEMBL619132,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,4582.0,,,81034.0,16597.0,N,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,BAO_0000218,F,,CHEMBL619133,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4583.0,,,81034.0,15684.0,N,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,BAO_0000219,F,,CHEMBL619134,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4584.0,,,81034.0,15684.0,N,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,BAO_0000219,F,,CHEMBL619135,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4585.0,,,81034.0,2040.0,N,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,BAO_0000219,F,,CHEMBL619136,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4586.0,,,81034.0,2040.0,N,,Relative resistance factor in A2780 cisplatin-resistant line,,BAO_0000219,F,,CHEMBL619137,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4587.0,,,81034.0,16165.0,N,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,BAO_0000219,F,,CHEMBL883713,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4588.0,,,81034.0,16165.0,N,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,BAO_0000219,F,,CHEMBL875412,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,4589.0,,,81034.0,16597.0,N,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,BAO_0000218,F,,CHEMBL619138,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,4590.0,,,81034.0,16597.0,N,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,BAO_0000218,F,,CHEMBL619262,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4591.0,,,81034.0,3992.0,N,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,BAO_0000219,F,,CHEMBL619139,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4592.0,,,81034.0,10553.0,N,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,BAO_0000219,F,,CHEMBL619140,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4593.0,,,81034.0,15608.0,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,BAO_0000219,F,,CHEMBL619141,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4594.0,,,81034.0,15608.0,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,BAO_0000219,F,,CHEMBL619142,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4595.0,,,81034.0,15608.0,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,BAO_0000219,F,,CHEMBL619143,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4596.0,,,81034.0,15608.0,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,BAO_0000219,F,,CHEMBL619144,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4597.0,,,81034.0,15608.0,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,BAO_0000219,F,,CHEMBL619145,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4598.0,,,81034.0,15608.0,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,BAO_0000219,F,,CHEMBL619146,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4599.0,,,81034.0,15569.0,N,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,BAO_0000219,F,,CHEMBL619147,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4600.0,,,81034.0,17420.0,N,,Antiproliferative effect of compound on A2780/DX cell line,,BAO_0000219,F,,CHEMBL619148,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4601.0,,,81034.0,17420.0,N,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,BAO_0000219,F,,CHEMBL619149,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4602.0,,,81034.0,15099.0,N,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,BAO_0000219,F,,CHEMBL619150,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4603.0,,,81034.0,15099.0,N,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,BAO_0000219,F,,CHEMBL619151,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4604.0,,,81034.0,17672.0,N,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,BAO_0000219,F,,CHEMBL883794,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4605.0,,,81034.0,17672.0,N,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,BAO_0000219,F,,CHEMBL619152,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4606.0,,,81034.0,17270.0,N,,In vitro cytotoxicity against A2780ADR cell line,,BAO_0000219,F,,CHEMBL619153,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4607.0,,,81034.0,17270.0,N,,In vitro cytotoxicity against A2780CIS cell line,,BAO_0000219,F,,CHEMBL619154,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4608.0,,,81034.0,5574.0,N,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,BAO_0000219,F,,CHEMBL619155,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4609.0,,,81034.0,2113.0,N,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,BAO_0000219,F,,CHEMBL619156,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4610.0,,,81034.0,16913.0,N,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,BAO_0000219,F,,CHEMBL619157,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4611.0,,,81034.0,16913.0,N,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,BAO_0000219,F,,CHEMBL619797,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Autocuration,,4612.0,,,22224.0,17839.0,U,,Oral bioavailability of compound in rhesus macaques,,BAO_0000218,A,In vivo,CHEMBL619798,1.0,,,9544.0,,0.0,,Macaca mulatta
Autocuration,,4613.0,,,22224.0,6821.0,U,,Oral bioavailability in monkey,,BAO_0000218,A,In vivo,CHEMBL619799,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4614.0,,,22224.0,6078.0,U,,Oral bioavailability evaluated in monkey,,BAO_0000218,A,In vivo,CHEMBL619800,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4615.0,,,22224.0,6535.0,U,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,BAO_0000218,A,In vivo,CHEMBL619801,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4616.0,,,22224.0,4449.0,U,,Oral bioavailability in Rhesus monkey,,BAO_0000218,A,In vivo,CHEMBL619802,1.0,,,9544.0,,0.0,,Macaca mulatta
Autocuration,,4617.0,,,22224.0,6057.0,U,,Oral bioavailability was calculated in rhesus monkey,,BAO_0000218,A,In vivo,CHEMBL619803,1.0,,,9544.0,,0.0,,Macaca mulatta
Autocuration,,4618.0,,,22224.0,5922.0,U,,Oral bioavailability in cynomolgus monkey,,BAO_0000218,A,In vivo,CHEMBL619965,1.0,,,9541.0,,0.0,,Macaca fascicularis
Autocuration,,4619.0,,,22224.0,5940.0,U,,Oral bioavailability in monkey,,BAO_0000218,A,In vivo,CHEMBL619966,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4620.0,,,22224.0,6265.0,U,,Oral bioavailability in monkey,,BAO_0000218,A,In vivo,CHEMBL619967,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4621.0,,,22224.0,6265.0,U,,Oral bioavailability in monkey (dose 1 mg/kg),,BAO_0000218,A,In vivo,CHEMBL620073,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4622.0,,,22224.0,6265.0,U,,Oral bioavailability in monkey (dose 5 mg/kg),,BAO_0000218,A,In vivo,CHEMBL620074,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4623.0,,,22224.0,5940.0,U,,Oral bioavailability in monkey,,BAO_0000218,A,In vivo,CHEMBL620075,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4624.0,,,22224.0,5940.0,U,,Oral bioavailability in monkey,,BAO_0000218,A,In vivo,CHEMBL620076,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4625.0,,,22224.0,4514.0,U,,Oral bioavailability in rhesus monkey,,BAO_0000218,A,In vivo,CHEMBL620077,1.0,,,9544.0,,0.0,,Macaca mulatta
Autocuration,,4626.0,,,22224.0,5546.0,U,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,BAO_0000218,A,In vivo,CHEMBL620078,1.0,,,9544.0,,0.0,,Macaca mulatta
Autocuration,,4627.0,,,22224.0,5553.0,U,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL620079,1.0,,,9521.0,,0.0,,Saimiri sciureus
Autocuration,,4628.0,,,22224.0,6641.0,U,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,A,In vivo,CHEMBL620080,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4629.0,,,22224.0,5472.0,U,,Oral bioavailability in Rhesus monkey,,BAO_0000218,A,In vivo,CHEMBL620081,1.0,,,9544.0,,0.0,,Macaca mulatta
Autocuration,,4630.0,,,22224.0,5668.0,U,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,BAO_0000218,A,In vivo,CHEMBL620082,1.0,,,9544.0,,0.0,,Macaca mulatta
Autocuration,,4631.0,,,22224.0,5711.0,U,,Oral bioavailability in monkey at 10 mg/kg of the compound,,BAO_0000218,A,In vivo,CHEMBL620083,1.0,,,9443.0,,0.0,,monkey
Autocuration,,4632.0,,,22224.0,5145.0,U,,Bioavailability in Rhesus monkey,,BAO_0000218,A,In vivo,CHEMBL620084,1.0,,,9544.0,,0.0,,Macaca mulatta
Autocuration,,4633.0,,,22224.0,3443.0,U,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,A,,CHEMBL620085,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4634.0,,,22224.0,3443.0,U,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,A,,CHEMBL874595,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4635.0,,,22224.0,3249.0,U,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL873352,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4636.0,,,22224.0,3249.0,U,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL620086,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4637.0,,,22224.0,5355.0,U,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,BAO_0000218,A,In vivo,CHEMBL620087,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4638.0,,,22224.0,5355.0,U,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,A,In vivo,CHEMBL620088,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4639.0,,,22224.0,5355.0,U,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,A,In vivo,CHEMBL620089,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4640.0,,,22224.0,4809.0,U,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,A,In vivo,CHEMBL620090,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4641.0,,,22224.0,4809.0,U,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,A,In vivo,CHEMBL620091,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4642.0,,,22224.0,14294.0,U,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),Microsomes,BAO_0000251,A,,CHEMBL620092,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4643.0,,,22224.0,14294.0,U,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),Microsomes,BAO_0000251,A,,CHEMBL620093,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4644.0,,,22224.0,14294.0,U,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),Microsomes,BAO_0000251,A,,CHEMBL620094,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4645.0,,,22224.0,14294.0,U,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),Microsomes,BAO_0000251,A,,CHEMBL620095,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4646.0,,,22224.0,3443.0,U,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,A,In vivo,CHEMBL620096,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4647.0,,,22224.0,3443.0,U,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,A,In vivo,CHEMBL620097,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4648.0,,,22224.0,11271.0,U,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,BAO_0000019,A,,CHEMBL620098,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4649.0,,,22224.0,3443.0,U,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,A,,CHEMBL620099,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4650.0,,,22224.0,3443.0,U,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,A,,CHEMBL620100,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4651.0,,,22224.0,6821.0,U,,Elimination Half-life of compound was determined in monkey,,BAO_0000019,A,,CHEMBL620101,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4652.0,,,22224.0,17267.0,U,,Half life of compound was determined in rhesus monkey,,BAO_0000019,A,,CHEMBL620102,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,4653.0,,,22224.0,5819.0,U,,Half life in monkey plasma,,BAO_0000366,A,,CHEMBL620103,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,4654.0,,,22224.0,5819.0,U,,Half life in monkey plasma; Not detected,,BAO_0000366,A,,CHEMBL620104,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4655.0,,,22224.0,1916.0,U,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,A,In vivo,CHEMBL874596,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4656.0,,,22224.0,17509.0,U,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,BAO_0000218,A,In vivo,CHEMBL873490,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4657.0,,,22224.0,1399.0,U,,Terminal half life of the compound.,,BAO_0000019,A,,CHEMBL620105,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4658.0,,,22224.0,1916.0,U,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,A,In vivo,CHEMBL620780,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4659.0,,,22224.0,4809.0,U,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,A,In vivo,CHEMBL620781,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4660.0,,,22224.0,5546.0,U,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,BAO_0000218,A,,CHEMBL620956,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Urine,4661.0,,,22224.0,3443.0,U,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,A,,CHEMBL620957,1.0,1088.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,Urine,4662.0,,,22224.0,3443.0,U,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,A,,CHEMBL620958,1.0,1088.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4663.0,,,22224.0,4257.0,U,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,BAO_0000218,A,In vivo,CHEMBL620959,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4664.0,,,22224.0,6221.0,U,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,A,In vivo,CHEMBL620960,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4665.0,,,22224.0,5472.0,U,,Volume of distribution was evaluated in rhesus,,BAO_0000218,A,In vivo,CHEMBL620961,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4666.0,,,22224.0,4727.0,U,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,BAO_0000218,A,In vivo,CHEMBL620962,1.0,,,10029.0,,0.0,,Cricetulus griseus
Autocuration,,4667.0,,,22224.0,4727.0,U,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,BAO_0000218,A,In vivo,CHEMBL620963,1.0,,,10029.0,,0.0,,Cricetulus griseus
Autocuration,,4668.0,,,22224.0,4727.0,U,,Bioavailability in hamster was determined,,BAO_0000218,A,In vivo,CHEMBL620964,1.0,,,10029.0,,0.0,,Cricetulus griseus
Autocuration,,4669.0,,,22224.0,4727.0,U,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,BAO_0000218,A,In vivo,CHEMBL620965,1.0,,,10029.0,,0.0,,Cricetulus griseus
Autocuration,,4670.0,,,22224.0,4727.0,U,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,BAO_0000218,A,In vivo,CHEMBL620966,1.0,,,10029.0,,0.0,,Cricetulus griseus
Autocuration,Blood,4671.0,,,22224.0,4727.0,U,,Half life of compound was determined in hamster blood,,BAO_0000221,A,,CHEMBL620967,1.0,178.0,,10029.0,,0.0,,Cricetulus griseus
Autocuration,,4672.0,,,22224.0,1452.0,U,,Michaelis-Menten constant of the compound.,,BAO_0000019,A,,CHEMBL620968,1.0,,,9823.0,,0.0,,Sus scrofa
Autocuration,,4673.0,,,22224.0,1452.0,U,,Vmax value was measured at 0 uM concentration of silyl ether.,,BAO_0000019,A,,CHEMBL874597,1.0,,,9823.0,,0.0,,Sus scrofa
Autocuration,,4674.0,,,22224.0,1452.0,U,,Vmax value was measured at 10 uM concentration of silyl ether.,,BAO_0000019,A,,CHEMBL620969,1.0,,,9823.0,,0.0,,Sus scrofa
Autocuration,,4675.0,,,22224.0,1452.0,U,,Vmax value was measured at 5 uM concentration of silyl ether.,,BAO_0000019,A,,CHEMBL620970,1.0,,,9823.0,,0.0,,Sus scrofa
Expert,,4676.0,,,235.0,11706.0,D,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,BAO_0000357,B,,CHEMBL620971,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,4677.0,,,22224.0,1916.0,U,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,A,,CHEMBL620972,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4678.0,,,22224.0,17791.0,U,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,BAO_0000019,A,,CHEMBL620973,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4679.0,,,22224.0,7766.0,U,,Active metabolite of ifosfamide determined in humans; A-Active,,BAO_0000019,A,,CHEMBL618243,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4680.0,,,22224.0,6567.0,U,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,BAO_0000019,A,,CHEMBL618244,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4681.0,,,22224.0,6567.0,U,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,BAO_0000019,A,,CHEMBL618245,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4682.0,,,22224.0,6567.0,U,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,BAO_0000019,A,,CHEMBL618246,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4683.0,,,22224.0,6567.0,U,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,BAO_0000019,A,,CHEMBL618247,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4684.0,,,22224.0,17791.0,U,,Compound was evaluated for oral bioavailability in human,,BAO_0000218,A,,CHEMBL618248,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,4685.0,,,22224.0,7766.0,U,,Metabolite of ifosfamide determined in urine; NF-Not found,,BAO_0000019,A,,CHEMBL618249,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,4686.0,,,22224.0,6852.0,U,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,BAO_0000019,A,,CHEMBL618250,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4687.0,,,22224.0,6852.0,U,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,BAO_0000019,A,,CHEMBL874598,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4688.0,,,22224.0,6852.0,U,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,BAO_0000019,A,,CHEMBL618251,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4689.0,,,22224.0,6852.0,U,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,BAO_0000019,A,,CHEMBL618252,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4690.0,,,22224.0,6852.0,U,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,BAO_0000019,A,,CHEMBL618253,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4691.0,,,22224.0,6852.0,U,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,BAO_0000019,A,,CHEMBL618254,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4692.0,,,22224.0,6852.0,U,,Percent of compound in healthy individuals (Group D),,BAO_0000019,A,,CHEMBL618255,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,4693.0,,,22224.0,4397.0,U,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Microsomes,BAO_0000251,A,,CHEMBL618983,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,4694.0,,,22224.0,17409.0,U,,Binding towards human plasma protein at 10 uM,,BAO_0000019,A,,CHEMBL618984,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4695.0,,,22224.0,17409.0,U,,Binding towards human plasma protein at 100 uM,,BAO_0000019,A,,CHEMBL618985,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4696.0,,,22224.0,17176.0,U,,Human plasma protein binding activity was determined,,BAO_0000019,A,,CHEMBL618986,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4697.0,,,22224.0,15444.0,U,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,BAO_0000019,A,,CHEMBL618987,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4698.0,,,22224.0,17267.0,U,,Percent binding of compound towards human plasma protein was determined,,BAO_0000019,A,,CHEMBL618988,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,4699.0,,,22224.0,5944.0,U,,Plasma clearance in human liver microsomes,Microsomes,BAO_0000251,A,In vitro,CHEMBL618989,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,4700.0,,,22224.0,5668.0,U,,In vitro intrinsic clearance in human liver microsome,Microsomes,BAO_0000251,A,In vitro,CHEMBL618990,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,4701.0,,,22224.0,5669.0,U,,In vitro intrinsic clearance in human liver microsome,Microsomes,BAO_0000251,A,In vitro,CHEMBL618991,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,4702.0,,,22224.0,5041.0,U,,In vitro microsome metabolism clearance in human was determined,Microsomes,BAO_0000251,A,In vitro,CHEMBL876725,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4703.0,,,22224.0,5041.0,U,,In vitro microsome metabolism clearance in human was determined; High,Microsomes,BAO_0000251,A,In vitro,CHEMBL618992,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4704.0,,,22224.0,5041.0,U,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,Microsomes,BAO_0000251,A,In vitro,CHEMBL618993,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,4705.0,,,22224.0,5676.0,U,,Pharmacokinetic property (clearance) in human liver microsome,Microsomes,BAO_0000251,A,In vitro,CHEMBL618994,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,4706.0,,,22224.0,5944.0,U,,Plasma clearance in human liver microsomes,Microsomes,BAO_0000251,A,In vitro,CHEMBL618995,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,4707.0,,,22224.0,17538.0,U,,In vitro clearance in human liver microsomes,Microsomes,BAO_0000251,A,In vitro,CHEMBL618996,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,4708.0,,,22224.0,6331.0,U,,Intrinsic clearance in human liver microsomes was determined,Microsomes,BAO_0000251,A,In vitro,CHEMBL618997,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,4709.0,,,22224.0,5948.0,U,,Intrinsic clearance in human liver microsomes was determined,Microsomes,BAO_0000251,A,In vitro,CHEMBL618998,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,4710.0,,,22224.0,5965.0,U,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,BAO_0000218,A,In vivo,CHEMBL618999,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4711.0,,,22224.0,1916.0,U,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,A,In vivo,CHEMBL620223,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4712.0,,,22224.0,5965.0,U,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,BAO_0000218,A,,CHEMBL620224,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4713.0,,,22224.0,1299.0,U,,Stability in human plasma 2 hr after incubation expressed as percent concentration,,BAO_0000019,A,,CHEMBL620225,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4714.0,,,22224.0,1299.0,U,,Stability in human plasma 4 hr after incubation expressed as percent concentration,,BAO_0000019,A,,CHEMBL620226,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,4715.0,,,22224.0,7766.0,U,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,A,,CHEMBL620227,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,4716.0,,,22224.0,7766.0,U,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,A,,CHEMBL876726,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,4717.0,,,22224.0,7766.0,U,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,A,,CHEMBL620228,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,4718.0,,,22224.0,7766.0,U,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,A,,CHEMBL620229,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Intermediate,,4719.0,,,50594.0,17764.0,N,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,F,In vivo,CHEMBL620230,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4720.0,,,50594.0,17764.0,N,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,BAO_0000218,F,In vivo,CHEMBL620231,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4721.0,,,50594.0,17764.0,N,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,BAO_0000218,F,In vivo,CHEMBL620232,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4722.0,,,50594.0,17764.0,N,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,BAO_0000218,F,In vivo,CHEMBL620233,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4723.0,,,50594.0,14294.0,N,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,BAO_0000218,A,,CHEMBL620234,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4724.0,,,50594.0,14294.0,N,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000218,A,,CHEMBL620235,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4725.0,,,50594.0,14294.0,N,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,BAO_0000218,A,,CHEMBL620236,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,4726.0,,,50594.0,6251.0,N,,In vitro metabolic potential in mouse liver microsomes,,BAO_0000218,A,,CHEMBL620237,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,,4727.0,,,50594.0,17582.0,N,,Ability of compound to bind to plasma protein was evaluated in HSA cells,,BAO_0000218,A,,CHEMBL620238,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Adrenal gland,4728.0,,,50594.0,17811.0,N,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,BAO_0000218,A,,CHEMBL620239,1.0,2369.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,4729.0,,,50594.0,17811.0,N,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,BAO_0000218,A,,CHEMBL620240,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,4730.0,,,50594.0,17811.0,N,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,BAO_0000218,A,,CHEMBL620241,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,,4731.0,,,50594.0,17811.0,N,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,BAO_0000218,A,,CHEMBL876727,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,4732.0,,,50594.0,17811.0,N,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,BAO_0000218,A,,CHEMBL620242,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,,4733.0,,,50594.0,17811.0,N,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,BAO_0000218,A,,CHEMBL620243,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4734.0,,,50594.0,5288.0,N,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,BAO_0000218,A,,CHEMBL620244,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Serum,4735.0,,,50594.0,2717.0,N,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,BAO_0000218,A,,CHEMBL620245,1.0,1977.0,,10090.0,,1.0,,Mus musculus
Intermediate,Serum,4736.0,,,50594.0,2717.0,N,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,BAO_0000218,A,,CHEMBL620246,1.0,1977.0,,10090.0,,1.0,,Mus musculus
Intermediate,Serum,4737.0,,,50594.0,2717.0,N,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,BAO_0000218,A,,CHEMBL620247,1.0,1977.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,4738.0,,,50594.0,17753.0,N,,Half life of compound was determined in plasma of mice at 24 mg/Kg,,BAO_0000218,A,In vivo,CHEMBL620248,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,4739.0,,,50594.0,17753.0,N,,Half life of compound was determined in plasma of mice at 40 mg/Kg,,BAO_0000218,A,In vivo,CHEMBL873497,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,4740.0,,,50594.0,17753.0,N,,Half life of compound was determined in plasma of mice at 5 mg/Kg,,BAO_0000218,A,In vivo,CHEMBL620249,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,,4741.0,,,50594.0,17764.0,N,,Half life after intraperitoneal administration in mice at 18 uM/kg,,BAO_0000218,F,In vivo,CHEMBL620250,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4742.0,,,50594.0,17764.0,N,,Half life after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,F,In vivo,CHEMBL620251,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4743.0,,,50594.0,17764.0,N,,Half life after intraperitoneal administration in mice at 25 uM/kg,,BAO_0000218,F,In vivo,CHEMBL620252,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4744.0,,,50594.0,17764.0,N,,Half life after intraperitoneal administration in mice at 26 uM/kg,,BAO_0000218,F,In vivo,CHEMBL620253,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4745.0,,,50594.0,17764.0,N,,Half life after intravenous administration in mice at 23 uM/kg,,BAO_0000218,F,In vivo,CHEMBL620254,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4746.0,,,50594.0,17764.0,N,,Half life after intravenous administration in mice at 24 uM/kg,,BAO_0000218,A,In vivo,CHEMBL620255,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4747.0,,,50594.0,16597.0,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,BAO_0000218,A,In vivo,CHEMBL620256,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4748.0,,,50594.0,2675.0,N,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,BAO_0000218,A,In vivo,CHEMBL876728,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4749.0,,,50594.0,2675.0,N,,Maximum time required to reach Cp max was evaluated in mice after oral administration,,BAO_0000218,A,In vivo,CHEMBL620257,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4750.0,,,50594.0,16597.0,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,BAO_0000218,A,In vivo,CHEMBL620258,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4751.0,,,50594.0,4890.0,N,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,BAO_0000218,A,In vivo,CHEMBL620259,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4752.0,,,50594.0,429.0,N,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,BAO_0000218,A,In vivo,CHEMBL620260,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,4753.0,,,50594.0,17837.0,N,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL620261,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,,4754.0,,,50594.0,16597.0,N,,Half life at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,A,In vivo,CHEMBL620262,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4755.0,,,50594.0,16597.0,N,,Half life at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,A,In vivo,CHEMBL620263,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4756.0,,,50594.0,6619.0,N,,Half life in ob/ob mice,,BAO_0000218,A,,CHEMBL620264,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4757.0,,,50594.0,4066.0,N,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,A,In vivo,CHEMBL620265,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4758.0,,,50594.0,4239.0,N,,Half-life was measured in mouse,,BAO_0000218,A,,CHEMBL620266,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4759.0,,,50594.0,5969.0,N,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL620267,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4760.0,,,50594.0,8999.0,N,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,BAO_0000218,A,,CHEMBL619364,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4761.0,,,50594.0,8999.0,N,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,BAO_0000218,A,,CHEMBL619365,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,4762.0,,,50594.0,17641.0,N,,T2 in brain of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,,CHEMBL619366,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,4763.0,,,50594.0,17641.0,N,,T2 in kidney of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,,CHEMBL619367,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,4764.0,,,50594.0,17641.0,N,,T2 in liver of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,,CHEMBL619368,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,4765.0,,,50594.0,17641.0,N,,T2 in lungs of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,,CHEMBL619369,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,4766.0,,,50594.0,17641.0,N,,T2 in spleen of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,,CHEMBL876729,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,,4767.0,,,50594.0,16597.0,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,BAO_0000218,A,In vivo,CHEMBL619370,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4768.0,,,50594.0,4890.0,N,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,BAO_0000218,A,In vivo,CHEMBL619371,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4769.0,,,50594.0,429.0,N,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,BAO_0000218,A,In vivo,CHEMBL619372,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4770.0,,,50594.0,429.0,N,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,BAO_0000218,A,In vivo,CHEMBL620012,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4771.0,,,50594.0,5969.0,N,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,A,In vivo,CHEMBL620013,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4772.0,,,81034.0,16913.0,N,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,BAO_0000219,F,,CHEMBL620014,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4773.0,,,81034.0,16913.0,N,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,BAO_0000219,F,,CHEMBL620015,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4774.0,,,81034.0,16913.0,N,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,BAO_0000219,F,,CHEMBL621010,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4775.0,,,81034.0,16913.0,N,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,BAO_0000219,F,,CHEMBL621011,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4776.0,,,81034.0,16913.0,N,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,BAO_0000219,F,,CHEMBL621012,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4777.0,,,81034.0,16913.0,N,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,BAO_0000219,F,,CHEMBL621013,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4778.0,,,81034.0,17270.0,N,,In vitro cytotoxicity against A2780TAX cell line,,BAO_0000219,F,,CHEMBL621014,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4779.0,,,80017.0,5618.0,N,,In vitro inhibitory activity against human tumor cell line A2780cis,,BAO_0000219,F,,CHEMBL618154,1.0,,,9606.0,A2780cisR,1.0,481.0,Homo sapiens
Expert,,4780.0,,,81034.0,17777.0,N,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,BAO_0000219,F,,CHEMBL618155,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4781.0,,,80017.0,16112.0,N,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,BAO_0000219,F,,CHEMBL618156,1.0,,,9606.0,A2780cisR,1.0,481.0,Homo sapiens
Intermediate,,4782.0,,,80017.0,15748.0,N,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,BAO_0000219,F,,CHEMBL618157,1.0,,,9606.0,A2780cisR,1.0,481.0,Homo sapiens
Intermediate,,4783.0,,,81034.0,6633.0,N,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,BAO_0000219,F,,CHEMBL618328,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4784.0,,,81034.0,16930.0,N,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,BAO_0000219,F,,CHEMBL618329,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4785.0,,,81034.0,17496.0,N,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,BAO_0000219,F,,CHEMBL618330,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,4786.0,,,81034.0,12989.0,N,,In vitro antitumor activity against A2780cisR cell line.,,BAO_0000219,F,,CHEMBL618331,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4787.0,,,81034.0,4840.0,N,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,BAO_0000219,F,,CHEMBL618332,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,4788.0,,,81034.0,12989.0,N,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,BAO_0000219,F,,CHEMBL618333,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,4789.0,,,80017.0,16745.0,N,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,BAO_0000219,F,,CHEMBL618334,1.0,,,9606.0,A2780cisR,1.0,481.0,Homo sapiens
Expert,,4790.0,,,81034.0,16597.0,N,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,BAO_0000219,F,,CHEMBL618335,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,4791.0,,,11736.0,16547.0,D,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,BAO_0000019,B,,CHEMBL618336,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,4792.0,,,11736.0,16547.0,H,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,BAO_0000019,F,,CHEMBL618337,1.0,,,,,8.0,,
Expert,,4793.0,,,11736.0,16547.0,D,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,BAO_0000019,F,,CHEMBL618338,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,4794.0,,,278.0,15856.0,D,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,BAO_0000219,F,,CHEMBL618339,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,4795.0,,,278.0,15856.0,D,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,BAO_0000219,F,,CHEMBL618340,1.0,,,9606.0,HEK293,9.0,722.0,Homo sapiens
Expert,,4796.0,,,11831.0,16547.0,D,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,BAO_0000019,B,,CHEMBL618341,1.0,,,10090.0,,9.0,,Mus musculus
Expert,,4797.0,,,11831.0,16547.0,H,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,BAO_0000019,F,,CHEMBL618342,1.0,,,,,8.0,,
Expert,,4798.0,,,11831.0,16547.0,D,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,BAO_0000019,F,,CHEMBL618343,1.0,,,10090.0,,9.0,,Mus musculus
Expert,,4799.0,,,280.0,17402.0,H,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,BAO_0000357,B,,CHEMBL621038,1.0,,,,,8.0,,
Autocuration,,4800.0,,,22226.0,11746.0,U,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,BAO_0000219,F,,CHEMBL621039,1.0,,,9606.0,T-cells,0.0,574.0,Homo sapiens
Autocuration,,4801.0,,,22226.0,11746.0,U,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,BAO_0000219,F,,CHEMBL621040,1.0,,,9606.0,T-cells,0.0,574.0,Homo sapiens
Intermediate,,4802.0,,,80018.0,5455.0,N,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,BAO_0000219,F,,CHEMBL621041,1.0,,,9606.0,A-375,1.0,455.0,Homo sapiens
Intermediate,,4803.0,,,80018.0,2068.0,N,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,BAO_0000219,F,,CHEMBL621042,1.0,,,9606.0,A-375,1.0,455.0,Homo sapiens
Intermediate,,4804.0,,,80018.0,2683.0,N,,In vitro antitumor activity against A375cell line extracted form melanoma,,BAO_0000219,F,,CHEMBL621043,1.0,,,9606.0,A-375,1.0,455.0,Homo sapiens
Expert,,4805.0,,,80018.0,15313.0,N,,Inhibition of cell growth in (A375) melan cell line,,BAO_0000219,F,,CHEMBL621044,1.0,,,9606.0,A-375,1.0,455.0,Homo sapiens
Intermediate,,4806.0,,,80018.0,13739.0,N,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,BAO_0000219,F,,CHEMBL621045,1.0,,,9606.0,A-375,1.0,455.0,Homo sapiens
Intermediate,,4807.0,,,80018.0,13739.0,N,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,BAO_0000219,F,,CHEMBL621046,1.0,,,9606.0,A-375,1.0,455.0,Homo sapiens
Intermediate,,4808.0,,,80018.0,14750.0,N,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,BAO_0000219,F,,CHEMBL621047,1.0,,,9606.0,A-375,1.0,455.0,Homo sapiens
Intermediate,,4809.0,,,80019.0,14777.0,N,,Antiproliferative activity measured against A427 human lung carcinoma,,BAO_0000219,F,,CHEMBL621048,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Intermediate,,4810.0,,,80019.0,14777.0,N,,Antiproliferative activity measured against A427 human lung carcinoma,,BAO_0000219,F,,CHEMBL883798,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Intermediate,,4811.0,,,80019.0,17672.0,N,,Cytotoxicity against lung carcinoma A427 tumor cell lines,,BAO_0000219,F,,CHEMBL621049,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Intermediate,,4812.0,,,80019.0,14368.0,N,,Inhibition of large cell lung carcinoma (A427),,BAO_0000219,F,,CHEMBL621050,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Intermediate,,4813.0,,,80019.0,14368.0,N,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,BAO_0000219,F,,CHEMBL621051,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Intermediate,,4814.0,,,80019.0,13866.0,N,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,BAO_0000219,F,,CHEMBL621052,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Intermediate,,4815.0,,,80019.0,2545.0,N,,Inhibitory concentration in human lung carcinoma A427 cell line,,BAO_0000219,F,,CHEMBL621053,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Intermediate,,4816.0,,,80019.0,2545.0,N,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,BAO_0000219,F,,CHEMBL621054,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Autocuration,,4817.0,,,22224.0,6062.0,U,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621055,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4818.0,,,22224.0,4578.0,U,,Tested for volume of distribution upon iv administration to african green monkey,,BAO_0000218,A,In vivo,CHEMBL876398,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4819.0,,,22224.0,17592.0,U,,Volume of distribution in monkey,,BAO_0000218,A,In vivo,CHEMBL621056,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4820.0,,,22224.0,5005.0,U,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,BAO_0000218,A,In vivo,CHEMBL621057,1.0,,,9544.0,,0.0,,Macaca mulatta
Autocuration,,4821.0,,,22224.0,5005.0,U,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,BAO_0000218,A,In vivo,CHEMBL621058,1.0,,,9544.0,,0.0,,Macaca mulatta
Autocuration,,4822.0,,,22224.0,5922.0,U,,Pharmacokinetic property(Vdss) in cynomolgus monkey,,BAO_0000218,A,In vivo,CHEMBL621059,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4823.0,,,22224.0,5355.0,U,,The distribution volume after intravenous administration in cynomolgus monkeys,,BAO_0000218,A,In vivo,CHEMBL621060,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4824.0,,,22224.0,5355.0,U,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,A,In vivo,CHEMBL621061,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4825.0,,,22224.0,5355.0,U,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,A,In vivo,CHEMBL621062,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4826.0,,,22224.0,6057.0,U,,Volume displacement was calculated in rhesus monkey,,BAO_0000218,A,In vivo,CHEMBL621063,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4827.0,,,22224.0,5145.0,U,,Volume of distribution in steady state was determined in rhesus monkey,,BAO_0000218,A,In vivo,CHEMBL621064,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4828.0,,,22224.0,6821.0,U,,Volume of distribution of compound was determined in monkey,,BAO_0000218,A,In vivo,CHEMBL621065,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4829.0,,,22224.0,5334.0,U,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,A,In vivo,CHEMBL621066,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4830.0,,,22224.0,5334.0,U,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,A,In vivo,CHEMBL621067,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4831.0,,,22224.0,6641.0,U,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,A,In vivo,CHEMBL621068,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4832.0,,,22224.0,2661.0,U,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,A,In vivo,CHEMBL876399,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4833.0,,,22224.0,6535.0,U,,Volume distribution in monkey after administration of 1 mg/kg iv,,BAO_0000218,A,In vivo,CHEMBL621069,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4834.0,,,22224.0,4809.0,U,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,A,In vivo,CHEMBL621070,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4835.0,,,22224.0,6062.0,U,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621071,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4836.0,,,22224.0,3443.0,U,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,A,In vivo,CHEMBL621072,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4837.0,,,22224.0,4578.0,U,,Oral systemic bioavailability upon iv administration to african green monkey,,BAO_0000218,A,In vivo,CHEMBL618209,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4838.0,,,22224.0,4809.0,U,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,A,In vivo,CHEMBL618210,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4839.0,,,22224.0,11271.0,U,,Baboon plasma free fraction. ,,BAO_0000019,A,,CHEMBL618211,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4840.0,,,22224.0,6057.0,U,,Area under the curve was calculated in rhesus monkey after iv administration,,BAO_0000218,A,,CHEMBL618212,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4841.0,,,22224.0,6057.0,U,,Area under the curve was calculated in rhesus monkey after peroral administration,,BAO_0000019,A,,CHEMBL618213,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4842.0,,,22224.0,17853.0,U,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,BAO_0000019,A,,CHEMBL618214,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4843.0,,,22224.0,5302.0,U,,Half life period in monkey after 5 mg/kg dose,,BAO_0000218,A,In vivo,CHEMBL873492,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4844.0,,,22224.0,4257.0,U,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,BAO_0000218,A,In vivo,CHEMBL618272,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4845.0,,,22224.0,4257.0,U,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,BAO_0000218,A,In vivo,CHEMBL618273,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,4846.0,,,22224.0,13501.0,U,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,BAO_0000218,A,In vivo,CHEMBL618274,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4847.0,,,22224.0,5394.0,U,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618275,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4848.0,,,22224.0,2661.0,U,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,A,In vivo,CHEMBL618276,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4849.0,,,22224.0,3341.0,U,,Compound was evaluated for terminal half life in monkey,,BAO_0000019,A,,CHEMBL618277,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4850.0,,,22224.0,3045.0,U,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,BAO_0000218,A,In vivo,CHEMBL618278,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,4851.0,,,22224.0,5005.0,U,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,BAO_0000218,A,In vivo,CHEMBL618279,1.0,1969.0,,9544.0,,0.0,,Macaca mulatta
Autocuration,,4852.0,,,22224.0,4847.0,U,,Half life of compound was determined in squirrel monkey,,BAO_0000019,A,,CHEMBL618280,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4853.0,,,22224.0,4256.0,U,,Half life after iv administration in cynomolgus monkey,,BAO_0000218,A,In vivo,CHEMBL618281,1.0,,,9541.0,,0.0,,Macaca fascicularis
Autocuration,Plasma,4854.0,,,22224.0,6535.0,U,,Half life in monkey plasma after administration of 1 mg/kg iv,,BAO_0000218,A,In vivo,CHEMBL618282,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4855.0,,,22224.0,6057.0,U,,Half life was calculated in rhesus monkey,,BAO_0000019,A,,CHEMBL618283,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4856.0,,,22224.0,17592.0,U,,Half life in monkey,,BAO_0000019,A,,CHEMBL618284,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4857.0,,,22224.0,6641.0,U,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,A,In vivo,CHEMBL618285,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4858.0,,,22224.0,5472.0,U,,Half life was evaluated in rhesus,,BAO_0000019,A,,CHEMBL618286,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4859.0,,,22224.0,6221.0,U,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,A,In vivo,CHEMBL618287,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4860.0,,,22224.0,5668.0,U,,Half life period was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000218,A,In vivo,CHEMBL618288,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4861.0,,,22224.0,4809.0,U,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,A,In vivo,CHEMBL876393,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4862.0,,,22224.0,5546.0,U,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,BAO_0000218,A,In vivo,CHEMBL618289,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4863.0,,,22224.0,5553.0,U,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618290,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4864.0,,,22224.0,6078.0,U,,Half-life was calculated in monkey,,BAO_0000019,A,,CHEMBL618291,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4865.0,,,22224.0,5147.0,U,,Half-life in Squirrel monkey,,BAO_0000019,A,,CHEMBL618292,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4866.0,,,22224.0,5145.0,U,,Half-life in rhesus monkey,,BAO_0000019,A,,CHEMBL618293,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4867.0,,,22224.0,6062.0,U,,Half-life was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618294,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4868.0,,,22224.0,5355.0,U,,Half-life period after intravenous administration in cynomolgus monkeys,,BAO_0000218,A,In vivo,CHEMBL618295,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4869.0,,,22224.0,5355.0,U,,Half-life period after oral administration in cynomolgus monkeys,,BAO_0000218,A,In vivo,CHEMBL618296,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,4870.0,,,22224.0,5355.0,U,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,BAO_0000218,A,In vivo,CHEMBL618297,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Urine,4871.0,,,22224.0,7766.0,U,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,A,,CHEMBL618298,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,4872.0,,,22224.0,7766.0,U,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,A,,CHEMBL618299,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,4873.0,,,22224.0,7766.0,U,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,A,,CHEMBL618300,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,4874.0,,,22224.0,7766.0,U,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,A,,CHEMBL618301,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,4875.0,,,22224.0,7766.0,U,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,BAO_0000019,A,,CHEMBL618302,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,4876.0,,,22224.0,7766.0,U,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,BAO_0000019,A,,CHEMBL876394,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,4877.0,,,22224.0,7766.0,U,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,BAO_0000019,A,,CHEMBL618303,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,4878.0,,,22224.0,7766.0,U,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,BAO_0000019,A,,CHEMBL618304,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,4879.0,,,22224.0,1916.0,U,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,BAO_0000218,A,In vivo,CHEMBL618305,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4880.0,,,22224.0,16643.0,U,,Oral bioavailability in human,,BAO_0000218,A,In vivo,CHEMBL618306,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4881.0,,,22224.0,17248.0,U,,Compound was tested for human plasma protein binding,,BAO_0000019,A,,CHEMBL618307,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4882.0,,,22224.0,17248.0,U,,Compound was tested for human plasma protein binding; Not determined,,BAO_0000019,A,,CHEMBL618308,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4883.0,,,22224.0,6241.0,U,,Protein binding activity of compound in human plasma; % Free,,BAO_0000019,A,,CHEMBL618309,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4884.0,,,22224.0,17716.0,U,,Unbound fraction (plasma),,BAO_0000019,A,,CHEMBL618310,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,4885.0,,,22224.0,17605.0,U,,Half life for the hydrolysis of compound in human blood serum,,BAO_0000366,A,,CHEMBL873353,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,4886.0,,,22224.0,17625.0,U,,Half life period in human plasma using phosphate buffer (0.08 M),,BAO_0000366,A,,CHEMBL618311,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,4887.0,,,22224.0,17625.0,U,,Half life period in human plasma using phosphate buffer (0.1 M),,BAO_0000366,A,,CHEMBL618312,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,4888.0,,,22224.0,17747.0,U,,Half-life in human plasma was determined,,BAO_0000366,A,,CHEMBL618313,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,4889.0,,,22224.0,15613.0,U,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,BAO_0000019,A,,CHEMBL618314,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4890.0,,,22224.0,354.0,U,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,BAO_0000019,A,,CHEMBL618315,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4891.0,,,22224.0,3741.0,U,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,BAO_0000019,A,,CHEMBL618316,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4892.0,,,22224.0,3741.0,U,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,BAO_0000019,A,,CHEMBL618317,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4893.0,,,22224.0,3741.0,U,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,BAO_0000019,A,,CHEMBL620138,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4894.0,,,22224.0,17599.0,U,,Partition coefficient (logP),,BAO_0000019,A,,CHEMBL858280,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4895.0,,,22224.0,5486.0,U,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,BAO_0000019,A,,CHEMBL620139,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4896.0,,,22224.0,5600.0,U,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,Microsomes,BAO_0000251,A,,CHEMBL620140,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4897.0,,,22224.0,14294.0,U,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,BAO_0000019,A,,CHEMBL620141,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4898.0,,,22224.0,14294.0,U,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,BAO_0000019,A,,CHEMBL620142,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4899.0,,,22224.0,14294.0,U,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,BAO_0000019,A,,CHEMBL620143,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4900.0,,,22224.0,14294.0,U,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),Microsomes,BAO_0000251,A,,CHEMBL620144,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4901.0,,,22224.0,14294.0,U,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),Microsomes,BAO_0000251,A,,CHEMBL620145,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4902.0,,,22224.0,14294.0,U,,Metabolism of compound in human microsomes; Trace,Microsomes,BAO_0000251,A,,CHEMBL620146,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,4903.0,,,22224.0,6260.0,U,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Microsomes,BAO_0000251,A,,CHEMBL620147,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,4904.0,,,22224.0,6187.0,U,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,Microsomes,BAO_0000251,A,,CHEMBL620148,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,4905.0,,,22224.0,6251.0,U,,In vitro metabolic potential in human liver microsomes,Microsomes,BAO_0000251,A,,CHEMBL620149,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,4906.0,,,22224.0,3246.0,U,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,BAO_0000019,A,,CHEMBL876412,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4907.0,,,22224.0,17313.0,U,,Tested for human plasma protein binding of the compound; Not tested,,BAO_0000019,A,,CHEMBL619352,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4908.0,,,22224.0,6227.0,U,,Compound was tested for percent protein binding (PB) in human,,BAO_0000019,A,,CHEMBL619353,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,4909.0,,,22224.0,5530.0,U,,Protein binding in human plasma,,BAO_0000019,A,,CHEMBL619354,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,4910.0,,,22224.0,6108.0,U,,Permeability coefficient (B to A) in Caco-2 cell,,BAO_0000019,A,,CHEMBL619355,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4911.0,,,22224.0,6108.0,U,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,BAO_0000019,A,,CHEMBL619356,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4912.0,,,22224.0,2774.0,U,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,BAO_0000019,A,,CHEMBL619357,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4913.0,,,22224.0,16643.0,U,,In vitro rate of absorption observed as Caco-2 permeability in humans,,BAO_0000019,A,,CHEMBL619358,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4914.0,,,22224.0,17582.0,U,,Cellular permeability of compound was determined in Caco-2 cells; High,,BAO_0000219,A,,CHEMBL619359,1.0,,,9606.0,Caco-2,0.0,495.0,Homo sapiens
Autocuration,,4915.0,,,22224.0,6838.0,U,,Permeability in Caco-2 cells of compound,,BAO_0000219,A,,CHEMBL619360,1.0,,,9606.0,Caco-2,0.0,495.0,Homo sapiens
Autocuration,,4916.0,,,22224.0,6108.0,U,,Permeability coefficient (A to B) in Caco-2 cell,,BAO_0000019,A,,CHEMBL619361,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4917.0,,,22224.0,6108.0,U,,Permeability coefficient (B to A) in Caco-2 cell,,BAO_0000019,A,,CHEMBL619362,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4918.0,,,22224.0,6108.0,U,,Permeability coefficient (Papp) (Caco-2 cell monolayer),,BAO_0000019,A,,CHEMBL619363,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4919.0,,,22224.0,2146.0,U,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,BAO_0000019,A,,CHEMBL618942,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4920.0,,,22224.0,4514.0,U,,Compound was tested for protein binding in human plasma,,BAO_0000019,A,,CHEMBL618943,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,4921.0,,,22224.0,6108.0,U,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,BAO_0000019,A,,CHEMBL618944,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,4922.0,,,22224.0,7766.0,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,BAO_0000019,A,,CHEMBL618945,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Intermediate,,4923.0,,,50594.0,5969.0,N,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618946,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4924.0,,,50594.0,3277.0,N,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,BAO_0000218,A,In vivo,CHEMBL876413,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4925.0,,,50594.0,3802.0,N,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,BAO_0000218,A,In vivo,CHEMBL618947,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,4926.0,,,50594.0,2862.0,N,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,BAO_0000218,A,In vivo,CHEMBL618948,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,4927.0,,,50594.0,6348.0,N,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,A,In vivo,CHEMBL618949,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,,4928.0,,,50594.0,17764.0,N,,Tmax after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,F,In vivo,CHEMBL618950,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4929.0,,,50594.0,5781.0,N,,Tmax after oral administration at 30 mg/kg in ICR mouse,,BAO_0000218,A,In vivo,CHEMBL618951,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4930.0,,,50594.0,17764.0,N,,Tmax after peroral administration in mice at 2.4 uM/kg,,BAO_0000218,A,In vivo,CHEMBL618952,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4931.0,,,50594.0,4066.0,N,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,A,In vivo,CHEMBL618953,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,4932.0,,,50594.0,17641.0,N,,Tmax in brain of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618954,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,4933.0,,,50594.0,17641.0,N,,Tmax in kidney of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618955,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,4934.0,,,50594.0,17641.0,N,,Tmax in liver of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618956,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,4935.0,,,50594.0,17641.0,N,,Tmax in lungs of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618957,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,,4936.0,,,50594.0,17764.0,N,,Tmax in mice at 18 uM/kg i.p. administration,,BAO_0000218,F,In vivo,CHEMBL618958,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4937.0,,,50594.0,17764.0,N,,Tmax in mice at 23 uM/kg i.v. administration,,BAO_0000218,F,In vivo,CHEMBL618959,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4938.0,,,50594.0,17764.0,N,,Tmax in mice at 25 uM/kg i.p. administration,,BAO_0000218,F,In vivo,CHEMBL618960,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4939.0,,,50594.0,17764.0,N,,Tmax in mice at 26 uM/kg i.p. administration,,BAO_0000218,F,In vivo,CHEMBL876723,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,4940.0,,,50594.0,17641.0,N,,Tmax in spleen of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618961,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,,4941.0,,,50594.0,16597.0,N,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,A,In vivo,CHEMBL618962,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4942.0,,,50594.0,16597.0,N,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,A,In vivo,CHEMBL618963,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4943.0,,,50594.0,5951.0,N,,Tmax value in IRC mice,,BAO_0000218,A,,CHEMBL618964,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4944.0,,,50594.0,5506.0,N,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,BAO_0000218,A,In vivo,CHEMBL618965,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4945.0,,,50594.0,5506.0,N,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,BAO_0000218,A,In vivo,CHEMBL618966,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Urine,4946.0,,,50594.0,429.0,N,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,BAO_0000218,A,,CHEMBL618967,1.0,1088.0,,10090.0,,1.0,,Mus musculus
Intermediate,Urine,4947.0,,,50594.0,429.0,N,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,BAO_0000218,A,,CHEMBL618968,1.0,1088.0,,10090.0,,1.0,,Mus musculus
Intermediate,Urine,4948.0,,,50594.0,4066.0,N,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,BAO_0000218,A,,CHEMBL618969,1.0,1088.0,,10090.0,,1.0,,Mus musculus
Intermediate,,4949.0,,,50594.0,17734.0,N,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,A,,CHEMBL618970,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4950.0,,,50594.0,17734.0,N,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,A,,CHEMBL618971,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4951.0,,,50594.0,6062.0,N,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618972,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4952.0,,,50594.0,5969.0,N,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618973,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4953.0,,,50594.0,5969.0,N,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618974,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4954.0,,,50594.0,5969.0,N,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,BAO_0000218,A,In vivo,CHEMBL618975,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4955.0,,,50594.0,5980.0,N,,Vd in mice,,BAO_0000218,A,In vivo,CHEMBL618976,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4956.0,,,50594.0,17592.0,N,,Volume of distribution in mouse,,BAO_0000218,A,In vivo,CHEMBL618977,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4957.0,,,50594.0,6348.0,N,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,A,In vivo,CHEMBL876724,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4958.0,,,50594.0,17753.0,N,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,BAO_0000218,A,In vivo,CHEMBL618978,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4959.0,,,50594.0,17753.0,N,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,BAO_0000218,A,In vivo,CHEMBL618979,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4960.0,,,50594.0,17753.0,N,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,BAO_0000218,A,In vivo,CHEMBL618980,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4961.0,,,50594.0,4239.0,N,,Pharmacokinetic property (vdss) was measured in mouse,,BAO_0000218,A,In vivo,CHEMBL618981,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4962.0,,,50594.0,2862.0,N,,Value distribution upon iv administration in mouse,,BAO_0000218,A,In vivo,CHEMBL618982,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4963.0,,,50594.0,17734.0,N,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,A,In vivo,CHEMBL620150,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4964.0,,,50594.0,2675.0,N,,Volume of distribution was evaluated in mice after intravenous administration,,BAO_0000218,A,In vivo,CHEMBL620151,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4965.0,,,50594.0,2675.0,N,,Volume of distribution was evaluated in mice after oral administration,,BAO_0000218,A,In vivo,CHEMBL620152,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4966.0,,,50594.0,17837.0,N,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL620153,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4967.0,,,50594.0,5727.0,N,,Steady state volume of distribution was determined in mice,,BAO_0000218,A,In vivo,CHEMBL876395,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4968.0,,,50594.0,17852.0,N,,Volume distribution (steady state) of compound was determined in mouse,,BAO_0000218,A,In vivo,CHEMBL620154,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4969.0,,,50594.0,17764.0,N,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,BAO_0000218,A,In vivo,CHEMBL620155,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4970.0,,,50594.0,16597.0,N,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,A,In vivo,CHEMBL620156,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,4971.0,,,50594.0,6062.0,N,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL620157,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,4972.0,,,50594.0,16438.0,N,,Biodistribution of compound (oxidized form) in in kidney tissue,,BAO_0000218,A,In vivo,CHEMBL620158,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,4973.0,,,50594.0,16438.0,N,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,BAO_0000218,A,In vivo,CHEMBL620159,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,4974.0,,,50594.0,16438.0,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,BAO_0000218,A,In vivo,CHEMBL620160,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,4975.0,,,50594.0,16438.0,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL620161,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,,4976.0,,,80019.0,10708.0,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,BAO_0000219,F,,CHEMBL620162,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Expert,,4977.0,,,80852.0,16597.0,N,,Inhibition of A431 human squamous cell carcinoma cell proliferation,,BAO_0000219,F,,CHEMBL620163,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,4978.0,,,80852.0,16062.0,N,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,BAO_0000219,F,,CHEMBL620833,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,4979.0,,,80852.0,16062.0,N,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,BAO_0000219,F,,CHEMBL876396,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,4980.0,,,80852.0,16958.0,N,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,BAO_0000219,F,,CHEMBL620834,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,4981.0,,,80852.0,6700.0,N,,Inhibition of A431 human carcinoma cell proliferation,,BAO_0000219,F,,CHEMBL620835,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,4982.0,,,80852.0,17226.0,N,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,BAO_0000219,F,,CHEMBL620836,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,4983.0,,,80852.0,6828.0,N,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,BAO_0000219,F,,CHEMBL620837,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,4984.0,,,80852.0,12314.0,N,,In vitro cytotoxicity against epidermoid carcinoma cell line,,BAO_0000219,F,,CHEMBL621017,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,4985.0,,,9.0,13412.0,D,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,BAO_0000218,F,,CHEMBL621018,1.0,,,9606.0,A-431,9.0,500.0,Homo sapiens
Intermediate,,4986.0,,,80852.0,13299.0,N,,Antiproliferative activity of compound was measured on human tumor cell line A431.,,BAO_0000219,F,,CHEMBL621019,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,4987.0,,,80852.0,17420.0,N,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,BAO_0000219,F,,CHEMBL621020,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,4988.0,,,80852.0,13678.0,N,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,BAO_0000219,F,,CHEMBL621021,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,4989.0,,,9.0,14171.0,H,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,BAO_0000219,F,,CHEMBL621022,1.0,,,,A-431,8.0,500.0,
Expert,,4990.0,,,80852.0,6333.0,N,,Tested for antiproliferative activity against human A431 cells,,BAO_0000219,F,,CHEMBL621023,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,4991.0,,,9.0,2356.0,D,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,BAO_0000219,F,,CHEMBL621024,1.0,,,9606.0,A-431,9.0,500.0,Homo sapiens
Expert,,4992.0,,,80852.0,15578.0,N,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,BAO_0000219,F,,CHEMBL621025,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,4993.0,,,80852.0,5126.0,N,,Inhibition of A431 cell proliferation,,BAO_0000219,F,,CHEMBL621026,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,4994.0,,,80852.0,6844.0,N,,Cytotoxic effect on A431 human epidermoid carcinoma cells,,BAO_0000219,F,,CHEMBL621027,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,4995.0,,,80852.0,6844.0,N,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,BAO_0000219,F,,CHEMBL876397,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,4996.0,,,80852.0,4925.0,N,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,BAO_0000219,F,,CHEMBL883797,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,4997.0,,,80852.0,4925.0,N,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,BAO_0000219,F,,CHEMBL621028,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,4998.0,,,80852.0,13978.0,N,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,BAO_0000219,F,,CHEMBL621029,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,4999.0,,,80852.0,16786.0,N,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,BAO_0000219,F,,CHEMBL621030,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,5000.0,,,9.0,13412.0,H,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,BAO_0000219,F,,CHEMBL621147,1.0,,,,A-431,8.0,500.0,
Intermediate,,5001.0,,,80852.0,17824.0,N,,In vivo antiproliferative activity against A431 cell line,,BAO_0000218,F,,CHEMBL621148,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,5002.0,,,9.0,12751.0,D,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,BAO_0000219,F,,CHEMBL621149,1.0,,,9606.0,A-431,9.0,500.0,Homo sapiens
Expert,,5003.0,,,80852.0,12380.0,N,,Inhibition of A431 human epidermoid carcinoma cell proliferation,,BAO_0000219,F,,CHEMBL621150,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,5004.0,,,9.0,4959.0,D,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,BAO_0000219,F,,CHEMBL621151,1.0,,,9606.0,A-431,9.0,500.0,Homo sapiens
Intermediate,,5005.0,,,80852.0,6333.0,N,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,BAO_0000219,F,,CHEMBL621152,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,5006.0,,,80852.0,6333.0,N,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,BAO_0000219,F,,CHEMBL621153,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,5007.0,,,80852.0,6333.0,N,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,BAO_0000219,F,,CHEMBL884000,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,5008.0,,,9.0,5296.0,D,,Inhibition of EGFR overexpressing A431 cell proliferation,,BAO_0000019,F,,CHEMBL621154,1.0,,,9606.0,,9.0,,Homo sapiens
Expert,,5009.0,,,80852.0,12624.0,N,,Inhibition of A431 cell proliferation,,BAO_0000219,F,,CHEMBL621155,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,5010.0,,,9.0,14926.0,D,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,BAO_0000219,F,,CHEMBL621156,1.0,,,9606.0,A-431,9.0,500.0,Homo sapiens
Expert,,5011.0,,,9.0,14926.0,D,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,BAO_0000219,F,,CHEMBL621157,1.0,,,9606.0,A-431,9.0,500.0,Homo sapiens
Expert,,5012.0,,,9.0,14926.0,H,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,BAO_0000219,F,,CHEMBL621158,1.0,,,,A-431,8.0,500.0,
Intermediate,,5013.0,,,80852.0,15144.0,N,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,BAO_0000219,F,,CHEMBL621159,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,5014.0,,,80852.0,15144.0,N,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,BAO_0000219,F,,CHEMBL621160,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,5015.0,,,80852.0,5245.0,N,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,BAO_0000219,F,,CHEMBL621161,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,5016.0,,,80852.0,5245.0,N,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,BAO_0000219,F,,CHEMBL621162,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,5017.0,,,80852.0,5245.0,N,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,BAO_0000219,F,,CHEMBL621163,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,5018.0,,,80852.0,5245.0,N,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,BAO_0000219,F,,CHEMBL621164,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,5019.0,,,80852.0,5245.0,N,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,BAO_0000219,F,,CHEMBL621165,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Autocuration,,5020.0,,,22224.0,5922.0,U,,Half-life period in cynomolgus monkey,,BAO_0000019,A,,CHEMBL619159,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,5021.0,,,22224.0,1116.0,U,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,BAO_0000366,A,In vitro,CHEMBL619160,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5022.0,,,22224.0,17853.0,U,,Longer half-life in monkey (i.v.) at 0.5 mpk,,BAO_0000218,A,In vivo,CHEMBL619161,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,5023.0,,,22224.0,993.0,U,,Plasma half life in monkey,,BAO_0000366,A,,CHEMBL619162,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,5024.0,,,22224.0,4514.0,U,,Plasma half-life in rhesus monkey,,BAO_0000366,A,,CHEMBL619163,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,5025.0,,,22224.0,5334.0,U,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,A,In vivo,CHEMBL619164,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,5026.0,,,22224.0,5334.0,U,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,A,In vivo,CHEMBL619320,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5027.0,,,22224.0,4578.0,U,,Tested for half life upon iv administration to african green monkey,,BAO_0000218,A,In vivo,CHEMBL619321,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5028.0,,,22224.0,2661.0,U,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000218,A,In vivo,CHEMBL873336,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5029.0,,,22224.0,5355.0,U,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,A,In vivo,CHEMBL619322,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5030.0,,,22224.0,5355.0,U,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,A,In vivo,CHEMBL619323,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5031.0,,,22224.0,5355.0,U,,The time for peak concentration value after oral administration in cynomolgus monkeys,,BAO_0000218,A,In vivo,CHEMBL619324,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5032.0,,,22224.0,11271.0,U,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,A,,CHEMBL619325,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5033.0,,,22224.0,11271.0,U,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,A,,CHEMBL876411,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5034.0,,,22224.0,11271.0,U,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,A,,CHEMBL619326,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5035.0,,,22224.0,11271.0,U,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,A,,CHEMBL619327,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5036.0,,,22224.0,11271.0,U,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,A,,CHEMBL619328,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5037.0,,,22224.0,11271.0,U,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,A,,CHEMBL619329,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5038.0,,,22224.0,11271.0,U,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,A,,CHEMBL619330,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5039.0,,,22224.0,11271.0,U,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,A,,CHEMBL619331,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5040.0,,,22224.0,11271.0,U,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,A,,CHEMBL619332,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5041.0,,,22224.0,11271.0,U,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,A,,CHEMBL619333,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5042.0,,,22224.0,11271.0,U,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,A,,CHEMBL619334,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5043.0,,,22224.0,11271.0,U,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,A,,CHEMBL619335,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5044.0,,,22224.0,11271.0,U,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,A,,CHEMBL619336,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5045.0,,,22224.0,11271.0,U,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,A,,CHEMBL619337,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5046.0,,,22224.0,11271.0,U,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,A,,CHEMBL619338,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5047.0,,,22224.0,11271.0,U,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,A,,CHEMBL619339,1.0,,,9527.0,,0.0,,Cercopithecidae
Intermediate,,5048.0,,,50597.0,5809.0,N,,Bioavailability in rat (cannulated) (dose 2 mg/kg),,BAO_0000218,A,In vivo,CHEMBL619340,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Plasma,5049.0,,,50597.0,17720.0,N,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,BAO_0000218,A,In vivo,CHEMBL873496,1.0,1969.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Plasma,5050.0,,,50597.0,3546.0,N,,AUC value in rat after IV administration at a dose of 10 mg/kg,,BAO_0000218,A,,CHEMBL619341,1.0,1969.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Plasma,5051.0,,,50597.0,3546.0,N,,AUC value in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,A,,CHEMBL619342,1.0,1969.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,5052.0,,,50597.0,3546.0,N,,Cmax value in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL619343,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,5053.0,,,50597.0,3546.0,N,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL619344,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,5054.0,,,50597.0,3546.0,N,,Tmax value in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL619345,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,5055.0,,,50597.0,3546.0,N,,Vc value in rat after IV administration at a dose of 10 mg/kg,,BAO_0000218,A,,CHEMBL619346,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,5056.0,,,50597.0,3546.0,N,,Half life period in rat after IV administration at a dose of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL619347,1.0,,,10116.0,,1.0,,Rattus norvegicus
Autocuration,,5057.0,,,22224.0,10625.0,U,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,BAO_0000019,A,,CHEMBL619348,1.0,,,9557.0,,0.0,,Papio hamadryas
Autocuration,,5058.0,,,22224.0,10625.0,U,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,BAO_0000019,A,,CHEMBL619349,1.0,,,9557.0,,0.0,,Papio hamadryas
Autocuration,,5059.0,,,22224.0,10625.0,U,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,BAO_0000019,A,,CHEMBL619350,1.0,,,9557.0,,0.0,,Papio hamadryas
Autocuration,,5060.0,,,22224.0,10625.0,U,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,BAO_0000019,A,,CHEMBL619351,1.0,,,9557.0,,0.0,,Papio hamadryas
Autocuration,,5061.0,,,22224.0,10625.0,U,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,BAO_0000019,A,,CHEMBL875953,1.0,,,9557.0,,0.0,,Papio hamadryas
Autocuration,,5062.0,,,22224.0,10625.0,U,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,BAO_0000019,A,,CHEMBL621716,1.0,,,9557.0,,0.0,,Papio hamadryas
Autocuration,,5063.0,,,22224.0,10625.0,U,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,BAO_0000019,A,,CHEMBL621717,1.0,,,9557.0,,0.0,,Papio hamadryas
Autocuration,,5064.0,,,22224.0,10625.0,U,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,BAO_0000019,A,,CHEMBL621718,1.0,,,9557.0,,0.0,,Papio hamadryas
Autocuration,,5065.0,,,22224.0,3510.0,U,,Area under curve after 1 mpk peroral administration to beagles,,BAO_0000019,A,,CHEMBL621719,1.0,,,9615.0,,0.0,,beagle
Autocuration,,5066.0,,,22224.0,3510.0,U,,Area under curve after 2 mpk peroral administration to beagles,,BAO_0000019,A,,CHEMBL621720,1.0,,,9615.0,,0.0,,beagle
Autocuration,,5067.0,,,22224.0,3510.0,U,,Cmax value after 1 mpk peroral administration to beagles,,BAO_0000218,A,In vivo,CHEMBL621721,1.0,,,9615.0,,0.0,,beagle
Autocuration,Urine,5068.0,,,22224.0,7766.0,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,BAO_0000019,A,,CHEMBL621722,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,5069.0,,,22224.0,7766.0,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,BAO_0000019,A,,CHEMBL621723,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,5070.0,,,22224.0,7766.0,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,BAO_0000019,A,,CHEMBL621724,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,5071.0,,,22224.0,7766.0,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,BAO_0000019,A,,CHEMBL623443,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,5072.0,,,22224.0,7766.0,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,BAO_0000019,A,,CHEMBL623444,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,5073.0,,,22224.0,7766.0,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,BAO_0000019,A,,CHEMBL623445,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Urine,5074.0,,,22224.0,7766.0,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,BAO_0000019,A,,CHEMBL623446,1.0,1088.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,5075.0,,,22224.0,16643.0,U,,Metabolic stability observed at 30 min after administration in human liver microsomes,Microsomes,BAO_0000251,A,,CHEMBL623447,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5076.0,,,22224.0,6852.0,U,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,BAO_0000019,A,,CHEMBL623448,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5077.0,,,22224.0,6852.0,U,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,BAO_0000019,A,,CHEMBL623449,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5078.0,,,22224.0,6852.0,U,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,BAO_0000019,A,,CHEMBL623450,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,5079.0,,,22224.0,6567.0,U,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Microsomes,BAO_0000251,A,,CHEMBL623451,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5080.0,,,22224.0,6570.0,U,,Metabolic stability (% remaining at 30 mins) in human S9.,,BAO_0000019,A,,CHEMBL623452,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5081.0,,,22224.0,6570.0,U,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,BAO_0000019,A,,CHEMBL623453,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,5082.0,,,22224.0,5237.0,U,,Percent parent compound remaining after 20 min incubation with human liver microsomes,Microsomes,BAO_0000251,A,,CHEMBL623454,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,5083.0,,,22224.0,5237.0,U,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Microsomes,BAO_0000251,A,,CHEMBL623455,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,5084.0,,,22224.0,5237.0,U,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Microsomes,BAO_0000251,A,,CHEMBL624371,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5085.0,,,22224.0,5202.0,U,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,BAO_0000218,A,,CHEMBL624372,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5086.0,,,22224.0,5481.0,U,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,BAO_0000019,A,,CHEMBL624373,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5087.0,,,22224.0,5481.0,U,,Percent remaining in human plasma after incubation for 60 min at 37 C.,,BAO_0000019,A,,CHEMBL624374,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5088.0,,,22224.0,3956.0,U,,The percent remaining in human plasma after 30 min was determined,,BAO_0000019,A,,CHEMBL624556,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5089.0,,,22224.0,5074.0,U,,Conversion rate of the prodrug in human plasma,,BAO_0000366,A,,CHEMBL624557,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5090.0,,,22224.0,5074.0,U,,Conversion rate of the prodrug in human plasma; ND means no data,,BAO_0000366,A,,CHEMBL624558,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Blood,5091.0,,,22224.0,4727.0,U,,Half life of compound was determined in human blood,,BAO_0000221,A,,CHEMBL624559,1.0,178.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5092.0,,,22224.0,5965.0,U,,Half life of compound was determined in man with once daily dosing,,BAO_0000019,A,,CHEMBL624560,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5093.0,,,22224.0,5732.0,U,,Half life in human microsomes,Microsomes,BAO_0000251,A,In vitro,CHEMBL624561,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5094.0,,,22224.0,5819.0,U,,Half life in human plasma,,BAO_0000366,A,,CHEMBL624562,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5095.0,,,22224.0,5819.0,U,,Half life in human plasma; Not detected,,BAO_0000366,A,,CHEMBL624563,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5096.0,,,22224.0,1916.0,U,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,A,In vivo,CHEMBL624564,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,5097.0,,,22224.0,6597.0,U,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Microsomes,BAO_0000251,A,In vitro,CHEMBL624565,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5098.0,,,22224.0,5229.0,U,,Half-life in human plasma,,BAO_0000366,A,,CHEMBL875152,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5099.0,,,22224.0,5229.0,U,,Half-life of the parent prodrug in plasma,,BAO_0000366,A,,CHEMBL624566,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5100.0,,,22224.0,2192.0,U,,In vitro half life in human plasma was determined,,BAO_0000366,A,In vitro,CHEMBL873805,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,5101.0,,,22224.0,3032.0,U,,The compound was tested In Vitro for half life in human liver microsomes.,Microsomes,BAO_0000251,A,In vitro,CHEMBL624567,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5102.0,,,22224.0,1916.0,U,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,A,In vivo,CHEMBL624568,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5103.0,,,22224.0,17716.0,U,,Observed volume of distribution,,BAO_0000218,A,In vivo,CHEMBL624569,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5104.0,,,22224.0,15778.0,U,,Oral bioavailability in human,,BAO_0000218,A,In vivo,CHEMBL624570,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5105.0,,,22224.0,17313.0,U,,Tested for human plasma protein binding of the compound,,BAO_0000019,A,,CHEMBL624571,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5106.0,,,22224.0,4231.0,U,,"First order rate constant, k was determined in human plasma",,BAO_0000019,A,,CHEMBL624572,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5107.0,,,22224.0,4755.0,U,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,BAO_0000019,A,,CHEMBL624573,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5108.0,,,22224.0,4755.0,U,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,BAO_0000019,A,,CHEMBL875153,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,5109.0,,,22224.0,16907.0,U,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Microsomes,BAO_0000251,A,,CHEMBL624574,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5110.0,,,22224.0,10839.0,U,,The compound was tested for the plasma binding in human,,BAO_0000019,A,,CHEMBL624575,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5111.0,,,22224.0,10839.0,U,,Plasma protein binding (human),,BAO_0000019,A,,CHEMBL624576,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,5112.0,,,22224.0,3199.0,U,,Compound was evaluated for half-life in human liver microsomes,Microsomes,BAO_0000251,A,In vitro,CHEMBL624577,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Blood,5113.0,,,22224.0,1345.0,U,,Half life measured in vitro for its stability in human blood,,BAO_0000221,A,In vitro,CHEMBL624578,1.0,178.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Serum,5114.0,,,22224.0,4297.0,U,,Half life in human serum,,BAO_0000019,A,,CHEMBL622796,1.0,1977.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Serum,5115.0,,,22224.0,4297.0,U,,Half life in human serum; ND=not determined,,BAO_0000019,A,,CHEMBL622797,1.0,1977.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5116.0,,,22224.0,4297.0,U,,Half life were determined in CEM-SS cell extract in decomposition step 1,,BAO_0000019,A,,CHEMBL622798,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5117.0,,,22224.0,4297.0,U,,Half life were determined in CEM-SS cell extract in decomposition step 2,,BAO_0000019,A,,CHEMBL622799,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5118.0,,,22224.0,4231.0,U,,Half life of the in human plasma,,BAO_0000366,A,,CHEMBL622800,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5119.0,,,22224.0,5633.0,U,,Half life period in human hepatic S9 fraction was determined,S9,BAO_0000220,A,In vitro,CHEMBL622801,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,5120.0,,,22224.0,5633.0,U,,Half life period in human liver microsome was determined,Microsomes,BAO_0000251,A,In vitro,CHEMBL622802,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5121.0,,,22224.0,17791.0,U,,Half life period was determined; 6-7,,BAO_0000019,A,,CHEMBL622803,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5122.0,,,22224.0,17791.0,U,,Half life period was evaluated in human,,BAO_0000019,A,,CHEMBL875154,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5123.0,,,22224.0,3160.0,U,,Half life time in human plasma,,BAO_0000366,A,,CHEMBL622804,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Intermediate,Brain,5124.0,,,50594.0,16438.0,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL622805,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,5125.0,,,50594.0,16438.0,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL622611,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,5126.0,,,50594.0,16438.0,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL622612,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,5127.0,,,50594.0,16438.0,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL875160,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,5128.0,,,50594.0,16438.0,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,BAO_0000218,A,In vivo,CHEMBL622613,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,5129.0,,,50594.0,16438.0,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL622614,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,5130.0,,,50594.0,16438.0,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL622615,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,5131.0,,,50594.0,16438.0,N,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,BAO_0000218,A,In vivo,CHEMBL622616,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,5132.0,,,50594.0,16438.0,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL622617,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,5133.0,,,50594.0,16438.0,N,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,BAO_0000218,A,In vivo,CHEMBL622618,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,5134.0,,,50594.0,16438.0,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,BAO_0000218,A,In vivo,CHEMBL622619,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,5135.0,,,50594.0,16438.0,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL622620,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,5136.0,,,50594.0,16438.0,N,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,A,In vivo,CHEMBL622621,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,5137.0,,,50594.0,16438.0,N,,Biodistribution of compound (oxidized form) in blood tissue,,BAO_0000218,A,In vivo,CHEMBL622622,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,5138.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL622623,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,5139.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,BAO_0000218,A,In vivo,CHEMBL622624,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,5140.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,A,In vivo,CHEMBL622625,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,5141.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL622626,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,5142.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,BAO_0000218,A,In vivo,CHEMBL622627,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,5143.0,,,50594.0,16438.0,N,,Biodistribution of compound (oxidized form) in brain tissue of mice,,BAO_0000218,A,In vivo,CHEMBL622628,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,5144.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL622629,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,5145.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,A,In vivo,CHEMBL622630,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,5146.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL622631,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,5147.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,BAO_0000218,A,In vivo,CHEMBL622632,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,5148.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,BAO_0000218,A,In vivo,CHEMBL622633,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,5149.0,,,50594.0,16438.0,N,,Biodistribution of compound (oxidized form) in heart tissue of mice,,BAO_0000218,A,In vivo,CHEMBL622634,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,5150.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL622635,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,5151.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL875161,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,5152.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,A,In vivo,CHEMBL622636,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,5153.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL623335,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,5154.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,BAO_0000218,A,In vivo,CHEMBL623336,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,5155.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL623337,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,5156.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,BAO_0000218,A,In vivo,CHEMBL623338,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,5157.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,A,In vivo,CHEMBL623339,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,5158.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL623524,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,5159.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,BAO_0000218,A,In vivo,CHEMBL623525,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,5160.0,,,50594.0,16438.0,N,,Biodistribution of compound (oxidized form) in liver tissue,,BAO_0000218,A,In vivo,CHEMBL623526,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,5161.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,A,In vivo,CHEMBL623527,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,5162.0,,,50594.0,16438.0,N,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,A,In vivo,CHEMBL623528,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,,5163.0,,,80852.0,5245.0,N,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,BAO_0000219,F,,CHEMBL624615,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,5164.0,,,80852.0,5245.0,N,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,BAO_0000219,F,,CHEMBL621672,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,5165.0,,,80852.0,16289.0,N,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,BAO_0000218,F,,CHEMBL621673,1.0,,,,A-431,1.0,500.0,
Expert,,5166.0,,,80852.0,16289.0,N,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,BAO_0000218,F,,CHEMBL621674,1.0,,,,A-431,1.0,500.0,
Expert,,5167.0,,,9.0,16093.0,D,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,BAO_0000219,F,,CHEMBL884002,1.0,,,9606.0,A-431,9.0,500.0,Homo sapiens
Intermediate,,5168.0,,,80852.0,16825.0,N,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,BAO_0000219,F,,CHEMBL621850,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,5169.0,,,80852.0,4848.0,N,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,BAO_0000219,F,,CHEMBL621851,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,5170.0,,,9.0,14827.0,D,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,BAO_0000219,F,,CHEMBL621852,1.0,,,9606.0,A-431,9.0,500.0,Homo sapiens
Expert,,5171.0,,,9.0,14827.0,D,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,BAO_0000219,F,,CHEMBL621853,1.0,,,9606.0,A-431,9.0,500.0,Homo sapiens
Expert,,5172.0,,,80852.0,16289.0,N,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,BAO_0000218,F,,CHEMBL621854,1.0,,,,A-431,1.0,500.0,
Expert,,5173.0,,,80852.0,16289.0,N,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,BAO_0000218,F,,CHEMBL621855,1.0,,,,A-431,1.0,500.0,
Expert,,5174.0,,,80852.0,16289.0,N,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,BAO_0000218,F,,CHEMBL623724,1.0,,,,A-431,1.0,500.0,
Expert,,5175.0,,,80852.0,16289.0,N,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,BAO_0000218,F,,CHEMBL623725,1.0,,,,A-431,1.0,500.0,
Expert,,5176.0,,,80852.0,16289.0,N,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,BAO_0000218,F,,CHEMBL623726,1.0,,,,A-431,1.0,500.0,
Expert,,5177.0,,,9.0,16289.0,D,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,BAO_0000219,F,,CHEMBL623727,1.0,,,9606.0,A-431,9.0,500.0,Homo sapiens
Expert,,5178.0,,,9.0,16289.0,H,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,BAO_0000219,F,,CHEMBL623728,1.0,,,,A-431,8.0,500.0,
Expert,,5179.0,,,80852.0,16289.0,N,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,BAO_0000218,F,,CHEMBL623729,1.0,,,,A-431,1.0,500.0,
Expert,,5180.0,,,80852.0,16289.0,N,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,BAO_0000218,F,,CHEMBL623730,1.0,,,,A-431,1.0,500.0,
Expert,,5181.0,,,80852.0,16289.0,N,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,BAO_0000218,F,,CHEMBL623731,1.0,,,,A-431,1.0,500.0,
Expert,,5182.0,,,80852.0,14555.0,N,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,BAO_0000218,F,,CHEMBL623732,1.0,,,10090.0,A-431,1.0,500.0,Mus musculus
Expert,,5183.0,,,80852.0,14555.0,N,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,BAO_0000218,F,,CHEMBL623733,1.0,,,10090.0,A-431,1.0,500.0,Mus musculus
Expert,,5184.0,,,80852.0,14555.0,N,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,BAO_0000218,F,,CHEMBL623734,1.0,,,10090.0,A-431,1.0,500.0,Mus musculus
Expert,,5185.0,,,80852.0,14555.0,N,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,BAO_0000218,F,,CHEMBL623735,1.0,,,10090.0,A-431,1.0,500.0,Mus musculus
Expert,,5186.0,,,80852.0,1937.0,N,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,BAO_0000219,F,,CHEMBL623736,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,5187.0,,,80852.0,13739.0,N,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,BAO_0000219,F,,CHEMBL623737,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,5188.0,,,80852.0,3558.0,N,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,BAO_0000219,F,,CHEMBL623738,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,5189.0,,,80852.0,3558.0,N,,Dose giving a 50% decrease in the living cell number (A437 cells),,BAO_0000219,F,,CHEMBL875168,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,5190.0,,,80682.0,17686.0,N,,In vitro inhibitory concentration against proliferation of A459 cell line.,,BAO_0000219,F,,CHEMBL623739,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5191.0,,,80682.0,5305.0,N,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,BAO_0000219,F,,CHEMBL623740,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5192.0,,,80682.0,3614.0,N,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,BAO_0000219,F,,CHEMBL624424,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5193.0,,,80021.0,17229.0,N,,In vitro antitumor activity against renal A498 tumor cell lines,,BAO_0000219,F,,CHEMBL624425,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5194.0,,,80021.0,15935.0,N,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,BAO_0000219,F,,CHEMBL624426,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5195.0,,,80021.0,15935.0,N,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,BAO_0000219,F,,CHEMBL624427,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5196.0,,,80021.0,15560.0,N,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,BAO_0000219,F,,CHEMBL624428,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5197.0,,,80021.0,13891.0,N,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,BAO_0000219,F,,CHEMBL624429,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5198.0,,,80021.0,13891.0,N,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,BAO_0000219,F,,CHEMBL624620,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5199.0,,,80021.0,13788.0,N,,Cytotoxicity on kidney carcinoma (A-498) cell line,,BAO_0000219,F,,CHEMBL624621,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5200.0,,,80021.0,15403.0,N,,Compound was evaluated against Human cell line renal A498,,BAO_0000219,F,,CHEMBL624622,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5201.0,,,80021.0,1009.0,N,,Compound was tested for inhibition of A498 human renal cancer cell line,,BAO_0000219,F,,CHEMBL624623,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5202.0,,,80021.0,1043.0,N,,Growth inhibitory activity against A498 human cancer cell line,,BAO_0000219,F,,CHEMBL874365,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5203.0,,,80021.0,5858.0,N,,In vitro antitumor activity against human renal A498 cell line,,BAO_0000219,F,,CHEMBL624624,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5204.0,,,80021.0,5958.0,N,,In vitro cytotoxic activity against renal (A498) cell line,,BAO_0000219,F,,CHEMBL624625,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5205.0,,,80021.0,5506.0,N,,In vitro cytotoxic activity against human renal cancer (A498) cell line,,BAO_0000219,F,,CHEMBL624626,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5206.0,,,80021.0,12781.0,N,,Tested for cytostatic activity against renal A498 cell line,,BAO_0000219,F,,CHEMBL624627,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5207.0,,,80021.0,14399.0,N,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,BAO_0000219,F,,CHEMBL883157,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Expert,,5208.0,,,80021.0,5958.0,N,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,BAO_0000219,F,,CHEMBL624628,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Autocuration,,5209.0,,,22224.0,3510.0,U,,Cmax value after 2 mpk peroral administration to beagles,,BAO_0000218,A,In vivo,CHEMBL624629,1.0,,,9615.0,,0.0,,beagle
Autocuration,,5210.0,beagle,,22224.0,3510.0,U,,Bioavailability,,BAO_0000218,A,In vivo,CHEMBL623551,1.0,,,9615.0,,0.0,,Canis lupus familiaris
Autocuration,,5211.0,beagle,,22224.0,3510.0,U,,Bioavailability after 1 mpk peroral administration to beagles,,BAO_0000218,A,In vivo,CHEMBL623552,1.0,,,9615.0,,0.0,,Canis lupus familiaris
Autocuration,,5212.0,beagle,,22224.0,3510.0,U,,Bioavailability after 2 mpk peroral administration to beagles,,BAO_0000218,A,In vivo,CHEMBL623553,1.0,,,9615.0,,0.0,,Canis lupus familiaris
Autocuration,,5213.0,,,22224.0,3085.0,U,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,BAO_0000019,A,,CHEMBL623554,1.0,,,9913.0,,0.0,,Bos taurus
Autocuration,,5214.0,,,22224.0,3085.0,U,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,BAO_0000019,A,,CHEMBL623555,1.0,,,9913.0,,0.0,,Bos taurus
Autocuration,,5215.0,,,22224.0,3085.0,U,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,BAO_0000019,A,,CHEMBL623556,1.0,,,9913.0,,0.0,,Bos taurus
Autocuration,,5216.0,,,22224.0,9372.0,U,,Solubility against bovine alpha-chymotrypsin,,BAO_0000019,A,,CHEMBL623557,1.0,,,9913.0,,0.0,,Bos taurus
Autocuration,,5217.0,,,22224.0,3085.0,U,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,BAO_0000019,A,,CHEMBL623558,1.0,,,9913.0,,0.0,,Bos taurus
Autocuration,,5218.0,,,22224.0,3085.0,U,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,BAO_0000019,A,,CHEMBL623559,1.0,,,9913.0,,0.0,,Bos taurus
Autocuration,Spleen,5219.0,,,22224.0,1469.0,U,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,BAO_0000221,A,,CHEMBL623560,1.0,2106.0,,9913.0,,0.0,,Bos taurus
Autocuration,,5220.0,,,22224.0,4297.0,U,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,BAO_0000019,A,,CHEMBL623561,1.0,,,9913.0,,0.0,,Bos taurus
Autocuration,,5221.0,,,22224.0,4297.0,U,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,BAO_0000019,A,,CHEMBL623562,1.0,,,9913.0,,0.0,,Bos taurus
Autocuration,,5222.0,,,22224.0,17585.0,U,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,BAO_0000019,A,,CHEMBL623563,1.0,,,9913.0,,0.0,,Bos taurus
Autocuration,Spleen,5223.0,,,22224.0,1336.0,U,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,BAO_0000221,A,,CHEMBL623564,1.0,2106.0,,9913.0,,0.0,,Bos taurus
Autocuration,,5224.0,,,22224.0,3085.0,U,,Half life in presence of 2 mg/mL BSA at pH 8.8,,BAO_0000019,A,,CHEMBL873806,1.0,,,9913.0,,0.0,,Bos taurus
Autocuration,,5225.0,,,22224.0,2857.0,U,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,BAO_0000019,A,,CHEMBL623565,1.0,,,9913.0,,0.0,,Bos taurus
Autocuration,,5226.0,,,22224.0,2857.0,U,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,BAO_0000019,A,,CHEMBL623566,1.0,,,9913.0,,0.0,,Bos taurus
Autocuration,,5227.0,,,22224.0,2857.0,U,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,BAO_0000019,A,,CHEMBL623567,1.0,,,9913.0,,0.0,,Bos taurus
Autocuration,,5228.0,,,22224.0,1540.0,U,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,BAO_0000019,A,,CHEMBL623568,1.0,,,9913.0,,0.0,,Bos taurus
Intermediate,Plasma,5229.0,,,50588.0,6316.0,N,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,BAO_0000218,A,,CHEMBL623569,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5230.0,,,50588.0,17594.0,N,,AUC after administration at 100 mg/kg/day in dogs,,BAO_0000218,A,,CHEMBL623570,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5231.0,,,50588.0,4953.0,N,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,BAO_0000218,A,,CHEMBL624254,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5232.0,,,50588.0,16907.0,N,,AUC value after 15 mg/kg iv dose in Dogs,,BAO_0000218,A,,CHEMBL624255,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5233.0,,,50588.0,16907.0,N,,AUC value after 30 mg/kg po dose in Dogs,,BAO_0000218,A,,CHEMBL624256,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5234.0,,,50588.0,2959.0,N,,AUC value after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,A,,CHEMBL624257,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5235.0,,,50588.0,17594.0,N,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,BAO_0000218,A,,CHEMBL624258,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5236.0,,,50588.0,5356.0,N,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,BAO_0000218,A,,CHEMBL875277,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5237.0,,,50588.0,16807.0,N,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,BAO_0000218,A,,CHEMBL622667,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5238.0,,,50588.0,4527.0,N,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,BAO_0000218,A,,CHEMBL622668,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5239.0,,,50588.0,4527.0,N,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,A,,CHEMBL622669,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5240.0,,,50588.0,15660.0,N,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,BAO_0000218,A,,CHEMBL622670,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5241.0,,,50588.0,15660.0,N,,Area under curve determined in dogs after oral administration of 10 mg/kg,,BAO_0000218,A,,CHEMBL622671,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5242.0,,,50588.0,5802.0,N,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,A,,CHEMBL622672,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Expert,,5243.0,,,50588.0,3598.0,N,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,A,,CHEMBL622673,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Expert,,5244.0,,,50588.0,3598.0,N,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,A,,CHEMBL622674,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5245.0,,,50588.0,5944.0,N,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,A,,CHEMBL622675,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5246.0,,,50588.0,5944.0,N,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,BAO_0000218,A,,CHEMBL622676,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5247.0,,,50588.0,5944.0,N,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,A,,CHEMBL622677,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5248.0,,,50588.0,5944.0,N,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,BAO_0000218,A,,CHEMBL622678,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5249.0,,,50588.0,4186.0,N,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,BAO_0000218,A,,CHEMBL622679,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5250.0,,,50588.0,5007.0,N,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,A,,CHEMBL622680,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5251.0,,,50588.0,5668.0,N,,Area under curve was determine after peroral administration at 10 mpk in dog,,BAO_0000218,A,,CHEMBL622681,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5252.0,,,50588.0,5668.0,N,,Area under curve was determine after peroral administration at 5 mpk in dog,,BAO_0000218,A,,CHEMBL875278,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5253.0,,,50588.0,5006.0,N,,Area under curve was determined,,BAO_0000218,A,,CHEMBL622682,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5254.0,,,50588.0,5006.0,N,,Area under curve in dogs,,BAO_0000218,A,,CHEMBL622683,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5255.0,,,50588.0,3771.0,N,,Area under curve in dogs at 10 mg/kg dose fo oral administration,,BAO_0000218,A,,CHEMBL622684,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5256.0,,,50588.0,3771.0,N,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,BAO_0000218,A,,CHEMBL622685,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5257.0,,,50588.0,3771.0,N,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,BAO_0000218,A,,CHEMBL622686,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5258.0,,,50588.0,1916.0,N,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,A,,CHEMBL618344,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5259.0,,,50588.0,5302.0,N,,Area under curve value in dog at a dose of 5 mg/kg,,BAO_0000218,A,,CHEMBL875582,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5260.0,,,50588.0,5600.0,N,,Area under curve was determined after 0.1 mg/kg iv administration in dog,,BAO_0000218,A,,CHEMBL618345,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5261.0,,,50588.0,5600.0,N,,Area under curve was determined after 0.3 mg/kg po administration in dog,,BAO_0000218,A,,CHEMBL618346,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5262.0,,,50588.0,17764.0,N,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,A,,CHEMBL618347,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5263.0,,,50588.0,4368.0,N,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,A,,CHEMBL618348,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Autocuration,,5264.0,,,22224.0,5318.0,U,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,BAO_0000019,A,,CHEMBL618349,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5265.0,,,22224.0,5318.0,U,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,BAO_0000019,A,,CHEMBL618350,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5266.0,,,22224.0,5318.0,U,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,BAO_0000019,A,,CHEMBL618351,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5267.0,,,22224.0,5318.0,U,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,BAO_0000019,A,,CHEMBL618352,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Blood,5268.0,,,22224.0,14518.0,U,,Time taken to reduce 50% of the concentration of compound in blood plasma,,BAO_0000221,A,,CHEMBL873494,1.0,178.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5269.0,,,22224.0,2209.0,U,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,BAO_0000366,A,,CHEMBL618353,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5270.0,,,22224.0,6787.0,U,,Half life in human plasma,,BAO_0000366,A,,CHEMBL618354,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5271.0,,,22224.0,4898.0,U,,Half life in human plasma was reported,,BAO_0000366,A,,CHEMBL875583,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Serum,5272.0,,,22224.0,6072.0,U,,Half life in human serum,,BAO_0000019,A,,CHEMBL618355,1.0,1977.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5273.0,,,22224.0,16907.0,U,,Half life upon exposure to human plasma,,BAO_0000366,A,,CHEMBL618356,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5274.0,,,22224.0,5656.0,U,,t1/2 in human microsomes,Microsomes,BAO_0000251,A,In vitro,CHEMBL618357,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5275.0,,,22224.0,4755.0,U,,Half life period in 80% human plasma at 37 degree Centigrade,,BAO_0000366,A,,CHEMBL618358,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Zone of skin,5276.0,,,22224.0,17503.0,U,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,BAO_0000221,A,,CHEMBL618359,1.0,14.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5277.0,,,22224.0,12357.0,U,,Half-life measured in in vitro Cathepsin B assay in human plasma,,BAO_0000366,A,In vitro,CHEMBL618360,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5278.0,,,22224.0,3076.0,U,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,BAO_0000019,A,,CHEMBL618361,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,5279.0,,,22224.0,6410.0,U,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Microsomes,BAO_0000251,A,In vitro,CHEMBL618362,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5280.0,,,22224.0,3741.0,U,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,BAO_0000366,A,,CHEMBL618363,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5281.0,,,22224.0,3741.0,U,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,BAO_0000366,A,,CHEMBL618364,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5282.0,,,22224.0,3741.0,U,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,BAO_0000366,A,,CHEMBL875584,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5283.0,,,22224.0,1540.0,U,,Half-life in the CEM cell extracts,,BAO_0000019,A,,CHEMBL618365,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5284.0,,,22224.0,2905.0,U,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,BAO_0000366,A,,CHEMBL873495,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5285.0,,,22224.0,2905.0,U,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,BAO_0000366,A,,CHEMBL618366,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5286.0,,,22224.0,5523.0,U,,Half-life was determined,,BAO_0000019,A,,CHEMBL618367,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Blood,5287.0,,,22224.0,1499.0,U,,Half-life (human blood stability),,BAO_0000221,A,,CHEMBL618368,1.0,178.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Blood,5288.0,,,22224.0,1499.0,U,,Half-life (human blood stability); no data,,BAO_0000221,A,,CHEMBL618369,1.0,178.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5289.0,,,22224.0,17065.0,U,,Half-life in human plasma,,BAO_0000366,A,,CHEMBL618370,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5290.0,,,22224.0,6861.0,U,,CYP3A4 metabolism half-life (t1/2),,BAO_0000019,A,,CHEMBL618371,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Blood,5291.0,,,22224.0,1499.0,U,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,BAO_0000221,A,,CHEMBL618372,1.0,178.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5292.0,,,22224.0,530.0,U,,In vitro half life in human plasma,,BAO_0000366,A,In vitro,CHEMBL618373,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5293.0,,,22224.0,1116.0,U,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,BAO_0000366,A,In vitro,CHEMBL618374,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5294.0,,,22224.0,6695.0,U,,In vitro hydrolysis in human plasma,,BAO_0000366,A,In vitro,CHEMBL618375,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5295.0,,,22224.0,6695.0,U,,In vitro hydrolysis in human plasma; no data,,BAO_0000366,A,In vitro,CHEMBL618376,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,5296.0,,,22224.0,10.0,U,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Microsomes,BAO_0000251,A,In vitro,CHEMBL618377,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5297.0,,,22224.0,993.0,U,,Plasma half life in human,,BAO_0000366,A,,CHEMBL618378,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5298.0,,,22224.0,15429.0,U,,Stability after incubation with human plasma (at 37 degree C),,BAO_0000366,A,,CHEMBL618379,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5299.0,,,22224.0,1675.0,U,,T1/2 was evaluated in human plasma,,BAO_0000366,A,,CHEMBL618380,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5300.0,,,22224.0,2209.0,U,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,BAO_0000366,A,,CHEMBL618381,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5301.0,,,22224.0,2209.0,U,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,BAO_0000366,A,,CHEMBL618382,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5302.0,,,22224.0,5318.0,U,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,BAO_0000019,A,,CHEMBL618383,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5303.0,,,22224.0,2412.0,U,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,BAO_0000019,A,In vitro,CHEMBL618384,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5304.0,,,22224.0,2412.0,U,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,BAO_0000019,A,In vitro,CHEMBL618385,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5305.0,,,22224.0,2906.0,U,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,BAO_0000366,A,,CHEMBL619099,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,Plasma,5306.0,,,22224.0,2906.0,U,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,BAO_0000366,A,,CHEMBL619100,1.0,1969.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5307.0,,,22224.0,5495.0,U,,Time taken for 50% to be consumed by serum PON1 was determined,,BAO_0000019,A,,CHEMBL619101,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,5308.0,,,22224.0,5495.0,U,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,BAO_0000019,A,,CHEMBL619102,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,Liver,5309.0,,,22224.0,4397.0,U,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Microsomes,BAO_0000251,A,,CHEMBL619103,1.0,2107.0,,9606.0,,0.0,,Homo sapiens
Autocuration,,5310.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,A,,CHEMBL619268,1.0,,,10095.0,,0.0,,Mus sp.
Autocuration,,5311.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,A,,CHEMBL619269,1.0,,,10095.0,,0.0,,Mus sp.
Autocuration,,5312.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,A,,CHEMBL619270,1.0,,,10095.0,,0.0,,Mus sp.
Autocuration,,5313.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,A,,CHEMBL619271,1.0,,,10095.0,,0.0,,Mus sp.
Autocuration,,5314.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,A,,CHEMBL875585,1.0,,,10095.0,,0.0,,Mus sp.
Autocuration,,5315.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,A,,CHEMBL619272,1.0,,,10095.0,,0.0,,Mus sp.
Intermediate,,5316.0,,,80640.0,6058.0,N,,Compound tested for growth inhibition of renal cancer cell line 786-0,,BAO_0000219,F,,CHEMBL619273,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5317.0,,,80640.0,17708.0,N,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,BAO_0000219,F,,CHEMBL619274,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Expert,,5318.0,,,80640.0,14017.0,N,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,BAO_0000219,F,,CHEMBL619275,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5319.0,,,80640.0,16818.0,N,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,BAO_0000219,F,,CHEMBL619276,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5320.0,,,80640.0,16818.0,N,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,BAO_0000219,F,,CHEMBL619277,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5321.0,,,80640.0,16818.0,N,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,BAO_0000219,F,,CHEMBL619278,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5322.0,,,80640.0,11970.0,N,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,BAO_0000219,F,,CHEMBL619279,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5323.0,,,80640.0,12400.0,N,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,BAO_0000219,F,,CHEMBL858458,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Expert,,5324.0,,,80640.0,12888.0,N,,Cytotoxic effect on renal cancer line 786-0,,BAO_0000219,F,,CHEMBL619280,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5325.0,,,80640.0,15300.0,N,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,BAO_0000219,F,,CHEMBL619281,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5326.0,,,80640.0,14769.0,N,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,BAO_0000219,F,,CHEMBL619282,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5327.0,,,80640.0,15895.0,N,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,BAO_0000219,F,,CHEMBL619283,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5328.0,,,80640.0,17376.0,N,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,BAO_0000219,F,,CHEMBL619284,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5329.0,,,80640.0,14882.0,N,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,BAO_0000219,F,,CHEMBL619285,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5330.0,,,80640.0,14882.0,N,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,BAO_0000219,F,,CHEMBL619286,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5331.0,,,80640.0,15176.0,N,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,BAO_0000219,F,,CHEMBL619287,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5332.0,,,80640.0,12696.0,N,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,BAO_0000219,F,,CHEMBL857455,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5333.0,,,80640.0,2496.0,N,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,BAO_0000219,F,,CHEMBL883801,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5334.0,,,80641.0,11831.0,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,BAO_0000219,F,,CHEMBL619288,1.0,,,9606.0,791T cell line,1.0,972.0,Homo sapiens
Intermediate,,5335.0,,,80641.0,11831.0,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,BAO_0000219,F,,CHEMBL619289,1.0,,,9606.0,791T cell line,1.0,972.0,Homo sapiens
Intermediate,,5336.0,,,80641.0,11831.0,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,BAO_0000219,F,,CHEMBL619290,1.0,,,9606.0,791T cell line,1.0,972.0,Homo sapiens
Intermediate,,5337.0,,,80641.0,11831.0,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,BAO_0000219,F,,CHEMBL619291,1.0,,,9606.0,791T cell line,1.0,972.0,Homo sapiens
Intermediate,,5338.0,,,80641.0,11831.0,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,BAO_0000219,F,,CHEMBL619292,1.0,,,9606.0,791T cell line,1.0,972.0,Homo sapiens
Intermediate,,5339.0,,,80641.0,11831.0,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,BAO_0000219,F,,CHEMBL619293,1.0,,,9606.0,791T cell line,1.0,972.0,Homo sapiens
Intermediate,,5340.0,,,80641.0,11831.0,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,BAO_0000219,F,,CHEMBL619294,1.0,,,9606.0,791T cell line,1.0,972.0,Homo sapiens
Intermediate,,5341.0,,,80641.0,11831.0,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,BAO_0000219,F,,CHEMBL619295,1.0,,,9606.0,791T cell line,1.0,972.0,Homo sapiens
Intermediate,,5342.0,,,80641.0,11831.0,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,BAO_0000219,F,,CHEMBL619296,1.0,,,9606.0,791T cell line,1.0,972.0,Homo sapiens
Intermediate,,5343.0,,,80641.0,11831.0,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,BAO_0000219,F,,CHEMBL619297,1.0,,,9606.0,791T cell line,1.0,972.0,Homo sapiens
Intermediate,,5344.0,,,80640.0,12782.0,N,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,BAO_0000219,F,,CHEMBL619298,1.0,,,9606.0,786-0,1.0,391.0,Homo sapiens
Intermediate,,5345.0,,,22226.0,1229.0,U,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,BAO_0000019,F,,CHEMBL619299,1.0,,,,,0.0,,
Expert,,5346.0,,,80433.0,15313.0,N,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,BAO_0000219,F,,CHEMBL619300,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Expert,,5347.0,,,80433.0,15313.0,N,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,BAO_0000219,F,,CHEMBL619301,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5348.0,,,80433.0,11544.0,N,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,BAO_0000219,F,,CHEMBL619302,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5349.0,,,80433.0,9424.0,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,BAO_0000219,F,,CHEMBL619303,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5350.0,,,80433.0,9424.0,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,BAO_0000219,F,,CHEMBL619304,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5351.0,,,80433.0,9424.0,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,BAO_0000219,F,,CHEMBL857706,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5352.0,,,80433.0,9424.0,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,BAO_0000219,F,,CHEMBL619305,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5353.0,,,80433.0,9424.0,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,BAO_0000219,F,,CHEMBL619306,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5354.0,,,80433.0,9424.0,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,BAO_0000219,F,,CHEMBL619307,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5355.0,,,80433.0,9424.0,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,BAO_0000219,F,,CHEMBL619308,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5356.0,,,80433.0,9424.0,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,BAO_0000219,F,,CHEMBL619309,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5357.0,,,80433.0,9424.0,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,BAO_0000219,F,,CHEMBL619310,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5358.0,,,80021.0,14769.0,N,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,BAO_0000219,F,,CHEMBL619311,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5359.0,,,80021.0,15354.0,N,,Compound was tested for the growth inhibition of A498 renal tumor cell line,,BAO_0000219,F,,CHEMBL619312,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5360.0,,,80021.0,17445.0,N,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,BAO_0000219,F,,CHEMBL619313,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5361.0,,,80021.0,4337.0,N,,In vitro inhibitory concentration against renal cancer cell line A498,,BAO_0000219,F,,CHEMBL619314,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5362.0,,,80021.0,15277.0,N,,Cytotoxicity against A 498 tumor cell line,,BAO_0000219,F,,CHEMBL619959,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5363.0,,,80021.0,4812.0,N,,In vitro antitumor activity against A498 human cancer cell line,,BAO_0000219,F,,CHEMBL619960,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5364.0,,,80021.0,4812.0,N,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,BAO_0000219,F,,CHEMBL619961,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5365.0,,,80021.0,4995.0,N,,Inhibitory dose required against A498 human tumor cell lines,,BAO_0000219,F,,CHEMBL619962,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5366.0,,,80021.0,5847.0,N,,Anticancer activity against one renal cancer (A498 cell line),,BAO_0000219,F,,CHEMBL875586,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5367.0,,,80021.0,6557.0,N,,In vitro cytotoxicity against melanoma A498 cell line,,BAO_0000219,F,,CHEMBL619963,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5368.0,,,80021.0,2597.0,N,,Compound was tested for growth inhibitory activity against A498 cell line,,BAO_0000219,F,,CHEMBL619964,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5369.0,,,80021.0,6058.0,N,,Compound tested for growth inhibition of renal cancer cell line A498,,BAO_0000219,F,,CHEMBL620108,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5370.0,,,80021.0,17708.0,N,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,BAO_0000219,F,,CHEMBL620109,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5371.0,,,80021.0,15176.0,N,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,BAO_0000219,F,,CHEMBL620110,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5372.0,,,80021.0,15300.0,N,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,BAO_0000219,F,,CHEMBL620111,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5373.0,,,80021.0,11970.0,N,,Tested for cytotoxicity against A498 cell lines in renal cancer,,BAO_0000219,F,,CHEMBL620112,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5374.0,,,80021.0,12400.0,N,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,BAO_0000219,F,,CHEMBL620113,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Expert,,5375.0,,,80021.0,12888.0,N,,Cytotoxic effect on renal cancer lines A498,,BAO_0000219,F,,CHEMBL620114,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5376.0,,,80021.0,3030.0,N,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,BAO_0000219,F,,CHEMBL620115,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5377.0,,,80021.0,14769.0,N,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,BAO_0000219,F,,CHEMBL620116,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5378.0,,,80021.0,17376.0,N,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,BAO_0000219,F,,CHEMBL620117,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5379.0,,,80021.0,16558.0,N,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,BAO_0000219,F,,CHEMBL620118,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5380.0,,,80021.0,5194.0,N,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,BAO_0000219,F,,CHEMBL620119,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5381.0,,,80021.0,10708.0,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,BAO_0000219,F,,CHEMBL620120,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Expert,,5382.0,,,80682.0,16880.0,N,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,BAO_0000219,F,,CHEMBL620121,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5383.0,,,80682.0,10196.0,N,,Antitumor activity against A549 human lung carcinoma cell line,,BAO_0000219,F,,CHEMBL620122,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5384.0,,,80682.0,10196.0,N,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,BAO_0000219,F,,CHEMBL620123,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5385.0,,,80682.0,10196.0,N,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,BAO_0000219,F,,CHEMBL620124,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5386.0,,,80682.0,12083.0,N,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,BAO_0000219,F,,CHEMBL620125,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5387.0,,,80682.0,16464.0,N,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,BAO_0000219,F,,CHEMBL620126,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5388.0,,,80682.0,16464.0,N,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,F,,CHEMBL883027,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5389.0,,,80682.0,16470.0,N,,In vitro cytotoxic activity against human lung A549 cell line,,BAO_0000219,F,,CHEMBL620127,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5390.0,,,80682.0,16470.0,N,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,BAO_0000219,F,,CHEMBL620128,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5391.0,,,80682.0,16470.0,N,,In vitro cytotoxic activity against human lung A549 cell line),,BAO_0000219,F,,CHEMBL620129,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5392.0,,,80682.0,16470.0,N,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,BAO_0000219,F,,CHEMBL620130,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5393.0,,,80682.0,16582.0,N,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,BAO_0000219,F,,CHEMBL620131,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5394.0,,,80682.0,15935.0,N,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,BAO_0000219,F,,CHEMBL620132,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5395.0,,,80682.0,15935.0,N,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,BAO_0000219,F,,CHEMBL620133,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5396.0,,,80682.0,16597.0,N,,Inhibition of A549 human lung carcinoma cell proliferation,,BAO_0000219,F,,CHEMBL620134,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5397.0,,,80682.0,17376.0,N,,Inhibitory activity against A549 lung adenocarcinoma cell line,,BAO_0000219,F,,CHEMBL620135,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5398.0,,,80682.0,16496.0,N,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,BAO_0000219,F,,CHEMBL620136,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5399.0,,,80682.0,16152.0,N,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,BAO_0000219,F,,CHEMBL620137,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5400.0,,,80682.0,16152.0,N,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,BAO_0000219,F,,CHEMBL620268,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5401.0,,,80682.0,16464.0,N,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,F,,CHEMBL620269,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5402.0,,,80682.0,2288.0,N,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,BAO_0000219,F,,CHEMBL620270,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5403.0,,,80682.0,17350.0,N,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,BAO_0000219,F,,CHEMBL620271,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5404.0,,,80682.0,4090.0,N,,Inhibition of A549 cancer cell proliferation,,BAO_0000219,F,,CHEMBL620272,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5405.0,,,80682.0,4090.0,N,,Inhibition of A549 cancer cell proliferation (Not tested),,BAO_0000219,F,,CHEMBL620273,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5406.0,,,80682.0,17350.0,N,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,BAO_0000219,F,,CHEMBL620274,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5407.0,,,80682.0,4197.0,N,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,BAO_0000219,F,,CHEMBL620275,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5408.0,,,80682.0,17072.0,N,,Antiproliferative potency determined as inhibitory concentration against A549 cells,,BAO_0000219,F,,CHEMBL620276,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5409.0,,,80682.0,17072.0,N,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,BAO_0000219,F,,CHEMBL620277,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5410.0,,,80682.0,5194.0,N,,Cytotoxicity against Renal cell lines A549 was determined,,BAO_0000219,F,,CHEMBL620278,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5411.0,,,50588.0,4257.0,N,,Area under curve was determined in dog after a 3 mg/kg of oral dose,,BAO_0000218,A,,CHEMBL620279,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5412.0,,,50588.0,6123.0,N,,Area under curve was determined in dog after oral administration at 1 mg/kg,,BAO_0000218,A,,CHEMBL620280,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5413.0,,,50588.0,1337.0,N,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,A,,CHEMBL620281,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5414.0,,,50588.0,1337.0,N,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,A,,CHEMBL620282,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5415.0,,,50588.0,8833.0,N,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,BAO_0000218,A,,CHEMBL621134,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5416.0,,,50588.0,8833.0,N,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,BAO_0000218,A,,CHEMBL621135,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5417.0,,,50588.0,8833.0,N,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,BAO_0000218,A,,CHEMBL621136,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5418.0,,,50588.0,8833.0,N,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,BAO_0000218,A,,CHEMBL621137,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5419.0,,,50588.0,17657.0,N,,Area under plasma concentration time curve in dog upon oral administration,,BAO_0000218,A,,CHEMBL621138,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5420.0,,,50588.0,17650.0,N,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,A,,CHEMBL875587,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5421.0,,,50588.0,1977.0,N,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,BAO_0000218,A,,CHEMBL621139,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5422.0,,,50588.0,1977.0,N,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,BAO_0000218,A,,CHEMBL621140,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5423.0,,,50588.0,3132.0,N,,Area under the curve for the compound was obtained when tested in dog,,BAO_0000218,A,,CHEMBL621141,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5424.0,,,50588.0,5473.0,N,,Area under the curve at a dose of 1 mg/kg,,BAO_0000218,A,,CHEMBL621142,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5425.0,,,50588.0,5474.0,N,,Area under the curve at a dose of 1 mg/kg (oral),,BAO_0000218,A,,CHEMBL621143,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5426.0,,,50588.0,5474.0,N,,Area under the curve at i.v. dose of 0.2 mg/kg,,BAO_0000218,A,,CHEMBL621144,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5427.0,,,50588.0,6062.0,N,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,A,,CHEMBL621145,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5428.0,,,50588.0,4709.0,N,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,BAO_0000218,A,,CHEMBL621146,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5429.0,,,50588.0,2652.0,N,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,BAO_0000218,A,,CHEMBL622567,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5430.0,,,50588.0,2652.0,N,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,BAO_0000218,A,,CHEMBL622568,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5431.0,,,50588.0,2877.0,N,,Compound was evaluated for area under the curve in dog blood.,,BAO_0000218,A,,CHEMBL622569,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5432.0,,,50588.0,5444.0,N,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,BAO_0000218,A,,CHEMBL622570,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5433.0,,,50588.0,5130.0,N,,AUC in dog after oral dose (1 mg/kg),,BAO_0000218,A,,CHEMBL622571,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5434.0,,,50588.0,6265.0,N,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,BAO_0000218,A,,CHEMBL622572,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5435.0,,,50588.0,4657.0,N,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,BAO_0000218,A,,CHEMBL622573,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5436.0,,,50588.0,16367.0,N,,Pharmacokinetic parameter AUC after intravenous administration to dogs,,BAO_0000218,A,,CHEMBL622574,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5437.0,,,50588.0,16367.0,N,,Pharmacokinetic parameter AUC after oral administration to dogs,,BAO_0000218,A,,CHEMBL622575,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5438.0,,,50588.0,9579.0,N,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,BAO_0000218,A,,CHEMBL622576,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5439.0,,,50588.0,9579.0,N,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,BAO_0000218,A,,CHEMBL622577,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5440.0,,,50588.0,5983.0,N,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,BAO_0000218,A,,CHEMBL622578,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5441.0,,,50588.0,6241.0,N,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,BAO_0000218,A,,CHEMBL622579,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5442.0,,,50588.0,5313.0,N,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,BAO_0000218,A,,CHEMBL622580,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5443.0,,,50588.0,5313.0,N,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,BAO_0000218,A,,CHEMBL622581,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5444.0,,,50588.0,6642.0,N,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,A,,CHEMBL622582,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5445.0,,,50588.0,6642.0,N,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,A,,CHEMBL622583,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5446.0,,,50588.0,6641.0,N,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,BAO_0000218,A,,CHEMBL622584,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5447.0,,,50588.0,6642.0,N,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,BAO_0000218,A,,CHEMBL622585,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5448.0,,,50588.0,17791.0,N,,Compound was evaluated for oral bioavailability in dog; 90-100,,BAO_0000218,A,,CHEMBL622586,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5449.0,,,50588.0,17655.0,N,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,BAO_0000218,A,,CHEMBL623281,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5450.0,,,50588.0,17655.0,N,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,BAO_0000218,A,,CHEMBL623282,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5451.0,,,50588.0,6596.0,N,,PAPP (membrane permeability) in dog kidney cell monolayer assay,,BAO_0000218,A,,CHEMBL623283,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5452.0,,,50588.0,3880.0,N,,Oral bioavailability in dog,,BAO_0000218,A,,CHEMBL623284,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5453.0,,,50588.0,16367.0,N,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,BAO_0000218,A,,CHEMBL623285,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5454.0,,,50588.0,17409.0,N,,Plasma protein binding towards dog plasma at 10 uM,,BAO_0000218,A,,CHEMBL623463,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5455.0,,,50588.0,17409.0,N,,Plasma protein binding towards dog plasma at 100 uM,,BAO_0000218,A,,CHEMBL875952,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5456.0,,,50588.0,2959.0,N,,Bioavailability in dog (dose 4 mg/kg p.o.),,BAO_0000218,A,In vivo,CHEMBL621705,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5457.0,,,50588.0,13501.0,N,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,BAO_0000218,A,In vivo,CHEMBL621706,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5458.0,,,50588.0,4527.0,N,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,A,In vivo,CHEMBL621707,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5459.0,,,50588.0,15145.0,N,,Bioavailability in dogs,,BAO_0000218,A,In vivo,CHEMBL621708,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5460.0,,,50588.0,4219.0,N,,Bioavailability,,BAO_0000218,A,In vivo,CHEMBL621709,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5461.0,,,50588.0,17538.0,N,,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,A,In vivo,CHEMBL621710,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5462.0,,,50588.0,17538.0,N,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,BAO_0000218,A,In vivo,CHEMBL621711,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5463.0,,,50588.0,1466.0,N,,Bioavailability in dog (dose 10.0 mg/kg p.o.),,BAO_0000218,A,In vivo,CHEMBL621712,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5464.0,,,50588.0,17650.0,N,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,A,In vivo,CHEMBL621713,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5465.0,,,50588.0,3132.0,N,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,BAO_0000218,A,In vivo,CHEMBL621714,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Autocuration,,5466.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,A,,CHEMBL621715,1.0,,,10095.0,,0.0,,Mus sp.
Autocuration,Liver,5467.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,A,,CHEMBL623717,1.0,2107.0,,10095.0,,0.0,,Mus sp.
Autocuration,Liver,5468.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,A,,CHEMBL623718,1.0,2107.0,,10095.0,,0.0,,Mus sp.
Autocuration,Liver,5469.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,A,,CHEMBL623719,1.0,2107.0,,10095.0,,0.0,,Mus sp.
Autocuration,,5470.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,A,,CHEMBL623720,1.0,,,10095.0,,0.0,,Mus sp.
Autocuration,,5471.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,A,,CHEMBL623721,1.0,,,10095.0,,0.0,,Mus sp.
Autocuration,Muscle tissue,5472.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,A,,CHEMBL623722,1.0,2385.0,,10095.0,,0.0,,Mus sp.
Autocuration,Muscle tissue,5473.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,A,,CHEMBL623723,1.0,2385.0,,10095.0,,0.0,,Mus sp.
Autocuration,Muscle tissue,5474.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,A,,CHEMBL618543,1.0,2385.0,,10095.0,,0.0,,Mus sp.
Autocuration,Spleen,5475.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,A,,CHEMBL618544,1.0,2106.0,,10095.0,,0.0,,Mus sp.
Autocuration,Spleen,5476.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,A,,CHEMBL875155,1.0,2106.0,,10095.0,,0.0,,Mus sp.
Autocuration,,5477.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,A,,CHEMBL618545,1.0,,,10095.0,,0.0,,Mus sp.
Autocuration,,5478.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,A,,CHEMBL618546,1.0,,,10095.0,,0.0,,Mus sp.
Autocuration,,5479.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,A,,CHEMBL623529,1.0,,,10095.0,,0.0,,Mus sp.
Autocuration,,5480.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,A,,CHEMBL623530,1.0,,,10095.0,,0.0,,Mus sp.
Autocuration,,5481.0,,,22224.0,2413.0,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,A,,CHEMBL621764,1.0,,,10095.0,,0.0,,Mus sp.
Autocuration,,5482.0,,,22224.0,17827.0,U,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,BAO_0000019,A,,CHEMBL621765,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Cerebellum,5483.0,,,22224.0,17827.0,U,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,BAO_0000019,A,,CHEMBL621766,1.0,2037.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,Frontal cortex,5484.0,,,22224.0,17827.0,U,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,BAO_0000019,A,,CHEMBL621767,1.0,1870.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5485.0,,,22224.0,17827.0,U,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,BAO_0000019,A,,CHEMBL621768,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Striatum,5486.0,,,22224.0,17827.0,U,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,BAO_0000019,A,,CHEMBL621769,1.0,2435.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5487.0,,,22224.0,17827.0,U,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,BAO_0000019,A,,CHEMBL621770,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Cerebellum,5488.0,,,22224.0,17827.0,U,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,BAO_0000019,A,,CHEMBL621771,1.0,2037.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,Frontal cortex,5489.0,,,22224.0,17827.0,U,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,BAO_0000019,A,,CHEMBL621772,1.0,1870.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5490.0,,,22224.0,17827.0,U,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,BAO_0000019,A,,CHEMBL621773,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Striatum,5491.0,,,22224.0,17827.0,U,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,BAO_0000019,A,,CHEMBL621774,1.0,2435.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5492.0,,,22224.0,17791.0,U,,Compound was evaluated for oral bioavailability in rats,,BAO_0000218,A,,CHEMBL621775,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,5493.0,,,22224.0,17667.0,U,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,BAO_0000218,A,In vivo,CHEMBL621776,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5494.0,,,22224.0,17791.0,U,,Half life period was evaluated in monkey,,BAO_0000019,A,,CHEMBL621777,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,5495.0,,,22224.0,110.0,U,,Half-life in rhesus monkeys by intravenous administration of dose,,BAO_0000218,A,In vivo,CHEMBL875162,1.0,,,9527.0,,0.0,,Cercopithecidae
Intermediate,Plasma,5496.0,,,50594.0,5781.0,N,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,BAO_0000218,A,,CHEMBL621778,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,5497.0,,,50594.0,17734.0,N,,AUC after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,A,,CHEMBL621779,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,5498.0,,,50594.0,17718.0,N,,AUC value was determined after oral administration,,BAO_0000218,A,,CHEMBL622479,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,,5499.0,,,50594.0,4573.0,N,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,BAO_0000218,A,,CHEMBL622480,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5500.0,,,50594.0,3277.0,N,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,BAO_0000218,A,,CHEMBL622481,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5501.0,,,50594.0,2862.0,N,,Area under curve by ioral administration in mouse,,BAO_0000218,A,,CHEMBL622482,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5502.0,,,50594.0,2862.0,N,,Area under curve by iv administration in mouse,,BAO_0000218,A,,CHEMBL622483,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5503.0,,,50594.0,5951.0,N,,Area under curve at 0-8 hr in IRC mice after peroral administration,,BAO_0000218,A,,CHEMBL622484,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5504.0,,,50594.0,17729.0,N,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,BAO_0000218,A,,CHEMBL622641,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5505.0,,,50594.0,17728.0,N,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,BAO_0000218,A,,CHEMBL622642,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5506.0,,,50594.0,17728.0,N,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,BAO_0000218,A,,CHEMBL622643,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5507.0,,,50594.0,17729.0,N,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,BAO_0000218,A,,CHEMBL622644,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5508.0,,,80433.0,9424.0,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,BAO_0000219,F,,CHEMBL622645,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5509.0,,,80433.0,9424.0,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,BAO_0000219,F,,CHEMBL622646,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5510.0,,,80433.0,9424.0,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,BAO_0000219,F,,CHEMBL621238,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5511.0,,,80433.0,9424.0,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,BAO_0000219,F,,CHEMBL621239,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5512.0,,,80433.0,9424.0,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,BAO_0000219,F,,CHEMBL621240,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5513.0,,,80433.0,9424.0,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,BAO_0000219,F,,CHEMBL621241,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5514.0,,,80433.0,9424.0,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,BAO_0000219,F,,CHEMBL621242,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5515.0,,,80433.0,9424.0,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,BAO_0000219,F,,CHEMBL620350,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5516.0,,,80433.0,9424.0,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,BAO_0000219,F,,CHEMBL620351,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5517.0,,,80433.0,9424.0,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,BAO_0000219,F,,CHEMBL620352,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5518.0,,,80433.0,9424.0,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,BAO_0000219,F,,CHEMBL620353,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5519.0,,,80433.0,9424.0,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,BAO_0000219,F,,CHEMBL620354,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5520.0,,,80433.0,9424.0,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,BAO_0000219,F,,CHEMBL620355,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5521.0,,,80433.0,9424.0,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,BAO_0000219,F,,CHEMBL620356,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5522.0,,,80433.0,9424.0,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,BAO_0000219,F,,CHEMBL620357,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5523.0,,,80433.0,9424.0,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,BAO_0000219,F,,CHEMBL620358,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Expert,,5524.0,,,80433.0,9424.0,N,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,BAO_0000219,F,,CHEMBL620359,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5525.0,,,80433.0,11544.0,N,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,BAO_0000219,F,,CHEMBL620360,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5526.0,,,80433.0,17378.0,N,,Cytotoxicity of compound against 8226/DOX1V cells,,BAO_0000219,F,,CHEMBL620361,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5527.0,,,80433.0,17378.0,N,,Cytotoxicity of compound against 8226/S cells,,BAO_0000219,F,,CHEMBL620362,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5528.0,,,80433.0,17079.0,N,,Inhibitory concentration against 8226 myeloma cancer cell line,,BAO_0000219,F,,CHEMBL620363,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5529.0,,,80433.0,17079.0,N,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,BAO_0000219,F,,CHEMBL620364,1.0,,,9606.0,RPMI-8226,1.0,741.0,Homo sapiens
Intermediate,,5530.0,,,80647.0,13466.0,N,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,BAO_0000219,F,,CHEMBL620365,1.0,,,9606.0,833K,1.0,854.0,Homo sapiens
Intermediate,,5531.0,,,80647.0,13466.0,N,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,BAO_0000219,F,,CHEMBL620366,1.0,,,9606.0,833K,1.0,854.0,Homo sapiens
Expert,,5532.0,,,80647.0,2392.0,N,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,BAO_0000219,F,,CHEMBL620367,1.0,,,9606.0,833K,1.0,854.0,Homo sapiens
Intermediate,,5533.0,,,80647.0,2392.0,N,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,BAO_0000219,F,,CHEMBL620368,1.0,,,9606.0,833K,1.0,854.0,Homo sapiens
Autocuration,,5534.0,,,22226.0,6608.0,U,,Inhibitory activity against caspase-1,,BAO_0000019,B,,CHEMBL620369,1.0,,,,,0.0,,
Autocuration,,5535.0,,,45.0,10199.0,H,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,BAO_0000357,B,,CHEMBL620370,1.0,,,1351.0,,8.0,,Enterococcus faecalis
Intermediate,,5536.0,,,80648.0,17749.0,N,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,BAO_0000219,F,,CHEMBL620371,1.0,,,9606.0,8701-BC,1.0,705.0,Homo sapiens
Intermediate,,5537.0,,,80648.0,17749.0,N,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,BAO_0000219,F,,CHEMBL620372,1.0,,,9606.0,8701-BC,1.0,705.0,Homo sapiens
Intermediate,,5538.0,,,22226.0,1229.0,U,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,BAO_0000019,F,,CHEMBL876492,1.0,,,,,0.0,,
Intermediate,,5539.0,,,22226.0,1229.0,U,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,BAO_0000019,F,,CHEMBL620373,1.0,,,,,0.0,,
Intermediate,,5540.0,,,22226.0,1229.0,U,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,BAO_0000019,F,,CHEMBL620374,1.0,,,,,0.0,,
Autocuration,,5541.0,,,22226.0,6390.0,U,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,BAO_0000019,B,,CHEMBL620375,1.0,,,,,0.0,,
Autocuration,,5542.0,,,22226.0,16219.0,U,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,BAO_0000019,F,,CHEMBL857902,1.0,,,1314.0,,0.0,,Streptococcus pyogenes
Autocuration,,5543.0,,,22226.0,16219.0,U,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,BAO_0000019,F,,CHEMBL620376,1.0,,,1314.0,,0.0,,Streptococcus pyogenes
Autocuration,,5544.0,,,11922.0,17043.0,H,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,BAO_0000357,B,,CHEMBL620377,1.0,,,,,8.0,,
Intermediate,,5545.0,,,81115.0,6929.0,N,,Tested for in vitro cytotoxic potency of compound in 9KB assay,,BAO_0000219,F,,CHEMBL620378,1.0,,,9606.0,KB ,1.0,324.0,Homo sapiens
Intermediate,,5546.0,,,81115.0,6929.0,N,,Tested for in vitro cytotoxic potency of compound in 9KB assay,,BAO_0000219,A,,CHEMBL620379,1.0,,,9606.0,KB ,1.0,324.0,Homo sapiens
Autocuration,,5547.0,,,22226.0,7083.0,U,,In vitro cytotoxicity of compound was tested against 9KB cells.,,BAO_0000219,F,,CHEMBL620380,1.0,,,9606.0,,0.0,,Homo sapiens
Intermediate,,5548.0,,,80653.0,12446.0,N,,Cytotoxic concentration against 9L cells was determined on day 3,,BAO_0000219,F,,CHEMBL884006,1.0,,,10116.0,9L,1.0,392.0,Rattus norvegicus
Expert,,5549.0,,,80653.0,15345.0,N,,Tested in vitro for anticancer activity against 9L cells,,BAO_0000219,F,,CHEMBL620381,1.0,,,10116.0,9L,1.0,392.0,Rattus norvegicus
Expert,,5550.0,,,80653.0,15345.0,N,,Tested in vitro for anticancer activity against 9L cells; Not determined,,BAO_0000219,F,,CHEMBL620382,1.0,,,10116.0,9L,1.0,392.0,Rattus norvegicus
Intermediate,,5551.0,,,80682.0,6301.0,N,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,BAO_0000219,F,,CHEMBL620383,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5552.0,,,80682.0,4833.0,N,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,BAO_0000219,F,,CHEMBL876493,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5553.0,,,80682.0,4833.0,N,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,BAO_0000219,F,,CHEMBL620384,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5554.0,,,80682.0,4833.0,N,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,BAO_0000219,F,,CHEMBL620385,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5555.0,,,80682.0,13330.0,N,,Cytotoxicity against human lung carcinoma A549 cell line,,BAO_0000219,F,,CHEMBL620386,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5556.0,,,25.0,17517.0,D,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,BAO_0000219,F,,CHEMBL620387,1.0,,,9606.0,A549,9.0,646.0,Homo sapiens
Expert,,5557.0,,,25.0,17517.0,D,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,BAO_0000219,F,,CHEMBL621404,1.0,,,9606.0,A549,9.0,646.0,Homo sapiens
Intermediate,,5558.0,,,80682.0,14425.0,N,,"In vitro growth inhibition of A549, lung carcinoma",,BAO_0000219,F,,CHEMBL621405,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5559.0,,,80682.0,14425.0,N,,"In vitro growth inhibition of A549, lung carcinoma.",,BAO_0000219,F,,CHEMBL621406,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5560.0,,,80682.0,5228.0,N,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,BAO_0000219,F,,CHEMBL621407,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5561.0,,,80682.0,5351.0,N,,Cytotoxic activity against human lung cancer A549 cell line was determined,,BAO_0000219,F,,CHEMBL621408,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5562.0,,,80682.0,12198.0,N,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,BAO_0000219,F,,CHEMBL885345,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5563.0,,,80682.0,13891.0,N,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,BAO_0000219,F,,CHEMBL621409,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5564.0,,,80682.0,5677.0,N,,Cytotoxicity in A549 (human carcinoma) cell line.,,BAO_0000219,F,,CHEMBL876034,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5565.0,,,80682.0,13788.0,N,,Cytotoxicity on lung carcinoma (A-549) cell line,,BAO_0000219,F,,CHEMBL621410,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5566.0,,,80682.0,13384.0,N,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,BAO_0000219,F,,CHEMBL621411,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5567.0,,,80682.0,6726.0,N,,Effective dose of compound against replication of A549 cell line was evaluated,,BAO_0000219,F,,CHEMBL621412,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5568.0,,,80682.0,3455.0,N,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,BAO_0000219,F,,CHEMBL621413,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5569.0,,,80682.0,5726.0,N,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,BAO_0000219,F,,CHEMBL621414,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5570.0,,,80682.0,5726.0,N,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,BAO_0000219,F,,CHEMBL621415,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5571.0,,,80682.0,3936.0,N,,The compound was evaluated for antiproliferative activity against A549 cell line,,BAO_0000219,F,,CHEMBL621416,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5572.0,,,80682.0,14991.0,N,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,BAO_0000219,F,,CHEMBL621417,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5573.0,,,80682.0,5243.0,N,,Concentration required for growth inhibition of human lung carcinoma cell line A549,,BAO_0000219,F,,CHEMBL621418,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5574.0,,,80682.0,12858.0,N,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,BAO_0000219,F,,CHEMBL621419,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5575.0,,,80682.0,6776.0,N,,Growth inhibition against A549 cell line was evaluated,,BAO_0000219,F,,CHEMBL621420,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5576.0,,,80682.0,16558.0,N,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,BAO_0000219,F,,CHEMBL875823,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5577.0,,,80682.0,4583.0,N,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,BAO_0000219,F,,CHEMBL621421,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5578.0,,,80682.0,13514.0,N,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,BAO_0000219,F,,CHEMBL621422,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5579.0,,,80682.0,15166.0,N,,Chemosensitivity against DT-diaphorase rich A549 cell lines,,BAO_0000219,F,,CHEMBL884014,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5580.0,,,80682.0,13873.0,N,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,BAO_0000219,F,,CHEMBL621423,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5581.0,,,80682.0,6447.0,N,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,BAO_0000219,F,,CHEMBL621424,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5582.0,,,80682.0,2068.0,N,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,BAO_0000219,F,,CHEMBL621425,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5583.0,,,80682.0,1863.0,N,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,BAO_0000219,F,,CHEMBL621426,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5584.0,,,80682.0,13873.0,N,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,BAO_0000219,F,,CHEMBL621427,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5585.0,,,80682.0,13873.0,N,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,BAO_0000219,F,,CHEMBL621428,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5586.0,,,80682.0,13873.0,N,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,BAO_0000219,F,,CHEMBL621429,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5587.0,,,80682.0,579.0,N,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,BAO_0000219,F,,CHEMBL621430,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5588.0,,,80682.0,579.0,N,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,BAO_0000219,F,,CHEMBL621431,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5589.0,,,80682.0,4584.0,N,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,BAO_0000219,F,,CHEMBL621432,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5590.0,,,80682.0,5421.0,N,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,BAO_0000219,F,,CHEMBL621433,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5591.0,,,80682.0,5421.0,N,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,BAO_0000219,F,,CHEMBL875824,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5592.0,,,80682.0,5421.0,N,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,BAO_0000219,F,,CHEMBL621434,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5593.0,,,80682.0,5421.0,N,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,BAO_0000219,F,,CHEMBL621435,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5594.0,,,80682.0,14188.0,N,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,BAO_0000219,F,,CHEMBL621436,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5595.0,,,80682.0,14188.0,N,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,BAO_0000219,F,,CHEMBL621437,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5596.0,,,80682.0,15354.0,N,,Compound was tested for the growth inhibition of A549 lung tumor cell line,,BAO_0000219,F,,CHEMBL621438,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5597.0,,,80682.0,14253.0,N,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,BAO_0000219,F,,CHEMBL621439,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5598.0,,,80682.0,13873.0,N,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,BAO_0000219,F,,CHEMBL621440,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5599.0,,,50588.0,3043.0,N,,Oral bioavailability in dog (conscious),,BAO_0000218,A,In vivo,CHEMBL621441,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5600.0,,,50588.0,3045.0,N,,Compound was evaluated for the oral bioavailability after oral administration in dog.,,BAO_0000218,A,In vivo,CHEMBL621442,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5601.0,,,50588.0,3022.0,N,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,BAO_0000218,A,In vivo,CHEMBL621443,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5602.0,,,50588.0,4453.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621444,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5603.0,,,50588.0,1696.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL625133,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5604.0,,,50588.0,5045.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL625134,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5605.0,,,50588.0,5356.0,N,,Oral bioavailability in dog (fasted),,BAO_0000218,A,In vivo,CHEMBL625135,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5606.0,,,50588.0,17764.0,N,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,A,In vivo,CHEMBL625136,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5607.0,,,50588.0,6448.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL625137,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5608.0,,,50588.0,1475.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL625138,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5609.0,,,50588.0,3788.0,N,,Percent bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL625139,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5610.0,,,50588.0,3639.0,N,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,BAO_0000218,A,In vivo,CHEMBL872264,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5611.0,,,50588.0,13397.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL625140,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5612.0,,,50588.0,2137.0,N,,The compound was evaluated for bioavailability in dogs; 34-44,,BAO_0000218,A,In vivo,CHEMBL624436,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5613.0,,,50588.0,2959.0,N,,Bioavailability in dog (dose 4 mg/kg p.o.),,BAO_0000218,A,In vivo,CHEMBL624437,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5614.0,,,50588.0,6448.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL872261,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5615.0,,,50588.0,6084.0,N,,8 hour trough Blood level in dog was measured after administration of compound,,BAO_0000218,A,,CHEMBL624438,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5616.0,,,50588.0,3639.0,N,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,BAO_0000218,A,In vivo,CHEMBL624439,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5617.0,,,50588.0,6316.0,N,,C24 after oral administration at 5 mg/kg,,BAO_0000218,A,,CHEMBL624440,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5618.0,,,50588.0,5238.0,N,,Clearance after oral and iv dosing in dogs,,BAO_0000218,A,,CHEMBL624441,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5619.0,,,50588.0,17796.0,N,,Clearance of the drug was measured in the plasma of dog,,BAO_0000218,A,,CHEMBL624442,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5620.0,,,50588.0,2652.0,N,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,BAO_0000218,A,,CHEMBL624443,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5621.0,,,50588.0,5654.0,N,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL624444,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5622.0,,,50588.0,6621.0,N,,Clearance of compound was determined in dogs,,BAO_0000218,A,In vivo,CHEMBL624445,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5623.0,,,50588.0,6505.0,N,,Clearance on i.v. administration of 2 mg/kg was measured in dog,,BAO_0000218,A,In vivo,CHEMBL624446,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5624.0,,,50588.0,5802.0,N,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,A,In vivo,CHEMBL624447,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5625.0,,,50588.0,17267.0,N,,Plasma clearance in dog was determined,,BAO_0000218,A,In vivo,CHEMBL624448,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5626.0,,,50588.0,4521.0,N,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,A,In vivo,CHEMBL624449,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5627.0,,,50588.0,6535.0,N,,Plasma clearance in dog after administration of 0.25 mg/kg iv,,BAO_0000218,A,In vivo,CHEMBL624450,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5628.0,,,50588.0,6535.0,N,,Plasma clearance in dog after administration of 1 mg/kg iv,,BAO_0000218,A,In vivo,CHEMBL875942,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5629.0,,,50588.0,6535.0,N,,Plasma clearance in dogs,,BAO_0000218,A,In vivo,CHEMBL624451,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5630.0,,,50588.0,5542.0,N,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,BAO_0000218,A,In vivo,CHEMBL624452,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5631.0,,,50588.0,5199.0,N,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,A,In vivo,CHEMBL624453,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5632.0,,,50588.0,16907.0,N,,Plasma clearance after 15 mg/kg iv dose in Dogs,,BAO_0000218,A,In vivo,CHEMBL624454,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5633.0,,,50588.0,16907.0,N,,Plasma clearance after 30 mg/kg po dose in Dogs,,BAO_0000218,A,In vivo,CHEMBL624455,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5634.0,,,50588.0,16367.0,N,,Plasma administration to dogs,,BAO_0000218,A,In vivo,CHEMBL624456,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5635.0,,,50588.0,5505.0,N,,Plasma clearance was determined,,BAO_0000218,A,In vivo,CHEMBL624457,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5636.0,,,50588.0,6215.0,N,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,BAO_0000218,A,In vivo,CHEMBL624458,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5637.0,,,50588.0,1466.0,N,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,BAO_0000218,A,In vivo,CHEMBL624459,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Liver,5638.0,,,102164.0,5007.0,S,,Intrinsic clearance in human liver microsomes,Microsomes,BAO_0000251,A,In vitro,CHEMBL624460,1.0,2107.0,,9606.0,,2.0,,Homo sapiens
Intermediate,Liver,5639.0,,,102164.0,5007.0,S,,Intrinsic clearance in human liver microsomes,Microsomes,BAO_0000251,A,In vitro,CHEMBL624461,1.0,2107.0,,9606.0,,2.0,,Homo sapiens
Intermediate,,5640.0,,,50588.0,16452.0,N,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,A,In vivo,CHEMBL875943,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5641.0,,,50588.0,16452.0,N,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,BAO_0000218,A,In vivo,CHEMBL624462,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5642.0,,,50588.0,16452.0,N,,Clearance in dog (dose 1 mg/kg i.v.),,BAO_0000218,A,In vivo,CHEMBL624463,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5643.0,,,50588.0,6221.0,N,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,BAO_0000218,A,In vivo,CHEMBL624464,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5644.0,,,50588.0,5007.0,N,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,A,In vivo,CHEMBL624465,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5645.0,,,50588.0,5668.0,N,,Plasma clearance after peroral administration at 10 mpk in dog,,BAO_0000218,A,In vivo,CHEMBL624466,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5646.0,,,50588.0,5668.0,N,,Plasma clearance after peroral administration at 5 mpk in dog,,BAO_0000218,A,In vivo,CHEMBL624467,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5647.0,,,50588.0,5668.0,N,,Plasma clearance after peroral administration at 5 mg/kg in dog,,BAO_0000218,A,In vivo,CHEMBL624468,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5648.0,,,50588.0,15660.0,N,,Plasma clearance was measured in dog,,BAO_0000218,A,In vivo,CHEMBL624469,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5649.0,,,50588.0,15660.0,N,,Plasma clearance was measured in dog,,BAO_0000218,A,In vivo,CHEMBL624470,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5650.0,,,50588.0,5983.0,N,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,BAO_0000218,A,In vivo,CHEMBL624471,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5651.0,,,50588.0,5600.0,N,,Total clearance was determined after 0.1 mg/kg iv administration in dog,,BAO_0000218,A,In vivo,CHEMBL624472,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5652.0,,,50588.0,17764.0,N,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,A,In vivo,CHEMBL622775,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5653.0,,,50588.0,6039.0,N,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,BAO_0000218,A,In vivo,CHEMBL622776,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5654.0,,,50588.0,6039.0,N,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,BAO_0000218,A,In vivo,CHEMBL622777,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5655.0,,,50588.0,6039.0,N,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,BAO_0000218,A,In vivo,CHEMBL622778,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5656.0,,,50588.0,4368.0,N,,Clearance by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,A,In vivo,CHEMBL622779,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5657.0,,,50588.0,4305.0,N,,Clearance by iv administration in dogs at a dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL622780,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5658.0,,,50588.0,1918.0,N,,Clearance value was evaluated in dog plasma,,BAO_0000218,A,In vivo,CHEMBL622781,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5659.0,,,50588.0,6005.0,N,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL622782,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5660.0,,,50588.0,4839.0,N,,Compound was tested for plasma clearance in dog,,BAO_0000218,A,In vivo,CHEMBL622783,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5661.0,,,50588.0,4239.0,N,,Pharmacokinetic property (Plasma clearance) was measured in dog,,BAO_0000218,A,In vivo,CHEMBL622784,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5662.0,,,50594.0,17729.0,N,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,BAO_0000218,A,,CHEMBL622785,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5663.0,,,50594.0,17728.0,N,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,BAO_0000218,A,,CHEMBL622786,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5664.0,,,50594.0,5302.0,N,,Area under curve value in mouse at a dose of 10 mg/kg,,BAO_0000218,A,,CHEMBL622787,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5665.0,,,50594.0,5506.0,N,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,BAO_0000218,A,,CHEMBL875949,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5666.0,,,50594.0,5506.0,N,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,BAO_0000218,A,,CHEMBL622788,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5667.0,,,50594.0,17764.0,N,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,BAO_0000218,F,,CHEMBL622789,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5668.0,,,50594.0,17764.0,N,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,F,,CHEMBL622790,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5669.0,,,50594.0,17764.0,N,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,BAO_0000218,F,,CHEMBL622791,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5670.0,,,50594.0,17764.0,N,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,BAO_0000218,F,,CHEMBL622792,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5671.0,,,50594.0,17764.0,N,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,BAO_0000218,A,,CHEMBL622793,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5672.0,,,50594.0,17753.0,N,,Area under curve was determined for the compound at 24 mg/Kg,,BAO_0000218,A,,CHEMBL622794,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5673.0,,,50594.0,17753.0,N,,Area under curve was determined for the compound at 40 mg/Kg,,BAO_0000218,A,,CHEMBL622795,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5674.0,,,50594.0,17753.0,N,,Area under curve was determined for the compound at 5 mg/Kg,,BAO_0000218,A,,CHEMBL621803,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5675.0,,,50594.0,3132.0,N,,Area under the curve for the compound is obtained at dose 25 mg/kg,,BAO_0000218,A,,CHEMBL621804,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5676.0,,,50594.0,3132.0,N,,Area under the curve for the compound was obtained when tested in mouse,,BAO_0000218,A,,CHEMBL621805,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5677.0,,,50594.0,17837.0,N,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,A,,CHEMBL621806,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5678.0,,,50594.0,17837.0,N,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,BAO_0000218,A,,CHEMBL621807,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5679.0,,,50594.0,6062.0,N,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,A,,CHEMBL621808,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5680.0,,,50594.0,4066.0,N,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,A,,CHEMBL621809,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5681.0,,,50594.0,16597.0,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,BAO_0000218,A,,CHEMBL621810,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5682.0,,,50594.0,14239.0,N,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,BAO_0000218,A,,CHEMBL875164,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5683.0,,,50594.0,14239.0,N,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,BAO_0000218,A,,CHEMBL621811,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5684.0,,,50594.0,4890.0,N,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,BAO_0000218,A,,CHEMBL621812,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5685.0,,,50594.0,429.0,N,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,BAO_0000218,A,,CHEMBL621813,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5686.0,,,50594.0,429.0,N,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,BAO_0000218,A,,CHEMBL621814,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5687.0,,,50594.0,5969.0,N,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,A,,CHEMBL621815,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5688.0,,,50594.0,5969.0,N,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,A,,CHEMBL621816,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5689.0,,,50594.0,5969.0,N,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,BAO_0000218,A,,CHEMBL621817,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5690.0,,,50594.0,6091.0,N,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,BAO_0000218,A,,CHEMBL621818,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5691.0,,,50594.0,6091.0,N,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,BAO_0000218,A,,CHEMBL621819,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5692.0,,,50594.0,6091.0,N,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,BAO_0000218,A,,CHEMBL621820,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5693.0,,,50594.0,6091.0,N,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,BAO_0000218,A,,CHEMBL621821,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5694.0,,,50594.0,6178.0,N,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,BAO_0000218,A,,CHEMBL621822,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5695.0,,,50594.0,6178.0,N,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,BAO_0000218,A,,CHEMBL619474,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5696.0,,,50594.0,6619.0,N,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,BAO_0000218,A,,CHEMBL619475,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5697.0,,,50594.0,6619.0,N,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,BAO_0000218,A,,CHEMBL619476,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5698.0,,,50594.0,3760.0,N,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,BAO_0000218,A,,CHEMBL619477,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5699.0,,,50594.0,3760.0,N,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,BAO_0000218,A,,CHEMBL619478,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5700.0,,,50594.0,3760.0,N,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,BAO_0000218,A,,CHEMBL619479,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5701.0,,,50594.0,3760.0,N,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,BAO_0000218,A,,CHEMBL619480,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5702.0,,,50594.0,3192.0,N,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,BAO_0000218,A,,CHEMBL619481,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5703.0,,,50594.0,3192.0,N,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,BAO_0000218,A,,CHEMBL619482,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5704.0,,,50594.0,2675.0,N,,Area under the curve was evaluated in mice after intravenous administration,,BAO_0000218,A,,CHEMBL619483,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5705.0,,,50594.0,2675.0,N,,Area under the curve was evaluated in mice after oral administration,,BAO_0000218,A,,CHEMBL619484,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,5706.0,,,50594.0,16597.0,N,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,A,,CHEMBL619485,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,5707.0,,,50594.0,16597.0,N,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,A,,CHEMBL619486,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,,5708.0,,,50594.0,16597.0,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,BAO_0000218,A,,CHEMBL619487,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5709.0,,,50594.0,17734.0,N,,AUMC after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,A,,CHEMBL619488,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,5710.0,,,50594.0,7767.0,N,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL620106,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,,5711.0,,,80653.0,15345.0,N,,The compound was tested in vitro for anticancer activity against 9L cells,,BAO_0000219,F,,CHEMBL620107,1.0,,,,9L,1.0,392.0,
Autocuration,,5712.0,,,22226.0,2181.0,U,,Anti proliferation activity determined; Weak effect,,BAO_0000019,F,,CHEMBL620283,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,5713.0,,,22226.0,2181.0,U,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,BAO_0000219,F,,CHEMBL875176,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,5714.0,,,22226.0,2181.0,U,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,BAO_0000219,F,,CHEMBL620284,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,5715.0,,,22226.0,2181.0,U,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,BAO_0000219,F,,CHEMBL623515,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,5716.0,,,22226.0,10486.0,U,,The cytotoxic activity was in vitro tested by 9PS assay method,,BAO_0000019,F,,CHEMBL623516,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,5717.0,,,22226.0,10486.0,U,,The cytotoxic activity was in vitro tested by 9PS assay method.,,BAO_0000019,F,,CHEMBL623517,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,5718.0,,,22224.0,15508.0,U,,Partition coefficient (logD6.5),,BAO_0000019,A,,CHEMBL857878,1.0,,,,,0.0,,
Expert,,5719.0,,,81034.0,5242.0,N,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,BAO_0000219,F,,CHEMBL623518,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,5720.0,,,80018.0,16167.0,N,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,BAO_0000219,F,,CHEMBL624195,1.0,,,9606.0,A-375,1.0,455.0,Homo sapiens
Expert,,5721.0,,,80852.0,4782.0,N,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,BAO_0000219,F,,CHEMBL624196,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Expert,,5722.0,,,9.0,16093.0,D,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,BAO_0000219,F,,CHEMBL624197,1.0,,,9606.0,A-431,9.0,500.0,Homo sapiens
Intermediate,,5723.0,,,80021.0,2596.0,N,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,BAO_0000219,F,,CHEMBL624198,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5724.0,,,80021.0,2596.0,N,,in vitro cytotoxicity against A 498 cancer cell line,,BAO_0000219,F,,CHEMBL621287,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5725.0,,,80021.0,3239.0,N,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,BAO_0000219,F,,CHEMBL621288,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5726.0,,,80021.0,1847.0,N,,Cytotoxic activity against A 498 renal cancer cell lines.,,BAO_0000219,F,,CHEMBL876496,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5727.0,,,80021.0,10553.0,N,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,BAO_0000219,F,,CHEMBL621289,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Autocuration,,5728.0,,,22226.0,16219.0,U,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,BAO_0000019,F,,CHEMBL621290,1.0,,,1280.0,,0.0,,Staphylococcus aureus
Autocuration,,5729.0,,,22226.0,16219.0,U,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,BAO_0000019,F,,CHEMBL621291,1.0,,,1280.0,,0.0,,Staphylococcus aureus
Autocuration,,5730.0,,,22226.0,16219.0,U,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,BAO_0000019,F,,CHEMBL621292,1.0,,,1280.0,,0.0,,Staphylococcus aureus
Autocuration,,5731.0,,,22226.0,16219.0,U,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,BAO_0000019,F,,CHEMBL621293,1.0,,,1280.0,,0.0,,Staphylococcus aureus
Intermediate,,5732.0,,,80682.0,4782.0,N,,Inhibitory concentration required against A 549 lung cancer cell line,,BAO_0000219,F,,CHEMBL621294,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5733.0,,,80682.0,11805.0,N,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,BAO_0000219,F,,CHEMBL621295,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5734.0,,,80682.0,11805.0,N,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,BAO_0000219,F,,CHEMBL884007,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5735.0,,,80682.0,2007.0,N,,In vitro cytotoxicity against lung cancer A 549 cell lines,,BAO_0000219,F,,CHEMBL621296,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5736.0,,,80682.0,4594.0,N,,Compound was tested for its cytotoxicity against A 549 cell line,,BAO_0000219,F,,CHEMBL621297,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5737.0,,,80682.0,6018.0,N,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,BAO_0000219,F,,CHEMBL839828,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5738.0,,,80682.0,6018.0,N,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,BAO_0000219,F,,CHEMBL620397,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5739.0,,,80682.0,3599.0,N,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,BAO_0000219,F,,CHEMBL620398,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5740.0,,,80682.0,2551.0,N,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,BAO_0000219,F,,CHEMBL620399,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5741.0,,,80682.0,16132.0,N,,In vitro inhibition of A549 (human lung cancer) cell growth.,,BAO_0000219,F,,CHEMBL620400,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5742.0,,,80682.0,16132.0,N,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,BAO_0000219,F,,CHEMBL620401,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5743.0,,,80682.0,2551.0,N,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,BAO_0000219,F,,CHEMBL620402,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5744.0,,,80682.0,2551.0,N,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,BAO_0000219,F,,CHEMBL620403,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Autocuration,,5745.0,,,22226.0,11913.0,U,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,BAO_0000218,F,,CHEMBL620404,1.0,,,,,0.0,,
Autocuration,,5746.0,,,104694.0,12621.0,H,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,BAO_0000218,F,In vivo,CHEMBL620405,1.0,,,,,4.0,,
Autocuration,,5747.0,,,104694.0,12621.0,H,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,BAO_0000218,F,In vivo,CHEMBL620406,1.0,,,,,4.0,,
Autocuration,,5748.0,,,104694.0,12621.0,H,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,BAO_0000218,F,In vivo,CHEMBL620407,1.0,,,,,4.0,,
Autocuration,,5749.0,,,104694.0,12621.0,H,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,BAO_0000218,F,In vivo,CHEMBL620408,1.0,,,,,4.0,,
Autocuration,,5750.0,,,104694.0,12621.0,H,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,BAO_0000218,F,In vivo,CHEMBL620409,1.0,,,,,4.0,,
Expert,,5751.0,,,80021.0,3600.0,N,,Inhibition of A-498 human Renal cell proliferation,,BAO_0000219,F,,CHEMBL620410,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Autocuration,,5752.0,,,22226.0,1796.0,U,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,BAO_0000019,F,,CHEMBL620411,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,5753.0,,,22226.0,1796.0,U,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,BAO_0000019,F,,CHEMBL620412,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,5754.0,,,22226.0,1796.0,U,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,BAO_0000019,F,,CHEMBL876596,1.0,,,10116.0,,0.0,,Rattus norvegicus
Expert,,5755.0,,,80012.0,16464.0,N,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,BAO_0000219,F,,CHEMBL620413,1.0,,,9606.0,A 172,1.0,622.0,Homo sapiens
Intermediate,,5756.0,,,80012.0,16464.0,N,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,F,,CHEMBL620414,1.0,,,9606.0,A 172,1.0,622.0,Homo sapiens
Intermediate,,5757.0,,,80012.0,16464.0,N,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,F,,CHEMBL620415,1.0,,,9606.0,A 172,1.0,622.0,Homo sapiens
Expert,,5758.0,,,80682.0,13617.0,N,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,BAO_0000219,F,,CHEMBL620416,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5759.0,,,80682.0,4584.0,N,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,BAO_0000219,F,,CHEMBL620417,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5760.0,,,80682.0,13799.0,N,,Cytotoxic activity evaluated against A549 tumor cells,,BAO_0000219,F,,CHEMBL620418,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5761.0,,,80682.0,16726.0,N,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,BAO_0000219,F,,CHEMBL620419,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5762.0,,,80682.0,16109.0,N,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,BAO_0000219,F,,CHEMBL620420,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5763.0,,,80682.0,16109.0,N,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,BAO_0000219,F,,CHEMBL620421,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5764.0,,,80682.0,15474.0,N,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,BAO_0000219,F,,CHEMBL620422,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5765.0,,,80682.0,6851.0,N,,Cytotoxicity of compound against A549 cell line,,BAO_0000219,F,,CHEMBL620423,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5766.0,,,80682.0,17534.0,N,,Cytotoxicity against human lung cell carcinoma A549 cell line,,BAO_0000219,F,,CHEMBL620424,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5767.0,,,80682.0,2621.0,N,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,BAO_0000219,F,,CHEMBL620425,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5768.0,,,80682.0,830.0,N,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,BAO_0000219,F,,CHEMBL620426,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5769.0,,,80682.0,14255.0,N,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,BAO_0000219,F,,CHEMBL620427,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5770.0,,,80682.0,14255.0,N,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,BAO_0000219,F,,CHEMBL620428,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5771.0,,,80682.0,1590.0,N,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,BAO_0000219,F,,CHEMBL620429,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5772.0,,,80682.0,6146.0,N,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,BAO_0000219,F,,CHEMBL620430,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5773.0,,,80682.0,17427.0,N,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,BAO_0000219,F,,CHEMBL839887,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5774.0,,,80682.0,5280.0,N,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,BAO_0000219,F,,CHEMBL620431,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5775.0,,,80682.0,16786.0,N,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,BAO_0000219,F,,CHEMBL884010,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5776.0,,,80682.0,5895.0,N,,In vitro cytotoxicity against A549 (human lung cancer),,BAO_0000219,F,,CHEMBL620538,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5777.0,,,80682.0,14297.0,N,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,BAO_0000219,F,,CHEMBL620539,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5778.0,,,80682.0,17824.0,N,,In vivo antiproliferative activity against A549 cell line,,BAO_0000218,F,,CHEMBL623373,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5779.0,,,80682.0,14368.0,N,,Inhibition of non-small-cell lung adenocarcinoma (A549),,BAO_0000219,F,,CHEMBL623374,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5780.0,,,80682.0,14368.0,N,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,BAO_0000219,F,,CHEMBL623375,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5781.0,,,80682.0,14254.0,N,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,BAO_0000219,F,,CHEMBL623376,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5782.0,,,80682.0,15897.0,N,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,BAO_0000219,F,,CHEMBL623377,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5783.0,,,80682.0,13866.0,N,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,BAO_0000219,F,,CHEMBL623378,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5784.0,,,80682.0,13370.0,N,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,BAO_0000219,F,,CHEMBL623379,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5785.0,,,80682.0,4862.0,N,,Inhibitory activity against A549 lung cancer cell line,,BAO_0000219,F,,CHEMBL623380,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5786.0,,,80682.0,4862.0,N,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,BAO_0000219,F,,CHEMBL623381,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5787.0,,,80682.0,4862.0,N,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,BAO_0000219,F,,CHEMBL623382,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5788.0,,,80682.0,15970.0,N,,Inhibitory concentration against A549 (lung cancer) cell line,,BAO_0000219,F,,CHEMBL623383,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5789.0,,,80682.0,17713.0,N,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,BAO_0000219,F,,CHEMBL623384,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5790.0,,,80682.0,4833.0,N,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,BAO_0000219,F,,CHEMBL623385,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5791.0,,,80682.0,13736.0,N,,Activity against A549 cancer cell line.,,BAO_0000219,F,,CHEMBL623386,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5792.0,,,80682.0,4312.0,N,,The compound was evaluated for cytotoxicity against A549 cell line,,BAO_0000219,F,,CHEMBL884105,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5793.0,,,80682.0,5421.0,N,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,BAO_0000219,F,,CHEMBL623387,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5794.0,,,80682.0,5421.0,N,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,BAO_0000219,F,,CHEMBL621568,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5795.0,,,80682.0,14717.0,N,,Growth inhibitory activity was measured for human A549 tumor cell line.,,BAO_0000219,F,,CHEMBL621569,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5796.0,,,80682.0,4634.0,N,,Inhibitory activity against A549 lung cancer cell line,,BAO_0000219,F,,CHEMBL621570,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5797.0,,,80682.0,1149.0,N,,Inhibitory activity against A549 cell line; inactive,,BAO_0000219,F,,CHEMBL621571,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5798.0,,,80682.0,5421.0,N,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,BAO_0000219,F,,CHEMBL621572,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5799.0,,,80682.0,5421.0,N,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,BAO_0000219,F,,CHEMBL621573,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5800.0,,,80682.0,5421.0,N,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,BAO_0000219,F,,CHEMBL621574,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5801.0,,,80682.0,3320.0,N,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,BAO_0000219,F,,CHEMBL621575,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5802.0,,,80682.0,3320.0,N,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,BAO_0000219,F,,CHEMBL621576,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5803.0,,,80682.0,3320.0,N,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,BAO_0000219,F,,CHEMBL621577,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5804.0,,,80682.0,3320.0,N,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,BAO_0000219,F,,CHEMBL621578,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5805.0,,,80682.0,3320.0,N,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,BAO_0000219,F,,CHEMBL621579,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5806.0,,,80682.0,5726.0,N,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,BAO_0000219,F,,CHEMBL621580,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5807.0,,,50588.0,17800.0,N,,Plasma clearance (in vivo) in mongrel dogs was determined,,BAO_0000218,A,In vivo,CHEMBL621581,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5808.0,,,50588.0,5985.0,N,,Plasma clearance was measured in dog,,BAO_0000218,A,In vivo,CHEMBL621582,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5809.0,,,50588.0,5530.0,N,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621583,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5810.0,,,50588.0,5530.0,N,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621584,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5811.0,,,50588.0,4839.0,N,,Tested for plasma clearance in dog,,BAO_0000218,A,In vivo,CHEMBL621585,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5812.0,,,50588.0,3639.0,N,,The compound was tested for clearance in dog plasma.,,BAO_0000218,A,In vivo,CHEMBL621586,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5813.0,,,50588.0,4838.0,N,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,BAO_0000218,A,In vivo,CHEMBL875835,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5814.0,,,50588.0,4137.0,N,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,A,In vivo,CHEMBL621587,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5815.0,,,50588.0,5017.0,N,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,BAO_0000218,A,In vivo,CHEMBL621588,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Liver,5816.0,,,50588.0,17538.0,N,,In vitro clearance in dog liver microsomes,Microsomes,BAO_0000218,A,In vitro,CHEMBL621589,1.0,2107.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5817.0,,,50588.0,6161.0,N,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,BAO_0000218,A,In vivo,CHEMBL621590,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5818.0,,,50588.0,6161.0,N,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,BAO_0000218,A,In vivo,CHEMBL621591,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5819.0,,,50588.0,1696.0,N,,Plasma clearance in dog,,BAO_0000218,A,In vivo,CHEMBL621592,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5820.0,,,50588.0,6762.0,N,,Clearance rate in dog,,BAO_0000218,A,In vivo,CHEMBL621593,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5821.0,,,50588.0,5932.0,N,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,BAO_0000218,A,In vivo,CHEMBL621594,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5822.0,,,50588.0,6305.0,N,,Clearance in dogs,,BAO_0000218,A,In vivo,CHEMBL621595,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5823.0,,,50588.0,4942.0,N,,Plasma clearance in dogs,,BAO_0000218,A,In vivo,CHEMBL621596,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5824.0,,,50588.0,4219.0,N,,Plasma clearance was determined,,BAO_0000218,A,In vivo,CHEMBL621597,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5825.0,,,50588.0,17853.0,N,,Lower clearance in dog (i.v.) at 0.5 mpk,,BAO_0000218,A,In vivo,CHEMBL621598,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5826.0,,,50588.0,4514.0,N,,Plasma clearance in Beagle dogs,,BAO_0000218,A,In vivo,CHEMBL621599,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5827.0,,,50588.0,6448.0,N,,Plasma clearance (Clp) in dog,,BAO_0000218,A,In vivo,CHEMBL875836,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5828.0,,,50588.0,6227.0,N,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621600,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5829.0,,,50588.0,6227.0,N,,Plasma clearance (pharmacokinetic parameter) in dog was determined,,BAO_0000218,A,In vivo,CHEMBL621601,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5830.0,,,50588.0,6062.0,N,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618474,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5831.0,,,50588.0,6821.0,N,,Plasma clearance of compound was determined in dog,,BAO_0000218,A,In vivo,CHEMBL618475,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5832.0,,,50588.0,4709.0,N,,Plasma clearance after intravenous administration of 1 mg/kg in dog,,BAO_0000218,A,In vivo,CHEMBL624524,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5833.0,,,50588.0,4521.0,N,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,BAO_0000218,A,In vivo,CHEMBL624525,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5834.0,,,50588.0,5374.0,N,,Plasma clearance in dog was determined,,BAO_0000218,A,In vivo,CHEMBL624526,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5835.0,,,50588.0,6057.0,N,,Plasma clearance was calculated in dog,,BAO_0000218,A,In vivo,CHEMBL624527,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5836.0,,,50588.0,4727.0,N,,Plasma clearance at the dose of 2 mg/kg in dog,,BAO_0000218,A,In vivo,CHEMBL624528,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5837.0,,,50588.0,5145.0,N,,Plasma clearance in dog,,BAO_0000218,A,In vivo,CHEMBL624529,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5838.0,,,50588.0,17657.0,N,,Plasma clearance in dog,,BAO_0000218,A,In vivo,CHEMBL624530,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5839.0,,,50588.0,17657.0,N,,Plasma clearance in dog; Unable to calculate,,BAO_0000218,A,In vivo,CHEMBL624531,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5840.0,,,50588.0,5145.0,N,,Plasma clearance in rhesus monkey,,BAO_0000218,A,In vivo,CHEMBL624532,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5841.0,,,50588.0,6642.0,N,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,A,In vivo,CHEMBL624533,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5842.0,,,50588.0,6641.0,N,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,A,In vivo,CHEMBL624534,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5843.0,,,50588.0,6642.0,N,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,A,In vivo,CHEMBL624535,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5844.0,,,50588.0,5472.0,N,,Plasma clearance was evaluated in dog,,BAO_0000218,A,In vivo,CHEMBL624536,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5845.0,,,50588.0,5472.0,N,,Plasma clearance was evaluated in dog; Not tested,,BAO_0000218,A,In vivo,CHEMBL624537,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5846.0,,,50588.0,5472.0,N,,Plasma clearance was evaluated in rhesus,,BAO_0000218,A,In vivo,CHEMBL624538,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5847.0,,,50588.0,5472.0,N,,Plasma clearance was evaluated in rhesus; Not tested,,BAO_0000218,A,In vivo,CHEMBL624539,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5848.0,,,50588.0,4257.0,N,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,BAO_0000218,A,In vivo,CHEMBL624540,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5849.0,,,50588.0,6679.0,N,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,A,In vivo,CHEMBL624541,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5850.0,,,50588.0,5546.0,N,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,BAO_0000218,A,In vivo,CHEMBL624542,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5851.0,,,50588.0,6348.0,N,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,A,In vivo,CHEMBL624543,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5852.0,,,50588.0,5474.0,N,,Clearance value at a dose of 0.2 mg/kg i.v.,,BAO_0000218,A,In vivo,CHEMBL624544,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5853.0,,,50588.0,6316.0,N,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL624545,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5854.0,,,50588.0,17594.0,N,,Cmax after oral dose of compound at 3 mg/kg in dogs,,BAO_0000218,A,In vivo,CHEMBL624546,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5855.0,,,50588.0,17594.0,N,,Cmax after single intravenous bolus of 1 mg/kg in dogs,,BAO_0000218,A,In vivo,CHEMBL875957,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5856.0,,,50588.0,5802.0,N,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,A,In vivo,CHEMBL624547,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5857.0,,,50588.0,6535.0,N,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,BAO_0000218,A,In vivo,CHEMBL624548,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5858.0,,,50588.0,6535.0,N,,Cmax in dog after administration of 1 mg/kg iv,,BAO_0000218,A,In vivo,CHEMBL624549,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,5859.0,,,50588.0,1466.0,N,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,BAO_0000218,A,In vivo,CHEMBL624550,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5860.0,,,50588.0,6505.0,N,,Cmax on p.o. administration of 10 mg/kg was measured in dog,,BAO_0000218,A,In vivo,CHEMBL621613,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5861.0,,,50588.0,5668.0,N,,Cmax was determine after peroral administration at 10 mpk in dog,,BAO_0000218,A,In vivo,CHEMBL621614,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5862.0,,,50588.0,5668.0,N,,Cmax was determine after peroral administration at 5 mpk in dog,,BAO_0000218,A,In vivo,CHEMBL623431,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5863.0,,,50588.0,5668.0,N,,Cmax was determine after peroral administration at 5 mg/kg in dog,,BAO_0000218,A,In vivo,CHEMBL623432,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5864.0,,,50588.0,5600.0,N,,Cmax after 0.3 mg/kg po administration in dog,,BAO_0000218,A,In vivo,CHEMBL623433,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5865.0,,,50588.0,17764.0,N,,Cmax after peroral administration in dogs at 2.4 uM/kg,,BAO_0000218,A,In vivo,CHEMBL623434,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5866.0,,,50588.0,6123.0,N,,Cmax in dog after oral administration at 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623435,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5867.0,,,50588.0,6123.0,N,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,BAO_0000218,A,In vivo,CHEMBL623436,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5868.0,,,50588.0,6757.0,N,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL875958,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5869.0,,,50588.0,16907.0,N,,Cmax value after 15 mg/kg iv dose in Dogs,,BAO_0000218,A,In vivo,CHEMBL623437,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Blood,5870.0,,,50594.0,7767.0,N,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL623438,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,5871.0,,,50594.0,7767.0,N,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL623439,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Bone,5872.0,,,50594.0,7767.0,N,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL623440,1.0,10000001.0,,10090.0,,1.0,,Mus musculus
Intermediate,Bone,5873.0,,,50594.0,7767.0,N,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL623441,1.0,10000001.0,,10090.0,,1.0,,Mus musculus
Intermediate,Bone,5874.0,,,50594.0,7767.0,N,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL623442,1.0,10000001.0,,10090.0,,1.0,,Mus musculus
Intermediate,,5875.0,,,50594.0,7767.0,N,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL623469,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5876.0,,,50594.0,7767.0,N,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL623470,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5877.0,,,50594.0,7767.0,N,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL623471,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,5878.0,,,50594.0,7767.0,N,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL623472,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,5879.0,,,50594.0,7767.0,N,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL623473,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,5880.0,,,50594.0,7767.0,N,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL623474,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,5881.0,,,50594.0,7767.0,N,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL623475,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,5882.0,,,50594.0,7767.0,N,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL623476,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,5883.0,,,50594.0,7767.0,N,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL623477,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Intestine,5884.0,,,50594.0,7767.0,N,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL621896,1.0,160.0,,10090.0,,1.0,,Mus musculus
Intermediate,Intestine,5885.0,,,50594.0,7767.0,N,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL621897,1.0,160.0,,10090.0,,1.0,,Mus musculus
Intermediate,Intestine,5886.0,,,50594.0,7767.0,N,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL621898,1.0,160.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,5887.0,,,50594.0,7767.0,N,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL621899,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,5888.0,,,50594.0,7767.0,N,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL621900,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,5889.0,,,50594.0,7767.0,N,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL621901,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,5890.0,,,50594.0,7767.0,N,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL621902,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,5891.0,,,50594.0,7767.0,N,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL621903,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,5892.0,,,50594.0,7767.0,N,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL622587,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Muscle tissue,5893.0,,,50594.0,7767.0,N,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL620285,1.0,2385.0,,10090.0,,1.0,,Mus musculus
Intermediate,Muscle tissue,5894.0,,,50594.0,7767.0,N,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL875285,1.0,2385.0,,10090.0,,1.0,,Mus musculus
Intermediate,Muscle tissue,5895.0,,,50594.0,7767.0,N,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL620286,1.0,2385.0,,10090.0,,1.0,,Mus musculus
Intermediate,,5896.0,,,50594.0,7767.0,N,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL620287,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5897.0,,,50594.0,7767.0,N,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL620288,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,5898.0,,,50594.0,7767.0,N,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL620289,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Intestine,5899.0,,,50594.0,7767.0,N,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL620290,1.0,160.0,,10090.0,,1.0,,Mus musculus
Intermediate,Intestine,5900.0,,,50594.0,7767.0,N,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL620291,1.0,160.0,,10090.0,,1.0,,Mus musculus
Intermediate,Intestine,5901.0,,,50594.0,7767.0,N,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL620292,1.0,160.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,5902.0,,,50594.0,7767.0,N,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL620293,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,5903.0,,,50594.0,7767.0,N,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL620294,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,5904.0,,,50594.0,7767.0,N,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL618614,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,Stomach,5905.0,,,50594.0,7767.0,N,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL618615,1.0,945.0,,10090.0,,1.0,,Mus musculus
Intermediate,Stomach,5906.0,,,50594.0,7767.0,N,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL618616,1.0,945.0,,10090.0,,1.0,,Mus musculus
Expert,,5907.0,,,80012.0,2036.0,N,,Cytotoxicity against A-172 human tumor cell lines,,BAO_0000219,F,,CHEMBL618617,1.0,,,9606.0,A 172,1.0,622.0,Homo sapiens
Intermediate,,5908.0,,,80012.0,2357.0,N,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,BAO_0000219,F,,CHEMBL618618,1.0,,,9606.0,A 172,1.0,622.0,Homo sapiens
Intermediate,,5909.0,,,80014.0,1457.0,N,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,BAO_0000219,F,,CHEMBL618619,1.0,,,9606.0,A204,1.0,623.0,Homo sapiens
Intermediate,,5910.0,,,81034.0,4379.0,N,,Tested for antiproliferative activity against A-2780 tumoral cell line,,BAO_0000219,F,,CHEMBL618620,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,5911.0,,,80018.0,1093.0,N,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,BAO_0000219,F,,CHEMBL618621,1.0,,,9606.0,A-375,1.0,455.0,Homo sapiens
Intermediate,,5912.0,,,80018.0,12152.0,N,,Tested in vitro against A-375 cell line human melanoma,,BAO_0000219,F,,CHEMBL618622,1.0,,,9606.0,A-375,1.0,455.0,Homo sapiens
Expert,,5913.0,,,80019.0,16464.0,N,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,BAO_0000219,F,,CHEMBL618623,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Intermediate,,5914.0,,,80019.0,16464.0,N,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,F,,CHEMBL618624,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Expert,,5915.0,,,80019.0,16582.0,N,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,BAO_0000219,F,,CHEMBL618625,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Intermediate,,5916.0,,,80019.0,16464.0,N,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,F,,CHEMBL618626,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Intermediate,,5917.0,,,80019.0,10413.0,N,,Antitumor activity on A-427 lung carcinoma cell lines,,BAO_0000219,F,,CHEMBL618627,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Intermediate,,5918.0,,,80019.0,6418.0,N,,Cytotoxic activity against human A-427 lung tumor cell line,,BAO_0000219,F,,CHEMBL618628,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Expert,,5919.0,,,80019.0,17134.0,N,,In vitro antitumor effects against human A-427 cell lines.,,BAO_0000219,F,,CHEMBL618629,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Expert,,5920.0,,,80019.0,16132.0,N,,In vitro inhibition of A-427 (human lung cancer) cell growth.,,BAO_0000219,F,,CHEMBL618630,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Intermediate,,5921.0,,,80019.0,16132.0,N,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,BAO_0000219,F,,CHEMBL618631,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Intermediate,,5922.0,,,80019.0,16780.0,N,,Cytotoxic activity of compound against A-427 lung human tumor cell line,,BAO_0000219,F,,CHEMBL618632,1.0,,,9606.0,A-427,1.0,797.0,Homo sapiens
Expert,,5923.0,,,80852.0,4085.0,N,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,BAO_0000219,F,,CHEMBL618633,1.0,,,9606.0,A-431,1.0,500.0,Homo sapiens
Intermediate,,5924.0,,,80021.0,1276.0,N,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,BAO_0000219,F,,CHEMBL619315,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Expert,,5925.0,,,80021.0,3498.0,N,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,BAO_0000219,F,,CHEMBL619316,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5926.0,,,80021.0,1169.0,N,,Cytotoxicity against human kidney carcinoma A-498cell lines,,BAO_0000219,F,,CHEMBL619317,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5927.0,,,80021.0,4450.0,N,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,BAO_0000219,F,,CHEMBL619318,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5928.0,,,80021.0,3311.0,N,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,BAO_0000219,F,,CHEMBL619319,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5929.0,,,80021.0,4461.0,N,,Antitumor cytotoxic activity against A-498 cell line was determined,,BAO_0000219,F,,CHEMBL619739,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5930.0,,,80021.0,3311.0,N,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,BAO_0000219,F,,CHEMBL619740,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5931.0,,,80021.0,3311.0,N,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,BAO_0000219,F,,CHEMBL883158,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5932.0,,,80021.0,1457.0,N,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,BAO_0000219,F,,CHEMBL884012,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5933.0,,,80021.0,3664.0,N,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,BAO_0000219,F,,CHEMBL619741,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5934.0,,,80021.0,15895.0,N,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,BAO_0000219,F,,CHEMBL619742,1.0,,,9606.0,A498,1.0,624.0,Homo sapiens
Intermediate,,5935.0,,,80682.0,11843.0,N,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,BAO_0000219,F,,CHEMBL876610,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5936.0,,,80682.0,11843.0,N,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,BAO_0000219,F,,CHEMBL619743,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5937.0,,,80682.0,17705.0,N,,In vitro antiproliferative activity against human A-549 NSCL cell line,,BAO_0000219,F,,CHEMBL619744,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5938.0,,,80682.0,17705.0,N,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,BAO_0000219,F,,CHEMBL619745,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5939.0,,,80682.0,4369.0,N,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,BAO_0000219,F,,CHEMBL619746,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5940.0,,,80682.0,4369.0,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,BAO_0000219,F,,CHEMBL619747,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5941.0,,,80682.0,4369.0,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,BAO_0000219,F,,CHEMBL619748,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5942.0,,,80682.0,4369.0,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,BAO_0000219,F,,CHEMBL619749,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5943.0,,,80682.0,4369.0,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,BAO_0000219,F,,CHEMBL619750,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5944.0,,,80682.0,4369.0,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,BAO_0000219,F,,CHEMBL624014,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5945.0,,,80682.0,4369.0,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,BAO_0000219,F,,CHEMBL624015,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5946.0,,,80682.0,4787.0,N,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,BAO_0000219,F,,CHEMBL885344,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5947.0,,,80682.0,4787.0,N,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,BAO_0000219,F,,CHEMBL623224,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5948.0,,,80682.0,6513.0,N,,Cytotoxic activity against A-549 cell line,,BAO_0000219,F,,CHEMBL623225,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5949.0,,,80682.0,6690.0,N,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,BAO_0000219,F,,CHEMBL622698,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5950.0,,,80682.0,6690.0,N,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,BAO_0000219,F,,CHEMBL622699,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5951.0,,,80682.0,12263.0,N,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,BAO_0000219,F,,CHEMBL622700,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5952.0,,,80682.0,1054.0,N,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,BAO_0000219,F,,CHEMBL622701,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5953.0,,,80682.0,1359.0,N,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,BAO_0000219,F,,CHEMBL622702,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5954.0,,,80682.0,3547.0,N,,Cytotoxic activity against human lung carcinoma (A-549) cell line,,BAO_0000219,F,,CHEMBL622703,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5955.0,,,80682.0,5771.0,N,,Cytotoxic activity towards A-549 cells,,BAO_0000219,F,,CHEMBL622704,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5956.0,,,80682.0,14425.0,N,,"In vitro percent inhibition of A549, lung carcinoma.",,BAO_0000219,F,,CHEMBL622705,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5957.0,,,80682.0,14425.0,N,,"In vitro percent inhibition of A549, lung carcinoma",,BAO_0000219,F,,CHEMBL622706,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5958.0,,,80682.0,14425.0,N,,"In vitro percent inhibition of A549, lung carcinoma.",,BAO_0000219,F,,CHEMBL622707,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5959.0,,,80682.0,14425.0,N,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,BAO_0000219,F,,CHEMBL622708,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5960.0,,,80682.0,5280.0,N,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,BAO_0000219,F,,CHEMBL622709,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5961.0,,,80682.0,15176.0,N,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,BAO_0000219,F,,CHEMBL622710,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5962.0,,,80682.0,15300.0,N,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,BAO_0000219,F,,CHEMBL622711,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5963.0,,,80682.0,17824.0,N,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,F,,CHEMBL622712,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5964.0,,,80682.0,17824.0,N,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,F,,CHEMBL622713,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5965.0,,,80682.0,17824.0,N,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,F,,CHEMBL622714,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5966.0,,,80682.0,17824.0,N,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,F,,CHEMBL622715,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5967.0,,,80682.0,17824.0,N,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,F,,CHEMBL622716,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5968.0,,,80682.0,17824.0,N,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,BAO_0000219,F,,CHEMBL622717,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5969.0,,,80682.0,17528.0,N,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,BAO_0000218,F,,CHEMBL622718,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5970.0,,,80682.0,6870.0,N,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,BAO_0000219,F,,CHEMBL622719,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5971.0,,,80682.0,6870.0,N,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,BAO_0000219,F,,CHEMBL622720,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5972.0,,,80682.0,6870.0,N,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,BAO_0000219,F,,CHEMBL622721,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5973.0,,,80682.0,6870.0,N,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,BAO_0000219,F,,CHEMBL622722,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5974.0,,,80682.0,16726.0,N,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,BAO_0000219,F,,CHEMBL876030,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5975.0,,,80682.0,6170.0,N,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,BAO_0000219,F,,CHEMBL620206,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5976.0,,,80682.0,6583.0,N,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,BAO_0000219,F,,CHEMBL620207,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5977.0,,,80682.0,6583.0,N,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,BAO_0000219,F,,CHEMBL620208,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5978.0,,,80682.0,6583.0,N,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,BAO_0000219,F,,CHEMBL620209,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5979.0,,,80682.0,6583.0,N,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,BAO_0000219,F,,CHEMBL620210,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5980.0,,,80682.0,6583.0,N,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,BAO_0000219,F,,CHEMBL621639,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5981.0,,,80682.0,17321.0,N,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,BAO_0000219,F,,CHEMBL621640,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5982.0,,,80682.0,17528.0,N,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,BAO_0000219,F,,CHEMBL621641,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,5983.0,,,80682.0,12888.0,N,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,BAO_0000219,F,,CHEMBL621642,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5984.0,,,80682.0,4312.0,N,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,BAO_0000219,F,,CHEMBL621643,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5985.0,,,80682.0,4312.0,N,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,BAO_0000219,F,,CHEMBL621644,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5986.0,,,80682.0,4312.0,N,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,BAO_0000219,F,,CHEMBL621645,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,5987.0,,,80682.0,17737.0,N,,In vitro antiproliferative activity against A549 cell line,,BAO_0000219,F,,CHEMBL621646,1.0,,,10090.0,A549,1.0,646.0,Mus musculus
Intermediate,,5988.0,,,80682.0,6630.0,N,,Synergism with indomethacin in A549 cells,,BAO_0000219,F,,CHEMBL621647,1.0,,,,A549,1.0,646.0,
Intermediate,,5989.0,,,80682.0,6630.0,N,,Synergism with tolmetin in A549 cells,,BAO_0000219,F,,CHEMBL621648,1.0,,,,A549,1.0,646.0,
Intermediate,,5990.0,,,80682.0,6630.0,N,,Synergism with sulindac in A549 cells,,BAO_0000219,F,,CHEMBL621649,1.0,,,,A549,1.0,646.0,
Intermediate,,5991.0,,,80682.0,6630.0,N,,Antagonism of indomethacin in A549 cells,,BAO_0000219,F,,CHEMBL621650,1.0,,,,A549,1.0,646.0,
Intermediate,,5992.0,,,80682.0,6630.0,N,,Antagonism of sulindac in A549 cells,,BAO_0000219,F,,CHEMBL621651,1.0,,,,A549,1.0,646.0,
Intermediate,,5993.0,,,80682.0,6630.0,N,,Antagonism of tolmetin in A549 cells,,BAO_0000219,F,,CHEMBL621652,1.0,,,,A549,1.0,646.0,
Intermediate,,5994.0,,,80682.0,6630.0,N,,Synergism with indomethacin in A549 cells,,BAO_0000219,F,,CHEMBL621653,1.0,,,,A549,1.0,646.0,
Intermediate,,5995.0,,,80682.0,6630.0,N,,Synergism with sulindac in A549 cells,,BAO_0000219,F,,CHEMBL621654,1.0,,,,A549,1.0,646.0,
Intermediate,,5996.0,,,80682.0,6630.0,N,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,BAO_0000219,F,,CHEMBL621655,1.0,,,,A549,1.0,646.0,
Intermediate,,5997.0,,,50588.0,16907.0,N,,Cmax value after 30 mg/kg po dose in Dogs,,BAO_0000218,A,In vivo,CHEMBL621656,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5998.0,,,50588.0,5944.0,N,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,A,In vivo,CHEMBL621657,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,5999.0,,,50588.0,5944.0,N,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,BAO_0000218,A,In vivo,CHEMBL621658,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6000.0,,,50588.0,5944.0,N,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,A,In vivo,CHEMBL621659,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6001.0,,,50588.0,5944.0,N,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,BAO_0000218,A,In vivo,CHEMBL621660,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6002.0,,,50588.0,2959.0,N,,Cmax value after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,A,In vivo,CHEMBL621661,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6003.0,,,50588.0,6241.0,N,,Cmax value in dog,,BAO_0000218,A,In vivo,CHEMBL621662,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6004.0,,,50588.0,6241.0,N,,Cmax value in dogs after oral administration at 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621663,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6005.0,,,50588.0,2652.0,N,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,BAO_0000218,A,In vivo,CHEMBL621664,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6006.0,,,50588.0,1806.0,N,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,BAO_0000218,A,In vivo,CHEMBL621665,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6007.0,,,50588.0,1806.0,N,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,BAO_0000218,A,In vivo,CHEMBL621666,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6008.0,,,50588.0,1021.0,N,,Concentration maxima after oral dosing in dogs,,BAO_0000218,A,In vivo,CHEMBL621667,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6009.0,,,50588.0,1021.0,N,,Concentration maxima after oral dosing in dogs; not available,,BAO_0000218,A,In vivo,CHEMBL876738,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6010.0,,,50588.0,1021.0,N,,Concentration maxima after oral dosing in dogs; not available,,BAO_0000218,A,In vivo,CHEMBL621668,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6011.0,,,50588.0,5444.0,N,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,BAO_0000218,A,In vivo,CHEMBL621669,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6012.0,,,50588.0,5444.0,N,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,BAO_0000218,A,In vivo,CHEMBL621670,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6013.0,,,50588.0,5444.0,N,,In vivo maximal concentration was calculated at 1 mg/kg in dog,,BAO_0000218,A,In vivo,CHEMBL621671,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6014.0,,,50588.0,5444.0,N,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,BAO_0000218,A,In vivo,CHEMBL622360,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6015.0,,,50588.0,5444.0,N,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,BAO_0000218,A,In vivo,CHEMBL622361,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6016.0,,,50588.0,5130.0,N,,Cmax in dog plasma after oral dose (1 mg/kg),,BAO_0000218,A,In vivo,CHEMBL622362,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6017.0,,,50588.0,3249.0,N,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL622363,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6018.0,,,50588.0,5473.0,N,,Maximal plasma concentration at a dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL622364,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6019.0,,,50588.0,5474.0,N,,Maximal plasma concentration at a dose of 1 mg/kg (oral),,BAO_0000218,A,In vivo,CHEMBL622365,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6020.0,,,50588.0,4657.0,N,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,BAO_0000218,A,In vivo,CHEMBL622533,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6021.0,,,50588.0,3031.0,N,,Maximum concentration of compound in dog was evaluated.,,BAO_0000218,A,In vivo,CHEMBL622534,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6022.0,,,50588.0,4527.0,N,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,A,In vivo,CHEMBL622535,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6023.0,,,50588.0,4186.0,N,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,BAO_0000218,A,In vivo,CHEMBL876739,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6024.0,,,50588.0,5007.0,N,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,A,In vivo,CHEMBL622536,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6025.0,,,50588.0,3132.0,N,,Maximum concentration obtained in dog plasma was determined,,BAO_0000218,A,In vivo,CHEMBL622537,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6026.0,,,50588.0,5006.0,N,,Maximum concentration was determined,,BAO_0000218,A,In vivo,CHEMBL622538,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6027.0,,,50588.0,4727.0,N,,Maximum concentration at the dose of 2 mg/kg in dog,,BAO_0000218,A,In vivo,CHEMBL627867,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6028.0,,,50588.0,1916.0,N,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,A,In vivo,CHEMBL627868,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6029.0,,,50588.0,1918.0,N,,Maximum concentration was evaluated in dog plasma,,BAO_0000218,A,In vivo,CHEMBL627869,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6030.0,,,50588.0,3045.0,N,,Maximum concentration was evaluated after 75 min after administration in dog,,BAO_0000218,A,In vivo,CHEMBL627870,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6031.0,,,50588.0,9579.0,N,,Maximum plasma concentration determined in dog after oral administration of 17b,,BAO_0000218,A,In vivo,CHEMBL627871,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6032.0,,,50588.0,9579.0,N,,Maximum plasma concentration determined in dog after oral administration of 2b,,BAO_0000218,A,In vivo,CHEMBL627872,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6033.0,,,50588.0,933.0,N,,Maximum plasma concentration in dog,,BAO_0000218,A,In vivo,CHEMBL627873,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6034.0,,,50588.0,17839.0,N,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL627874,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6035.0,,,50588.0,17839.0,N,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,BAO_0000218,A,In vivo,CHEMBL627875,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6036.0,,,50588.0,17839.0,N,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,BAO_0000218,A,In vivo,CHEMBL627876,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6037.0,,,50588.0,17839.0,N,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL627877,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6038.0,,,50588.0,6348.0,N,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,A,In vivo,CHEMBL627878,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6039.0,,,50588.0,16367.0,N,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL627879,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6040.0,,,50588.0,1337.0,N,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,A,In vivo,CHEMBL875355,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6041.0,,,50588.0,1337.0,N,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,A,In vivo,CHEMBL627880,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6042.0,,,50588.0,5199.0,N,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,BAO_0000218,A,In vivo,CHEMBL627881,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6043.0,,,50588.0,17650.0,N,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,A,In vivo,CHEMBL627882,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6044.0,,,50588.0,6679.0,N,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,BAO_0000218,A,In vivo,CHEMBL627883,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6045.0,,,50588.0,5356.0,N,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,BAO_0000218,A,In vivo,CHEMBL628526,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6046.0,,,50588.0,5356.0,N,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,BAO_0000218,A,In vivo,CHEMBL628527,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6047.0,,,50588.0,6227.0,N,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL628528,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6048.0,,,50588.0,6227.0,N,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL628529,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6049.0,,,50588.0,6227.0,N,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,BAO_0000218,A,In vivo,CHEMBL628530,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6050.0,,,50588.0,6227.0,N,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL625243,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Expert,Plasma,6051.0,,,50588.0,3598.0,N,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL625244,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6052.0,,,50588.0,4368.0,N,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,A,In vivo,CHEMBL625245,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6053.0,,,50588.0,6265.0,N,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL625246,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Stomach,6054.0,,,50594.0,7767.0,N,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL625247,1.0,945.0,,10090.0,,1.0,,Mus musculus
Intermediate,Urine,6055.0,,,50594.0,7767.0,N,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,A,In vivo,CHEMBL625248,1.0,1088.0,,10090.0,,1.0,,Mus musculus
Intermediate,Urine,6056.0,,,50594.0,7767.0,N,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,BAO_0000218,A,In vivo,CHEMBL625249,1.0,1088.0,,10090.0,,1.0,,Mus musculus
Intermediate,Urine,6057.0,,,50594.0,7767.0,N,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,BAO_0000218,A,In vivo,CHEMBL625250,1.0,1088.0,,10090.0,,1.0,,Mus musculus
Intermediate,,6058.0,,,50594.0,17811.0,N,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,BAO_0000218,A,,CHEMBL625251,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6059.0,,,50594.0,17811.0,N,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,BAO_0000218,A,,CHEMBL875356,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6060.0,,,50594.0,17827.0,N,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,BAO_0000218,A,,CHEMBL625252,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,6061.0,,,50594.0,17827.0,N,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,BAO_0000218,A,,CHEMBL625253,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,,6062.0,,,50594.0,17827.0,N,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,BAO_0000218,A,,CHEMBL625254,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6063.0,,,50594.0,17827.0,N,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,BAO_0000218,A,,CHEMBL625255,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6064.0,,,50594.0,17827.0,N,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,BAO_0000218,A,,CHEMBL625256,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,6065.0,,,50594.0,17827.0,N,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,BAO_0000218,A,,CHEMBL625257,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,6066.0,,,50594.0,17827.0,N,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,BAO_0000218,A,,CHEMBL625258,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,,6067.0,,,50594.0,17827.0,N,,Compound was evaluated for washout rate in mice (Radiolabeled compound),,BAO_0000218,A,,CHEMBL625259,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6068.0,,,50594.0,17827.0,N,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,BAO_0000218,A,,CHEMBL625260,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6069.0,,,50594.0,17827.0,N,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,BAO_0000218,A,,CHEMBL625261,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6070.0,,,50594.0,17827.0,N,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,BAO_0000218,A,,CHEMBL625262,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6071.0,,,50594.0,17827.0,N,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,BAO_0000218,A,,CHEMBL622639,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6072.0,,,50594.0,17257.0,N,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,BAO_0000218,A,,CHEMBL622640,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6073.0,,,50594.0,17257.0,N,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,BAO_0000218,A,,CHEMBL622812,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6074.0,,,50594.0,17257.0,N,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,BAO_0000218,A,,CHEMBL622813,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6075.0,,,50594.0,17257.0,N,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,BAO_0000218,A,,CHEMBL622814,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6076.0,,,50594.0,17827.0,N,,Time at maximum activity in mice (Radiolabeled compound),,BAO_0000218,A,,CHEMBL622815,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6077.0,,,50594.0,3760.0,N,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,BAO_0000218,A,,CHEMBL625342,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6078.0,,,50594.0,3760.0,N,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,BAO_0000218,A,,CHEMBL625343,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6079.0,,,50594.0,17409.0,N,,Binding towards mouse plasma protein at 10 uM,,BAO_0000218,A,,CHEMBL877591,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6080.0,,,50594.0,17409.0,N,,Binding towards mouse plasma protein at 100 uM,,BAO_0000218,A,,CHEMBL625344,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6081.0,,,50594.0,2675.0,N,,Bioavailability was evaluated in mice after intravenous administration,,BAO_0000218,A,In vivo,CHEMBL625345,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6082.0,,,50594.0,2675.0,N,,Bioavailability was evaluated in mice after oral administration,,BAO_0000218,A,In vivo,CHEMBL625346,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6083.0,,,50594.0,3132.0,N,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,BAO_0000218,A,In vivo,CHEMBL625347,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6084.0,,,50594.0,3132.0,N,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,BAO_0000218,A,In vivo,CHEMBL625348,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6085.0,,,50594.0,16597.0,N,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,A,In vivo,CHEMBL625349,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6086.0,,,50594.0,2862.0,N,,Oral bioavailability in mouse,,BAO_0000218,A,In vivo,CHEMBL625350,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6087.0,,,50594.0,17764.0,N,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,BAO_0000218,A,In vivo,CHEMBL882952,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,6088.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL625351,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,6089.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL625352,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,6090.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL877592,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,6091.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL625353,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,6092.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL625354,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,6093.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL626019,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,6094.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL626020,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,6095.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL626021,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,6096.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL626022,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,6097.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL626192,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,,6098.0,,,80682.0,1276.0,N,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,BAO_0000219,F,,CHEMBL626193,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6099.0,,,80682.0,3498.0,N,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,BAO_0000219,F,,CHEMBL626194,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6100.0,,,80682.0,1169.0,N,,Cytotoxicity against human lung carcinoma A-549 cell lines,,BAO_0000219,F,,CHEMBL626195,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6101.0,,,80682.0,4450.0,N,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,BAO_0000219,F,,CHEMBL626196,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6102.0,,,80682.0,358.0,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549,,BAO_0000219,F,,CHEMBL626197,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6103.0,,,80682.0,358.0,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,BAO_0000219,F,,CHEMBL626198,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6104.0,,,80682.0,358.0,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,BAO_0000219,F,,CHEMBL626199,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6105.0,,,80682.0,358.0,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,BAO_0000219,F,,CHEMBL626200,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6106.0,,,80682.0,358.0,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,BAO_0000219,F,,CHEMBL626201,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6107.0,,,80682.0,358.0,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,BAO_0000219,F,,CHEMBL626202,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6108.0,,,80682.0,358.0,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,BAO_0000219,F,,CHEMBL626203,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6109.0,,,80682.0,15167.0,N,,In vitro cytotoxicity against A-549 human lung cancer cells,,BAO_0000219,F,,CHEMBL626204,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6110.0,,,80682.0,4139.0,N,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,BAO_0000219,F,,CHEMBL624701,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6111.0,,,80682.0,833.0,N,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,BAO_0000219,F,,CHEMBL624702,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6112.0,,,80682.0,15718.0,N,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,BAO_0000219,F,,CHEMBL624703,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6113.0,,,80682.0,12373.0,N,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,BAO_0000219,F,,CHEMBL624704,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6114.0,,,80682.0,637.0,N,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,BAO_0000219,F,,CHEMBL624705,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6115.0,,,80682.0,14867.0,N,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,BAO_0000219,F,,CHEMBL624706,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6116.0,,,80682.0,4461.0,N,,Antitumor cytotoxic activity against A-549 cell line was determined,,BAO_0000219,F,,CHEMBL624707,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6117.0,,,80682.0,5406.0,N,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,BAO_0000219,F,,CHEMBL624708,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6118.0,,,80682.0,4457.0,N,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,BAO_0000219,F,,CHEMBL624709,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6119.0,,,80682.0,1386.0,N,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,BAO_0000219,F,,CHEMBL884107,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6120.0,,,80682.0,3265.0,N,,Antitumoral activity was assayed against A-549 cell line,,BAO_0000219,F,,CHEMBL624710,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6121.0,,,80682.0,2359.0,N,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,BAO_0000219,F,,CHEMBL624711,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6122.0,,,80682.0,4457.0,N,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,BAO_0000219,F,,CHEMBL624712,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6123.0,,,80682.0,12454.0,N,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,BAO_0000219,F,,CHEMBL624713,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6124.0,,,80682.0,1481.0,N,,Compound was tested for inhibition of cell growth of A-549 cells,,BAO_0000219,F,,CHEMBL624714,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6125.0,,,80682.0,1750.0,N,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,BAO_0000219,F,,CHEMBL624715,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6126.0,,,80682.0,5065.0,N,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,BAO_0000219,F,,CHEMBL624716,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6127.0,,,80682.0,808.0,N,,In vitro cytotoxicity against A549-human lung carcinoma cells.,,BAO_0000219,F,,CHEMBL619505,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6128.0,,,80682.0,16364.0,N,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,BAO_0000219,F,,CHEMBL619506,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6129.0,,,80682.0,1847.0,N,,Cytotoxic activity against A-549 cell lines.,,BAO_0000219,F,,CHEMBL619507,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6130.0,,,80682.0,1747.0,N,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,BAO_0000219,F,,CHEMBL619508,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6131.0,,,80682.0,1003.0,N,,Cytotoxicity against human A549 non small cell lung cell lines,,BAO_0000219,F,,CHEMBL619509,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6132.0,,,80682.0,15313.0,N,,Inhibition of cell growth in (A-549) lung cell line,,BAO_0000219,F,,CHEMBL619510,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6133.0,,,80682.0,3122.0,N,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,BAO_0000219,F,,CHEMBL619511,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6134.0,,,80682.0,16049.0,N,,In vitro antitumor activity against A-549 tumor cells.,,BAO_0000219,F,,CHEMBL619512,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6135.0,,,80682.0,17134.0,N,,In vitro antitumor effects against human A-549 cell lines.,,BAO_0000219,F,,CHEMBL619513,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6136.0,,,80682.0,6406.0,N,,In vitro cytotoxic activity of compound against A-549 cell line,,BAO_0000219,F,,CHEMBL619514,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6137.0,,,80682.0,627.0,N,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,BAO_0000219,F,,CHEMBL619515,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6138.0,,,80682.0,12307.0,N,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,BAO_0000219,F,,CHEMBL619516,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6139.0,,,80682.0,17861.0,N,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,BAO_0000219,F,,CHEMBL884005,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6140.0,,,80682.0,6682.0,N,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,BAO_0000219,F,,CHEMBL619517,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6141.0,,,80682.0,6663.0,N,,Inhibitory concentration of compound against A-549 cell line,,BAO_0000219,F,,CHEMBL619518,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6142.0,,,80682.0,2454.0,N,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,BAO_0000219,F,,CHEMBL619519,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6143.0,,,80682.0,14709.0,N,,cytotoxic activity against leukemia (A-549) cancer cell line,,BAO_0000219,F,,CHEMBL876489,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6144.0,,,80682.0,15718.0,N,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,BAO_0000219,F,,CHEMBL619520,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6145.0,,,80682.0,15718.0,N,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,BAO_0000219,F,,CHEMBL619521,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6146.0,,,80682.0,17130.0,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,BAO_0000219,F,,CHEMBL619522,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6147.0,,,80682.0,17130.0,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,BAO_0000219,F,,CHEMBL619523,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6148.0,,,80682.0,17130.0,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,BAO_0000219,F,,CHEMBL619524,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6149.0,,,80682.0,17130.0,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,BAO_0000219,F,,CHEMBL619525,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6150.0,,,80682.0,6630.0,N,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,BAO_0000219,F,,CHEMBL619526,1.0,,,,A549,1.0,646.0,
Intermediate,,6151.0,,,80682.0,16726.0,N,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,BAO_0000219,F,,CHEMBL619527,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6152.0,,,80682.0,17846.0,N,,Cytotoxicity against A549 cells; No cytotoxicity,,BAO_0000219,F,,CHEMBL619528,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6153.0,,,80682.0,3415.0,N,,Cytotoxicity against human lung carcinoma (A549) cell lines,,BAO_0000219,F,,CHEMBL619529,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6154.0,,,80682.0,3415.0,N,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,BAO_0000219,F,,CHEMBL619530,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6155.0,,,80682.0,5609.0,N,,In vitro anticancer activity against human lung (A549) cell line,,BAO_0000219,F,,CHEMBL876490,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6156.0,,,80682.0,17206.0,N,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,BAO_0000219,F,,CHEMBL619531,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6157.0,,,80682.0,17206.0,N,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,BAO_0000219,F,,CHEMBL619532,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6158.0,,,80682.0,17206.0,N,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,BAO_0000219,F,,CHEMBL619533,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6159.0,,,80682.0,17206.0,N,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,BAO_0000219,F,,CHEMBL619534,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6160.0,,,80682.0,17206.0,N,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,BAO_0000219,F,,CHEMBL620164,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6161.0,,,80682.0,17206.0,N,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,BAO_0000219,F,,CHEMBL620165,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6162.0,,,80682.0,16295.0,N,,Inhibition of A549 human lung tumor cell proliferation,,BAO_0000219,F,,CHEMBL620166,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6163.0,,,80682.0,16825.0,N,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,BAO_0000219,F,,CHEMBL620167,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6164.0,,,80682.0,3439.0,N,,In vitro cytotoxicity against human tumor cell line A549,,BAO_0000219,F,,CHEMBL620168,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6165.0,,,80682.0,10870.0,N,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,BAO_0000219,F,,CHEMBL620338,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6166.0,,,80682.0,4845.0,N,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,BAO_0000219,F,,CHEMBL620339,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6167.0,,,80682.0,5822.0,N,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,BAO_0000219,F,,CHEMBL620340,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6168.0,,,80682.0,5822.0,N,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,BAO_0000219,F,,CHEMBL620341,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6169.0,,,80682.0,5822.0,N,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,BAO_0000219,F,,CHEMBL876491,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6170.0,,,80682.0,16381.0,N,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,BAO_0000219,F,,CHEMBL620342,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6171.0,,,80682.0,16381.0,N,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,BAO_0000219,F,,CHEMBL620343,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6172.0,,,80682.0,16381.0,N,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,BAO_0000219,F,,CHEMBL620344,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6173.0,,,80682.0,5609.0,N,,In vitro anticancer activity against human lung (A549) cell line,,BAO_0000219,F,,CHEMBL620345,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6174.0,,,80682.0,4644.0,N,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,BAO_0000219,F,,CHEMBL620346,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6175.0,,,80682.0,4644.0,N,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,BAO_0000219,F,,CHEMBL620347,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6176.0,,,80682.0,4644.0,N,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,BAO_0000219,F,,CHEMBL620348,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6177.0,,,80682.0,4644.0,N,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,BAO_0000219,F,,CHEMBL620349,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6178.0,,,80682.0,5822.0,N,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,BAO_0000219,F,,CHEMBL618667,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6179.0,,,80682.0,3415.0,N,,Percentage inhibition of human lung carcinoma (A549) cell lines,,BAO_0000219,F,,CHEMBL618668,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6180.0,,,80682.0,16726.0,N,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,BAO_0000219,F,,CHEMBL876031,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6181.0,,,80682.0,17206.0,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,BAO_0000219,F,,CHEMBL618759,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6182.0,,,80682.0,17206.0,N,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,BAO_0000219,F,,CHEMBL618760,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6183.0,,,80682.0,17206.0,N,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,BAO_0000219,F,,CHEMBL619000,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6184.0,,,80682.0,17206.0,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,BAO_0000219,F,,CHEMBL619001,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6185.0,,,80682.0,17206.0,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,BAO_0000219,F,,CHEMBL619002,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6186.0,,,80682.0,17206.0,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,BAO_0000219,F,,CHEMBL619003,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6187.0,,,80682.0,17206.0,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,BAO_0000219,F,,CHEMBL619597,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6188.0,,,80682.0,17206.0,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,BAO_0000219,F,,CHEMBL619598,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6189.0,,,80682.0,17206.0,N,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,BAO_0000219,F,,CHEMBL619599,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6190.0,,,80682.0,17206.0,N,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,BAO_0000219,F,,CHEMBL619600,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6191.0,,,80682.0,16726.0,N,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,BAO_0000219,F,,CHEMBL619601,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6192.0,,,80682.0,17206.0,N,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,BAO_0000219,F,,CHEMBL619602,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6193.0,,,80682.0,17206.0,N,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,BAO_0000219,F,,CHEMBL619603,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6194.0,,,80682.0,17206.0,N,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,BAO_0000219,F,,CHEMBL619604,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6195.0,,,80682.0,17206.0,N,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,BAO_0000219,F,,CHEMBL619605,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6196.0,,,50588.0,6084.0,N,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,BAO_0000218,A,In vivo,CHEMBL619606,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6197.0,,,50588.0,6084.0,N,,Pharmacokinetic activity (Cmax) in dog,,BAO_0000218,A,In vivo,CHEMBL876032,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6198.0,,,50588.0,4809.0,N,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,BAO_0000218,A,In vivo,CHEMBL619607,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6199.0,,,50588.0,5983.0,N,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,BAO_0000218,A,In vivo,CHEMBL619608,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6200.0,,,50588.0,6251.0,N,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,BAO_0000218,A,In vivo,CHEMBL619609,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6201.0,,,50588.0,5932.0,N,,Cmax in dog plasma after 30mg/kg oral dose,,BAO_0000218,A,In vivo,CHEMBL619610,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Blood,6202.0,,,50588.0,4273.0,N,,Tested for the peak blood level in dog,,BAO_0000218,A,In vivo,CHEMBL619611,1.0,178.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6203.0,,,50588.0,5313.0,N,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,BAO_0000218,A,In vivo,CHEMBL619612,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6204.0,,,50588.0,5313.0,N,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,BAO_0000218,A,In vivo,CHEMBL619613,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Blood,6205.0,,,50588.0,6221.0,N,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,BAO_0000218,A,In vivo,CHEMBL619614,1.0,178.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6206.0,,,50588.0,4709.0,N,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,BAO_0000218,A,,CHEMBL619615,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6207.0,,,50588.0,167.0,N,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,BAO_0000218,A,,CHEMBL619616,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6208.0,,,50588.0,6241.0,N,,Final plasma concentration in dogs after oral administration at 1 mg/kg,,BAO_0000218,A,,CHEMBL619617,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6209.0,,,50588.0,344.0,N,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,BAO_0000218,A,,CHEMBL619618,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6210.0,,,50588.0,344.0,N,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,BAO_0000218,A,,CHEMBL876033,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6211.0,,,50588.0,344.0,N,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,BAO_0000218,A,,CHEMBL619619,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6212.0,,,50588.0,2189.0,N,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,BAO_0000218,A,,CHEMBL619620,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Urine,6213.0,,,50588.0,2189.0,N,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,BAO_0000218,A,,CHEMBL619621,1.0,1088.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Urine,6214.0,,,50588.0,2189.0,N,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,BAO_0000218,A,,CHEMBL619622,1.0,1088.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Urine,6215.0,,,50588.0,2189.0,N,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,BAO_0000218,A,,CHEMBL618874,1.0,1088.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6216.0,,,50588.0,4257.0,N,,Absolute bioavailability was evaluated in dog,,BAO_0000218,A,In vivo,CHEMBL618875,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6217.0,,,50588.0,6221.0,N,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,BAO_0000218,A,In vivo,CHEMBL618876,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6218.0,,,50588.0,6215.0,N,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,BAO_0000218,A,In vivo,CHEMBL618877,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6219.0,,,50588.0,17267.0,N,,Bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL618878,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6220.0,,,50588.0,6621.0,N,,Bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL618879,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6221.0,,,50588.0,3854.0,N,,Bioavailability after intravenous administration in dogs,,BAO_0000218,A,In vivo,CHEMBL618880,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6222.0,,,50588.0,3854.0,N,,Bioavailability after peroral administration in dogs,,BAO_0000218,A,In vivo,CHEMBL618881,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6223.0,,,50588.0,5007.0,N,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,BAO_0000218,A,In vivo,CHEMBL618882,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6224.0,,,50588.0,4333.0,N,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,BAO_0000218,A,In vivo,CHEMBL624226,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6225.0,,,50588.0,4333.0,N,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,BAO_0000218,A,In vivo,CHEMBL624227,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6226.0,,,50588.0,5006.0,N,,Bioavailability,,BAO_0000218,A,In vivo,CHEMBL624228,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6227.0,,,50588.0,5199.0,N,,Bioavailability,,BAO_0000218,A,In vivo,CHEMBL624229,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6228.0,,,50588.0,4368.0,N,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,A,In vivo,CHEMBL624230,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6229.0,,,50588.0,3771.0,N,,Bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL624231,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6230.0,,,50588.0,4953.0,N,,Bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL624232,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6231.0,,,50588.0,5064.0,N,,Bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL625127,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6232.0,,,50588.0,17657.0,N,,Bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL625128,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6233.0,,,50588.0,17796.0,N,,Bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621675,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6234.0,,,50588.0,17853.0,N,,Bioavailability in dog (p.o.) at 2.0 mpk,,BAO_0000218,A,In vivo,CHEMBL621676,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6235.0,,,50588.0,4521.0,N,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,BAO_0000218,A,In vivo,CHEMBL621677,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6236.0,,,50588.0,4521.0,N,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,A,In vivo,CHEMBL621678,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6237.0,,,50588.0,5006.0,N,,Bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621679,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6238.0,,,50588.0,16365.0,N,,Bioavailability was evaluated after oral administration in dog,,BAO_0000218,A,In vivo,CHEMBL621680,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6239.0,,,50588.0,1916.0,N,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,A,In vivo,CHEMBL621681,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6240.0,,,50588.0,1918.0,N,,Bioavailability was evaluated in dog,,BAO_0000218,A,In vivo,CHEMBL876740,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6241.0,,,50588.0,4239.0,N,,Bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621682,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6242.0,,,50588.0,6505.0,N,,Bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621683,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6243.0,,,50588.0,5334.0,N,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,BAO_0000218,A,In vivo,CHEMBL621684,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6244.0,,,50588.0,5334.0,N,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,BAO_0000218,A,In vivo,CHEMBL621685,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6245.0,,,50588.0,4809.0,N,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,BAO_0000218,A,In vivo,CHEMBL621686,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6246.0,,,50588.0,6348.0,N,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,A,In vivo,CHEMBL621687,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6247.0,,,50588.0,6005.0,N,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621688,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6248.0,,,50588.0,17804.0,N,,Bioavailability of compound in dog was determined after peroral administration,,BAO_0000218,A,In vivo,CHEMBL621689,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6249.0,,,50588.0,3184.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621690,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6250.0,,,50588.0,1806.0,N,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,BAO_0000218,A,In vivo,CHEMBL621691,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6251.0,,,50588.0,1806.0,N,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,BAO_0000218,A,In vivo,CHEMBL875941,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6252.0,,,50588.0,1806.0,N,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,BAO_0000218,A,In vivo,CHEMBL621692,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6253.0,,,50588.0,4839.0,N,,Bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621693,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6254.0,,,50588.0,5017.0,N,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,BAO_0000218,A,In vivo,CHEMBL621694,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Heart,6255.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL621695,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,6256.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL621696,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,6257.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL621697,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,6258.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL621698,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,6259.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL623420,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,6260.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL623421,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,6261.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL623422,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,6262.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL623423,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,6263.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL623424,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,6264.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL623425,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,6265.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL623426,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,6266.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL623427,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,6267.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL623428,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,6268.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL875947,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,6269.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL623429,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,6270.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL623430,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,6271.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL622588,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,6272.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL622589,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,6273.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL622751,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,6274.0,,,50594.0,846.0,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,A,In vivo,CHEMBL622752,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,,6275.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,BAO_0000218,A,,CHEMBL622753,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6276.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,BAO_0000218,A,,CHEMBL622647,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6277.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,BAO_0000218,A,,CHEMBL875163,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6278.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,BAO_0000218,A,,CHEMBL622648,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6279.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,BAO_0000218,A,,CHEMBL622649,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Brain,6280.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,BAO_0000218,A,,CHEMBL622650,1.0,955.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Brain,6281.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,BAO_0000218,A,,CHEMBL622651,1.0,955.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Brain,6282.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,BAO_0000218,A,,CHEMBL622652,1.0,955.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Brain,6283.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,BAO_0000218,A,,CHEMBL622653,1.0,955.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Brain,6284.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,BAO_0000218,A,,CHEMBL622654,1.0,955.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Heart,6285.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,BAO_0000218,A,,CHEMBL622655,1.0,948.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Heart,6286.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,BAO_0000218,A,,CHEMBL622656,1.0,948.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Heart,6287.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,BAO_0000218,A,,CHEMBL622657,1.0,948.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Heart,6288.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,BAO_0000218,A,,CHEMBL622658,1.0,948.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Heart,6289.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,BAO_0000218,A,,CHEMBL622659,1.0,948.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Kidney,6290.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,BAO_0000218,A,,CHEMBL624630,1.0,2113.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Kidney,6291.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,BAO_0000218,A,,CHEMBL624631,1.0,2113.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Kidney,6292.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,BAO_0000218,A,,CHEMBL624632,1.0,2113.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6293.0,,,80682.0,17130.0,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,BAO_0000219,F,,CHEMBL624633,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6294.0,,,80682.0,17130.0,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,BAO_0000219,F,,CHEMBL624634,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6295.0,,,80682.0,17130.0,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,BAO_0000219,F,,CHEMBL624635,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6296.0,,,80682.0,17130.0,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,BAO_0000219,F,,CHEMBL624636,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6297.0,,,80682.0,3263.0,N,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,BAO_0000219,F,,CHEMBL857055,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6298.0,,,80682.0,6663.0,N,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,BAO_0000219,F,,CHEMBL624637,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6299.0,,,80682.0,6663.0,N,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,BAO_0000219,F,,CHEMBL624638,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6300.0,,,80682.0,6663.0,N,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,BAO_0000219,F,,CHEMBL874366,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6301.0,,,80682.0,6663.0,N,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,BAO_0000219,F,,CHEMBL624639,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6302.0,,,80682.0,6663.0,N,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,BAO_0000219,F,,CHEMBL624640,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6303.0,,,80682.0,6663.0,N,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,BAO_0000219,F,,CHEMBL624641,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6304.0,,,80682.0,6663.0,N,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,BAO_0000219,F,,CHEMBL624642,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6305.0,,,80682.0,6663.0,N,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,BAO_0000219,F,,CHEMBL624643,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6306.0,,,80682.0,6663.0,N,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,BAO_0000219,F,,CHEMBL624644,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6307.0,,,80682.0,6663.0,N,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,BAO_0000219,F,,CHEMBL624645,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6308.0,,,80682.0,3983.0,N,,The compound was evaluated for its cytotoxic potency against A-549 cell line,,BAO_0000219,F,,CHEMBL619445,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6309.0,,,80682.0,11141.0,N,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,BAO_0000219,F,,CHEMBL839886,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6310.0,,,80682.0,5076.0,N,,Cytotoxic activity of compound against A-549 tumor cell line.,,BAO_0000219,F,,CHEMBL619446,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6311.0,,,80682.0,3311.0,N,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,BAO_0000219,F,,CHEMBL619447,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6312.0,,,80682.0,3311.0,N,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,BAO_0000219,F,,CHEMBL619448,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6313.0,,,80682.0,3311.0,N,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,BAO_0000219,F,,CHEMBL619449,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6314.0,,,80682.0,5076.0,N,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,BAO_0000219,F,,CHEMBL619450,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6315.0,,,80682.0,4150.0,N,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,BAO_0000219,F,,CHEMBL619451,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6316.0,,,80682.0,2150.0,N,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,BAO_0000219,F,,CHEMBL619452,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6317.0,,,80682.0,4644.0,N,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,BAO_0000219,F,,CHEMBL619453,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6318.0,,,80682.0,263.0,N,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,BAO_0000219,F,,CHEMBL874367,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6319.0,,,80682.0,11333.0,N,,Cytotoxic concentration against A-549 tumor cells.,,BAO_0000219,F,,CHEMBL619454,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6320.0,,,80682.0,11333.0,N,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,BAO_0000219,F,,CHEMBL619455,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6321.0,,,80682.0,15895.0,N,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,BAO_0000219,F,,CHEMBL619456,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6322.0,,,50191.0,16677.0,N,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,BAO_0000218,F,,CHEMBL619457,1.0,,,470.0,,1.0,,Acinetobacter baumannii
Intermediate,,6323.0,,,50192.0,10624.0,N,,Activity against Acinetobacter calcoaceticus (AC54),,BAO_0000218,F,,CHEMBL619458,1.0,,,471.0,,1.0,,Acinetobacter calcoaceticus
Expert,,6324.0,,,50274.0,16717.0,N,,In vitro antifungal activity against Aspergillus flavus CM74,,BAO_0000218,F,,CHEMBL619459,1.0,,,5059.0,,1.0,,Aspergillus flavus
Expert,,6325.0,,,50274.0,16717.0,N,,In vitro antifungal activity against Aspergillus flavus CM74,,BAO_0000218,F,,CHEMBL619460,1.0,,,5059.0,,1.0,,Aspergillus flavus
Intermediate,,6326.0,,,50416.0,5513.0,N,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,BAO_0000218,F,,CHEMBL619461,1.0,,,746128.0,,1.0,,Aspergillus fumigatus
Intermediate,,6327.0,,,50416.0,15962.0,N,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,BAO_0000218,F,,CHEMBL619462,1.0,,,746128.0,,1.0,,Aspergillus fumigatus
Intermediate,,6328.0,,,50416.0,15962.0,N,,Antimicrobial activity against Aspergillus fumigatus (MIC),,BAO_0000218,F,,CHEMBL620388,1.0,,,746128.0,,1.0,,Aspergillus fumigatus
Intermediate,,6329.0,,,50416.0,15962.0,N,,Antimicrobial activity against Aspergillus fumigatus (MIC),,BAO_0000218,F,,CHEMBL620389,1.0,,,746128.0,,1.0,,Aspergillus fumigatus
Intermediate,,6330.0,,,50416.0,15962.0,N,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,BAO_0000218,F,,CHEMBL620390,1.0,,,746128.0,,1.0,,Aspergillus fumigatus
Expert,,6331.0,,,50416.0,16717.0,N,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,BAO_0000218,F,,CHEMBL620391,1.0,,,746128.0,,1.0,,Aspergillus fumigatus
Expert,,6332.0,,,50416.0,16717.0,N,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,BAO_0000218,F,,CHEMBL621073,1.0,,,746128.0,,1.0,,Aspergillus fumigatus
Intermediate,,6333.0,,,50296.0,8117.0,N,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,BAO_0000218,F,,CHEMBL621074,1.0,,,1655.0,,1.0,,Actinomyces naeslundii
Intermediate,,6334.0,,,50366.0,8117.0,N,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,BAO_0000218,F,,CHEMBL621075,1.0,,,1656.0,,1.0,,Actinomyces viscosus
Intermediate,,6335.0,,,50535.0,15472.0,N,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,BAO_0000218,F,,CHEMBL619554,1.0,,,6277.0,,1.0,,Acanthocheilonema viteae
Intermediate,,6336.0,,,50535.0,15472.0,N,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,BAO_0000218,F,,CHEMBL619555,1.0,,,6277.0,,1.0,,Acanthocheilonema viteae
Intermediate,,6337.0,,,50169.0,16443.0,N,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,BAO_0000218,F,,CHEMBL619556,1.0,,,714.0,,1.0,,Aggregatibacter actinomycetemcomitans
Intermediate,,6338.0,,,50169.0,16443.0,N,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,BAO_0000218,F,,CHEMBL619557,1.0,,,714.0,,1.0,,Aggregatibacter actinomycetemcomitans
Intermediate,,6339.0,,,50169.0,16443.0,N,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,BAO_0000218,F,,CHEMBL619558,1.0,,,714.0,,1.0,,Aggregatibacter actinomycetemcomitans
Intermediate,,6340.0,,,80682.0,17206.0,N,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,BAO_0000219,F,,CHEMBL619559,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6341.0,,,80682.0,17206.0,N,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,BAO_0000219,F,,CHEMBL619560,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6342.0,,,80682.0,16381.0,N,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,BAO_0000219,F,,CHEMBL619561,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6343.0,,,80682.0,16381.0,N,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,BAO_0000219,F,,CHEMBL619562,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6344.0,,,80682.0,16381.0,N,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,BAO_0000219,F,,CHEMBL619563,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6345.0,,,80682.0,16381.0,N,,GI values against A549 cells (lung cancer),,BAO_0000219,F,,CHEMBL857457,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6346.0,,,80682.0,17206.0,N,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,BAO_0000219,F,,CHEMBL619564,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6347.0,,,80682.0,16325.0,N,,Inhibitory activity against A549 human adenocarcinoma,,BAO_0000219,F,,CHEMBL619565,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6348.0,,,80682.0,10708.0,N,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,BAO_0000218,F,,CHEMBL619566,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6349.0,,,80682.0,10708.0,N,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,BAO_0000218,F,,CHEMBL619567,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6350.0,,,80682.0,17376.0,N,,Inhibitory activity against A549 lung adenocarcinoma cell line,,BAO_0000219,F,,CHEMBL619568,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6351.0,,,80682.0,17376.0,N,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,BAO_0000219,F,,CHEMBL619569,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6352.0,,,80682.0,17488.0,N,,Cytotoxicity against human A549 lung cells,,BAO_0000219,F,,CHEMBL619570,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6353.0,,,80682.0,17404.0,N,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,BAO_0000218,F,,CHEMBL619571,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6354.0,,,80682.0,10958.0,N,,Growth inhibition of A549 (human lung carcinoma) cell line.,,BAO_0000219,F,,CHEMBL619572,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6355.0,,,80682.0,17099.0,N,,Effective dose required for inhibitory activity against A549 human tumor cell line.,,BAO_0000219,F,,CHEMBL619573,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6356.0,,,80682.0,17099.0,N,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,BAO_0000219,F,,CHEMBL619574,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6357.0,,,80682.0,4096.0,N,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,BAO_0000219,F,,CHEMBL619575,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6358.0,,,80682.0,4096.0,N,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,BAO_0000219,F,,CHEMBL619576,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6359.0,,,80682.0,4096.0,N,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,BAO_0000219,F,,CHEMBL619577,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6360.0,,,80682.0,2525.0,N,,In vitro inhibitory activity against A549 tumor cell culture,,BAO_0000219,F,,CHEMBL619578,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6361.0,,,80682.0,2525.0,N,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,BAO_0000219,F,,CHEMBL884009,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6362.0,,,80682.0,5302.0,N,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,BAO_0000219,F,,CHEMBL619579,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6363.0,,,80682.0,16325.0,N,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,BAO_0000219,F,,CHEMBL619580,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6364.0,,,80682.0,16939.0,N,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,BAO_0000219,F,,CHEMBL619581,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6365.0,,,80682.0,17229.0,N,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,BAO_0000219,F,,CHEMBL619582,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6366.0,,,80682.0,17380.0,N,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,BAO_0000219,F,,CHEMBL619583,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6367.0,,,80682.0,17380.0,N,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,BAO_0000219,F,,CHEMBL876502,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6368.0,,,80682.0,1903.0,N,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,BAO_0000219,F,,CHEMBL619584,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6369.0,,,80682.0,3838.0,N,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,BAO_0000219,F,,CHEMBL619585,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6370.0,,,80682.0,14696.0,N,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,BAO_0000219,F,,CHEMBL619586,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6371.0,,,80682.0,3838.0,N,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,BAO_0000219,F,,CHEMBL619587,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6372.0,,,80682.0,1522.0,N,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,BAO_0000219,F,,CHEMBL619588,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6373.0,,,80682.0,12400.0,N,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,BAO_0000219,F,,CHEMBL619589,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6374.0,,,80682.0,14696.0,N,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,BAO_0000219,F,,CHEMBL619590,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6375.0,,,80682.0,14769.0,N,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,BAO_0000219,F,,CHEMBL619591,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6376.0,,,80682.0,14696.0,N,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,BAO_0000219,F,,CHEMBL619592,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6377.0,,,80682.0,1888.0,N,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,BAO_0000219,F,,CHEMBL619593,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6378.0,,,80682.0,12016.0,N,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,BAO_0000219,F,,CHEMBL620217,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6379.0,,,80682.0,6058.0,N,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,BAO_0000219,F,,CHEMBL620218,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6380.0,,,80682.0,17708.0,N,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,BAO_0000219,F,,CHEMBL620219,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6381.0,,,80682.0,12301.0,N,,Antitumor activity against A549/ATCC cell line,,BAO_0000219,F,,CHEMBL620220,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6382.0,,,80682.0,11970.0,N,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,BAO_0000219,F,,CHEMBL625141,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Expert,,6383.0,,,80682.0,11818.0,N,,In vitro cytotoxicity against A549/ATCC cell line.,,BAO_0000219,F,,CHEMBL625142,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6384.0,,,80682.0,12400.0,N,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,BAO_0000219,F,,CHEMBL625143,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6385.0,,,80682.0,3381.0,N,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,BAO_0000219,F,,CHEMBL625144,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6386.0,,,80682.0,17376.0,N,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,BAO_0000219,F,,CHEMBL622474,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Intermediate,,6387.0,,,80682.0,10708.0,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,BAO_0000219,F,,CHEMBL884104,1.0,,,9606.0,A549,1.0,646.0,Homo sapiens
Autocuration,,6388.0,,,22226.0,2964.0,U,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,BAO_0000219,F,,CHEMBL622475,1.0,,,9606.0,,0.0,,Homo sapiens
Intermediate,,6389.0,,,22224.0,5005.0,U,,Compound was tested for oral bioavailability in dogs,,BAO_0000218,A,In vivo,CHEMBL622476,1.0,,,9615.0,,0.0,,Canis lupus familiaris
Intermediate,,6390.0,,,50588.0,6229.0,N,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,BAO_0000218,A,In vivo,CHEMBL875831,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6391.0,,,50588.0,6229.0,N,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,BAO_0000218,A,In vivo,CHEMBL622477,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6392.0,,,50588.0,5374.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL622478,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6393.0,,,50588.0,5374.0,N,,Compound was tested for the oral bioavailability in dog; No availability,,BAO_0000218,A,In vivo,CHEMBL623172,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6394.0,,,50588.0,6265.0,N,,Oral bioavailability in dog (dose 5 mg/kg),,BAO_0000218,A,In vivo,CHEMBL623173,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6395.0,,,50588.0,5654.0,N,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,BAO_0000218,A,In vivo,CHEMBL623174,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6396.0,,,50588.0,5654.0,N,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,BAO_0000218,A,In vivo,CHEMBL623175,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6397.0,,,50588.0,16456.0,N,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,BAO_0000218,A,In vivo,CHEMBL623340,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6398.0,,,50588.0,5302.0,N,,Oral bioavailability in dog (dose 5 mg/kg),,BAO_0000218,A,In vivo,CHEMBL623341,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6399.0,,,50588.0,3624.0,N,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,BAO_0000218,A,In vivo,CHEMBL623342,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6400.0,,,50588.0,16452.0,N,,Oral bioavailability of active FTIs in dogs,,BAO_0000218,A,In vivo,CHEMBL623343,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6401.0,,,50588.0,5802.0,N,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,BAO_0000218,A,In vivo,CHEMBL623344,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Expert,,6402.0,,,50588.0,3598.0,N,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623345,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6403.0,,,50588.0,17839.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL875832,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6404.0,,,50588.0,6762.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL623346,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6405.0,,,50588.0,6821.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL623347,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6406.0,,,50588.0,6821.0,N,,Oral bioavailability of compound was determined in dog; Not tested,,BAO_0000218,A,In vivo,CHEMBL623348,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6407.0,,,50588.0,5210.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL623349,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6408.0,,,50588.0,6227.0,N,,Oral bioavailability (10 mg/kg) was determined in dog,,BAO_0000218,A,In vivo,CHEMBL623350,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6409.0,,,50588.0,761.0,N,,Oral bioavailability,,BAO_0000218,A,In vivo,CHEMBL623351,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6410.0,,,50588.0,761.0,N,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,BAO_0000218,A,In vivo,CHEMBL623352,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6411.0,,,50588.0,761.0,N,,Oral bioavailability administered in solution in rats,,BAO_0000218,A,In vivo,CHEMBL623353,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6412.0,,,50588.0,16907.0,N,,Oral bioavailability after 30 mg/kg po dose in Dogs,,BAO_0000218,A,In vivo,CHEMBL875833,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6413.0,,,50588.0,5474.0,N,,Oral bioavailability at a dose of 1 mg/kg in dogs,,BAO_0000218,A,In vivo,CHEMBL623354,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6414.0,,,50588.0,6535.0,N,,Oral bioavailability in dog (dose 1 mg/kg p.o.),,BAO_0000218,A,In vivo,CHEMBL623355,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6415.0,,,50588.0,6535.0,N,,Oral bioavailability in Dog; ND = not determined,,BAO_0000218,A,In vivo,CHEMBL623356,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6416.0,,,50588.0,3352.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL623357,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6417.0,,,50588.0,6168.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL623358,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6418.0,,,50588.0,5988.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL623359,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6419.0,,,50588.0,4942.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL623360,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6420.0,,,50588.0,4942.0,N,,Oral bioavailability in dogs; No data,,BAO_0000218,A,In vivo,CHEMBL623361,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6421.0,,,50588.0,14541.0,N,,Oral bioavailability measured in dogs,,BAO_0000218,A,In vivo,CHEMBL623362,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6422.0,,,50588.0,4449.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL623363,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6423.0,,,50588.0,6057.0,N,,Oral bioavailability was calculated in dog,,BAO_0000218,A,In vivo,CHEMBL623364,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6424.0,,,50588.0,5600.0,N,,Oral bioavailability after 0.3 mg/kg po administration in dog,,BAO_0000218,A,In vivo,CHEMBL875834,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6425.0,,,50588.0,5542.0,N,,Oral bioavailability in dog (i.v. dosing),,BAO_0000218,A,In vivo,CHEMBL623365,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6426.0,,,50588.0,5542.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL623366,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6427.0,,,50588.0,5546.0,N,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,BAO_0000218,A,In vivo,CHEMBL623367,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6428.0,,,50588.0,4514.0,N,,Oral bioavailability in Beagle dogs,,BAO_0000218,A,In vivo,CHEMBL623368,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6429.0,,,50588.0,3624.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL623369,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6430.0,,,50588.0,3854.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL623370,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6431.0,,,50588.0,5836.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL623371,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6432.0,,,50588.0,5940.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL623372,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6433.0,,,50588.0,6168.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621351,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6434.0,,,50588.0,6227.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621352,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6435.0,,,50588.0,6251.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621353,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6436.0,,,50588.0,6448.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621354,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6437.0,,,50588.0,6647.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621355,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6438.0,,,50588.0,5940.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621356,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6439.0,,,50588.0,933.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621357,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6440.0,,,50588.0,5210.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621358,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6441.0,,,50588.0,6642.0,N,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,BAO_0000218,A,In vivo,CHEMBL621359,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6442.0,,,50588.0,6641.0,N,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,BAO_0000218,A,In vivo,CHEMBL621360,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6443.0,,,50588.0,6642.0,N,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,BAO_0000218,A,In vivo,CHEMBL621361,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6444.0,,,50588.0,5472.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621362,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6445.0,,,50588.0,5985.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621363,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6446.0,,,50588.0,15660.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621364,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6447.0,,,50588.0,5530.0,N,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,BAO_0000218,A,In vivo,CHEMBL621166,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6448.0,,,50588.0,5530.0,N,,Oral bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,A,In vivo,CHEMBL621167,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6449.0,,,50588.0,6305.0,N,,Oral bioavailability (F) in dogs,,BAO_0000218,A,In vivo,CHEMBL621168,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6450.0,,,50588.0,5210.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL621169,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6451.0,,,50588.0,5238.0,N,,Bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL875950,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6452.0,,,50588.0,5668.0,N,,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,A,In vivo,CHEMBL621170,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6453.0,,,50588.0,5668.0,N,,Oral bioavailability after peroral administration at 5 mpk in Dog,,BAO_0000218,A,In vivo,CHEMBL621171,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6454.0,,,50588.0,5668.0,N,,Oral bioavailability in dog (dose 5 mg/kg),,BAO_0000218,A,In vivo,CHEMBL621172,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6455.0,,,50588.0,6084.0,N,,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,A,In vivo,CHEMBL621173,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Kidney,6456.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,BAO_0000218,A,,CHEMBL621174,1.0,2113.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Kidney,6457.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,BAO_0000218,A,,CHEMBL621175,1.0,2113.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Liver,6458.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,BAO_0000218,A,,CHEMBL621176,1.0,2107.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Liver,6459.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,BAO_0000218,A,,CHEMBL621177,1.0,2107.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Liver,6460.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,BAO_0000218,A,,CHEMBL621178,1.0,2107.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Liver,6461.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,BAO_0000218,A,,CHEMBL621179,1.0,2107.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Liver,6462.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,BAO_0000218,A,,CHEMBL621180,1.0,2107.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Lung,6463.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,BAO_0000218,A,,CHEMBL875951,1.0,2048.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Lung,6464.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,BAO_0000218,A,,CHEMBL621181,1.0,2048.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Lung,6465.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,BAO_0000218,A,,CHEMBL621182,1.0,2048.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Lung,6466.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,BAO_0000218,A,,CHEMBL621183,1.0,2048.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Lung,6467.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,BAO_0000218,A,,CHEMBL621184,1.0,2048.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6468.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,BAO_0000218,A,,CHEMBL621185,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6469.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,BAO_0000218,A,,CHEMBL621186,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6470.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,BAO_0000218,A,,CHEMBL621187,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6471.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,BAO_0000218,A,,CHEMBL621188,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6472.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,BAO_0000218,A,,CHEMBL621189,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Spleen,6473.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,BAO_0000218,A,,CHEMBL621190,1.0,2106.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Spleen,6474.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,BAO_0000218,A,,CHEMBL618520,1.0,2106.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Spleen,6475.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,BAO_0000218,A,,CHEMBL621739,1.0,2106.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Spleen,6476.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,BAO_0000218,A,,CHEMBL621740,1.0,2106.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Spleen,6477.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,BAO_0000218,A,,CHEMBL621741,1.0,2106.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6478.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,BAO_0000218,A,,CHEMBL621742,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6479.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,BAO_0000218,A,,CHEMBL621743,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6480.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,BAO_0000218,A,,CHEMBL621744,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6481.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,BAO_0000218,A,,CHEMBL621745,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6482.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,BAO_0000218,A,,CHEMBL621746,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6483.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,BAO_0000218,A,,CHEMBL621747,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6484.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,BAO_0000218,A,,CHEMBL621748,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6485.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,BAO_0000218,A,,CHEMBL621749,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6486.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,BAO_0000218,A,,CHEMBL621750,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6487.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,BAO_0000218,A,,CHEMBL621751,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Heart,6488.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,BAO_0000218,A,,CHEMBL621752,1.0,948.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Heart,6489.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,BAO_0000218,A,,CHEMBL621753,1.0,948.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Heart,6490.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,BAO_0000218,A,,CHEMBL875955,1.0,948.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Heart,6491.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,BAO_0000218,A,,CHEMBL621754,1.0,948.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Heart,6492.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,BAO_0000218,A,,CHEMBL621755,1.0,948.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Liver,6493.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,BAO_0000218,A,,CHEMBL621756,1.0,2107.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Liver,6494.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,BAO_0000218,A,,CHEMBL624199,1.0,2107.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Liver,6495.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,BAO_0000218,A,,CHEMBL624200,1.0,2107.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Liver,6496.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,BAO_0000218,A,,CHEMBL624375,1.0,2107.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Liver,6497.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,BAO_0000218,A,,CHEMBL624376,1.0,2107.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Lung,6498.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,BAO_0000218,A,,CHEMBL624377,1.0,2048.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Lung,6499.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,BAO_0000218,A,,CHEMBL624378,1.0,2048.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6500.0,,,50067.0,12269.0,N,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,F,,CHEMBL857901,1.0,,,107673.0,,1.0,,aeinetobacter anitrotap
Intermediate,,6501.0,,,50067.0,12269.0,N,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,F,,CHEMBL875274,1.0,,,107673.0,,1.0,,Acinetobacter calcoaceticus subsp. anitratus
Intermediate,,6502.0,,,50067.0,12269.0,N,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,F,,CHEMBL624379,1.0,,,107673.0,,1.0,,Acinetobacter calcoaceticus subsp. anitratus
Intermediate,,6503.0,,,50067.0,12269.0,N,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,F,,CHEMBL624380,1.0,,,107673.0,,1.0,,aeinetobacter anitrotap
Intermediate,,6504.0,,,50192.0,10624.0,N,,Activity against Acinetobacter calcoaceticus (AC54),,BAO_0000218,F,,CHEMBL624381,1.0,,,471.0,,1.0,,Acinetobacter calcoaceticus
Intermediate,,6505.0,,,50714.0,17216.0,N,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,BAO_0000218,F,,CHEMBL624382,1.0,,,28377.0,,1.0,,Anolis carolinensis
Intermediate,,6506.0,,,50714.0,17216.0,N,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,BAO_0000218,F,,CHEMBL624383,1.0,,,28377.0,,1.0,,Anolis carolinensis
Intermediate,,6507.0,,,50296.0,9560.0,N,,Chlorohexidine coefficient for Actinomyces naeslundii 631,,BAO_0000218,F,,CHEMBL624384,1.0,,,1655.0,,1.0,,Actinomyces naeslundii
Intermediate,,6508.0,,,50296.0,9560.0,N,,Chlorohexidine coefficient for Actinomyces naeslundii B74,,BAO_0000218,F,,CHEMBL624385,1.0,,,1655.0,,1.0,,Actinomyces naeslundii
Intermediate,,6509.0,,,50296.0,9560.0,N,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,BAO_0000218,F,,CHEMBL624386,1.0,,,1655.0,,1.0,,Actinomyces naeslundii
Intermediate,,6510.0,,,50296.0,9560.0,N,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,BAO_0000218,F,,CHEMBL624387,1.0,,,1655.0,,1.0,,Actinomyces naeslundii
Intermediate,,6511.0,,,50296.0,9560.0,N,,Plaque bactericidal index against Actinomyces naeslundii 631,,BAO_0000218,F,,CHEMBL624388,1.0,,,1655.0,,1.0,,Actinomyces naeslundii
Intermediate,,6512.0,,,50296.0,9560.0,N,,Plaque bactericidal index against Actinomyces naeslundii N/9,,BAO_0000218,F,,CHEMBL624389,1.0,,,1655.0,,1.0,,Actinomyces naeslundii
Intermediate,,6513.0,,,50296.0,9560.0,N,,Plaque bactericidal index against Actinomyces naeslundii B74,,BAO_0000218,F,,CHEMBL624390,1.0,,,1655.0,,1.0,,Actinomyces naeslundii
Intermediate,,6514.0,,,50296.0,9560.0,N,,Plaque bactericidal index against Actinomyces naeslundii N/3,,BAO_0000218,F,,CHEMBL875275,1.0,,,1655.0,,1.0,,Actinomyces naeslundii
Intermediate,,6515.0,,,50056.0,114.0,N,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,BAO_0000218,F,,CHEMBL624391,1.0,,,85549.0,,1.0,,Artemia salina
Intermediate,,6516.0,,,50056.0,114.0,N,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,BAO_0000218,F,,CHEMBL623636,1.0,,,85549.0,,1.0,,Artemia salina
Intermediate,,6517.0,,,50532.0,10841.0,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,BAO_0000218,F,,CHEMBL623637,1.0,,,6253.0,,1.0,,Ascaris suum
Intermediate,,6518.0,,,50532.0,10841.0,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,BAO_0000218,F,,CHEMBL623638,1.0,,,6253.0,,1.0,,Ascaris suum
Intermediate,,6519.0,,,50532.0,10841.0,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,BAO_0000218,F,,CHEMBL623639,1.0,,,6253.0,,1.0,,Ascaris suum
Intermediate,,6520.0,,,50532.0,10841.0,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,BAO_0000218,F,,CHEMBL623640,1.0,,,6253.0,,1.0,,Ascaris suum
Intermediate,,6521.0,,,50532.0,10841.0,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,BAO_0000218,F,,CHEMBL623641,1.0,,,6253.0,,1.0,,Ascaris suum
Intermediate,,6522.0,,,50532.0,10841.0,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,BAO_0000218,F,,CHEMBL623642,1.0,,,6253.0,,1.0,,Ascaris suum
Intermediate,,6523.0,,,50532.0,10841.0,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,BAO_0000218,F,,CHEMBL623643,1.0,,,6253.0,,1.0,,Ascaris suum
Intermediate,,6524.0,,,50532.0,10841.0,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,BAO_0000218,F,,CHEMBL623644,1.0,,,6253.0,,1.0,,Ascaris suum
Intermediate,,6525.0,,,50532.0,10841.0,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,BAO_0000218,F,,CHEMBL623645,1.0,,,6253.0,,1.0,,Ascaris suum
Intermediate,,6526.0,,,50532.0,10841.0,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,BAO_0000218,F,,CHEMBL623646,1.0,,,6253.0,,1.0,,Ascaris suum
Intermediate,,6527.0,,,50532.0,10841.0,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,BAO_0000218,F,,CHEMBL623647,1.0,,,6253.0,,1.0,,Ascaris suum
Intermediate,,6528.0,,,50532.0,10841.0,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,BAO_0000218,F,,CHEMBL623648,1.0,,,6253.0,,1.0,,Ascaris suum
Intermediate,,6529.0,,,50366.0,8117.0,N,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,BAO_0000218,F,,CHEMBL623649,1.0,,,1656.0,,1.0,,Actinomyces viscosus
Intermediate,,6530.0,,,50366.0,8117.0,N,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,BAO_0000218,F,,CHEMBL623650,1.0,,,1656.0,,1.0,,Actinomyces viscosus
Intermediate,,6531.0,,,50366.0,9560.0,N,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,BAO_0000218,F,,CHEMBL623651,1.0,,,1656.0,,1.0,,Actinomyces viscosus
Expert,,6532.0,,,50366.0,9560.0,N,,Chlorohexidine coefficient for Actinomyces viscosus M-100,,BAO_0000218,F,,CHEMBL623652,1.0,,,1656.0,,1.0,,Actinomyces viscosus
Intermediate,,6533.0,,,50366.0,9560.0,N,,Chlorohexidine coefficient for Actinomyces viscosus M-626,,BAO_0000218,F,,CHEMBL623653,1.0,,,1656.0,,1.0,,Actinomyces viscosus
Intermediate,,6534.0,,,50366.0,9560.0,N,,Chlorohexidine coefficient for Actinomyces viscosus T14V,,BAO_0000218,F,,CHEMBL623654,1.0,,,1656.0,,1.0,,Actinomyces viscosus
Intermediate,,6535.0,,,50366.0,9560.0,N,,Plaque bactericidal index against Actinomyces viscosus 8A06,,BAO_0000218,F,,CHEMBL623655,1.0,,,1656.0,,1.0,,Actinomyces viscosus
Intermediate,,6536.0,,,50366.0,9560.0,N,,Plaque bactericidal index against Actinomyces viscosus M-100,,BAO_0000218,F,,CHEMBL623656,1.0,,,1656.0,,1.0,,Actinomyces viscosus
Expert,,6537.0,,,50366.0,9560.0,N,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,BAO_0000218,F,,CHEMBL623657,1.0,,,1656.0,,1.0,,Actinomyces viscosus
Intermediate,,6538.0,,,50366.0,9560.0,N,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,BAO_0000218,F,,CHEMBL623658,1.0,,,1656.0,,1.0,,Actinomyces viscosus
Intermediate,,6539.0,,,50366.0,9560.0,N,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,BAO_0000218,F,,CHEMBL623659,1.0,,,1656.0,,1.0,,Actinomyces viscosus
Intermediate,,6540.0,,,50366.0,9560.0,N,,Plaque bactericidal index against Actinomyces viscosus 626,,BAO_0000218,F,,CHEMBL623660,1.0,,,1656.0,,1.0,,Actinomyces viscosus
Intermediate,,6541.0,,,50366.0,9560.0,N,,Plaque bactericidal index against Actinomyces viscosus T14V,,BAO_0000218,F,,CHEMBL623661,1.0,,,1656.0,,1.0,,Actinomyces viscosus
Intermediate,,6542.0,,,50535.0,10986.0,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,BAO_0000218,F,,CHEMBL875281,1.0,,,6277.0,,1.0,,Acanthocheilonema viteae
Intermediate,,6543.0,,,50535.0,10986.0,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,BAO_0000218,F,,CHEMBL623662,1.0,,,6277.0,,1.0,,Acanthocheilonema viteae
Intermediate,,6544.0,,,50535.0,10986.0,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,BAO_0000218,F,,CHEMBL623663,1.0,,,6277.0,,1.0,,Acanthocheilonema viteae
Intermediate,,6545.0,,,50535.0,10986.0,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,BAO_0000218,F,,CHEMBL623664,1.0,,,6277.0,,1.0,,Acanthocheilonema viteae
Intermediate,,6546.0,,,50535.0,10986.0,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,BAO_0000218,F,,CHEMBL623665,1.0,,,6277.0,,1.0,,Acanthocheilonema viteae
Intermediate,,6547.0,,,80023.0,10708.0,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,BAO_0000219,F,,CHEMBL621856,1.0,,,9606.0,A673,1.0,165.0,Homo sapiens
Intermediate,,6548.0,,,80661.0,10708.0,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,BAO_0000219,F,,CHEMBL620432,1.0,,,9606.0,A704,1.0,645.0,Homo sapiens
Autocuration,,6549.0,,,22226.0,416.0,U,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,BAO_0000219,F,,CHEMBL620433,1.0,,,10116.0,,0.0,,Rattus norvegicus
Intermediate,,6550.0,,,80024.0,14354.0,N,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,BAO_0000219,F,,CHEMBL620434,1.0,,,10090.0,A9,1.0,625.0,Mus musculus
Intermediate,,6551.0,,,80024.0,14354.0,N,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,BAO_0000219,F,,CHEMBL620435,1.0,,,10090.0,A9,1.0,625.0,Mus musculus
Intermediate,,6552.0,,,80024.0,5116.0,N,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,BAO_0000219,F,,CHEMBL620436,1.0,,,9606.0,A9,1.0,625.0,Homo sapiens
Intermediate,,6553.0,,,80024.0,5116.0,N,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,BAO_0000219,F,,CHEMBL876597,1.0,,,9606.0,A9,1.0,625.0,Homo sapiens
Expert,,6554.0,,,81037.0,15694.0,N,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,BAO_0000219,F,,CHEMBL620437,1.0,,,9606.0,Human ovarian carcinoma cell line,1.0,874.0,Homo sapiens
Expert,,6555.0,,,80024.0,13038.0,N,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,BAO_0000219,F,,CHEMBL620438,1.0,,,10090.0,A9,1.0,625.0,Mus musculus
Expert,,6556.0,,,80024.0,13038.0,N,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,BAO_0000219,F,,CHEMBL620439,1.0,,,10090.0,A9,1.0,625.0,Mus musculus
Expert,,6557.0,,,80024.0,10923.0,N,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,BAO_0000219,F,,CHEMBL619657,1.0,,,10090.0,A9,1.0,625.0,Mus musculus
Intermediate,,6558.0,,,80024.0,10923.0,N,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,BAO_0000219,F,,CHEMBL619658,1.0,,,10090.0,A9,1.0,625.0,Mus musculus
Intermediate,,6559.0,,,80024.0,10923.0,N,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,BAO_0000219,F,,CHEMBL619659,1.0,,,10090.0,A9,1.0,625.0,Mus musculus
Expert,,6560.0,,,10649.0,10923.0,H,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,BAO_0000019,F,,CHEMBL619660,1.0,,,,,8.0,,
Intermediate,,6561.0,,,80024.0,10923.0,N,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,BAO_0000219,F,,CHEMBL619661,1.0,,,10090.0,A9,1.0,625.0,Mus musculus
Intermediate,,6562.0,,,80024.0,10923.0,N,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,BAO_0000219,F,,CHEMBL619662,1.0,,,10090.0,A9,1.0,625.0,Mus musculus
Intermediate,,6563.0,,,80663.0,8158.0,N,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,BAO_0000219,F,,CHEMBL619663,1.0,,,10029.0,AA6,1.0,975.0,Cricetulus griseus
Autocuration,,6564.0,,,22226.0,15494.0,U,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,BAO_0000219,F,,CHEMBL619664,1.0,,,9606.0,,0.0,,Homo sapiens
Autocuration,,6565.0,,,22226.0,15494.0,U,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,BAO_0000219,F,,CHEMBL619665,1.0,,,9606.0,,0.0,,Homo sapiens
Intermediate,,6566.0,,,80662.0,12348.0,N,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,BAO_0000219,F,,CHEMBL883244,1.0,,,9606.0,AA5,1.0,974.0,Homo sapiens
Intermediate,,6567.0,,,80662.0,12348.0,N,,Cytotoxicity was measured against AA5/HIV-1(IIIB),,BAO_0000219,F,,CHEMBL884011,1.0,,,9606.0,AA5,1.0,974.0,Homo sapiens
Intermediate,,6568.0,,,80662.0,2726.0,N,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,BAO_0000219,F,,CHEMBL619666,1.0,,,9606.0,AA5,1.0,974.0,Homo sapiens
Intermediate,,6569.0,,,80566.0,2726.0,N,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,BAO_0000219,F,,CHEMBL619667,1.0,,,9606.0,U-937,1.0,379.0,Homo sapiens
Intermediate,,6570.0,,,80578.0,10747.0,N,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,BAO_0000219,F,,CHEMBL619668,1.0,,,10029.0,UV4,1.0,274.0,Cricetulus griseus
Expert,,6571.0,,,80089.0,11005.0,N,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,BAO_0000219,F,,CHEMBL619669,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6572.0,,,80089.0,12687.0,N,,Average intracellular compound concentration when the hypoxic SER=1.6,,BAO_0000219,F,,CHEMBL876608,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6573.0,,,80089.0,12687.0,N,,Average intracellular compound concentration when the hypoxic SER=1.6.,,BAO_0000219,F,,CHEMBL619670,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6574.0,,,80089.0,12687.0,N,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,BAO_0000219,F,,CHEMBL619671,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6575.0,,,80089.0,12687.0,N,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,BAO_0000219,F,,CHEMBL619672,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6576.0,,,80089.0,12687.0,N,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,BAO_0000219,F,,CHEMBL619673,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6577.0,,,80089.0,13436.0,N,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,BAO_0000219,F,,CHEMBL619674,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6578.0,,,80089.0,13435.0,N,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,BAO_0000219,F,,CHEMBL619675,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6579.0,,,80089.0,13302.0,N,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,BAO_0000219,F,,CHEMBL619676,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6580.0,,,80089.0,12687.0,N,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,BAO_0000219,F,,CHEMBL619677,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6581.0,,,80089.0,12687.0,N,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,BAO_0000219,A,,CHEMBL619678,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6582.0,,,80089.0,12687.0,N,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,BAO_0000219,A,,CHEMBL619679,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Expert,,6583.0,,,80089.0,12878.0,N,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,BAO_0000219,A,,CHEMBL619680,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6584.0,,,80089.0,12878.0,N,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,BAO_0000219,A,,CHEMBL621457,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Expert,,6585.0,,,80089.0,14367.0,N,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,BAO_0000219,F,,CHEMBL876609,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6586.0,,,80089.0,14367.0,N,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,BAO_0000219,F,,CHEMBL621458,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Expert,,6587.0,,,80089.0,12398.0,N,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,BAO_0000219,F,,CHEMBL621459,1.0,,,36483.0,CHO-AA8,1.0,185.0,hampster
Expert,,6588.0,,,80089.0,12878.0,N,,Aerobic growth inhibition in Chinese hamster cell line AA8,,BAO_0000219,F,,CHEMBL621460,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Expert,,6589.0,,,80089.0,13820.0,N,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,BAO_0000219,F,,CHEMBL621461,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Expert,,6590.0,,,80089.0,13436.0,N,,Inhibition of growth under aerobic conditions in AA8 cells,,BAO_0000219,F,,CHEMBL621462,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6591.0,,,50588.0,6084.0,N,,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,A,In vivo,CHEMBL621463,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6592.0,,,50588.0,5711.0,N,,Oral bioavailability in dog at 10 mg/kg of the compound,,BAO_0000218,A,In vivo,CHEMBL621464,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6593.0,,,50588.0,4353.0,N,,Oral bioavailability in dog (dose 5 uM/kg),,BAO_0000218,A,In vivo,CHEMBL621465,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6594.0,,,50588.0,4353.0,N,,Oral bioavailability in dog (dose 5 uM/kg),,BAO_0000218,A,In vivo,CHEMBL621466,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6595.0,,,50588.0,17800.0,N,,Oral bioavailability in dog (mongrel),,BAO_0000218,A,In vivo,CHEMBL621467,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6596.0,,,50588.0,3994.0,N,,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,A,In vivo,CHEMBL621468,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6597.0,,,50588.0,3994.0,N,,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,F,In vivo,CHEMBL876734,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6598.0,,,50588.0,5145.0,N,,Bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL618476,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6599.0,,,50588.0,16452.0,N,,Bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,A,In vivo,CHEMBL618477,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6600.0,,,50588.0,16452.0,N,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,BAO_0000218,A,In vivo,CHEMBL618478,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6601.0,,,50588.0,5983.0,N,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618479,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6602.0,,,50588.0,4273.0,N,,Bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL618480,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6603.0,,,50588.0,12500.0,N,,Bioavailability in dog (dose 3-10 mg/kg),,BAO_0000218,A,In vivo,CHEMBL618481,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6604.0,,,50588.0,12500.0,N,,The compound was tested for bioavailability of compound in plasma of dog; Complete,,BAO_0000218,A,In vivo,CHEMBL618482,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6605.0,,,50588.0,3639.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL618483,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6606.0,,,50588.0,3880.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL618484,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6607.0,,,50588.0,4838.0,N,,Bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL618485,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6608.0,,,50588.0,15600.0,N,,oral bioavailability was measured in dogs,,BAO_0000218,A,In vivo,CHEMBL618486,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6609.0,,,50588.0,17248.0,N,,Compound was tested for plasma protein binding in dog; Not determined,,BAO_0000218,A,,CHEMBL618487,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6610.0,,,50588.0,17248.0,N,,Compound was tested for plasma protein binding of dog,,BAO_0000218,A,,CHEMBL618488,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6611.0,,,50588.0,17248.0,N,,Compound was tested for plasma protein binding of dog; Not determined,,BAO_0000218,A,,CHEMBL876735,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6612.0,,,50588.0,17443.0,N,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,BAO_0000218,A,,CHEMBL618489,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6613.0,,,50588.0,4186.0,N,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,BAO_0000218,A,In vivo,CHEMBL618490,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6614.0,,,50588.0,3749.0,N,,Half life was determined,,BAO_0000218,A,,CHEMBL618491,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6615.0,,,50588.0,3249.0,N,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618492,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6616.0,,,50588.0,3022.0,N,,Half life was evaluated in dog,,BAO_0000218,A,,CHEMBL873354,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6617.0,,,50588.0,3749.0,N,,Half life was determined,,BAO_0000218,A,,CHEMBL618493,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6618.0,,,50588.0,2517.0,N,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,A,In vivo,CHEMBL618494,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Heart,6619.0,,,50588.0,2517.0,N,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,A,In vivo,CHEMBL618495,1.0,948.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Kidney,6620.0,,,50588.0,2517.0,N,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,A,In vivo,CHEMBL618496,1.0,2113.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Liver,6621.0,,,50588.0,2517.0,N,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,A,In vivo,CHEMBL618497,1.0,2107.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Lung,6622.0,,,50588.0,2517.0,N,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,A,In vivo,CHEMBL618498,1.0,2048.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Spleen,6623.0,,,50588.0,2517.0,N,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,A,In vivo,CHEMBL618499,1.0,2106.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6624.0,,,50588.0,3639.0,N,,LogP in dog,,BAO_0000218,A,,CHEMBL876736,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6625.0,,,50588.0,6227.0,N,,Partition coefficient (logP),,BAO_0000218,A,,CHEMBL618500,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6626.0,,,50588.0,6227.0,N,,Partition coefficient in dog,,BAO_0000218,A,,CHEMBL857831,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6627.0,,,50588.0,17764.0,N,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,A,In vivo,CHEMBL618501,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6628.0,,,50588.0,4809.0,N,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,BAO_0000218,A,In vivo,CHEMBL618502,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6629.0,,,50588.0,5600.0,N,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,BAO_0000218,A,,CHEMBL618503,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6630.0,,,50588.0,14294.0,N,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,BAO_0000218,A,,CHEMBL618504,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6631.0,,,50588.0,14294.0,N,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,BAO_0000218,A,,CHEMBL618505,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6632.0,,,50588.0,14294.0,N,,Metabolism of compound in dog S9 microsomes; Trace,,BAO_0000218,A,,CHEMBL618506,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Liver,6633.0,,,50588.0,6251.0,N,,In vitro metabolic potential in dog liver microsomes,,BAO_0000218,A,,CHEMBL618507,1.0,2107.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6634.0,,,50588.0,3748.0,N,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,BAO_0000218,A,In vivo,CHEMBL876737,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6635.0,,,50588.0,2713.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL618508,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6636.0,,,50588.0,6512.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL618509,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6637.0,,,50588.0,6679.0,N,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,A,In vivo,CHEMBL618510,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6638.0,,,50588.0,3749.0,N,,The compound was tested for bioavailability in dogs,,BAO_0000218,A,In vivo,CHEMBL618511,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6639.0,,,50588.0,3749.0,N,,The compound was tested for oral bioavailability in dogs,,BAO_0000218,A,In vivo,CHEMBL618512,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6640.0,,,50588.0,6742.0,N,,Oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL618513,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6641.0,,,50588.0,6227.0,N,,Compound was tested for percent protein binding (PB) in dog,,BAO_0000218,A,,CHEMBL618514,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6642.0,,,50588.0,6874.0,N,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,BAO_0000218,A,,CHEMBL620052,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6643.0,,,50588.0,2877.0,N,,Compound was evaluated for plasma clearance.,,BAO_0000218,A,In vivo,CHEMBL620053,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6644.0,,,50588.0,12500.0,N,,The compound was tested for plasma clearance in dog,,BAO_0000218,A,In vivo,CHEMBL620054,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6645.0,,,50588.0,12500.0,N,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,BAO_0000218,A,In vivo,CHEMBL620055,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6646.0,,,50588.0,4709.0,N,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,BAO_0000218,A,,CHEMBL620056,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Liver,6647.0,,,50588.0,5542.0,N,,In vitro relative rate of metabolism was determined in dog liver microsomes,,BAO_0000218,A,,CHEMBL620057,1.0,2107.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6648.0,,,50588.0,17594.0,N,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,BAO_0000218,A,In vivo,CHEMBL618939,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6649.0,,,50588.0,2652.0,N,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,BAO_0000218,A,In vivo,CHEMBL618940,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6650.0,,,50588.0,17764.0,N,,Half life after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,A,In vivo,CHEMBL618941,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Lung,6651.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,BAO_0000218,A,,CHEMBL624473,1.0,2048.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Lung,6652.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,BAO_0000218,A,,CHEMBL624474,1.0,2048.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Lung,6653.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,BAO_0000218,A,,CHEMBL624475,1.0,2048.0,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6654.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,BAO_0000218,A,,CHEMBL624476,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6655.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,BAO_0000218,A,,CHEMBL623478,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6656.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,BAO_0000218,A,,CHEMBL623479,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6657.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,BAO_0000218,A,,CHEMBL623480,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,,6658.0,,,50594.0,6599.0,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,BAO_0000218,A,,CHEMBL623481,1.0,,,10090.0,CCRF S-180,1.0,42.0,Mus musculus
Intermediate,Brain,6659.0,,,50594.0,17641.0,N,,C2 in brain of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,,CHEMBL623482,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,6660.0,,,50594.0,17641.0,N,,C2 in kidney of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,,CHEMBL623483,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,6661.0,,,50594.0,17641.0,N,,C2 in liver of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,,CHEMBL623484,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,6662.0,,,50594.0,17641.0,N,,C2 in lungs of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,,CHEMBL623485,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,6663.0,,,50594.0,17641.0,N,,C2 in spleen of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,,CHEMBL623486,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,,6664.0,,,50594.0,17852.0,N,,Plasma clearance in mouse,,BAO_0000218,A,In vivo,CHEMBL623487,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6665.0,,,50594.0,17764.0,N,,Clearance of compound after intravenous administration in mice at 24 uM/kg,,BAO_0000218,A,In vivo,CHEMBL623488,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6666.0,,,50594.0,17837.0,N,,Clearance from mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623489,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6667.0,,,50594.0,2675.0,N,,Clearance was evaluated in mice after intravenous administration,,BAO_0000218,A,In vivo,CHEMBL875157,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6668.0,,,50594.0,2675.0,N,,Clearance was evaluated in mice after oral administration,,BAO_0000218,A,In vivo,CHEMBL623490,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6669.0,,,50594.0,4239.0,N,,Pharmacokinetic property (Plasma clearance) was measured in mouse,,BAO_0000218,A,In vivo,CHEMBL623491,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6670.0,,,50594.0,17753.0,N,,Plasma clearance of compound was determined at 40 mg/Kg,,BAO_0000218,A,In vivo,CHEMBL623492,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6671.0,,,50594.0,17753.0,N,,Plasma clearance of at 24 mg/Kg,,BAO_0000218,A,In vivo,CHEMBL623493,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6672.0,,,50594.0,17753.0,N,,Plasma clearance at 24 mg/Kg,,BAO_0000218,A,In vivo,CHEMBL623494,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6673.0,,,50594.0,17753.0,N,,Plasma clearance at 5 mg/Kg,,BAO_0000218,A,In vivo,CHEMBL623495,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6674.0,,,50594.0,5727.0,N,,Plasma clearance in mice,,BAO_0000218,A,In vivo,CHEMBL623496,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6675.0,,,50594.0,2862.0,N,,Plasma clearance value upon iv administration in mouse,,BAO_0000218,A,In vivo,CHEMBL623497,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6676.0,,,50594.0,5980.0,N,,Total plasma clearance in mice,,BAO_0000218,A,In vivo,CHEMBL623498,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,,6677.0,,,50594.0,17592.0,N,,Clearance in mouse,,BAO_0000218,A,In vivo,CHEMBL623499,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6678.0,,,50594.0,17718.0,N,,Clearance value was determined,,BAO_0000218,A,In vivo,CHEMBL623500,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6679.0,,,50594.0,16597.0,N,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,A,In vivo,CHEMBL623501,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6680.0,,,22229.0,17384.0,U,,Calculated partition coefficient (clogP),,BAO_0000100,P,,CHEMBL875158,1.0,,,,,0.0,,
Intermediate,,6681.0,,,50594.0,6062.0,N,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623502,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6682.0,,,50594.0,17734.0,N,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,A,In vivo,CHEMBL623503,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6683.0,,,50594.0,6348.0,N,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,A,In vivo,CHEMBL623504,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6684.0,,,50594.0,5969.0,N,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623505,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6685.0,,,50594.0,5969.0,N,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623506,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6686.0,,,50594.0,5969.0,N,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,BAO_0000218,A,In vivo,CHEMBL623507,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6687.0,,,50594.0,16597.0,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,BAO_0000218,A,In vivo,CHEMBL623508,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6688.0,,,50594.0,5781.0,N,,Cmax after oral administration at 30 mg/kg in ICR mouse,,BAO_0000218,A,In vivo,CHEMBL623509,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6689.0,,,50594.0,17764.0,N,,Cmax after peroral administration in mice at 2.4 uM/kg,,BAO_0000218,A,In vivo,CHEMBL875159,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Brain,6690.0,,,50594.0,17641.0,N,,Cmax in brain of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623510,1.0,955.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,6691.0,,,50594.0,17641.0,N,,Cmax in kidney of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623511,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,6692.0,,,50594.0,17641.0,N,,Cmax in liver of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623512,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,6693.0,,,50594.0,17641.0,N,,Cmax in lungs of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623513,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,,6694.0,,,50594.0,17764.0,N,,Cmax in mice at 18 uM/kg i.p. administration,,BAO_0000218,F,In vivo,CHEMBL623514,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6695.0,,,50594.0,17764.0,N,,Cmax in mice at 23 uM/kg i.v. administration,,BAO_0000218,F,In vivo,CHEMBL622609,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6696.0,,,50594.0,17764.0,N,,Cmax in mice at 24 uM/kg i.p. administration,,BAO_0000218,F,In vivo,CHEMBL622610,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6697.0,,,50594.0,17764.0,N,,Cmax in mice at 25 uM/kg i.p. administration,,BAO_0000218,F,In vivo,CHEMBL621823,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6698.0,,,50594.0,17764.0,N,,Cmax in mice at 26 uM/kg i.p. administration,,BAO_0000218,F,In vivo,CHEMBL621824,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,6699.0,,,50594.0,17641.0,N,,Cmax in spleen of mice at the oral dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621825,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,,6700.0,,,50594.0,16597.0,N,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,A,In vivo,CHEMBL621826,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6701.0,,,50594.0,16597.0,N,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,A,In vivo,CHEMBL621827,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6702.0,,,50594.0,5727.0,N,,Cmax value was determined,,BAO_0000218,A,In vivo,CHEMBL621828,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6703.0,,,50594.0,5951.0,N,,Cmax value in IRC mice,,BAO_0000218,A,In vivo,CHEMBL621829,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6704.0,,,50594.0,5506.0,N,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,BAO_0000218,A,In vivo,CHEMBL621830,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6705.0,,,50594.0,5506.0,N,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,BAO_0000218,A,In vivo,CHEMBL621831,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6706.0,,,50594.0,14239.0,N,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,BAO_0000218,A,In vivo,CHEMBL621832,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6707.0,,,50594.0,4890.0,N,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,BAO_0000218,A,In vivo,CHEMBL624579,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,,6708.0,,,50594.0,429.0,N,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,BAO_0000218,A,In vivo,CHEMBL624580,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6709.0,,,50535.0,10986.0,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,BAO_0000218,F,,CHEMBL624581,1.0,,,6277.0,,1.0,,Acanthocheilonema viteae
Intermediate,,6710.0,,,50535.0,10986.0,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,BAO_0000218,F,,CHEMBL624582,1.0,,,6277.0,,1.0,,Acanthocheilonema viteae
Intermediate,,6711.0,,,50535.0,10986.0,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,BAO_0000218,F,,CHEMBL624583,1.0,,,6277.0,,1.0,,Acanthocheilonema viteae
Intermediate,,6712.0,,,80018.0,13227.0,N,,Inhibitory activity against human tumor cell line A0375 melanoma.,,BAO_0000219,F,,CHEMBL624584,1.0,,,9606.0,A-375,1.0,455.0,Homo sapiens
Expert,,6713.0,,,12512.0,4481.0,D,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,Brain membranes,BAO_0000249,B,,CHEMBL624585,1.0,,,10116.0,,9.0,,Rattus norvegicus
Expert,,6714.0,,,114.0,16931.0,D,,Forskolin-induced cAMP production at human A1 adenosine receptor,,BAO_0000019,F,,CHEMBL875165,1.0,,,9606.0,,9.0,,Homo sapiens
Autocuration,,6715.0,,,114.0,3850.0,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,BAO_0000219,F,,CHEMBL619490,1.0,,,,CHO,8.0,449.0,
Autocuration,,6716.0,,,114.0,3850.0,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,BAO_0000219,F,,CHEMBL619491,1.0,,,,CHO,8.0,449.0,
Expert,,6717.0,,,114.0,3850.0,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,BAO_0000219,F,,CHEMBL619492,1.0,,,,CHO,8.0,449.0,
Expert,,6718.0,,,114.0,3850.0,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,BAO_0000219,F,,CHEMBL619493,1.0,,,,CHO,8.0,449.0,
Autocuration,,6719.0,,,114.0,3850.0,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,BAO_0000219,F,,CHEMBL619494,1.0,,,,CHO,8.0,449.0,
Autocuration,,6720.0,,,114.0,3850.0,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,BAO_0000219,F,,CHEMBL619495,1.0,,,,CHO,8.0,449.0,
Autocuration,,6721.0,,,114.0,3850.0,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,BAO_0000219,F,,CHEMBL619496,1.0,,,,CHO,8.0,449.0,
Expert,,6722.0,,,114.0,3850.0,D,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,BAO_0000219,F,,CHEMBL619497,1.0,,,9606.0,CHO,9.0,449.0,Homo sapiens
Autocuration,,6723.0,,,114.0,3850.0,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,BAO_0000219,F,,CHEMBL619498,1.0,,,,CHO,8.0,449.0,
Autocuration,,6724.0,,,114.0,3850.0,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,BAO_0000219,F,,CHEMBL619499,1.0,,,,CHO,8.0,449.0,
Expert,,6725.0,,,114.0,3850.0,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,BAO_0000219,F,,CHEMBL619500,1.0,,,,CHO,8.0,449.0,
Autocuration,,6726.0,,,114.0,3850.0,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,BAO_0000219,F,,CHEMBL619501,1.0,,,,CHO,8.0,449.0,
Expert,,6727.0,,,114.0,3850.0,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,BAO_0000219,F,,CHEMBL619502,1.0,,,,CHO,8.0,449.0,
Autocuration,,6728.0,,,114.0,3850.0,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,BAO_0000219,F,,CHEMBL619503,1.0,,,,CHO,8.0,449.0,
Autocuration,,6729.0,,,114.0,3850.0,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,BAO_0000219,F,,CHEMBL619504,1.0,,,,CHO,8.0,449.0,
Autocuration,,6730.0,,,114.0,3850.0,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,BAO_0000219,F,,CHEMBL621298,1.0,,,,CHO,8.0,449.0,
Expert,,6731.0,,,114.0,3850.0,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,BAO_0000219,F,,CHEMBL621299,1.0,,,,CHO,8.0,449.0,
Autocuration,,6732.0,,,114.0,3850.0,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,BAO_0000219,F,,CHEMBL621300,1.0,,,,CHO,8.0,449.0,
Autocuration,,6733.0,,,114.0,3850.0,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,BAO_0000219,F,,CHEMBL621301,1.0,,,,CHO,8.0,449.0,
Expert,,6734.0,,,114.0,3850.0,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,BAO_0000219,F,,CHEMBL621302,1.0,,,,CHO,8.0,449.0,
Intermediate,,6735.0,,,80013.0,12680.0,N,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,BAO_0000219,F,,CHEMBL621303,1.0,,,9986.0,A10,1.0,164.0,Oryctolagus cuniculus
Autocuration,,6736.0,,,22226.0,1313.0,U,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,BAO_0000219,F,,CHEMBL621304,1.0,,,10116.0,A10,0.0,164.0,Rattus norvegicus
Autocuration,,6737.0,,,22226.0,1313.0,U,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,BAO_0000219,F,,CHEMBL621305,1.0,,,10116.0,A10,0.0,164.0,Rattus norvegicus
Intermediate,,6738.0,,,80013.0,17567.0,N,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,BAO_0000219,F,,CHEMBL621306,1.0,,,10116.0,A10,1.0,164.0,Rattus norvegicus
Intermediate,,6739.0,,,80013.0,17567.0,N,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,BAO_0000219,F,,CHEMBL618444,1.0,,,10116.0,A10,1.0,164.0,Rattus norvegicus
Intermediate,,6740.0,,,80013.0,11819.0,N,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,BAO_0000219,F,,CHEMBL618445,1.0,,,10116.0,A10,1.0,164.0,Rattus norvegicus
Intermediate,,6741.0,,,80089.0,13436.0,N,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,BAO_0000219,F,,CHEMBL618446,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6742.0,,,80089.0,12687.0,N,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,BAO_0000219,F,,CHEMBL618447,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6743.0,,,80089.0,12651.0,N,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,BAO_0000219,F,,CHEMBL618448,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6744.0,,,80089.0,13300.0,N,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,BAO_0000219,F,,CHEMBL618449,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6745.0,,,80089.0,15296.0,N,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,BAO_0000219,F,,CHEMBL618637,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6746.0,,,80089.0,15328.0,N,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,BAO_0000219,F,,CHEMBL618638,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6747.0,,,80089.0,13302.0,N,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,BAO_0000219,F,,CHEMBL618639,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Expert,,6748.0,,,80089.0,14367.0,N,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,BAO_0000219,F,,CHEMBL618640,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Expert,,6749.0,,,80089.0,17002.0,N,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,BAO_0000219,F,,CHEMBL618641,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6750.0,,,80089.0,13436.0,N,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,BAO_0000219,F,,CHEMBL618642,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6751.0,,,80089.0,13435.0,N,,Inhibitory activity against aerobic growth of AA8 cells.,,BAO_0000219,F,,CHEMBL618643,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6752.0,,,80089.0,10503.0,N,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,BAO_0000219,A,,CHEMBL884013,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Expert,,6753.0,,,80089.0,10503.0,N,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,BAO_0000219,F,,CHEMBL622723,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6754.0,,,80089.0,10503.0,N,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,BAO_0000219,F,,CHEMBL622724,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Expert,,6755.0,,,80089.0,15090.0,N,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,BAO_0000219,F,,CHEMBL622725,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Expert,,6756.0,,,80089.0,10368.0,N,,Cytotoxicity against AA8 cell line,,BAO_0000219,F,,CHEMBL622726,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6757.0,,,80089.0,12651.0,N,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,BAO_0000219,F,,CHEMBL622727,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6758.0,,,80089.0,12687.0,N,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,BAO_0000219,A,,CHEMBL622728,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6759.0,,,80089.0,12687.0,N,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,BAO_0000219,F,,CHEMBL622729,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6760.0,,,80089.0,12687.0,N,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,BAO_0000219,A,,CHEMBL622730,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6761.0,,,80089.0,1890.0,N,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,BAO_0000219,F,,CHEMBL622731,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6762.0,,,80089.0,10747.0,N,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,BAO_0000219,F,,CHEMBL622732,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Intermediate,,6763.0,,,80089.0,10747.0,N,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,BAO_0000219,F,,CHEMBL622733,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Autocuration,,6764.0,,,22224.0,11616.0,U,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,BAO_0000218,F,,CHEMBL622734,1.0,,,10029.0,,0.0,,Cricetulus griseus
Expert,,6765.0,,,80089.0,11616.0,N,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,BAO_0000219,F,,CHEMBL622735,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Autocuration,,6766.0,,,22224.0,3471.0,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,BAO_0000219,F,,CHEMBL618746,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6767.0,,,22224.0,3471.0,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,BAO_0000219,F,,CHEMBL618747,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6768.0,,,22224.0,3471.0,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,BAO_0000219,F,,CHEMBL620540,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6769.0,,,22224.0,3471.0,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,BAO_0000219,F,,CHEMBL620541,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6770.0,,,22224.0,3471.0,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,BAO_0000219,F,,CHEMBL620542,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6771.0,,,22224.0,3471.0,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,BAO_0000219,F,,CHEMBL620543,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6772.0,,,22224.0,3471.0,U,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,BAO_0000219,F,,CHEMBL618832,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Expert,,6773.0,,,80089.0,11616.0,N,,Concentration required to reduce AA8 cell survival by 10%,,BAO_0000219,F,,CHEMBL618833,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Autocuration,,6774.0,,,22224.0,2656.0,U,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,BAO_0000219,F,,CHEMBL618834,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6775.0,,,22224.0,10518.0,U,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,BAO_0000219,F,,CHEMBL618835,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6776.0,,,22224.0,10518.0,U,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,BAO_0000219,F,,CHEMBL618836,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6777.0,,,22224.0,10518.0,U,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,BAO_0000219,F,,CHEMBL618837,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6778.0,,,22224.0,10518.0,U,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,BAO_0000219,F,,CHEMBL618838,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6779.0,,,22224.0,16156.0,U,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,BAO_0000219,F,,CHEMBL618839,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6780.0,,,22224.0,2656.0,U,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,BAO_0000219,F,,CHEMBL618840,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6781.0,,,22224.0,11005.0,U,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,BAO_0000019,F,,CHEMBL618841,1.0,,,10029.0,,0.0,,Cricetulus griseus
Autocuration,,6782.0,,,22224.0,11942.0,U,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,BAO_0000219,F,,CHEMBL618842,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6783.0,,,22224.0,2128.0,U,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,BAO_0000219,F,,CHEMBL618843,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Intermediate,,6784.0,,,50588.0,16907.0,N,,Half life period after 15 mg/kg iv dose in Dogs,,BAO_0000218,A,In vivo,CHEMBL618844,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6785.0,,,50588.0,16907.0,N,,Half life period after 30 mg/kg po dose in Dogs,,BAO_0000218,A,In vivo,CHEMBL618845,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6786.0,,,50588.0,9579.0,N,,Half life was measured after oral 2b administration (tested in 6 dogs),,BAO_0000218,A,In vivo,CHEMBL618846,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6787.0,,,50588.0,9579.0,N,,Half life was measured in dog after oral 17b administration,,BAO_0000218,A,In vivo,CHEMBL618847,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6788.0,,,50588.0,9579.0,N,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,BAO_0000218,A,In vivo,CHEMBL618848,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6789.0,,,50588.0,9579.0,N,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,BAO_0000218,A,In vivo,CHEMBL618849,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6790.0,,,50588.0,16907.0,N,,Tmax value after 15 mg/kg iv dose in Dogs,,BAO_0000218,A,In vivo,CHEMBL618850,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6791.0,,,50588.0,16907.0,N,,Tmax value after 30 mg/kg po dose in Dogs,,BAO_0000218,A,In vivo,CHEMBL618851,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6792.0,,,50588.0,3184.0,N,,Compound was evaluated for its half life when administered intravenously in dog,,BAO_0000218,A,In vivo,CHEMBL873815,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6793.0,,,50588.0,5017.0,N,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,BAO_0000218,A,In vivo,CHEMBL618852,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6794.0,,,50588.0,6821.0,N,,Elimination Half-life of compound was determined in dog,,BAO_0000218,A,,CHEMBL618853,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6795.0,,,50588.0,17839.0,N,,Half life of compound in dog following oral administration,,BAO_0000218,A,In vivo,CHEMBL618854,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6796.0,,,50588.0,17267.0,N,,Half life of compound was determined in dog,,BAO_0000218,A,,CHEMBL618855,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Blood,6797.0,,,50588.0,4727.0,N,,Half life of compound was determined in dog blood,,BAO_0000218,A,,CHEMBL618856,1.0,178.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6798.0,,,50588.0,5238.0,N,,Half life after oral and iv dosing in dogs,,BAO_0000218,A,In vivo,CHEMBL875827,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6799.0,,,50588.0,4942.0,N,,Half life in dogs in hours,,BAO_0000218,A,,CHEMBL618857,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6800.0,,,50588.0,6505.0,N,,Half life on i.v. administration of 2 mg/kg was measured in dog,,BAO_0000218,A,In vivo,CHEMBL618858,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6801.0,,,50588.0,5130.0,N,,t1/2 in dog after oral dose (1 mg/kg),,BAO_0000218,A,In vivo,CHEMBL618859,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6802.0,,,50588.0,1475.0,N,,Half life was evaluated in dog,,BAO_0000218,A,,CHEMBL618860,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6803.0,,,50588.0,17804.0,N,,Half life period of compound was determined after intravenous administration at 2 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618861,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6804.0,,,50588.0,17804.0,N,,Half life period of compound was determined after peroral administration at 2 mg/kg,,BAO_0000218,A,In vivo,CHEMBL622539,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6805.0,,,50588.0,6084.0,N,,Half life period (10 mg/kg) was determined in dog,,BAO_0000218,A,In vivo,CHEMBL622540,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6806.0,,,50588.0,6084.0,N,,Half life period (10 mg/kg) was determined in dog,,BAO_0000218,A,In vivo,CHEMBL873803,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6807.0,,,50588.0,5542.0,N,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,BAO_0000218,A,In vivo,CHEMBL873804,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6808.0,,,50588.0,5542.0,N,,Half life period by po administration in dog at a dose of 0.3 mg/kg,,BAO_0000218,A,In vivo,CHEMBL624311,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6809.0,,,50588.0,6084.0,N,,Half life period in dog,,BAO_0000218,A,,CHEMBL624312,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6810.0,,,50588.0,6241.0,N,,Half life period in dogs after oral administration at 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL624313,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6811.0,,,50588.0,1916.0,N,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,A,In vivo,CHEMBL624314,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6812.0,,,50588.0,6621.0,N,,Half-life of compound was determined in dogs,,BAO_0000218,A,,CHEMBL624315,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6813.0,,,50588.0,1696.0,N,,Half-life in dog plasma,,BAO_0000218,A,,CHEMBL624316,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6814.0,,,50588.0,17800.0,N,,Half-life in mongrel dogs was determined,,BAO_0000218,A,,CHEMBL624317,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6815.0,,,50588.0,17657.0,N,,Half-life in dog upon oral administration,,BAO_0000218,A,In vivo,CHEMBL624318,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6816.0,,,50588.0,17657.0,N,,Half-life in dog upon oral administration; Unable to calculate,,BAO_0000218,A,In vivo,CHEMBL624319,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6817.0,,,50588.0,4239.0,N,,Half-life was measured in dog,,BAO_0000218,A,,CHEMBL624496,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6818.0,,,50588.0,5985.0,N,,Half-life was measured in dog,,BAO_0000218,A,,CHEMBL624497,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6819.0,,,50588.0,9932.0,N,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,BAO_0000218,A,,CHEMBL624498,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6820.0,,,50588.0,5199.0,N,,Oral half life was determined,,BAO_0000218,A,In vivo,CHEMBL624499,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6821.0,,,50588.0,5199.0,N,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,BAO_0000218,A,In vivo,CHEMBL624500,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6822.0,,,50588.0,1475.0,N,,Plasma half life was evaluated,,BAO_0000218,A,,CHEMBL624501,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6823.0,,,50588.0,1475.0,N,,Plasma half life was evaluated in Dog,,BAO_0000218,A,,CHEMBL623666,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6824.0,,,50588.0,1475.0,N,,Plasma half life was evaluated in dog,,BAO_0000218,A,,CHEMBL623667,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6825.0,,,50588.0,6316.0,N,,T1/2 (Half-life) was after oral administration at 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623668,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6826.0,,,50588.0,4883.0,N,,Tested for the half life value in dog,,BAO_0000218,A,,CHEMBL623669,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6827.0,,,50588.0,4727.0,N,,Maximum time at the dose of 2 mg/kg in dog,,BAO_0000218,A,In vivo,CHEMBL623670,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6828.0,,,50588.0,1916.0,N,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,A,In vivo,CHEMBL623671,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Blood,6829.0,,,50588.0,1337.0,N,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,A,In vivo,CHEMBL875945,1.0,178.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Blood,6830.0,,,50588.0,1337.0,N,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,A,In vivo,CHEMBL623672,1.0,178.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6831.0,,,50588.0,6265.0,N,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623673,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6832.0,,,50588.0,4809.0,N,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,BAO_0000218,A,In vivo,CHEMBL623674,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6833.0,,,50588.0,5983.0,N,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,BAO_0000218,A,In vivo,CHEMBL623675,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6834.0,,,50588.0,5313.0,N,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,BAO_0000218,A,,CHEMBL872526,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6835.0,,,50588.0,5313.0,N,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,BAO_0000218,A,In vivo,CHEMBL623676,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6836.0,,,50588.0,17650.0,N,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,A,In vivo,CHEMBL623677,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6837.0,,,50588.0,5199.0,N,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,BAO_0000218,A,In vivo,CHEMBL623678,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6838.0,,,50588.0,933.0,N,,Time taken for maximum plasma concentration in dog,,BAO_0000218,A,,CHEMBL623679,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6839.0,,,50588.0,16367.0,N,,Time to reach Cmax after oral administration to dogs,,BAO_0000218,A,In vivo,CHEMBL623680,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,6840.0,,,50588.0,6348.0,N,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,A,In vivo,CHEMBL623681,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6841.0,,,50588.0,6316.0,N,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623682,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6842.0,,,50588.0,6215.0,N,,Tmax after peroral administration (1 mg/kg) was determined in dog,,BAO_0000218,A,In vivo,CHEMBL623683,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Expert,,6843.0,,,50588.0,3598.0,N,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623684,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6844.0,,,50588.0,4527.0,N,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,A,In vivo,CHEMBL622745,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6845.0,,,50588.0,17764.0,N,,Tmax after peroral administration in dogs at 2.4 uM/kg,,BAO_0000218,A,In vivo,CHEMBL622746,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6846.0,,,50594.0,5969.0,N,,In vivo Cmax in mice at dose of 100 mg/kg,,BAO_0000218,A,In vivo,CHEMBL622747,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6847.0,,,50594.0,5969.0,N,,In vivo Cmax in mice at dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL622748,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6848.0,,,50594.0,4573.0,N,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,BAO_0000218,A,In vivo,CHEMBL622749,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6849.0,,,50594.0,3277.0,N,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,BAO_0000218,A,In vivo,CHEMBL622750,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6850.0,,,50594.0,17734.0,N,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,A,In vivo,CHEMBL623411,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6851.0,,,50594.0,3132.0,N,,Maximum concentration obtained in mouse plasma was determined,,BAO_0000218,A,In vivo,CHEMBL875946,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6852.0,,,50594.0,3132.0,N,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623412,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6853.0,,,50594.0,6348.0,N,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,A,In vivo,CHEMBL623413,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6854.0,,,50594.0,17729.0,N,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623414,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6855.0,,,50594.0,17729.0,N,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623415,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6856.0,,,50594.0,17729.0,N,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,BAO_0000218,A,In vivo,CHEMBL623416,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6857.0,,,50594.0,17728.0,N,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,BAO_0000218,A,In vivo,CHEMBL623417,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6858.0,,,50594.0,17728.0,N,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,BAO_0000218,A,In vivo,CHEMBL623418,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6859.0,,,50594.0,17728.0,N,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,BAO_0000218,A,In vivo,CHEMBL623419,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,,6860.0,,,50594.0,4066.0,N,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,A,In vivo,CHEMBL622816,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6861.0,,,50594.0,6178.0,N,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,BAO_0000218,A,In vivo,CHEMBL623313,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6862.0,,,50594.0,6178.0,N,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,BAO_0000218,A,In vivo,CHEMBL623314,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6863.0,,,50594.0,3760.0,N,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,BAO_0000218,A,In vivo,CHEMBL876788,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6864.0,,,50594.0,3760.0,N,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,BAO_0000218,A,In vivo,CHEMBL623315,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6865.0,,,50594.0,3760.0,N,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,BAO_0000218,A,In vivo,CHEMBL623316,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6866.0,,,50594.0,3760.0,N,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,BAO_0000218,A,In vivo,CHEMBL623317,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6868.0,,,50594.0,5961.0,N,,Cmax in male mice after 2 mg/kg oral dose,,BAO_0000218,A,In vivo,CHEMBL623319,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6869.0,,,50594.0,6137.0,N,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,BAO_0000218,A,In vivo,CHEMBL623320,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6870.0,,,50594.0,3802.0,N,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,BAO_0000218,A,In vivo,CHEMBL623321,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6871.0,,,50594.0,3535.0,N,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,BAO_0000218,A,,CHEMBL623322,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6872.0,,,50594.0,3535.0,N,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,BAO_0000218,A,,CHEMBL623323,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6873.0,,,50594.0,3535.0,N,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,BAO_0000218,A,,CHEMBL623324,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6874.0,,,50594.0,3535.0,N,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,BAO_0000218,A,,CHEMBL623325,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6875.0,,,50594.0,3535.0,N,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,BAO_0000218,A,,CHEMBL623326,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,6876.0,,,50594.0,3535.0,N,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,BAO_0000218,A,,CHEMBL623327,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6877.0,,,50594.0,2862.0,N,,Maximum concentration in plasma upon oral administration in mouse,,BAO_0000218,A,,CHEMBL623328,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6878.0,,,50594.0,2675.0,N,,Maximum plasma concentration was evaluated in mice after oral administration,,BAO_0000218,A,,CHEMBL623329,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,6879.0,,,50594.0,2675.0,N,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,BAO_0000218,A,In vivo,CHEMBL623330,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,,6880.0,,,50594.0,5399.0,N,,Dose at which the compound induced fecal excretion in mice,,BAO_0000218,A,,CHEMBL876789,1.0,,,10090.0,,1.0,,Mus musculus
Expert,,6893.0,,,80013.0,11819.0,N,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,BAO_0000219,F,,CHEMBL623333,1.0,,,10116.0,A10,1.0,164.0,Rattus norvegicus
Expert,,6894.0,,,80013.0,11819.0,N,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,BAO_0000219,F,,CHEMBL623334,1.0,,,10116.0,A10,1.0,164.0,Rattus norvegicus
Expert,,6895.0,,,80013.0,11819.0,N,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,BAO_0000219,F,,CHEMBL627536,1.0,,,10116.0,A10,1.0,164.0,Rattus norvegicus
Expert,,6896.0,,,80013.0,11819.0,N,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,BAO_0000219,F,,CHEMBL627537,1.0,,,10116.0,A10,1.0,164.0,Rattus norvegicus
Intermediate,,6897.0,,,80013.0,16361.0,N,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,BAO_0000219,F,,CHEMBL627538,1.0,,,10116.0,A10,1.0,164.0,Rattus norvegicus
Intermediate,,6898.0,,,80655.0,2288.0,N,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,BAO_0000219,F,,CHEMBL884106,1.0,,,9606.0,A121,1.0,393.0,Homo sapiens
Intermediate,,6899.0,,,80655.0,10404.0,N,,Anticancer activity against human ovarian carcinoma A121 cells,,BAO_0000219,F,,CHEMBL625294,1.0,,,9606.0,A121,1.0,393.0,Homo sapiens
Intermediate,,6900.0,,,80655.0,14790.0,N,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,BAO_0000219,F,,CHEMBL625295,1.0,,,9606.0,A121,1.0,393.0,Homo sapiens
Intermediate,,6901.0,,,80655.0,14790.0,N,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,BAO_0000219,F,,CHEMBL625296,1.0,,,9606.0,A121,1.0,393.0,Homo sapiens
Expert,,6902.0,,,80655.0,14253.0,N,,Growth inhibition of human ovarian carcinoma (A121) cell line,,BAO_0000219,F,,CHEMBL625297,1.0,,,9606.0,A121,1.0,393.0,Homo sapiens
Expert,,6903.0,,,80655.0,13617.0,N,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,BAO_0000219,F,,CHEMBL625298,1.0,,,9606.0,A121,1.0,393.0,Homo sapiens
Intermediate,,6904.0,,,80655.0,1003.0,N,,Cytotoxicity against human A121 ovarian cells,,BAO_0000219,F,,CHEMBL625960,1.0,,,9606.0,A121,1.0,393.0,Homo sapiens
Intermediate,,6905.0,,,80655.0,830.0,N,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,BAO_0000219,F,,CHEMBL625961,1.0,,,9606.0,A121,1.0,393.0,Homo sapiens
Intermediate,,6906.0,,,80655.0,12307.0,N,,In vitro cytotoxicity against human ovarian carcinoma A21,,BAO_0000219,F,,CHEMBL625962,1.0,,,9606.0,A121,1.0,393.0,Homo sapiens
Intermediate,,6907.0,,,80655.0,14254.0,N,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,BAO_0000219,F,,CHEMBL624717,1.0,,,9606.0,A121,1.0,393.0,Homo sapiens
Intermediate,,6908.0,,,80655.0,13370.0,N,,Inhibitory activity of compound against human A121 ovarian cell line.,,BAO_0000219,F,,CHEMBL624718,1.0,,,9606.0,A121,1.0,393.0,Homo sapiens
Intermediate,,6909.0,,,80655.0,14790.0,N,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,BAO_0000219,F,,CHEMBL624719,1.0,,,9606.0,A121,1.0,393.0,Homo sapiens
Intermediate,,6910.0,,,80655.0,3614.0,N,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,BAO_0000219,F,,CHEMBL624720,1.0,,,9606.0,A121,1.0,393.0,Homo sapiens
Intermediate,,6911.0,,,80012.0,2664.0,N,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,BAO_0000219,F,,CHEMBL624721,1.0,,,9606.0,A 172,1.0,622.0,Homo sapiens
Expert,,6912.0,,,80012.0,2037.0,N,,In vitro cytotoxicity against A172 human tumor cell lines.,,BAO_0000219,F,,CHEMBL624722,1.0,,,9606.0,A 172,1.0,622.0,Homo sapiens
Intermediate,,6913.0,,,80012.0,14539.0,N,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,BAO_0000219,F,,CHEMBL877597,1.0,,,9606.0,A 172,1.0,622.0,Homo sapiens
Intermediate,,6914.0,,,80012.0,2836.0,N,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,BAO_0000219,F,,CHEMBL624723,1.0,,,9606.0,A 172,1.0,622.0,Homo sapiens
Intermediate,,6915.0,,,80012.0,10708.0,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,BAO_0000219,F,,CHEMBL624724,1.0,,,9606.0,A 172,1.0,622.0,Homo sapiens
Autocuration,,6916.0,,,104729.0,8975.0,H,,Association constant against A2 adenosine receptor,,BAO_0000224,B,,CHEMBL624725,1.0,,,9615.0,,4.0,,Canis lupus familiaris
Intermediate,,6917.0,,,80656.0,7645.0,N,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,BAO_0000219,F,,CHEMBL624726,1.0,,,,A2,1.0,1085.0,fish
Autocuration,,6918.0,,,104713.0,11377.0,D,,Ratio of Ki for adenosine A2 and A1 receptor binding,,BAO_0000224,B,,CHEMBL857535,1.0,,,10116.0,,5.0,,Rattus norvegicus
Expert,,6919.0,,,80014.0,13528.0,N,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,BAO_0000219,F,,CHEMBL624727,1.0,,,9606.0,A204,1.0,623.0,Homo sapiens
Expert,,6920.0,,,80014.0,10160.0,N,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,BAO_0000219,F,,CHEMBL624728,1.0,,,9606.0,A204,1.0,623.0,Homo sapiens
Intermediate,,6921.0,,,80015.0,15144.0,N,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,BAO_0000219,F,,CHEMBL624729,1.0,,,9606.0,A2058,1.0,404.0,Homo sapiens
Intermediate,,6922.0,,,80657.0,13160.0,N,,Growth inhibition against Human squamous cell line(A 253),,BAO_0000219,F,,CHEMBL624730,1.0,,,9606.0,A253 cell line,1.0,973.0,Homo sapiens
Intermediate,,6923.0,,,80657.0,12898.0,N,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,BAO_0000219,F,,CHEMBL624731,1.0,,,9606.0,A253 cell line,1.0,973.0,Homo sapiens
Intermediate,,6924.0,,,80657.0,13069.0,N,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,BAO_0000219,F,,CHEMBL624732,1.0,,,9606.0,A253 cell line,1.0,973.0,Homo sapiens
Intermediate,,6925.0,,,80657.0,15984.0,N,,Growth inhibition of A253 cell lines.,,BAO_0000219,F,,CHEMBL883245,1.0,,,9606.0,A253 cell line,1.0,973.0,Homo sapiens
Intermediate,,6926.0,,,80657.0,15564.0,N,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,BAO_0000219,F,,CHEMBL624733,1.0,,,9606.0,A253 cell line,1.0,973.0,Homo sapiens
Intermediate,,6927.0,,,80657.0,15564.0,N,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,BAO_0000219,F,,CHEMBL624734,1.0,,,9606.0,A253 cell line,1.0,973.0,Homo sapiens
Intermediate,,6928.0,,,80657.0,15564.0,N,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,BAO_0000219,F,,CHEMBL624735,1.0,,,9606.0,A253 cell line,1.0,973.0,Homo sapiens
Intermediate,,6929.0,,,81034.0,4720.0,N,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,BAO_0000219,F,,CHEMBL621780,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,6930.0,,,81034.0,16112.0,N,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,BAO_0000219,F,,CHEMBL877598,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,6931.0,,,81034.0,16597.0,N,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,BAO_0000219,F,,CHEMBL621781,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,6932.0,,,81034.0,16378.0,N,,Cytotoxicity against human cancer cell lines A2780 (ovarian),,BAO_0000219,F,,CHEMBL621782,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,6933.0,,,81034.0,16085.0,N,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,BAO_0000219,F,,CHEMBL621783,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,6934.0,,,81034.0,16317.0,N,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,BAO_0000219,F,,CHEMBL621784,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,6935.0,,,81034.0,15748.0,N,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,BAO_0000219,F,,CHEMBL621785,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,6936.0,,,81034.0,16597.0,N,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,BAO_0000219,F,,CHEMBL621968,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,6937.0,,,81034.0,16597.0,N,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,BAO_0000219,F,,CHEMBL621969,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,6938.0,,,81034.0,16597.0,N,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,BAO_0000219,F,,CHEMBL621970,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,6939.0,,,81034.0,15608.0,N,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,BAO_0000219,F,,CHEMBL621971,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,6940.0,,,81034.0,15608.0,N,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,BAO_0000219,F,,CHEMBL621972,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,6941.0,,,81034.0,15608.0,N,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,BAO_0000219,F,,CHEMBL884108,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Autocuration,,6942.0,,,22224.0,15296.0,U,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,BAO_0000019,F,,CHEMBL623826,1.0,,,10029.0,,0.0,,Cricetulus griseus
Autocuration,,6943.0,,,22224.0,10251.0,U,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,BAO_0000219,A,,CHEMBL623827,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6944.0,,,22224.0,10251.0,U,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,BAO_0000219,F,,CHEMBL623828,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6945.0,,,22224.0,10251.0,U,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,BAO_0000219,F,,CHEMBL623829,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6946.0,,,22224.0,10251.0,U,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,BAO_0000219,F,,CHEMBL623830,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6947.0,,,22224.0,11858.0,U,,Growth inhibition against CHO-derived cell line AA8,,BAO_0000019,F,,CHEMBL623831,1.0,,,10029.0,,0.0,,Cricetulus griseus
Autocuration,,6948.0,,,22224.0,11858.0,U,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,BAO_0000219,F,,CHEMBL623832,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Expert,,6949.0,,,80089.0,11616.0,N,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,BAO_0000219,F,,CHEMBL623833,1.0,,,36483.0,CHO-AA8,1.0,185.0,hampster
Expert,,6950.0,,,80089.0,11616.0,N,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,BAO_0000219,F,,CHEMBL623834,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Autocuration,,6951.0,,,22224.0,10518.0,U,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,BAO_0000219,F,,CHEMBL623835,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6952.0,,,22224.0,11396.0,U,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,BAO_0000219,F,,CHEMBL623836,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Autocuration,,6953.0,,,22224.0,10518.0,U,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,BAO_0000219,F,,CHEMBL623837,1.0,,,10029.0,CHO-AA8,0.0,185.0,Cricetulus griseus
Expert,,6954.0,,,80089.0,11616.0,N,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,BAO_0000219,F,,CHEMBL623838,1.0,,,10029.0,CHO-AA8,1.0,185.0,Cricetulus griseus
Autocuration,,6955.0,,,12675.0,14837.0,H,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,BAO_0000019,F,,CHEMBL623839,1.0,,,,,8.0,,
Autocuration,,6956.0,,,12675.0,14837.0,H,,Number of binding sites (n) of isolated serum protein AAG,,BAO_0000019,F,,CHEMBL623840,1.0,,,,,8.0,,
Intermediate,,6957.0,,,22222.0,16037.0,M,,Association constant for binding to AATT duplex,,BAO_0000225,B,,CHEMBL623841,1.0,,,,,3.0,,
Expert,,6958.0,,,100090.0,16597.0,N,,Inhibition of ABAE human fibroblast cell proliferation,,BAO_0000219,F,,CHEMBL623842,1.0,,,9606.0,ABAE,1.0,416.0,Homo sapiens
Intermediate,,6959.0,,,80668.0,8831.0,N,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,BAO_0000218,F,,CHEMBL623843,1.0,,,10090.0,AC755,1.0,1064.0,Mus musculus
Expert,,6960.0,,,102444.0,13419.0,D,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,BAO_0000218,F,,CHEMBL618669,1.0,,,9986.0,,9.0,,Oryctolagus cuniculus
Expert,,6961.0,,,102444.0,13419.0,D,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,BAO_0000218,F,In vivo,CHEMBL618670,1.0,,,9986.0,,9.0,,Oryctolagus cuniculus
Autocuration,,6962.0,,,69.0,15778.0,H,,Inhibitory activity against angiotensin-converting enzyme (ACE).,,BAO_0000357,B,,CHEMBL618671,1.0,,,,,8.0,,
Autocuration,,6963.0,,,69.0,15778.0,H,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,BAO_0000357,B,,CHEMBL618672,1.0,,,,,8.0,,
Intermediate,,6964.0,,,80669.0,12988.0,N,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,BAO_0000219,F,,CHEMBL618673,1.0,,,9606.0,ACH-2 cell line,1.0,978.0,Homo sapiens
Intermediate,,6965.0,,,80669.0,12988.0,N,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,BAO_0000219,F,,CHEMBL618674,1.0,,,9606.0,ACH-2 cell line,1.0,978.0,Homo sapiens
Autocuration,,6966.0,,,22224.0,12988.0,U,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,BAO_0000219,F,,CHEMBL618675,1.0,,,11676.0,T cell line,0.0,998.0,Human immunodeficiency virus 1
Autocuration,,6967.0,,,22224.0,12988.0,U,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,BAO_0000219,F,,CHEMBL618676,1.0,,,11676.0,T cell line,0.0,998.0,Human immunodeficiency virus 1
Autocuration,,6968.0,,,22224.0,12988.0,U,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,BAO_0000219,F,,CHEMBL618677,1.0,,,11676.0,T cell line,0.0,998.0,Human immunodeficiency virus 1
Intermediate,,6969.0,,,80025.0,11843.0,N,,Inhibition of growth of renal cancer ACHN cell line,,BAO_0000219,F,,CHEMBL618678,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6970.0,,,80025.0,16939.0,N,,Inhibition of growth of ACHN renal cancer cell line,,BAO_0000219,F,,CHEMBL618679,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6971.0,,,80025.0,4782.0,N,,Inhibitory concentration required against ACHN renal cancer cell line,,BAO_0000219,F,,CHEMBL618680,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Expert,,6972.0,,,80025.0,6310.0,N,,Concentration required to inhibit growth of human renal (ACHN) cell line,,BAO_0000219,F,,CHEMBL618681,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6973.0,,,80025.0,6310.0,N,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,BAO_0000219,F,,CHEMBL618682,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6974.0,,,80025.0,12858.0,N,,Cytotoxic activity against ACHN Renal cancer cell line,,BAO_0000219,F,,CHEMBL618683,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6975.0,,,80025.0,17380.0,N,,Cytotoxicity evaluation against ACHN renal cancer cells,,BAO_0000219,F,,CHEMBL618684,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6976.0,,,80025.0,5858.0,N,,In vitro antitumor activity against human renal ACHN cell line,,BAO_0000219,F,,CHEMBL618685,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6977.0,,,80025.0,3838.0,N,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,BAO_0000219,F,,CHEMBL876499,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6978.0,,,80025.0,3838.0,N,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,BAO_0000219,F,,CHEMBL618686,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6979.0,,,80025.0,5406.0,N,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,BAO_0000219,F,,CHEMBL618687,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6980.0,,,80025.0,4071.0,N,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,BAO_0000219,F,,CHEMBL618688,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Expert,,6981.0,,,80025.0,4071.0,N,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,BAO_0000219,F,,CHEMBL618689,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6982.0,,,80025.0,4071.0,N,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,BAO_0000219,F,,CHEMBL618690,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6983.0,,,80025.0,15002.0,N,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,BAO_0000219,F,,CHEMBL618691,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6984.0,,,80025.0,14769.0,N,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,BAO_0000219,F,,CHEMBL619373,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6985.0,,,80025.0,13958.0,N,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,BAO_0000219,F,,CHEMBL884008,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6986.0,,,80025.0,1665.0,N,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,BAO_0000219,F,,CHEMBL619374,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6987.0,,,80025.0,15354.0,N,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,BAO_0000219,F,,CHEMBL619375,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6988.0,,,80025.0,15354.0,N,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,BAO_0000219,F,,CHEMBL619376,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6989.0,,,80025.0,13978.0,N,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,BAO_0000219,F,,CHEMBL619377,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6990.0,,,80025.0,6798.0,N,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,BAO_0000219,F,,CHEMBL619378,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,6991.0,,,50588.0,2959.0,N,,Tmax value after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,A,In vivo,CHEMBL872527,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6992.0,,,50588.0,9932.0,N,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,BAO_0000218,A,,CHEMBL876500,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6993.0,,,50588.0,5546.0,N,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,BAO_0000218,A,,CHEMBL619379,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6994.0,,,50588.0,16907.0,N,,Volume distribution after 15 mg/kg iv dose in Dogs,,BAO_0000218,A,In vivo,CHEMBL619538,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6995.0,,,50588.0,16907.0,N,,Volume distribution after 30 mg/kg po dose in Dogs,,BAO_0000218,A,In vivo,CHEMBL619539,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6996.0,,,50588.0,4257.0,N,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,BAO_0000218,A,In vivo,CHEMBL619540,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6997.0,,,50588.0,4305.0,N,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL619541,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6998.0,,,50588.0,5472.0,N,,Volume of distribution was evaluated in dog,,BAO_0000218,A,In vivo,CHEMBL619542,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,6999.0,,,50588.0,6062.0,N,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL619543,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Expert,,7000.0,,,50588.0,3598.0,N,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,A,,CHEMBL619544,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7001.0,,,50588.0,12500.0,N,,The compound was tested for volume of distribution in dog,,BAO_0000218,A,In vivo,CHEMBL619545,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7002.0,,,50588.0,12500.0,N,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,BAO_0000218,A,In vivo,CHEMBL619546,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7003.0,,,50588.0,6227.0,N,,Vd (1 mg/kg) was determined in dog (in vivo),,BAO_0000218,A,In vivo,CHEMBL619547,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7004.0,,,50588.0,6227.0,N,,Vd in dog,,BAO_0000218,A,In vivo,CHEMBL619548,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7005.0,,,50588.0,4219.0,N,,Volume distribution was determined,,BAO_0000218,A,In vivo,CHEMBL619549,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7006.0,,,50588.0,1696.0,N,,Volume of distribution in dog,,BAO_0000218,A,In vivo,CHEMBL619550,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7007.0,,,50588.0,5542.0,N,,Volume of distribution by as 4 fold increase by iv administration in dogs,,BAO_0000218,A,In vivo,CHEMBL876501,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7008.0,,,50588.0,5199.0,N,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,A,In vivo,CHEMBL619551,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7009.0,,,50588.0,6348.0,N,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,A,In vivo,CHEMBL619552,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7010.0,,,50588.0,4727.0,N,,Volume distribution at the dose of 2 mg/kg in dog,,BAO_0000218,A,In vivo,CHEMBL619553,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7011.0,,,50588.0,16367.0,N,,Steady state volume of distribution was determined,,BAO_0000218,A,In vivo,CHEMBL618722,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7012.0,,,50588.0,2652.0,N,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,BAO_0000218,A,In vivo,CHEMBL618723,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7013.0,,,50588.0,16452.0,N,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,A,In vivo,CHEMBL618724,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7014.0,,,50588.0,16452.0,N,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,BAO_0000218,A,In vivo,CHEMBL618725,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7015.0,,,50588.0,16452.0,N,,Bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,A,In vivo,CHEMBL618726,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7016.0,,,50588.0,5334.0,N,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,BAO_0000218,A,In vivo,CHEMBL618727,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7017.0,,,50588.0,4239.0,N,,Pharmacokinetic property (vdss) was measured in dog,,BAO_0000218,A,In vivo,CHEMBL624233,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7018.0,,,50588.0,4709.0,N,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,BAO_0000218,A,In vivo,CHEMBL624234,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7019.0,,,50588.0,5600.0,N,,Vdss was determined after iv 0.1 mg/kg administration in dog,,BAO_0000218,A,In vivo,CHEMBL624235,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7020.0,,,50588.0,6057.0,N,,Volume displacement was calculated in dog,,BAO_0000218,A,In vivo,CHEMBL624236,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7021.0,,,50588.0,5654.0,N,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL624237,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7022.0,,,50588.0,5505.0,N,,Volume distribution constant was determined,,BAO_0000218,A,In vivo,CHEMBL624238,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7023.0,,,50588.0,4527.0,N,,Volume distribution at a dose of 1 uM/kg in dog was determined,,BAO_0000218,A,In vivo,CHEMBL624239,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7024.0,,,50588.0,4521.0,N,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,BAO_0000218,A,In vivo,CHEMBL875829,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7025.0,,,50588.0,4521.0,N,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,A,In vivo,CHEMBL624240,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7026.0,,,50588.0,15660.0,N,,Volume distribution (Vdss) was measured in dog,,BAO_0000218,A,In vivo,CHEMBL624241,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7027.0,,,50588.0,15660.0,N,,Volume distribution (Vdss) was measured in dog,,BAO_0000218,A,In vivo,CHEMBL624242,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7028.0,,,50588.0,6679.0,N,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,A,In vivo,CHEMBL624243,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7029.0,,,50588.0,5145.0,N,,Volume of distribution in steady state was determined in dog,,BAO_0000218,A,In vivo,CHEMBL624244,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7030.0,,,50588.0,6821.0,N,,Volume of distribution of compound was determined in dog,,BAO_0000218,A,In vivo,CHEMBL624245,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7031.0,,,50588.0,4137.0,N,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,A,In vivo,CHEMBL624246,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7032.0,,,50588.0,5334.0,N,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,BAO_0000218,A,In vivo,CHEMBL624247,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7033.0,,,50588.0,15660.0,N,,Volume of distribution (Vdss) was measured in dog,,BAO_0000218,A,In vivo,CHEMBL624248,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7034.0,,,50588.0,6642.0,N,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,A,In vivo,CHEMBL624249,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7035.0,,,50588.0,6641.0,N,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,A,In vivo,CHEMBL624250,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7036.0,,,50588.0,6642.0,N,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,A,In vivo,CHEMBL624251,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7037.0,,,50588.0,11659.0,N,,Maximum rate of depolarization of the upstroke of the action potential,,BAO_0000218,A,,CHEMBL624252,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7038.0,,,50588.0,6448.0,N,,Steady state volume distribution in dog,,BAO_0000218,A,In vivo,CHEMBL624253,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7039.0,,,50588.0,5474.0,N,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,BAO_0000218,A,In vivo,CHEMBL624950,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7040.0,,,50588.0,1466.0,N,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,BAO_0000218,A,In vivo,CHEMBL624951,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7041.0,,,50588.0,6535.0,N,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,BAO_0000218,A,In vivo,CHEMBL875830,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7042.0,,,50588.0,6535.0,N,,Volume distribution in dog after administration of 1 mg/kg iv,,BAO_0000218,A,In vivo,CHEMBL624952,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7043.0,,,50588.0,17764.0,N,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,A,In vivo,CHEMBL624953,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7044.0,,,50588.0,6215.0,N,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,BAO_0000218,A,In vivo,CHEMBL624954,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7045.0,,,50588.0,6505.0,N,,Vss on i.v. administration of 2 mg/kg was measured in dog,,BAO_0000218,A,In vivo,CHEMBL624955,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7046.0,,,50588.0,3639.0,N,,Vss was determined,,BAO_0000218,A,,CHEMBL624956,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7047.0,,,50588.0,3639.0,N,,Vss in dog,,BAO_0000218,A,,CHEMBL625129,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7048.0,,,50588.0,6062.0,N,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL625130,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7049.0,,,50588.0,4942.0,N,,Volume distribution in dogs,,BAO_0000218,A,In vivo,CHEMBL625131,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7050.0,,,50588.0,17796.0,N,,Volume of distribution in dog,,BAO_0000218,A,In vivo,CHEMBL625132,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7051.0,,,50588.0,4883.0,N,,Tested for the oral bioavailability in dog,,BAO_0000218,A,In vivo,CHEMBL872263,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7060.0,,,50594.0,17837.0,N,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,BAO_0000218,A,In vivo,CHEMBL624336,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7061.0,,,50594.0,17729.0,N,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,BAO_0000218,A,In vivo,CHEMBL624337,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7062.0,,,50594.0,17729.0,N,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,BAO_0000218,A,In vivo,CHEMBL624338,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7063.0,,,50594.0,4239.0,N,,Bioavailability was measured in mouse,,BAO_0000218,A,In vivo,CHEMBL624339,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7064.0,,,50594.0,17592.0,N,,Bioavailability in mouse,,BAO_0000218,A,In vivo,CHEMBL624340,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7065.0,,,50594.0,6348.0,N,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,A,In vivo,CHEMBL624341,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7066.0,,,50594.0,2801.0,N,,Bioavailability in mouse,,BAO_0000218,A,In vivo,CHEMBL624342,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7067.0,,,50594.0,2801.0,N,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL624343,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7068.0,,,50594.0,17718.0,N,,Oral bioavailability in mouse,,BAO_0000218,A,In vivo,CHEMBL624344,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7069.0,,,50594.0,5727.0,N,,Oral availability at 50 mg/kg po in male mice,,BAO_0000218,A,In vivo,CHEMBL624345,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7070.0,,,50594.0,5302.0,N,,Oral bioavailability in mouse (dose 10 mg/kg),,BAO_0000218,A,In vivo,CHEMBL624346,1.0,,,10090.0,,1.0,,Mus musculus
Expert,,7071.0,,,50594.0,3598.0,N,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL624347,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7072.0,,,50594.0,5961.0,N,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,BAO_0000218,A,In vivo,CHEMBL624348,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7074.0,,,50594.0,6091.0,N,,Oral bioavailability in mouse,,BAO_0000218,A,In vivo,CHEMBL622754,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7075.0,,,50594.0,6091.0,N,,Oral bioavailability in vivo in mice;ND=Not determined,,BAO_0000218,A,In vivo,CHEMBL622755,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7076.0,,,50594.0,5711.0,N,,Oral bioavailability in mouse at 10 mg/kg of the compound,,BAO_0000218,A,In vivo,CHEMBL622756,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7077.0,,,50594.0,17728.0,N,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,BAO_0000218,A,In vivo,CHEMBL622757,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7078.0,,,50594.0,17728.0,N,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,BAO_0000218,A,In vivo,CHEMBL622758,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7079.0,,,50594.0,3802.0,N,,Tested for bioavailability of the compound,,BAO_0000218,A,In vivo,CHEMBL622759,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7080.0,,,50594.0,3802.0,N,,Tested for half life at the dose of 10 mg/kg when administered intravenously,,BAO_0000218,A,In vivo,CHEMBL622760,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,7081.0,,,50594.0,14029.0,N,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,BAO_0000218,A,,CHEMBL622761,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,7082.0,,,50594.0,14029.0,N,,The plasma half life of compound was determined on heparin prepared by human plasma. ,,BAO_0000218,A,,CHEMBL622762,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,7083.0,,,50594.0,14029.0,N,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,BAO_0000218,A,,CHEMBL622763,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,7084.0,,,50594.0,14029.0,N,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,BAO_0000218,A,,CHEMBL622764,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,Plasma,7085.0,,,50594.0,14029.0,N,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,BAO_0000218,A,,CHEMBL622765,1.0,1969.0,,10090.0,,1.0,,Mus musculus
Intermediate,,7086.0,,,50594.0,17753.0,N,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,BAO_0000218,F,,CHEMBL622766,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7087.0,,,50594.0,17753.0,N,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,BAO_0000218,A,,CHEMBL622767,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,,7088.0,,,50594.0,17753.0,N,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,BAO_0000218,A,,CHEMBL622768,1.0,,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,7089.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,A,In vivo,CHEMBL875948,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,7090.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,A,In vivo,CHEMBL622769,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,7091.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,A,In vivo,CHEMBL622770,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,7092.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,A,In vivo,CHEMBL622771,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,7093.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,A,In vivo,CHEMBL622772,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,7094.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,A,In vivo,CHEMBL622773,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Blood,7095.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,A,In vivo,CHEMBL622774,1.0,178.0,,10090.0,,1.0,,Mus musculus
Intermediate,Bone,7096.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,A,In vivo,CHEMBL621725,1.0,10000001.0,,10090.0,,1.0,,Mus musculus
Intermediate,Bone,7097.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,BAO_0000218,A,In vivo,CHEMBL621726,1.0,10000001.0,,10090.0,,1.0,,Mus musculus
Intermediate,,7098.0,,,81034.0,15608.0,N,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,BAO_0000219,F,,CHEMBL621727,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7099.0,,,81034.0,3290.0,N,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,BAO_0000219,F,,CHEMBL622413,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7100.0,,,81034.0,2859.0,N,,Compound was evaluated for cytotoxicity against A2780 cell line,,BAO_0000219,F,,CHEMBL622414,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7101.0,,,81034.0,15688.0,N,,Inhibition of A2780 cell clonogenic assay,,BAO_0000219,F,,CHEMBL622415,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7102.0,,,81034.0,5642.0,N,,Cytotoxic effect on ovarian cancer cell line (A2780),,BAO_0000219,F,,CHEMBL884001,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7103.0,,,81034.0,6633.0,N,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,BAO_0000219,F,,CHEMBL622416,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7104.0,,,81034.0,3906.0,N,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,BAO_0000219,F,,CHEMBL622417,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7105.0,,,81034.0,6788.0,N,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,BAO_0000219,F,,CHEMBL622590,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7106.0,,,81034.0,17582.0,N,,Antiproliferative activity against human A2780 cells,,BAO_0000219,F,,CHEMBL622591,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7107.0,,,81034.0,17764.0,N,,Inhibition of human A2780 cell proliferation,,BAO_0000219,F,,CHEMBL622592,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7108.0,,,81034.0,17764.0,N,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,BAO_0000219,F,,CHEMBL622593,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7109.0,,,81034.0,17764.0,N,,Inhibition of human A2780 cell proliferation (No data),,BAO_0000219,F,,CHEMBL622594,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7110.0,,,81034.0,2815.0,N,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,BAO_0000219,F,,CHEMBL622595,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7111.0,,,81034.0,16930.0,N,,Compound was evaluated against human Ovarian carcinoma cell line A2780,,BAO_0000219,F,,CHEMBL622596,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7112.0,,,81034.0,17777.0,N,,Growth inhibition against A2780 wild-type ovarian cell lines,,BAO_0000219,F,,CHEMBL622597,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7113.0,,,81034.0,17777.0,N,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,BAO_0000219,F,,CHEMBL622598,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Autocuration,,7114.0,,,104766.0,16936.0,D,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,BAO_0000019,F,,CHEMBL622599,1.0,,,9606.0,,5.0,,Homo sapiens
Intermediate,,7115.0,,,81034.0,13759.0,N,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,BAO_0000219,F,,CHEMBL622600,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7116.0,,,81034.0,13759.0,N,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,BAO_0000219,F,,CHEMBL622601,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7117.0,,,81034.0,13759.0,N,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,BAO_0000219,F,,CHEMBL622602,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7118.0,,,81034.0,13759.0,N,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,BAO_0000219,F,,CHEMBL622603,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7119.0,,,81034.0,15292.0,N,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,BAO_0000219,F,,CHEMBL622604,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7120.0,,,81034.0,15292.0,N,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,BAO_0000219,F,,CHEMBL622605,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7121.0,,,81034.0,15069.0,N,,In vitro inhibition of human ovarian cell line A2780,,BAO_0000219,F,,CHEMBL622606,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7122.0,,,81034.0,15069.0,N,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,BAO_0000219,F,,CHEMBL619463,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7123.0,,,81034.0,14073.0,N,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,BAO_0000219,F,,CHEMBL619464,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7124.0,,,81034.0,14553.0,N,,Concentration required to inhibit A2780-cell growth by 50%,,BAO_0000219,F,,CHEMBL619465,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7125.0,,,81034.0,13040.0,N,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,BAO_0000219,F,,CHEMBL619466,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7126.0,,,81034.0,6891.0,N,,Cytotoxic effect on human ovarian (A2780) cancer cell line,,BAO_0000219,F,,CHEMBL619467,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7127.0,,,81034.0,15569.0,N,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,BAO_0000219,F,,CHEMBL619468,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7128.0,,,81034.0,14190.0,N,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,BAO_0000219,F,,CHEMBL619469,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7129.0,,,81034.0,15014.0,N,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,BAO_0000219,F,,CHEMBL619470,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7130.0,,,81034.0,15014.0,N,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,BAO_0000219,F,,CHEMBL619471,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7131.0,,,81034.0,17496.0,N,,Cytotoxicity against human ovarian carcinoma A2780 cell line,,BAO_0000219,F,,CHEMBL619472,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7132.0,,,81034.0,13617.0,N,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,BAO_0000219,F,,CHEMBL619473,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7133.0,,,81034.0,13617.0,N,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,BAO_0000219,F,,CHEMBL874368,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7134.0,,,81034.0,13617.0,N,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,BAO_0000219,F,,CHEMBL884003,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7135.0,,,81034.0,13617.0,N,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,BAO_0000219,F,,CHEMBL622690,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7136.0,,,81034.0,17672.0,N,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,BAO_0000219,F,,CHEMBL622691,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7137.0,,,81034.0,4544.0,N,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,BAO_0000219,F,,CHEMBL622692,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7138.0,,,81034.0,4544.0,N,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,BAO_0000219,F,,CHEMBL623406,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7139.0,,,81034.0,16317.0,N,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,BAO_0000219,F,,CHEMBL884004,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7140.0,,,81034.0,15099.0,N,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,BAO_0000219,F,,CHEMBL623407,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7141.0,,,81034.0,13978.0,N,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,BAO_0000219,F,,CHEMBL623408,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7142.0,,,81034.0,12989.0,N,,In vitro antitumor activity against A2780 cell line.,,BAO_0000219,F,,CHEMBL623409,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7143.0,,,81034.0,5574.0,N,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,BAO_0000219,F,,CHEMBL623410,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7144.0,,,81034.0,13528.0,N,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,BAO_0000219,F,,CHEMBL623576,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7145.0,,,80025.0,12782.0,N,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,BAO_0000219,F,,CHEMBL623577,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7146.0,,,80025.0,14255.0,N,,The IC50 value was measured on ACHN cell line in renal tumor type.,,BAO_0000219,F,,CHEMBL623578,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7147.0,,,80025.0,16364.0,N,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,BAO_0000219,F,,CHEMBL623579,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Expert,,7148.0,,,80025.0,17376.0,N,,In vitro lethal concentration against most sensitive ACHN cell line,,BAO_0000219,F,,CHEMBL623580,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7149.0,,,80025.0,12016.0,N,,Tested for cytotoxic activity against renal cancer ACHN cell line,,BAO_0000219,F,,CHEMBL623581,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7150.0,,,80025.0,6058.0,N,,Compound tested for growth inhibition of renal cancer cell line ACHN,,BAO_0000219,F,,CHEMBL857456,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7151.0,,,80025.0,17708.0,N,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,BAO_0000219,F,,CHEMBL623582,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7152.0,,,80025.0,15176.0,N,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,BAO_0000219,F,,CHEMBL623583,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7153.0,,,80025.0,2806.0,N,,In vitro anticancer activity against ACHN renal cancer cell line,,BAO_0000219,F,,CHEMBL623584,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7154.0,,,80025.0,15300.0,N,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,BAO_0000219,F,,CHEMBL623585,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7155.0,,,80025.0,16364.0,N,,Percent selectivity was evaluated in renal ACHN cell lines,,BAO_0000219,F,,CHEMBL623586,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7156.0,,,80025.0,13859.0,N,,In vitro inhibitory activity against renal ACHN cancer cell line,,BAO_0000219,F,,CHEMBL623587,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7157.0,,,80025.0,11970.0,N,,Tested for cytotoxicity against ACHN cell lines in renal cancer,,BAO_0000219,F,,CHEMBL875279,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7158.0,,,80025.0,2450.0,N,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,BAO_0000219,F,,CHEMBL623588,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7159.0,,,80025.0,12696.0,N,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,BAO_0000219,F,,CHEMBL623589,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7160.0,,,80025.0,12400.0,N,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,BAO_0000219,F,,CHEMBL623590,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Expert,,7161.0,,,80025.0,12888.0,N,,Cytotoxic effect on renal cancer line ACHN,,BAO_0000219,F,,CHEMBL623591,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7162.0,,,80025.0,3156.0,N,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,BAO_0000219,F,,CHEMBL623592,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7163.0,,,80025.0,3381.0,N,,In vitro inhibition of Renal Cancer ACHN cell lines,,BAO_0000219,F,,CHEMBL623593,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7164.0,,,80025.0,16747.0,N,,Antitumor activity against human renal adenocarcinoma ACHN cells,,BAO_0000219,F,,CHEMBL623594,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Expert,,7165.0,,,80025.0,16748.0,N,,Antitumor activity against human renal adenocarcinoma ACHN cells.,,BAO_0000219,F,,CHEMBL621833,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7166.0,,,80025.0,12062.0,N,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,BAO_0000219,F,,CHEMBL621834,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7167.0,,,80025.0,14769.0,N,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,BAO_0000219,F,,CHEMBL621835,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7168.0,,,80025.0,15895.0,N,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,BAO_0000219,F,,CHEMBL621836,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7169.0,,,80025.0,17376.0,N,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,BAO_0000219,F,,CHEMBL621837,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7170.0,,,80025.0,14882.0,N,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,BAO_0000219,F,,CHEMBL875280,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7171.0,,,80025.0,14882.0,N,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,BAO_0000219,F,,CHEMBL621838,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Intermediate,,7172.0,,,80025.0,15661.0,N,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,BAO_0000219,F,,CHEMBL621839,1.0,,,9606.0,ACHN,1.0,626.0,Homo sapiens
Autocuration,,7173.0,,,22224.0,9680.0,U,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,BAO_0000019,A,,CHEMBL621840,1.0,,,,,0.0,,
Autocuration,,7174.0,,,10647.0,14579.0,H,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,BAO_0000019,F,,CHEMBL621841,1.0,,,,,8.0,,
Expert,,7175.0,,,50529.0,17290.0,N,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,BAO_0000218,F,,CHEMBL622979,1.0,,,10358.0,HEL,1.0,468.0,Cytomegalovirus
Intermediate,,7176.0,,,50529.0,17290.0,N,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,BAO_0000218,F,,CHEMBL876595,1.0,,,10358.0,,1.0,,Cytomegalovirus
Autocuration,,7177.0,,,12159.0,15891.0,H,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,BAO_0000357,B,,CHEMBL620221,1.0,,,,,8.0,,
Autocuration,,7178.0,,,12159.0,15890.0,H,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,BAO_0000357,B,,CHEMBL620222,1.0,,,,,8.0,,
Intermediate,,7179.0,,,80670.0,3801.0,N,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,BAO_0000219,F,,CHEMBL620506,1.0,,,9913.0,ADDP cell line,1.0,979.0,Bos taurus
Intermediate,,7180.0,,,80671.0,9222.0,N,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,BAO_0000219,F,,CHEMBL620507,1.0,,,10090.0,ADJ/PC6,1.0,980.0,Mus musculus
Intermediate,,7181.0,,,80671.0,9222.0,N,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,BAO_0000219,F,,CHEMBL620508,1.0,,,10090.0,ADJ/PC6,1.0,980.0,Mus musculus
Intermediate,,7182.0,,,80671.0,7257.0,N,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,BAO_0000219,F,,CHEMBL620509,1.0,,,10090.0,ADJ/PC6,1.0,980.0,Mus musculus
Intermediate,,7183.0,,,80671.0,7257.0,N,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,BAO_0000219,F,,CHEMBL620510,1.0,,,10090.0,ADJ/PC6,1.0,980.0,Mus musculus
Intermediate,,7184.0,,,80671.0,7257.0,N,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,BAO_0000219,A,,CHEMBL620511,1.0,,,10090.0,ADJ/PC6,1.0,980.0,Mus musculus
Intermediate,,7185.0,,,80671.0,8084.0,N,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,BAO_0000219,F,,CHEMBL620512,1.0,,,10090.0,ADJ/PC6,1.0,980.0,Mus musculus
Autocuration,,7186.0,,,22224.0,14943.0,U,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,BAO_0000019,F,,CHEMBL620513,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,7187.0,,,22224.0,14943.0,U,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,BAO_0000019,F,,CHEMBL620514,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,7188.0,,,22224.0,14943.0,U,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,BAO_0000019,F,,CHEMBL620515,1.0,,,10090.0,,0.0,,Mus musculus
Autocuration,,7189.0,,,22224.0,10524.0,U,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,BAO_0000218,A,In vivo,CHEMBL620516,1.0,,,1423.0,,0.0,,Bacillus subtilis
Intermediate,Plasma,7190.0,,,50588.0,3546.0,N,,AUC value in dog after IV administration at a dose of 5 mg/kg,,BAO_0000218,A,,CHEMBL620517,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,7191.0,,,50588.0,3546.0,N,,AUC value in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,A,,CHEMBL620518,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7192.0,,,50588.0,3546.0,N,,Cmax value in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL620519,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7193.0,,,50588.0,3546.0,N,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621386,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7194.0,,,50588.0,3546.0,N,,Tmax value in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621387,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7195.0,,,50588.0,3184.0,N,,Compound was evaluated for its clearance when administered intravenously in dog,,BAO_0000218,A,In vivo,CHEMBL621388,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7196.0,,,50588.0,16456.0,N,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621389,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7197.0,,,50588.0,4809.0,N,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,BAO_0000218,A,In vivo,CHEMBL621390,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7198.0,,,22229.0,4219.0,U,,Calculated partition coefficient (clogP),,BAO_0000100,P,,CHEMBL621391,1.0,,,,,0.0,,
Intermediate,,7199.0,,,50588.0,3748.0,N,,Half life in dog,,BAO_0000218,A,,CHEMBL621392,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7200.0,,,50588.0,3132.0,N,,Time taken for EC90 was determined when tested in dog,,BAO_0000218,A,,CHEMBL621393,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7201.0,,,50588.0,4219.0,N,,Half life (iv) was determined,,BAO_0000218,A,,CHEMBL621394,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Liver,7202.0,,,50588.0,16907.0,N,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,BAO_0000218,A,,CHEMBL621395,1.0,2107.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7203.0,,,50588.0,6057.0,N,,Area under the curve was calculated in dog after iv administration,,BAO_0000218,A,,CHEMBL621396,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7204.0,,,50588.0,6057.0,N,,Area under the curve was calculated in dog after peroral administration,,BAO_0000218,A,,CHEMBL621397,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7205.0,,,50588.0,17853.0,N,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,BAO_0000218,A,,CHEMBL621398,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7206.0,,,50588.0,3639.0,N,,pKa was evaluated in dog,,BAO_0000218,A,,CHEMBL618818,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7207.0,,,50588.0,14541.0,N,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,BAO_0000218,A,,CHEMBL618819,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7208.0,,,50588.0,16456.0,N,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL618820,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7209.0,,,50588.0,16456.0,N,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL873810,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7210.0,,,50588.0,2652.0,N,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,BAO_0000218,A,In vivo,CHEMBL876606,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7211.0,,,50588.0,3624.0,N,,Compound was evaluated for the half-life (t 1/2) in hours,,BAO_0000218,A,,CHEMBL618821,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Blood,7212.0,,,50588.0,1337.0,N,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,A,In vivo,CHEMBL618822,1.0,178.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Blood,7213.0,,,50588.0,1337.0,N,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,A,In vivo,CHEMBL618823,1.0,178.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7214.0,,,50588.0,4709.0,N,,Half life after intravenous administration of 1 mg/kg in dog,,BAO_0000218,A,In vivo,CHEMBL618824,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7215.0,,,50588.0,15660.0,N,,Half life was measured in dog,,BAO_0000218,A,,CHEMBL618825,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7216.0,,,50588.0,5302.0,N,,Half life period in dog after 5 mg/kg dose,,BAO_0000218,A,In vivo,CHEMBL618826,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7217.0,,,50588.0,17791.0,N,,Half life period was evaluated in dog; 4-4.8,,BAO_0000218,A,,CHEMBL618827,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7218.0,,,50588.0,6348.0,N,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,A,In vivo,CHEMBL618828,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7219.0,,,50588.0,4257.0,N,,Half-life was determined in dog after a3 mg/kg of iv dose,,BAO_0000218,A,In vivo,CHEMBL618829,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7220.0,,,50588.0,3771.0,N,,Half-life was determined,,BAO_0000218,A,,CHEMBL618830,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7221.0,,,50588.0,6305.0,N,,Half life in dogs,,BAO_0000218,A,,CHEMBL618831,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,7222.0,,,50588.0,13501.0,N,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,BAO_0000218,A,In vivo,CHEMBL619489,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7223.0,,,50588.0,17594.0,N,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,BAO_0000218,A,In vivo,CHEMBL619649,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7224.0,,,50588.0,3045.0,N,,Compound was evaluated for the half life period after iv administration in Beagle dog.,,BAO_0000218,A,In vivo,CHEMBL876607,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7225.0,,,50588.0,3043.0,N,,Compound was evaluated for the half life period after oral administration in conscious dog.,,BAO_0000218,A,In vivo,CHEMBL619650,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7226.0,,,50588.0,4839.0,N,,Compound was tested for half life in dog,,BAO_0000218,A,,CHEMBL619651,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7227.0,,,50588.0,4839.0,N,,Compound was tested for its half life in dog,,BAO_0000218,A,,CHEMBL619652,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7228.0,,,50588.0,5802.0,N,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,A,In vivo,CHEMBL619653,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7229.0,,,50588.0,17839.0,N,,Half life of compound in dog was determined,,BAO_0000218,A,,CHEMBL619654,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7230.0,,,50588.0,4219.0,N,,Half life (iv) was determined,,BAO_0000218,A,In vivo,CHEMBL619655,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Blood,7231.0,,,50588.0,13966.0,N,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,BAO_0000218,A,,CHEMBL619656,1.0,178.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,7232.0,,,50588.0,3994.0,N,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,BAO_0000218,A,In vivo,CHEMBL873812,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,7233.0,,,50588.0,3994.0,N,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,BAO_0000218,F,In vivo,CHEMBL621365,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7234.0,,,50588.0,4453.0,N,,Half life in dog,,BAO_0000218,A,,CHEMBL621366,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,7235.0,,,50588.0,6535.0,N,,Half life in dog plasma,,BAO_0000218,A,,CHEMBL621367,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,7236.0,,,50588.0,6535.0,N,,Half life in dog plasma after administration of 0.25 mg/kg iv,,BAO_0000218,A,In vivo,CHEMBL621368,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,7237.0,,,50588.0,6535.0,N,,Half life in dog plasma after administration of 1 mg/kg iv,,BAO_0000218,A,In vivo,CHEMBL621369,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,7238.0,,,50588.0,3132.0,N,,Half life in dog plasma was determined at dose 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621370,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7239.0,,,50588.0,5374.0,N,,Half life in dog was determined,,BAO_0000218,A,,CHEMBL621371,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7240.0,,,50588.0,5007.0,N,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,A,In vivo,CHEMBL621372,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,7241.0,,,50588.0,16907.0,N,,Half life upon exposure to human plasma,,BAO_0000218,A,,CHEMBL621373,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7242.0,,,50588.0,6057.0,N,,Half life was calculated in dog,,BAO_0000218,A,,CHEMBL621374,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7243.0,,,50588.0,5006.0,N,,Half life was determined,,BAO_0000218,A,,CHEMBL621375,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7244.0,,,50588.0,5473.0,N,,Half life was determined,,BAO_0000218,A,,CHEMBL621376,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7245.0,,,50588.0,4368.0,N,,Half life by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,A,In vivo,CHEMBL619624,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7246.0,,,50588.0,6448.0,N,,Half life in dog,,BAO_0000218,A,,CHEMBL875840,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7247.0,,,50588.0,4353.0,N,,Half life in dog after intra venous administration of the compound,,BAO_0000218,A,,CHEMBL619625,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7248.0,,,50588.0,4353.0,N,,Half life in dog after intra venous administration of the compound; ND means Not determined,,BAO_0000218,A,,CHEMBL619626,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7249.0,,,50588.0,4353.0,N,,Half life in dog after po administration of the compound,,BAO_0000218,A,In vivo,CHEMBL619627,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7250.0,,,50588.0,4353.0,N,,Half life in dog after po administration of the compound; ND means Not determined,,BAO_0000218,A,In vivo,CHEMBL873817,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7251.0,,,50588.0,6265.0,N,,Half life in dog at the single oral dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL619628,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7252.0,,,50588.0,5006.0,N,,Half life in dogs,,BAO_0000218,A,,CHEMBL619629,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7253.0,,,50588.0,5356.0,N,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,BAO_0000218,A,In vivo,CHEMBL619630,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7254.0,,,50588.0,405.0,N,,Half life in rat,,BAO_0000218,A,,CHEMBL619631,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7255.0,,,50588.0,6642.0,N,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,A,In vivo,CHEMBL619632,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Bone,7256.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,A,In vivo,CHEMBL619633,1.0,10000001.0,,10090.0,,1.0,,Mus musculus
Intermediate,Bone,7257.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,A,In vivo,CHEMBL875841,1.0,10000001.0,,10090.0,,1.0,,Mus musculus
Intermediate,Bone,7258.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,A,In vivo,CHEMBL619634,1.0,10000001.0,,10090.0,,1.0,,Mus musculus
Intermediate,Bone,7259.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,A,In vivo,CHEMBL619635,1.0,10000001.0,,10090.0,,1.0,,Mus musculus
Intermediate,Bone,7260.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,A,In vivo,CHEMBL619636,1.0,10000001.0,,10090.0,,1.0,,Mus musculus
Intermediate,Gut,7261.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,A,In vivo,CHEMBL619637,1.0,10000004.0,,10090.0,,1.0,,Mus musculus
Intermediate,Gut,7262.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,A,In vivo,CHEMBL619638,1.0,10000004.0,,10090.0,,1.0,,Mus musculus
Intermediate,Gut,7263.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,A,In vivo,CHEMBL619639,1.0,10000004.0,,10090.0,,1.0,,Mus musculus
Intermediate,Gut,7264.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,A,In vivo,CHEMBL619640,1.0,10000004.0,,10090.0,,1.0,,Mus musculus
Intermediate,Gut,7265.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,A,In vivo,CHEMBL619641,1.0,10000004.0,,10090.0,,1.0,,Mus musculus
Intermediate,Gut,7266.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,A,In vivo,CHEMBL619642,1.0,10000004.0,,10090.0,,1.0,,Mus musculus
Intermediate,Gut,7267.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,A,In vivo,CHEMBL619643,1.0,10000004.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,7268.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,A,In vivo,CHEMBL619644,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,7269.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,A,In vivo,CHEMBL621112,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,7270.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,A,In vivo,CHEMBL621113,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,7271.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,A,In vivo,CHEMBL621114,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,7272.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,A,In vivo,CHEMBL621115,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,7273.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,A,In vivo,CHEMBL621116,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Heart,7274.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,A,In vivo,CHEMBL621117,1.0,948.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,7275.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,A,In vivo,CHEMBL621118,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,7276.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,BAO_0000218,A,In vivo,CHEMBL621119,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,7277.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,A,In vivo,CHEMBL621120,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,7278.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,A,In vivo,CHEMBL621757,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,7279.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,A,In vivo,CHEMBL621758,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,7280.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,A,In vivo,CHEMBL621759,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Kidney,7281.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,A,In vivo,CHEMBL621760,1.0,2113.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,7282.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,A,In vivo,CHEMBL621761,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,7283.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,A,In vivo,CHEMBL621762,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,7284.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,A,In vivo,CHEMBL621763,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,7285.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,A,In vivo,CHEMBL624502,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,7286.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,A,In vivo,CHEMBL624503,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,7287.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,A,In vivo,CHEMBL624504,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Liver,7288.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,A,In vivo,CHEMBL624505,1.0,2107.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,7289.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,A,In vivo,CHEMBL624506,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,,7290.0,,,81034.0,5895.0,N,,In vitro cytotoxicity against A2780 (human ovarian cancer),,BAO_0000219,F,,CHEMBL624507,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7291.0,,,81034.0,6338.0,N,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,BAO_0000219,F,,CHEMBL624508,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7292.0,,,81034.0,15163.0,N,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,BAO_0000219,F,,CHEMBL624509,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7293.0,,,81034.0,15163.0,N,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,BAO_0000219,F,,CHEMBL624510,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7294.0,,,81034.0,15000.0,N,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,BAO_0000219,F,,CHEMBL875956,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7295.0,,,81034.0,15000.0,N,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,BAO_0000219,F,,CHEMBL839885,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7296.0,,,81034.0,14729.0,N,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,BAO_0000219,F,,CHEMBL624511,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7297.0,,,81034.0,17270.0,N,,In vitro cytotoxicity against A2780 cell line,,BAO_0000219,F,,CHEMBL624512,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7298.0,,,81034.0,5685.0,N,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,BAO_0000219,F,,CHEMBL624513,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7299.0,,,81034.0,3563.0,N,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,BAO_0000219,F,,CHEMBL624514,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7300.0,,,81034.0,17753.0,N,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,BAO_0000218,F,,CHEMBL618547,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7301.0,,,81034.0,16317.0,N,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,BAO_0000219,F,,CHEMBL618548,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7302.0,,,81034.0,16936.0,N,,Inhibition of tubulin polymerization in analogy of ca.,,BAO_0000219,F,,CHEMBL618549,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7303.0,,,81034.0,3801.0,N,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,BAO_0000219,F,,CHEMBL618550,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7304.0,,,81034.0,6181.0,N,,Cytotoxic effect in ovarian cancer cell line (A2780),,BAO_0000219,F,,CHEMBL618551,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7305.0,,,81034.0,5318.0,N,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,BAO_0000219,F,,CHEMBL618552,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7306.0,,,81034.0,4840.0,N,,Tested for the cytotoxicity in A2780 ovarian cell line,,BAO_0000219,F,,CHEMBL618553,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7307.0,,,81034.0,15748.0,N,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,BAO_0000219,F,,CHEMBL618554,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7308.0,,,81034.0,15748.0,N,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,BAO_0000219,F,,CHEMBL618555,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7309.0,,,80017.0,15748.0,N,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,BAO_0000219,F,,CHEMBL618556,1.0,,,,A2780cisR,1.0,481.0,
Intermediate,,7310.0,,,80017.0,15748.0,N,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,BAO_0000219,F,,CHEMBL618557,1.0,,,,A2780cisR,1.0,481.0,
Intermediate,,7311.0,,,80017.0,15748.0,N,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,BAO_0000219,F,,CHEMBL618558,1.0,,,,A2780cisR,1.0,481.0,
Intermediate,,7312.0,,,80017.0,15748.0,N,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,BAO_0000219,F,,CHEMBL618559,1.0,,,,A2780cisR,1.0,481.0,
Intermediate,,7313.0,,,81034.0,17753.0,N,,In vivo log of cells killed after administration of compound in A2780 cell line,,BAO_0000218,F,,CHEMBL618560,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7314.0,,,81034.0,17753.0,N,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,BAO_0000218,F,In vivo,CHEMBL618561,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7315.0,,,81034.0,16936.0,N,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,BAO_0000219,F,,CHEMBL618562,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7316.0,,,81034.0,16936.0,N,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,BAO_0000219,F,,CHEMBL618563,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7317.0,,,81034.0,16936.0,N,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,BAO_0000219,F,,CHEMBL618564,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7318.0,,,81034.0,16936.0,N,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,BAO_0000219,F,,CHEMBL618565,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7319.0,,,81034.0,17528.0,N,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,BAO_0000218,F,,CHEMBL618566,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7320.0,,,81034.0,6633.0,N,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,BAO_0000219,F,,CHEMBL618567,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7321.0,,,81034.0,15000.0,N,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,BAO_0000219,F,,CHEMBL618568,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7322.0,,,81034.0,17528.0,N,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,BAO_0000219,F,,CHEMBL618569,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7323.0,,,81034.0,16936.0,N,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,BAO_0000219,F,,CHEMBL621857,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7324.0,,,81034.0,16936.0,N,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,BAO_0000219,F,,CHEMBL621858,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7325.0,,,81034.0,16936.0,N,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,BAO_0000219,F,,CHEMBL621859,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7326.0,,,81034.0,16936.0,N,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,BAO_0000219,F,,CHEMBL621860,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7327.0,,,81034.0,16936.0,N,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,BAO_0000219,F,,CHEMBL621861,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Expert,,7328.0,,,81034.0,16936.0,N,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,BAO_0000219,F,,CHEMBL621862,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7329.0,,,81034.0,16936.0,N,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,BAO_0000219,F,,CHEMBL621863,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7330.0,,,81034.0,16936.0,N,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,BAO_0000219,F,,CHEMBL621864,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7331.0,,,81034.0,16936.0,N,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,BAO_0000219,F,,CHEMBL621865,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7332.0,,,81034.0,17737.0,N,,In vitro antiproliferative activity against A2780 cell line,,BAO_0000219,F,,CHEMBL621866,1.0,,,10090.0,A2780,1.0,478.0,Mus musculus
Expert,,7333.0,,,81034.0,17764.0,N,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,BAO_0000219,F,,CHEMBL621867,1.0,,,10090.0,A2780,1.0,478.0,Mus musculus
Intermediate,,7334.0,,,81034.0,3830.0,N,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,BAO_0000219,F,,CHEMBL621868,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7335.0,,,81034.0,3829.0,N,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,BAO_0000219,F,,CHEMBL875282,1.0,,,9606.0,A2780,1.0,478.0,Homo sapiens
Intermediate,,7336.0,,,50588.0,3546.0,N,,Vc value in dog after IV administration at a dose of 5 mg/kg,,BAO_0000218,A,,CHEMBL621869,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7337.0,,,50588.0,3546.0,N,,Half life period in dog after IV administration at a dose of 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621870,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Autocuration,,7338.0,,,22224.0,5668.0,U,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000019,A,,CHEMBL621871,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,7339.0,,,22224.0,3443.0,U,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,A,,CHEMBL621243,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,7340.0,,,22224.0,3443.0,U,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,A,,CHEMBL621244,1.0,1969.0,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7341.0,,,22224.0,4256.0,U,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,BAO_0000218,A,In vivo,CHEMBL621245,1.0,,,9541.0,,0.0,,Macaca fascicularis
Autocuration,,7342.0,,,22224.0,4256.0,U,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,BAO_0000218,A,In vivo,CHEMBL621246,1.0,,,9541.0,,0.0,,Macaca fascicularis
Autocuration,,7343.0,,,22224.0,4256.0,U,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,BAO_0000218,A,In vivo,CHEMBL621247,1.0,,,9541.0,,0.0,,Macaca fascicularis
Autocuration,,7344.0,,,22224.0,4256.0,U,,Oral Bioavailability in rat,,BAO_0000218,A,In vivo,CHEMBL618386,1.0,,,10116.0,,0.0,,Rattus norvegicus
Autocuration,,7345.0,,,22224.0,1916.0,U,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,A,,CHEMBL618387,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7346.0,,,22224.0,5302.0,U,,Area under curve value in monkey at a dose of 5 mg/kg,,BAO_0000218,A,,CHEMBL618388,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7347.0,,,22224.0,4257.0,U,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,BAO_0000218,A,,CHEMBL618389,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7348.0,,,22224.0,5355.0,U,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,BAO_0000019,A,,CHEMBL618574,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7349.0,,,22224.0,5355.0,U,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,BAO_0000019,A,,CHEMBL618575,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7350.0,,,22224.0,5355.0,U,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,BAO_0000019,A,,CHEMBL618576,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7351.0,,,22224.0,6078.0,U,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,BAO_0000218,A,,CHEMBL618577,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7352.0,,,22224.0,6078.0,U,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,BAO_0000218,A,,CHEMBL876487,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7353.0,,,22224.0,6062.0,U,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,A,,CHEMBL618578,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7354.0,,,22224.0,2661.0,U,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,A,,CHEMBL618579,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7355.0,,,22224.0,2661.0,U,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000019,A,,CHEMBL618580,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7356.0,,,22224.0,5394.0,U,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,BAO_0000218,A,,CHEMBL618581,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7357.0,,,22224.0,4397.0,U,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,BAO_0000218,A,,CHEMBL618582,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7358.0,,,22224.0,17509.0,U,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,BAO_0000218,A,,CHEMBL618583,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7359.0,,,22224.0,17509.0,U,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,BAO_0000218,A,,CHEMBL618584,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7360.0,,,22224.0,6641.0,U,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,BAO_0000218,A,In vivo,CHEMBL618585,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7361.0,,,22224.0,5355.0,U,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,BAO_0000218,A,,CHEMBL618586,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7362.0,,,22224.0,3443.0,U,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,A,In vivo,CHEMBL618587,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7363.0,,,22224.0,3443.0,U,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,A,In vivo,CHEMBL618588,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7364.0,,,22224.0,17409.0,U,,Binding towards monkey plasma protein at 10 uM,,BAO_0000019,A,,CHEMBL618589,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7365.0,,,22224.0,17409.0,U,,Binding towards monkey plasma protein at 100 uM,,BAO_0000019,A,,CHEMBL618590,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7366.0,,,22224.0,1052.0,U,,Apparent bioavailability in squirrel monkey was determined,,BAO_0000218,A,In vivo,CHEMBL872262,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7367.0,,,22224.0,13501.0,U,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,BAO_0000218,A,In vivo,CHEMBL618591,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7368.0,,,22224.0,17509.0,U,,Bioavailability in monkey (dose 2 mg/kg),,BAO_0000218,A,In vivo,CHEMBL618592,1.0,,,9443.0,,0.0,,monkey
Autocuration,,7369.0,,,22224.0,5394.0,U,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,BAO_0000218,A,In vivo,CHEMBL876488,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7370.0,,,22224.0,2661.0,U,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000218,A,In vivo,CHEMBL618593,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7371.0,,,22224.0,11219.0,U,,Bioavailability in monkey (i.d. dosing),,BAO_0000218,A,In vivo,CHEMBL618594,1.0,,,9443.0,,0.0,,monkey
Autocuration,,7372.0,,,22224.0,3045.0,U,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,BAO_0000218,A,In vivo,CHEMBL618595,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7373.0,,,22224.0,17796.0,U,,Clearance of the drug was measured in cynomolgus,,BAO_0000019,A,,CHEMBL621469,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7374.0,,,22224.0,1399.0,U,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621470,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7375.0,,,22224.0,2661.0,U,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,A,In vivo,CHEMBL621471,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,Plasma,7376.0,,,22224.0,5005.0,U,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,BAO_0000218,A,In vivo,CHEMBL621472,1.0,1969.0,,9544.0,,0.0,,Macaca mulatta
Autocuration,,7377.0,,,22224.0,17267.0,U,,Plasma clearance in rhesus monkey was determined,,BAO_0000218,A,In vivo,CHEMBL621473,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7378.0,,,22224.0,6535.0,U,,Plasma clearance in monkey after administration of 1 mg/kg iv,,BAO_0000218,A,In vivo,CHEMBL621474,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7379.0,,,22224.0,5922.0,U,,Plasma clearance in cynomolgus monkey,,BAO_0000218,A,In vivo,CHEMBL621475,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7380.0,,,22224.0,6221.0,U,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,A,In vivo,CHEMBL621476,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7381.0,,,22224.0,5668.0,U,,Plasma clearance after peroral administration at 10 mpk in Rhesus,,BAO_0000218,A,In vivo,CHEMBL624290,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7382.0,,,22224.0,5355.0,U,,The total clearance was determined after intravenous administration in cynomolgus monkeys,,BAO_0000218,A,In vivo,CHEMBL624291,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7383.0,,,22224.0,5355.0,U,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,A,In vivo,CHEMBL624292,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7384.0,,,22224.0,5355.0,U,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,A,In vivo,CHEMBL624293,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7385.0,,,22224.0,4578.0,U,,Tested for Clearance upon iv administration to african green monkey,,BAO_0000218,A,In vivo,CHEMBL624294,1.0,,,9527.0,,0.0,,Cercopithecidae
Autocuration,,7386.0,,,22224.0,17592.0,U,,Clearance in monkey,,BAO_0000218,A,In vivo,CHEMBL624295,1.0,,,9527.0,,0.0,,Cercopithecidae
Intermediate,,7387.0,,,50588.0,6641.0,N,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,A,In vivo,CHEMBL624296,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7388.0,,,50588.0,6642.0,N,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,A,In vivo,CHEMBL624297,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7389.0,,,50588.0,16367.0,N,,Half life was evaluated after intravenous administration to dogs,,BAO_0000218,A,In vivo,CHEMBL624298,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7390.0,,,50588.0,5472.0,N,,Half life was evaluated in dog,,BAO_0000218,A,,CHEMBL624299,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7391.0,,,50588.0,5474.0,N,,Half life was evaluated in dog,,BAO_0000218,A,,CHEMBL624300,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7392.0,,,50588.0,5654.0,N,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL624301,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7393.0,,,50588.0,6227.0,N,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,BAO_0000218,A,In vivo,CHEMBL624302,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7394.0,,,50588.0,6227.0,N,,Half life period after intravenous administration in dog,,BAO_0000218,A,In vivo,CHEMBL876026,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7395.0,,,50588.0,6221.0,N,,Half life period after oral administration (2.5 mg/kg) in dog was determined,,BAO_0000218,A,In vivo,CHEMBL624303,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7396.0,,,50588.0,4527.0,N,,Half life period at a dose of 1 uM/kg in dog was determined,,BAO_0000218,A,,CHEMBL624304,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7397.0,,,50588.0,5668.0,N,,Half life period was determine after peroral administration at 10 mpk in dog,,BAO_0000218,A,In vivo,CHEMBL624305,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7398.0,,,50588.0,5668.0,N,,Half life period was determine after peroral administration at 5 mpk in dog,,BAO_0000218,A,In vivo,CHEMBL624306,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7399.0,,,50588.0,3854.0,N,,Half life period was determined,,BAO_0000218,A,,CHEMBL624307,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7400.0,,,50588.0,5505.0,N,,Half life period was determined,,BAO_0000218,A,,CHEMBL624308,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7401.0,,,50588.0,6251.0,N,,Half life period by iv administration in dog at a dose of 6 mg/kg,,BAO_0000218,A,In vivo,CHEMBL624309,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7402.0,,,50588.0,1918.0,N,,Half life period was evaluated in dog,,BAO_0000218,A,,CHEMBL624310,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7403.0,,,50588.0,5546.0,N,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,BAO_0000218,A,In vivo,CHEMBL625003,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7404.0,,,50588.0,4809.0,N,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,BAO_0000218,A,In vivo,CHEMBL625004,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7405.0,,,50588.0,6215.0,N,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,BAO_0000218,A,In vivo,CHEMBL625005,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7406.0,,,50588.0,4527.0,N,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,A,In vivo,CHEMBL873813,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7407.0,,,50588.0,17594.0,N,,Half-life after oral dose of compound at 3 mg/kg in dogs,,BAO_0000218,A,In vivo,CHEMBL625006,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7408.0,,,50588.0,17839.0,N,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,BAO_0000218,A,In vivo,CHEMBL625007,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7409.0,,,50588.0,17839.0,N,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,BAO_0000218,A,In vivo,CHEMBL876027,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7410.0,,,50588.0,17839.0,N,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,BAO_0000218,A,In vivo,CHEMBL625008,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7411.0,,,50588.0,17839.0,N,,Half-life of compound in dog following p.o. administration of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL625009,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,7412.0,,,50588.0,5210.0,N,,Half-life of compound in plasma of dog was determined,,BAO_0000218,A,,CHEMBL625010,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7413.0,,,50588.0,5210.0,N,,Half-life of compound was determined in dogs,,BAO_0000218,A,,CHEMBL625011,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7414.0,,,50588.0,2959.0,N,,Half-life after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,A,In vivo,CHEMBL621553,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7415.0,,,50588.0,4137.0,N,,Half-life after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,A,In vivo,CHEMBL621554,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7416.0,,,50588.0,5064.0,N,,Half-life in Dog,,BAO_0000218,A,,CHEMBL621555,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7417.0,,,50588.0,5147.0,N,,Half-life in Dog,,BAO_0000218,A,,CHEMBL621556,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7418.0,,,50588.0,5145.0,N,,Half-life in dog,,BAO_0000218,A,,CHEMBL621557,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7419.0,,,50588.0,6123.0,N,,Half-life in dog after oral administration at 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621558,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7420.0,,,50588.0,6123.0,N,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,BAO_0000218,A,In vivo,CHEMBL621559,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7421.0,,,50588.0,4333.0,N,,Half-life in dogs,,BAO_0000218,A,,CHEMBL621560,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7422.0,,,50588.0,4333.0,N,,Half-life in dogs; ND indicates not determined,,BAO_0000218,A,,CHEMBL876028,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,7423.0,,,50588.0,12500.0,N,,Half-life in plasma of dog,,BAO_0000218,A,,CHEMBL621561,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,7424.0,,,50588.0,12500.0,N,,Half-life in plasma of dog at dose of 3-10 mgkg,,BAO_0000218,A,,CHEMBL621562,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7425.0,,,50588.0,6005.0,N,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621563,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7426.0,,,50588.0,6062.0,N,,Half-life was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621564,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7427.0,,,50588.0,17650.0,N,,Half-life was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,A,In vivo,CHEMBL621565,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7428.0,,,50588.0,5530.0,N,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621566,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7429.0,,,50588.0,5530.0,N,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,BAO_0000218,A,In vivo,CHEMBL621567,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7430.0,,,50588.0,5600.0,N,,Half-life of the compound after 0.3 mg/kg po administration in dog,,BAO_0000218,A,In vivo,CHEMBL622978,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7431.0,,,50588.0,6039.0,N,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,BAO_0000218,A,In vivo,CHEMBL873814,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7432.0,,,50588.0,6039.0,N,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,BAO_0000218,A,In vivo,CHEMBL623219,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7433.0,,,50588.0,6039.0,N,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,BAO_0000218,A,In vivo,CHEMBL624477,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7434.0,,,50588.0,6227.0,N,,t1/2 in dog,,BAO_0000218,A,,CHEMBL624478,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7435.0,,,50588.0,14541.0,N,,Half-life period measured in dogs,,BAO_0000218,A,,CHEMBL624479,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7436.0,,,50588.0,4521.0,N,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,BAO_0000218,A,In vivo,CHEMBL624480,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7437.0,,,50588.0,4521.0,N,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,A,In vivo,CHEMBL623595,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7438.0,,,50588.0,6679.0,N,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,A,In vivo,CHEMBL623596,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Plasma,7439.0,,,50588.0,1116.0,N,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,BAO_0000218,A,In vitro,CHEMBL623597,1.0,1969.0,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7440.0,,,50588.0,5444.0,N,,In vivo half life period was calculated at 1 mg/kg in dog,,BAO_0000218,A,In vivo,CHEMBL623598,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7441.0,,,50588.0,5444.0,N,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,BAO_0000218,A,In vivo,CHEMBL623599,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7442.0,,,50588.0,17853.0,N,,Longer half-life in dog (i.v.) at 0.5 mpk,,BAO_0000218,A,In vivo,CHEMBL623600,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7443.0,,,50588.0,4353.0,N,,Oral bioavailability in dog (dose 5 uM/kg),,BAO_0000218,A,In vivo,CHEMBL623601,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7444.0,,,50588.0,16452.0,N,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,A,In vivo,CHEMBL623602,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7445.0,,,50588.0,16452.0,N,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,BAO_0000218,A,In vivo,CHEMBL623603,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,,7446.0,,,50588.0,16452.0,N,,Bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,A,In vivo,CHEMBL623604,1.0,,,9615.0,,1.0,,Canis lupus familiaris
Intermediate,Lung,7447.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,BAO_0000218,A,In vivo,CHEMBL623605,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,7448.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,A,In vivo,CHEMBL623606,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,7449.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,A,In vivo,CHEMBL623607,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,7450.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,A,In vivo,CHEMBL623608,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,7451.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,A,In vivo,CHEMBL623609,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Lung,7452.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,A,In vivo,CHEMBL623610,1.0,2048.0,,10090.0,,1.0,,Mus musculus
Intermediate,Muscle tissue,7453.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,A,In vivo,CHEMBL623611,1.0,2385.0,,10090.0,,1.0,,Mus musculus
Intermediate,Muscle tissue,7454.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,BAO_0000218,A,In vivo,CHEMBL623612,1.0,2385.0,,10090.0,,1.0,,Mus musculus
Intermediate,Muscle tissue,7455.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,A,In vivo,CHEMBL623613,1.0,2385.0,,10090.0,,1.0,,Mus musculus
Intermediate,Muscle tissue,7456.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,A,In vivo,CHEMBL623614,1.0,2385.0,,10090.0,,1.0,,Mus musculus
Intermediate,Muscle tissue,7457.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,A,In vivo,CHEMBL623615,1.0,2385.0,,10090.0,,1.0,,Mus musculus
Intermediate,Muscle tissue,7458.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,A,In vivo,CHEMBL623616,1.0,2385.0,,10090.0,,1.0,,Mus musculus
Intermediate,Muscle tissue,7459.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,A,In vivo,CHEMBL623617,1.0,2385.0,,10090.0,,1.0,,Mus musculus
Intermediate,Zone of skin,7460.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,A,In vivo,CHEMBL875944,1.0,14.0,,10090.0,,1.0,,Mus musculus
Intermediate,Zone of skin,7461.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,A,In vivo,CHEMBL623618,1.0,14.0,,10090.0,,1.0,,Mus musculus
Intermediate,Zone of skin,7462.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,A,In vivo,CHEMBL623619,1.0,14.0,,10090.0,,1.0,,Mus musculus
Intermediate,Zone of skin,7463.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,A,In vivo,CHEMBL623620,1.0,14.0,,10090.0,,1.0,,Mus musculus
Intermediate,Zone of skin,7464.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,A,In vivo,CHEMBL623621,1.0,14.0,,10090.0,,1.0,,Mus musculus
Intermediate,Zone of skin,7465.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,A,In vivo,CHEMBL623622,1.0,14.0,,10090.0,,1.0,,Mus musculus
Intermediate,Zone of skin,7466.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,A,In vivo,CHEMBL623623,1.0,14.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,7467.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,A,In vivo,CHEMBL623624,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,7468.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,A,In vivo,CHEMBL618521,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,7469.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,A,In vivo,CHEMBL618522,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,7470.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,A,In vivo,CHEMBL618523,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,7471.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,A,In vivo,CHEMBL618524,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,7472.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,A,In vivo,CHEMBL618525,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,Spleen,7473.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,A,In vivo,CHEMBL624586,1.0,2106.0,,10090.0,,1.0,,Mus musculus
Intermediate,Stomach,7474.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,A,In vivo,CHEMBL624587,1.0,945.0,,10090.0,,1.0,,Mus musculus
Intermediate,Stomach,7475.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,A,In vivo,CHEMBL624588,1.0,945.0,,10090.0,,1.0,,Mus musculus
Intermediate,Stomach,7476.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,A,In vivo,CHEMBL624589,1.0,945.0,,10090.0,,1.0,,Mus musculus
Intermediate,Stomach,7477.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,A,In vivo,CHEMBL624590,1.0,945.0,,10090.0,,1.0,,Mus musculus
Intermediate,Stomach,7478.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,A,In vivo,CHEMBL624591,1.0,945.0,,10090.0,,1.0,,Mus musculus
Intermediate,Stomach,7479.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,A,In vivo,CHEMBL624592,1.0,945.0,,10090.0,,1.0,,Mus musculus
Intermediate,Stomach,7480.0,,,50594.0,10107.0,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,A,In vivo,CHEMBL624593,1.0,945.0,,10090.0,,1.0,,Mus musculus
Intermediate,,7481.0,,,50597.0,4689.0,N,,Oral bioavailability in rat,,BAO_0000218,A,In vivo,CHEMBL624594,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,7482.0,,,50597.0,4950.0,N,,Tested for the bioavailability in rat,,BAO_0000218,A,In vivo,CHEMBL624595,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,7483.0,,,50597.0,5328.0,N,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,A,In vivo,CHEMBL624596,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,7484.0,,,50597.0,406.0,N,,Bioavailability in rat,,BAO_0000218,A,In vivo,CHEMBL624597,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,7485.0,,,50597.0,12500.0,N,,Bioavailability in rat,,BAO_0000218,A,In vivo,CHEMBL624598,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,7486.0,,,50597.0,12500.0,N,,Bioavailability in rat (dose 3-10 mg/kg),,BAO_0000218,A,In vivo,CHEMBL624599,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,7487.0,,,50597.0,5247.0,N,,Bioavailability in rat,,BAO_0000218,A,In vivo,CHEMBL875166,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Plasma,7488.0,,,50597.0,4186.0,N,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,BAO_0000218,A,In vivo,CHEMBL624600,1.0,1969.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Plasma,7489.0,,,50597.0,4186.0,N,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,BAO_0000218,A,In vivo,CHEMBL624601,1.0,1969.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,7490.0,,,50597.0,6647.0,N,,Half life after oral administration was determined in rats at 6 mg/kg,,BAO_0000218,A,In vivo,CHEMBL624602,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,7491.0,,,50597.0,6484.0,N,,Half life was determined,,BAO_0000218,A,,CHEMBL624603,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,7492.0,,,50597.0,3249.0,N,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,BAO_0000218,A,In vivo,CHEMBL624604,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Plasma,7493.0,,,50597.0,6281.0,N,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,BAO_0000218,A,In vivo,CHEMBL624605,1.0,1969.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,7494.0,,,50597.0,3307.0,N,,Half life in rats,,BAO_0000218,A,,CHEMBL624606,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Blood,7495.0,,,50597.0,12058.0,N,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,BAO_0000218,A,In vivo,CHEMBL624607,1.0,178.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,7496.0,,,50597.0,8833.0,N,,Hill coefficient of the compound,,BAO_0000218,A,,CHEMBL624608,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Blood,7497.0,,,50597.0,3193.0,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,BAO_0000218,A,,CHEMBL624609,1.0,178.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Blood,7498.0,,,50597.0,3193.0,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,BAO_0000218,A,,CHEMBL624610,1.0,178.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Blood,7499.0,,,50597.0,3193.0,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,BAO_0000218,A,,CHEMBL624611,1.0,178.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Blood,7500.0,,,50597.0,3193.0,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,BAO_0000218,A,,CHEMBL624612,1.0,178.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Blood,7501.0,,,50597.0,3193.0,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,BAO_0000218,A,,CHEMBL875167,1.0,178.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Blood,7502.0,,,50597.0,3193.0,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,BAO_0000218,A,,CHEMBL624613,1.0,178.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Blood,7503.0,,,50597.0,3193.0,N,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,BAO_0000218,A,,CHEMBL624614,1.0,178.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,,7504.0,,,50597.0,5960.0,N,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,BAO_0000218,A,,CHEMBL624392,1.0,,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Brain,7505.0,,,50597.0,13950.0,N,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,BAO_0000218,A,In vivo,CHEMBL624393,1.0,955.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Brain,7506.0,,,50597.0,13950.0,N,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,BAO_0000218,A,In vivo,CHEMBL624394,1.0,955.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Brain,7507.0,,,50597.0,13950.0,N,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,BAO_0000218,A,In vivo,CHEMBL624395,1.0,955.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Brain,7508.0,,,50597.0,13950.0,N,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,BAO_0000218,A,In vivo,CHEMBL624396,1.0,955.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Brain,7509.0,,,50597.0,13950.0,N,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,BAO_0000218,A,In vivo,CHEMBL624397,1.0,955.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Thyroid gland,7510.0,,,50597.0,13950.0,N,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,BAO_0000218,A,In vivo,CHEMBL624398,1.0,2046.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Thyroid gland,7511.0,,,50597.0,13950.0,N,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,BAO_0000218,A,In vivo,CHEMBL624399,1.0,2046.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Thyroid gland,7512.0,,,50597.0,13950.0,N,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,BAO_0000218,A,In vivo,CHEMBL624400,1.0,2046.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Thyroid gland,7513.0,,,50597.0,13950.0,N,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,BAO_0000218,A,In vivo,CHEMBL624401,1.0,2046.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Thyroid gland,7514.0,,,50597.0,13950.0,N,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,BAO_0000218,A,In vivo,CHEMBL624402,1.0,2046.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Blood,7515.0,,,50597.0,9866.0,N,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,BAO_0000218,A,In vivo,CHEMBL624403,1.0,178.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Blood,7516.0,,,50597.0,9866.0,N,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,BAO_0000218,A,In vivo,CHEMBL624404,1.0,178.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Blood,7517.0,,,50597.0,9866.0,N,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,BAO_0000218,A,In vivo,CHEMBL624405,1.0,178.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Bone,7518.0,,,50597.0,9866.0,N,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,BAO_0000218,A,In vivo,CHEMBL624406,1.0,10000001.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Bone,7519.0,,,50597.0,9866.0,N,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,BAO_0000218,A,In vivo,CHEMBL624407,1.0,10000001.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Bone,7520.0,,,50597.0,9866.0,N,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,BAO_0000218,A,In vivo,CHEMBL624408,1.0,10000001.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Heart,7521.0,,,50597.0,9866.0,N,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,BAO_0000218,A,In vivo,CHEMBL618644,1.0,948.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Heart,7522.0,,,50597.0,9866.0,N,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,BAO_0000218,A,In vivo,CHEMBL618645,1.0,948.0,,10116.0,,1.0,,Rattus norvegicus
Intermediate,Heart,7523.0,,,50597.0,9866.0,N,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,BAO_0000218,A,In vivo,CHEMBL618646,1.0,948.0,,10116.0,,1.0,,Rattus norvegicus
